<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20404173</PMID><DateCompleted><Year>2010</Year><Month>06</Month><Day>08</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>107</Volume><Issue>18</Issue><PubDate><Year>2010</Year><Month>May</Month><Day>04</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>A commonly carried allele of the obesity-related FTO gene is associated with reduced brain volume in the healthy elderly.</ArticleTitle><Pagination><StartPage>8404</StartPage><EndPage>8409</EndPage><MedlinePgn>8404-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0910878107</ELocationID><Abstract><AbstractText>A recently identified variant within the fat mass and obesity-associated (FTO) gene is carried by 46% of Western Europeans and is associated with an approximately 1.2 kg higher weight, on average, in adults and an approximately 1 cm greater waist circumference. With &gt;1 billion overweight and 300 million obese persons worldwide, it is crucial to understand the implications of carrying this very common allele for the health of our aging population. FTO is highly expressed in the brain and elevated body mass index (BMI) is associated with brain atrophy, but it is unknown how the obesity-associated risk allele affects human brain structure. We therefore generated 3D maps of regional brain volume differences in 206 healthy elderly subjects scanned with MRI and genotyped as part of the Alzheimer's Disease Neuroimaging Initiative. We found a pattern of systematic brain volume deficits in carriers of the obesity-associated risk allele versus noncarriers. Relative to structure volumes in the mean template, FTO risk allele carriers versus noncarriers had an average brain volume difference of approximately 8% in the frontal lobes and 12% in the occipital lobes-these regions also showed significant volume deficits in subjects with higher BMI. These brain differences were not attributable to differences in cholesterol levels, hypertension, or the volume of white matter hyperintensities; which were not detectably higher in FTO risk allele carriers versus noncarriers. These brain maps reveal that a commonly carried susceptibility allele for obesity is associated with structural brain atrophy, with implications for the health of the elderly.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>April J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Laboratory of Neuroimaging, Department of Neurology, University of California School of Medicine, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stein</LastName><ForeName>Jason L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Hua</LastName><ForeName>Xue</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Suh</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Hibar</LastName><ForeName>Derrek P</ForeName><Initials>DP</Initials></Author><Author ValidYN="Y"><LastName>Leow</LastName><ForeName>Alex D</ForeName><Initials>AD</Initials></Author><Author ValidYN="Y"><LastName>Dinov</LastName><ForeName>Ivo D</ForeName><Initials>ID</Initials></Author><Author ValidYN="Y"><LastName>Toga</LastName><ForeName>Arthur W</ForeName><Initials>AW</Initials></Author><Author ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Li</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Foroud</LastName><ForeName>Tatiana</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Pankratz</LastName><ForeName>Nathan</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Huentelman</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Craig</LastName><ForeName>David W</ForeName><Initials>DW</Initials></Author><Author ValidYN="Y"><LastName>Gerber</LastName><ForeName>Jill D</ForeName><Initials>JD</Initials></Author><Author ValidYN="Y"><LastName>Allen</LastName><ForeName>April N</ForeName><Initials>AN</Initials></Author><Author ValidYN="Y"><LastName>Corneveaux</LastName><ForeName>Jason J</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>Stephan</LastName><ForeName>Dietrich A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>DeCarli</LastName><ForeName>Charles S</ForeName><Initials>CS</Initials></Author><Author ValidYN="Y"><LastName>DeChairo</LastName><ForeName>Bryan M</ForeName><Initials>BM</Initials></Author><Author ValidYN="Y"><LastName>Potkin</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials></Author><Author ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix></Author><Author ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials></Author><Author ValidYN="Y"><LastName>Raji</LastName><ForeName>Cyrus A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials></Author><Author ValidYN="Y"><LastName>Becker</LastName><ForeName>James T</ForeName><Initials>JT</Initials></Author><Author ValidYN="Y"><LastName>Carmichael</LastName><ForeName>Owen T</ForeName><Initials>OT</Initials></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Paul M</ForeName><Initials>PM</Initials></Author><Author ValidYN="Y"><CollectiveName>Alzheimer's Disease Neuroimaging Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K01 AG030514</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 MH087061</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 RR019771</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM005639</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027342</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HD050735</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>EB01651</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1-T90-DA022768:02</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RR019771</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G016570</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HD050735</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1F31MH087061</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG020098</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>LM05639</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS059873</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T90 DA022768</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>04</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.11.33</RegistryNumber><NameOfSubstance UI="D000071516">Alpha-Ketoglutarate-Dependent Dioxygenase FTO</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.11.33</RegistryNumber><NameOfSubstance UI="C526492">FTO protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="Y">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071516" MajorTopicYN="N">Alpha-Ketoglutarate-Dependent Dioxygenase FTO</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="Y">anatomy &amp; histology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021621" MajorTopicYN="N">Imaging, Three-Dimensional</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009765" MajorTopicYN="N">Obesity</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009929" MajorTopicYN="N">Organ Size</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thal</LastName><ForeName>Leon</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jagust</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trojanowki</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toga</LastName><ForeName>Arthur W</ForeName><Initials>AW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beckett</LastName><ForeName>Laurel</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Green</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gamst</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potter</LastName><ForeName>William Z</ForeName><Initials>WZ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montine</LastName><ForeName>Tom</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anders</LastName><ForeName>Dale</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernstein</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Felmlee</LastName><ForeName>Joel</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thompson</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schuff</LastName><ForeName>Norbert</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alexander</LastName><ForeName>Gene</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bandy</LastName><ForeName>Dan</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koeppe</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foster</LastName><ForeName>Norm</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Kewei</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trojanowki</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shaw</LastName><ForeName>Les</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Korecka</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toga</LastName><ForeName>Arthur</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crawford</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neu</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harvey</LastName><ForeName>Danielle</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gamst</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kornak</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kachaturian</LastName><ForeName>Zaven</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frank</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Snyder</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Molchan</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaye</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vorobik</LastName><ForeName>Remi</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quinn</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pawluczyk</LastName><ForeName>Sonia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spann</LastName><ForeName>Bryan</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fleisher</LastName><ForeName>Adam S</ForeName><Initials>AS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vanderswag</LastName><ForeName>Helen</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heidebrink</LastName><ForeName>Judith L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lord</LastName><ForeName>Joanne L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Kris</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doody</LastName><ForeName>Rachelle S</ForeName><Initials>RS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Villanueva</LastName><ForeName>Javier</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chowdhury</LastName><ForeName>Munir</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stern</LastName><ForeName>Yaakov</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Honig</LastName><ForeName>Lawrence S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bell</LastName><ForeName>Karen L</ForeName><Initials>KL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mintun</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Stacy</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marson</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Griffith</LastName><ForeName>Randall</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Badger</LastName><ForeName>Beverly</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grossman</LastName><ForeName>Hillel</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tang</LastName><ForeName>Cheuk</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stern</LastName><ForeName>Jessica</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>deToledo-Morrell</LastName><ForeName>Leyla</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shah</LastName><ForeName>Raj C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bach</LastName><ForeName>Julie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duara</LastName><ForeName>Ranjan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Issacson</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Strauman</LastName><ForeName>Silvia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albert</LastName><ForeName>Marilyn S</ForeName><Initials>MS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pedroso</LastName><ForeName>Julia</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toroney</LastName><ForeName>Jaimie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rusinek</LastName><ForeName>Henry</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Leon</LastName><ForeName>Mony J</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Santi</LastName><ForeName>Susan M</ForeName><Initials>SM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doraiswamy</LastName><ForeName>P Murali</ForeName><Initials>PM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petrella</LastName><ForeName>Jeffrey R</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aiello</LastName><ForeName>Marilyn</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clark</LastName><ForeName>Christopher M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pham</LastName><ForeName>Cassie</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nunez</LastName><ForeName>Jessica</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Charles D</ForeName><Initials>CD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Given</LastName><ForeName>Curtis A</ForeName><Initials>CA</Initials><Suffix>2nd</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Hardy</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeKosky</LastName><ForeName>Steven T</ForeName><Initials>ST</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oakley</LastName><ForeName>Mary Ann</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simpson</LastName><ForeName>Donna M</ForeName><Initials>DM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ismail</LastName><ForeName>M Saleem</ForeName><Initials>MS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Porsteinsson</LastName><ForeName>Anton</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCallum</LastName><ForeName>Colleen</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cramer</LastName><ForeName>Steven C</ForeName><Initials>SC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mulnard</LastName><ForeName>Ruth A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>McAdams-Ortiz</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Diaz-Arrastia</LastName><ForeName>Ramon</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin-Cook</LastName><ForeName>Kristen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeVous</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levey</LastName><ForeName>Allan I</ForeName><Initials>AI</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lah</LastName><ForeName>James J</ForeName><Initials>JJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cellar</LastName><ForeName>Janet S</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burns</LastName><ForeName>Jeffrey M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderson</LastName><ForeName>Heather S</ForeName><Initials>HS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laubinger</LastName><ForeName>Mary M</ForeName><Initials>MM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bartzokis</LastName><ForeName>George</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Silverman</LastName><ForeName>Daniel H S</ForeName><Initials>DH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lu</LastName><ForeName>Po H</ForeName><Initials>PH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fletcher</LastName><ForeName>Rita</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parfitt</LastName><ForeName>Francine</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Heather</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farlow</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Herring</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hake</LastName><ForeName>Ann</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Van Dyck</LastName><ForeName>Christopher H</ForeName><Initials>CH</Initials></Investigator><Investigator ValidYN="Y"><LastName>MacAvoy</LastName><ForeName>Martha G</ForeName><Initials>MG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bifano</LastName><ForeName>Laurel G</ForeName><Initials>LG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chertkow</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bergman</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hosein</LastName><ForeName>Chris</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Black</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Graham</LastName><ForeName>Simon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caldwell</LastName><ForeName>Curtis</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Feldman</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Assaly</LastName><ForeName>Michele</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hsiung</LastName><ForeName>Ging-Yuek R</ForeName><Initials>GY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kertesz</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rogers</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trost</LastName><ForeName>Dick</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernick</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gitelman</LastName><ForeName>Darren</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mesulam</LastName><ForeName>Marsel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sadowsky</LastName><ForeName>Carl</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Villena</LastName><ForeName>Teresa</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mesner</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul S</ForeName><Initials>PS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Kathleen B</ForeName><Initials>KB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Behan</LastName><ForeName>Kelly E</ForeName><Initials>KE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rentz</LastName><ForeName>Dorene M</ForeName><Initials>DM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosen</LastName><ForeName>Allyson</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tinklenberg</LastName><ForeName>Jared</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ashford</LastName><ForeName>Wes</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sabbagh</LastName><ForeName>Marwan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Connor</LastName><ForeName>Donald</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Obradov</LastName><ForeName>Sanja</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Killiany</LastName><ForeName>Ron</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Norbash</LastName><ForeName>Alex</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Obisesan</LastName><ForeName>Thomas O</ForeName><Initials>TO</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jayam-Trouth</LastName><ForeName>Annapurni</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Auchus</LastName><ForeName>Alexander P</ForeName><Initials>AP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huang</LastName><ForeName>Juebin</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Friedland</LastName><ForeName>Robert P</ForeName><Initials>RP</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeCarli</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fletcher</LastName><ForeName>Evan</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carmichael</LastName><ForeName>Owen</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kittur</LastName><ForeName>Smita</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mirje</LastName><ForeName>Seema</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Sterling C</ForeName><Initials>SC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borrie</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>T -Y</ForeName><Initials>T-</Initials></Investigator><Investigator ValidYN="Y"><LastName>Asthana</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carlsson</LastName><ForeName>Cynthia M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potkin</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Highum</LastName><ForeName>Diane</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Preda</LastName><ForeName>Adrian</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Dana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tariot</LastName><ForeName>Pierre N</ForeName><Initials>PN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hendin</LastName><ForeName>Barry A</ForeName><Initials>BA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scharre</LastName><ForeName>Douglas W</ForeName><Initials>DW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kataki</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beversdorf</LastName><ForeName>David Q</ForeName><Initials>DQ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zimmerman</LastName><ForeName>Earl A</ForeName><Initials>EA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Celmins</LastName><ForeName>Dzintra</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>Alice D</ForeName><Initials>AD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gandy</LastName><ForeName>Sam</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marenberg</LastName><ForeName>Marjorie E</ForeName><Initials>ME</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rovner</LastName><ForeName>Barry W</ForeName><Initials>BW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pearlson</LastName><ForeName>Godfrey</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blank</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderson</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Santulli</LastName><ForeName>Robert B</ForeName><Initials>RB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pare</LastName><ForeName>Nadia</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williamson</LastName><ForeName>Jeff D</ForeName><Initials>JD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sink</LastName><ForeName>Kaycee M</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potter</LastName><ForeName>Huntington</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ashok Raj</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Giordano</LastName><ForeName>Amy</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ott</LastName><ForeName>Brian R</ForeName><Initials>BR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wu</LastName><ForeName>Chuang-Kuo</ForeName><Initials>CK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cohen</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilks</LastName><ForeName>Kerri L</ForeName><Initials>KL</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>4</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>4</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>4</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20404173</ArticleId><ArticleId IdType="pmc">PMC2889537</ArticleId><ArticleId IdType="doi">10.1073/pnas.0910878107</ArticleId><ArticleId IdType="pii">0910878107</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Must A, et al. The disease burden associated with overweight and obesity. JAMA. 1999;282:1523&#x2013;1529.</Citation><ArticleIdList><ArticleId IdType="pubmed">10546691</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO . Obesity and Overweight. Geneva: World Health Organization; 2009.</Citation></Reference><Reference><Citation>Ceska R. Clinical implications of the metabolic syndrome. Diab Vasc Dis Res. 2007;4(Suppl 3):S2&#x2013;S4.</Citation><ArticleIdList><ArticleId IdType="pubmed">17935057</ArticleId></ArticleIdList></Reference><Reference><Citation>Elias MF, Elias PK, Sullivan LM, Wolf PA, D'Agostino RB. Obesity, diabetes and cognitive deficit: The Framingham Heart Study. Neurobiol Aging. 2005;26(Suppl 1):11&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">16223549</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes HH, Neale MC, Eaves LJ. Genetic and environmental factors in relative body weight and human adiposity. Behav Genet. 1997;27:325&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">9519560</ArticleId></ArticleIdList></Reference><Reference><Citation>Dina C, et al. Variation in FTO contributes to childhood obesity and severe adult obesity. Nat Genet. 2007;39:724&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pubmed">17496892</ArticleId></ArticleIdList></Reference><Reference><Citation>Frayling TM, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science. 2007;316:889&#x2013;894.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2646098</ArticleId><ArticleId IdType="pubmed">17434869</ArticleId></ArticleIdList></Reference><Reference><Citation>Scuteri A, et al. Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity-related traits. PLoS Genet. 2007;3:e115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1934391</ArticleId><ArticleId IdType="pubmed">17658951</ArticleId></ArticleIdList></Reference><Reference><Citation>Frazer KA, et al. International HapMap Consortium A second generation human haplotype map of over 3.1 million SNPs. Nature. 2007;449:851&#x2013;861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2689609</ArticleId><ArticleId IdType="pubmed">17943122</ArticleId></ArticleIdList></Reference><Reference><Citation>Hennig BJ, et al. FTO gene variation and measures of body mass in an African population. BMC Med Genet. 2009;10:21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2666669</ArticleId><ArticleId IdType="pubmed">19265514</ArticleId></ArticleIdList></Reference><Reference><Citation>Wardle J, et al. Obesity associated genetic variation in FTO is associated with diminished satiety. J Clin Endocrinol Metab. 2008;93:3640&#x2013;3643.</Citation><ArticleIdList><ArticleId IdType="pubmed">18583465</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer J, et al. Inactivation of the Fto gene protects from obesity. Nature. 2009;458:894&#x2013;898.</Citation><ArticleIdList><ArticleId IdType="pubmed">19234441</ArticleId></ArticleIdList></Reference><Reference><Citation>Fredriksson R, et al. The obesity gene, FTO, is of ancient origin, up-regulated during food deprivation and expressed in neurons of feeding-related nuclei of the brain. Endocrinology. 2008;149:2062&#x2013;2071.</Citation><ArticleIdList><ArticleId IdType="pubmed">18218688</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerken T, et al. The obesity-associated FTO gene encodes a 2-oxoglutarate-dependent nucleic acid demethylase. Science. 2007;318:1469&#x2013;1472.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2668859</ArticleId><ArticleId IdType="pubmed">17991826</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters T, Ausmeier K, Dildrop R, R&#xfc;ther U. The mouse Fused toes (Ft) mutation is the result of a 1.6-Mb deletion including the entire Iroquois B gene cluster. Mamm Genome. 2002;13:186&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">11956760</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Hoeven F, et al. Programmed cell death is affected in the novel mouse mutant Fused toes (Ft) Development. 1994;120:2601&#x2013;2607.</Citation><ArticleIdList><ArticleId IdType="pubmed">7956835</ArticleId></ArticleIdList></Reference><Reference><Citation>Stratakis CA, et al. Anisomastia associated with interstitial duplication of chromosome 16, mental retardation, obesity, dysmorphic facies, and digital anomalies: Molecular mapping of a new syndrome by fluorescent in situ hybridization and microsatellites to 16q13 (D16S419-D16S503) J Clin Endocrinol Metab. 2000;85:3396&#x2013;3401.</Citation><ArticleIdList><ArticleId IdType="pubmed">10999840</ArticleId></ArticleIdList></Reference><Reference><Citation>Boissel S, et al. Loss-of-function mutation in the dioxygenase-encoding FTO gene causes severe growth retardation and multiple malformations. Am J Hum Genet. 2009;85:106&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2706958</ArticleId><ArticleId IdType="pubmed">19559399</ArticleId></ArticleIdList></Reference><Reference><Citation>Raji C, et al. Brain structure and obesity. Hum Brain Mapp. 2010;31:353&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2826530</ArticleId><ArticleId IdType="pubmed">19662657</ArticleId></ArticleIdList></Reference><Reference><Citation>Gazdzinski S, Kornak J, Weiner MW, Meyerhoff DJ. Body mass index and magnetic resonance markers of brain integrity in adults. Ann Neurol. 2008;63:652&#x2013;657.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2542059</ArticleId><ArticleId IdType="pubmed">18409192</ArticleId></ArticleIdList></Reference><Reference><Citation>Pannacciulli N, et al. Brain abnormalities in human obesity: A voxel-based morphometric study. Neuroimage. 2006;31:1419&#x2013;1425.</Citation><ArticleIdList><ArticleId IdType="pubmed">16545583</ArticleId></ArticleIdList></Reference><Reference><Citation>Taki Y, et al. Relationship between body mass index and gray matter volume in 1,428 healthy individuals. Obesity. 2008;16:119&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">18223623</ArticleId></ArticleIdList></Reference><Reference><Citation>Colman RJ, et al. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science. 2009;325:201&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2812811</ArticleId><ArticleId IdType="pubmed">19590001</ArticleId></ArticleIdList></Reference><Reference><Citation>Hua X, et al. 3D characterization of brain atrophy in Alzheimer's disease and mild cognitive impairment using tensor-based morphometry. Neuroimage. 2008;41:19&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2556222</ArticleId><ArticleId IdType="pubmed">18378167</ArticleId></ArticleIdList></Reference><Reference><Citation>Hua X, et al. Tensor-based morphometry as a neuroimaging biomarker for Alzheimer's disease: an MRI study of 676 AD, MCI, and normal subjects. Neuroimage. 2008;43:458&#x2013;469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3197851</ArticleId><ArticleId IdType="pubmed">18691658</ArticleId></ArticleIdList></Reference><Reference><Citation>Leow A, et al. Inverse consistent mapping in 3D deformable image registration: Its construction and statistical properties. Inf Process Med Imaging. 2005;19:493&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">17354720</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc Ser B. 1995;57:289&#x2013;300.</Citation></Reference><Reference><Citation>Hua X, et al. Detecting brain growth patterns in normal children using tensor-based morphometry. Hum Brain Mapp. 2009;30:209&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2975704</ArticleId><ArticleId IdType="pubmed">18064588</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichols T, Brett M, Andersson J, Wager T, Poline JB. Valid conjunction inference with the minimum statistic. Neuroimage. 2005;25:653&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pubmed">15808966</ArticleId></ArticleIdList></Reference><Reference><Citation>Raz N, Gunning-Dixon FM, Head D, Dupuis JH, Acker JD. Neuroanatomical correlates of cognitive aging: Evidence from structural magnetic resonance imaging. Neuropsychology. 1998;12:95&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pubmed">9460738</ArticleId></ArticleIdList></Reference><Reference><Citation>Cserj&#xe9;si R, Luminet O, Poncelet AS, L&#xe9;n&#xe1;rd L. Altered executive function in obesity. Exploration of the role of affective states on cognitive abilities. Appetite. 2009;52:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">19260167</ArticleId></ArticleIdList></Reference><Reference><Citation>Elias MF, Elias PK, Sullivan LM, Wolf PA, D'Agostino RB. Lower cognitive function in the presence of obesity and hypertension: The Framingham heart study. Int J Obes Relat Metab Disord. 2003;27:260&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pubmed">12587008</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunstad J, et al. Elevated body mass index is associated with executive dysfunction in otherwise healthy adults. Compr Psychiatry. 2007;48:57&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">17145283</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustafson D, Lissner L, Bengtsson C, Bj&#xf6;rkelund C, Skoog I. A 24-year follow-up of body mass index and cerebral atrophy. Neurology. 2004;63:1876&#x2013;1881.</Citation><ArticleIdList><ArticleId IdType="pubmed">15557505</ArticleId></ArticleIdList></Reference><Reference><Citation>Wessels AM, et al. Voxel-based morphometry demonstrates reduced grey matter density on brain MRI in patients with diabetic retinopathy. Diabetologia. 2006;49:2474&#x2013;2480.</Citation><ArticleIdList><ArticleId IdType="pubmed">16703329</ArticleId></ArticleIdList></Reference><Reference><Citation>Last D, et al. Global and regional effects of type 2 diabetes on brain tissue volumes and cerebral vasoreactivity. Diabetes Care. 2007;30:1193&#x2013;1199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2031924</ArticleId><ArticleId IdType="pubmed">17290035</ArticleId></ArticleIdList></Reference><Reference><Citation>DeCarli C, et al. The effect of white matter hyperintensity volume on brain structure, cognitive performance, and cerebral metabolism of glucose in 51 healthy adults. Neurology. 1995;45:2077&#x2013;2084.</Citation><ArticleIdList><ArticleId IdType="pubmed">7501162</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen W, Sachdev PS, Chen X, Anstey K. Gray matter reduction is correlated with white matter hyperintensity volume: A voxel-based morphometric study in a large epidemiological sample. Neuroimage. 2006;29:1031&#x2013;1039.</Citation><ArticleIdList><ArticleId IdType="pubmed">16253521</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonestedt E, et al. Fat and carbohydrate intake modify the association between genetic variation in the FTO genotype and obesity. Am J Clin Nutr. 2009;90:1418&#x2013;1425.</Citation><ArticleIdList><ArticleId IdType="pubmed">19726594</ArticleId></ArticleIdList></Reference><Reference><Citation>Rampersaud E, et al. Physical activity and the association of common FTO gene variants with body mass index and obesity. Arch Intern Med. 2008;168:1791&#x2013;1797.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3635949</ArticleId><ArticleId IdType="pubmed">18779467</ArticleId></ArticleIdList></Reference><Reference><Citation>Vimaleswaran KS, et al. Physical activity attenuates the body mass index-increasing influence of genetic variation in the FTO gene. Am J Clin Nutr. 2009;90:425&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pubmed">19553294</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller SG, et al. The Alzheimer's disease neuroimaging initiative. Neuroimaging Clin N Am. 2005;15:869&#x2013;877. xi&#x2013;xii.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2376747</ArticleId><ArticleId IdType="pubmed">16443497</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller SG, et al. Ways toward an early diagnosis in Alzheimer's disease: The Alzheimer's Disease Neuroimaging Initiative (ADNI) Alzheimers Dement. 2005;1:55&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1864941</ArticleId><ArticleId IdType="pubmed">17476317</ArticleId></ArticleIdList></Reference><Reference><Citation>Lander ES, Schork NJ. Genetic dissection of complex traits. Science. 1994;265:2037&#x2013;2048.</Citation><ArticleIdList><ArticleId IdType="pubmed">8091226</ArticleId></ArticleIdList></Reference><Reference><Citation>Wellcome Trust Case Control Consortium Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447:661&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2719288</ArticleId><ArticleId IdType="pubmed">17554300</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, et al. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging. 2008;27:685&#x2013;691.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2544629</ArticleId><ArticleId IdType="pubmed">18302232</ArticleId></ArticleIdList></Reference><Reference><Citation>Leow AD, et al. Longitudinal stability of MRI for mapping brain change using tensor-based morphometry. Neuroimage. 2006;31:627&#x2013;640.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1941663</ArticleId><ArticleId IdType="pubmed">16480900</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho A, et al. Comparing 3 T and 1.5 T MRI for tracking AD progression with tensor-based morphometry. Hum Brain Mapp. 2010</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2875376</ArticleId><ArticleId IdType="pubmed">19780044</ArticleId></ArticleIdList></Reference><Reference><Citation>Leow AD, et al. Statistical properties of Jacobian maps and the realization of unbiased large-deformation nonlinear image registration. IEEE Trans Med Imaging. 2007;26:822&#x2013;832.</Citation><ArticleIdList><ArticleId IdType="pubmed">17679333</ArticleId></ArticleIdList></Reference><Reference><Citation>Morra JH, et al. Automated 3D mapping of hippocampal atrophy and its clinical correlates in 400 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. Hum Brain Mapp. 2009;30:2766&#x2013;2788.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2733926</ArticleId><ArticleId IdType="pubmed">19172649</ArticleId></ArticleIdList></Reference><Reference><Citation>Morra JH, et al. Validation of a fully automated 3D hippocampal segmentation method using subjects with Alzheimer's disease mild cognitive impairment, and elderly controls. Neuroimage. 2008;43:59&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2624575</ArticleId><ArticleId IdType="pubmed">18675918</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20428114</PMID><DateCompleted><Year>2010</Year><Month>06</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>465</Volume><Issue>7295</Issue><PubDate><Year>2010</Year><Month>May</Month><Day>13</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Mutations of optineurin in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>223</StartPage><EndPage>226</EndPage><MedlinePgn>223-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature08971</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) has its onset in middle age and is a progressive disorder characterized by degeneration of motor neurons of the primary motor cortex, brainstem and spinal cord. Most cases of ALS are sporadic, but about 10% are familial. Genes known to cause classic familial ALS (FALS) are superoxide dismutase 1 (SOD1), ANG encoding angiogenin, TARDP encoding transactive response (TAR) DNA-binding protein TDP-43 (ref. 4) and fused in sarcoma/translated in liposarcoma (FUS, also known as TLS). However, these genetic defects occur in only about 20-30% of cases of FALS, and most genes causing FALS are unknown. Here we show that there are mutations in the gene encoding optineurin (OPTN), earlier reported to be a causative gene of primary open-angle glaucoma (POAG), in patients with ALS. We found three types of mutation of OPTN: a homozygous deletion of exon 5, a homozygous Q398X nonsense mutation and a heterozygous E478G missense mutation within its ubiquitin-binding domain. Analysis of cell transfection showed that the nonsense and missense mutations of OPTN abolished the inhibition of activation of nuclear factor kappa B (NF-kappaB), and the E478G mutation revealed a cytoplasmic distribution different from that of the wild type or a POAG mutation. A case with the E478G mutation showed OPTN-immunoreactive cytoplasmic inclusions. Furthermore, TDP-43- or SOD1-positive inclusions of sporadic and SOD1 cases of ALS were also noticeably immunolabelled by anti-OPTN antibodies. Our findings strongly suggest that OPTN is involved in the pathogenesis of ALS. They also indicate that NF-kappaB inhibitors could be used to treat ALS and that transgenic mice bearing various mutations of OPTN will be relevant in developing new drugs for this disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Maruyama</LastName><ForeName>Hirofumi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima 734-8553, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morino</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Ito</LastName><ForeName>Hidefumi</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Izumi</LastName><ForeName>Yuishin</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Kato</LastName><ForeName>Hidemasa</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Watanabe</LastName><ForeName>Yasuhito</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Kinoshita</LastName><ForeName>Yoshimi</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Kamada</LastName><ForeName>Masaki</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Nodera</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Hidenori</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Komure</LastName><ForeName>Osamu</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Matsuura</LastName><ForeName>Shinya</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Kobatake</LastName><ForeName>Keitaro</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Morimoto</LastName><ForeName>Nobutoshi</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Abe</LastName><ForeName>Koji</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Naoki</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Aoki</LastName><ForeName>Masashi</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kawata</LastName><ForeName>Akihiro</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Hirai</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Kato</LastName><ForeName>Takeo</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Ogasawara</LastName><ForeName>Kazumasa</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Hirano</LastName><ForeName>Asao</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Takumi</LastName><ForeName>Toru</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Kusaka</LastName><ForeName>Hirofumi</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Hagiwara</LastName><ForeName>Koichi</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Kaji</LastName><ForeName>Ryuji</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Kawakami</LastName><ForeName>Hideshi</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>04</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018797">Cell Cycle Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018389">Codon, Nonsense</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026901">Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050505">Mutant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C409460">OPTN protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035582">Transcription Factor TFIIIA</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="C000606291">Sod1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044466" MajorTopicYN="N">Asian People</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018797" MajorTopicYN="N">Cell Cycle Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018389" MajorTopicYN="N">Codon, Nonsense</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003241" MajorTopicYN="N">Consanguinity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003593" MajorTopicYN="N">Cytoplasm</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005091" MajorTopicYN="N">Exons</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007564" MajorTopicYN="N" Type="Geographic">Japan</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026901" MajorTopicYN="N">Membrane Transport Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050505" MajorTopicYN="N">Mutant Proteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020125" MajorTopicYN="N">Mutation, Missense</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName><QualifierName UI="Q000819" MajorTopicYN="N">agonists</QualifierName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010375" MajorTopicYN="N">Pedigree</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017384" MajorTopicYN="N">Sequence Deletion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035582" MajorTopicYN="N">Transcription Factor TFIIIA</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>8</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>3</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20428114</ArticleId><ArticleId IdType="doi">10.1038/nature08971</ArticleId><ArticleId IdType="pii">nature08971</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Science. 2009 Feb 27;323(5918):1208-1211</Citation><ArticleIdList><ArticleId IdType="pubmed">19251628</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1993 Mar 4;362(6415):59-62</Citation><ArticleIdList><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Biol. 2007 Aug 21;17(16):1438-43</Citation><ArticleIdList><ArticleId IdType="pubmed">17702576</ArticleId></ArticleIdList></Reference><Reference><Citation>FEBS J. 2008 Jun;275(12):3178-92</Citation><ArticleIdList><ArticleId IdType="pubmed">18485006</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2009 Feb 27;323(5918):1205-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19251627</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Eye Res. 2008 Jul;87(1):1-2</Citation><ArticleIdList><ArticleId IdType="pubmed">18068704</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2006 Jun 9;281(23):16147-56</Citation><ArticleIdList><ArticleId IdType="pubmed">16569640</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Respir Crit Care Med. 2007 Feb 1;175(3):263-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17095743</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Pharmacol. 2006 Sep 1;545(1):22-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16854410</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2005 Feb;57(2):236-51</Citation><ArticleIdList><ArticleId IdType="pubmed">15668976</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2006 Apr;38(4):411-3</Citation><ArticleIdList><ArticleId IdType="pubmed">16501576</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Biol. 2005 Apr 25;169(2):285-95</Citation><ArticleIdList><ArticleId IdType="pubmed">15837803</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Biol. 1998 Mar;18(3):1601-10</Citation><ArticleIdList><ArticleId IdType="pubmed">9488477</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Biol. 2006 Dec 5;16(23):2345-51</Citation><ArticleIdList><ArticleId IdType="pubmed">17141617</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Biol. 2000 Dec 14-28;10(24):1603-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11137014</ArticleId></ArticleIdList></Reference><Reference><Citation>Ophthalmology. 2004 Sep;111(9):1641-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15350316</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2008 Mar 21;319(5870):1668-72</Citation><ArticleIdList><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2000 Jul 28;275(30):22780-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10807909</ArticleId></ArticleIdList></Reference><Reference><Citation>Oncogene. 2008 Jun 12;27(26):3739-45</Citation><ArticleIdList><ArticleId IdType="pubmed">18212736</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2009 Sep;110(5):1457-68</Citation><ArticleIdList><ArticleId IdType="pubmed">19558455</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Biol Cell. 2009 Mar;20(5):1478-92</Citation><ArticleIdList><ArticleId IdType="pubmed">19144827</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2002 Feb 8;295(5557):1077-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11834836</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20442494</PMID><DateCompleted><Year>2010</Year><Month>09</Month><Day>13</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-8908</ISSN><JournalIssue CitedMedium="Internet"><Volume>20 Suppl 2</Volume><Issue>Suppl 2</Issue><PubDate><Year>2010</Year></PubDate></JournalIssue><Title>Journal of Alzheimer's disease : JAD</Title><ISOAbbreviation>J Alzheimers Dis</ISOAbbreviation></Journal><ArticleTitle>The Alzheimer's disease mitochondrial cascade hypothesis.</ArticleTitle><Pagination><StartPage>S265</StartPage><EndPage>S279</EndPage><MedlinePgn>S265-79</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/JAD-2010-100339</ELocationID><Abstract><AbstractText>We first proposed the mitochondrial cascade hypothesis of sporadic Alzheimer's disease (AD) in 2004. Our core assumptions were a person's genes determine baseline mitochondrial function and durability, this durability determines how mitochondria change with advancing age, and critical changes in mitochondrial function initiate other pathologies characteristic of AD. Since then several lines of investigation report data consistent with or supportive of our hypothesis. In particular, AD endophenotype studies suggest a strong maternal genetic contribution, and links between mitochondrial function, tau phosphorylation, and amyloid-beta (Abeta) amyloidosis are increasingly recognized. As predicted, AD therapies designed to reduce Abeta thus far have had at best very limited clinical benefits; our hypothesis identifies alternative therapeutic targets. While placing mitochondria at the apex of an AD cascade certainly remains controversial, it is increasingly accepted by the AD research community that mitochondria play an important role in the late-onset forms of the disease. Even if the mitochondrial cascade hypothesis proves incorrect, considering its assumptions could potentially advance our understanding of sporadic, late-onset AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Swerdlow</LastName><ForeName>Russell H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>Departments of Neurology and Molecular and Integrative Physiology, University of Kansas School of Medicine, Kansas City, KS, USA. rswerdlow@kumc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burns</LastName><ForeName>Jeffrey M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Shaharyar M</ForeName><Initials>SM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>M01RR023940</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 EY018474</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG029615</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG026374</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>M01 RR023940</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG022407</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>EY018474</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG029615</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R03 AG026374</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23NS058252</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG022407</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 NS058252</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Alzheimers Dis</MedlineTA><NlmUniqueID>9814863</NlmUniqueID><ISSNLinking>1387-2877</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004272">DNA, Mitochondrial</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.9.3.1</RegistryNumber><NameOfSubstance UI="D003576">Electron Transport Complex IV</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004272" MajorTopicYN="N">DNA, Mitochondrial</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003576" MajorTopicYN="N">Electron Transport Complex IV</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>6</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20442494</ArticleId><ArticleId IdType="mid">NIHMS209369</ArticleId><ArticleId IdType="pmc">PMC2883665</ArticleId><ArticleId IdType="doi">10.3233/JAD-2010-100339</ArticleId><ArticleId IdType="pii">LT7G735323635781</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992;256:184&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">1566067</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Selkoe DJ. A beta oligomers - a decade of discovery. J Neurochem. 2007;101:1172&#x2013;1184.</Citation><ArticleIdList><ArticleId IdType="pubmed">17286590</ArticleId></ArticleIdList></Reference><Reference><Citation>Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irving N, James L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 1991;349:704&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pubmed">1671712</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature. 1995;375:754&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pubmed">7596406</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH, Yu CE, Jondro PD, Schmidt SD, Wang K, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science. 1995;269:973&#x2013;977.</Citation><ArticleIdList><ArticleId IdType="pubmed">7638622</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature. 1999;398:513&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206644</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimberly WT, Xia W, Rahmati T, Wolfe MS, Selkoe DJ. The transmembrane aspartates in presenilin 1 and 2 are obligatory for gamma-secretase activity and amyloid beta-protein generation. J Biol Chem. 2000;275:3173&#x2013;3178.</Citation><ArticleIdList><ArticleId IdType="pubmed">10652302</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, Larson E, Levy-Lahad E, Viitanen M, Peskind E, Poorkaj P, Schellenberg G, Tanzi R, Wasco W, Lannfelt L, Selkoe D, Younkin S. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med. 1996;2:864&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pubmed">8705854</ArticleId></ArticleIdList></Reference><Reference><Citation>Swerdlow RH. Pathogenesis of Alzheimer's disease. Clin Interv Aging. 2007;2:347&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2685260</ArticleId><ArticleId IdType="pubmed">18044185</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown P, Salazar AM, Gibbs CJ, Jr., Gajdusek DC. Alzheimer's disease and transmissible virus dementia (Creutzfeldt-Jakob disease) Ann N Y Acad Sci. 1982;396:131&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">6758661</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledano-Gasca A. Hypotheses concerning the aetiology of Alzheimer's disease. Pharmacopsychiatry. 1988;21(Suppl 1):17&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">3064109</ArticleId></ArticleIdList></Reference><Reference><Citation>Trojanowski JQ. Tauists, Baptists, Syners, Apostates, and new data. Ann Neurol. 2002;52:263&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">12205637</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X, Raina AK, Perry G, Smith MA. Alzheimer's disease: the two-hit hypothesis. Lancet Neurol. 2004;3:219&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">15039034</ArticleId></ArticleIdList></Reference><Reference><Citation>Swerdlow RH, Khan SM. A &#x201c;mitochondrial cascade hypothesis&#x201d; for sporadic Alzheimer's disease. Med Hypotheses. 2004;63:8&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">15193340</ArticleId></ArticleIdList></Reference><Reference><Citation>Swerdlow RH, Khan SM. The Alzheimer's disease mitochondrial cascade hypothesis: an update. Exp Neurol. 2009;218:308&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2710413</ArticleId><ArticleId IdType="pubmed">19416677</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry EK, Perry RH, Tomlinson BE, Blessed G, Gibson PH. Coenzyme A-acetylating enzymes in Alzheimer's disease: possible cholinergic `compartment' of pyruvate dehydrogenase. Neurosci Lett. 1980;18:105&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pubmed">6133246</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorbi S, Bird ED, Blass JP. Decreased pyruvate dehydrogenase complex activity in Huntington and Alzheimer brain. Ann Neurol. 1983;13:72&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">6219611</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson GE, Sheu KF, Blass JP, Baker A, Carlson KC, Harding B, Perrino P. Reduced activities of thiamine-dependent enzymes in the brains and peripheral tissues of patients with Alzheimer's disease. Arch Neurol. 1988;45:836&#x2013;840.</Citation><ArticleIdList><ArticleId IdType="pubmed">3395256</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker WD, Jr., Filley CM, Parks JK. Cytochrome oxidase deficiency in Alzheimer's disease. Neurology. 1990;40:1302&#x2013;1303.</Citation><ArticleIdList><ArticleId IdType="pubmed">2166249</ArticleId></ArticleIdList></Reference><Reference><Citation>Kish SJ, Bergeron C, Rajput A, Dozic S, Mastrogiacomo F, Chang LJ, Wilson JM, DiStefano LM, Nobrega JN. Brain cytochrome oxidase in Alzheimer's disease. J Neurochem. 1992;59:776&#x2013;779.</Citation><ArticleIdList><ArticleId IdType="pubmed">1321237</ArticleId></ArticleIdList></Reference><Reference><Citation>Swerdlow RH, Kish SJ. Mitochondria in Alzheimer's disease. Int Rev Neurobiol. 2002;53:341&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pubmed">12512346</ArticleId></ArticleIdList></Reference><Reference><Citation>King MP, Attardi G. Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. Science. 1989;246:500&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">2814477</ArticleId></ArticleIdList></Reference><Reference><Citation>Swerdlow RH, Parks JK, Cassarino DS, Maguire DJ, Maguire RS, Bennett JP, Jr., Davis RE, Parker WD., Jr. Cybrids in Alzheimer's disease: a cellular model of the disease? Neurology. 1997;49:918&#x2013;925.</Citation><ArticleIdList><ArticleId IdType="pubmed">9339668</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheehan JP, Swerdlow RH, Miller SW, Davis RE, Parks JK, Parker WD, Tuttle JB. Calcium homeostasis and reactive oxygen species production in cells transformed by mitochondria from individuals with sporadic Alzheimer's disease. J Neurosci. 1997;17:4612&#x2013;4622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573324</ArticleId><ArticleId IdType="pubmed">9169522</ArticleId></ArticleIdList></Reference><Reference><Citation>Swerdlow RH. Mitochondria in cybrids containing mtDNA from persons with mitochondriopathies. J Neurosci Res. 2007;85:3416&#x2013;3428.</Citation><ArticleIdList><ArticleId IdType="pubmed">17243174</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia W, Yang T, Shankar G, Smith IM, Shen Y, Walsh DM, Selkoe DJ. A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch Neurol. 2009;66:190&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3618974</ArticleId><ArticleId IdType="pubmed">19204155</ArticleId></ArticleIdList></Reference><Reference><Citation>Swerdlow RH. Is aging part of Alzheimer's disease, or is Alzheimer's disease part of aging? Neurobiol Aging. 2007;28:1465&#x2013;1480.</Citation><ArticleIdList><ArticleId IdType="pubmed">16876913</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunes T, Fragata I, Ribeiro F, Palma T, Maroco J, Cannas J, Secca M, Menezes C, Carmo I, Cunha G, Branco MC, Guerreiro M, de Mendonca A. The Outcome of Elderly Patients with Cognitive Complaints but Normal Neuropsychological Tests. J Alzheimers Dis. 2009</Citation><ArticleIdList><ArticleId IdType="pubmed">20061633</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorm AF, Jolley D. The incidence of dementia: a meta-analysis. Neurology. 1998;51:728&#x2013;733.</Citation><ArticleIdList><ArticleId IdType="pubmed">9748017</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrada MM, Brookmeyer R, Berlau D, Paganini-Hill A, Kawas CH. Prevalence of dementia after age 90: results from the 90+ study. Neurology. 2008;71:337&#x2013;343.</Citation><ArticleIdList><ArticleId IdType="pubmed">18596243</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogan DB. If we live long enough, will we all be demented?: redux. Neurology. 2008;71:310&#x2013;311.</Citation><ArticleIdList><ArticleId IdType="pubmed">18663177</ArticleId></ArticleIdList></Reference><Reference><Citation>Katzman R. Editorial: The prevalence and malignancy of Alzheimer disease. A major killer. Arch Neurol. 1976;33:217&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pubmed">1259639</ArticleId></ArticleIdList></Reference><Reference><Citation>Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C. Age, neuropathology, and dementia. N Engl J Med. 2009;360:2302&#x2013;2309.</Citation><ArticleIdList><ArticleId IdType="pubmed">19474427</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Morris JC. Tangles and plaques in nondemented aging and &#x201c;preclinical&#x201d; Alzheimer's disease. Ann Neurol. 1999;45:358&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">10072051</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM, Fagan AM, Holtzman DM, Mintun MA. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol. 2009;66:1469&#x2013;1475.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2798814</ArticleId><ArticleId IdType="pubmed">20008650</ArticleId></ArticleIdList></Reference><Reference><Citation>Navarro A, Boveris A. The mitochondrial energy transduction system and the aging process. Am J Physiol Cell Physiol. 2007;292:C670&#x2013;686.</Citation><ArticleIdList><ArticleId IdType="pubmed">17020935</ArticleId></ArticleIdList></Reference><Reference><Citation>Trifunovic A, Wredenberg A, Falkenberg M, Spelbrink JN, Rovio AT, Bruder CE, Bohlooly YM, Gidlof S, Oldfors A, Wibom R, Tornell J, Jacobs HT, Larsson NG. Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature. 2004;429:417&#x2013;423.</Citation><ArticleIdList><ArticleId IdType="pubmed">15164064</ArticleId></ArticleIdList></Reference><Reference><Citation>Katzman R. Alzheimer's disease. N Engl J Med. 1986;314:964&#x2013;973.</Citation><ArticleIdList><ArticleId IdType="pubmed">2870433</ArticleId></ArticleIdList></Reference><Reference><Citation>Edland SD, Silverman JM, Peskind ER, Tsuang D, Wijsman E, Morris JC. Increased risk of dementia in mothers of Alzheimer's disease cases: evidence for maternal inheritance. Neurology. 1996;47:254&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pubmed">8710088</ArticleId></ArticleIdList></Reference><Reference><Citation>Duara R, Lopez-Alberola RF, Barker WW, Loewenstein DA, Zatinsky M, Eisdorfer CE, Weinberg GB. A comparison of familial and sporadic Alzheimer's disease. Neurology. 1993;43:1377&#x2013;1384.</Citation><ArticleIdList><ArticleId IdType="pubmed">8327141</ArticleId></ArticleIdList></Reference><Reference><Citation>Silverman DH, Small GW, Chang CY, Lu CS, Kung De Aburto MA, Chen W, Czernin J, Rapoport SI, Pietrini P, Alexander GE, Schapiro MB, Jagust WJ, Hoffman JM, Welsh-Bohmer KA, Alavi A, Clark CM, Salmon E, de Leon MJ, Mielke R, Cummings JL, Kowell AP, Gambhir SS, Hoh CK, Phelps ME. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA. 2001;286:2120&#x2013;2127.</Citation><ArticleIdList><ArticleId IdType="pubmed">11694153</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L, Brys M, Switalski R, Mistur R, Glodzik L, Pirraglia E, Tsui W, De Santi S, de Leon MJ. Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism. Proc Natl Acad Sci U S A. 2007;104:19067&#x2013;19072.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2141909</ArticleId><ArticleId IdType="pubmed">18003925</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L, Mistur R, Switalski R, Brys M, Glodzik L, Rich K, Pirraglia E, Tsui W, De Santi S, de Leon MJ. Declining brain glucose metabolism in normal individuals with a maternal history of Alzheimer disease. Neurology. 2009;72:513&#x2013;520.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677512</ArticleId><ArticleId IdType="pubmed">19005175</ArticleId></ArticleIdList></Reference><Reference><Citation>Honea RA, Swerdlow RH, Vidoni ED, Goodwin J, Burns JM. Reduced gray matter volume in normal adults with a maternal family history of Alzheimer disease. Neurology. 2010;74:113&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2809030</ArticleId><ArticleId IdType="pubmed">20065246</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA. Amyloid imaging of Alzheimer's disease using Pittsburgh Compound B. Curr Neurol Neurosci Rep. 2006;6:496&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">17074285</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L, Rinne JO, Tsui WH, Berti V, Li Y, Wang H, Murray J, Scheinin N, MNagren K, Glodzik L, De Santi S, Vallabhajosula S, de Leon MJ. Increased fibrillar amyloid-beta burden in normal individuals with a family history of late-onset Alzheimer's. Proc Natl Acad Sci U S A. in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2851906</ArticleId><ArticleId IdType="pubmed">20231448</ArticleId></ArticleIdList></Reference><Reference><Citation>Debette S, Wolf PA, Beiser A, Au R, Himali JJ, Pikula A, Auerbach S, Decarli C, Seshadri S. Association of parental dementia with cognitive and brain MRI measures in middle-aged adults. Neurology. 2009;73:2071&#x2013;2078.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2790222</ArticleId><ArticleId IdType="pubmed">20007524</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu J, Wang KX, Rodova M, Esteves R, Berry D, E L, Crafter A, Barrett M, Cardoso SM, Onyango I, Parker WD, Fontes J, Burns JM, Swerdlow RH. Polymorphic variation in cytochrome oxidase subunit genes. J Alzheimers Dis. in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2910218</ArticleId><ArticleId IdType="pubmed">20413852</ArticleId></ArticleIdList></Reference><Reference><Citation>Kujoth GC, Hiona A, Pugh TD, Someya S, Panzer K, Wohlgemuth SE, Hofer T, Seo AY, Sullivan R, Jobling WA, Morrow JD, Van Remmen H, Sedivy JM, Yamasoba T, Tanokura M, Weindruch R, Leeuwenburgh C, Prolla TA. Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. Science. 2005;309:481&#x2013;484.</Citation><ArticleIdList><ArticleId IdType="pubmed">16020738</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin MT, Simon DK, Ahn CH, Kim LM, Beal MF. High aggregate burden of somatic mtDNA point mutations in aging and Alzheimer's disease brain. Hum Mol Genet. 2002;11:133&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">11809722</ArticleId></ArticleIdList></Reference><Reference><Citation>Coskun PE, Beal MF, Wallace DC. Alzheimer's brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. Proc Natl Acad Sci U S A. 2004;101:10726&#x2013;10731.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC490002</ArticleId><ArticleId IdType="pubmed">15247418</ArticleId></ArticleIdList></Reference><Reference><Citation>Corral-Debrinski M, Horton T, Lott MT, Shoffner JM, McKee AC, Beal MF, Graham BH, Wallace DC. Marked changes in mitochondrial DNA deletion levels in Alzheimer brains. Genomics. 1994;23:471&#x2013;476.</Citation><ArticleIdList><ArticleId IdType="pubmed">7835898</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamblet NS, Castora FJ. Elevated levels of the Kearns-Sayre syndrome mitochondrial DNA deletion in temporal cortex of Alzheimer's patients. Mutat Res. 1997;379:253&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pubmed">9357554</ArticleId></ArticleIdList></Reference><Reference><Citation>Bender A, Krishnan KJ, Morris CM, Taylor GA, Reeve AK, Perry RH, Jaros E, Hersheson JS, Betts J, Klopstock T, Taylor RW, Turnbull DM. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet. 2006;38:515&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pubmed">16604074</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraytsberg Y, Kudryavtseva E, McKee AC, Geula C, Kowall NW, Khrapko K. Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nat Genet. 2006;38:518&#x2013;520.</Citation><ArticleIdList><ArticleId IdType="pubmed">16604072</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, Johnson AB, Kress Y, Vinters HV, Tabaton M, Shimohama S, Cash AD, Siedlak SL, Harris PL, Jones PK, Petersen RB, Perry G, Smith MA. Mitochondrial abnormalities in Alzheimer's disease. J Neurosci. 2001;21:3017&#x2013;3023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762571</ArticleId><ArticleId IdType="pubmed">11312286</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Monte SM, Luong T, Neely TR, Robinson D, Wands JR. Mitochondrial DNA damage as a mechanism of cell loss in Alzheimer's disease. Lab Invest. 2000;80:1323&#x2013;1335.</Citation><ArticleIdList><ArticleId IdType="pubmed">10950123</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown AM, Sheu RK, Mohs R, Haroutunian V, Blass JP. Correlation of the clinical severity of Alzheimer's disease with an aberration in mitochondrial DNA (mtDNA) J Mol Neurosci. 2001;16:41&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">11345519</ArticleId></ArticleIdList></Reference><Reference><Citation>Szabados T, Dul C, Majtenyi K, Hargitai J, Penzes Z, Urbanics R. A chronic Alzheimer's model evoked by mitochondrial poison sodium azide for pharmacological investigations. Behav Brain Res. 2004;154:31&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">15302108</ArticleId></ArticleIdList></Reference><Reference><Citation>Escobar-Khondiker M, Hollerhage M, Muriel MP, Champy P, Bach A, Depienne C, Respondek G, Yamada ES, Lannuzel A, Yagi T, Hirsch EC, Oertel WH, Jacob R, Michel PP, Ruberg M, Hoglinger GU. Annonacin, a natural mitochondrial complex I inhibitor, causes tau pathology in cultured neurons. J Neurosci. 2007;27:7827&#x2013;7837.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672878</ArticleId><ArticleId IdType="pubmed">17634376</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoglinger GU, Lannuzel A, Khondiker ME, Michel PP, Duyckaerts C, Feger J, Champy P, Prigent A, Medja F, Lombes A, Oertel WH, Ruberg M, Hirsch EC. The mitochondrial complex I inhibitor rotenone triggers a cerebral tauopathy. J Neurochem. 2005;95:930&#x2013;939.</Citation><ArticleIdList><ArticleId IdType="pubmed">16219024</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabuzda D, Busciglio J, Chen LB, Matsudaira P, Yankner BA. Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative. J Biol Chem. 1994;269:13623&#x2013;13628.</Citation><ArticleIdList><ArticleId IdType="pubmed">8175797</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasparini L, Racchi M, Benussi L, Curti D, Binetti G, Bianchetti A, Trabucchi M, Govoni S. Effect of energy shortage and oxidative stress on amyloid precursor protein metabolism in COS cells. Neurosci Lett. 1997;231:113&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">9291153</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan SM, Cassarino DS, Abramova NN, Keeney PM, Borland MK, Trimmer PA, Krebs CT, Bennett JC, Parks JK, Swerdlow RH, Parker WD, Jr., Bennett JP., Jr. Alzheimer's disease cybrids replicate beta-amyloid abnormalities through cell death pathways. Ann Neurol. 2000;48:148&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pubmed">10939564</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamagno E, Bardini P, Obbili A, Vitali A, Borghi R, Zaccheo D, Pronzato MA, Danni O, Smith MA, Perry G, Tabaton M. Oxidative stress increases expression and activity of BACE in NT2 neurons. Neurobiol Dis. 2002;10:279&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pubmed">12270690</ArticleId></ArticleIdList></Reference><Reference><Citation>Clerk A, Fuller SJ, Michael A, Sugden PH. Stimulation of &#x201c;stress-regulated&#x201d; mitogen-activated protein kinases (stress-activated protein kinases/c-Jun N-terminal kinases and p38-mitogen-activated protein kinases) in perfused rat hearts by oxidative and other stresses. J Biol Chem. 1998;273:7228&#x2013;7234.</Citation><ArticleIdList><ArticleId IdType="pubmed">9516415</ArticleId></ArticleIdList></Reference><Reference><Citation>Shigenaga MK, Hagen TM, Ames BN. Oxidative damage and mitochondrial decay in aging. Proc Natl Acad Sci U S A. 1994;91:10771&#x2013;10778.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC45108</ArticleId><ArticleId IdType="pubmed">7971961</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett MJ, Alones V, Wang KX, Phan L, Swerdlow RH. Mitochondria-derived oxidative stress induces a heat shock protein response. J Neurosci Res. 2004;78:420&#x2013;429.</Citation><ArticleIdList><ArticleId IdType="pubmed">15389841</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardoso SM, Santana I, Swerdlow RH, Oliveira CR. Mitochondria dysfunction of Alzheimer's disease cybrids enhances Abeta toxicity. J Neurochem. 2004;89:1417&#x2013;1426.</Citation><ArticleIdList><ArticleId IdType="pubmed">15189344</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira C, Santos MS, Oliveira C. Mitochondrial function impairment induced by amyloid beta-peptide on PC12 cells. Neuroreport. 1998;9:1749&#x2013;1755.</Citation><ArticleIdList><ArticleId IdType="pubmed">9665595</ArticleId></ArticleIdList></Reference><Reference><Citation>Canevari L, Clark JB, Bates TE. beta-Amyloid fragment 25-35 selectively decreases complex IV activity in isolated mitochondria. FEBS Lett. 1999;457:131&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">10486579</ArticleId></ArticleIdList></Reference><Reference><Citation>Crouch PJ, Blake R, Duce JA, Ciccotosto GD, Li QX, Barnham KJ, Curtain CC, Cherny RA, Cappai R, Dyrks T, Masters CL, Trounce IA. Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-beta1-42. J Neurosci. 2005;25:672&#x2013;679.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725334</ArticleId><ArticleId IdType="pubmed">15659604</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardoso SM, Santos S, Swerdlow RH, Oliveira CR. Functional mitochondria are required for amyloid beta-mediated neurotoxicity. FASEB J. 2001;15:1439&#x2013;1441.</Citation><ArticleIdList><ArticleId IdType="pubmed">11387250</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaguchi H, Yamazaki T, Ishiguro K, Shoji M, Nakazato Y, Hirai S. Ultrastructural localization of Alzheimer amyloid beta/A4 protein precursor in the cytoplasm of neurons and senile plaque-associated astrocytes. Acta Neuropathol. 1992;85:15&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">1363016</ArticleId></ArticleIdList></Reference><Reference><Citation>Anandatheerthavarada HK, Biswas G, Robin MA, Avadhani NG. Mitochondrial targeting and a novel transmembrane arrest of Alzheimer's amyloid precursor protein impairs mitochondrial function in neuronal cells. J Cell Biol. 2003;161:41&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172865</ArticleId><ArticleId IdType="pubmed">12695498</ArticleId></ArticleIdList></Reference><Reference><Citation>Caspersen C, Wang N, Yao J, Sosunov A, Chen X, Lustbader JW, Xu HW, Stern D, McKhann G, Yan SD. Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. FASEB J. 2005;19:2040&#x2013;2041.</Citation><ArticleIdList><ArticleId IdType="pubmed">16210396</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson Petersen CA, Alikhani N, Behbahani H, Wiehager B, Pavlov PF, Alafuzoff I, Leinonen V, Ito A, Winblad B, Glaser E, Ankarcrona M. The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. Proc Natl Acad Sci U S A. 2008;105:13145&#x2013;13150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2527349</ArticleId><ArticleId IdType="pubmed">18757748</ArticleId></ArticleIdList></Reference><Reference><Citation>Lustbader JW, Cirilli M, Lin C, Xu HW, Takuma K, Wang N, Caspersen C, Chen X, Pollak S, Chaney M, Trinchese F, Liu S, Gunn-Moore F, Lue LF, Walker DG, Kuppusamy P, Zewier ZL, Arancio O, Stern D, Yan SS, Wu H. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science. 2004;304:448&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">15087549</ArticleId></ArticleIdList></Reference><Reference><Citation>Anandatheerthavarada HK, Devi L. Amyloid precursor protein and mitochondrial dysfunction in Alzheimer's disease. Neuroscientist. 2007;13:626&#x2013;638.</Citation><ArticleIdList><ArticleId IdType="pubmed">17911214</ArticleId></ArticleIdList></Reference><Reference><Citation>Devi L, Prabhu BM, Galati DF, Avadhani NG, Anandatheerthavarada HK. Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer's disease brain is associated with mitochondrial dysfunction. J Neurosci. 2006;26:9057&#x2013;9068.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675337</ArticleId><ArticleId IdType="pubmed">16943564</ArticleId></ArticleIdList></Reference><Reference><Citation>Manczak M, Anekonda TS, Henson E, Park BS, Quinn J, Reddy PH. Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet. 2006;15:1437&#x2013;1449.</Citation><ArticleIdList><ArticleId IdType="pubmed">16551656</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukui H, Diaz F, Garcia S, Moraes CT. Cytochrome c oxidase deficiency in neurons decreases both oxidative stress and amyloid formation in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2007;104:14163&#x2013;14168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1955773</ArticleId><ArticleId IdType="pubmed">17715058</ArticleId></ArticleIdList></Reference><Reference><Citation>Brody DL, Magnoni S, Schwetye KE, Spinner ML, Esparza TJ, Stocchetti N, Zipfel GJ, Holtzman DM. Amyloid-beta dynamics correlate with neurological status in the injured human brain. Science. 2008;321:1221&#x2013;1224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2577829</ArticleId><ArticleId IdType="pubmed">18755980</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang JE, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, Fujiki N, Nishino S, Holtzman DM. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science. 2009;326:1005&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2789838</ArticleId><ArticleId IdType="pubmed">19779148</ArticleId></ArticleIdList></Reference><Reference><Citation>Valla J, Schneider L, Niedzielko T, Coon KD, Caselli R, Sabbagh MN, Ahern GL, Baxter L, Alexander G, Walker DG, Reiman EM. Impaired platelet mitochondrial activity in Alzheimer's disease and mild cognitive impairment. Mitochondrion. 2006;6:323&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1864936</ArticleId><ArticleId IdType="pubmed">17123871</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemppainen NM, Aalto S, Wilson IA, Nagren K, Helin S, Bruck A, Oikonen V, Kailajarvi M, Scheinin M, Viitanen M, Parkkola R, Rinne JO. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology. 2007;68:1603&#x2013;1606.</Citation><ArticleIdList><ArticleId IdType="pubmed">17485647</ArticleId></ArticleIdList></Reference><Reference><Citation>Valla J, Yaari R, Wolf AB, Kusne Y, Beach TG, Roher AE, Corneveaux JJ, Huentelman MJ, Caselli RJ, Reiman EM. Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the APOEepsilon4 allele the major late-onset Alzheimer's susceptibility gene. J Alzheimers Dis. in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3124564</ArticleId><ArticleId IdType="pubmed">20847408</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans DA, Funkenstein HH, Albert MS, Scherr PA, Cook NR, Chown MJ, Hebert LE, Hennekens CH, Taylor JO. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA. 1989;262:2551&#x2013;2556.</Citation><ArticleIdList><ArticleId IdType="pubmed">2810583</ArticleId></ArticleIdList></Reference><Reference><Citation>De Benedictis G, Rose G, Carrieri G, De Luca M, Falcone E, Passarino G, Bonafe M, Monti D, Baggio G, Bertolini S, Mari D, Mattace R, Franceschi C. Mitochondrial DNA inherited variants are associated with successful aging and longevity in humans. FASEB J. 1999;13:1532&#x2013;1536.</Citation><ArticleIdList><ArticleId IdType="pubmed">10463944</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Walt JM, Dementieva YA, Martin ER, Scott WK, Nicodemus KK, Kroner CC, Welsh-Bohmer KA, Saunders AM, Roses AD, Small GW, Schmechel DE, Murali Doraiswamy P, Gilbert JR, Haines JL, Vance JM, Pericak-Vance MA. Analysis of European mitochondrial haplogroups with Alzheimer disease risk. Neurosci Lett. 2004;365:28&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">15234467</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg RJ, Larson M, Levy D. Factors associated with survival to 75 years of age in middle-aged men and women. The Framingham Study. Arch Intern Med. 1996;156:505&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pubmed">8604956</ArticleId></ArticleIdList></Reference><Reference><Citation>Brand FN, Kiely DK, Kannel WB, Myers RH. Family patterns of coronary heart disease mortality: the Framingham Longevity Study. J Clin Epidemiol. 1992;45:169&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">1573433</ArticleId></ArticleIdList></Reference><Reference><Citation>Pericak-Vance MA, Bebout JL, Gaskell PC, Jr., Yamaoka LH, Hung WY, Alberts MJ, Walker AP, Bartlett RJ, Haynes CA, Welsh KA, et al. Linkage studies in familial Alzheimer disease: evidence for chromosome 19 linkage. Am J Hum Genet. 1991;48:1034&#x2013;1050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1683100</ArticleId><ArticleId IdType="pubmed">2035524</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandy S, Petanceska S. Regulation of alzheimer beta-amyloid precursor trafficking and metabolism. Adv Exp Med Biol. 2001;487:85&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">11403168</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter WJ. Apolipoprotein E and Alzheimer's disease: signal transduction mechanisms. Biochem Soc Symp. 2001:101&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pubmed">11447826</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang S, ran Ma T, Miranda RD, Balestra ME, Mahley RW, Huang Y. Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity. Proc Natl Acad Sci U S A. 2005;102:18694&#x2013;18699.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1311737</ArticleId><ArticleId IdType="pubmed">16344479</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu CE, Seltman H, Peskind ER, Galloway N, Zhou PX, Rosenthal E, Wijsman EM, Tsuang DW, Devlin B, Schellenberg GD. Comprehensive analysis of APOE and selected proximate markers for late-onset Alzheimer's disease: patterns of linkage disequilibrium and disease/marker association. Genomics. 2007;89:655&#x2013;665.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1978251</ArticleId><ArticleId IdType="pubmed">17434289</ArticleId></ArticleIdList></Reference><Reference><Citation>Potkin SG, Guffanti G, Lakatos A, Turner JA, Kruggel F, Fallon JH, Saykin AJ, Orro A, Lupoli S, Salvi E, Weiner M, Macciardi F. Hippocampal atrophy as a quantitative trait in a genome-wide association study identifying novel susceptibility genes for Alzheimer's disease. PLoS One. 2009;4:e6501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2719581</ArticleId><ArticleId IdType="pubmed">19668339</ArticleId></ArticleIdList></Reference><Reference><Citation>Roses AD, Lutz MW, Amrine-Madsen H, Saunders AM, Crenshaw DG, Sundseth SS, Huentelman MJ, Welsh-Bohmer KA, Reiman EM. A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease. Pharmacogenomics J. 2009</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2946560</ArticleId><ArticleId IdType="pubmed">20029386</ArticleId></ArticleIdList></Reference><Reference><Citation>Takei N, Miyashita A, Tsukie T, Arai H, Asada T, Imagawa M, Shoji M, Higuchi S, Urakami K, Kimura H, Kakita A, Takahashi H, Tsuji S, Kanazawa I, Ihara Y, Odani S, Kuwano R. Genetic association study on in and around the APOE in late-onset Alzheimer disease in Japanese. Genomics. 2009;93:441&#x2013;448.</Citation><ArticleIdList><ArticleId IdType="pubmed">19442637</ArticleId></ArticleIdList></Reference><Reference><Citation>Bekris LM, Galloway NM, Montine TJ, Schellenberg GD, Yu CE. APOE mRNA and protein expression in postmortem brain are modulated by an extended haplotype structure. Am J Med Genet B Neuropsychiatr Genet. 2009;153B:409&#x2013;417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2829359</ArticleId><ArticleId IdType="pubmed">19554612</ArticleId></ArticleIdList></Reference><Reference><Citation>Bekris LM, Millard SP, Galloway NM, Vuletic S, Albers JJ, Li G, Galasko DR, DeCarli C, Farlow MR, Clark CM, Quinn JF, Kaye JA, Schellenberg GD, Tsuang D, Peskind ER, Yu CE. Multiple SNPs within and surrounding the apolipoprotein E gene influence cerebrospinal fluid apolipoprotein E protein levels. J Alzheimers Dis. 2008;13:255&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3192652</ArticleId><ArticleId IdType="pubmed">18430993</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson DK, Wilkins CH, Morris JC. Accelerated weight loss may precede diagnosis in Alzheimer disease. Arch Neurol. 2006;63:1312&#x2013;1317.</Citation><ArticleIdList><ArticleId IdType="pubmed">16966511</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchman AS, Wilson RS, Bienias JL, Shah RC, Evans DA, Bennett DA. Change in body mass index and risk of incident Alzheimer disease. Neurology. 2005;65:892&#x2013;897.</Citation><ArticleIdList><ArticleId IdType="pubmed">16186530</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart R, Masaki K, Xue QL, Peila R, Petrovitch H, White LR, Launer LJ. A 32-year prospective study of change in body weight and incident dementia: the Honolulu-Asia Aging Study. Arch Neurol. 2005;62:55&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">15642850</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett-Connor E, Edelstein SL, Corey-Bloom J, Wiederholt WC. Weight loss precedes dementia in community-dwelling older adults. J Am Geriatr Soc. 1996;44:1147&#x2013;1152.</Citation><ArticleIdList><ArticleId IdType="pubmed">8855991</ArticleId></ArticleIdList></Reference><Reference><Citation>White H, Pieper C, Schmader K, Fillenbaum G. Weight change in Alzheimer's disease. J Am Geriatr Soc. 1996;44:265&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pubmed">8600194</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Edland SD, Cha RH, Petersen RC, Rocca WA. Incident dementia in women is preceded by weight loss by at least a decade. Neurology. 2007;69:739&#x2013;746.</Citation><ArticleIdList><ArticleId IdType="pubmed">17709705</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson DK, Wilkins CH, Morris JC. Accelerated Weight Loss May Precede Diagnosis in Alzheimer Disease. Arch Neurol. 2006;63:1312&#x2013;1317.</Citation><ArticleIdList><ArticleId IdType="pubmed">16966511</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart R, Masaki K, Xue QL, Peila R, Petrovitch H, White LR, Launer LJ. A 32-Year Prospective Study of Change in Body Weight and Incident Dementia: The Honolulu-Asia Aging Study. Archives of Neurology. 2005;62:55&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">15642850</ArticleId></ArticleIdList></Reference><Reference><Citation>BarrettConnor E, Edelstein SL, CoreyBloom J, Wiederholt WC. Weight loss precedes dementia in community-dwelling older adults. Journal of the American Geriatrics Society. 1996;44:1147&#x2013;1152.</Citation><ArticleIdList><ArticleId IdType="pubmed">8855991</ArticleId></ArticleIdList></Reference><Reference><Citation>White H, Pieper C, Schmader K, Fillenbaum G. Weight change in Alzheimer's disease. J Am Geriatr Soc. 1996;44:265&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pubmed">8600194</ArticleId></ArticleIdList></Reference><Reference><Citation>Cronk BB, Johnson DK, Burns JM. Body Mass Index and Cognitive Decline in Mild Cognitive Impairment. Alzheimer Dis Assoc Disord. 2009</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3068614</ArticleId><ArticleId IdType="pubmed">19571736</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns JM, Johnson DK, Watts A, Swerdlow RH, Brooks WM. Lean mass is reduced in early Alzheimer's disease and associated with brain atrophy. Arch Neurol. in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2855150</ArticleId><ArticleId IdType="pubmed">20385908</ArticleId></ArticleIdList></Reference><Reference><Citation>Loskutova N, Honea RA, Brooks WM, Burns JM. Low Volumes of Limbic Grey Matter and the Hypothalamus Correlate with Low Bone Density in Early Alzheimer's Disease. J Alzheimers Dis. 2010</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2892930</ArticleId><ArticleId IdType="pubmed">20164583</ArticleId></ArticleIdList></Reference><Reference><Citation>Loskutova N, Honea RA, Vidoni ED, Brooks WM, Burns JM. Bone Density and Brain Atrophy in Early Alzheimer's Disease. J Alzheimers Dis. 2009</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2842449</ArticleId><ArticleId IdType="pubmed">19661621</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns JM, Mayo MS, Anderson HS, Smith HJ, Donnelly JE. Cardiorespiratory fitness in early-stage Alzheimer disease. Alzheimer Dis Assoc Disord. 2008;22:39&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">18317245</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns JM, Cronk BB, Anderson HS, Donnelly JE, Thomas GP, Harsha A, Brooks WM, Swerdlow RH. Cardiorespiratory fitness and brain atrophy in early Alzheimer disease. Neurology. 2008;71:210&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2657657</ArticleId><ArticleId IdType="pubmed">18625967</ArticleId></ArticleIdList></Reference><Reference><Citation>Honea RA, Thomas GP, Harsha A, Anderson HS, Donnelly JE, Brooks WM, Burns JM. Cardiorespiratory fitness and preserved medial temporal lobe volume in Alzheimer disease. Alzheimer Dis Assoc Disord. 2009;23:188&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2760037</ArticleId><ArticleId IdType="pubmed">19812458</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasparini L, Netzer WJ, Greengard P, Xu H. Does insulin dysfunction play a role in Alzheimer's disease? Trends Pharmacol Sci. 2002;23:288&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pubmed">12084635</ArticleId></ArticleIdList></Reference><Reference><Citation>Craft S, Peskind E, Schwartz MW, Schellenberg GD, Raskind M, Porte D., Jr. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology. 1998;50:164&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">9443474</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns JM, Donnelly JE, Anderson HS, Mayo MS, Spencer-Gardner L, Thomas G, Cronk BB, Haddad Z, Klima D, Hansen D, Brooks WM. Peripheral insulin and brain structure in early Alzheimer disease. Neurology. 2007;69:1094&#x2013;1104.</Citation><ArticleIdList><ArticleId IdType="pubmed">17846409</ArticleId></ArticleIdList></Reference><Reference><Citation>Swerdlow RH. Treating neurodegeneration by modifying mitochondria: potential solutions to a &#x201c;complex&#x201d; problem. Antioxid Redox Signal. 2007;9:1591&#x2013;1603.</Citation><ArticleIdList><ArticleId IdType="pubmed">17663643</ArticleId></ArticleIdList></Reference><Reference><Citation>Swerdlow RH. Mitochondrial medicine and the neurodegenerative mitochondriopathies. Pharmaceuticals. 2009;2:150&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3148068</ArticleId><ArticleId IdType="pubmed">21814473</ArticleId></ArticleIdList></Reference><Reference><Citation>Swerdlow R, Marcus DM, Landman J, Harooni M, Freedman ML. Brain glucose and ketone body metabolism in patients with Alzheimer's disease. Clin Res. 1989;37:461A.</Citation></Reference><Reference><Citation>Henderson ST, Vogel JL, Barr LJ, Garvin F, Jones JJ, Costantini LC. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr Metab (Lond) 2009;6:31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2731764</ArticleId><ArticleId IdType="pubmed">19664276</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh S, Patel N, Rahn D, McAllister J, Sadeghi S, Horwitz G, Berry D, Wang KX, Swerdlow RH. The thiazolidinedione pioglitazone alters mitochondrial function in human neuron-like cells. Mol Pharmacol. 2007;71:1695&#x2013;1702.</Citation><ArticleIdList><ArticleId IdType="pubmed">17387142</ArticleId></ArticleIdList></Reference><Reference><Citation>Strum JC, Shehee R, Virley D, Richardson J, Mattie M, Selley P, Ghosh S, Nock C, Saunders A, Roses A. Rosiglitazone induces mitochondrial biogenesis in mouse brain. J Alzheimers Dis. 2007;11:45&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">17361034</ArticleId></ArticleIdList></Reference><Reference><Citation>Onyango IG, Lu J, Rodova M, Lezi E, Crafter AB, Swerdlow RH. Regulation of neuron mitochondrial biogenesis and relevance to brain health. Biochim Biophys Acta. 2009</Citation><ArticleIdList><ArticleId IdType="pubmed">19682571</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan SM, Smigrodzki RM, Swerdlow RH. Cell and animal models of mtDNA biology: progress and prospects. Am J Physiol Cell Physiol. 2007;292:C658&#x2013;669.</Citation><ArticleIdList><ArticleId IdType="pubmed">16899549</ArticleId></ArticleIdList></Reference><Reference><Citation>Keeney PM, Quigley CK, Dunham LD, Papageorge CM, Iyer S, Thomas RR, Schwarz KM, Trimmer PA, Khan SM, Portell FR, Bergquist KE, Bennett JP., Jr. Mitochondrial gene therapy augments mitochondrial physiology in a Parkinson's disease cell model. Hum Gene Ther. 2009;20:897&#x2013;907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2829286</ArticleId><ArticleId IdType="pubmed">19374590</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JA. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008;372:216&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pubmed">18640458</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64:1553&#x2013;1562.</Citation><ArticleIdList><ArticleId IdType="pubmed">15883316</ArticleId></ArticleIdList></Reference><Reference><Citation>Swanoski MT. Homotaurine: a failed drug for Alzheimer's disease and now a nutraceutical for memory protection. Am J Health Syst Pharm. 2009;66:1950&#x2013;1953.</Citation><ArticleIdList><ArticleId IdType="pubmed">19850791</ArticleId></ArticleIdList></Reference><Reference><Citation>Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, Zavitz KH. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA. 2009;302:2557&#x2013;2564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2902875</ArticleId><ArticleId IdType="pubmed">20009055</ArticleId></ArticleIdList></Reference><Reference><Citation>Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2009;73:2061&#x2013;2070.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2790221</ArticleId><ArticleId IdType="pubmed">19923550</ArticleId></ArticleIdList></Reference><Reference><Citation>Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med. 2010;362:329&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">20107219</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20445057</PMID><DateCompleted><Year>2010</Year><Month>06</Month><Day>02</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>18</Issue><PubDate><Year>2010</Year><Month>May</Month><Day>05</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Blood-borne amyloid-beta dimer correlates with clinical markers of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>6315</StartPage><EndPage>6322</EndPage><MedlinePgn>6315-22</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.5180-09.2010</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is the most common age-related dementia. Unfortunately due to a lack of validated biomarkers definitive diagnosis relies on the histological demonstration of amyloid-beta (Abeta) plaques and tau neurofibrillary tangles. Abeta processing is implicated in AD progression and many therapeutic strategies target various aspects of this biology. While Abeta deposition is the most prominent feature of AD, oligomeric forms of Abeta have been implicated as the toxic species inducing the neuronal dysfunction. Currently there are no methods allowing routine monitoring of levels of such species in living populations. We have used surface enhanced laser desorption ionization time of flight (SELDI-TOF) mass spectrometry incorporating antibody capture to investigate whether the cellular membrane-containing fraction of blood provides a new source of biomarkers. There are significant differences in the mass spectra profiles of AD compared with HC subjects, with significantly higher levels of Abeta monomer and dimer in the blood of AD subjects. Furthermore, levels of these species correlated with clinical markers of AD including brain Abeta burden, cognitive impairment and brain atrophy. These results indicate that fundamental biochemical events relevant to AD can be monitored in blood, and that the species detected may be useful clinical biomarkers for AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Villemagne</LastName><ForeName>Victor L</ForeName><Initials>VL</Initials><AffiliationInfo><Affiliation>Mental Health Research Institute, The University of Melbourne, Parkville, Melbourne, Victoria 3052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perez</LastName><ForeName>Keyla A</ForeName><Initials>KA</Initials></Author><Author ValidYN="Y"><LastName>Pike</LastName><ForeName>Kerryn E</ForeName><Initials>KE</Initials></Author><Author ValidYN="Y"><LastName>Kok</LastName><ForeName>W Mei</ForeName><Initials>WM</Initials></Author><Author ValidYN="Y"><LastName>Rowe</LastName><ForeName>Christopher C</ForeName><Initials>CC</Initials></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>Anthony R</ForeName><Initials>AR</Initials></Author><Author ValidYN="Y"><LastName>Bourgeat</LastName><ForeName>Pierrick</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Salvado</LastName><ForeName>Olivier</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Bedo</LastName><ForeName>Justin</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Hutton</LastName><ForeName>Craig A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Faux</LastName><ForeName>Noel G</ForeName><Initials>NG</Initials></Author><Author ValidYN="Y"><LastName>Masters</LastName><ForeName>Colin L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Barnham</LastName><ForeName>Kevin J</ForeName><Initials>KJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055503" MajorTopicYN="N">Protein Multimerization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011877" MajorTopicYN="N">Radionuclide Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019032" MajorTopicYN="N">Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>5</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>5</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>11</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20445057</ArticleId><ArticleId IdType="pmc">PMC6632738</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.5180-09.2010</ArticleId><ArticleId IdType="pii">30/18/6315</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Adlard PA, Cherny RA, Finkelstein DI, Gautier E, Robb E, Cortes M, Volitakis I, Liu X, Smith JP, Perez K, Laughton K, Li QX, Charman SA, Nicolazzo JA, Wilkins S, Deleva K, Lynch T, Kok G, Ritchie CW, Tanzi RE, et al. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron. 2008;59:43&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">18614028</ArticleId></ArticleIdList></Reference><Reference><Citation>Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, Ziolko SK, James JA, Snitz BE, Houck PR, Bi W, Cohen AD, Lopresti BJ, DeKosky ST, Halligan EM, Klunk WE. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008;65:1509&#x2013;1517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2636844</ArticleId><ArticleId IdType="pubmed">19001171</ArticleId></ArticleIdList></Reference><Reference><Citation>Atwood CS, Perry G, Zeng H, Kato Y, Jones WD, Ling KQ, Huang X, Moir RD, Wang D, Sayre LM, Smith MA, Chen SG, Bush AI. Copper mediates dityrosine cross-linking of Alzheimer's amyloid-beta. Biochemistry. 2004;43:560&#x2013;568.</Citation><ArticleIdList><ArticleId IdType="pubmed">14717612</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnham KJ, Ciccotosto GD, Tickler AK, Ali FE, Smith DG, Williamson NA, Lam YH, Carrington D, Tew D, Kocak G, Volitakis I, Separovic F, Barrow CJ, Wade JD, Masters CL, Cherny RA, Curtain CC, Bush AI, Cappai R. Neurotoxic, redox-competent Alzheimer's beta-amyloid is released from lipid membrane by methionine oxidation. J Biol Chem. 2003;278:42959&#x2013;42965.</Citation><ArticleIdList><ArticleId IdType="pubmed">12925530</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnham KJ, Haeffner F, Ciccotosto GD, Curtain CC, Tew D, Mavros C, Beyreuther K, Carrington D, Masters CL, Cherny RA, Cappai R, Bush AI. Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease beta-amyloid. FASEB J. 2004;18:1427&#x2013;1429.</Citation><ArticleIdList><ArticleId IdType="pubmed">15231727</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B. 1995;57:289&#x2013;300.</Citation></Reference><Reference><Citation>Britschgi M, Olin CE, Johns HT, Takeda-Uchimura Y, LeMieux MC, Rufibach K, Rajadas J, Zhang H, Tomooka B, Robinson WH, Clark CM, Fagan AM, Galasko DR, Holtzman DM, Jutel M, Kaye JA, Lemere CA, Leszek J, Li G, Peskind ER, et al. Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. Proc Natl Acad Sci U S A. 2009;106:12145&#x2013;12150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2715538</ArticleId><ArticleId IdType="pubmed">19581601</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappai R, Barnham KJ. Delineating the mechanism of Alzheimer's disease A beta peptide neurotoxicity. Neurochem Res. 2008;33:526&#x2013;532.</Citation><ArticleIdList><ArticleId IdType="pubmed">17762917</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark CM, Davatzikos C, Borthakur A, Newberg A, Leight S, Lee VM, Trojanowski JQ. Biomarkers for early detection of Alzheimer pathology. Neurosignals. 2008;16:11&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2866153</ArticleId><ArticleId IdType="pubmed">18097155</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins DL, Zijdenbos AP, Kollokian V, Sled JG, Kabani NJ, Holmes CJ, Evans AC. Design and construction of a realistic digital brain phantom. IEEE Trans Med Imaging. 1998;17:463&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pubmed">9735909</ArticleId></ArticleIdList></Reference><Reference><Citation>Fassbender K, Masters C, Beyreuther K. Alzheimer's disease: molecular concepts and therapeutic targets. Naturwissenschaften. 2001;88:261&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pubmed">11544953</ArticleId></ArticleIdList></Reference><Reference><Citation>Glabe CG, Kayed R. Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. Neurology. 2006;66:S74&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">16432151</ArticleId></ArticleIdList></Reference><Reference><Citation>Higaki J, Catalano R, Guzzetta AW, Quon D, Nav&#xe9; JF, Tarnus C, D'Orchymont H, Cordell B. Processing of beta-amyloid precursor protein by cathepsin D. J Biol Chem. 1996;271:31885&#x2013;31893.</Citation><ArticleIdList><ArticleId IdType="pubmed">8943232</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung LW, Ciccotosto GD, Giannakis E, Tew DJ, Perez K, Masters CL, Cappai R, Wade JD, Barnham KJ. Amyloid-beta peptide (Abeta) neurotoxicity is modulated by the rate of peptide aggregation: Abeta dimers and trimers correlate with neurotoxicity. J Neurosci. 2008;28:11950&#x2013;11958.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6671645</ArticleId><ArticleId IdType="pubmed">19005060</ArticleId></ArticleIdList></Reference><Reference><Citation>Ida N, Hartmann T, Pantel J, Schr&#xf6;der J, Zerfass R, F&#xf6;rstl H, Sandbrink R, Masters CL, Beyreuther K. Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J Biol Chem. 1996;271:22908&#x2013;22914.</Citation><ArticleIdList><ArticleId IdType="pubmed">8798471</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston JA, Liu WW, Coulson DT, Todd S, Murphy S, Brennan S, Foy CJ, Craig D, Irvine GB, Passmore AP. Platelet beta-secretase activity is increased in Alzheimer's disease. Neurobiol Aging. 2008;29:661&#x2013;668.</Citation><ArticleIdList><ArticleId IdType="pubmed">17174011</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstr&#xf6;m M, Savitcheva I, Huang GF, Estrada S, Aus&#xe9;n B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, L&#xe5;ngstr&#xf6;m B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Kok WM, Scanlon DB, Karas JA, Tew D, Miles LA, Parker MW, Barnham KJ, Hutton CA. Solid-phase synthesis of homodimeric peptides: preparation of covalently-linked dimers of amyloid-beta peptide. Chem Commun (Camb) 2009;41:6228&#x2013;6230.</Citation><ArticleIdList><ArticleId IdType="pubmed">19826677</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol. 1999;155:853&#x2013;862.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866907</ArticleId><ArticleId IdType="pubmed">10487842</ArticleId></ArticleIdList></Reference><Reference><Citation>Masters CL, Cappai R, Barnham KJ, Villemagne VL. Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics. J Neurochem. 2006;97:1700&#x2013;1725.</Citation><ArticleIdList><ArticleId IdType="pubmed">16805778</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical Diagnosis of Alzheimer's Disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL. Soluble pool of A&#x3b2; amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol. 1999;46:860&#x2013;866.</Citation><ArticleIdList><ArticleId IdType="pubmed">10589538</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, Klunk WE, Mathis CA, DeKosky ST, Morris JC. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894106</ArticleId></ArticleIdList></Reference><Reference><Citation>Moir RD, Tseitlin KA, Soscia S, Hyman BT, Irizarry MC, Tanzi RE. Autoantibodies to redox-modified oligomeric Abeta are attenuated in the plasma of Alzheimer's disease patients. J Biol Chem. 2005;280:17458&#x2013;17463.</Citation><ArticleIdList><ArticleId IdType="pubmed">15728175</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoll JA, Barton E, Boche D, Neal JW, Ferrer I, Thompson P, Vlachouli C, Wilkinson D, Bayer A, Games D, Seubert P, Schenk D, Holmes C. Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol. 2006;65:1040&#x2013;1048.</Citation><ArticleIdList><ArticleId IdType="pubmed">17086100</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitz M, Fenili D, Darabie AA, Wu L, Cousins JE, McLaurin J. Modulation of amyloid-beta aggregation and toxicity by inosose stereoisomers. FEBS J. 2008;275:1663&#x2013;1674.</Citation><ArticleIdList><ArticleId IdType="pubmed">18331344</ArticleId></ArticleIdList></Reference><Reference><Citation>Olson RE, Albright CF. Recent progress in the medicinal chemistry of gamma-secretase inhibitors. Curr Top Med Chem. 2008;8:17&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">18220929</ArticleId></ArticleIdList></Reference><Reference><Citation>Ourselin S, Roche A, Subsol G, Pennec X, Ayache N. Reconstructing a 3D structure from serial histological sections. Image Vis Comput. 2001;19:25&#x2013;31.</Citation></Reference><Reference><Citation>Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">10190820</ArticleId></ArticleIdList></Reference><Reference><Citation>Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P, Mathis CA, Klunk WE, Masters CL, Rowe CC. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain. 2007;130:2837&#x2013;2844.</Citation><ArticleIdList><ArticleId IdType="pubmed">17928318</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Morris JC. Tangles and plaques in nondemented aging and &#x201c;preclinical&#x201d; Alzheimer's disease. Ann Neurol. 1999;45:358&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">10072051</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, Cowie TF, Dickinson KL, Maruff P, Darby D, Smith C, Woodward M, Merory J, Tochon-Danguy H, O'Keefe G, Klunk WE, Mathis CA, Price JC, Masters CL, Villemagne VL. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007;68:1718&#x2013;1725.</Citation><ArticleIdList><ArticleId IdType="pubmed">17502554</ArticleId></ArticleIdList></Reference><Reference><Citation>Schupf N, Tang MX, Fukuyama H, Manly J, Andrews H, Mehta P, Ravetch J, Mayeux R. Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease. Proc Natl Acad Sci U S A. 2008;105:14052&#x2013;14057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2544577</ArticleId><ArticleId IdType="pubmed">18779561</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008;14:837&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Sj&#xf6;gren M, Andreasen N, Blennow K. Advances in the detection of Alzheimer's disease-use of cerebrospinal fluid biomarkers. Clin Chim Acta. 2003;332:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">12763273</ArticleId></ArticleIdList></Reference><Reference><Citation>Skaff O, Jolliffe KA, Hutton CA. Synthesis of the side chain cross-linked tyrosine oligomers dityrosine, trityrosine, and pulcherosine. J Org Chem. 2005;70:7353&#x2013;7363.</Citation><ArticleIdList><ArticleId IdType="pubmed">16122259</ArticleId></ArticleIdList></Reference><Reference><Citation>Sokal RR, Michener CD. A statistical method for evaluating systematic relationships. Univ Kans Sci Bull. 1958;38:1409&#x2013;1438.</Citation></Reference><Reference><Citation>Straface E, Matarrese P, Gambardella L, Vona R, Sgadari A, Silveri MC, Malorni W. Oxidative imbalance and cathepsin D changes as peripheral blood biomarkers of Alzheimer disease: a pilot study. FEBS Lett. 2005;579:2759&#x2013;2766.</Citation><ArticleIdList><ArticleId IdType="pubmed">15907478</ArticleId></ArticleIdList></Reference><Reference><Citation>Tickler AK, Barrow CJ, Wade JD. Improved preparation of amyloid-beta peptides using DBU as Nalpha-Fmoc deprotection reagent. J Pept Sci. 2001;7:488&#x2013;494.</Citation><ArticleIdList><ArticleId IdType="pubmed">11587187</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, Mazoyer B, Joliot M. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002;15:273&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">11771995</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron. 2004;44:181&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">15450169</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia W, Yang T, Shankar G, Smith IM, Shen Y, Walsh DM, Selkoe DJ. A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch Neurol. 2009;66:190&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3618974</ArticleId><ArticleId IdType="pubmed">19204155</ArticleId></ArticleIdList></Reference><Reference><Citation>Zainaghi IA, Forlenza OV, Gattaz WF. Abnormal APP processing in platelets of patients with Alzheimer's disease: correlations with membrane fluidity and cognitive decline. Psychopharmacology (Berl) 2007;192:547&#x2013;553.</Citation><ArticleIdList><ArticleId IdType="pubmed">17356877</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterberg H, Blennow K. Plasma Abeta in Alzheimer's disease&#x2014;up or down? Lancet Neurol. 2006;5:638&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">16857565</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20445084</PMID><DateCompleted><Year>2010</Year><Month>06</Month><Day>29</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>107</Volume><Issue>21</Issue><PubDate><Year>2010</Year><Month>May</Month><Day>25</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Structural investigation of the C-terminal catalytic fragment of presenilin 1.</ArticleTitle><Pagination><StartPage>9644</StartPage><EndPage>9649</EndPage><MedlinePgn>9644-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1000778107</ELocationID><Abstract><AbstractText>The gamma-secretase complex has a decisive role in the development of Alzheimer's disease, in that it cleaves a precursor to create the amyloid beta peptide whose aggregates form the senile plaques encountered in the brains of patients. Gamma-secretase is a member of the intramembrane-cleaving proteases which process their transmembrane substrates within the bilayer. Many of the mutations encountered in early onset familial Alzheimer's disease are linked to presenilin 1, the catalytic component of gamma-secretase, whose active form requires its endoproteolytic cleavage into N-terminal and C-terminal fragments. Although there is general agreement regarding the topology of the N-terminal fragment, studies of the C-terminal fragment have yielded ambiguous and contradictory results that may be difficult to reconcile in the absence of structural information. Here we present the first structure of the C-terminal fragment of human presenilin 1, as obtained from NMR studies in SDS micelles. The structure reveals a topology where the membrane is likely traversed three times in accordance with the more generally accepted nine transmembrane domain model of presenilin 1, but contains unique structural features adapted to accommodate the unusual intramembrane catalysis. These include a putative half-membrane-spanning helix N-terminally harboring the catalytic aspartate, a severely kinked helical structure toward the C terminus as well as a soluble helix in the assumed-to-be unstructured N-terminal loop.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sobhanifar</LastName><ForeName>Solmaz</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Biophysical Chemistry and Center for Biomolecular Magnetic Resonance and Cluster of Excellence Macromolecular Complexes, Goethe University, 60438 Frankfurt/Main, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Birgit</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>L&#xf6;hr</LastName><ForeName>Frank</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Gottstein</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Ikeya</LastName><ForeName>Teppei</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Mlynarczyk</LastName><ForeName>Krzysztof</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Pulawski</LastName><ForeName>Wojciech</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Ghoshdastider</LastName><ForeName>Umesh</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Kolinski</LastName><ForeName>Michal</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Filipek</LastName><ForeName>Slawomir</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>G&#xfc;ntert</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Bernhard</LastName><ForeName>Frank</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>D&#xf6;tsch</LastName><ForeName>Volker</ForeName><Initials>V</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>05</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008051">Lipid Bilayers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008823">Micelles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055162" MajorTopicYN="Y">Biocatalysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057927" MajorTopicYN="N">Hydrophobic and Hydrophilic Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008051" MajorTopicYN="N">Lipid Bilayers</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008823" MajorTopicYN="N">Micelles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019906" MajorTopicYN="N">Nuclear Magnetic Resonance, Biomolecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017433" MajorTopicYN="N">Protein Structure, Secondary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>5</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>5</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>6</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>11</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20445084</ArticleId><ArticleId IdType="pmc">PMC2906861</ArticleId><ArticleId IdType="doi">10.1073/pnas.1000778107</ArticleId><ArticleId IdType="pii">1000778107</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dahlgren KN, et al. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem. 2002;277:32046&#x2013;32053.</Citation><ArticleIdList><ArticleId IdType="pubmed">12058030</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomic JL, Pensalfini A, Head E, Glabe CG. Soluble fibrillar oligomer levels are elevated in Alzheimer&#x2019;s disease brain and correlate with cognitive dysfunction. Neurobiol Dis. 2009;35:352&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2725199</ArticleId><ArticleId IdType="pubmed">19523517</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato T, et al. Active gamma-secretase complexes contain only one of each component. J Biol Chem. 2007;282:33985&#x2013;33993.</Citation><ArticleIdList><ArticleId IdType="pubmed">17911105</ArticleId></ArticleIdList></Reference><Reference><Citation>Roher AE, et al. beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. Proc Natl Acad Sci USA. 1993;90:10836&#x2013;10840.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47873</ArticleId><ArticleId IdType="pubmed">8248178</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe MS, et al. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature. 1999;398:513&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206644</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE, Bertram L. Twenty years of the Alzheimer&#x2019;s disease amyloid hypothesis: A genetic perspective. Cell. 2005;120:545&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">15734686</ArticleId></ArticleIdList></Reference><Reference><Citation>Knappenberger KS, et al. Mechanism of gamma-secretase cleavage activation: Is gamma-secretase regulated through autoinhibition involving the presenilin-1 exon 9 loop? Biochemistry. 2004;43:6208&#x2013;6218.</Citation><ArticleIdList><ArticleId IdType="pubmed">15147205</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarov VK, et al. Electron microscopic structure of purified, active gamma-secretase reveals an aqueous intramembrane chamber and two pores. Proc Natl Acad Sci USA. 2006;103:6889&#x2013;6894.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1458989</ArticleId><ArticleId IdType="pubmed">16636269</ArticleId></ArticleIdList></Reference><Reference><Citation>Osenkowski P, et al. Cryoelectron microscopy structure of purified gamma-secretase at 12 A resolution. J Mol Biol. 2009;385:642&#x2013;652.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2830092</ArticleId><ArticleId IdType="pubmed">19013469</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaether C, et al. The presenilin C-terminus is required for ER-retention, nicastrin-binding and gamma-secretase activity. EMBO J. 2004;23:4738&#x2013;4748.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC535090</ArticleId><ArticleId IdType="pubmed">15549135</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Brunkan AL, Hecimovic S, Walker E, Goate A. Conserved &#x201c;PAL&#x201d; sequence in presenilins is essential for gamma-secretase activity, but not required for formation or stabilization of gamma-secretase complexes. Neurobiol Dis. 2004;15:654&#x2013;666.</Citation><ArticleIdList><ArticleId IdType="pubmed">15056474</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, et al. C-terminal PAL motif of presenilin and presenilin homologues required for normal active site conformation. J Neurochem. 2006;96:218&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">16305624</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato C, Takagi S, Tomita T, Iwatsubo T. The C-terminal PAL motif and transmembrane domain 9 of presenilin 1 are involved in the formation of the catalytic pore of the gamma-secretase. J Neurosci. 2008;28:6264&#x2013;6271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6670534</ArticleId><ArticleId IdType="pubmed">18550769</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh YS, Turner RJ. Topology of the C-terminal fragment of human presenilin 1. Biochemistry. 2005;44:11821&#x2013;11828.</Citation><ArticleIdList><ArticleId IdType="pubmed">16128583</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Greenwald I. Additional evidence for an eight-transmembrane-domain topology for Caenorhabditis elegans and human presenilins. Proc Natl Acad Sci USA. 1998;95:7109&#x2013;7114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22757</ArticleId><ArticleId IdType="pubmed">9618547</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewji NN, Valdez D, Singer SJ. The presenilins turned inside out: Implications for their structures and functions. Proc Natl Acad Sci USA. 2004;101:1057&#x2013;1062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC327150</ArticleId><ArticleId IdType="pubmed">14732691</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakai T, et al. Membrane topology of Alzheimer&#x2019;s disease-related presenilin 1. Evidence for the existence of a molecular species with a seven membrane-spanning and one membrane-embedded structure. J Biol Chem. 1999;274:23647&#x2013;23658.</Citation><ArticleIdList><ArticleId IdType="pubmed">10438548</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmann S, Chiesa R, Harris DA. Evidence for a six-transmembrane domain structure of presenilin 1. J Biol Chem. 1997;272:12047&#x2013;12051.</Citation><ArticleIdList><ArticleId IdType="pubmed">9115271</ArticleId></ArticleIdList></Reference><Reference><Citation>Henricson A, Kall L, Sonnhammer EL. A novel transmembrane topology of presenilin based on reconciling experimental and computational evidence. FEBS J. 2005;272:2727&#x2013;2733.</Citation><ArticleIdList><ArticleId IdType="pubmed">15943807</ArticleId></ArticleIdList></Reference><Reference><Citation>Doan A, et al. Protein topology of presenilin 1. Neuron. 1996;17:1023&#x2013;1030.</Citation><ArticleIdList><ArticleId IdType="pubmed">8938133</ArticleId></ArticleIdList></Reference><Reference><Citation>Spasic D, et al. Presenilin-1 maintains a nine-transmembrane topology throughout the secretory pathway. J Biol Chem. 2006;281:26569&#x2013;26577.</Citation><ArticleIdList><ArticleId IdType="pubmed">16846981</ArticleId></ArticleIdList></Reference><Reference><Citation>Laudon H, et al. A nine-transmembrane domain topology for presenilin 1. J Biol Chem. 2005;280:35352&#x2013;35360.</Citation><ArticleIdList><ArticleId IdType="pubmed">16046406</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewji NN, Singer SJ. The seven-transmembrane spanning topography of the Alzheimer disease-related presenilin proteins in the plasma membranes of cultured cells. Proc Natl Acad Sci USA. 1997;94:14025&#x2013;14030.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC28426</ArticleId><ArticleId IdType="pubmed">9391146</ArticleId></ArticleIdList></Reference><Reference><Citation>Klammt C, Schwarz D, Dotsch V, Bernhard F. Cell-free production of integral membrane proteins on a preparative scale. Method Mol Biol. 2007;375:57&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">17634596</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarz D, et al. Preparative scale expression of membrane proteins in Escherichia coli-based continuous exchange cell-free systems. Nat Protoc. 2007;2:2945&#x2013;2957.</Citation><ArticleIdList><ArticleId IdType="pubmed">18007631</ArticleId></ArticleIdList></Reference><Reference><Citation>Sobhanifar S, et al. Cell-free expression and stable isotope labelling strategies for membrane proteins. J Biomol NMR. 2010;46:33&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">19680602</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YJ, et al. X-ray structure of EmrE supports dual topology model. Proc Natl Acad Sci USA. 2007;104:18999&#x2013;19004.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2141897</ArticleId><ArticleId IdType="pubmed">18024586</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller T, et al. Cell free expression and functional reconstitution of eukaryotic drug transporters. Biochemistry. 2008;47:4552&#x2013;4564.</Citation><ArticleIdList><ArticleId IdType="pubmed">18361503</ArticleId></ArticleIdList></Reference><Reference><Citation>Klammt C, et al. Evaluation of detergents for the soluble expression of alpha-helical and beta-barrel-type integral membrane proteins by a preparative scale individual cell-free expression system. FEBS J . 2005;272:6024&#x2013;6038.</Citation><ArticleIdList><ArticleId IdType="pubmed">16302967</ArticleId></ArticleIdList></Reference><Reference><Citation>Reckel S, et al. Transmembrane segment enhanced labeling as a tool for the backbone assignment of alpha-helical membrane proteins. Proc Natl Acad Sci USA. 2008;105:8262&#x2013;8267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2448825</ArticleId><ArticleId IdType="pubmed">18550820</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyte J, Doolittle RF. A simple method for displaying the hydropathic character of a protein. J Mol Biol. 1982;157:105&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">7108955</ArticleId></ArticleIdList></Reference><Reference><Citation>Krogh A, Larsson B, von Heijne G, Sonnhammer EL. Predicting transmembrane protein topology with a hidden Markov model: Application to complete genomes. J Mol Biol. 2001;305:567&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">11152613</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, et al. NMR solution structure of the integral membrane enzyme DsbB: Functional insights into DsbB-catalyzed disulfide bond formation. Mol Cell. 2008;31:896&#x2013;908.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2622435</ArticleId><ArticleId IdType="pubmed">18922471</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnell JR, Chou JJ. Structure and mechanism of the M2 proton channel of influenza A virus. Nature. 2008;451:591&#x2013;595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3108054</ArticleId><ArticleId IdType="pubmed">18235503</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Horn WD, et al. Solution nuclear magnetic resonance structure of membrane-integral diacylglycerol kinase. Science. 2009;324:1726&#x2013;1729.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2764269</ArticleId><ArticleId IdType="pubmed">19556511</ArticleId></ArticleIdList></Reference><Reference><Citation>Krueger-Koplin RD, et al. An evaluation of detergents for NMR structural studies of membrane proteins. J Biomol NMR . 2004;28:43&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">14739638</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang B, Bushweller JH, Tamm LK. Site-directed parallel spin-labeling and paramagnetic relaxation enhancement in structure determination of membrane proteins by solution NMR spectroscopy. J Am Chem Soc. 2006;128:4389&#x2013;4397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3199951</ArticleId><ArticleId IdType="pubmed">16569016</ArticleId></ArticleIdList></Reference><Reference><Citation>Roosild TP, et al. NMR structure of Mistic, a membrane-integrating protein for membrane protein expression. Science. 2005;307:1317&#x2013;1321.</Citation><ArticleIdList><ArticleId IdType="pubmed">15731457</ArticleId></ArticleIdList></Reference><Reference><Citation>Battiste JL, Wagner G. Utilization of site-directed spin labeling and high-resolution heteronuclear nuclear magnetic resonance for global fold determination of large proteins with limited nuclear overhauser effect data. Biochemistry. 2000;39:5355&#x2013;5365.</Citation><ArticleIdList><ArticleId IdType="pubmed">10820006</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato C, Morohashi Y, Tomita T, Iwatsubo T. Structure of the catalytic pore of gamma-secretase probed by the accessibility of substituted cysteines. J Neurosci. 2006;26:12081&#x2013;12088.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674866</ArticleId><ArticleId IdType="pubmed">17108181</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolia A, Chavez-Gutierrez L, De Strooper B. Contribution of presenilin transmembrane domains 6 and 7 to a water-containing cavity in the gamma-secretase complex. J Biol Chem. 2006;281:27633&#x2013;27642.</Citation><ArticleIdList><ArticleId IdType="pubmed">16844686</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xfc;ntert P. Automated NMR structure calculation with CYANA. Method Mol Biol. 2004;278:353&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pubmed">15318003</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolia A, Horre K, De Strooper B. Transmembrane domain 9 of presenilin determines the dynamic conformation of the catalytic site of gamma-secretase. J Biol Chem. 2008;283:19793&#x2013;19803.</Citation><ArticleIdList><ArticleId IdType="pubmed">18482978</ArticleId></ArticleIdList></Reference><Reference><Citation>Bond PJ, Sansom MS. Insertion and assembly of membrane proteins via simulation. J Am Chem Soc. 2006;128:2697&#x2013;2704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4618310</ArticleId><ArticleId IdType="pubmed">16492056</ArticleId></ArticleIdList></Reference><Reference><Citation>Marrink SJ, Risselada HJ, Yefimov S, Tieleman DP, de Vries AH. The MARTINI force field: Coarse grained model for biomolecular simulations. J Phys Chem B. 2007;111:7812&#x2013;7824.</Citation><ArticleIdList><ArticleId IdType="pubmed">17569554</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazaridis T. Effective energy function for proteins in lipid membranes. Proteins. 2003;52:176&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">12833542</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks B, et al. CHARMM: A program for macromolecular energy, minimization, and dynamics calculations. J Comput Chem. 1983;4:187&#x2013;217.</Citation></Reference><Reference><Citation>Tanford C, Reynolds JA. Characterization of membrane proteins in detergent solutions. Biochim Biophys Acta. 1976;457:133&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">135582</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher LE, Engelman DM, Sturgis JN. Effect of detergents on the association of the glycophorin a transmembrane helix. Biophys J . 2003;85:3097&#x2013;3105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1303586</ArticleId><ArticleId IdType="pubmed">14581210</ArticleId></ArticleIdList></Reference><Reference><Citation>Thevenin D, Lazarova T. Stable interactions between the transmembrane domains of the adenosine A2A receptor. Protein Sci. 2008;17:1188&#x2013;1199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2441997</ArticleId><ArticleId IdType="pubmed">18434504</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou FX, Cocco MJ, Russ WP, Brunger AT, Engelman DM. Interhelical hydrogen bonding drives strong interactions in membrane proteins. Nat Struct Biol. 2000;7:154&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">10655619</ArticleId></ArticleIdList></Reference><Reference><Citation>Chill JH, Louis JM, Miller C, Bax A. NMR study of the tetrameric KcsA potassium channel in detergent micelles. Protein Sci. 2006;15:684&#x2013;698.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2242490</ArticleId><ArticleId IdType="pubmed">16522799</ArticleId></ArticleIdList></Reference><Reference><Citation>Teriete P, Franzin CM, Choi J, Marassi FM. Structure of the Na,K-ATPase regulatory protein FXYD1 in micelles. Biochemistry. 2007;46:6774&#x2013;6783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2527028</ArticleId><ArticleId IdType="pubmed">17511473</ArticleId></ArticleIdList></Reference><Reference><Citation>Howell SC, Mesleh MF, Opella SJ. NMR structure determination of a membrane protein with two transmembrane helices in micelles: MerF of the bacterial mercury detoxification system. Biochemistry. 2005;44:5196&#x2013;5206.</Citation><ArticleIdList><ArticleId IdType="pubmed">15794657</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthey U, Kaim G, Braun D, Wuthrich K, Dimroth P. NMR studies of subunit c of the ATP synthase from Propionigenium modestum in dodecylsulphate micelles. Eur J Biochem. 1999;261:459&#x2013;467.</Citation><ArticleIdList><ArticleId IdType="pubmed">10215857</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Greenwald I. Membrane topology of the C. elegans SEL-12 presenilin. Neuron. 1996;17:1015&#x2013;1021.</Citation><ArticleIdList><ArticleId IdType="pubmed">8938132</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng L, et al. Structure of a site-2 protease family intramembrane metalloprotease. Science. 2007;318:1608&#x2013;1612.</Citation><ArticleIdList><ArticleId IdType="pubmed">18063795</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Zhang Y, Ha Y. Crystal structure of a rhomboid family intramembrane protease. Nature. 2006;444:179&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">17051161</ArticleId></ArticleIdList></Reference><Reference><Citation>Kutzner C, et al. Speeding up parallel GROMACS on high-latency networks. J Comput Chem. 2007;28:2075&#x2013;2084.</Citation><ArticleIdList><ArticleId IdType="pubmed">17405124</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Der Spoel D, et al. GROMACS: Fast, flexible, and free. J Comput Chem. 2005;26:1701&#x2013;1718.</Citation><ArticleIdList><ArticleId IdType="pubmed">16211538</ArticleId></ArticleIdList></Reference><Reference><Citation>Koradi R, Billeter M, Wuthrich K. MOLMOL: A program for display and analysis of macromolecular structures. J Mol Graphics. 1996;14:51&#x2013;55. 29&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">8744573</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20448184</PMID><DateCompleted><Year>2010</Year><Month>05</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>328</Volume><Issue>5979</Issue><PubDate><Year>2010</Year><Month>May</Month><Day>07</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Altered histone acetylation is associated with age-dependent memory impairment in mice.</ArticleTitle><Pagination><StartPage>753</StartPage><EndPage>756</EndPage><MedlinePgn>753-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.1186088</ELocationID><Abstract><AbstractText>As the human life span increases, the number of people suffering from cognitive decline is rising dramatically. The mechanisms underlying age-associated memory impairment are, however, not understood. Here we show that memory disturbances in the aging brain of the mouse are associated with altered hippocampal chromatin plasticity. During learning, aged mice display a specific deregulation of histone H4 lysine 12 (H4K12) acetylation and fail to initiate a hippocampal gene expression program associated with memory consolidation. Restoration of physiological H4K12 acetylation reinstates the expression of learning-induced genes and leads to the recovery of cognitive abilities. Our data suggest that deregulated H4K12 acetylation may represent an early biomarker of an impaired genome-environment interaction in the aging mouse brain.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Peleg</LastName><ForeName>Shahaf</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratory for Aging and Cognitive Diseases, European Neuroscience Institute, Grisebach Str. 5, D-37077 Goettingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sananbenesi</LastName><ForeName>Farahnaz</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Zovoilis</LastName><ForeName>Athanasios</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Burkhardt</LastName><ForeName>Susanne</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Bahari-Javan</LastName><ForeName>Sanaz</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Agis-Balboa</LastName><ForeName>Roberto Carlos</ForeName><Initials>RC</Initials></Author><Author ValidYN="Y"><LastName>Cota</LastName><ForeName>Perla</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Wittnam</LastName><ForeName>Jessica Lee</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Gogol-Doering</LastName><ForeName>Andreas</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Opitz</LastName><ForeName>Lennart</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Salinas-Riester</LastName><ForeName>Gabriella</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Dettenhofer</LastName><ForeName>Markus</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Hui</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Farinelli</LastName><ForeName>Laurent</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Wei</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Fischer</LastName><ForeName>Andr&#xe9;</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>GEO</DataBankName><AccessionNumberList><AccessionNumber>GSE20270</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002843">Chromatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000080865">Formins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D056572">Histone Deacetylase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006657">Histones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006877">Hydroxamic Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008840">Microfilament Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C549436">formin 2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C528828">suberoyl bis-hydroxamic acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>K3Z4F929H6</RegistryNumber><NameOfSubstance UI="D008239">Lysine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Science. 2010 Jun 25;328(5986):1634</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Science. 2010 May 7;328(5979):701-2. doi: 10.1126/science.1189968.</RefSource><PMID Version="1">20448174</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000107" MajorTopicYN="N">Acetylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002843" MajorTopicYN="N">Chromatin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042002" MajorTopicYN="Y">Chromatin Assembly and Disassembly</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003213" MajorTopicYN="N">Conditioning, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044127" MajorTopicYN="N">Epigenesis, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005239" MajorTopicYN="N">Fear</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000080865" MajorTopicYN="N">Formins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="Y">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056572" MajorTopicYN="N">Histone Deacetylase Inhibitors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006657" MajorTopicYN="N">Histones</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006877" MajorTopicYN="N">Hydroxamic Acids</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007858" MajorTopicYN="N">Learning</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008239" MajorTopicYN="N">Lysine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008840" MajorTopicYN="N">Microfilament Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009687" MajorTopicYN="N">Nuclear Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024363" MajorTopicYN="N">Transcription Initiation Site</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>5</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>5</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20448184</ArticleId><ArticleId IdType="doi">10.1126/science.1186088</ArticleId><ArticleId IdType="pii">328/5979/753</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20457961</PMID><DateCompleted><Year>2010</Year><Month>07</Month><Day>01</Day></DateCompleted><DateRevised><Year>2010</Year><Month>11</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3687</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>5</Issue><PubDate><Year>2010</Year><Month>May</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Identification of 2 Loci at chromosomes 9 and 14 in a multiplex family with frontotemporal lobar degeneration and amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>606</StartPage><EndPage>616</EndPage><MedlinePgn>606-16</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/archneurol.2010.82</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Frontotemporal lobar degeneration (FTLD) is a neurodegenerative brain disorder that can be accompanied by signs of amyotrophic lateral sclerosis (ALS).</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To identify a novel gene for FTLD-ALS.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Genome-wide linkage study in a multiplex family with FTLD-ALS with subsequent fine mapping and mutation analyses.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Memory Clinic of the Middelheim General Hospital.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">An extended Belgian family with autosomal dominant FTLD-ALS, DR14, with a mean age at onset of 58.1 years (range, 51-65 years [n = 9]) and mean disease duration of 6.4 years (range, 1-17 years [n = 9]). The proband with clinical FTLD showed typical FTLD pathology with neuronal ubiquitin-immunoreactive inclusions that were positive for the transactivation response DNA-binding protein 43 (TDP-43).</AbstractText><AbstractText Label="MAIN OUTCOME MEASURE" NlmCategory="METHODS">Linkage to chromosome 9 and 14.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We found significant linkage to chromosome 9p23-q21 (multipoint logarithm of odds [LOD] score = 3.38) overlapping with a known FTLD-ALS locus (ALSFTD2) and nearly significant linkage to a second locus at chromosome 14q31-q32 (multipoint LOD score = 2.79). Obligate meiotic recombinants defined candidate regions of 74.7 megabase pairs (Mb) at chromosome 9 and 14.6 Mb near the telomere of chromosome 14q. In both loci, the disease haplotype segregated in all patients in the family. Mutation analysis of selected genes and copy number variation analysis in both loci did not reveal segregating pathogenic mutations.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Family DR14 provides additional significant evidence for the importance of the chromosome 9 gene to FTLD-ALS and reveals a possible novel locus for FTLD-ALS at chromosome 14. The identification of the underlying genetic defect(s) will significantly contribute to the understanding of neurodegenerative disease mechanisms in FTLD, ALS, and associated neurodegenerative disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gijselinck</LastName><ForeName>Ilse</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>University of Antwerp, B-2610 Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Engelborghs</LastName><ForeName>Sebastiaan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Maes</LastName><ForeName>Githa</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Cuijt</LastName><ForeName>Ivy</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Peeters</LastName><ForeName>Karin</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Mattheijssens</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Joris</LastName><ForeName>Geert</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Cras</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Jean-Jacques</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>De Deyn</LastName><ForeName>Peter P</ForeName><Initials>PP</Initials></Author><Author ValidYN="Y"><LastName>Kumar-Singh</LastName><ForeName>Samir</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Van Broeckhoven</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Cruts</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001530" MajorTopicYN="N" Type="Geographic">Belgium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002874" MajorTopicYN="N">Chromosome Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002883" MajorTopicYN="N">Chromosomes, Human, Pair 14</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002899" MajorTopicYN="N">Chromosomes, Human, Pair 9</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004252" MajorTopicYN="N">DNA Mutational Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017809" MajorTopicYN="N">Fatal Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="N">Frontotemporal Lobar Degeneration</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008040" MajorTopicYN="N">Genetic Linkage</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005820" MajorTopicYN="N">Genetic Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006239" MajorTopicYN="N">Haplotypes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20457961</ArticleId><ArticleId IdType="doi">10.1001/archneurol.2010.82</ArticleId><ArticleId IdType="pii">67/5/606</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20457965</PMID><DateCompleted><Year>2010</Year><Month>07</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3687</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>5</Issue><PubDate><Year>2010</Year><Month>May</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>The N141I mutation in PSEN2: implications for the quintessential case of Alzheimer disease.</ArticleTitle><Pagination><StartPage>631</StartPage><EndPage>633</EndPage><MedlinePgn>631-3</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/archneurol.2010.87</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To connect a new family with early-onset Alzheimer disease (EOAD) in Germany to the American Volga German pedigrees.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Pedigree molecular genetic analysis.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">University Medical Centers in Fulda and Giessen, Germany, and in Seattle, Washington.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The families from Fulda, Germany, and the American Volga German families with EOAD share the same N141I PSEN2 mutation on an identical haplotypic background. This establishes that the N141I mutation occurred prior to emigration of the families from the Hesse region to Russia in the 1760s, and documents that relatives of the original immigrant families are presently living in Germany with the mutation and the disease.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">A family with the N141I mutation in PSEN2 that presently lives in Germany has been connected to the haplotype that carries the same mutation in pedigrees descended from the Volga Germans. This raises the possibility that the original patient with Alzheimer disease (Auguste D.), who had EOAD and lived in this same region of Germany, may also have had the PSEN2 N141I mutation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Chang-En</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Geriatric Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, University of Washington, Seattle, WA 98108, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marchani</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Nikisch</LastName><ForeName>Georg</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>Ulrich</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Nolte</LastName><ForeName>Dagmar</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Hertel</LastName><ForeName>Andreas</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Wijsman</LastName><ForeName>Ellen M</ForeName><Initials>EM</Initials></Author><Author ValidYN="Y"><LastName>Bird</LastName><ForeName>Thomas D</ForeName><Initials>TD</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005819">Genetic Markers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508861">PSEN2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053766">Presenilin-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Arch Neurol. 2011 Sep;68(9):1210-1, author reply 1211. doi: 10.1001/archneurol.2011.218.</RefSource><PMID Version="1">21911706</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000208" MajorTopicYN="Y">ethnology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004252" MajorTopicYN="N">DNA Mutational Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018703" MajorTopicYN="N">Founder Effect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005819" MajorTopicYN="N">Genetic Markers</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005820" MajorTopicYN="N">Genetic Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006239" MajorTopicYN="N">Haplotypes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040582" MajorTopicYN="N">Inheritance Patterns</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010375" MajorTopicYN="N">Pedigree</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053766" MajorTopicYN="N">Presenilin-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012426" MajorTopicYN="N" Type="Geographic">Russia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>1</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20457965</ArticleId><ArticleId IdType="mid">NIHMS258288</ArticleId><ArticleId IdType="pmc">PMC3016011</ArticleId><ArticleId IdType="doi">10.1001/archneurol.2010.87</ArticleId><ArticleId IdType="pii">67/5/631</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bird TD, Lampe TH, Nemens EJ, Miner GD, Sumi SM, Schellenberg GD. Familial Alzheimer&#x2019;s disease in American descendents of the Volga Germans: probable genetic founder effect. Ann Neurol. 1988;23(1):25&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">3345066</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy-Lahad E, Wijsman EM, Nemens E, et al. A familial Alzheimer&#x2019;s disease locus on chromosome 1. Science. 1995;269(5226):970&#x2013;973.</Citation><ArticleIdList><ArticleId IdType="pubmed">7638621</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy-Lahad E, Wasco W, Poorkaj P, et al. Candidate gene for the chromosome 1 familial Alzheimer&#x2019;s disease locus. Science. 1995;269(5226):973&#x2013;977.</Citation><ArticleIdList><ArticleId IdType="pubmed">7638622</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikisch G, Hertel A, Kiessling B, et al. Three-year follow-up of a patient with early-onset Alzheimer&#x2019;s disease with presenilin-2 N141I mutation case report and review of the literature. Eur J Med Res. 2008;13(12):579&#x2013;584.</Citation><ArticleIdList><ArticleId IdType="pubmed">19073399</ArticleId></ArticleIdList></Reference><Reference><Citation>Excoffier L, Slatkin M. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol. 1995;12(5):921&#x2013;927.</Citation><ArticleIdList><ArticleId IdType="pubmed">7476138</ArticleId></ArticleIdList></Reference><Reference><Citation>Huttley GA, Smith MW, Carrington M, O&#x2019;Brien SJ. A scan for linkage disequilibrium across the human genome. Genetics. 1999;152(4):1711&#x2013;1722.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1460700</ArticleId><ArticleId IdType="pubmed">10430595</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurer K. The history of Alois Alzheimer&#x2019;s first case Auguste D.: how did the eponym &#x201c;Alzheimer&#x2019;s Disease&#x201d; come into being? In: Jucker M, Beyreuther K, Haass C, Nitsch R, Christen Y, editors. Alzheimer: 100 Years and Beyond. Berlin, Germany: Springer-Verlag; 2006. pp. 13&#x2013;34.</Citation></Reference><Reference><Citation>Maurer K, Volk S, Gerbaldo H. Auguste D and Alzheimer&#x2019;s disease. Lancet. 1997;349(9064):1546&#x2013;1549.</Citation><ArticleIdList><ArticleId IdType="pubmed">9167474</ArticleId></ArticleIdList></Reference><Reference><Citation>Graeber MB, Kosel S, Grasbon-Frodi E, Moller HJ, Mehraein P. Histopathology and ApoE genotype of the first Alzheimer disease patient, Auguste D. Neurogenetics. 1998;1(3):223&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pubmed">10737127</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20460622</PMID><DateCompleted><Year>2010</Year><Month>05</Month><Day>12</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><Volume>303</Volume><Issue>18</Issue><PubDate><Year>2010</Year><Month>May</Month><Day>12</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Genome-wide analysis of genetic loci associated with Alzheimer disease.</ArticleTitle><Pagination><StartPage>1832</StartPage><EndPage>1840</EndPage><MedlinePgn>1832-40</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2010.574</ELocationID><Abstract><AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">Genome-wide association studies (GWAS) have recently identified CLU, PICALM, and CR1 as novel genes for late-onset Alzheimer disease (AD).</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To identify and strengthen additional loci associated with AD and confirm these in an independent sample and to examine the contribution of recently identified genes to AD risk prediction in a 3-stage analysis of new and previously published GWAS on more than 35,000 persons (8371 AD cases).</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">In stage 1, we identified strong genetic associations (P &lt; 10(-3)) in a sample of 3006 AD cases and 14,642 controls by combining new data from the population-based Cohorts for Heart and Aging Research in Genomic Epidemiology consortium (1367 AD cases [973 incident]) with previously reported results from the Translational Genomics Research Institute and the Mayo AD GWAS. We identified 2708 single-nucleotide polymorphisms (SNPs) with P &lt; 10(-3). In stage 2, we pooled results for these SNPs with the European AD Initiative (2032 cases and 5328 controls) to identify 38 SNPs (10 loci) with P &lt; 10(-5). In stage 3, we combined data for these 10 loci with data from the Genetic and Environmental Risk in AD consortium (3333 cases and 6995 controls) to identify 4 SNPs with P &lt; 1.7x10(-8). These 4 SNPs were replicated in an independent Spanish sample (1140 AD cases and 1209 controls). Genome-wide association analyses were completed in 2007-2008 and the meta-analyses and replication in 2009.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURE" NlmCategory="METHODS">Presence of Alzheimer disease.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Two loci were identified to have genome-wide significance for the first time: rs744373 near BIN1 (odds ratio [OR],1.13; 95% confidence interval [CI],1.06-1.21 per copy of the minor allele; P = 1.59x10(-11)) and rs597668 near EXOC3L2/BLOC1S3/MARK4 (OR, 1.18; 95% CI, 1.07-1.29; P = 6.45x10(-9)). Associations of these 2 loci plus the previously identified loci CLU and PICALM with AD were confirmed in the Spanish sample (P &lt; .05). However, although CLU and PICALM were confirmed to be associated with AD in this independent sample, they did not improve the ability of a model that included age, sex, and APOE to predict incident AD (improvement in area under the receiver operating characteristic curve from 0.847 to 0.849 in the Rotterdam Study and 0.702 to 0.705 in the Cardiovascular Health Study).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Two genetic loci for AD were found for the first time to reach genome-wide statistical significance. These findings were replicated in an independent population. Two recently reported associations were also confirmed. These loci did not improve AD risk prediction. While not clinically useful, they may implicate biological pathways useful for future research.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Seshadri</LastName><ForeName>Sudha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fitzpatrick</LastName><ForeName>Annette L</ForeName><Initials>AL</Initials></Author><Author ValidYN="Y"><LastName>Ikram</LastName><ForeName>M Arfan</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>DeStefano</LastName><ForeName>Anita L</ForeName><Initials>AL</Initials></Author><Author ValidYN="Y"><LastName>Gudnason</LastName><ForeName>Vilmundur</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Boada</LastName><ForeName>Merce</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Bis</LastName><ForeName>Joshua C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Albert V</ForeName><Initials>AV</Initials></Author><Author ValidYN="Y"><LastName>Carassquillo</LastName><ForeName>Minerva M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Lambert</LastName><ForeName>Jean Charles</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Harold</LastName><ForeName>Denise</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Schrijvers</LastName><ForeName>Elisabeth M C</ForeName><Initials>EM</Initials></Author><Author ValidYN="Y"><LastName>Ramirez-Lorca</LastName><ForeName>Reposo</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Debette</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Longstreth</LastName><ForeName>W T</ForeName><Initials>WT</Initials><Suffix>Jr</Suffix></Author><Author ValidYN="Y"><LastName>Janssens</LastName><ForeName>A Cecile J W</ForeName><Initials>AC</Initials></Author><Author ValidYN="Y"><LastName>Pankratz</LastName><ForeName>V Shane</ForeName><Initials>VS</Initials></Author><Author ValidYN="Y"><LastName>Dartigues</LastName><ForeName>Jean Fran&#xe7;ois</ForeName><Initials>JF</Initials></Author><Author ValidYN="Y"><LastName>Hollingworth</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Aspelund</LastName><ForeName>Thor</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Hernandez</LastName><ForeName>Isabel</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Beiser</LastName><ForeName>Alexa</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Kuller</LastName><ForeName>Lewis H</ForeName><Initials>LH</Initials></Author><Author ValidYN="Y"><LastName>Koudstaal</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials></Author><Author ValidYN="Y"><LastName>Tzourio</LastName><ForeName>Christophe</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Abraham</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Antunez</LastName><ForeName>Carmen</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Yangchun</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Rotter</LastName><ForeName>Jerome I</ForeName><Initials>JI</Initials></Author><Author ValidYN="Y"><LastName>Aulchenko</LastName><ForeName>Yurii S</ForeName><Initials>YS</Initials></Author><Author ValidYN="Y"><LastName>Harris</LastName><ForeName>Tamara B</ForeName><Initials>TB</Initials></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials></Author><Author ValidYN="Y"><LastName>Berr</LastName><ForeName>Claudine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Owen</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Lopez-Arrieta</LastName><ForeName>Jesus</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Varadarajan</LastName><ForeName>Badri N</ForeName><Initials>BN</Initials></Author><Author ValidYN="Y"><LastName>Becker</LastName><ForeName>James T</ForeName><Initials>JT</Initials></Author><Author ValidYN="Y"><LastName>Rivadeneira</LastName><ForeName>Fernando</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Nalls</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill R</ForeName><Initials>NR</Initials></Author><Author ValidYN="Y"><LastName>Campion</LastName><ForeName>Dominique</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Auerbach</LastName><ForeName>Sanford</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Rice</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Hofman</LastName><ForeName>Albert</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Jonsson</LastName><ForeName>Palmi V</ForeName><Initials>PV</Initials></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Helena</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Lathrop</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Mosley</LastName><ForeName>Thomas H</ForeName><Initials>TH</Initials></Author><Author ValidYN="Y"><LastName>Au</LastName><ForeName>Rhoda</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Psaty</LastName><ForeName>Bruce M</ForeName><Initials>BM</Initials></Author><Author ValidYN="Y"><LastName>Uitterlinden</LastName><ForeName>Andre G</ForeName><Initials>AG</Initials></Author><Author ValidYN="Y"><LastName>Farrer</LastName><ForeName>Lindsay A</ForeName><Initials>LA</Initials></Author><Author ValidYN="Y"><LastName>Lumley</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Ruiz</LastName><ForeName>Agustin</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Julie</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Amouyel</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Younkin</LastName><ForeName>Steve G</ForeName><Initials>SG</Initials></Author><Author ValidYN="Y"><LastName>Wolf</LastName><ForeName>Philip A</ForeName><Initials>PA</Initials></Author><Author ValidYN="Y"><LastName>Launer</LastName><ForeName>Lenore J</ForeName><Initials>LJ</Initials></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials></Author><Author ValidYN="Y"><LastName>van Duijn</LastName><ForeName>Cornelia M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Breteler</LastName><ForeName>Monique M B</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><CollectiveName>CHARGE Consortium</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>GERAD1 Consortium</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>EADI1 Consortium</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>N01-HC-85081</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC025195</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG03991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG08122</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG031287</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG16574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N02-HL-6-4278</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-HC-25195</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC085086</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG05681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS017950</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG15928</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>N01 AG012100</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG016495</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC085081</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015928</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL080295</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC075150</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC015103</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC085083</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0300429</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC085085</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG033193</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL087652</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-HC-85086</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS17950</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>Z01 AG000950</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DK033651</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC085082</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-HC-85082</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK063491</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC085080</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG008122</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC-55222</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG05133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>M01RR00425</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG033193</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC055222</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AG013846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-HC-85083</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-HC-75150</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-HC-85080</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG06576</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>M01 RR000425</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC085084</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG020098</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-AG-12100</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG25711</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG18023</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG025259</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DK063491</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003949</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG16495</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-HC-85079</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG21886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL064278</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG20098</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC085079</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG025259</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC045133</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG017216</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC035129</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG018023</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG006786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG17216</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG03949</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG031287</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2010 May 12;303(18):1864-5. doi: 10.1001/jama.2010.609.</RefSource><PMID Version="1">20460629</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2010 Aug 25;304(8):858; author reply 858. doi: 10.1001/jama.2010.1172.</RefSource><PMID Version="1">20736468</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Arch Neurol. 2010 Oct;67(10):1267-8. doi: 10.1001/archneurol.2010.251.</RefSource><PMID Version="1">20937956</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056426" MajorTopicYN="Y">Genetic Loci</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="Y">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Olson</LastName><ForeName>Jean</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kronmal</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Robbins</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fried</LastName><ForeName>Linda P</ForeName><Initials>LP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burke</LastName><ForeName>Gregory</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuller</LastName><ForeName>Lewis H</ForeName><Initials>LH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tracy</LastName><ForeName>Russell</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gottdiener</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prineas</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Becker</LastName><ForeName>James T</ForeName><Initials>JT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Enright</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klein</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Leary</LastName><ForeName>Daniel H</ForeName><Initials>DH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Furberg</LastName><ForeName>Curt</ForeName><Initials>C</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>5</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>5</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>5</Month><Day>13</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>5</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20460622</ArticleId><ArticleId IdType="mid">NIHMS208236</ArticleId><ArticleId IdType="pmc">PMC2989531</ArticleId><ArticleId IdType="doi">10.1001/jama.2010.574</ArticleId><ArticleId IdType="pii">303/18/1832</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Seshadri S, Wolf PA. Lifetime risk of stroke and dementia: current concepts, and estimates from the Framingham Study. Lancet Neurol. 2007;6(12):1106&#x2013;1114.</Citation><ArticleIdList><ArticleId IdType="pubmed">18031707</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatz M, Reynolds CA, Fratiglioni L, et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry. 2006;63(2):168&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">16461860</ArticleId></ArticleIdList></Reference><Reference><Citation>Ertekin-Taner N. Genetics of Alzheimer's disease: a centennial review. Neurol Clin. 2007;25(3):611&#x2013;667.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2735049</ArticleId><ArticleId IdType="pubmed">17659183</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Webster JA, Myers AJ, et al. GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron. 2007;54(5):713&#x2013;720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2587162</ArticleId><ArticleId IdType="pubmed">17553421</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrasquillo MM, Zou F, Pankratz VS, et al. Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease. Nat.Genet. 2009;41(2):192&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2873177</ArticleId><ArticleId IdType="pubmed">19136949</ArticleId></ArticleIdList></Reference><Reference><Citation>Poduslo SE, Huang R, Huang J, Smith S. Genome screen of late-onset Alzheimer's extended pedigrees identifies TRPC4AP by haplotype analysis. Am.J.Med.Genet B Neuropsychiatr.Genet. 2009;150B(1):50&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">18449908</ArticleId></ArticleIdList></Reference><Reference><Citation>Beecham GW, Martin ER, Li YJ, et al. Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease. Am.J.Hum.Genet. 2009;84(1):35&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2668056</ArticleId><ArticleId IdType="pubmed">19118814</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L, Lange C, Mullin K, et al. Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. Am.J.Hum.Genet. 2008;83(5):623&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2668052</ArticleId><ArticleId IdType="pubmed">18976728</ArticleId></ArticleIdList></Reference><Reference><Citation>Myers A, Holmans P, Marshall H, et al. Susceptibility locus for Alzheimer's disease on chromosome 10. Science. 2000;290(5500):2304&#x2013;2305.</Citation><ArticleIdList><ArticleId IdType="pubmed">11125144</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Wetten S, Li L, et al. Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch.Neurol. 2008;65(1):45&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">17998437</ArticleId></ArticleIdList></Reference><Reference><Citation>Coon KD, Myers AJ, Craig DW, et al. A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J Clin Psychiatry. 2007;68(4):613&#x2013;618.</Citation><ArticleIdList><ArticleId IdType="pubmed">17474819</ArticleId></ArticleIdList></Reference><Reference><Citation>Feulner TM, Laws SM, Friedrich P, et al. Examination of the current top candidate genes for AD in a genome-wide association study. Mol.Psychiatry. 2009</Citation><ArticleIdList><ArticleId IdType="pubmed">19125160</ArticleId></ArticleIdList></Reference><Reference><Citation>Harold D, Abraham R, Hollingworth P, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat.Genet. 2009;41(10):1088&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845877</ArticleId><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Heath S, Even G, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat.Genet. 2009;41(10):1094&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>Psaty BM, O'Donnell CJ, Gudnason V, et al. Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium: Design of prospective meta-analyses of genome-wide association studies from five cohorts. Circ Cardiovasc Genet. 2009;2:73&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2875693</ArticleId><ArticleId IdType="pubmed">20031568</ArticleId></ArticleIdList></Reference><Reference><Citation>Association AP. Diagnostic and statistical manual of mental disorders (DSM-IV) Washington, D.C: American Psychiatric Association; 1994.</Citation></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Pe'er I, Yelensky R, Altshuler D, Daly MJ. Estimation of the multiple testing burden for genomewide association studies of nearly all common variants. Genet Epidemiol. 2008;32(4):381&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pubmed">18348202</ArticleId></ArticleIdList></Reference><Reference><Citation>Antunez C, Boada M, Lopez-Arrieta J, et al. GOLPH2 Gene Markers are Not Associated with Alzheimer's Disease in a Sample of the Spanish Population. J Alzheimers Dis. 2009 ahead of print.</Citation><ArticleIdList><ArticleId IdType="pubmed">19749441</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez-Lorca R, Boada M, Saez ME, et al. GAB2 gene does not modify the risk of Alzheimer's disease in Spanish APOE 4 carriers. J Nutr Health Aging. 2009;13(3):214&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pubmed">19262956</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet. 2007;39(1):17&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">17192785</ArticleId></ArticleIdList></Reference><Reference><Citation>Janssens AC, van Duijn CM. Genome-based prediction of common diseases: methodological considerations for future research. Genome Med. 2009;1(2):20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2664953</ArticleId><ArticleId IdType="pubmed">19341491</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler-Reya R, Sakamuro D, Zhang J, Duhadaway J, Prendergast GC. Structural analysis of the human BIN1 gene. Evidence for tissue-specific transcriptional regulation and alternate RNA splicing. J.Biol.Chem. 1997;272(50):31453&#x2013;31458.</Citation><ArticleIdList><ArticleId IdType="pubmed">9395479</ArticleId></ArticleIdList></Reference><Reference><Citation>Wigge P, Kohler K, Vallis Y, et al. Amphiphysin heterodimers: potential role in clathrin-mediated endocytosis. Mol.Biol.Cell. 1997;8(10):2003&#x2013;2015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC25662</ArticleId><ArticleId IdType="pubmed">9348539</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly BL, Ferreira A. Beta-amyloid disrupted synaptic vesicle endocytosis in cultured hippocampal neurons. Neuroscience. 2007;147(1):60&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1993833</ArticleId><ArticleId IdType="pubmed">17499934</ArticleId></ArticleIdList></Reference><Reference><Citation>Di PG, Sankaranarayanan S, Wenk MR, et al. Decreased synaptic vesicle recycling efficiency and cognitive deficits in amphiphysin 1 knockout mice. Neuron. 2002;33(5):789&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pubmed">11879655</ArticleId></ArticleIdList></Reference><Reference><Citation>English JA, Dicker P, Focking M, Dunn MJ, Cotter DR. 2-D DIGE analysis implicates cytoskeletal abnormalities in psychiatric disease. Proteomics. 2009;9(12):3368&#x2013;3382.</Citation><ArticleIdList><ArticleId IdType="pubmed">19562803</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S, Liu T, Li S, et al. Comparative proteomic analysis of brains of naturally aging mice. Neuroscience. 2008;154(3):1107&#x2013;1120.</Citation><ArticleIdList><ArticleId IdType="pubmed">18495355</ArticleId></ArticleIdList></Reference><Reference><Citation>Poduslo SE, Yin X. A new locus on chromosome 19 linked with late-onset Alzheimer's disease. Neuroreport. 2001;12(17):3759&#x2013;3761.</Citation><ArticleIdList><ArticleId IdType="pubmed">11726789</ArticleId></ArticleIdList></Reference><Reference><Citation>Starcevic M, Dell'Angelica EC. Identification of snapin and three novel proteins (BLOS1, BLOS2, and BLOS3/reduced pigmentation) as subunits of biogenesis of lysosome-related organelles complex-1 (BLOC-1) J.Biol.Chem. 2004;279(27):28393&#x2013;28401.</Citation><ArticleIdList><ArticleId IdType="pubmed">15102850</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris DW, Murphy K, Kenny N, et al. Dysbindin (DTNBP1) and the biogenesis of lysosome-related organelles complex 1 (BLOC-1): main and epistatic gene effects are potential contributors to schizophrenia susceptibility. Biol.Psychiatry. 2008;63(1):24&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">17618940</ArticleId></ArticleIdList></Reference><Reference><Citation>Moroni RF, De BS, Colapietro P, Larizza L, Beghini A. Distinct expression pattern of microtubule-associated protein/microtubule affinity-regulating kinase 4 in differentiated neurons. Neuroscience. 2006;143(1):83&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">16973293</ArticleId></ArticleIdList></Reference><Reference><Citation>Trinczek B, Brajenovic M, Ebneth A, Drewes G. MARK4 is a novel microtubule-associated proteins/microtubule affinity-regulating kinase that binds to the cellular microtubule network and to centrosomes. J.Biol.Chem. 2004;279(7):5915&#x2013;5923.</Citation><ArticleIdList><ArticleId IdType="pubmed">14594945</ArticleId></ArticleIdList></Reference><Reference><Citation>Purcell SM, Wray NR, Stone JL, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature. 2009;460(7256):748&#x2013;752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3912837</ArticleId><ArticleId IdType="pubmed">19571811</ArticleId></ArticleIdList></Reference><Reference><Citation>Janssens AC, van Duijn CM. Genome-based prediction of common diseases: advances and prospects. Hum Mol Genet. 2008;17(R2):R166&#x2013;R173.</Citation><ArticleIdList><ArticleId IdType="pubmed">18852206</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20463236</PMID><DateCompleted><Year>2010</Year><Month>06</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>19</Issue><PubDate><Year>2010</Year><Month>May</Month><Day>12</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Acute gamma-secretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from amyloid-beta production to alternative APP fragments without amyloid-beta rebound.</ArticleTitle><Pagination><StartPage>6743</StartPage><EndPage>6750</EndPage><MedlinePgn>6743-50</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.1381-10.2010</ELocationID><Abstract><AbstractText>The accumulation of amyloid beta (Abeta) in Alzheimer's disease is caused by an imbalance of production and clearance, which leads to increased soluble Abeta species and extracellular plaque formation in the brain. Multiple Abeta-lowering therapies are currently in development: an important goal is to characterize the molecular mechanisms of action and effects on physiological processing of Abeta, as well as other amyloid precursor protein (APP) metabolites, in models which approximate human Abeta physiology. To this end, we report the translation of the human in vivo stable-isotope-labeling kinetics (SILK) method to a rhesus monkey cisterna magna ported (CMP) nonhuman primate model, and use the model to test the mechanisms of action of a gamma-secretase inhibitor (GSI). A major concern of inhibiting the enzymes which produce Abeta (beta- and gamma-secretase) is that precursors of Abeta may accumulate and cause a rapid increase in Abeta production when enzyme inhibition discontinues. In this study, the GSI MK-0752 was administered to conscious CMP rhesus monkeys in conjunction with in vivo stable-isotope-labeling, and dose-dependently reduced newly generated CNS Abeta. In contrast to systemic Abeta metabolism, CNS Abeta production was not increased after the GSI was cleared. These results indicate that most of the CNS APP was metabolized to products other than Abeta, including C-terminal truncated forms of Abeta: 1-14, 1-15 and 1-16; this demonstrates an alternative degradation pathway for CNS amyloid precursor protein during gamma-secretase inhibition.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cook</LastName><ForeName>Jacquelynn J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Imaging, Merck Research Laboratories, West Point, Pennsylvania 19486, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wildsmith</LastName><ForeName>Kristin R</ForeName><Initials>KR</Initials></Author><Author ValidYN="Y"><LastName>Gilberto</LastName><ForeName>David B</ForeName><Initials>DB</Initials></Author><Author ValidYN="Y"><LastName>Holahan</LastName><ForeName>Marie A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Kinney</LastName><ForeName>Gene G</ForeName><Initials>GG</Initials></Author><Author ValidYN="Y"><LastName>Mathers</LastName><ForeName>Parker D</ForeName><Initials>PD</Initials></Author><Author ValidYN="Y"><LastName>Michener</LastName><ForeName>Maria S</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>Eric A</ForeName><Initials>EA</Initials></Author><Author ValidYN="Y"><LastName>Shearman</LastName><ForeName>Mark S</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Simon</LastName><ForeName>Adam J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jennifer X</ForeName><Initials>JX</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Guoxin</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Yarasheski</LastName><ForeName>Kevin E</ForeName><Initials>KE</Initials></Author><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall J</ForeName><Initials>RJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 NS057105</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG030946</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 AG027091</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41 RR000954</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>L30 AG024455</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30-RR000954</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS065667</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-NS065667</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>M01 RR000036</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002250">Carbon Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002250" MajorTopicYN="N">Carbon Radioisotopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007553" MajorTopicYN="N">Isotope Labeling</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008253" MajorTopicYN="N">Macaca mulatta</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D023421" MajorTopicYN="N">Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013045" MajorTopicYN="N">Species Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>5</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>5</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>11</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20463236</ArticleId><ArticleId IdType="mid">NIHMS204164</ArticleId><ArticleId IdType="pmc">PMC2913973</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.1381-10.2010</ArticleId><ArticleId IdType="pii">30/19/6743</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bateman RJ, Klunk WE. Measuring target effect of proposed disease-modifying therapies in Alzheimer's disease. Neurotherapeutics. 2008;5:381&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2588423</ArticleId><ArticleId IdType="pubmed">18625449</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med. 2006;12:856&#x2013;861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2983090</ArticleId><ArticleId IdType="pubmed">16799555</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Wen G, Morris JC, Holtzman DM. Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology. 2007a;68:666&#x2013;669.</Citation><ArticleIdList><ArticleId IdType="pubmed">17325273</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Munsell LY, Chen X, Holtzman DM, Yarasheski KE. Stable isotope labeling tandem mass spectrometry (SILT) to quantify protein production and clearance rates. J Am Soc Mass Spectrom. 2007b;18:997&#x2013;1006.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2040126</ArticleId><ArticleId IdType="pubmed">17383190</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, Sigurdson WC, Yarasheski KE, Friedrich SW, Demattos RB, May PC, Paul SM, Holtzman DM. A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol. 2009;66:48&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730994</ArticleId><ArticleId IdType="pubmed">19360898</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet. 2006;368:387&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">16876668</ArticleId></ArticleIdList></Reference><Reference><Citation>Burton CR, Meredith JE, Barten DM, Goldstein ME, Krause CM, Kieras CJ, Sisk L, Iben LG, Polson C, Thompson MW, Lin XA, Corsa J, Fiedler T, Pierdomenico M, Cao Y, Roach AH, Cantone JL, Ford MJ, Drexler DM, Olson RE, et al. The amyloid-beta rise and gamma-secretase inhibitor potency depend on the level of substrate expression. J Biol Chem. 2008;283:22992&#x2013;23003.</Citation><ArticleIdList><ArticleId IdType="pubmed">18574238</ArticleId></ArticleIdList></Reference><Reference><Citation>Duff K, Suleman F. Transgenic mouse models of Alzheimer's disease: how useful have they been for therapeutic development? Brief Funct Genomic Proteomic. 2004;3:47&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">15163359</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilberto DB, Zeoli AH, Szczerba PJ, Gehret JR, Holahan MA, Sitko GR, Johnson CA, Cook JJ, Motzel SL. An alternative method of chronic cerebrospinal fluid collection via the cisterna magna in conscious rhesus monkeys. Contemp Top Lab Anim Sci. 2003;42:53&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">12906404</ArticleId></ArticleIdList></Reference><Reference><Citation>Golde TE. The Abeta hypothesis: leading us to rationally-designed therapeutic strategies for the treatment or prevention of Alzheimer disease. Brain Pathol. 2005;15:84&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095797</ArticleId><ArticleId IdType="pubmed">15779241</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, M&#xfc;ller-Tillmanns B, Lemke U, Henke K, Moritz E, Garcia E, Wollmer MA, Umbricht D, de Quervain DJ, Hofmann M, Maddalena A, Papassotiropoulos A, Nitsch RM. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron. 2003;38:547&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pubmed">12765607</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanz TA, Hosley JD, Adams WJ, Merchant KM. Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-l-alaninamide (LY-411575) J Pharmacol Exp Ther. 2004;309:49&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">14718585</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanz TA, Karmilowicz MJ, Wood KM, Pozdnyakov N, Du P, Piotrowski MA, Brown TM, Nolan CE, Richter KE, Finley JE, Fei Q, Ebbinghaus CF, Chen YL, Spracklin DK, Tate B, Geoghegan KF, Lau LF, Auperin DD, Schachter JB. Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139. J Pharmacol Exp Ther. 2006;319:924&#x2013;933.</Citation><ArticleIdList><ArticleId IdType="pubmed">16920992</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemere CA, Beierschmitt A, Iglesias M, Spooner ET, Bloom JK, Leverone JF, Zheng JB, Seabrook TJ, Louard D, Li D, Selkoe DJ, Palmour RM, Ervin FR. Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. Am J Pathol. 2004;165:283&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1618542</ArticleId><ArticleId IdType="pubmed">15215183</ArticleId></ArticleIdList></Reference><Reference><Citation>Maillard I, Adler SH, Pear WS. Notch and the immune system. Immunity. 2003;19:781&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">14670296</ArticleId></ArticleIdList></Reference><Reference><Citation>Michener MS, Holahan MA, Gilberto DB, Sitko GR, Shearman MS, Harrison T, Lewis H, Sankaranarayanan S, Crouthamel M, Wu G, Pietrak BL, Simon AJ, Cook JJ. P2-069: nonhuman primate model for prediction of human A&#x3b2; effects. Targeting &#x3b3;-secretase: effects of enzyme inhibition vs modulation of cleavage specificity on CSF and plasma A&#x3b2; in conscious rhesus monkeys. Alzheimers Dement. 2006;2(Suppl):S252&#x2013;S253.</Citation></Reference><Reference><Citation>Nantermet PG, Rajapakse HA, Stanton MG, Stauffer SR, Barrow JC, Gregro AR, Moore KP, Steinbeiser MA, Swestock J, Selnick HG, Graham SL, McGaughey GB, Colussi D, Lai MT, Sankaranarayanan S, Simon AJ, Munshi S, Cook JJ, Holahan MA, Michener MS, et al. Evolution of tertiary carbinamine BACE-1 inhibitors: Abeta reduction in rhesus CSF upon oral dosing. ChemMedChem. 2009;4:37&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">19085994</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E, Price E, Brinkmalm G, Stiteler M, Olsson M, Persson R, Westman-Brinkmalm A, Zetterberg H, Simon AJ, Blennow K. A novel pathway for amyloid precursor protein processing. Neurobiol Aging. 2009 doi: 10.1016/j.neurobiolaging.2009.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2009.06.002</ArticleId><ArticleId IdType="pubmed">19604603</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen LB, Stone JA, Plump A, Yuan J, Harrison T, Flynn M, Dallob A, Matthews C, Stevenson D, Schmidt D, Palmieri T, Leibowitz M, Jhee S, Ereshefsky L, Salomon R, Winchell G, Shearman MS, Murphy MG, Gottesdiener KM. O4-03-02: the gamma secretase inhibitor MK-0752 acutely and significantly reduces CSF A&#x3b2;40 concentrations in humans. Alzheimers Dement. 2006;2(Suppl):S79&#x2013;S79.</Citation></Reference><Reference><Citation>Sankaranarayanan S, Holahan MA, Colussi D, Crouthamel MC, Devanarayan V, Ellis J, Espeseth A, Gates AT, Graham SL, Gregro AR, Hazuda D, Hochman JH, Holloway K, Jin L, Kahana J, Lai MT, Lineberger J, McGaughey G, Moore KP, Nantermet P, et al. First demonstration of cerebrospinal fluid and plasma A beta lowering with oral administration of a beta-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates. J Pharmacol Exp Ther. 2009;328:131&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">18854490</ArticleId></ArticleIdList></Reference><Reference><Citation>Searfoss GH, Jordan WH, Calligaro DO, Galbreath EJ, Schirtzinger LM, Berridge BR, Gao H, Higgins MA, May PC, Ryan TP. Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional gamma-secretase inhibitor. J Biol Chem. 2003;278:46107&#x2013;46116.</Citation><ArticleIdList><ArticleId IdType="pubmed">12949072</ArticleId></ArticleIdList></Reference><Reference><Citation>Siemers E, Skinner M, Dean RA, Gonzales C, Satterwhite J, Farlow M, Ness D, May PC. Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. Clin Neuropharmacol. 2005;28:126&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">15965311</ArticleId></ArticleIdList></Reference><Reference><Citation>Siemers ER, Quinn JF, Kaye J, Farlow MR, Porsteinsson A, Tariot P, Zoulnouni P, Galvin JE, Holtzman DM, Knopman DS, Satterwhite J, Gonzales C, Dean RA, May PC. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology. 2006;66:602&#x2013;604.</Citation><ArticleIdList><ArticleId IdType="pubmed">16505324</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanger BZ, Datar R, Murtaugh LC, Melton DA. Direct regulation of intestinal fate by Notch. Proc Natl Acad Sci U S A. 2005;102:12443&#x2013;12448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1194941</ArticleId><ArticleId IdType="pubmed">16107537</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner H, Fluhrer R, Haass C. Intramembrane proteolysis by gamma-secretase. J Biol Chem. 2008;283:29627&#x2013;29631.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2662049</ArticleId><ArticleId IdType="pubmed">18650432</ArticleId></ArticleIdList></Reference><Reference><Citation>Struble RG, Price DL, Jr, Cork LC, Price DL. Senile plaques in cortex of aged normal monkeys. Brain Res. 1985;361:267&#x2013;275.</Citation><ArticleIdList><ArticleId IdType="pubmed">4084799</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomita T. Secretase inhibitors and modulators for Alzheimer's disease treatment. Expert Rev Neurother. 2009;9:661&#x2013;679.</Citation><ArticleIdList><ArticleId IdType="pubmed">19402777</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R. BACE1: the beta-secretase enzyme in Alzheimer's disease. J Mol Neurosci. 2004;23:105&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pubmed">15126696</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe MS. Selective amyloid-beta lowering agents. BMC Neurosci 9 Suppl. 2008a;2:S4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2604888</ArticleId><ArticleId IdType="pubmed">19090992</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe MS. Inhibition and modulation of gamma-secretase for Alzheimer's disease. Neurotherapeutics. 2008b;5:391&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2572079</ArticleId><ArticleId IdType="pubmed">18625450</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe RR, Chinkes DL, Wolfe RR. Ed 2. Hoboken, NJ: Wiley; 2005. Isotope tracers in metabolic research: principles and practice of kinetic analysis.</Citation></Reference><Reference><Citation>Wong GT, Manfra D, Poulet FM, Zhang Q, Josien H, Bara T, Engstrom L, Pinzon-Ortiz M, Fine JS, Lee HJ, Zhang L, Higgins GA, Parker EM. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem. 2004;279:12876&#x2013;12882.</Citation><ArticleIdList><ArticleId IdType="pubmed">14709552</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan P, Hu X, Song H, Yin K, Bateman RJ, Cirrito JR, Xiao Q, Hsu FF, Turk JW, Xu J, Hsu CY, Holtzman DM, Lee JM. Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ. J Biol Chem. 2006;281:24566&#x2013;24574.</Citation><ArticleIdList><ArticleId IdType="pubmed">16787929</ArticleId></ArticleIdList></Reference><Reference><Citation>Yarasheski KE, Smith K, Rennie MJ, Bier DM. Measurement of muscle protein fractional synthetic rate by capillary gas chromatography/combustion isotope ratio mass spectrometry. Biol Mass Spectrom. 1992;21:486&#x2013;490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4003887</ArticleId><ArticleId IdType="pubmed">1420371</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20463288</PMID><DateCompleted><Year>2010</Year><Month>07</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>24</Issue><PubDate><Year>2010</Year><Month>Jun</Month><Day>15</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Longitudinal fMRI in elderly reveals loss of hippocampal activation with clinical decline.</ArticleTitle><Pagination><StartPage>1969</StartPage><EndPage>1976</EndPage><MedlinePgn>1969-76</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0b013e3181e3966e</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Previous cross-sectional fMRI studies in subjects with prodromal Alzheimer disease (AD) have reported variable results, ranging from hypoactivation, similar to patients with AD, to paradoxically increased activation or hyperactivation compared to cognitively normal older individuals. We have hypothesized that subjects in early phases of prodromal AD may experience a period of hippocampal hyperactivation, followed by loss of hippocampal activation as the disease progresses.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We studied 51 older individuals without dementia (Clinical Dementia Rating [CDR] at baseline of 0, n = 21, and 0.5, n = 30) with longitudinal clinical and neuropsychological assessments, as well as fMRI during a face-name associative memory paradigm. Whole brain and region-of-interest analyses were applied to the longitudinal fMRI data.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Subjects classified as CDR 0 at baseline showed no difference in fMRI activity over 2 years, whereas those who were CDR 0.5 at baseline demonstrated a decrease in fMRI activity in the right hippocampus (p &lt; 0.001). Dividing the subjects on the basis of their clinical and neuropsychological change over the 2 years, we found that subjects with more rapid decline demonstrated both the highest hippocampal activation at baseline, and the greatest loss of hippocampal activation. These findings remained significant after accounting for age, hippocampal volume, and APOE epsilon4 carrier status.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Clinical decline is associated with loss of hippocampal activation in older subjects. Longitudinal fMRI provides a reliable indicator of brain activation over time, and may prove useful in identifying functional brain changes associated with cognitive decline on the trajectory toward clinical Alzheimer disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>O'Brien</LastName><ForeName>J L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Keefe</LastName><ForeName>K M</ForeName><Initials>KM</Initials></Author><Author ValidYN="Y"><LastName>LaViolette</LastName><ForeName>P S</ForeName><Initials>PS</Initials></Author><Author ValidYN="Y"><LastName>DeLuca</LastName><ForeName>A N</ForeName><Initials>AN</Initials></Author><Author ValidYN="Y"><LastName>Blacker</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Dickerson</LastName><ForeName>B C</ForeName><Initials>BC</Initials></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>R A</ForeName><Initials>RA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG029411</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134-25</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 MH017119</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG29411</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032984</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NS062028</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5 P50 AG005134-25</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R01AG029411-01</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG027435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG-027435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>2 R01 AG007370-15</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>4 R37 MH060009-09</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>05</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2010 Jun 15;74(24):1940-1. doi: 10.1212/WNL.0b013e3181e533f8.</RefSource><PMID Version="1">20484684</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>5</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>5</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>7</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>6</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20463288</ArticleId><ArticleId IdType="pmc">PMC2905893</ArticleId><ArticleId IdType="doi">10.1212/WNL.0b013e3181e3966e</ArticleId><ArticleId IdType="pii">WNL.0b013e3181e3966e</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Petrella JR, Prince SE, Wang L, Hellegers C, Doraiswamy PM. Prognostic value of posteromedial cortex deactivation in mild cognitive impairment. PLoS ONE 2007;2:e1104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2040216</ArticleId><ArticleId IdType="pubmed">17971867</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller SL, Fenstermacher E, Bates J, Blacker D, Sperling RA, Dickerson BC. Hippocampal activation in adults with mild cognitive impairment predicts subsequent cognitive decline. J Neurol Neurosurg Psychiatry 2008;79:630&#x2013;635.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2683145</ArticleId><ArticleId IdType="pubmed">17846109</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Salat DH, Bates JF, et al. Medial temporal lobe function and structure in mild cognitive impairment. Ann Neurol 2004;56:27&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4335689</ArticleId><ArticleId IdType="pubmed">15236399</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, Perera GM, DeLaPaz R, Mayeux R, Stern Y. Differential regional dysfunction of the hippocampal formation among elderly with memory decline and Alzheimer's disease. Ann Neurol 1999;45:466&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pubmed">10211471</ArticleId></ArticleIdList></Reference><Reference><Citation>Machulda MM, Ward HA, Borowski B, et al. Comparison of memory fMRI response among normal, MCI, and Alzheimer's patients. Neurology 2003;61:500&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2744465</ArticleId><ArticleId IdType="pubmed">12939424</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson SC, Schmitz TW, Trivedi MA, et al. The influence of Alzheimer disease family history and apolipoprotein E epsilon4 on mesial temporal lobe activation. J Neurosci 2006;26:6069&#x2013;6076.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2684824</ArticleId><ArticleId IdType="pubmed">16738250</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrella JR, Krishnan S, Slavin MJ, Tran TT, Murty L, Doraiswamy PM. Mild cognitive impairment: evaluation with 4-T functional MR imaging. Radiology 2006;240:177&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pubmed">16684919</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamalainen A, Pihlajamaki M, Tanila H, et al. Increased fMRI responses during encoding in mild cognitive impairment. Neurobiol Aging 2007;28:1889&#x2013;1903.</Citation><ArticleIdList><ArticleId IdType="pubmed">16997428</ArticleId></ArticleIdList></Reference><Reference><Citation>Kircher TT, Weis S, Freymann K, et al. Hippocampal activation in patients with mild cognitive impairment is necessary for successful memory encoding. J Neurol Neurosurg Psychiatry 2007;78:812&#x2013;818.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2117738</ArticleId><ArticleId IdType="pubmed">17287238</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Sperling RA. Functional abnormalities of the medial temporal lobe memory system in mild cognitive impairment and Alzheimer's disease: insights from functional MRI studies. Neuropsychologia 2008;46:1624&#x2013;1635.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2760288</ArticleId><ArticleId IdType="pubmed">18206188</ArticleId></ArticleIdList></Reference><Reference><Citation>Bookheimer SY, Strojwas MH, Cohen MS, et al. Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med 2000;343:450&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2831477</ArticleId><ArticleId IdType="pubmed">10944562</ArticleId></ArticleIdList></Reference><Reference><Citation>Bondi MW, Houston WS, Eyler LT, Brown GG. fMRI evidence of compensatory mechanisms in older adults at genetic risk for Alzheimer disease. Neurology 2005;64:501&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1761695</ArticleId><ArticleId IdType="pubmed">15699382</ArticleId></ArticleIdList></Reference><Reference><Citation>Filippini N, Zarei M, Beckmann CF, et al. Regional atrophy of transcallosal prefrontal connections in cognitively normal APOE epsilon4 carriers. J Magn Reson Imaging 2009;29:1021&#x2013;1026.</Citation><ArticleIdList><ArticleId IdType="pubmed">19388128</ArticleId></ArticleIdList></Reference><Reference><Citation>Grundman M, Petersen RC, Ferris SH, et al. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol 2004;61:59&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">14732621</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004;256:183&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">15324362</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Bates J, Cocchiarella A, Schacter D, Rosen B, Albert M. Encoding novel face-name associations: a functional MRI study. Hum Brain Mapp 2001;14:129&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871827</ArticleId><ArticleId IdType="pubmed">11559958</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Greve D, Dale A, et al. fMRI detection of pharmacologically induced memory impairment. Proc Natl Acad Sci USA 2002;99:455&#x2013;460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC117581</ArticleId><ArticleId IdType="pubmed">11756667</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Bates JF, Chua EF, et al. fMRI studies of associative encoding in young and elderly controls and mild Alzheimer's disease. J Neurol Neurosurg Psychiatry 2003;74:44&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1738201</ArticleId><ArticleId IdType="pubmed">12486265</ArticleId></ArticleIdList></Reference><Reference><Citation>Daly E, Zaitchik D, Copeland M, Schmahmann J, Gunther J, Albert M. Predicting conversion to Alzheimer disease using standardized clinical information. Arch Neurol 2000;57:675&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pubmed">10815133</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Salat D, Greve D, et al. Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology 2005;65:404&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4335677</ArticleId><ArticleId IdType="pubmed">16087905</ArticleId></ArticleIdList></Reference><Reference><Citation>Celone KA, Calhoun VD, Dickerson BC, et al. Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: an independent component analysis. J Neurosci 2006;26:10222&#x2013;10231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674636</ArticleId><ArticleId IdType="pubmed">17021177</ArticleId></ArticleIdList></Reference><Reference><Citation>Heun R, Freymann K, Erb M, et al. Mild cognitive impairment (MCI) and actual retrieval performance affect cerebral activation in the elderly. Neurobiol Aging 2007;28:404&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pubmed">16530885</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassett SS, Yousem DM, Cristinzio C, et al. Familial risk for Alzheimer's disease alters fMRI activation patterns. Brain 2006;129:1229&#x2013;1239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2744898</ArticleId><ArticleId IdType="pubmed">16627465</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto M, Masliah E. Cycles of aberrant synaptic sprouting and neurodegeneration in Alzheimer's and dementia with Lewy bodies. Neurochem Res 2003;28:1743&#x2013;1756.</Citation><ArticleIdList><ArticleId IdType="pubmed">14584828</ArticleId></ArticleIdList></Reference><Reference><Citation>Hynd MR, Scott HL, Dodd PR. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochem Int 2004;45:583&#x2013;595.</Citation><ArticleIdList><ArticleId IdType="pubmed">15234100</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Chin J, Roberson ED, et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 2007;55:697&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055171</ArticleId><ArticleId IdType="pubmed">17785178</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher AS, Podraza KM, Bangen KJ, et al. Cerebral perfusion and oxygenation differences in Alzheimer's disease risk. Neurobiol Aging 2009;30:1737&#x2013;1748.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2746874</ArticleId><ArticleId IdType="pubmed">18325636</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci 2004;5:347&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pubmed">15100718</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Kluth JT, Madison CM, et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 2009;132:1310&#x2013;1323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677792</ArticleId><ArticleId IdType="pubmed">19042931</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr., Lowe VJ, Weigand SD, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009;132:1355&#x2013;1365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677798</ArticleId><ArticleId IdType="pubmed">19339253</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrella JR, Prince SE, Krishnan S, Husn H, Kelley L, Doraiswamy PM. Effects of donepezil on cortical activation in mild cognitive impairment: a pilot double-blind placebo-controlled trial using functional MR imaging. AJNR Am J Neuroradiol 2009;30:411&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7051379</ArticleId><ArticleId IdType="pubmed">19001543</ArticleId></ArticleIdList></Reference><Reference><Citation>Clement F, Belleville S. Test-retest reliability of fMRI verbal episodic memory paradigms in healthy older adults and in persons with mild cognitive impairment. Hum Brain Mapp 2009;30:4033&#x2013;4047.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871015</ArticleId><ArticleId IdType="pubmed">19492301</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20479234</PMID><DateCompleted><Year>2010</Year><Month>06</Month><Day>29</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>107</Volume><Issue>22</Issue><PubDate><Year>2010</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>10256</StartPage><EndPage>10261</EndPage><MedlinePgn>10256-61</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1001412107</ELocationID><Abstract><AbstractText>The epsilon4 allele of the apolipoprotein E (APOE) gene is the major genetic risk factor for Alzheimer's disease (AD), but limited work has suggested that APOE genotype may modulate disease phenotype. Carriers of the epsilon4 allele have been reported to have greater medial temporal lobe (MTL) pathology and poorer memory than noncarriers. Less attention has focused on whether there are domains of cognition and neuroanatomical regions more affected in noncarriers. Further, a major potential confound of prior in vivo studies is the possibility of different rates of clinical misdiagnosis for carriers vs. noncarriers. We compared phenotypic differences in cognition and topography of regional cortical atrophy of epsilon4 carriers (n = 67) vs. noncarriers (n = 24) with mild AD from the Alzheimer's Disease Neuroimaging Initiative, restricted to those with a cerebrospinal fluid (CSF) molecular profile consistent with AD. Between-group comparisons were made for psychometric tests and morphometric measures of cortical thickness and hippocampal volume. Carriers displayed significantly greater impairment on measures of memory retention, whereas noncarriers were more impaired on tests of working memory, executive control, and lexical access. Consistent with this cognitive dissociation, carriers exhibited greater MTL atrophy, whereas noncarriers had greater frontoparietal atrophy. Performance deficits in particular cognitive domains were associated with disproportionate regional brain atrophy within nodes of cortical networks thought to subserve these cognitive processes. These convergent cognitive and neuroanatomic findings in individuals with a CSF molecular profile consistent with AD support the hypothesis that APOE genotype modulates the clinical phenotype of AD through influence on specific large-scale brain networks.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wolk</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, PA 19104, USA. david.wolk@uphs.upenn.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickerson</LastName><ForeName>Bradford C</ForeName><Initials>BC</Initials></Author><Author ValidYN="Y"><CollectiveName>Alzheimer's Disease Neuroimaging Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50-AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21-AG29840</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG029840</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG022374</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG029411</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027342</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-AG29411</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG012101</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23-AG028018</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG028018</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>05</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001288" MajorTopicYN="N">Attention</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056344" MajorTopicYN="N">Executive Function</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056726" MajorTopicYN="N">Genetic Association Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thal</LastName><ForeName>Leon</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jagust</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trojanowki</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toga</LastName><ForeName>Arthur</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beckett</LastName><ForeName>Laurel</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Green</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gamst</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potter</LastName><ForeName>William Z</ForeName><Initials>WZ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montine</LastName><ForeName>Tom</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anders</LastName><ForeName>Dale</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernstein</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Felmlee</LastName><ForeName>Joel</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thompson</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schuff</LastName><ForeName>Norbert</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alexander</LastName><ForeName>Gene</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bandy</LastName><ForeName>Dan</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koeppe</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foster</LastName><ForeName>Norm</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Kewei</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trojanowki</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shaw</LastName><ForeName>Les</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia M -Y</ForeName><Initials>VM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Korecka</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toga</LastName><ForeName>Arthur</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crawford</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neu</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harvey</LastName><ForeName>Danielle</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gamst</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kornak</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kachaturian</LastName><ForeName>Zaven</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frank</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Snyder</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Molchan</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaye</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vorobik</LastName><ForeName>Remi</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quinn</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pawluczyk</LastName><ForeName>Sonia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spann</LastName><ForeName>Bryan</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fleisher</LastName><ForeName>Adam S</ForeName><Initials>AS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vanderswag</LastName><ForeName>Helen</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heidebrink</LastName><ForeName>Judith L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lord</LastName><ForeName>Joanne L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Kris</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doody</LastName><ForeName>Rachelle S</ForeName><Initials>RS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Villanueva-Meyer</LastName><ForeName>Javier</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chowdhury</LastName><ForeName>Munir</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stern</LastName><ForeName>Yaakov</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Honig</LastName><ForeName>Lawrence S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bell</LastName><ForeName>Karen L</ForeName><Initials>KL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mintun</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Stacy</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marson</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Griffith</LastName><ForeName>Randall</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Badger</LastName><ForeName>Beverly</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grossman</LastName><ForeName>Hillel</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tang</LastName><ForeName>Cheuk</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stern</LastName><ForeName>Jessica</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>deToledo-Morrell</LastName><ForeName>Leyla</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shah</LastName><ForeName>Raj C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bach</LastName><ForeName>Julie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duara</LastName><ForeName>Ranjan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Isaacson</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Strauman</LastName><ForeName>Silvia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albert</LastName><ForeName>Marilyn</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pedroso</LastName><ForeName>Julia</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toroney</LastName><ForeName>Jaimie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rusinek</LastName><ForeName>Henry</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Leon</LastName><ForeName>Mony J</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Santi</LastName><ForeName>Susan M</ForeName><Initials>SM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doraiswamy</LastName><ForeName>P Murali</ForeName><Initials>PM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petrella</LastName><ForeName>Jeffrey R</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aiello</LastName><ForeName>Marilyn</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clark</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pham</LastName><ForeName>Cassie</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nunez</LastName><ForeName>Jessica</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Charles D</ForeName><Initials>CD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Given</LastName><ForeName>Curtis A</ForeName><Initials>CA</Initials><Suffix>2nd</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Hardy</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeKosky</LastName><ForeName>Steven T</ForeName><Initials>ST</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oakley</LastName><ForeName>Mary Ann</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simpson</LastName><ForeName>Donna</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ismail</LastName><ForeName>M Saleem</ForeName><Initials>MS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Porsteinsson</LastName><ForeName>Anton</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCallum</LastName><ForeName>Colleen</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cramer</LastName><ForeName>Steven C</ForeName><Initials>SC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mulnard</LastName><ForeName>Ruth A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>McAdams-Ortiz</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Diaz-Arrastia</LastName><ForeName>Ramon</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin-Cook</LastName><ForeName>Kristen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeVous</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levey</LastName><ForeName>Allan I</ForeName><Initials>AI</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lah</LastName><ForeName>James J</ForeName><Initials>JJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cellar</LastName><ForeName>Janet S</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burns</LastName><ForeName>Jeffrey M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderson</LastName><ForeName>Heather S</ForeName><Initials>HS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laubinger</LastName><ForeName>Mary M</ForeName><Initials>MM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bartzokis</LastName><ForeName>George</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Silverman</LastName><ForeName>Daniel H S</ForeName><Initials>DH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lu</LastName><ForeName>Po H</ForeName><Initials>PH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fletcher</LastName><ForeName>Rita</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parfitt</LastName><ForeName>Francine</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Heather</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farlow</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Herring</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hake</LastName><ForeName>Ann M</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Dyck</LastName><ForeName>Christopher H</ForeName><Initials>CH</Initials></Investigator><Investigator ValidYN="Y"><LastName>MacAvoy</LastName><ForeName>Martha G</ForeName><Initials>MG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bifano</LastName><ForeName>Laurel A</ForeName><Initials>LA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chertkow</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bergman</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hosein</LastName><ForeName>Chris</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Black</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Graham</LastName><ForeName>Simon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caldwell</LastName><ForeName>Curtis</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Feldman</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Assaly</LastName><ForeName>Michele</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hsiung</LastName><ForeName>Ging-Yuek R</ForeName><Initials>GY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kertesz</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rogers</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trost</LastName><ForeName>Dick</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernick</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gitelman</LastName><ForeName>Darren</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mesulam</LastName><ForeName>Marsel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sadowsky</LastName><ForeName>Carl</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Villena</LastName><ForeName>Teresa</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mesner</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul S</ForeName><Initials>PS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Kathleen B</ForeName><Initials>KB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Behan</LastName><ForeName>Kelly E</ForeName><Initials>KE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rentz</LastName><ForeName>Dorene M</ForeName><Initials>DM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosen</LastName><ForeName>Allyson</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tinklenberg</LastName><ForeName>Jared</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ashford</LastName><ForeName>Wes</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sabbagh</LastName><ForeName>Marwan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Connor</LastName><ForeName>Donald</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Obradov</LastName><ForeName>Sanja</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Killiany</LastName><ForeName>Ron</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Norbash</LastName><ForeName>Alex</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Obisesan</LastName><ForeName>Thomas O</ForeName><Initials>TO</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jayam-Trouth</LastName><ForeName>Annapurni</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Auchus</LastName><ForeName>Alexander P</ForeName><Initials>AP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huang</LastName><ForeName>Juebin</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Friedland</LastName><ForeName>Robert P</ForeName><Initials>RP</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeCarli</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fletcher</LastName><ForeName>Evan</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carmichael</LastName><ForeName>Owen</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kittur</LastName><ForeName>Smita</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mirje</LastName><ForeName>Seema</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Sterling C</ForeName><Initials>SC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borrie</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>T -Y</ForeName><Initials>T-</Initials></Investigator><Investigator ValidYN="Y"><LastName>Asthana</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carlsson</LastName><ForeName>Cynthia M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potkin</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Highum</LastName><ForeName>Diane</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Preda</LastName><ForeName>Adrian</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Dana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tariot</LastName><ForeName>Pierre N</ForeName><Initials>PN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hendin</LastName><ForeName>Barry A</ForeName><Initials>BA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scharre</LastName><ForeName>Douglas W</ForeName><Initials>DW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kataki</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beversdorf</LastName><ForeName>David Q</ForeName><Initials>DQ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zimmerman</LastName><ForeName>Earl A</ForeName><Initials>EA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Celmins</LastName><ForeName>Dzintra</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>Alice D</ForeName><Initials>AD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gandy</LastName><ForeName>Sam</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marenberg</LastName><ForeName>Marjorie E</ForeName><Initials>ME</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rovner</LastName><ForeName>Barry W</ForeName><Initials>BW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pearlson</LastName><ForeName>Godfrey</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blank</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderson</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Santulli</LastName><ForeName>Robert B</ForeName><Initials>RB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pare</LastName><ForeName>Nadia</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williamson</LastName><ForeName>Jeff D</ForeName><Initials>JD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sink</LastName><ForeName>Kaycee M</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potter</LastName><ForeName>Huntington</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ashok Raj</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Giordano</LastName><ForeName>Amy</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ott</LastName><ForeName>Brian R</ForeName><Initials>BR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chuang-Kuo</LastName><ForeName>Wu</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cohen</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilks</LastName><ForeName>Kerri L</ForeName><Initials>KL</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>6</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>12</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20479234</ArticleId><ArticleId IdType="pmc">PMC2890481</ArticleId><ArticleId IdType="doi">10.1073/pnas.1001412107</ArticleId><ArticleId IdType="pii">1001412107</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>McKhann G, et al. Clinical diagnosis of Alzheimer&#x2019;s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer&#x2019;s disease. Cereb Cortex. 1991;1:103&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">1822725</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, et al. Research criteria for the diagnosis of Alzheimer&#x2019;s disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6:734&#x2013;746.</Citation><ArticleIdList><ArticleId IdType="pubmed">17616482</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson JK, Head E, Kim R, Starr A, Cotman CW. Clinical and pathological evidence for a frontal variant of Alzheimer disease. Arch Neurol. 1999;56:1233&#x2013;1239.</Citation><ArticleIdList><ArticleId IdType="pubmed">10520939</ArticleId></ArticleIdList></Reference><Reference><Citation>Hof PR, Bouras C, Constantinidis J, Morrison JH. Balint&#x2019;s syndrome in Alzheimer&#x2019;s disease: Specific disruption of the occipito-parietal visual pathway. Brain Res. 1989;493:368&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pubmed">2765903</ArticleId></ArticleIdList></Reference><Reference><Citation>Alladi S, et al. Focal cortical presentations of Alzheimer&#x2019;s disease. Brain. 2007;130:2636&#x2013;2645.</Citation><ArticleIdList><ArticleId IdType="pubmed">17898010</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanne SM, Balota DA, Storandt M, McKeel DW, Jr, Morris JC. Relating anatomy to function in Alzheimer&#x2019;s disease: Neuropsychological profiles predict regional neuropathology 5 years later. Neurology. 1998;50:979&#x2013;985.</Citation><ArticleIdList><ArticleId IdType="pubmed">9566382</ArticleId></ArticleIdList></Reference><Reference><Citation>Stopford CL, Snowden JS, Thompson JC, Neary D. Variability in cognitive presentation of Alzheimer&#x2019;s disease. Cortex. 2008;44:185&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">18387548</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesulam M. Primary progressive aphasia pathology. Ann Neurol. 2008;63:124&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pubmed">16912979</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter WJ, et al. Apolipoprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA. 1993;90:1977&#x2013;1981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC46003</ArticleId><ArticleId IdType="pubmed">8446617</ArticleId></ArticleIdList></Reference><Reference><Citation>Poirier J, et al. Apolipoprotein E polymorphism and Alzheimer&#x2019;s disease. Lancet. 1993;342:697&#x2013;699.</Citation><ArticleIdList><ArticleId IdType="pubmed">8103819</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahley RW. Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology. Science. 1988;240:622&#x2013;630.</Citation><ArticleIdList><ArticleId IdType="pubmed">3283935</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer&#x2019;s disease. Proc Natl Acad Sci USA. 2000;97:2892&#x2013;2897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16026</ArticleId><ArticleId IdType="pubmed">10694577</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter WJ, et al. Hypothesis: Microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype. Exp Neurol. 1994;125:163&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">8313935</ArticleId></ArticleIdList></Reference><Reference><Citation>Polvikoski T, et al. Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. N Engl J Med. 1995;333:1242&#x2013;1247.</Citation><ArticleIdList><ArticleId IdType="pubmed">7566000</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto M, et al. Apolipoprotein E epsilon 4 and the pattern of regional brain atrophy in Alzheimer&#x2019;s disease. Neurology. 2001;57:1461&#x2013;1466.</Citation><ArticleIdList><ArticleId IdType="pubmed">11673590</ArticleId></ArticleIdList></Reference><Reference><Citation>Pievani M, et al. Mapping the effect of APOE epsilon4 on gray matter loss in Alzheimer&#x2019;s disease in vivo. Neuroimage. 2009;45:1090&#x2013;1098.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2739903</ArticleId><ArticleId IdType="pubmed">19349226</ArticleId></ArticleIdList></Reference><Reference><Citation>Geroldi C, et al. APOE-epsilon4 is associated with less frontal and more medial temporal lobe atrophy in AD. Neurology. 1999;53:1825&#x2013;1832.</Citation><ArticleIdList><ArticleId IdType="pubmed">10563634</ArticleId></ArticleIdList></Reference><Reference><Citation>Agosta F, et al. Apolipoprotein E epsilon4 is associated with disease-specific effects on brain atrophy in Alzheimer&#x2019;s disease and frontotemporal dementia. Proc Natl Acad Sci USA. 2009;106:2018&#x2013;2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2644156</ArticleId><ArticleId IdType="pubmed">19164761</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehtovirta M, et al. Volumes of hippocampus, amygdala and frontal lobe in Alzheimer patients with different apolipoprotein E genotypes. Neuroscience. 1995;67:65&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">7477910</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, et al. Hippocampal atrophy and apolipoprotein E genotype are independently associated with Alzheimer&#x2019;s disease. Ann Neurol. 1998;43:303&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2752747</ArticleId><ArticleId IdType="pubmed">9506546</ArticleId></ArticleIdList></Reference><Reference><Citation>Drzezga A, et al. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology. 2009;72:1487&#x2013;1494.</Citation><ArticleIdList><ArticleId IdType="pubmed">19339712</ArticleId></ArticleIdList></Reference><Reference><Citation>Marra C, et al. Apolipoprotein E epsilon4 allele differently affects the patterns of neuropsychological presentation in early- and late-onset Alzheimer&#x2019;s disease patients. Dement Geriatr Cogn Disord. 2004;18:125&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">15211066</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Vlies AE, et al. Cognitive impairment in Alzheimer&#x2019;s disease is modified by APOE genotype. Dement Geriatr Cogn Disord. 2007;24:98&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">17596691</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehtovirta M, et al. Clinical and neuropsychological characteristics in familial and sporadic Alzheimer&#x2019;s disease: Relation to apolipoprotein E polymorphism. Neurology. 1996;46:413&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pubmed">8614504</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith GE, et al. Apolipoprotein E genotype influences cognitive &#x2018;phenotype&#x2019; in patients with Alzheimer&#x2019;s disease but not in healthy control subjects. Neurology. 1998;50:355&#x2013;362.</Citation><ArticleIdList><ArticleId IdType="pubmed">9484353</ArticleId></ArticleIdList></Reference><Reference><Citation>Varma AR, et al. Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer&#x2019;s disease and frontotemporal dementia. J Neurol Neurosurg Psychiatry. 1999;66:184&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1736233</ArticleId><ArticleId IdType="pubmed">10071097</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, et al. Imaging brain amyloid in Alzheimer&#x2019;s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative. Cerebrospinal fluid biomarker signature in Alzheimer&#x2019;s disease neuroimaging initiative subjects. Ann Neurol. 2009;65:403&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, et al. The cortical signature of Alzheimer&#x2019;s disease: Regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex. 2009;19:497&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2638813</ArticleId><ArticleId IdType="pubmed">18632739</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, Kahn I, Snyder AZ, Raichle ME, Buckner RL. Evidence for a frontoparietal control system revealed by intrinsic functional connectivity. J Neurophysiol. 2008;100:3328&#x2013;3342.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2604839</ArticleId><ArticleId IdType="pubmed">18799601</ArticleId></ArticleIdList></Reference><Reference><Citation>Juottonen K, Lehtovirta M, Helisalmi S, Riekkinen PJ, Sr, Soininen H. Major decrease in the volume of the entorhinal cortex in patients with Alzheimer&#x2019;s disease carrying the apolipoprotein E epsilon4 allele. J Neurol Neurosurg Psychiatry. 1998;65:322&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2170244</ArticleId><ArticleId IdType="pubmed">9728943</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbetta M, Shulman GL. Control of goal-directed and stimulus-driven attention in the brain. Nat Rev Neurosci. 2002;3:201&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">11994752</ArticleId></ArticleIdList></Reference><Reference><Citation>Filippini N, et al. Anatomically-distinct genetic associations of APOE epsilon4 allele load with regional cortical atrophy in Alzheimer&#x2019;s disease. Neuroimage. 2009;44:724&#x2013;728.</Citation><ArticleIdList><ArticleId IdType="pubmed">19013250</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakkour A, Morris JC, Dickerson BC. The cortical signature of prodromal AD: Regional thinning predicts mild AD dementia. Neurology. 2009;72:1048&#x2013;1055.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677470</ArticleId><ArticleId IdType="pubmed">19109536</ArticleId></ArticleIdList></Reference><Reference><Citation>Weintraub S, Mesulam M. With or without FUS, it is the anatomy that dictates the dementia phenotype. Brain. 2009;132:2906&#x2013;2908.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2915502</ArticleId><ArticleId IdType="pubmed">19861505</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander MP, Stuss DT, Fansabedian N. California Verbal Learning Test: Performance by patients with focal frontal and non-frontal lesions. Brain. 2003;126:1493&#x2013;1503.</Citation><ArticleIdList><ArticleId IdType="pubmed">12764068</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller E. Short- and long-term memory in patients with presenile dementia (Alzheimer&#x2019;s disease) Psychol Med. 1973;3:221&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">4715855</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker JT, Bajulaiye O, Smith C. Longitudinal analysis of a two-component model of the memory deficit in Alzheimer&#x2019;s disease. Psychol Med. 1992;22:437&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pubmed">1615111</ArticleId></ArticleIdList></Reference><Reference><Citation>Baddeley A, Della Sala S, Spinnler H. The two-component hypothesis of memory deficit in Alzheimer&#x2019;s disease. J Clin Exp Neuropsychol. 1991;13:372&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pubmed">1864922</ArticleId></ArticleIdList></Reference><Reference><Citation>Stopford CL, Snowden JS, Thompson JC, Neary D. Distinct memory profiles in Alzheimer&#x2019;s disease. Cortex. 2007;43:846&#x2013;857.</Citation><ArticleIdList><ArticleId IdType="pubmed">17941343</ArticleId></ArticleIdList></Reference><Reference><Citation>Shallice T, Warrington EK. Independent functioning of verbal memory stores: A neuropsychological study. Q J Exp Psychol. 1970;22:261&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pubmed">5431401</ArticleId></ArticleIdList></Reference><Reference><Citation>Markowitsch HJ, et al. Short-term memory deficit after focal parietal damage. J Clin Exp Neuropsychol. 1999;21:784&#x2013;797.</Citation><ArticleIdList><ArticleId IdType="pubmed">10649534</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchsbaum BR, D&#x2019;Esposito M. The search for the phonological store: from loop to convolution. J Cogn Neurosci. 2008;20:762&#x2013;778.</Citation><ArticleIdList><ArticleId IdType="pubmed">18201133</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, et al. Detection of cortical thickness correlates of cognitive performance: Reliability across MRI scan sessions, scanners, and field strengths. Neuroimage. 2008;39:10&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2141650</ArticleId><ArticleId IdType="pubmed">17942325</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, et al. Differential effects of aging and Alzheimer&#x2019;s disease on medial temporal lobe cortical thickness and surface area. Neurobiol Aging. 2009;30:432&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3703585</ArticleId><ArticleId IdType="pubmed">17869384</ArticleId></ArticleIdList></Reference><Reference><Citation>Feczko E, Augustinack JC, Fischl B, Dickerson BC. An MRI-based method for measuring volume, thickness and surface area of entorhinal, perirhinal, and posterior parahippocampal cortex. Neurobiol Aging. 2009;30:420&#x2013;431.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3665765</ArticleId><ArticleId IdType="pubmed">17850926</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler AM, et al. Cortical thickness or grey matter volume? The importance of selecting the phenotype for imaging genetics studies. Neuroimage. 2009 10.1016/j.neuroimage.2009.12.028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2891595</ArticleId><ArticleId IdType="pubmed">20006715</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E4: A causative factor and therapeutic target in neuropathology, including Alzheimer&#x2019;s disease. Proc Natl Acad Sci USA. 2006;103:5644&#x2013;5651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1414631</ArticleId><ArticleId IdType="pubmed">16567625</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris FM, et al. Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer&#x2019;s disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc Natl Acad Sci USA. 2003;100:10966&#x2013;10971.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC196910</ArticleId><ArticleId IdType="pubmed">12939405</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarmeas N, et al. APOE related alterations in cerebral activation even at college age. J Neurol Neurosurg Psychiatry. 2005;76:1440&#x2013;1444.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1739360</ArticleId><ArticleId IdType="pubmed">16170092</ArticleId></ArticleIdList></Reference><Reference><Citation>Brecht WJ, et al. Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. J Neurosci. 2004;24:2527&#x2013;2534.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729489</ArticleId><ArticleId IdType="pubmed">15014128</ArticleId></ArticleIdList></Reference><Reference><Citation>Beffert U, et al. Apolipoprotein E and beta-amyloid levels in the hippocampus and frontal cortex of Alzheimer&#x2019;s disease subjects are disease-related and apolipoprotein E genotype dependent. Brain Res. 1999;843:87&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">10528114</ArticleId></ArticleIdList></Reference><Reference><Citation>Acevedo SF, Piper BJ, Craytor MJ, Benice TS, Raber J. Apolipoprotein E4 and sex affect neurobehavioral performance in primary school children. Pediatr Res. 2010;67:293&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2853744</ArticleId><ArticleId IdType="pubmed">19952867</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu YW, Lin CH, Chen SP, Hong CJ, Tsai SJ. Intelligence and event-related potentials for young female human volunteer apolipoprotein E epsilon4 and non-epsilon4 carriers. Neurosci Lett. 2000;294:179&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">11072144</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw P, et al. Cortical morphology in children and adolescents with different apolipoprotein E gene polymorphisms: An observational study. Lancet Neurol. 2007;6:494&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pubmed">17509484</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchant NL, King SL, Tabet N, Rusted JM. Positive effects of cholinergic stimulation favor young APOE epsilon4 carriers. Neuropsychopharmacology. 2010;35:1090&#x2013;1096.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3055410</ArticleId><ArticleId IdType="pubmed">20072115</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC. The entorhinal cortex: An anatomical mediator of genetic vulnerability to Alzheimer&#x2019;s disease? Lancet Neurol. 2007;6:471&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pubmed">17509474</ArticleId></ArticleIdList></Reference><Reference><Citation>Snodgrass JG, Corwin J. Pragmatics of measuring recognition memory: Applications to dementia and amnesia. J Exp Psychol Gen. 1988;117:34&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">2966230</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20484626</PMID><DateCompleted><Year>2010</Year><Month>06</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>20</Issue><PubDate><Year>2010</Year><Month>May</Month><Day>19</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival.</ArticleTitle><Pagination><StartPage>6838</StartPage><EndPage>6851</EndPage><MedlinePgn>6838-51</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.5699-09.2010</ELocationID><Abstract><AbstractText>alpha-Synuclein is central in Parkinson's disease pathogenesis. Although initially alpha-synuclein was considered a purely intracellular protein, recent data suggest that it can be detected in the plasma and CSF of humans and in the culture media of neuronal cells. To address a role of secreted alpha-synuclein in neuronal homeostasis, we have generated wild-type alpha-synuclein and beta-galactosidase inducible SH-SY5Y cells. Soluble oligomeric and monomeric species of alpha-synuclein are readily detected in the conditioned media (CM) of these cells at concentrations similar to those observed in human CSF. We have found that, in this model, alpha-synuclein is secreted by externalized vesicles in a calcium-dependent manner. Electron microscopy and liquid chromatography-mass spectrometry proteomic analysis demonstrate that these vesicles have the characteristic hallmarks of exosomes, secreted intraluminar vesicles of multivesicular bodies. Application of CM containing secreted alpha-synuclein causes cell death of recipient neuronal cells, which can be reversed after alpha-synuclein immunodepletion from the CM. High- and low-molecular-weight alpha-synuclein species, isolated from this CM, significantly decrease cell viability. Importantly, treatment of the CM with oligomer-interfering compounds before application rescues the recipient neuronal cells from the observed toxicity. Our results show for the first time that cell-produced alpha-synuclein is secreted via an exosomal, calcium-dependent mechanism and suggest that alpha-synuclein secretion serves to amplify and propagate Parkinson's disease-related pathology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Emmanouilidou</LastName><ForeName>Evangelia</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Basic Neurosciences, Biomedical Research Foundation of the Academy of Athens, Athens 11527, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Melachroinou</LastName><ForeName>Katerina</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Roumeliotis</LastName><ForeName>Theodoros</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Garbis</LastName><ForeName>Spiros D</ForeName><Initials>SD</Initials></Author><Author ValidYN="Y"><LastName>Ntzouni</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Margaritis</LastName><ForeName>Lukas H</ForeName><Initials>LH</Initials></Author><Author ValidYN="Y"><LastName>Stefanis</LastName><ForeName>Leonidas</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Vekrellis</LastName><ForeName>Kostas</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R21 NS0556</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C524478">1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017077">Culture Media, Conditioned</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010880">Piperidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011500">Protein Synthesis Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011990">Receptors, Transferrin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>20350-15-6</RegistryNumber><NameOfSubstance UI="D020126">Brefeldin A</NameOfSubstance></Chemical><Chemical><RegistryNumber>BBX060AN9V</RegistryNumber><NameOfSubstance UI="D006861">Hydrogen Peroxide</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.23</RegistryNumber><NameOfSubstance UI="D001616">beta-Galactosidase</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020126" MajorTopicYN="N">Brefeldin A</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002851" MajorTopicYN="N">Chromatography, High Pressure Liquid</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017077" MajorTopicYN="N">Culture Media, Conditioned</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003601" MajorTopicYN="N">Cytotoxicity Tests, Immunologic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004705" MajorTopicYN="N">Endocytosis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055354" MajorTopicYN="N">Exosomes</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006861" MajorTopicYN="N">Hydrogen Peroxide</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047468" MajorTopicYN="N">Immunoprecipitation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013058" MajorTopicYN="N">Mass Spectrometry</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018613" MajorTopicYN="N">Microscopy, Confocal</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046529" MajorTopicYN="N">Microscopy, Electron, Transmission</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008970" MajorTopicYN="N">Molecular Weight</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057146" MajorTopicYN="N">Multivesicular Bodies</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009447" MajorTopicYN="N">Neuroblastoma</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011500" MajorTopicYN="N">Protein Synthesis Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011720" MajorTopicYN="N">Pyrazoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011990" MajorTopicYN="N">Receptors, Transferrin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044967" MajorTopicYN="N">Serum</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013347" MajorTopicYN="N">Subcellular Fractions</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013696" MajorTopicYN="N">Temperature</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001616" MajorTopicYN="N">beta-Galactosidase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>11</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20484626</ArticleId><ArticleId IdType="pmc">PMC3842464</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.5699-09.2010</ArticleId><ArticleId IdType="pii">30/20/6838</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ahn KJ, Paik SR, Chung KC, Kim J. Amino acid sequence motifs and mechanistic features of the membrane translocation of alpha-synuclein. J Neurochem. 2006;97:265&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pubmed">16524375</ArticleId></ArticleIdList></Reference><Reference><Citation>Albani D, Peverelli E, Rametta R, Batelli S, Veschini L, Negro A, Forloni G. Protective effect of TAT-delivered alpha-synuclein: relevance of the C-terminal domain and involvement of HSP70. FASEB J. 2004;18:1713&#x2013;1715.</Citation><ArticleIdList><ArticleId IdType="pubmed">15345691</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrei C, Dazzi C, Lotti L, Torrisi MR, Chimini G, Rubartelli A. The secretory route of the leaderless protein interleukin 1beta involves exocytosis of endolysosome-related vesicles. Mol Biol Cell. 1999;10:1463&#x2013;1475.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC25302</ArticleId><ArticleId IdType="pubmed">10233156</ArticleId></ArticleIdList></Reference><Reference><Citation>Barclay JW, Morgan A, Burgoyne RD. Calcium-dependent regulation of exocytosis. Cell Calcium. 2005;38:343&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pubmed">16099500</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg D, Holzmann C, Riess O. 14-3-3 proteins in the nervous system. Nat Rev Neurosci. 2003;4:752&#x2013;762.</Citation><ArticleIdList><ArticleId IdType="pubmed">12951567</ArticleId></ArticleIdList></Reference><Reference><Citation>Borghi R, Marchese R, Negro A, Marinelli L, Forloni G, Zaccheo D, Abbruzzese G, Tabaton M. Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci Lett. 2000;287:65&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">10841992</ArticleId></ArticleIdList></Reference><Reference><Citation>Brundin P, Li JY, Holton JL, Lindvall O, Revesz T. Research in motion: the enigma of Parkinson's disease pathology spread. Nat Rev Neurosci. 2008;9:741&#x2013;745.</Citation><ArticleIdList><ArticleId IdType="pubmed">18769444</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter DB, Chou KC. A model for structure-dependent binding of Congo red to Alzheimer beta-amyloid fibrils. Neurobiol Aging. 1998;19:37&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">9562501</ArticleId></ArticleIdList></Reference><Reference><Citation>Caughey B. Transmissible spongiform encephalopathies, amyloidoses and yeast prions: common threads? Nat Med. 2000;6:751&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pubmed">10888922</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang HC, Samaniego F, Nair BC, Buonaguro L, Ensoli B. HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. AIDS. 1997;11:1421&#x2013;1431.</Citation><ArticleIdList><ArticleId IdType="pubmed">9342064</ArticleId></ArticleIdList></Reference><Reference><Citation>Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, Levecque C, Larvor L, Andrieux J, Hulihan M, Waucquier N, Defebvre L, Amouyel P, Farrer M, Dest&#xe9;e A. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet. 2004;364:1167&#x2013;1169.</Citation><ArticleIdList><ArticleId IdType="pubmed">15451224</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT., Jr Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci U S A. 2000;97:571&#x2013;576.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15371</ArticleId><ArticleId IdType="pubmed">10639120</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway KA, Rochet JC, Bieganski RM, Lansbury PT., Jr Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science. 2001;294:1346&#x2013;1349.</Citation><ArticleIdList><ArticleId IdType="pubmed">11701929</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper DN, Barondes SH. Evidence for export of a muscle lectin from cytosol to extracellular matrix and for a novel secretory mechanism. J Cell Biol. 1990;110:1681&#x2013;1691.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2200163</ArticleId><ArticleId IdType="pubmed">2335567</ArticleId></ArticleIdList></Reference><Reference><Citation>Denzer K, Kleijmeer MJ, Heijnen HF, Stoorvogel W, Geuze HJ. Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. J Cell Sci. 2000;113:3365&#x2013;3374.</Citation><ArticleIdList><ArticleId IdType="pubmed">10984428</ArticleId></ArticleIdList></Reference><Reference><Citation>Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, Spencer B, Masliah E, Lee SJ. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A. 2009;106:13010&#x2013;13015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2722313</ArticleId><ArticleId IdType="pubmed">19651612</ArticleId></ArticleIdList></Reference><Reference><Citation>Du HN, Tang L, Luo XY, Li HT, Hu J, Zhou JW, Hu HY. A peptide motif consisting of glycine, alanine, and valine is required for the fibrillization and cytotoxicity of human alpha-synuclein. Biochemistry. 2003;42:8870&#x2013;8878.</Citation><ArticleIdList><ArticleId IdType="pubmed">12873148</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Agnaf OM, Jakes R, Curran MD, Middleton D, Ingenito R, Bianchi E, Pessi A, Neill D, Wallace A. Aggregates from mutant and wild-type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments. FEBS Lett. 1998;440:71&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">9862428</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Agnaf OM, Salem SA, Paleologou KE, Cooper LJ, Fullwood NJ, Gibson MJ, Curran MD, Court JA, Mann DM, Ikeda S, Cookson MR, Hardy J, Allsop D. Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J. 2003;17:1945&#x2013;1947.</Citation><ArticleIdList><ArticleId IdType="pubmed">14519670</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Agnaf OM, Salem SA, Paleologou KE, Curran MD, Gibson MJ, Court JA, Schlossmacher MG, Allsop D. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J. 2006;20:419&#x2013;425.</Citation><ArticleIdList><ArticleId IdType="pubmed">16507759</ArticleId></ArticleIdList></Reference><Reference><Citation>Emmanouilidou E, Stefanis L, Vekrellis K. Cell-produced alpha-synuclein oligomers are targeted to, and impair, the 26S proteasome. Neurobiol Aging. 2010;31:953&#x2013;968.</Citation><ArticleIdList><ArticleId IdType="pubmed">18715677</ArticleId></ArticleIdList></Reference><Reference><Citation>Faur&#xe9; J, Lachenal G, Court M, Hirrlinger J, Chatellard-Causse C, Blot B, Grange J, Schoehn G, Goldberg Y, Boyer V, Kirchhoff F, Raposo G, Garin J, Sadoul R. Exosomes are released by cultured cortical neurones. Mol Cell Neurosci. 2006;31:642&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pubmed">16446100</ArticleId></ArticleIdList></Reference><Reference><Citation>Fevrier B, Vilette D, Archer F, Loew D, Faigle W, Vidal M, Laude H, Raposo G. Cells release prions in association with exosomes. Proc Natl Acad Sci U S A. 2004;101:9683&#x2013;9688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC470735</ArticleId><ArticleId IdType="pubmed">15210972</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujiki Y, Hubbard AL, Fowler S, Lazarow PB. Isolation of intracellular membranes by means of sodium carbonate treatment: application to endoplasmic reticulum. J Cell Biol. 1982;93:97&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2112113</ArticleId><ArticleId IdType="pubmed">7068762</ArticleId></ArticleIdList></Reference><Reference><Citation>Geetha T, Wooten MW. TrkA receptor endolysosomal degradation is both ubiquitin and proteasome dependent. Traffic. 2008;9:1146&#x2013;1156.</Citation><ArticleIdList><ArticleId IdType="pubmed">18419753</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghidoni R, Benussi L, Binetti G. Exosomes: the Trojan horses of neurodegeneration. Med Hypotheses. 2008;70:1226&#x2013;1227.</Citation><ArticleIdList><ArticleId IdType="pubmed">18226468</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg MS, Lansbury PT., Jr Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease? Nat Cell Biol. 2000;2:E115&#x2013;E119.</Citation><ArticleIdList><ArticleId IdType="pubmed">10878819</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Begne M, Lu B, Han X, Hagen FK, Hand AR, Melvin JE, Yates JR. Proteomic analysis of human parotid gland exosomes by multidimensional protein identification technology (MudPIT) J Proteome Res. 2009;8:1304&#x2013;1314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2693447</ArticleId><ArticleId IdType="pubmed">19199708</ArticleId></ArticleIdList></Reference><Reference><Citation>Heiser V, Scherzinger E, Boeddrich A, Nordhoff E, Lurz R, Schugardt N, Lehrach H, Wanker EE. Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy. Proc Natl Acad Sci U S A. 2000;97:6739&#x2013;6744.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18723</ArticleId><ArticleId IdType="pubmed">10829068</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes RC. Secretion of the galectin family of mammalian carbohydrate-binding proteins. Biochim Biophys Acta. 1999;1473:172&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">10580137</ArticleId></ArticleIdList></Reference><Reference><Citation>Ib&#xe1;&#xf1;ez P, Bonnet AM, D&#xe9;barges B, Lohmann E, Tison F, Pollak P, Agid Y, D&#xfc;rr A, Brice A. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet. 2004;364:1169&#x2013;1171.</Citation><ArticleIdList><ArticleId IdType="pubmed">15451225</ArticleId></ArticleIdList></Reference><Reference><Citation>Inouye H, Kirschner DA. Alzheimer's beta-amyloid: insights into fibril formation and structure from Congo red binding. Subcell Biochem. 2005;38:203&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">15709480</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson A, Friedman S, Zhan X, Engleka KA, Forough R, Maciag T. Heat shock induces the release of fibroblast growth factor 1 from NIH 3T3 cells. Proc Natl Acad Sci U S A. 1992;89:10691&#x2013;10695.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC50407</ArticleId><ArticleId IdType="pubmed">1279690</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnstone RM, Adam M, Hammond JR, Orr L, Turbide C. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes) J Biol Chem. 1987;262:9412&#x2013;9420.</Citation><ArticleIdList><ArticleId IdType="pubmed">3597417</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller S, Sanderson MP, Stoeck A, Altevogt P. Exosomes: from biogenesis and secretion to biological function. Immunol Lett. 2006;107:102&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">17067686</ArticleId></ArticleIdList></Reference><Reference><Citation>Klinkspoor JH, Tytgat GN, Lee SP, Groen AK. Mechanism of bile salt-induced mucin secretion by cultured dog gallbladder epithelial cells. Biochem J. 1996;316:873&#x2013;877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1217431</ArticleId><ArticleId IdType="pubmed">8670165</ArticleId></ArticleIdList></Reference><Reference><Citation>Kouri ED, Labrou NE, Garbis SD, Kalliampakou KI, Stedel C, Dimou M, Udvardi MK, Katinakis P, Flemetakis E. Molecular and biochemical characterization of the parvulin-type PPIases in Lotus japonicus. Plant Physiol. 2009;150:1160&#x2013;1173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2705032</ArticleId><ArticleId IdType="pubmed">19403733</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanzetti L. Actin in membrane trafficking. Curr Opin Cell Biol. 2007;19:453&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pubmed">17616384</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HJ, Patel S, Lee SJ. Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J Neurosci. 2005;25:6016&#x2013;6024.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6724798</ArticleId><ArticleId IdType="pubmed">15976091</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HJ, Suk JE, Bae EJ, Lee JH, Paik SR, Lee SJ. Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein. Int J Biochem Cell Biol. 2008;40:1835&#x2013;1849.</Citation><ArticleIdList><ArticleId IdType="pubmed">18291704</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SJ. Origins and effects of extracellular alpha-synuclein: implications in Parkinson's disease. J Mol Neurosci. 2008;34:17&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">18157654</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindstedt R, Apodaca G, Barondes SH, Mostov KE, Leffler H. Apical secretion of a cytosolic protein by Madin-Darby canine kidney cells. Evidence for polarized release of an endogenous lectin by a nonclassical secretory pathway. J Biol Chem. 1993;268:11750&#x2013;11757.</Citation><ArticleIdList><ArticleId IdType="pubmed">8505302</ArticleId></ArticleIdList></Reference><Reference><Citation>Luk KC, Song C, O'Brien P, Stieber A, Branch JR, Brunden KR, Trojanowski JQ, Lee VM. Exogenous &#x3b1;-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc Natl Acad Sci U S A. 2009;106:20051&#x2013;20056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2785290</ArticleId><ArticleId IdType="pubmed">19892735</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaurin J, Golomb R, Jurewicz A, Antel JP, Fraser PE. Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit A&#x3b2;-induced toxicity. J Biol Chem. 2000;275:18495&#x2013;18502.</Citation><ArticleIdList><ArticleId IdType="pubmed">10764800</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehul B, Hughes RC. Plasma membrane targetting, vesicular budding and release of galectin 3 from the cytoplasm of mammalian cells during secretion. J Cell Sci. 1997;110:1169&#x2013;1178.</Citation><ArticleIdList><ArticleId IdType="pubmed">9191041</ArticleId></ArticleIdList></Reference><Reference><Citation>Melchior F, Gerace L. Mechanisms of nuclear protein import. Curr Opin Cell Biol. 1995;7:310&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">7662359</ArticleId></ArticleIdList></Reference><Reference><Citation>Mills IG, Urb&#xe9; S, Clague MJ. Relationships between EEA1 binding partners and their role in endosome fusion. J Cell Sci. 2001;114:1959&#x2013;1965.</Citation><ArticleIdList><ArticleId IdType="pubmed">11329382</ArticleId></ArticleIdList></Reference><Reference><Citation>Olanow CW, Perl DP, DeMartino GN, McNaught KS. Lewy-body formation is an aggresome-related process: a hypothesis. Lancet Neurol. 2004;3:496&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">15261611</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan BT, Teng K, Wu C, Adam M, Johnstone RM. Electron microscopic evidence for externalization of the transferrin receptor in vesicular form in sheep reticulocytes. J Cell Biol. 1985;101:942&#x2013;948.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2113705</ArticleId><ArticleId IdType="pubmed">2993317</ArticleId></ArticleIdList></Reference><Reference><Citation>Poole B, Ohkuma S. Effect of weak bases on the intralysosomal pH in mouse peritoneal macrophages. J Cell Biol. 1981;90:665&#x2013;669.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2111912</ArticleId><ArticleId IdType="pubmed">6169733</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajendran L, Honsho M, Zahn TR, Keller P, Geiger KD, Verkade P, Simons K. Alzheimer's disease beta-amyloid peptides are released in association with exosomes. Proc Natl Acad Sci U S A. 2006;103:11172&#x2013;11177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1544060</ArticleId><ArticleId IdType="pubmed">16837572</ArticleId></ArticleIdList></Reference><Reference><Citation>Raposo G, Tenza D, Mecheri S, Peronet R, Bonnerot C, Desaymard C. Accumulation of major histocompatibility complex class II molecules in mast cell secretory granules and their release upon degranulation. Mol Biol Cell. 1997;8:2631&#x2013;2645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC25733</ArticleId><ArticleId IdType="pubmed">9398681</ArticleId></ArticleIdList></Reference><Reference><Citation>Rideout HJ, Larsen KE, Sulzer D, Stefanis L. Proteasomal inhibition leads to formation of ubiquitin/alpha-synuclein-immunoreactive inclusions in PC12 cells. J Neurochem. 2001;78:899&#x2013;908.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520910</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubartelli A, Cozzolino F, Talio M, Sitia R. A novel secretory pathway for interleukin-1 beta, a protein lacking a signal sequence. EMBO J. 1990;9:1503&#x2013;1510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC551842</ArticleId><ArticleId IdType="pubmed">2328723</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe1;nchez I, Mahlke C, Yuan J. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature. 2003;421:373&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pubmed">12540902</ArticleId></ArticleIdList></Reference><Reference><Citation>Saraste J, Palade GE, Farquhar MG. Temperature-sensitive steps in the transport of secretory proteins through the Golgi complex in exocrine pancreatic cells. Proc Natl Acad Sci U S A. 1986;83:6425&#x2013;6429.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC386516</ArticleId><ArticleId IdType="pubmed">3462704</ArticleId></ArticleIdList></Reference><Reference><Citation>Savina A, Furl&#xe1;n M, Vidal M, Colombo MI. Exosome release is regulated by a calcium-dependent mechanism in K562 cells. J Biol Chem. 2003;278:20083&#x2013;20090.</Citation><ArticleIdList><ArticleId IdType="pubmed">12639953</ArticleId></ArticleIdList></Reference><Reference><Citation>Savina A, Fader CM, Damiani MT, Colombo MI. Rab11 promotes docking and fusion of multivesicular bodies in a calcium-dependent manner. Traffic. 2005;6:131&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">15634213</ArticleId></ArticleIdList></Reference><Reference><Citation>Seino S, Shibasaki T. PKA-dependent and PKA-independent pathways for cAMP-regulated exocytosis. Physiol Rev. 2005;85:1303&#x2013;1342.</Citation><ArticleIdList><ArticleId IdType="pubmed">16183914</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherer TB, Betarbet R, Stout AK, Lund S, Baptista M, Panov AV, Cookson MR, Greenamyre JT. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered &#x3b1;-synuclein metabolism and oxidative damage. J Neurosci. 2002;22:7006&#x2013;7015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757862</ArticleId><ArticleId IdType="pubmed">12177198</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson RJ, Jensen SS, Lim JW. Proteomic profiling of exosomes: current perspectives. Proteomics. 2008;8:4083&#x2013;4099.</Citation><ArticleIdList><ArticleId IdType="pubmed">18780348</ArticleId></ArticleIdList></Reference><Reference><Citation>Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K. alpha-Synuclein locus triplication causes Parkinson's disease. Science. 2003;302:841.</Citation><ArticleIdList><ArticleId IdType="pubmed">14593171</ArticleId></ArticleIdList></Reference><Reference><Citation>Smolian H, Aurer A, Sittinger M, Zacher J, Bernimoulin JP, Burmester GR, Kolkenbrock H. Secretion of gelatinases and activation of gelatinase A (MMP-2) by human rheumatoid synovial fibroblasts. Biol Chem. 2001;382:1491&#x2013;1499.</Citation><ArticleIdList><ArticleId IdType="pubmed">11727833</ArticleId></ArticleIdList></Reference><Reference><Citation>Su X, Maguire-Zeiss KA, Giuliano R, Prifti L, Venkatesh K, Federoff HJ. Synuclein activates microglia in a model of Parkinson's disease. Neurobiol Aging. 2008;29:1690&#x2013;1701.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2621109</ArticleId><ArticleId IdType="pubmed">17537546</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung JY, Kim J, Paik SR, Park JH, Ahn YS, Chung KC. Induction of neuronal cell death by Rab5A-dependent endocytosis of alpha-synuclein. J Biol Chem. 2001;276:27441&#x2013;27448.</Citation><ArticleIdList><ArticleId IdType="pubmed">11316809</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung JY, Park SM, Lee CH, Um JW, Lee HJ, Kim J, Oh YJ, Lee ST, Paik SR, Chung KC. Proteolytic cleavage of extracellular secreted {alpha}-synuclein via matrix metalloproteinases. J Biol Chem. 2005;280:25216&#x2013;25224.</Citation><ArticleIdList><ArticleId IdType="pubmed">15863497</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanudji M, Hevi S, Chuck SL. Improperly folded green fluorescent protein is secreted via a non-classical pathway. J Cell Sci. 2002;115:3849&#x2013;3857.</Citation><ArticleIdList><ArticleId IdType="pubmed">12235295</ArticleId></ArticleIdList></Reference><Reference><Citation>Thastrup O, Cullen PJ, Dr&#xf8;bak BK, Hanley MR, Dawson AP. Thapsigargin, a tumor promoter, discharges intracellular Ca2+ stores by specific inhibition of the endoplasmic reticulum Ca2+-ATPase. Proc Natl Acad Sci U S A. 1990;87:2466&#x2013;2470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC53710</ArticleId><ArticleId IdType="pubmed">2138778</ArticleId></ArticleIdList></Reference><Reference><Citation>Th&#xe9;ry C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002;2:569&#x2013;579.</Citation><ArticleIdList><ArticleId IdType="pubmed">12154376</ArticleId></ArticleIdList></Reference><Reference><Citation>Th&#xe9;ry C, Amigorena S, Raposo G, Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol. 2006 Chapter 3:Unit 3.22.</Citation><ArticleIdList><ArticleId IdType="pubmed">18228490</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend M, Cleary JP, Mehta T, Hofmeister J, Lesne S, O'Hare E, Walsh DM, Selkoe DJ. Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers. Ann Neurol. 2006;60:668&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">17192927</ArticleId></ArticleIdList></Reference><Reference><Citation>Trajkovic K, Hsu C, Chiantia S, Rajendran L, Wenzel D, Wieland F, Schwille P, Br&#xfc;gger B, Simons M. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science. 2008;319:1244&#x2013;1247.</Citation><ArticleIdList><ArticleId IdType="pubmed">18309083</ArticleId></ArticleIdList></Reference><Reference><Citation>Valadi H, Ekstr&#xf6;m K, Bossios A, Sj&#xf6;strand M, Lee JJ, L&#xf6;tvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9:654&#x2013;659.</Citation><ArticleIdList><ArticleId IdType="pubmed">17486113</ArticleId></ArticleIdList></Reference><Reference><Citation>van Niel G, Porto-Carreiro I, Simoes S, Raposo G. Exosomes: a common pathway for a specialized function. J Biochem. 2006;140:13&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">16877764</ArticleId></ArticleIdList></Reference><Reference><Citation>Vekrellis K, Rideout HJ, Stefanis L. Neurobiology of alpha-synuclein. Mol Neurobiol. 2004;30:1&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">15247485</ArticleId></ArticleIdList></Reference><Reference><Citation>Vekrellis K, Xilouri M, Emmanouilidou E, Stefanis L. Inducible over-expression of wild type alpha-synuclein in human neuronal cells leads to caspase-dependent non-apoptotic death. J Neurochem. 2009;109:1348&#x2013;1362.</Citation><ArticleIdList><ArticleId IdType="pubmed">19476547</ArticleId></ArticleIdList></Reference><Reference><Citation>Vella LJ, Sharples RA, Lawson VA, Masters CL, Cappai R, Hill AF. Packaging of prions into exosomes is associated with a novel pathway of PrP processing. J Pathol. 2007;211:582&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pubmed">17334982</ArticleId></ArticleIdList></Reference><Reference><Citation>Vella LJ, Sharples RA, Nisbet RM, Cappai R, Hill AF. The role of exosomes in the processing of proteins associated with neurodegenerative diseases. Eur Biophys J. 2008;37:323&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pubmed">18064447</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JP, Magee T. Argosomes: membrane fragments on the run. Trends Cell Biol. 2002;12:57&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">11849963</ArticleId></ArticleIdList></Reference><Reference><Citation>Vingtdeux V, Hamdane M, Loyens A, Gel&#xe9; P, Drobeck H, B&#xe9;gard S, Galas MC, Delacourte A, Beauvillain JC, Bu&#xe9;e L, Sergeant N. Alkalizing drugs induce accumulation of amyloid precursor protein by-products in luminal vesicles of multivesicular bodies. J Biol Chem. 2007;282:18197&#x2013;18205.</Citation><ArticleIdList><ArticleId IdType="pubmed">17468104</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogiatzi T, Xilouri M, Vekrellis K, Stefanis L. Wild type alpha-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells. J Biol Chem. 2008;283:23542&#x2013;23556.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2527094</ArticleId><ArticleId IdType="pubmed">18566453</ArticleId></ArticleIdList></Reference><Reference><Citation>Volles MJ, Lansbury PT., Jr Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry. 2003;42:7871&#x2013;7878.</Citation><ArticleIdList><ArticleId IdType="pubmed">12834338</ArticleId></ArticleIdList></Reference><Reference><Citation>Volles MJ, Lee SJ, Rochet JC, Shtilerman MD, Ding TT, Kessler JC, Lansbury PT., Jr Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry. 2001;40:7812&#x2013;7819.</Citation><ArticleIdList><ArticleId IdType="pubmed">11425308</ArticleId></ArticleIdList></Reference><Reference><Citation>Wubbolts R, Leckie RS, Veenhuizen PT, Schwarzmann G, M&#xf6;bius W, Hoernschemeyer J, Slot JW, Geuze HJ, Stoorvogel W. Proteomic and biochemical analyses of human B cell-derived exosomes. Potential implications for their function and multivesicular body formation. J Biol Chem. 2003;278:10963&#x2013;10972.</Citation><ArticleIdList><ArticleId IdType="pubmed">12519789</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuyama K, Yamamoto N, Yanagisawa K. Accelerated release of exosome-associated GM1 ganglioside (GM1) by endocytic pathway abnormality: another putative pathway for GM1-induced amyloid fibril formation. J Neurochem. 2008;105:217&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">18021298</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, Wilson B, Zhang W, Zhou Y, Hong JS, Zhang J. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J. 2005;19:533&#x2013;542.</Citation><ArticleIdList><ArticleId IdType="pubmed">15791003</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20484632</PMID><DateCompleted><Year>2010</Year><Month>06</Month><Day>04</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>20</Issue><PubDate><Year>2010</Year><Month>May</Month><Day>19</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Presenilin 1 mutants impair the self-renewal and differentiation of adult murine subventricular zone-neuronal progenitors via cell-autonomous mechanisms involving notch signaling.</ArticleTitle><Pagination><StartPage>6903</StartPage><EndPage>6915</EndPage><MedlinePgn>6903-15</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.0527-10.2010</ELocationID><Abstract><AbstractText>The vast majority of pedigrees with familial Alzheimer's disease (FAD) are caused by inheritance of mutations in the PSEN1 1 gene. While genetic ablation studies have revealed a role for presenilin 1 (PS1) in embryonic neurogenesis, little information has emerged regarding the potential effects of FAD-linked PS1 variants on proliferation, self-renewal and differentiation, key events that control cell fate commitment of adult brain neural progenitors (NPCs). We used adult brain subventricular zone (SVZ)-derived NPC cultures transduced with recombinant lentivirus as a means to investigate the effects of various PS1 mutants on self-renewal and differentiation properties. We now show that viral expression of several PS1 mutants in NPCs leads to impaired self-renewal and altered differentiation toward neuronal lineage, in vitro. In line with these observations, diminished constitutive proliferation and steady-state SVZ progenitor pool size was observed in vivo in transgenic mice expressing the PS1DeltaE9 variant. Moreover, NPC cultures established from the SVZ of adult mice expressing PS1DeltaE9 exhibit reduced self-renewal capacity and premature exit toward neuronal fates. To these findings, we show that both the levels of endogenous Notch/CBF-1-transcriptional activity and transcripts encoding Notch target genes are diminished in SVZ NPCs expressing PS1DeltaE9. The deficits in self-renewal and multipotency are restored by expression of Notch1-ICD or a downstream target of the Notch pathway, Hes1. Hence, we argue that a partial reduction in PS-dependent gamma-secretase processing of the Notch, at least in part, accounts for the impairments observed in SVZ NPCs expressing the FAD-linked PS1DeltaE9 variant.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Veeraraghavalu</LastName><ForeName>Karthikeyan</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, The University of Chicago, Chicago, Illinois 60637, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Se Hoon</ForeName><Initials>SH</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xiaoqiong</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Sisodia</LastName><ForeName>Sangram S</ForeName><Initials>SS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG021494</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG021494</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG027854</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027854</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG040185</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011518">Proto-Oncogene Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051880">Receptors, Notch</NameOfSubstance></Chemical><Chemical><RegistryNumber>G34N38R2N1</RegistryNumber><NameOfSubstance UI="D001973">Bromodeoxyuridine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D053687" MajorTopicYN="N">Adult Stem Cells</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001973" MajorTopicYN="N">Bromodeoxyuridine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020547" MajorTopicYN="N">Lateral Ventricles</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011518" MajorTopicYN="N">Proto-Oncogene Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051880" MajorTopicYN="N">Receptors, Notch</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>11</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20484632</ArticleId><ArticleId IdType="mid">NIHMS206674</ArticleId><ArticleId IdType="pmc">PMC2879010</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.0527-10.2010</ArticleId><ArticleId IdType="pii">30/20/6903</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alvarez-Buylla A, Lim DA. For the long run: maintaining germinal niches in the adult brain. Neuron. 2004;41:683&#x2013;686.</Citation><ArticleIdList><ArticleId IdType="pubmed">15003168</ArticleId></ArticleIdList></Reference><Reference><Citation>Androutsellis-Theotokis A, Leker RR, Soldner F, Hoeppner DJ, Ravin R, Poser SW, Rueger MA, Bae SK, Kittappa R, McKay RD. Notch signalling regulates stem cell numbers in vitro and in vivo. Nature. 2006;442:823&#x2013;826.</Citation><ArticleIdList><ArticleId IdType="pubmed">16799564</ArticleId></ArticleIdList></Reference><Reference><Citation>Bentahir M, Nyabi O, Verhamme J, Tolia A, Horr&#xe9; K, Wiltfang J, Esselmann H, De Strooper B. Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. J Neurochem. 2006;96:732&#x2013;742.</Citation><ArticleIdList><ArticleId IdType="pubmed">16405513</ArticleId></ArticleIdList></Reference><Reference><Citation>Berechid BE, Kitzmann M, Foltz DR, Roach AH, Seiffert D, Thompson LA, Olson RE, Bernstein A, Donoviel DB, Nye JS. Identification and characterization of presenilin-independent Notch signaling. J Biol Chem. 2002;277:8154&#x2013;8165.</Citation><ArticleIdList><ArticleId IdType="pubmed">11756438</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, Prada CM, Kim G, Seekins S, Yager D, Slunt HH, Wang R, Seeger M, Levey AI, Gandy SE, Copeland NG, Jenkins NA, Price DL, Younkin SG, Sisodia SS. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1&#x2013;42/1&#x2013;40 ratio in vitro and in vivo. Neuron. 1996;17:1005&#x2013;1013.</Citation><ArticleIdList><ArticleId IdType="pubmed">8938131</ArticleId></ArticleIdList></Reference><Reference><Citation>Capowski EE, Schneider BL, Ebert AD, Seehus CR, Szulc J, Zufferey R, Aebischer P, Svendsen CN. Lentiviral vector-mediated genetic modification of human neural progenitor cells for ex vivo gene therapy. J Neurosci Methods. 2007;163:338&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">17397931</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen F, Yang DS, Petanceska S, Yang A, Tandon A, Yu G, Rozmahel R, Ghiso J, Nishimura M, Zhang DM, Kawarai T, Levesque G, Mills J, Levesque L, Song YQ, Rogaeva E, Westaway D, Mount H, Gandy S, St George-Hyslop P, et al. Carboxyl-terminal fragments of Alzheimer beta-amyloid precursor protein accumulate in restricted and unpredicted intracellular compartments in presenilin 1-deficient cells. J Biol Chem. 2000;275:36794&#x2013;36802.</Citation><ArticleIdList><ArticleId IdType="pubmed">10962005</ArticleId></ArticleIdList></Reference><Reference><Citation>Chevallier NL, Soriano S, Kang DE, Masliah E, Hu G, Koo EH. Perturbed neurogenesis in the adult hippocampus associated with presenilin-1 A246E mutation. Am J Pathol. 2005;167:151&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1603433</ArticleId><ArticleId IdType="pubmed">15972961</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiasson BJ, Tropepe V, Morshead CM, van der Kooy D. Adult mammalian forebrain ependymal and subependymal cells demonstrate proliferative potential, but only subependymal cells have neural stem cell characteristics. J Neurosci. 1999;19:4462&#x2013;4471.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782600</ArticleId><ArticleId IdType="pubmed">10341247</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SH, Veeraraghavalu K, Lazarov O, Marler S, Ransohoff RM, Ramirez JM, Sisodia SS. Non-cell-autonomous effects of presenilin 1 variants on enrichment-mediated hippocampal progenitor cell proliferation and differentiation. Neuron. 2008;59:568&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3489017</ArticleId><ArticleId IdType="pubmed">18760694</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B. Aph-1, Pen-2, and nicastrin with presenilin generate an active gamma-secretase complex. Neuron. 2003;38:9&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">12691659</ArticleId></ArticleIdList></Reference><Reference><Citation>Doetsch F, Garc&#xed;a-Verdugo JM, Alvarez-Buylla A. Cellular composition and three-dimensional organization of the subventricular germinal zone in the adult mammalian brain. J Neurosci. 1997;17:5046&#x2013;5061.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573289</ArticleId><ArticleId IdType="pubmed">9185542</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferron SR, Andreu-Agullo C, Mira H, Sanchez P, Marques-Torrejon MA, Farinas I. A combined ex/in vivo assay to detect effects of exogenously added factors in neural stem cells. Nat Protoc. 2007;2:849&#x2013;859.</Citation><ArticleIdList><ArticleId IdType="pubmed">17474182</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia AD, Doan NB, Imura T, Bush TG, Sofroniew MV. GFAP-expressing progenitors are the principal source of constitutive neurogenesis in adult mouse forebrain. Nat Neurosci. 2004;7:1233&#x2013;1241.</Citation><ArticleIdList><ArticleId IdType="pubmed">15494728</ArticleId></ArticleIdList></Reference><Reference><Citation>Givogri MI, de Planell M, Galbiati F, Superchi D, Gritti A, Vescovi A, de Vellis J, Bongarzone ER. Notch signaling in astrocytes and neuroblasts of the adult subventricular zone in health and after cortical injury. Dev Neurosci. 2006;28:81&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">16508306</ArticleId></ArticleIdList></Reference><Reference><Citation>Gritti A, Fr&#xf6;lichsthal-Schoeller P, Galli R, Parati EA, Cova L, Pagano SF, Bjornson CR, Vescovi AL. Epidermal and fibroblast growth factors behave as mitogenic regulators for a single multipotent stem cell-like population from the subventricular region of the adult mouse forebrain. J Neurosci. 1999;19:3287&#x2013;3297.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782245</ArticleId><ArticleId IdType="pubmed">10212288</ArticleId></ArticleIdList></Reference><Reference><Citation>Handler M, Yang X, Shen J. Presenilin-1 regulates neuronal differentiation during neurogenesis. Development. 2000;127:2593&#x2013;2606.</Citation><ArticleIdList><ArticleId IdType="pubmed">10821758</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatakeyama J, Bessho Y, Katoh K, Ookawara S, Fujioka M, Guillemot F, Kageyama R. Hes genes regulate size, shape and histogenesis of the nervous system by control of the timing of neural stem cell differentiation. Development. 2004;131:5539&#x2013;5550.</Citation><ArticleIdList><ArticleId IdType="pubmed">15496443</ArticleId></ArticleIdList></Reference><Reference><Citation>Hitoshi S, Alexson T, Tropepe V, Donoviel D, Elia AJ, Nye JS, Conlon RA, Mak TW, Bernstein A, van der Kooy D. Notch pathway molecules are essential for the maintenance, but not the generation, of mammalian neural stem cells. Genes Dev. 2002;16:846&#x2013;858.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC186324</ArticleId><ArticleId IdType="pubmed">11937492</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeuchi T, Sisodia SS. The Notch ligands, Delta1 and Jagged2, are substrates for presenilin-dependent &#x201c;gamma-secretase&#x201d; cleavage. J Biol Chem. 2003;278:7751&#x2013;7754.</Citation><ArticleIdList><ArticleId IdType="pubmed">12551931</ArticleId></ArticleIdList></Reference><Reference><Citation>Iso T, Kedes L, Hamamori Y. HES and HERP families: multiple effectors of the Notch signaling pathway. J Cell Physiol. 2003;194:237&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pubmed">12548545</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarriault S, Brou C, Logeat F, Schroeter EH, Kopan R, Israel A. Signalling downstream of activated mammalian Notch. Nature. 1995;377:355&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pubmed">7566092</ArticleId></ArticleIdList></Reference><Reference><Citation>Jessberger S, Toni N, Clemenson GD, Jr, Ray J, Gage FH. Directed differentiation of hippocampal stem/progenitor cells in the adult brain. Nat Neurosci. 2008;11:888&#x2013;893.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2795354</ArticleId><ArticleId IdType="pubmed">18587391</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiao J, Chen DF. Induction of neurogenesis in nonconventional neurogenic regions of the adult central nervous system by niche astrocyte-produced signals. Stem Cells. 2008;26:1221&#x2013;1230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2683670</ArticleId><ArticleId IdType="pubmed">18323412</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung KM, Tan S, Landman N, Petrova K, Murray S, Lewis R, Kim PK, Kim DS, Ryu SH, Chao MV, Kim TW. Regulated intramembrane proteolysis of the p75 neurotrophin receptor modulates its association with the TrkA receptor. J Biol Chem. 2003;278:42161&#x2013;42169.</Citation><ArticleIdList><ArticleId IdType="pubmed">12913006</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang DE, Soriano S, Frosch MP, Collins T, Naruse S, Sisodia SS, Leibowitz G, Levine F, Koo EH. Presenilin 1 facilitates the constitutive turnover of beta-catenin: differential activity of Alzheimer's disease-linked PS1 mutants in the beta-catenin-signaling pathway. J Neurosci. 1999;19:4229&#x2013;4237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782616</ArticleId><ArticleId IdType="pubmed">10341227</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SH, Sisodia SS. A sequence within the first transmembrane domain of PEN-2 is critical for PEN-2-mediated endoproteolysis of presenilin 1. J Biol Chem. 2005;280:1992&#x2013;2001.</Citation><ArticleIdList><ArticleId IdType="pubmed">15537629</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim WY, Shen J. Presenilins are required for maintenance of neural stem cells in the developing brain. Mol Neurodegener. 2008;3:2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2235867</ArticleId><ArticleId IdType="pubmed">18182109</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MK, Borchelt DR, Kim G, Thinakaran G, Slunt HH, Ratovitski T, Martin LJ, Kittur A, Gandy S, Levey AI, Jenkins N, Copeland N, Price DL, Sisodia SS. Hyperaccumulation of FAD-linked presenilin 1 variants in vivo. Nat Med. 1997;3:756&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pubmed">9212102</ArticleId></ArticleIdList></Reference><Reference><Citation>Leventhal C, Rafii S, Rafii D, Shahar A, Goldman SA. Endothelial trophic support of neuronal production and recruitment from the adult mammalian subependyma. Mol Cell Neurosci. 1999;13:450&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">10383830</ArticleId></ArticleIdList></Reference><Reference><Citation>Lie DC, Colamarino SA, Song HJ, D&#xe9;sir&#xe9; L, Mira H, Consiglio A, Lein ES, Jessberger S, Lansford H, Dearie AR, Gage FH. Wnt signalling regulates adult hippocampal neurogenesis. Nature. 2005;437:1370&#x2013;1375.</Citation><ArticleIdList><ArticleId IdType="pubmed">16251967</ArticleId></ArticleIdList></Reference><Reference><Citation>Martys-Zage JL, Kim SH, Berechid B, Bingham SJ, Chu S, Sklar J, Nye J, Sisodia SS. Requirement for presenilin 1 in facilitating lagged 2-mediated endoproteolysis and signaling of notch 1. J Mol Neurosci. 2000;15:189&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">11303783</ArticleId></ArticleIdList></Reference><Reference><Citation>Merkle FT, Mirzadeh Z, Alvarez-Buylla A. Mosaic organization of neural stem cells in the adult brain. Science. 2007;317:381&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">17615304</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizutani K, Saito T. Progenitors resume generating neurons after temporary inhibition of neurogenesis by Notch activation in the mammalian cerebral cortex. Development. 2005;132:1295&#x2013;1304.</Citation><ArticleIdList><ArticleId IdType="pubmed">15750183</ArticleId></ArticleIdList></Reference><Reference><Citation>Molofsky AV, Pardal R, Morrison SJ. Diverse mechanisms regulate stem cell self-renewal. Curr Opin Cell Biol. 2004;16:700&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pubmed">15530784</ArticleId></ArticleIdList></Reference><Reference><Citation>Molofsky AV, Slutsky SG, Joseph NM, He S, Pardal R, Krishnamurthy J, Sharpless NE, Morrison SJ. Increasing p16INK4a expression decreases forebrain progenitors and neurogenesis during ageing. Nature. 2006;443:448&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2586960</ArticleId><ArticleId IdType="pubmed">16957738</ArticleId></ArticleIdList></Reference><Reference><Citation>Morshead CM, Reynolds BA, Craig CG, McBurney MW, Staines WA, Morassutti D, Weiss S, van der Kooy D. Neural stem cells in the adult mammalian forebrain: a relatively quiescent subpopulation of subependymal cells. Neuron. 1994;13:1071&#x2013;1082.</Citation><ArticleIdList><ArticleId IdType="pubmed">7946346</ArticleId></ArticleIdList></Reference><Reference><Citation>Moyse E, Segura S, Liard O, Mahaut S, Mechawar N. Microenvironmental determinants of adult neural stem cell proliferation and lineage commitment in the healthy and injured central nervous system. Curr Stem Cell Res Ther. 2008;3:163&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">18782000</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakajima M, Shimizu T, Shirasawa T. Notch-1 activation by familial Alzheimer's disease (FAD)-linked mutant forms of presenilin-1. J Neurosci Res. 2000;62:311&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pubmed">11020224</ArticleId></ArticleIdList></Reference><Reference><Citation>Naldini L, Bl&#xf6;mer U, Gage FH, Trono D, Verma IM. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci U S A. 1996;93:11382&#x2013;11388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC38066</ArticleId><ArticleId IdType="pubmed">8876144</ArticleId></ArticleIdList></Reference><Reference><Citation>Nowakowski RS, Lewin SB, Miller MW. Bromodeoxyuridine immunohistochemical determination of the lengths of the cell cycle and the DNA-synthetic phase for an anatomically defined population. J Neurocytol. 1989;18:311&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">2746304</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyfeler Y, Kirch RD, Mantei N, Leone DP, Radtke F, Suter U, Taylor V. Jagged1 signals in the postnatal subventricular zone are required for neural stem cell self-renewal. EMBO J. 2005;24:3504&#x2013;3515.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1276174</ArticleId><ArticleId IdType="pubmed">16163386</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohtsuka T, Ishibashi M, Gradwohl G, Nakanishi S, Guillemot F, Kageyama R. Hes1 and Hes5 as notch effectors in mammalian neuronal differentiation. EMBO J. 1999;18:2196&#x2013;2207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1171303</ArticleId><ArticleId IdType="pubmed">10205173</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohtsuka T, Imayoshi I, Shimojo H, Nishi E, Kageyama R, McConnell SK. Visualization of embryonic neural stem cells using Hes promoters in transgenic mice. Mol Cell Neurosci. 2006;31:109&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">16214363</ArticleId></ArticleIdList></Reference><Reference><Citation>Palma V, Lim DA, Dahmane N, S&#xe1;nchez P, Brionne TC, Herzberg CD, Gitton Y, Carleton A, Alvarez-Buylla A, Ruiz i Altaba A. Sonic hedgehog controls stem cell behavior in the postnatal and adult brain. Development. 2005;132:335&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1431583</ArticleId><ArticleId IdType="pubmed">15604099</ArticleId></ArticleIdList></Reference><Reference><Citation>Parent A, Linden DJ, Sisodia SS, Borchelt DR. Synaptic transmission and hippocampal long-term potentiation in transgenic mice expressing FAD-linked presenilin 1. Neurobiol Dis. 1999;6:56&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">10078973</ArticleId></ArticleIdList></Reference><Reference><Citation>Pear WS, Nolan GP, Scott ML, Baltimore D. Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci U S A. 1993;90:8392&#x2013;8396.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47362</ArticleId><ArticleId IdType="pubmed">7690960</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray J, Gage FH. Differential properties of adult rat and mouse brain-derived neural stem/progenitor cells. Mol Cell Neurosci. 2006;31:560&#x2013;573.</Citation><ArticleIdList><ArticleId IdType="pubmed">16426857</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeter EH, Kisslinger JA, Kopan R. Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. Nature. 1998;393:382&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pubmed">9620803</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol. 1998;8:447&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">9854312</ArticleId></ArticleIdList></Reference><Reference><Citation>Shawber C, Nofziger D, Hsieh JJ, Lindsell C, B&#xf6;gler O, Hayward D, Weinmaster G. Notch signaling inhibits muscle cell differentiation through a CBF1-independent pathway. Development. 1996;122:3765&#x2013;3773.</Citation><ArticleIdList><ArticleId IdType="pubmed">9012498</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen J, Bronson RT, Chen DF, Xia W, Selkoe DJ, Tonegawa S. Skeletal and CNS defects in Presenilin-1-deficient mice. Cell. 1997;89:629&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">9160754</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Q, Goderie SK, Jin L, Karanth N, Sun Y, Abramova N, Vincent P, Pumiglia K, Temple S. Endothelial cells stimulate self-renewal and expand neurogenesis of neural stem cells. Science. 2004;304:1338&#x2013;1340.</Citation><ArticleIdList><ArticleId IdType="pubmed">15060285</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisodia SS, St George-Hyslop PH. gamma-Secretase, Notch, Abeta and Alzheimer's disease: where do the presenilins fit in? Nat Rev Neurosci. 2002;3:281&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pubmed">11967558</ArticleId></ArticleIdList></Reference><Reference><Citation>Song H, Stevens CF, Gage FH. Astroglia induce neurogenesis from adult neural stem cells. Nature. 2002;417:39&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">11986659</ArticleId></ArticleIdList></Reference><Reference><Citation>Song W, Nadeau P, Yuan M, Yang X, Shen J, Yankner BA. Proteolytic release and nuclear translocation of Notch-1 are induced by presenilin-1 and impaired by pathogenic presenilin-1 mutations. Proc Natl Acad Sci U S A. 1999;96:6959&#x2013;6963.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22024</ArticleId><ArticleId IdType="pubmed">10359821</ArticleId></ArticleIdList></Reference><Reference><Citation>Takebayashi K, Sasai Y, Sakai Y, Watanabe T, Nakanishi S, Kageyama R. Structure, chromosomal locus, and promoter analysis of the gene encoding the mouse helix-loop-helix factor HES-1. Negative autoregulation through the multiple N box elements. J Biol Chem. 1994;269:5150&#x2013;5156.</Citation><ArticleIdList><ArticleId IdType="pubmed">7906273</ArticleId></ArticleIdList></Reference><Reference><Citation>Takebayashi K, Akazawa C, Nakanishi S, Kageyama R. Structure and promoter analysis of the gene encoding the mouse helix-loop-helix factor HES-5. Identification of the neural precursor cell-specific promoter element. J Biol Chem. 1995;270:1342&#x2013;1349.</Citation><ArticleIdList><ArticleId IdType="pubmed">7836401</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran G, Borchelt DR, Lee MK, Slunt HH, Spitzer L, Kim G, Ratovitsky T, Davenport F, Nordstedt C, Seeger M, Hardy J, Levey AI, Gandy SE, Jenkins NA, Copeland NG, Price DL, Sisodia SS. Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron. 1996;17:181&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">8755489</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderluit JL, Ferguson KL, Nikoletopoulou V, Parker M, Ruzhynsky V, Alexson T, McNamara SM, Park DS, Rudnicki M, Slack RS. p107 regulates neural precursor cells in the mammalian brain. J Cell Biol. 2004;166:853&#x2013;863.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172121</ArticleId><ArticleId IdType="pubmed">15353549</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidal GA, Naresh A, Marrero L, Jones FE. Presenilin-dependent gamma-secretase processing regulates multiple ERBB4/HER4 activities. J Biol Chem. 2005;280:19777&#x2013;19783.</Citation><ArticleIdList><ArticleId IdType="pubmed">15746097</ArticleId></ArticleIdList></Reference><Reference><Citation>Walton NM, Sutter BM, Laywell ED, Levkoff LH, Kearns SM, Marshall GP, 2nd, Scheffler B, Steindler DA. Microglia instruct subventricular zone neurogenesis. Glia. 2006;54:815&#x2013;825.</Citation><ArticleIdList><ArticleId IdType="pubmed">16977605</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R, Dineley KT, Sweatt JD, Zheng H. Presenilin 1 familial Alzheimer's disease mutation leads to defective associative learning and impaired adult neurogenesis. Neuroscience. 2004;126:305&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pubmed">15207348</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen PH, Friedrich VL, Jr, Shioi J, Robakis NK, Elder GA. Presenilin-1 is expressed in neural progenitor cells in the hippocampus of adult mice. Neurosci Lett. 2002;318:53&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">11796184</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen PH, Hof PR, Chen X, Gluck K, Austin G, Younkin SG, Younkin LH, DeGasperi R, Gama Sosa MA, Robakis NK, Haroutunian V, Elder GA. The presenilin-1 familial Alzheimer disease mutant P117L impairs neurogenesis in the hippocampus of adult mice. Exp Neurol. 2004;188:224&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pubmed">15246822</ArticleId></ArticleIdList></Reference><Reference><Citation>West MJ. Stereological methods for estimating the total number of neurons and synapses: issues of precision and bias. Trends Neurosci. 1999;22:51&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">10092043</ArticleId></ArticleIdList></Reference><Reference><Citation>West MJ, Gundersen HJ. Unbiased stereological estimation of the number of neurons in the human hippocampus. J Comp Neurol. 1990;296:1&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">2358525</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature. 1999;398:513&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206644</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong PC, Zheng H, Chen H, Becher MW, Sirinathsinghji DJ, Trumbauer ME, Chen HY, Price DL, Van der Ploeg LH, Sisodia SS. Presenilin 1 is required for Notch1 and DII1 expression in the paraxial mesoderm. Nature. 1997;387:288&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pubmed">9153393</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Liu Y, Levine EM, Rao MS. Hes1 but not Hes5 regulates an astrocyte versus oligodendrocyte fate choice in glial restricted precursors. Dev Dyn. 2003;226:675&#x2013;689.</Citation><ArticleIdList><ArticleId IdType="pubmed">12666205</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia W, Zhang J, Ostaszewski BL, Kimberly WT, Seubert P, Koo EH, Shen J, Selkoe DJ. Presenilin 1 regulates the processing of beta-amyloid precursor protein C-terminal fragments and the generation of amyloid beta-protein in endoplasmic reticulum and Golgi. Biochemistry. 1998;37:16465&#x2013;16471.</Citation><ArticleIdList><ArticleId IdType="pubmed">9843412</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu X, Zhan X, D'Costa J, Tanavde VM, Ye Z, Peng T, Malehorn MT, Yang X, Civin CI, Cheng L. Lentiviral vectors with two independent internal promoters transfer high-level expression of multiple transgenes to human hematopoietic stem-progenitor cells. Mol Ther. 2003;7:827&#x2013;838.</Citation><ArticleIdList><ArticleId IdType="pubmed">12788657</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu X, Zou J, Ye Z, Hammond H, Chen G, Tokunaga A, Mali P, Li YM, Civin C, Gaiano N, Cheng L. Notch signaling activation in human embryonic stem cells is required for embryonic, but not trophoblastic, lineage commitment. Cell Stem Cell. 2008;2:461&#x2013;471.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2442567</ArticleId><ArticleId IdType="pubmed">18462696</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaman SH, Parent A, Laskey A, Lee MK, Borchelt DR, Sisodia SS, Malinow R. Enhanced synaptic potentiation in transgenic mice expressing presenilin 1 familial Alzheimer's disease mutation is normalized with a benzodiazepine. Neurobiol Dis. 2000;7:54&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">10671322</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20505094</PMID><DateCompleted><Year>2010</Year><Month>06</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>21</Issue><PubDate><Year>2010</Year><Month>May</Month><Day>26</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline.</ArticleTitle><Pagination><StartPage>7281</StartPage><EndPage>7289</EndPage><MedlinePgn>7281-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.0490-10.2010</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD), the most prevalent age-related neurodegenerative disorder, is characterized pathologically by the accumulation of beta-amyloid (Abeta) plaques and tau-laden neurofibrillary tangles. Interestingly, up to 50% of AD cases exhibit a third prevalent neuropathology: the aggregation of alpha-synuclein into Lewy bodies. Importantly, the presence of Lewy body pathology in AD is associated with a more aggressive disease course and accelerated cognitive dysfunction. Thus, Abeta, tau, and alpha-synuclein may interact synergistically to promote the accumulation of each other. In this study, we used a genetic approach to generate a model that exhibits the combined pathologies of AD and dementia with Lewy bodies (DLB). To achieve this goal, we introduced a mutant human alpha-synuclein transgene into 3xTg-AD mice. As occurs in human disease, transgenic mice that develop both DLB and AD pathologies (DLB-AD mice) exhibit accelerated cognitive decline associated with a dramatic enhancement of Abeta, tau, and alpha-synuclein pathologies. Our findings also provide additional evidence that the accumulation of alpha-synuclein alone can significantly disrupt cognition. Together, our data support the notion that Abeta, tau, and alpha-synuclein interact in vivo to promote the aggregation and accumulation of each other and accelerate cognitive dysfunction.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Clinton</LastName><ForeName>Lani K</ForeName><Initials>LK</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, University of California, Irvine, Irvine, California 92697-4545, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blurton-Jones</LastName><ForeName>Mathew</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Myczek</LastName><ForeName>Kristoffer</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials></Author><Author ValidYN="Y"><LastName>LaFerla</LastName><ForeName>Frank M</ForeName><Initials>FM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG027544</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG16573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS053488</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG029378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG000096</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS-053488</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R29 AG015409</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG00096</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001362" MajorTopicYN="N">Avoidance Learning</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018507" MajorTopicYN="N">Gene Expression Regulation, Developmental</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007266" MajorTopicYN="N">Inhibition, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016631" MajorTopicYN="N">Lewy Bodies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>11</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20505094</ArticleId><ArticleId IdType="mid">NIHMS217727</ArticleId><ArticleId IdType="pmc">PMC3308018</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.0490-10.2010</ArticleId><ArticleId IdType="pii">30/21/7281</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Barnes CA. Memory deficits associated with senescence: a neurophysiological and behavioral study in the rat. J Comp Physiol Psychol. 1979;93:74&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">221551</ArticleId></ArticleIdList></Reference><Reference><Citation>Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron. 2005;45:675&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pubmed">15748844</ArticleId></ArticleIdList></Reference><Reference><Citation>Blurton-Jones M, Tuszynski MH. Estradiol-induced modulation of estrogen receptor-beta and GABA within the adult neocortex: a potential transsynaptic mechanism for estrogen modulation of BDNF. J Comp Neurol. 2006;499:603&#x2013;612.</Citation><ArticleIdList><ArticleId IdType="pubmed">17029253</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinton LK, Billings LM, Green KN, Caccamo A, Ngo J, Oddo S, McGaugh JL, LaFerla FM. Age-dependent sexual dimorphism in cognition and stress response in the 3xTg-AD mice. Neurobiol Dis. 2007;28:76&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2756084</ArticleId><ArticleId IdType="pubmed">17659878</ArticleId></ArticleIdList></Reference><Reference><Citation>F&#xf6;rstl H, Burns A, Luthert P, Cairns N, Levy R. The Lewy-body variant of Alzheimer's disease. Clinical and pathological findings. Br J Psychiatry. 1993;162:385&#x2013;392.</Citation><ArticleIdList><ArticleId IdType="pubmed">8453435</ArticleId></ArticleIdList></Reference><Reference><Citation>Frasier M, Walzer M, McCarthy L, Magnuson D, Lee JM, Haas C, Kahle P, Wolozin B. Tau phosphorylation increases in symptomatic mice overexpressing A30P alpha-synuclein. Exp Neurol. 2005;192:274&#x2013;287.</Citation><ArticleIdList><ArticleId IdType="pubmed">15755545</ArticleId></ArticleIdList></Reference><Reference><Citation>Freichel C, Neumann M, Ballard T, M&#xfc;ller V, Woolley M, Ozmen L, Borroni E, Kretzschmar HA, Haass C, Spooren W, Kahle PJ. Age-dependent cognitive decline and amygdala pathology in alpha-synuclein transgenic mice. Neurobiol Aging. 2007;28:1421&#x2013;1435.</Citation><ArticleIdList><ArticleId IdType="pubmed">16872721</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Iwatsubo T. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002;4:160&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">11813001</ArticleId></ArticleIdList></Reference><Reference><Citation>Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron. 2002;34:521&#x2013;533.</Citation><ArticleIdList><ArticleId IdType="pubmed">12062037</ArticleId></ArticleIdList></Reference><Reference><Citation>Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT, Trojanowski JQ, Lee VM. Initiation and synergistic fibrillization of tau and alpha-synuclein. Science. 2003;300:636&#x2013;640.</Citation><ArticleIdList><ArticleId IdType="pubmed">12714745</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton RL. Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol. 2000;10:378&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8098522</ArticleId><ArticleId IdType="pubmed">10885656</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen L, Salmon D, Galasko D, Masliah E, Katzman R, DeTeresa R, Thal L, Pay MM, Hofstetter R, Klauber M, Rice V, Butters N, Alford M. The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity. Neurology. 1990;40:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">2153271</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarrett JT, Berger EP, Lansbury PT., Jr The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry. 1993;32:4693&#x2013;4697.</Citation><ArticleIdList><ArticleId IdType="pubmed">8490014</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotzbauer PT, Giasson BI, Kravitz AV, Golbe LI, Mark MH, Trojanowski JQ, Lee VM. Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation. Exp Neurol. 2004;187:279&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pubmed">15144854</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraybill ML, Larson EB, Tsuang DW, Teri L, McCormick WC, Bowen JD, Kukull WA, Leverenz JB, Cherrier MM. Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both. Neurology. 2005;64:2069&#x2013;2073.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1513627</ArticleId><ArticleId IdType="pubmed">15985574</ArticleId></ArticleIdList></Reference><Reference><Citation>Langlais PJ, Thal L, Hansen L, Galasko D, Alford M, Masliah E. Neurotransmitters in basal ganglia and cortex of Alzheimer's disease with and without Lewy bodies. Neurology. 1993;43:1927&#x2013;1934.</Citation><ArticleIdList><ArticleId IdType="pubmed">8105420</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HJ, Patel S, Lee SJ. Intravesicular localization and exocytosis of &#x3b1;-synuclein and its aggregates. J Neurosci. 2005;25:6016&#x2013;6024.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6724798</ArticleId><ArticleId IdType="pubmed">15976091</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee VM, Giasson BI, Trojanowski JQ. More than just two peas in a pod: common amyloidogenic properties of tau and alpha-synuclein in neurodegenerative diseases. Trends Neurosci. 2004;27:129&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">15036877</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehman EJ, Kulnane LS, Gao Y, Petriello MC, Pimpis KM, Younkin L, Dolios G, Wang R, Younkin SG, Lamb BT. Genetic background regulates beta-amyloid precursor protein processing and beta-amyloid deposition in the mouse. Hum Mol Genet. 2003;12:2949&#x2013;2956.</Citation><ArticleIdList><ArticleId IdType="pubmed">14506131</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandal PK, Pettegrew JW, Masliah E, Hamilton RL, Mandal R. Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease. Neurochem Res. 2006;31:1153&#x2013;1162.</Citation><ArticleIdList><ArticleId IdType="pubmed">16947080</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M, Mucke L. &#x3b2;-Amyloid peptides enhance &#x3b1;-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci U S A. 2001;98:12245&#x2013;12250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC59799</ArticleId><ArticleId IdType="pubmed">11572944</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003;39:409&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron. 2004;43:321&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pubmed">15294141</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Tran L, Lambert MP, Glabe CG, Klein WL, LaFerla FM. Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J Biol Chem. 2006;281:1599&#x2013;1604.</Citation><ArticleIdList><ArticleId IdType="pubmed">16282321</ArticleId></ArticleIdList></Reference><Reference><Citation>Okochi M, Walter J, Koyama A, Nakajo S, Baba M, Iwatsubo T, Meijer L, Kahle PJ, Haass C. Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein. J Biol Chem. 2000;275:390&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pubmed">10617630</ArticleId></ArticleIdList></Reference><Reference><Citation>Olichney JM, Galasko D, Salmon DP, Hofstetter CR, Hansen LA, Katzman R, Thal LJ. Cognitive decline is faster in Lewy body variant than in Alzheimer's disease. Neurology. 1998;51:351&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">9710002</ArticleId></ArticleIdList></Reference><Reference><Citation>Postina R. A closer look at alpha-secretase. Curr Alzheimer Res. 2008;5:179&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pubmed">18393803</ArticleId></ArticleIdList></Reference><Reference><Citation>Raghavan R, Khin-Nu C, Brown A, Irving D, Ince PG, Day K, Tyrer SP, Perry RH. Detection of Lewy bodies in trisomy 21 (Down's syndrome) Can J Neurol Sci. 1993;20:48&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">8467429</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith WW, Margolis RL, Li X, Troncoso JC, Lee MK, Dawson VL, Dawson TM, Iwatsubo T, Ross CA. &#x3b1;-Synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. J Neurosci. 2005;25:5544&#x2013;5552.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6724982</ArticleId><ArticleId IdType="pubmed">15944382</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki N, Cheung TT, Cai XD, Odaka A, Otvos L, Jr, Eckman C, Golde TE, Younkin SG. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science. 1994;264:1336&#x2013;1340.</Citation><ArticleIdList><ArticleId IdType="pubmed">8191290</ArticleId></ArticleIdList></Reference><Reference><Citation>Trojanowski JQ. &#x201c;Emerging Alzheimer's disease therapies: focusing on the future.&#x201d;. Neurobiol Aging. 2002;23:985&#x2013;990.</Citation><ArticleIdList><ArticleId IdType="pubmed">12470793</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsigelny IF, Crews L, Desplats P, Shaked GM, Sharikov Y, Mizuno H, Spencer B, Rockenstein E, Trejo M, Platoshyn O, Yuan JX, Masliah E. Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases. PLoS ONE. 2008;3:e3135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2519786</ArticleId><ArticleId IdType="pubmed">18769546</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamasaki TR, Blurton-Jones M, Morrissette DA, Kitazawa M, Oddo S, LaFerla FM. Neural stem cells improve memory in an inducible mouse model of neuronal loss. J Neurosci. 2007;27:11925&#x2013;11933.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673368</ArticleId><ArticleId IdType="pubmed">17978032</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasojima K, Kuret J, DeMaggio AJ, McGeer E, McGeer PL. Casein kinase 1 delta mRNA is upregulated in Alzheimer disease brain. Brain Res. 2000;865:116&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">10814741</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20538376</PMID><DateCompleted><Year>2011</Year><Month>03</Month><Day>29</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1558-1497</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>8</Issue><PubDate><Year>2010</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Neurobiology of aging</Title><ISOAbbreviation>Neurobiol Aging</ISOAbbreviation></Journal><ArticleTitle>3D maps localize caudate nucleus atrophy in 400 Alzheimer's disease, mild cognitive impairment, and healthy elderly subjects.</ArticleTitle><Pagination><StartPage>1312</StartPage><EndPage>1325</EndPage><MedlinePgn>1312-25</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neurobiolaging.2010.05.002</ELocationID><Abstract><AbstractText>MRI research examining structural brain atrophy in Alzheimer's disease (AD) generally focuses on medial temporal and cortical structures, but amyloid and tau deposits also accumulate in the caudate. Here we mapped the 3D profile of caudate atrophy using a surface mapping approach in subjects with AD and mild cognitive impairment (MCI) to identify potential clinical and pathological correlates. 3D surface models of the caudate were automatically extracted from 400 baseline MRI scans (100 AD, 200 MCI, 100 healthy elderly). Compared to controls, caudate volumes were lower in MCI (2.64% left, 4.43% right) and AD (4.74% left, 8.47% right). Caudate atrophy was associated with age, sum-of-boxes and global Clinical Dementia Ratings, Delayed Logical Memory scores, MMSE decline 1 year later, and body mass index. Reduced right (but not left) volume was associated with MCI-to-AD conversion and CSF tau levels. Normal caudate asymmetry (with the right 3.9% larger than left) was lost in AD, suggesting preferential right caudate atrophy. Automated caudate maps may complement other MRI-derived measures of disease burden in AD.</AbstractText><CopyrightInformation>2010 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Madsen</LastName><ForeName>S K</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Laboratory of Neuro Imaging, Department of Neurology, University of California, Los Angeles, School of Medicine, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>A J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Hua</LastName><ForeName>X</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Saharan</LastName><ForeName>P S</ForeName><Initials>PS</Initials></Author><Author ValidYN="Y"><LastName>Toga</LastName><ForeName>A W</ForeName><Initials>AW</Initials></Author><Author ValidYN="Y"><LastName>Jack</LastName><ForeName>C R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix></Author><Author ValidYN="Y"><LastName>Weiner</LastName><ForeName>M W</ForeName><Initials>MW</Initials></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>P M</ForeName><Initials>PM</Initials></Author><Author ValidYN="Y"><CollectiveName>Alzheimer's Disease Neuroimaging Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K01 AG030514</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>06</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Aging</MedlineTA><NlmUniqueID>8100437</NlmUniqueID><ISSNLinking>0197-4580</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002421" MajorTopicYN="N">Caudate Nucleus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021621" MajorTopicYN="Y">Imaging, Three-Dimensional</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Disclosure Statement:</b> The authors have no potential financial or personal conflicts of interest including relationships with other people or organizations within three years of beginning the work submitted that could inappropriately influence this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>2</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>8</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20538376</ArticleId><ArticleId IdType="mid">NIHMS203917</ArticleId><ArticleId IdType="pmc">PMC2903198</ArticleId><ArticleId IdType="doi">10.1016/j.neurobiolaging.2010.05.002</ArticleId><ArticleId IdType="pii">S0197-4580(10)00213-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ballmaier M, Schlagenhauf F, Toga AW, Gallinat J, Koslowski M, Zoli M, Hojatkashani C, Narr KL, Heinz A. Regional patterns and clinical correlates of basal ganglia morphology in non-medicated schizophrenia. Schizophrenia Research. 2008;106(2-3):140&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2709178</ArticleId><ArticleId IdType="pubmed">18818054</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartzokis G, Sultzer D, Cummings J, Holt LE, Hance DB, Henderson VW, Mintz J. In vivo evaluation of brain iron in Alzheimer disease using magnetic resonance imaging. Arch Gen Psychiatry. 2000;57(1):47&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">10632232</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumann B, Danos P, Krell D, Diekmann S, Leschinger A, Stauch R, Wurthmann C, Berstein HG, Bogerts B. Reduced volume of limbic system-affiliated basal ganglia in mood disorders: Preliminary data from a postmortem study. Journal of Neuropsychiatry and Clinical Neurosciences. 1999;11:71&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">9990559</ArticleId></ArticleIdList></Reference><Reference><Citation>Beacher F, Daly E, Simmons A, Prasher V, Morris R, Robinson C, Lovestone S, Murphy K, Murphy DG. Alzheimer's disease and Down's syndrome, an in vivo MRI study. Psychol Med. 2009;39(4):675&#x2013;684.</Citation><ArticleIdList><ArticleId IdType="pubmed">18667098</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker JT, Davis SW, Hayashi KM, Meltzer CC, Toga AW, Lopez OL, Thompson PM. Three-dimensional patterns of hippocampal atrophy in mild cognitive impairment. Arch Neurol. 2006;63:97&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">16401741</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanton RE, Levitt J, Thompson PM, Badrtalei S, Capetillo-Cunliffe L, Toga AW. Average 3-Dimensional Caudate Surface Representations in a Juvenile-Onset Schizophrenia and Normal Pediatric Population. 5th International Conference on Functional Mapping of the Human Brain; 1999. Presentation 621.</Citation></Reference><Reference><Citation>Braak H, Braak E. Alzheimer's disease, Striatal amyloid deposits and neurofibrillary changes. J Neuropathol Exp Neurol. 1990;49(3):215&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">1692337</ArticleId></ArticleIdList></Reference><Reference><Citation>Butters MA, Aizenstein HJ, Hayashi KM, Meltzer CC, Seaman J, Reynolds CF, Toga AW, Thompson PM, Becker JT IMAGe Research Group. Three-dimensional mapping of the caudate nucleus in late-life depression. American Journal of Geriatric Psychiatry. 2008;17(1):4&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2970509</ArticleId><ArticleId IdType="pubmed">18790876</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlson JN, Glick SD. Cerebral lateralization as a source of interindividual differences in behavior. Cellular and Molecular Life Sciences. 1989;45(9):788&#x2013;798.</Citation><ArticleIdList><ArticleId IdType="pubmed">2673833</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellanos FX, Giedd JN, Marsh WL, Hamburger SD, Vaituzis AC, Dicktein DP, Sarfatti SE, Vauss YC, Snell JW, Lange N, Kaysen D, Krain AL, Ritchie GF, Rajapakse JC, Rapoport JL. Quantitative brain magnetic resonance imaging in attention-deficit hyperactivity disorder. Archives of General Psychiatry. 1996;35(7):607&#x2013;616.</Citation><ArticleIdList><ArticleId IdType="pubmed">8660127</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou YY, Lepore N, Avedissian C, Madsen SK, Parikshak N, Hua X, Shaw LM, Trojanowski JQ, Weiner MW, Toga AW, Thompson PM the Alzheimer's Disease Neuroimaging Initiative. Mapping correlations between ventricular expansion and CSF amyloid and tau biomarkers in 240 subjects with Alzheimer's disease, mild cognitive impairment and elderly controls. Neuroimage. 2009;46(2):394&#x2013;410.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696357</ArticleId><ArticleId IdType="pubmed">19236926</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou YY, Lepore N, Saharan P, Madsen SK, Hua X, Jack CJ, Jr, Shaw L, Trojanowski JQ, Weiner MW, Toga AW, Thomspon PM the Alzheimer's Disease Neuroimaging Initiative. Ranking the Clinical and Pathological Correlates of Ventricular Expansion Mapped in 804 Alzheimer's Disease, MCI, and Normal Elderly Subjects. Neurobiology of Aging, Special Issue on ADNI. 2010 Revision to be submitted 23 April 2010.</Citation></Reference><Reference><Citation>Cockrell JR, Folstein MF. Mini-Mental State Examination (MMSE) Psychopharmacol Bull. 1988;24(4):689&#x2013;692.</Citation><ArticleIdList><ArticleId IdType="pubmed">3249771</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins DL, Neelin P, Peters TM, Evans AC. Automatic 3D intersubject registration of MR volumetric data in standardized Talairach space. J Comput Assist Tomogr. 1994;18:192&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">8126267</ArticleId></ArticleIdList></Reference><Reference><Citation>Crow TJ, Done DJ, Sacker A. Cerebral lateralization is delayed in children who later develop schizophrenia. Schizophrenia Research. 1996;22(3):181&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">9000315</ArticleId></ArticleIdList></Reference><Reference><Citation>Csernansky JG, Wang L, Joshi SC, Ratnanather JT, Miller MI. Computational anatomy and neuropsychiatric disease, Probabilistic assessment of variation and statistical inference of group difference, hemispheric asymmetry, and time-dependent change. Neuroimage. 2004;23(Suppl 1):S56&#x2013;S68.</Citation><ArticleIdList><ArticleId IdType="pubmed">15501101</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL. Anatomic and behavioural aspects of frontal-subcortical circuits. Ann N Y Acad Sci. 1995;769:1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">8595019</ArticleId></ArticleIdList></Reference><Reference><Citation>De Jong LW, van der Hiele K, Veer IM, Houwing JJ, Westendorp RG, Bollen EL, de Bruin PW, Middelkoop HA, van Buchem MA, van der Grond J. Strongly reduced volumes of putamen and thalamus in Alzheimer's disease, an MRI study. Brain. 2008;131(12):3277&#x2013;3285.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2639208</ArticleId><ArticleId IdType="pubmed">19022861</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, van der Kouwe A, Killiany R, Kennedy D, Klaveness S, Montillo A, Makris N, Rosen B, Dale AM. Whole brain segmentation, Automated labeling of neuroanatomical structures in the human brain. Neuron. 2002;33:341&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">11832223</ArticleId></ArticleIdList></Reference><Reference><Citation>Frisoni GB, Lorenzi M, Caroli A, Kemppainen N, N&#xe5;gren K, Rinne JO. In vivo mapping of amyloid toxicity in Alzheimer disease. Neurology. 2009;72(17):1504&#x2013;1511.</Citation><ArticleIdList><ArticleId IdType="pubmed">19398705</ArticleId></ArticleIdList></Reference><Reference><Citation>Giedd JN, Snell JW, Lange N, Rajapakse JC, Casey BJ, Kozuch PL, Vaituzis AC, Vauss YC, Hamburger SD, Kaysen D, Rapoport JL. Quantitative magnetic resonance imaging of human brain development, ages 4-18. Cereb Cortex. 1996;6(4):551&#x2013;560.</Citation><ArticleIdList><ArticleId IdType="pubmed">8670681</ArticleId></ArticleIdList></Reference><Reference><Citation>Good CD, Scahill RI, Fox NC, Ashburner J, Friston KJ, Chan D, Crum WR, Rossor MN, Frackowiak RSJ. Automatic Differentiation of anatomical patterns in the human brain: validation with studies of degenerative dementias. NeuroImage. 2002;17(1):29&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">12482066</ArticleId></ArticleIdList></Reference><Reference><Citation>Gothelf D, Furfaro JA, Eckert MA, Hall SS, O'Hara R, Erba HW, Ringel J, Hayashi KM, Patnaik S, Golianu B, Kraemer HC, Thompson PM, Piven J, Reiss AL. Neuroanatomy of Fragile X Syndrome is Associated with Aberrant Behavior and FMRP. Annals of Neurology. 2008;63(1):40&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2773141</ArticleId><ArticleId IdType="pubmed">17932962</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunning-Dixon FM, Head D, McQuain J, Acker JD, Raz N. Differential aging of the human striatum, A prospective MR imaging study. American Journal of Neuroradiology. 1998;19(8):1501&#x2013;1507.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8338671</ArticleId><ArticleId IdType="pubmed">9763385</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunter J, Bernstein M, Borowski B, Felmlee J, Blezek D, Mallozzi R. Validation testing of the MRI calibration phantom for the Alzheimer's disease neuroimaging initiative study. ISMRM 14th Scientific Meeting and Exhibition; Seattle, Washington. 2006.</Citation></Reference><Reference><Citation>Helzner EP, Luchsinger JA, Scarmeas N, Cosentino S, Brickman AM, Glymour MM, Stern Y. Contribution of vascular risk factors to the progression in Alzheimer Disease. Archives of Neurology. 2009;66(3):3434&#x2013;348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3105324</ArticleId><ArticleId IdType="pubmed">19273753</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho AJ, Raji CA, Becker JT, Lopez OL, Kuller LW, Hua X, Lee S, Hibar D, Dinov ID, Stein JL, Jack CR, Weiner MW, Toga AW, Thompson PM. Obesity and Brain Structure in 700 AD and MCI Patients. Neurobiology of Aging, Special Issue on ADNI. 2010a April; in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3197833</ArticleId><ArticleId IdType="pubmed">20570405</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho AJ, Stein JL, Hua X, Lee S, Hibar DP, Leow AD, Dinov ID, Toga AW, Saykin AJ, Shen L, Foround T, Pankratz N, Huentelman MJ, Craig DW, Gerber JD, Allen AN, Corneveaux JJ, Stephan DA, Decarli CS, Dechairo BM, Potkin SG, Jack CR, Jr, Weiner MW, Raji CA, Lopez OL, Becker JT, Carmichael OT, Thompson PM the Alzheimer's Disease Neuroimaging Initiative. A commonly carried allele of the obesity-related FTO gene is associated with reduced brain volume in the healthy elderly. PNAS Epub ahead of print 2010b</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2889537</ArticleId><ArticleId IdType="pubmed">20404173</ArticleId></ArticleIdList></Reference><Reference><Citation>Hynd GW, Hern KL, Novey ES, Eliopulos D, Marshall R, Gonzalez JJ, Voeller KK. Attention deficit-hyperactivity disorder and asymmetry of the caudate nucleus. J Child Neurol. 1993;8(4):339&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pubmed">8228029</ArticleId></ArticleIdList></Reference><Reference><Citation>Ifthikharuddin SF, Shrier DA, Numaguchi Y, Tang X, Ning R, Shibata DK, Kurlan R. MR volumetric analysis of the human basal ganglia, normative data. Acad Radiol. 2000;7:627&#x2013;634.</Citation><ArticleIdList><ArticleId IdType="pubmed">10952114</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, Lopresti BJ, Ziolko S, Bi W, Paljug WR, Debnath ML, Hope CE, Isanski BA, Hamilton RL, DeKosky ST. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain. 2008;131(6):1630&#x2013;1645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2408940</ArticleId><ArticleId IdType="pubmed">18339640</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, Borowski B, Britson PJ, Whitwell J, Ward C, Dale AM, Felmlee JP, Gunter JL, Hill DL, Killiany R, Schuff N, Fox-Bosetti S, Lin C, Studholme C, DeCarli CS, Krueger G, Ward HA, Metzger GJ, Scott KT, Mallozzi R, Blezek D, Levy J, Debbins JP, Fleisher AS, Albert M, Green R, Bartzokis G, Glover G, Mugler J, Weiner MW. The Alzheimer's Disease Neuroimaging Initiative (ADNI), MRI methods. J Magn Reson Imaging. 2008;27:685&#x2013;691.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2544629</ArticleId><ArticleId IdType="pubmed">18302232</ArticleId></ArticleIdList></Reference><Reference><Citation>Javadapour A, Malhim GS, Ivandovski B, Chen X, Wen W, Sachdev P. Hippocampal volumes in adults with bipolar disorder. Journal of Neuropsychiatry and Clinical Neurosciences. 2010;22:55&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">20160210</ArticleId></ArticleIdList></Reference><Reference><Citation>Jernigan TL, Archibald SL, Fennema-Notestine C, Gamst AC, Stout JC, Bonner J, Hesselink JR. Effects of age on tissues and regions of the cerebrum and cerebellum. Neurobiol Aging. 2001;22:581&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">11445259</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorm AF, Korten AE, Henderson AS. The prevalence of dementia, a quantitative integration of the literature. Acta Pscyhiatr Scan. 1987;765:465&#x2013;479.</Citation><ArticleIdList><ArticleId IdType="pubmed">3324647</ArticleId></ArticleIdList></Reference><Reference><Citation>Jovicich J, Czanner S, Greve D, Haley E, van der Kouwe A, Gollub R, Kennedy D, Schmitt F, Brown G, Macfall J, Fischl B, Dale A. Reliability in multi-site structural MRI studies, Effects of gradient non-linearity correction on phantom and human data. Neuroimage. 2006;30:436&#x2013;443.</Citation><ArticleIdList><ArticleId IdType="pubmed">16300968</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemppainen N, Ruottinen H, N&#xe2;gren K, Rinne JO. PET shows that striatal dopamine D1 and D2 receptors are differentially affected in AD. Neurology. 2000;55(2):205&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pubmed">10908891</ArticleId></ArticleIdList></Reference><Reference><Citation>Klieger PS, Fett KA, Dimitsopulos T, Kurlan R. Asymmetry of basal ganglia perfusion in Tourette's syndrome shown by technetium-99m-HMPAO SPECT. The Journal of Nuclear Medicine. 1997;38(2):188&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pubmed">9025732</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowlton BJ, Mangels JA, Squire LR. A Neostriatal Habit Learning System in Humans. Science. 1996;273(5280):1399&#x2013;1402.</Citation><ArticleIdList><ArticleId IdType="pubmed">8703077</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohannim O, Hua X, Hibar DP, Lee S, Chou YY, Toga AW, Jack CR, Jr, Weiner MW, Thompson PM the Alzheimer's Disease Neuroimaging Initiative. Boosting power for AD clinical trials using classifiers based on multiple biomarkers. Neurobiology of Aging, Special Issue on ADNI studies Unpublished results. PM.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2903199</ArticleId><ArticleId IdType="pubmed">20541286</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnan KR, Husain MM, McDonald WM, Doraiswamy PM, Figiel GS, Boyko OB, Ellinwood EH, Nemeroff CB. In vivo stereological assessment of caudate volume in man, effect of normal aging. Life Sci. 1990;47:1325&#x2013;1329.</Citation><ArticleIdList><ArticleId IdType="pubmed">2233134</ArticleId></ArticleIdList></Reference><Reference><Citation>Larisch R, Meyer W, Klimke A, Kehren F, Vosberg H, Muller-Gartner HW. Left-right asymmetry of striatal dopamine D2 receptors. Nucl Med Commun. 1998;19(8):781&#x2013;787.</Citation><ArticleIdList><ArticleId IdType="pubmed">9751933</ArticleId></ArticleIdList></Reference><Reference><Citation>Laval SH, Dann JC, Butler RJ, Loftus J, Rue J, Leask SJ, Bass N, Comazzi M, Vita A, Nanko S, Shaw S, Peterson P, Shields G, Smith AB, Stewart J, Delisi LE, Crow TJ. Evidence for linkage to psychosis and cerebral asymmetry (relative hand skill) on the X chromosome. American Journal of Medical Genetics Part B. Neuropsychiatric Genetics. 2004;81(5):420&#x2013;427.</Citation><ArticleIdList><ArticleId IdType="pubmed">9754628</ArticleId></ArticleIdList></Reference><Reference><Citation>Leow AD, Yanovsky I, Parikshark N, Hua X, Lee S, Toga AW, Jack CR, Jr, Bernstein MA, Britson PJ, Gunter JL, Ward CP, Borowski B, Shaw LM, Trojanowski JQ, Fleisner AS, Harvey D, Kornak J, Schuff N, Alexander GE, Weiner MW, Thompson PM the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's Disease Neuroimaging Initiative: A 1-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers, and cognition. Neuroimage. 2009;45(3):645&#x2013;655.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696624</ArticleId><ArticleId IdType="pubmed">19280686</ArticleId></ArticleIdList></Reference><Reference><Citation>Looi JCL, Lindberg O, Liberg B, Tatham V, Kumar R, Maller J, Millard E, Sachdev P, Hogberg G, Pagani M, Botes L, Engman EL, Yi Z, Svensson L, Wahlun LO. Volumetrics of the caudate nucleus, Reliability and validity of a new manual tracing protocol. Psychiatry Research. Neuroimaging. 2007;163:279&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pubmed">18657402</ArticleId></ArticleIdList></Reference><Reference><Citation>Looi JC, Svensson L, Lindberg O, Zandbelt BB, Ostberg P, Orndahl E, Wahlund LO. Putaminal volume in frontotemporal lobar degeneration and Alzheimer's disease, differential volumes in dementia subtypes and controls. AJNR Am J Neuroradiol. 2009;30(8):1552&#x2013;1560.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7051615</ArticleId><ArticleId IdType="pubmed">19497964</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazziotta J, Toga A, Evans A, Fox P, Lancaster J, Zilles K, Woods R, Paus T, Simpson G, Pike B, Holmes C, Collins L, Thompson P, MacDonald D, Iacoboni M, Schormann T, Amunts K, Palomero-Gallagher N, Geyer S, Parsons L, Narr K, Kabani N, Le Goualher G, Boomsma D, Cannon T, Kawashima R, Mazoyer B. A probabilistic atlas and reference system for the human brain, International Consortium for Brain Mapping (ICBM) Philos Trans R Soc Lond B Biol Sci. 2001;356:1293&#x2013;1322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1088516</ArticleId><ArticleId IdType="pubmed">11545704</ArticleId></ArticleIdList></Reference><Reference><Citation>Morra J, Tu Z, Apostolova LG, Green AE, Avedissian C, Madsen SK, Parikshak N, Hua X, Toga AW, Jack CR, Weiner MW, Thompson PM the Alzheimer's Disease Neuroimaging Iniative. Validation of a fully automated 3D hippocampal segmentation method using subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. Neuroimage. 2008;43(1):59&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2624575</ArticleId><ArticleId IdType="pubmed">18675918</ArticleId></ArticleIdList></Reference><Reference><Citation>Morra JH, Tu Z, Apostolova LG, Green AE, Avedissian C, Madsen SK, Parikshak N, Hua X, Toga AW, Jack CR, Jr, Schuff N, Weiner MW, Thompson PM Alzheimer's Disease Neuroimaging Initiative. Automated 3D mapping of hippocampal atrophy and its clinical correlates in 400 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. Human Brain Mapping. 2009a;30(90):2766&#x2013;2788.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2733926</ArticleId><ArticleId IdType="pubmed">19172649</ArticleId></ArticleIdList></Reference><Reference><Citation>Morra JH, Tu Z, Apostolova LG, Green AE, Avedissian C, Madsen SK, Parikshak N, Toga AW, Jack CR, Jr, Schuff N, Weiner MW, Thompson PM, Alzheimer's Disease Neuroimaging Initiative. Automated mapping of hippocampal atrophy in 1-year repeat MRI data from 490 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. Neuroimage. 2009b;45(1S):S3&#x2013;S15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2733354</ArticleId><ArticleId IdType="pubmed">19041724</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Edland S, Clark C, Galasko D, Koss E, Mohs R, van Belle G, Fillenbaum G, Heyman A. The consortium to establish a registry for Alzheimer's disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer's disease. Neurology. 1993;43(12):2457&#x2013;2565.</Citation><ArticleIdList><ArticleId IdType="pubmed">8255439</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura T, Ghilardi MF, Mentis M, Dhawan V, Fukuda M, Hacking A, Moeller JR, Ghez C, Eidelberg D. Functional networks in motor sequence learning, abnormal topographies in Parkinson's disease. Hum Brain Mapp. 2001;12:42&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6872067</ArticleId><ArticleId IdType="pubmed">11198104</ArticleId></ArticleIdList></Reference><Reference><Citation>Peterson BS, Riddle MA, Cohen DJ, Katz LD, Smith JC, Leckman JF. Human basal ganglia volume asymmetries on magnetic resonance images. Magn Reson Imaging. 1993;11(4):493&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pubmed">8316062</ArticleId></ArticleIdList></Reference><Reference><Citation>Powell S, Magnotta VA, Johnson H, Jammalamadaka VK, Pierson R, Andreasen NC. Registration and machine learning-based automated segmentation of subcortical and cerebellar brain structures. Neuroimage. 2008;39:238&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2253948</ArticleId><ArticleId IdType="pubmed">17904870</ArticleId></ArticleIdList></Reference><Reference><Citation>Raji CA, Ho AJ, Parikshak NN, Becker JT, Lopez OL, Kuller LH, Hua X, Leow AD, Toga AW, Thompson PM. Brain Structure and Obesity. Human Brain Mapping. 2009 in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2826530</ArticleId><ArticleId IdType="pubmed">19662657</ArticleId></ArticleIdList></Reference><Reference><Citation>Raz N, Rodrigue KM, Kennedy KM, Head D, Gunning-Dixon F, Acker JD. Differential aging of the human striatum, longitudinal evidence. American Journal of Neuroradiol. 2003;003(24):1849&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7976312</ArticleId><ArticleId IdType="pubmed">14561615</ArticleId></ArticleIdList></Reference><Reference><Citation>Rombouts SA, Barkhof F, Witter MP, Scheltens P. Unbiased whole-brain analysis of gray matter loss in Alzheimer's disease. Neurosci Lett. 2000;285:231&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pubmed">10806328</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin DC. Frontal-striatal circuits in cognitive aging, evidence for caudate involvement. Aging Neuropsych Cog. 1999;6:241&#x2013;259.</Citation></Reference><Reference><Citation>Schuff N, Woerner N, Boreta L, Kornfield T, Shaw LM, Trojnakowski JQ, Thompson PM, Jack CR, Jr, Weiner MW the Alzheimer's Disease Neuroimaging Initiative. MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain. 2009;132:1067&#x2013;1077.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2668943</ArticleId><ArticleId IdType="pubmed">19251758</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VMY, Trojanowski JQ the Alzheimer's Disease Neuroimaging Initiative. Cerebrospinal fluid biomarker signature in Alzheimer's Disease Neuroimaging Initiative subjects. Annals of Neruology. 2009;65(4):403&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen L, Saykin AJ, Kim S, Firpi HA, West JD, Risacher SL, McDonald BC, McHugh TL, Wishart HA, Flashman LA. Comparison of Manual and Automated Determination of Hippocampal Volumes in MCI and Early. AD Brain Imaging and Behavior. 2010;4:86&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2863347</ArticleId><ArticleId IdType="pubmed">20454594</ArticleId></ArticleIdList></Reference><Reference><Citation>Sled JG, Zijdenbos AP, Evans AC. IEEE Trans Med Imaging. Vol. 17. 1998. A nonparametric method for automatic correction of intensity nonuniformity in MRI data; pp. 87&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">9617910</ArticleId></ArticleIdList></Reference><Reference><Citation>Szabo A, Lancaster JL, Xiong J, Cook C, Fox P. MR Imaging Volumetry of Subcortical structures and cerebellar hemispheres in normal persons. AJNR Am J Neuroradiol. 2003;24:644&#x2013;647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8148703</ArticleId><ArticleId IdType="pubmed">12695196</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson PM, Hayashi KM, de Zubicaray G, Janke AL, Rose SE, Semple J, Herman D, Hong MS, Dittmer SS, Doddrell DM, Toga AW. Dynamics of gray matter loss in Alzheimer's disease. J Neurosci. 2003;23:994&#x2013;1005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741905</ArticleId><ArticleId IdType="pubmed">12574429</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson PM, Hayashi KM, De Zubicaray GI, Janke AL, Rose SE, Semple J, Hong MS, Herman DH, Gravano D, Doddrell DM, Toga AW. Mapping hippocampal and ventricular change in Alzheimer disease. Neuroimage. 2004;22:1754&#x2013;1766.</Citation><ArticleIdList><ArticleId IdType="pubmed">15275931</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner KC, Frost L, Linsenbardt D, McIlroy JR, M&#xfc;ller RA. Atypically diffuse functional connectivity between caudate nuclei and cerebral cortex in autism. Behav Brain Funct. 2006;2:34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1635430</ArticleId><ArticleId IdType="pubmed">17042953</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Beg F, Ratnanather T, Ceritoglu C, Younes L, Morris JC, Csernansky JG, Miller MI. IEEE Trans Med Imaging. Vol. 26. 2007. Large deformation diffeomorphism and momentum based hippocampal shape discrimination in dementia of the Alzheimer type; pp. 462&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2848689</ArticleId><ArticleId IdType="pubmed">17427733</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D. The Psychological Corporation, Texas. 1987. Wechsler Memory Scale&#x2014;Revised.</Citation></Reference><Reference><Citation>Yamashita K, Yoshiura T, Hiwatashi A, Noguchi T, Togao O, Takayama Y, Nagao E, Kamano H, Hatakenaka M, Honda H. Volumetric Asymmetry and Differential Aging Effect of the Human Caudate Nucleus in Normal Individuals, A Prospective MR Imaging Study. J Neuroimaging. 2009 in press.</Citation><ArticleIdList><ArticleId IdType="pubmed">19659682</ArticleId></ArticleIdList></Reference><Reference><Citation>Yushkevich PA, Piven J, Hazlett HC, Smith RG, Ho S, Gee JC, Gerig G. User-guided 3D active contour segmentation of anatomical structures, Significantly improved efficiency and reliability. Neuroimage. 2006;31:1116&#x2013;1128.</Citation><ArticleIdList><ArticleId IdType="pubmed">16545965</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20542579</PMID><DateCompleted><Year>2010</Year><Month>11</Month><Day>12</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-108X</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>8</Issue><PubDate><Year>2010</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Trends in neurosciences</Title><ISOAbbreviation>Trends Neurosci</ISOAbbreviation></Journal><ArticleTitle>'Too much good news' - are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease?</ArticleTitle><Pagination><StartPage>381</StartPage><EndPage>389</EndPage><MedlinePgn>381-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.tins.2010.05.004</ELocationID><Abstract><AbstractText>Scores of compounds ameliorate cognitive deficits or neuropathology in transgenic mouse models of Alzheimer's disease (AD), yet these triumphs in mice have not translated into successful therapies for people. Why have studies in mice failed to predict results of human trials? We argue that most transgenic mouse 'models of AD' actually simulate the asymptomatic phase of the disease, and the results of interventional studies in these mice should be considered in the context of disease prevention. In addition, recent advances in imaging technology and biomarker discovery should aid in comparisons of mouse and human neurological status and, importantly, might allow us to predict better the response of people to drugs tested in mice.</AbstractText><CopyrightInformation>Copyright 2010. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zahs</LastName><ForeName>Kathleen R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>N. Bud Grossman Center for Memory Research and Care, University of Minnesota Medical School, Minneapolis, MN 55455, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ashe</LastName><ForeName>Karen H</ForeName><Initials>KH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>06</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trends Neurosci</MedlineTA><NlmUniqueID>7808616</NlmUniqueID><ISSNLinking>0166-2236</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>5</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>5</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>5</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20542579</ArticleId><ArticleId IdType="doi">10.1016/j.tins.2010.05.004</ArticleId><ArticleId IdType="pii">S0166-2236(10)00078-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20610750</PMID><DateCompleted><Year>2010</Year><Month>08</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>27</Issue><PubDate><Year>2010</Year><Month>Jul</Month><Day>07</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Amyloid-beta peptide oligomers disrupt axonal transport through an NMDA receptor-dependent mechanism that is mediated by glycogen synthase kinase 3beta in primary cultured hippocampal neurons.</ArticleTitle><Pagination><StartPage>9166</StartPage><EndPage>9171</EndPage><MedlinePgn>9166-71</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.1074-10.2010</ELocationID><Abstract><AbstractText>Disruption of axonal transport is a hallmark of several neurodegenerative diseases, including Alzheimer's disease (AD). Even though defective transport is considered an early pathologic event, the mechanisms by which neurodegenerative insults impact transport are poorly understood. We show that soluble oligomers of the amyloid-beta peptide (AbetaOs), increasingly recognized as the proximal neurotoxins in AD pathology, induce disruption of organelle transport in primary hippocampal neurons in culture. Live imaging of fluorescent protein-tagged organelles revealed a marked decrease in axonal trafficking of dense-core vesicles and mitochondria in the presence of 0.5 microm AbetaOs. NMDA receptor (NMDAR) antagonists, including d-AP5, MK-801, and memantine, prevented the disruption of trafficking, thereby identifying signals for AbetaO action at the cell membrane. Significantly, both pharmacological inhibition of glycogen synthase kinase-3beta (GSK-3beta) and transfection of neurons with a kinase-dead form of GSK-3beta prevented the transport defect. Finally, we demonstrate by biochemical and immunocytochemical means that AbetaOs do not affect microtubule stability, indicating that disruption of transport involves a more subtle mechanism than microtubule destabilization, likely the dysregulation of intracellular signaling cascades. Results demonstrate that AbetaOs negatively impact axonal transport by a mechanism that is initiated by NMDARs and mediated by GSK-3beta and establish a new connection between toxic Abeta oligomers and AD pathology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Decker</LastName><ForeName>Helena</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, Simon Fraser University, Burnaby, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lo</LastName><ForeName>Karen Y</ForeName><Initials>KY</Initials></Author><Author ValidYN="Y"><LastName>Unger</LastName><ForeName>Sandra M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Ferreira</LastName><ForeName>Sergio T</ForeName><Initials>ST</Initials></Author><Author ValidYN="Y"><LastName>Silverman</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>90396</GrantID><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019208">Brain-Derived Neurotrophic Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018691">Excitatory Amino Acid Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008164">Luminescent Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014404">Tubulin</NameOfSubstance></Chemical><Chemical><RegistryNumber>147336-22-9</RegistryNumber><NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D000071679">Glycogen Synthase Kinase 3 beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C000605507">Gsk3b protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.26</RegistryNumber><NameOfSubstance UI="D038362">Glycogen Synthase Kinase 3</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001370" MajorTopicYN="N">Axonal Transport</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019208" MajorTopicYN="N">Brain-Derived Neurotrophic Factor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018691" MajorTopicYN="N">Excitatory Amino Acid Antagonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D038362" MajorTopicYN="N">Glycogen Synthase Kinase 3</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071679" MajorTopicYN="N">Glycogen Synthase Kinase 3 beta</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049452" MajorTopicYN="N">Green Fluorescent Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008164" MajorTopicYN="N">Luminescent Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014404" MajorTopicYN="N">Tubulin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>8</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>1</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20610750</ArticleId><ArticleId IdType="pmc">PMC6632489</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.1074-10.2010</ArticleId><ArticleId IdType="pii">30/27/9166</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ally S, Larson AG, Barlan K, Rice SE, Gelfand VI. Opposite-polarity motors activate one another to trigger cargo transport in live cells. J Cell Biol. 2009;187:1071&#x2013;1082.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2806283</ArticleId><ArticleId IdType="pubmed">20038680</ArticleId></ArticleIdList></Reference><Reference><Citation>Black MM, Slaughter T, Moshiach S, Obrocka M, Fischer I. Tau is enriched on dynamic microtubules in the distal region of growing axons. J Neurosci. 1996;16:3601&#x2013;3619.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578833</ArticleId><ArticleId IdType="pubmed">8642405</ArticleId></ArticleIdList></Reference><Reference><Citation>Blurton-Jones M, Laferla FM. Pathways by which Abeta facilitates tau pathology. Curr Alzheimer Res. 2006;3:437&#x2013;448.</Citation><ArticleIdList><ArticleId IdType="pubmed">17168643</ArticleId></ArticleIdList></Reference><Reference><Citation>Brady ST, Lasek RJ, Allen RD, Yin HL, Stossel TP. Gelsolin inhibition of fast axonal transport indicates a requirement for actin microfilaments. Nature. 1984;310:56&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">6204208</ArticleId></ArticleIdList></Reference><Reference><Citation>De Felice FG, Velasco PT, Lambert MP, Viola K, Fernandez SJ, Ferreira ST, Klein WL. Abeta oligomers induce neuronal oxidative stress through an N-methyl-d-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem. 2007;282:11590&#x2013;11601.</Citation><ArticleIdList><ArticleId IdType="pubmed">17308309</ArticleId></ArticleIdList></Reference><Reference><Citation>De Felice FG, Wu D, Lambert MP, Fernandez SJ, Velasco PT, Lacor PN, Bigio EH, Jerecic J, Acton PJ, Shughrue PJ, Chen-Dodson E, Kinney GG, Klein WL. Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers. Neurobiol Aging. 2008;29:1334&#x2013;1347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3142933</ArticleId><ArticleId IdType="pubmed">17403556</ArticleId></ArticleIdList></Reference><Reference><Citation>De Felice FG, Vieira MN, Bomfim TR, Decker H, Velasco PT, Lambert MP, Viola KL, Zhao WQ, Ferreira ST, Klein WL. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci U S A. 2009;106:1971&#x2013;1976.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2634809</ArticleId><ArticleId IdType="pubmed">19188609</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshpande A, Mina E, Glabe C, Busciglio J. Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. J Neurosci. 2006;26:6011&#x2013;6018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675207</ArticleId><ArticleId IdType="pubmed">16738244</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira ST, Vieira MN, De Felice FG. Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases. IUBMB Life. 2007;59:332&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pubmed">17505973</ArticleId></ArticleIdList></Reference><Reference><Citation>Giese KP. GSK-3: a key player in neurodegeneration and memory. IUBMB Life. 2009;61:516&#x2013;521.</Citation><ArticleIdList><ArticleId IdType="pubmed">19391164</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg ME, Xu B, Lu B, Hempstead BL. New insights in the biology of BDNF synthesis and release: implications in CNS function. J Neurosci. 2009;29:12764&#x2013;12767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3091387</ArticleId><ArticleId IdType="pubmed">19828787</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirokawa N, Noda Y. Intracellular transport and kinesin superfamily proteins, KIFs: structure, function, and dynamics. Physiol Rev. 2008;88:1089&#x2013;1118.</Citation><ArticleIdList><ArticleId IdType="pubmed">18626067</ArticleId></ArticleIdList></Reference><Reference><Citation>Hiruma H, Katakura T, Takahashi S, Ichikawa T, Kawakami T. Glutamate and amyloid beta-protein rapidly inhibit fast axonal transport in cultured rat hippocampal neurons by different mechanisms. J Neurosci. 2003;23:8967&#x2013;8977.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740390</ArticleId><ArticleId IdType="pubmed">14523099</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoshi M, Sato M, Matsumoto S, Noguchi A, Yasutake K, Yoshida N, Sato K. Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta. Proc Natl Acad Sci U S A. 2003;100:6370&#x2013;6375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC164453</ArticleId><ArticleId IdType="pubmed">12750461</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaech S, Banker G. Culturing hippocampal neurons. Nat Protoc. 2006;1:2406&#x2013;2415.</Citation><ArticleIdList><ArticleId IdType="pubmed">17406484</ArticleId></ArticleIdList></Reference><Reference><Citation>Kempf M, Clement A, Faissner A, Lee G, Brandt R. Tau binds to the distal axon early in development of polarity in a microtubule- and microfilament-dependent manner. J Neurosci. 1996;16:5583&#x2013;5592.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578978</ArticleId><ArticleId IdType="pubmed">8795614</ArticleId></ArticleIdList></Reference><Reference><Citation>King ME, Kan HM, Baas PW, Erisir A, Glabe CG, Bloom GS. Tau-dependent microtubule disassembly initiated by prefibrillar beta-amyloid. J Cell Biol. 2006;175:541&#x2013;546.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2064590</ArticleId><ArticleId IdType="pubmed">17101697</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein WL. Synaptic targeting by Abeta oligomers (ADDLS) as a basis for memory loss in early Alzheimer's disease. Alzheimers Dement. 2006;2:43&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">19595855</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwinter DM, Lo K, Mafi P, Silverman MA. Dynactin regulates bidirectional transport of dense-core vesicles in the axon and dendrites of cultured hippocampal neurons. Neuroscience. 2009;162:1001&#x2013;1010.</Citation><ArticleIdList><ArticleId IdType="pubmed">19497353</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A. 1998;95:6448&#x2013;6453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP, Gleichmann M, Cheng A. Mitochondria in neuroplasticity and neurological disorders. Neuron. 2008;60:748&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2692277</ArticleId><ArticleId IdType="pubmed">19081372</ArticleId></ArticleIdList></Reference><Reference><Citation>Morfini GA, Burns M, Binder LI, Kanaan NM, LaPointe N, Bosco DA, Brown RH, Jr, Brown H, Tiwari A, Hayward L, Edgar J, Nave KA, Garberrn J, Atagi Y, Song Y, Pigino G, Brady ST. Axonal transport defects in neurodegenerative diseases. J Neurosci. 2009;29:12776&#x2013;12786.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2801051</ArticleId><ArticleId IdType="pubmed">19828789</ArticleId></ArticleIdList></Reference><Reference><Citation>Morfini G, Szebenyi G, Elluru R, Ratner N, Brady ST. Glycogen synthase kinase 3 phosphorylates kinesin light chains and negatively regulates kinesin-based motility. EMBO J. 2002;21:281&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125832</ArticleId><ArticleId IdType="pubmed">11823421</ArticleId></ArticleIdList></Reference><Reference><Citation>Muresan V, Muresan Z. Is abnormal axonal transport a cause, a contributing factor or a consequence of the neuronal pathology in Alzheimer's disease? Future Neurol. 2009;4:761&#x2013;773.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2805861</ArticleId><ArticleId IdType="pubmed">20076770</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JJ, Cawley NX, Loh YP. A bi-directional carboxypeptidase E-driven transport mechanism controls BDNF vesicle homeostasis in hippocampal neurons. Mol Cell Neurosci. 2008;39:63&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2606928</ArticleId><ArticleId IdType="pubmed">18573344</ArticleId></ArticleIdList></Reference><Reference><Citation>Peineau S, Taghibiglou C, Bradley C, Wong TP, Liu L, Lu J, Lo E, Wu D, Saule E, Bouschet T, Matthews P, Isaac JT, Bortolotto ZA, Wang YT, Collingridge GL. LTP inhibits LTD in the hippocampus via regulation of GSK3beta. Neuron. 2007;53:703&#x2013;717.</Citation><ArticleIdList><ArticleId IdType="pubmed">17329210</ArticleId></ArticleIdList></Reference><Reference><Citation>Peineau S, Bradley C, Taghibiglou C, Doherty A, Bortolotto ZA, Wang YT, Collingridge GL. The role of GSK-3 in synaptic plasticity. Br J Pharmacol. 2008;153(Suppl 1):S428&#x2013;437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2268071</ArticleId><ArticleId IdType="pubmed">18311157</ArticleId></ArticleIdList></Reference><Reference><Citation>Pigino G, Morfini G, Atagi Y, Deshpande A, Yu C, Jungbauer L, LaDu M, Busciglio J, Brady S. Disruption of fast axonal transport is a pathogenic mechanism for intraneuronal amyloid beta. Proc Natl Acad Sci U S A. 2009;106:5907&#x2013;5912.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2667037</ArticleId><ArticleId IdType="pubmed">19321417</ArticleId></ArticleIdList></Reference><Reference><Citation>Roselli F, Tirard M, Lu J, Hutzler P, Lamberti P, Livrea P, Morabito M, Almeida OF. Soluble beta-amyloid1-40 induces NMDA-dependent degradation of postsynaptic density-95 at glutamatergic synapses. J Neurosci. 2005;25:11061&#x2013;11070.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725651</ArticleId><ArticleId IdType="pubmed">16319306</ArticleId></ArticleIdList></Reference><Reference><Citation>Rui Y, Li R, Liu Y, Zhu S, Yu X, Sheng Z, Xie Z. Acute effect of beta amyloid on synchronized spontaneous Ca2+ oscillations in cultured hippocampal networks. Cell Biol Int. 2006;30:733&#x2013;740.</Citation><ArticleIdList><ArticleId IdType="pubmed">16798022</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlager MA, Hoogenraad CC. Basic mechanisms for recognition and transport of synaptic cargos. Mol Brain. 2009;2:25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2732917</ArticleId><ArticleId IdType="pubmed">19653898</ArticleId></ArticleIdList></Reference><Reference><Citation>Seo YH, Jung HJ, Shin HT, Kim YM, Yim H, Chung HY, Lim IK, Yoon G. Enhanced glycogenesis is involved in cellular senescence via GSK3/GS modulation. Aging Cell. 2008;7:894&#x2013;907.</Citation><ArticleIdList><ArticleId IdType="pubmed">18782348</ArticleId></ArticleIdList></Reference><Reference><Citation>Stokin GB, Lillo C, Falzone TL, Brusch RG, Rockenstein E, Mount SL, Raman R, Davies P, Masliah E, Williams DS, Goldstein LS. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science. 2005;307:1282&#x2013;1288.</Citation><ArticleIdList><ArticleId IdType="pubmed">15731448</ArticleId></ArticleIdList></Reference><Reference><Citation>Szydlowska K, Tymianski M. Calcium, ischemia and excitotoxicity. Cell Calcium. 2010;47:122&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">20167368</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HW, Pasternak JF, Kuo H, Ristic H, Lambert MP, Chromy B, Viola KL, Klein WL, Stine WB, Krafft GA, Trommer BL. Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res. 2002;924:133&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">11750898</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Schwarz TL. The mechanism of Ca2+-dependent regulation of kinesin-mediated mitochondrial motility. Cell. 2009;136:163&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2768392</ArticleId><ArticleId IdType="pubmed">19135897</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Edwards JG, Riley N, Provance DW, Jr, Karcher R, Li XD, Davison IG, Ikebe M, Mercer JA, Kauer JA, Ehlers MD. Myosin Vb mobilizes recycling endosomes and AMPA receptors for postsynaptic plasticity. Cell. 2008;135:535&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2585749</ArticleId><ArticleId IdType="pubmed">18984164</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong MY, Shakiryanova D, Levitan ES. Presynaptic ryanodine receptor-CamKII signaling is required for activity-dependent capture of transiting vesicles. J Mol Neurosci. 2009;37:146&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2610243</ArticleId><ArticleId IdType="pubmed">18592416</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20634593</PMID><DateCompleted><Year>2011</Year><Month>01</Month><Day>18</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-8908</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>3</Issue><PubDate><Year>2010</Year></PubDate></JournalIssue><Title>Journal of Alzheimer's disease : JAD</Title><ISOAbbreviation>J Alzheimers Dis</ISOAbbreviation></Journal><ArticleTitle>Validating predicted biological effects of Alzheimer's disease associated SNPs using CSF biomarker levels.</ArticleTitle><Pagination><StartPage>833</StartPage><EndPage>842</EndPage><MedlinePgn>833-42</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/JAD-2010-091711</ELocationID><Abstract><AbstractText>Recent large-scale genetic studies of late-onset Alzheimer's disease have identified risk variants in CALHM1, GAB2, and SORL1. The mechanisms by which these genes might modulate risk are not definitively known. CALHM1 and SORL1 may alter amyloid-&#x3b2; (A&#x3b2;) levels and GAB2 may influence phosphorylation of the tau protein. In this study we have analyzed disease associated genetic variants in each of these genes for association with cerebrospinal fluid (CSF) A&#x3b2; or tau levels in 602 samples from two independent CSF series. We failed to detect association between CSF A&#x3b2;42 levels and single nucleotide polymorphisms in SORL1 despite substantial statistical power to detect association. While we also failed to detect association between variants in GAB2 and CSF tau levels, power to detect this association was limited. Finally, our data suggest that the minor allele of rs2986017, in CALHM1, is marginally associated with CSF A&#x3b2;42 levels. This association is consistent with previous reports that this non-synonymous coding substitution results in increased A&#x3b2; levels in vitro and provides support for an A&#x3b2;-related mechanism for modulating risk for Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kauwe</LastName><ForeName>John S K</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Biology, Brigham Young University, Provo, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruchaga</LastName><ForeName>Carlos</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Bertelsen</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Mayo</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Latu</LastName><ForeName>Wayne</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Nowotny</LastName><ForeName>Petra</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Hinrichs</LastName><ForeName>Anthony L</ForeName><Initials>AL</Initials></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><CollectiveName>Alzheimer's Disease Neuroimaging Initiative</CollectiveName></Author><Author ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison M</ForeName><Initials>AM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32MH14677</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01-AG02627</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR024992</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1-TL1-RR024995-01</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50-AG05681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 MH014677</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-AG16208</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG016208</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01-AG03991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS057105</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1-KL2--RR024994-01</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>TL1 RR024995</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>KL2 RR024994</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30-N5057105</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Alzheimers Dis</MedlineTA><NlmUniqueID>9814863</NlmUniqueID><ISSNLinking>1387-2877</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C530077">CALHM1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015220">Calcium Channels</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C490895">GAB2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026502">LDL-Receptor Related Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026901">Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C102582">SORL1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D048868" MajorTopicYN="N">Adaptor Proteins, Signal Transducing</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015220" MajorTopicYN="N">Calcium Channels</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026502" MajorTopicYN="N">LDL-Receptor Related Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D026901" MajorTopicYN="N">Membrane Transport Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>1</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>2</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20634593</ArticleId><ArticleId IdType="mid">NIHMS264464</ArticleId><ArticleId IdType="pmc">PMC3032214</ArticleId><ArticleId IdType="doi">10.3233/JAD-2010-091711</ArticleId><ArticleId IdType="pii">61N0P2G744853281</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet. 2007;39:17&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">17192785</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, Letenneur L, Bettens K, Berr C, Pasquier F, Fievet N, Barberger-Gateau P, Engelborghs S, De Deyn P, Mateo I, Franck A, Helisalmi S, Porcellini E, Hanon O, de Pancorbo MM, Lendon C, Dufouil C, Jaillard C, Leveillard T, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Bossu P, Piccardi P, Annoni G, Seripa D, Galimberti D, Hannequin D, Licastro F, Soininen H, Ritchie K, Blanche H, Dartigues JF, Tzourio C, Gut I, Van Broeckhoven C, Alperovitch A, Lathrop M, Amouyel P. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet. 2009;41:1094&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Schurmann B, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frolich L, Hampel H, Hull M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Muhleisen TW, Nothen MM, Moebus S, Jockel KH, Klopp N, Wichmann HE, Carrasquillo MM, Pankratz VS, Younkin SG, Holmans PA, O'Donovan M, Owen MJ, Williams J. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet. 2009;41:1088&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845877</ArticleId><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference><Reference><Citation>Dreses-Werringloer U, Lambert JC, Vingtdeux V, Zhao H, Vais H, Siebert A, Jain A, Koppel J, Rovelet-Lecrux A, Hannequin D, Pasquier F, Galimberti D, Scarpini E, Mann D, Lendon C, Campion D, Amouyel P, Davies P, Foskett JK, Campagne F, Marambaud P. A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and Alzheimer's disease risk. Cell. 2008;133:1149&#x2013;1161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2577842</ArticleId><ArticleId IdType="pubmed">18585350</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogaeva E, Meng Y, Lee JH, Gu Y, Kawarai T, Zou F, Katayama T, Baldwin CT, Cheng R, Hasegawa H, Chen F, Shibata N, Lunetta KL, Pardossi-Piquard R, Bohm C, Wakutani Y, Cupples LA, Cuenco KT, Green RC, Pinessi L, Rainero I, Sorbi S, Bruni A, Duara R, Friedland RP, Inzelberg R, Hampe W, Bujo H, Song YQ, Andersen OM, Willnow TE, Graff-Radford N, Petersen RC, Dickson D, Der SD, Fraser PE, Schmitt-Ulms G, Younkin S, Mayeux R, Farrer LA, St George-Hyslop P. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet. 2007;39:168&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2657343</ArticleId><ArticleId IdType="pubmed">17220890</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Webster JA, Myers AJ, Hardy J, Dunckley T, Zismann VL, Joshipura KD, Pearson JV, Hu-Lince D, Huentelman MJ, Craig DW, Coon KD, Liang WS, Herbert RH, Beach T, Rohrer KC, Zhao AS, Leung D, Bryden L, Marlowe L, Kaleem M, Mastroeni D, Grover A, Heward CB, Ravid R, Rogers J, Hutton ML, Melquist S, Petersen RC, Alexander GE, Caselli RJ, Kukull W, Papassotiropoulos A, Stephan DA. GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron. 2007;54:713&#x2013;720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2587162</ArticleId><ArticleId IdType="pubmed">17553421</ArticleId></ArticleIdList></Reference><Reference><Citation>Coon KD, Myers AJ, Craig DW, Webster JA, Pearson JV, Lince DH, Zismann VL, Beach TG, Leung D, Bryden L, Halperin RF, Marlowe L, Kaleem M, Walker DG, Ravid R, Heward CB, Rogers J, Papassotiropoulos A, Reiman EM, Hardy J, Stephan DA. A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J Clin Psychiatry. 2007;68:613&#x2013;618.</Citation><ArticleIdList><ArticleId IdType="pubmed">17474819</ArticleId></ArticleIdList></Reference><Reference><Citation>Nacmias B, Tedde A, Bagnoli S, Cellini E, Guarnieri BM, Piacentini S, Sorbi S. Implication of GAB2 gene polymorphism in Italian patients with Alzheimer's disease. J Alzheimers Dis. 2009;16:513&#x2013;515.</Citation><ArticleIdList><ArticleId IdType="pubmed">19276544</ArticleId></ArticleIdList></Reference><Reference><Citation>Schjeide BM, Hooli B, Parkinson M, Hogan MF, DiVito J, Mullin K, Blacker D, Tanzi RE, Bertram L. GAB2 as an Alzheimer disease susceptibility gene: follow-up of genomewide association results. Arch Neurol. 2009;66:250&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2841135</ArticleId><ArticleId IdType="pubmed">19204163</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikram MA, Liu F, Oostra BA, Hofman A, van Duijn CM, Breteler MM. The GAB2 gene and the risk of Alzheimer's disease: replication and meta-analysis. Biol Psychiatry. 2009;65:995&#x2013;999.</Citation><ArticleIdList><ArticleId IdType="pubmed">19118819</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleegers K, Brouwers N, Bettens K, Engelborghs S, van Miegroet H, De Deyn PP, Van Broeckhoven C. No association between CALHM1 and risk for Alzheimer dementia in a Belgian population. Hum Mutat. 2009;30:E570&#x2013;E574.</Citation><ArticleIdList><ArticleId IdType="pubmed">19191332</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapuis J, Hannequin D, Pasquier F, Bentham P, Brice A, Leber I, Frebourg T, Deleuze JF, Cousin E, Thaker U, Amouyel P, Mann D, Lendon C, Campion D, Lambert JC. Association study of the GAB2 gene with the risk of developing Alzheimer's disease. Neurobiol Dis. 2008;30:103&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">18272374</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue K, Tanaka N, Yamashita F, Sawano Y, Asada T, Goto YI. The P86L common allele of CALHM1 does not influence risk for Alzheimer disease in Japanese cohorts. Am J Med Genet B Neuropsychiatr Genet. 2009</Citation><ArticleIdList><ArticleId IdType="pubmed">19655363</ArticleId></ArticleIdList></Reference><Reference><Citation>Beecham GW, Schnetz-Boutaud N, Haines JL, Pericak-Vance MA. CALHM1 polymorphism is not associated with late-onset Alzheimer disease. Ann Hum Genet. 2009;73:379&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2918418</ArticleId><ArticleId IdType="pubmed">19472444</ArticleId></ArticleIdList></Reference><Reference><Citation>Minster RL, Demirci FY, DeKosky ST, Kamboh MI. No association between CALHM1 variation and risk of Alzheimer disease. Hum Mutat. 2009;30:E566&#x2013;E569.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2810280</ArticleId><ArticleId IdType="pubmed">19191331</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L, Schjeide BM, Hooli B, Mullin K, Hiltunen M, Soininen H, Ingelsson M, Lannfelt L, Blacker D, Tanzi RE. No association between CALHM1 and Alzheimer's disease risk. Cell. 2008;135:993&#x2013;994. author reply 994&#x2013;996.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2841134</ArticleId><ArticleId IdType="pubmed">19070563</ArticleId></ArticleIdList></Reference><Reference><Citation>Giedraitis V, Glaser A, Sarajarvi T, Brundin R, Gunnarsson MD, Schjeide BM, Tanzi RE, Helisalmi S, Pirttila T, Kilander L, Lannfelt L, Soininen H, Bertram L, Ingelsson M, Hiltunen M. CALHM1 P86L polymorphism does not alter amyloid-beta or tau in cerebrospinal fluid. Neurosci Lett. 469:265&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2860374</ArticleId><ArticleId IdType="pubmed">20005921</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherzer CR, Offe K, Gearing M, Rees HD, Fang G, Heilman CJ, Schaller C, Bujo H, Levey AI, Lah JJ. Loss of apolipoprotein E receptor LR11 in Alzheimer disease. Arch Neurol. 2004;61:1200&#x2013;1205.</Citation><ArticleIdList><ArticleId IdType="pubmed">15313836</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Rowland C, Catanese J, Morris J, Lovestone S, O'Donovan MC, Goate A, Owen M, Williams J, Grupe A. SORL1 variants and risk of late-onset Alzheimer's disease. Neurobiol Dis. 2008;29:293&#x2013;296.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2323581</ArticleId><ArticleId IdType="pubmed">17949987</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettens K, Brouwers N, Engelborghs S, De Deyn PP, Van Broeckhoven C, Sleegers K. SORL1 is genetically associated with increased risk for late-onset Alzheimer disease in the Belgian population. Hum Mutat. 2008;29:769&#x2013;770.</Citation><ArticleIdList><ArticleId IdType="pubmed">18407551</ArticleId></ArticleIdList></Reference><Reference><Citation>Feulner TM, Laws SM, Friedrich P, Wagenpfeil S, Wurst SH, Riehle C, Kuhn KA, Krawczak M, Schreiber S, Nikolaus S, Forstl H, Kurz A, Riemenschneider M. Examination of the current top candidate genes for AD in a genome-wide association study. Mol Psychiatry. 2009</Citation><ArticleIdList><ArticleId IdType="pubmed">19125160</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura R, Yamamoto M, Morihara T, Akatsu H, Kudo T, Kamino K, Takeda M. SORL1 is genetically associated with Alzheimer disease in a Japanese population. Neurosci Lett. 2009;461:177&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">19539718</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, Cheng R, Schupf N, Manly J, Lantigua R, Stern Y, Rogaeva E, Wakutani Y, Farrer L, St George-Hyslop P, Mayeux R. The association between genetic variants in SORL1 and Alzheimer disease in an urban, multiethnic, community-based cohort. Arch Neurol. 2007;64:501&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2639214</ArticleId><ArticleId IdType="pubmed">17420311</ArticleId></ArticleIdList></Reference><Reference><Citation>Birney E, Stamatoyannopoulos JA, Dutta A, Guigo R, Gingeras TR, Margulies EH, Weng Z, Snyder M, Dermitzakis ET, Thurman RE, Kuehn MS, Taylor CM, Neph S, Koch CM, Asthana S, Malhotra A, Adzhubei I, Greenbaum JA, Andrews RM, Flicek P, Boyle PJ, Cao H, Carter NP, Clelland GK, Davis S, Day N, Dhami P, Dillon SC, Dorschner MO, Fiegler H, Giresi PG, Goldy J, Hawrylycz M, Haydock A, Humbert R, James KD, Johnson BE, Johnson EM, Frum TT, Rosenzweig ER, Karnani N, Lee K, Lefebvre GC, Navas PA, Neri F, Parker SC, Sabo PJ, Sandstrom R, Shafer A, Vetrie D, Weaver M, Wilcox S, Yu M, Collins FS, Dekker J, Lieb JD, Tullius TD, Crawford GE, Sunyaev S, Noble WS, Dunham I, Denoeud F, Reymond A, Kapranov P, Rozowsky J, Zheng D, Castelo R, Frankish A, Harrow J, Ghosh S, Sandelin A, Hofacker IL, Baertsch R, Keefe D, Dike S, Cheng J, Hirsch HA, Sekinger EA, Lagarde J, Abril JF, Shahab A, Flamm C, Fried C, Hackermuller J, Hertel J, Lindemeyer M, Missal K, Tanzer A, Washietl S, Korbel J, Emanuelsson O, Pedersen JS, Holroyd N, Taylor R, Swarbreck D, Matthews N, Dickson MC, Thomas DJ, Weirauch MT, Gilbert J, Drenkow J, Bell I, Zhao X, Srinivasan KG, Sung WK, Ooi HS, Chiu KP, Foissac S, Alioto T, Brent M, Pachter L, Tress ML, Valencia A, Choo SW, Choo CY, Ucla C, Manzano C, Wyss C, Cheung E, Clark TG, Brown JB, Ganesh M, Patel S, Tammana H, Chrast J, Henrichsen CN, Kai C, Kawai J, Nagalakshmi U, Wu J, Lian Z, Lian J, Newburger P, Zhang X, Bickel P, Mattick JS, Carninci P, Hayashizaki Y, Weissman S, Hubbard T, Myers RM, Rogers J, Stadler PF, Lowe TM, Wei CL, Ruan Y, Struhl K, Gerstein M, Antonarakis SE, Fu Y, Green ED, Karaoz U, Siepel A, Taylor J, Liefer LA, Wetterstrand KA, Good PJ, Feingold EA, Guyer MS, Cooper GM, Asimenos G, Dewey CN, Hou M, Nikolaev S, Montoya-Burgos JI, Loytynoja A, Whelan S, Pardi F, Massingham T, Huang H, Zhang NR, Holmes I, Mullikin JC, Ureta-Vidal A, Paten B, Seringhaus M, Church D, Rosenbloom K, Kent WJ, Stone EA, Batzoglou S, Goldman N, Hardison RC, Haussler D, Miller W, Sidow A, Trinklein ND, Zhang ZD, Barrera L, Stuart R, King DC, Ameur A, Enroth S, Bieda MC, Kim J, Bhinge AA, Jiang N, Liu J, Yao F, Vega VB, Lee CW, Ng P, Shahab A, Yang A, Moqtaderi Z, Zhu Z, Xu X, Squazzo S, Oberley MJ, Inman D, Singer MA, Richmond TA, Munn KJ, Rada-Iglesias A, Wallerman O, Komorowski J, Fowler JC, Couttet P, Bruce AW, Dovey OM, Ellis PD, Langford CF, Nix DA, Euskirchen G, Hartman S, Urban AE, Kraus P, Van Calcar S, Heintzman N, Kim TH, Wang K, Qu C, Hon G, Luna R, Glass CK, Rosenfeld MG, Aldred SF, Cooper SJ, Halees A, Lin JM, Shulha HP, Zhang X, Xu M, Haidar JN, Yu Y, Ruan Y, Iyer VR, Green RD, Wadelius C, Farnham PJ, Ren B, Harte RA, Hinrichs AS, Trumbower H, Clawson H, Hillman-Jackson J, Zweig AS, Smith K, Thakkapallayil A, Barber G, Kuhn RM, Karolchik D, Armengol L, Bird CP, de Bakker PI, Kern AD, Lopez-Bigas N, Martin JD, Stranger BE, Woodroffe A, Davydov E, Dimas A, Eyras E, Hallgrimsdottir IB, Huppert J, Zody MC, Abecasis GR, Estivill X, Bouffard GG, Guan X, Hansen NF, Idol JR, Maduro VV, Maskeri B, McDowell JC, Park M, Thomas PJ, Young AC, Blakesley RW, Muzny DM, Sodergren E, Wheeler DA, Worley KC, Jiang H, Weinstock GM, Gibbs RA, Graves T, Fulton R, Mardis ER, Wilson RK, Clamp M, Cuff J, Gnerre S, Jaffe DB, Chang JL, Lindblad-Toh K, Lander ES, Koriabine M, Nefedov M, Osoegawa K, Yoshinaga Y, Zhu B, de Jong PJ. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature. 2007;447:798&#x2013;816.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2212820</ArticleId><ArticleId IdType="pubmed">17571346</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolsch H, Jessen F, Wiltfang J, Lewczuk P, Dichgans M, Kornhuber J, Frolich L, Heuser I, Peters O, Schulz JB, Schwab SG, Maier W. Influence of SORL1 gene variants: association with CSF amyloid-beta products in probable Alzheimer's disease. Neurosci Lett. 2008;440:68&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">18541377</ArticleId></ArticleIdList></Reference><Reference><Citation>Minster RL, DeKosky ST, Neurosci MI. No association of SORL1 SNPs with Alzheimer's disease. Neurosci Lett. 2008;440:190&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2519047</ArticleId><ArticleId IdType="pubmed">18562096</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F, Ikram MA, Janssens AC, Schuur M, de Koning I, Isaacs A, Struchalin M, Uitterlinden AG, den Dunnen JT, Sleegers K, Bettens K, Van Broeckhoven C, van Swieten J, Hofman A, Oostra BA, Aulchenko YS, Breteler MM, van Duijn CM. A study of the SORL1 gene in Alzheimer's disease and cognitive function. J Alzheimers Dis. 2009;18:51&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">19584446</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds CA, Hong MG, Eriksson UK, Blennow K, Johansson B, Malmberg B, Berg S, Gatz M, Pedersen NL, Bennet AM, Prince JA. Sequence variation in SORL1 and dementia risk in Swedes. Neurogenetics. 2009</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2867467</ArticleId><ArticleId IdType="pubmed">19653016</ArticleId></ArticleIdList></Reference><Reference><Citation>Kauwe JS, Wang J, Mayo K, Morris JC, Fagan AM, Holtzman DM, Goate AM. Alzheimer's disease risk variants show association with cerebrospinal fluid amyloid beta. Neurogenetics. 2009;10:13&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2726757</ArticleId><ArticleId IdType="pubmed">18813964</ArticleId></ArticleIdList></Reference><Reference><Citation>Kauwe JS, Jacquart S, Chakraverty S, Wang J, Mayo K, Fagan AM, Holtzman DM, Morris JC, Goate AM. Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer's disease presenilin 1 mutation. Ann Neurol. 2007;61:446&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">17366635</ArticleId></ArticleIdList></Reference><Reference><Citation>Kauwe JS, Cruchaga C, Mayo K, Fenoglio C, Bertelsen S, Nowotny P, Galimberti D, Scarpini E, Morris JC, Fagan AM, Holtzman DM, Goate AM. Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition. Proc Natl Acad Sci U S A. 2008;105:8050&#x2013;8054.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2430357</ArticleId><ArticleId IdType="pubmed">18541914</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC, Holtzman DM. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006;59:512&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">16372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>K TC, Lunetta KL, Baldwin CT, McKee AC, Guo J, Cupples LA, Green RC, St George-Hyslop PH, Chui H, DeCarli C, Farrer LA. Association of distinct variants in SORL1 with cerebrovascular and neurodegenerative changes related to Alzheimer disease. Arch Neurol. 2008;65:1640&#x2013;1648.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2719762</ArticleId><ArticleId IdType="pubmed">19064752</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolsch H, Jessen F, Wiltfang J, Lewczuk P, Dichgans M, Teipel SJ, Kornhuber J, Frolich L, Heuser I, Peters O, Wiese B, Kaduszkiewicz H, van den Bussche H, Hull M, Kurz A, Ruther E, Henn FA, Maier W. Association of SORL1 gene variants with Alzheimer's disease. Brain Res. 2009;1264:1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">19368828</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, Cheng R, Honig LS, Vonsattel JP, Clark L, Mayeux R. Association between genetic variants in SORL1 and autopsy-confirmed Alzheimer disease. Neurology. 2008;70:887&#x2013;889.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2634845</ArticleId><ArticleId IdType="pubmed">17978276</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng Y, Lee JH, Cheng R, St George-Hyslop P, Mayeux R, Farrer LA. Association between SORL1 and Alzheimer's disease in a genome-wide study. Neuroreport. 2007;18:1761&#x2013;1764.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2631643</ArticleId><ArticleId IdType="pubmed">18090307</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan EK, Lee J, Chen CP, Teo YY, Zhao Y, Lee WL. SORL1 haplotypes modulate risk of Alzheimer's disease in Chinese. Neurobiol Aging. 2009;30:1048&#x2013;1051.</Citation><ArticleIdList><ArticleId IdType="pubmed">18063222</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunner E, Dette H, Munk A. Box-type approximations in nonparametric factorial designs. Journal of the American Statistical Association. 1997;92:1494&#x2013;1502.</Citation></Reference><Reference><Citation>Smach MA, Charfeddine B, Lammouchi T, Harrabi I, Ben Othman L, Dridi H, Bennamou S, Limem K. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele. Neurosci Lett. 2008;440:145&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pubmed">18555606</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G, Sokal I, Quinn JF, Leverenz JB, Brodey M, Schellenberg GD, Kaye JA, Raskind MA, Zhang J, Peskind ER, Montine TJ. CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology. 2007;69:631&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">17698783</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64:343&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">17210801</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20660724</PMID><DateCompleted><Year>2010</Year><Month>09</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>107</Volume><Issue>32</Issue><PubDate><Year>2010</Year><Month>Aug</Month><Day>10</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Genome-wide analysis reveals mechanisms modulating autophagy in normal brain aging and in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>14164</StartPage><EndPage>14169</EndPage><MedlinePgn>14164-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1009485107</ELocationID><Abstract><AbstractText>Dysregulation of autophagy, a cellular catabolic mechanism essential for degradation of misfolded proteins, has been implicated in multiple neurodegenerative diseases. However, the mechanisms that lead to the autophagy dysfunction are still not clear. Based on the results of a genome-wide screen, we show that reactive oxygen species (ROS) serve as common mediators upstream of the activation of the type III PI3 kinase, which is critical for the initiation of autophagy. Furthermore, ROS play an essential function in the induction of the type III PI3 kinase and autophagy in response to amyloid beta peptide, the main pathogenic mediator of Alzheimer's disease (AD). However, lysosomal blockage also caused by Abeta is independent of ROS. In addition, we demonstrate that autophagy is transcriptionally down-regulated during normal aging in the human brain. Strikingly, in contrast to normal aging, we observe transcriptional up-regulation of autophagy in the brains of AD patients, suggesting that there might be a compensatory regulation of autophagy. Interestingly, we show that an AD drug and an AD drug candidate have inhibitory effects on autophagy, raising the possibility that decreasing input into the lysosomal system may help to reduce cellular stress in AD. Finally, we provide a list of candidate drug targets that can be used to safely modulate levels of autophagy without causing cell death.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lipinski</LastName><ForeName>Marta M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Bin</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Tao</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Zhenyu</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Py</LastName><ForeName>B&#xe9;n&#xe9;dicte F</ForeName><Initials>BF</Initials></Author><Author ValidYN="Y"><LastName>Ng</LastName><ForeName>Aylwin</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Xavier</LastName><ForeName>Ramnik J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Cheng</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Yankner</LastName><ForeName>Bruce A</ForeName><Initials>BA</Initials></Author><Author ValidYN="Y"><LastName>Scherzer</LastName><ForeName>Clemens R</ForeName><Initials>CR</Initials></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Junying</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AI062773</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DK043351</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK040561</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS058793</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS064155</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK043351</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG027916</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI062773</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS060227</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG012859</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DP1 AG044161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>07</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.-</RegistryNumber><NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="Y">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>2</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20660724</ArticleId><ArticleId IdType="pmc">PMC2922576</ArticleId><ArticleId IdType="doi">10.1073/pnas.1009485107</ArticleId><ArticleId IdType="pii">1009485107</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Levine B, Klionsky DJ. Development by self-digestion: Molecular mechanisms and biological functions of autophagy. Dev Cell. 2004;6:463&#x2013;477.</Citation><ArticleIdList><ArticleId IdType="pubmed">15068787</ArticleId></ArticleIdList></Reference><Reference><Citation>Hara T, et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature. 2006;441:885&#x2013;889.</Citation><ArticleIdList><ArticleId IdType="pubmed">16625204</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravikumar B, et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet. 2004;36:585&#x2013;595.</Citation><ArticleIdList><ArticleId IdType="pubmed">15146184</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA, et al. Extensive involvement of autophagy in Alzheimer disease: An immuno-electron microscopy study. J Neuropathol Exp Neurol. 2005;64:113&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">15751225</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipinski MM, et al. Multiple mTORC1 independent signaling pathways regulate autophagy through type III PI3 kinase under normal nutritional conditions. Dev Cell. 2010;18:1041&#x2013;1052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2935848</ArticleId><ArticleId IdType="pubmed">20627085</ArticleId></ArticleIdList></Reference><Reference><Citation>Pattingre S, et al. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell. 2005;122:927&#x2013;939.</Citation><ArticleIdList><ArticleId IdType="pubmed">16179260</ArticleId></ArticleIdList></Reference><Reference><Citation>Kane DJ, et al. Bcl-2 inhibition of neural death: Decreased generation of reactive oxygen species. Science. 1993;262:1274&#x2013;1277.</Citation><ArticleIdList><ArticleId IdType="pubmed">8235659</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang WS, et al. Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons. Proc Natl Acad Sci USA. 2008;105:4441&#x2013;4446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2393743</ArticleId><ArticleId IdType="pubmed">18332434</ArticleId></ArticleIdList></Reference><Reference><Citation>Takuma K, et al. ABAD enhances Abeta-induced cell stress via mitochondrial dysfunction. FASEB J. 2005;19:597&#x2013;598.</Citation><ArticleIdList><ArticleId IdType="pubmed">15665036</ArticleId></ArticleIdList></Reference><Reference><Citation>Loerch PM, et al. Evolution of the aging brain transcriptome and synaptic regulation. PLoS ONE. 2008;3:e3329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2553198</ArticleId><ArticleId IdType="pubmed">18830410</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibata M, et al. Regulation of intracellular accumulation of mutant Huntingtin by Beclin 1. J Biol Chem. 2006;281:14474&#x2013;14485.</Citation><ArticleIdList><ArticleId IdType="pubmed">16522639</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho Y, et al. Systematic identification of protein complexes in Saccharomyces cerevisiae by mass spectrometry. Nature. 2002;415:180&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pubmed">11805837</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito T, et al. A comprehensive two-hybrid analysis to explore the yeast protein interactome. Proc Natl Acad Sci USA. 2001;98:4569&#x2013;4574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC31875</ArticleId><ArticleId IdType="pubmed">11283351</ArticleId></ArticleIdList></Reference><Reference><Citation>Hara T, et al. FIP200, a ULK-interacting protein, is required for autophagosome formation in mammalian cells. J Cell Biol. 2008;181:497&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2364687</ArticleId><ArticleId IdType="pubmed">18443221</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, et al. Unc-51-like kinase 1/2-mediated endocytic processes regulate filopodia extension and branching of sensory axons. Proc Natl Acad Sci USA. 2007;104:5842&#x2013;5847.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1851579</ArticleId><ArticleId IdType="pubmed">17389358</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen W, Ganetzky B. Autophagy promotes synapse development in Drosophila. J Cell Biol. 2009;187:71&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2762098</ArticleId><ArticleId IdType="pubmed">19786572</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherz-Shouval R, et al. Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4. EMBO J. 2007;26:1749&#x2013;1760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1847657</ArticleId><ArticleId IdType="pubmed">17347651</ArticleId></ArticleIdList></Reference><Reference><Citation>Lustbader JW, et al. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science. 2004;304:448&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">15087549</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy PH, Beal MF. Amyloid beta, mitochondrial dysfunction and synaptic damage: Implications for cognitive decline in aging and Alzheimer's disease. Trends Mol Med. 2008;14:45&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3107703</ArticleId><ArticleId IdType="pubmed">18218341</ArticleId></ArticleIdList></Reference><Reference><Citation>Komatsu M, et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature. 2006;441:880&#x2013;884.</Citation><ArticleIdList><ArticleId IdType="pubmed">16625205</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickford F, et al. The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. J Clin Invest. 2008;118:2190&#x2013;2199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2391284</ArticleId><ArticleId IdType="pubmed">18497889</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung SY, Huang WP, Liou HC, Fu WM. Autophagy protects neuron from Abeta-induced cytotoxicity. Autophagy. 2009;5:502&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pubmed">19270530</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia HG, et al. Control of basal autophagy by calpain1 mediated cleavage of ATG5. Autophagy. 2010;6:61&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2883879</ArticleId><ArticleId IdType="pubmed">19901552</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, et al. Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J Biol Chem. 1999;274:25945&#x2013;25952.</Citation><ArticleIdList><ArticleId IdType="pubmed">10464339</ArticleId></ArticleIdList></Reference><Reference><Citation>Carpenter AE, et al. CellProfiler: Image analysis software for identifying and quantifying cell phenotypes. Genome Biol. 2006;7:R100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1794559</ArticleId><ArticleId IdType="pubmed">17076895</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545&#x2013;15550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1239896</ArticleId><ArticleId IdType="pubmed">16199517</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang WS, et al. Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: A reference data set. Physiol Genomics. 2008;33:240&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2826117</ArticleId><ArticleId IdType="pubmed">18270320</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Wong WH. Model-based analysis of oligonucleotide arrays: Expression index computation and outlier detection. Proc Natl Acad Sci USA. 2001;98:31&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC14539</ArticleId><ArticleId IdType="pubmed">11134512</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20668263</PMID><DateCompleted><Year>2010</Year><Month>10</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>75</Volume><Issue>6</Issue><PubDate><Year>2010</Year><Month>Aug</Month><Day>10</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century.</ArticleTitle><Pagination><StartPage>494</StartPage><EndPage>499</EndPage><MedlinePgn>494-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0b013e3181ec7fac</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Idiopathic REM sleep behavior disorder (RBD) may be the initial manifestation of synucleinopathies (Parkinson disease [PD], multiple system atrophy [MSA], or dementia with Lewy bodies [DLB]).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We used the Mayo medical records linkage system to identify cases presenting from 2002 to 2006 meeting the criteria of idiopathic RBD at onset, plus at least 15 years between RBD and development of other neurodegenerative symptoms. All patients underwent evaluations by specialists in sleep medicine to confirm RBD, and behavioral neurology or movement disorders to confirm the subsequent neurodegenerative syndrome.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Clinical criteria were met by 27 patients who experienced isolated RBD for at least 15 years before evolving into PD, PD dementia (PDD), DLB, or MSA. The interval between RBD and subsequent neurologic syndrome ranged up to 50 years, with the median interval 25 years. At initial presentation, primary motor symptoms occurred in 13 patients: 9 with PD, 3 with PD and mild cognitive impairment (MCI), and 1 with PDD. Primary cognitive symptoms occurred in 13 patients: 10 with probable DLB and 3 with MCI. One patient presented with primary autonomic symptoms, diagnosed as MSA. At most recent follow-up, 63% of patients progressed to develop dementia (PDD or DLB). Concomitant autonomic dysfunction was confirmed in 74% of all patients.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These cases illustrate that the alpha-synuclein pathogenic process may start decades before the first symptoms of PD, DLB, or MSA. A long-duration preclinical phase has important implications for epidemiologic studies and future interventions designed to slow or halt the neurodegenerative process.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Claassen</LastName><ForeName>D O</ForeName><Initials>DO</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Josephs</LastName><ForeName>K A</ForeName><Initials>KA</Initials></Author><Author ValidYN="Y"><LastName>Ahlskog</LastName><ForeName>J E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Silber</LastName><ForeName>M H</ForeName><Initials>MH</Initials></Author><Author ValidYN="Y"><LastName>Tippmann-Peikert</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Boeve</LastName><ForeName>B F</ForeName><Initials>BF</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>07</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2010 Aug 10;75(6):488-9. doi: 10.1212/WNL.0b013e3181ec804a.</RefSource><PMID Version="1">20668262</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016347" MajorTopicYN="N">Medical Records Systems, Computerized</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019578" MajorTopicYN="N">Multiple System Atrophy</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020187" MajorTopicYN="N">REM Sleep Behavior Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>8</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20668263</ArticleId><ArticleId IdType="pmc">PMC2918473</ArticleId><ArticleId IdType="doi">10.1212/WNL.0b013e3181ec7fac</ArticleId><ArticleId IdType="pii">WNL.0b013e3181ec7fac</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Boeve BF, Silber MH, Saper CB, et al. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain 2007;130:2770&#x2013;2788.</Citation><ArticleIdList><ArticleId IdType="pubmed">17412731</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeve BF, Silber MH, Ferman TJ, et al. REM sleep behavior disorder and degenerative dementia: an association likely reflecting Lewy body disease. Neurology 1998;51:363&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pubmed">9710004</ArticleId></ArticleIdList></Reference><Reference><Citation>Postuma RB, Gagnon JF, Vendette M, Fantini ML, Massicotte-Marquez J, Montplaisir J. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology 2009;72:1296&#x2013;1300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2828948</ArticleId><ArticleId IdType="pubmed">19109537</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeve BF, Silber MH, Parisi JE, et al. Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism. Neurology 2003;61:40&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">12847154</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenck CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 1996;46:388&#x2013;393.</Citation><ArticleIdList><ArticleId IdType="pubmed">8614500</ArticleId></ArticleIdList></Reference><Reference><Citation>Iranzo A, Molinuevo JL, Santamaria J, et al. Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol 2006;5:572&#x2013;577.</Citation><ArticleIdList><ArticleId IdType="pubmed">16781987</ArticleId></ArticleIdList></Reference><Reference><Citation>Sateia M. International Classification of Sleep Disorders: Diagnostic and Coding Manual. Westchester, IL: American Academy of Sleep Medicine; 2005.</Citation></Reference><Reference><Citation>McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863&#x2013;1872.</Citation><ArticleIdList><ArticleId IdType="pubmed">16237129</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferman TJ, Smith GE, Boeve BF, et al. DLB fluctuations: specific features that reliably differentiate DLB from AD and normal aging. Neurology 2004;62:181&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">14745051</ArticleId></ArticleIdList></Reference><Reference><Citation>Molano J, Boeve B, Ferman T, et al. Mild cognitive impairment associated with limbic and neocortical Lewy body disease: a clinicopathological study. Brain 2010;133:540&#x2013;556.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2822633</ArticleId><ArticleId IdType="pubmed">19889717</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1014720</ArticleId><ArticleId IdType="pubmed">1564476</ArticleId></ArticleIdList></Reference><Reference><Citation>Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007;22:1689&#x2013;1707.</Citation><ArticleIdList><ArticleId IdType="pubmed">17542011</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 1999;163:94&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">10223419</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrish PK, Sawle GV, Brooks DJ. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996;119:585&#x2013;591.</Citation><ArticleIdList><ArticleId IdType="pubmed">8800950</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrish PK, Sawle GV, Brooks DJ. The rate of progression of Parkinson's disease: a longitudinal [18F]DOPA PET study. Adv Neurol 1996;69:427&#x2013;431.</Citation><ArticleIdList><ArticleId IdType="pubmed">8615162</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry 1998;64:314&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2170010</ArticleId><ArticleId IdType="pubmed">9527140</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks DJ. Morphological and functional imaging studies on the diagnosis and progression of Parkinson's disease. J Neurol 2000;247(suppl 2):II11&#x2013;II18.</Citation><ArticleIdList><ArticleId IdType="pubmed">10991656</ArticleId></ArticleIdList></Reference><Reference><Citation>Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283&#x2013;2301.</Citation><ArticleIdList><ArticleId IdType="pubmed">1933245</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbott RD, Petrovitch H, White LR, et al. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 2001;57:456&#x2013;462.</Citation><ArticleIdList><ArticleId IdType="pubmed">11502913</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiba M, Bower JH, Maraganore DM, et al. Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study. Mov Disord 2000;15:669&#x2013;677.</Citation><ArticleIdList><ArticleId IdType="pubmed">10928577</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishihara L, Brayne C. What is the evidence for a premorbid parkinsonian personality: a systematic review. Mov Disord 2006;21:1066&#x2013;1072.</Citation><ArticleIdList><ArticleId IdType="pubmed">16755553</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">12498954</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004;318:121&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">15338272</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu J, Sherman D, Devor M, Saper CB. A putative flip-flop switch for control of REM sleep. Nature 2006;441:589&#x2013;594.</Citation><ArticleIdList><ArticleId IdType="pubmed">16688184</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufmann H, Nahm K, Purohit D, Wolfe D. Autonomic failure as the initial presentation of Parkinson disease and dementia with Lewy bodies. Neurology 2004;63:1093&#x2013;1095.</Citation><ArticleIdList><ArticleId IdType="pubmed">15452307</ArticleId></ArticleIdList></Reference><Reference><Citation>Larner AJ, Mathias CJ, Rossor MN. Autonomic failure preceding dementia with Lewy bodies. J Neurol 2000;247:229&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">10787124</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanaka Y, Asahina M, Hiraga A, Sakakibara R, Oka H, Hattori T. Over 10 years of isolated autonomic failure preceding dementia and Parkinsonism in 2 patients with Lewy body disease. Mov Disord 2007;22:595&#x2013;597.</Citation><ArticleIdList><ArticleId IdType="pubmed">17230479</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyamoto T, Miyamoto M, Inoue Y, Usui Y, Suzuki K, Hirata K. Reduced cardiac 123I-MIBG scintigraphy in idiopathic REM sleep behavior disorder. Neurology 2006;67:2236&#x2013;2238.</Citation><ArticleIdList><ArticleId IdType="pubmed">17190953</ArticleId></ArticleIdList></Reference><Reference><Citation>Vendette M, Gagnon JF, Decary A, et al. REM sleep behavior disorder predicts cognitive impairment in Parkinson disease without dementia. Neurology 2007;69:1843&#x2013;1849.</Citation><ArticleIdList><ArticleId IdType="pubmed">17984452</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinforiani E, Pacchetti C, Zangaglia R, Pasotti C, Manni R, Nappi G. REM behavior disorder, hallucinations and cognitive impairment in Parkinson's disease: a two-year follow up. Mov Disord 2008;23:1441&#x2013;1445.</Citation><ArticleIdList><ArticleId IdType="pubmed">18512749</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenck CH, Bundlie SR, Mahowald MW. REM behavior disorder (RBD): delayed emergence of parkinsonism and/or dementia in 65% of older men initially diagnosed with idiopathic RBD, and an analysis of the minimum &amp; maximum tonic and/or phasic electromyographic abnormalities found during REM sleep. Sleep 2003;26(suppl):A316.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20676056</PMID><DateCompleted><Year>2010</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2075</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>17</Issue><PubDate><Year>2010</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>The EMBO journal</Title><ISOAbbreviation>EMBO J</ISOAbbreviation></Journal><ArticleTitle>ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons.</ArticleTitle><Pagination><StartPage>3020</StartPage><EndPage>3032</EndPage><MedlinePgn>3020-32</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/emboj.2010.167</ELocationID><Abstract><AbstractText>The amyloid precursor protein (APP) undergoes constitutive shedding by a protease activity called alpha-secretase. This is considered an important mechanism preventing the generation of the Alzheimer's disease amyloid-beta peptide (Abeta). alpha-Secretase appears to be a metalloprotease of the ADAM family, but its identity remains to be established. Using a novel alpha-secretase-cleavage site-specific antibody, we found that RNAi-mediated knockdown of ADAM10, but surprisingly not of ADAM9 or 17, completely suppressed APP alpha-secretase cleavage in different cell lines and in primary murine neurons. Other proteases were not able to compensate for this loss of alpha-cleavage. This finding was further confirmed by mass-spectrometric detection of APP-cleavage fragments. Surprisingly, in different cell lines, the reduction of alpha-secretase cleavage was not paralleled by a corresponding increase in the Abeta-generating beta-secretase cleavage, revealing that both proteases do not always compete for APP as a substrate. Instead, our data suggest a novel pathway for APP processing, in which ADAM10 can partially compete with gamma-secretase for the cleavage of a C-terminal APP fragment generated by beta-secretase. We conclude that ADAM10 is the physiologically relevant, constitutive alpha-secretase of APP.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kuhn</LastName><ForeName>Peer-Hendrik</ForeName><Initials>PH</Initials><AffiliationInfo><Affiliation>Adolf-Butenandt-Institute, Biochemistry, Ludwig-Maximilians-University, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Huanhuan</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Dislich</LastName><ForeName>Bastian</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Colombo</LastName><ForeName>Alessio</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Zeitschel</LastName><ForeName>Ulrike</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Ellwart</LastName><ForeName>Joachim W</ForeName><Initials>JW</Initials></Author><Author ValidYN="Y"><LastName>Kremmer</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Rossner</LastName><ForeName>Steffen</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Lichtenthaler</LastName><ForeName>Stefan F</ForeName><Initials>SF</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>07</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>EMBO J</MedlineTA><NlmUniqueID>8208664</NlmUniqueID><ISSNLinking>0261-4189</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078201">Aplp1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.-</RegistryNumber><NameOfSubstance UI="D051722">ADAM Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.81</RegistryNumber><NameOfSubstance UI="D000072197">ADAM10 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.81</RegistryNumber><NameOfSubstance UI="C491234">Adam10 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051722" MajorTopicYN="N">ADAM Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072197" MajorTopicYN="N">ADAM10 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013058" MajorTopicYN="N">Mass Spectrometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>8</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>8</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20676056</ArticleId><ArticleId IdType="pmc">PMC2944055</ArticleId><ArticleId IdType="doi">10.1038/emboj.2010.167</ArticleId><ArticleId IdType="pii">emboj2010167</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Allinson TM, Parkin ET, Condon TP, Schwager SL, Sturrock ED, Turner AJ, Hooper NM (2004) The role of ADAM10 and ADAM17 in the ectodomain shedding of angiotensin converting enzyme and the amyloid precursor protein. Eur J Biochem 271: 2539&#x2013;2547</Citation><ArticleIdList><ArticleId IdType="pubmed">15182369</ArticleId></ArticleIdList></Reference><Reference><Citation>Asai M, Hattori C, Szabo B, Sasagawa N, Maruyama K, Tanuma S, Ishiura S (2003) Putative function of ADAM9, ADAM10, and ADAM17 as APP alpha-secretase. Biochem Biophys Res Commun 301: 231&#x2013;235</Citation><ArticleIdList><ArticleId IdType="pubmed">12535668</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandyopadhyay S, Goldstein LE, Lahiri DK, Rogers JT (2007) Role of the APP non-amyloidogenic signaling pathway and targeting alpha-secretase as an alternative drug target for treatment of Alzheimer's disease. Curr Med Chem 14: 2848&#x2013;2864</Citation><ArticleIdList><ArticleId IdType="pubmed">18045131</ArticleId></ArticleIdList></Reference><Reference><Citation>Buxbaum JD, Liu KN, Luo Y, Slack JL, Stocking KL, Peschon JJ, Johnson RS, Castner BJ, Cerretti DP, Black RA (1998) Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J Biol Chem 273: 27765&#x2013;27767</Citation><ArticleIdList><ArticleId IdType="pubmed">9774383</ArticleId></ArticleIdList></Reference><Reference><Citation>Caescu CI, Jeschke GR, Turk BE (2009) Active-site determinants of substrate recognition by the metalloproteinases TACE and ADAM10. Biochem J 424: 79&#x2013;88</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2774824</ArticleId><ArticleId IdType="pubmed">19715556</ArticleId></ArticleIdList></Reference><Reference><Citation>Cagavi Bozkulak E, Weinmaster G (2009) Selective use of Adam10 and Adam17 in activation of Notch1 signaling. Mol Cell Biol 29: 5679&#x2013;5695</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772745</ArticleId><ArticleId IdType="pubmed">19704010</ArticleId></ArticleIdList></Reference><Reference><Citation>Camden JM, Schrader AM, Camden RE, Gonzalez FA, Erb L, Seye CI, Weisman GA (2005) P2Y2 nucleotide receptors enhance alpha-secretase-dependent amyloid precursor protein processing. J Biol Chem 280: 18696&#x2013;18702</Citation><ArticleIdList><ArticleId IdType="pubmed">15778502</ArticleId></ArticleIdList></Reference><Reference><Citation>Cupers P, Bentahir M, Craessaerts K, Orlans I, Vanderstichele H, Saftig P, De Strooper B, Annaert W (2001) The discrepancy between presenilin subcellular localization and gamma-secretase processing of amyloid precursor protein. J Cell Biol 154: 731&#x2013;740</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2196466</ArticleId><ArticleId IdType="pubmed">11502763</ArticleId></ArticleIdList></Reference><Reference><Citation>Esch FS, Keim PS, Beattie EC, Blacher RW, Culwell AR, Oltersdorf T, McClure D, Ward PJ (1990) Cleavage of amyloid b peptide during constitutive processing of its precursor. Science 248: 1122&#x2013;1124</Citation><ArticleIdList><ArticleId IdType="pubmed">2111583</ArticleId></ArticleIdList></Reference><Reference><Citation>Fahrenholz F (2007) Alpha-secretase as a therapeutic target. Curr Alzheimer Res 4: 412&#x2013;417</Citation><ArticleIdList><ArticleId IdType="pubmed">17908044</ArticleId></ArticleIdList></Reference><Reference><Citation>Fellgiebel A, Kojro E, Muller MJ, Scheurich A, Schmidt LG, Fahrenholz F (2009) CSF APPs alpha and phosphorylated tau protein levels in mild cognitive impairment and dementia of Alzheimer's type. J Geriatr Psychiatry Neurol 22: 3&#x2013;9</Citation><ArticleIdList><ArticleId IdType="pubmed">19073834</ArticleId></ArticleIdList></Reference><Reference><Citation>Freese C, Garratt AN, Fahrenholz F, Endres K (2009) The effects of alpha-secretase ADAM10 on the proteolysis of neuregulin-1. FEBS J 276: 1568&#x2013;1580</Citation><ArticleIdList><ArticleId IdType="pubmed">19220854</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa K, Sopher BL, Rydel RE, Begley JG, Pham DG, Martin GM, Fox M, Mattson MP (1996) Increased activity-regulating and neuroprotective efficacy of alpha-secretase-derived secreted amyloid precursor protein conferred by a C-terminal heparin-binding domain. J Neurochem 67: 1882&#x2013;1896</Citation><ArticleIdList><ArticleId IdType="pubmed">8863493</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C (2004) Take five-BACE and the gamma-secretase quartet conduct Alzheimer's amyloid beta-peptide generation. EMBO J 23: 483&#x2013;488</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1271800</ArticleId><ArticleId IdType="pubmed">14749724</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Lemere CA, Capell A, Citron M, Seubert P, Schenk D, Lannfelt L, Selkoe DJ (1995) The Swedish mutation causes early-onset Alzheimer's disease by beta-secretase cleavage within the secretory pathway. Nat Med 1: 1291&#x2013;1296</Citation><ArticleIdList><ArticleId IdType="pubmed">7489411</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartmann D, de Strooper B, Serneels L, Craessaerts K, Herreman A, Annaert W, Umans L, Lubke T, Lena Illert A, von Figura K, Saftig P (2002) The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts. Hum Mol Genet 11: 2615&#x2013;2624</Citation><ArticleIdList><ArticleId IdType="pubmed">12354787</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, Mao M, Li B, Cavet G, Linsley PS (2003) Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 21: 635&#x2013;637</Citation><ArticleIdList><ArticleId IdType="pubmed">12754523</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim M, Suh J, Romano D, Truong MH, Mullin K, Hooli B, Norton D, Tesco G, Elliott K, Wagner SL, Moir RD, Becker KD, Tanzi RE (2009) Potential late-onset Alzheimer's disease-associated mutations in the ADAM10 gene attenuate {alpha}-secretase activity. Hum Mol Genet 18: 3987&#x2013;3996</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2748890</ArticleId><ArticleId IdType="pubmed">19608551</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim ML, Zhang B, Mills IP, Milla ME, Brunden KR, Lee VM (2008) Effects of TNFalpha-converting enzyme inhibition on amyloid beta production and APP processing in vitro and in vivo. J Neurosci 28: 12052&#x2013;12061</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2646261</ArticleId><ArticleId IdType="pubmed">19005070</ArticleId></ArticleIdList></Reference><Reference><Citation>Koike H, Tomioka S, Sorimachi H, Saido TC, Maruyama K, Okuyama A, Fujisawa-Sehara A, Ohno S, Suzuki K, Ishiura S (1999) Membrane-anchored metalloprotease MDC9 has an alpha-secretase activity responsible for processing the amyloid precursor protein. Biochem J 343 (Part 2): 371&#x2013;375</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1220563</ArticleId><ArticleId IdType="pubmed">10510302</ArticleId></ArticleIdList></Reference><Reference><Citation>Kojro E, Postina R, Buro C, Meiringer C, Gehrig-Burger K, Fahrenholz F (2006) The neuropeptide PACAP promotes the alpha-secretase pathway for processing the Alzheimer amyloid precursor protein. FASEB J 20: 512&#x2013;514</Citation><ArticleIdList><ArticleId IdType="pubmed">16401644</ArticleId></ArticleIdList></Reference><Reference><Citation>Koo EH, Squazzo SL (1994) Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J Biol Chem 269: 17386&#x2013;17389</Citation><ArticleIdList><ArticleId IdType="pubmed">8021238</ArticleId></ArticleIdList></Reference><Reference><Citation>Lammich S, Kojro E, Postina R, Gilbert S, Pfeiffer R, Jasionowski M, Haass C, Fahrenholz F (1999) Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci USA 96: 3922&#x2013;3927</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22396</ArticleId><ArticleId IdType="pubmed">10097139</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Gall SM, Bobe P, Reiss K, Horiuchi K, Niu XD, Lundell D, Gibb DR, Conrad D, Saftig P, Blobel CP (2009) ADAMs 10 and 17 represent differentially regulated components of a general shedding machinery for membrane proteins such as transforming growth factor alpha, L-selectin, and tumor necrosis factor alpha. Mol Biol Cell 20: 1785&#x2013;1794</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2655247</ArticleId><ArticleId IdType="pubmed">19158376</ArticleId></ArticleIdList></Reference><Reference><Citation>Meziane H, Dodart JC, Mathis C, Little S, Clemens J, Paul SM, Ungerer A (1998) Memory-enhancing effects of secreted forms of the beta-amyloid precursor protein in normal and amnestic mice. Proc Natl Acad Sci USA 95: 12683&#x2013;12688</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22891</ArticleId><ArticleId IdType="pubmed">9770546</ArticleId></ArticleIdList></Reference><Reference><Citation>Miles LA, Wun KS, Crespi GA, Fodero-Tavoletti MT, Galatis D, Bagley CJ, Beyreuther K, Masters CL, Cappai R, McKinstry WJ, Barnham KJ, Parker MW (2008) Amyloid-beta-anti-amyloid-beta complex structure reveals an extended conformation in the immunodominant B-cell epitope. J Mol Biol 377: 181&#x2013;192</Citation><ArticleIdList><ArticleId IdType="pubmed">18237744</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann S, Schobel S, Jager S, Trautwein A, Haass C, Pietrzik CU, Lichtenthaler SF (2006) Amyloid precursor-like protein 1 influences endocytosis and proteolytic processing of the amyloid precursor protein. J Biol Chem 281: 7583&#x2013;7594</Citation><ArticleIdList><ArticleId IdType="pubmed">16344553</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolaev A, McLaughlin T, O'Leary DD, Tessier-Lavigne M (2009) APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 457: 981&#x2013;989</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677572</ArticleId><ArticleId IdType="pubmed">19225519</ArticleId></ArticleIdList></Reference><Reference><Citation>Page RM, Baumann K, Tomioka M, Perez-Revuelta BI, Fukumori A, Jacobsen H, Flohr A, Luebbers T, Ozmen L, Steiner H, Haass C (2008) Generation of Abeta38 and Abeta42 is independently and differentially affected by familial Alzheimer disease-associated presenilin mutations and gamma-secretase modulation. J Biol Chem 283: 677&#x2013;683</Citation><ArticleIdList><ArticleId IdType="pubmed">17962197</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasternack JM, Palmert MR, Usiak M, Wang R, Zurcher-Neely H, Gonzalez-De Whitt PA, Fairbanks MB, Cheung T, Blades D, Heinrikson RL, Greenberg BD, Cotter RJ, Younkin SG (1992) Alzheimer's disease and control brain contain soluble derivatives of the amyloid protein precursor that end within the beta amyloid protein region. Biochemistry 31: 10936&#x2013;10940</Citation><ArticleIdList><ArticleId IdType="pubmed">1420205</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E, Price E, Brinkmalm G, Stiteler M, Olsson M, Persson R, Westman-Brinkmalm A, Zetterberg H, Simon AJ, Blennow K (2009) A novel pathway for amyloid precursor protein processing. Neurobiol Aging (in press)</Citation><ArticleIdList><ArticleId IdType="pubmed">19604603</ArticleId></ArticleIdList></Reference><Reference><Citation>Postina R, Schroeder A, Dewachter I, Bohl J, Schmitt U, Kojro E, Prinzen C, Endres K, Hiemke C, Blessing M, Flamez P, Dequenne A, Godaux E, van Leuven F, Fahrenholz F (2004) A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J Clin Invest 113: 1456&#x2013;1464</Citation><ArticleIdList><ArticleId IdType="pmc">PMC406531</ArticleId><ArticleId IdType="pubmed">15146243</ArticleId></ArticleIdList></Reference><Reference><Citation>Pruessmeyer J, Ludwig A (2009) The good, the bad and the ugly substrates for ADAM10 and ADAM17 in brain pathology, inflammation and cancer. Semin Cell Dev Biol 20: 164&#x2013;174</Citation><ArticleIdList><ArticleId IdType="pubmed">18951988</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiss K, Maretzky T, Ludwig A, Tousseyn T, de Strooper B, Hartmann D, Saftig P (2005) ADAM10 cleavage of N-cadherin and regulation of cell-cell adhesion and beta-catenin nuclear signalling. EMBO J 24: 742&#x2013;752</Citation><ArticleIdList><ArticleId IdType="pmc">PMC549617</ArticleId><ArticleId IdType="pubmed">15692570</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiss K, Saftig P (2009) The &#x2018;A disintegrin and metalloprotease' (ADAM) family of sheddases: physiological and cellular functions. Semin Cell Dev Biol 20: 126&#x2013;137</Citation><ArticleIdList><ArticleId IdType="pubmed">19049889</ArticleId></ArticleIdList></Reference><Reference><Citation>Roghani M, Becherer JD, Moss ML, Atherton RE, Erdjument-Bromage H, Arribas J, Blackburn RK, Weskamp G, Tempst P, Blobel CP (1999) Metalloprotease-disintegrin MDC9: intracellular maturation and catalytic activity. J Biol Chem 274: 3531&#x2013;3540</Citation><ArticleIdList><ArticleId IdType="pubmed">9920899</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahin U, Weskamp G, Kelly K, Zhou HM, Higashiyama S, Peschon J, Hartmann D, Saftig P, Blobel CP (2004) Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol 164: 769&#x2013;779</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172154</ArticleId><ArticleId IdType="pubmed">14993236</ArticleId></ArticleIdList></Reference><Reference><Citation>Sastre M, Steiner H, Fuchs K, Capell A, Multhaup G, Condron MM, Teplow DB, Haass C (2001) Presenilin-dependent gamma-secretase processing of beta-amyloid precursor protein at a site corresponding to the S3 cleavage of Notch. EMBO Rep 2: 835&#x2013;841</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1084035</ArticleId><ArticleId IdType="pubmed">11520861</ArticleId></ArticleIdList></Reference><Reference><Citation>Schobel S, Neumann S, Hertweck M, Dislich B, Kuhn PH, Kremmer E, Seed B, Baumeister R, Haass C, Lichtenthaler SF (2008) A novel sorting nexin modulates endocytic trafficking and alpha-secretase cleavage of the amyloid precursor protein. J Biol Chem 283: 14257&#x2013;14268</Citation><ArticleIdList><ArticleId IdType="pubmed">18353773</ArticleId></ArticleIdList></Reference><Reference><Citation>Schobel S, Neumann S, Seed B, Lichtenthaler SF (2006) Expression cloning screen for modifiers of amyloid precursor protein shedding. Int J Dev Neurosci 24: 141&#x2013;148</Citation><ArticleIdList><ArticleId IdType="pubmed">16446073</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ, Schenk D (2003) Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 43: 545&#x2013;584</Citation><ArticleIdList><ArticleId IdType="pubmed">12415125</ArticleId></ArticleIdList></Reference><Reference><Citation>Sennvik K, Fastbom J, Blomberg M, Wahlund LO, Winblad B, Benedikz E (2000) Levels of alpha- and beta-secretase cleaved amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients. Neurosci Lett 278: 169&#x2013;172</Citation><ArticleIdList><ArticleId IdType="pubmed">10653020</ArticleId></ArticleIdList></Reference><Reference><Citation>Simons M, Destrooper B, Multhaup G, Tienari PJ, Dotti CG, Beyreuther K (1996) Amyloidogenic processing of the human amyloid precursor protein in primary cultures of rat hippocampal neurons. J Neurosci 16: 899&#x2013;908</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578819</ArticleId><ArticleId IdType="pubmed">8558258</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisodia SS (1992) Beta-amyloid precursor protein cleavage by a membrane-bound protease. Proc Natl Acad Sci USA 89: 6075&#x2013;6079</Citation><ArticleIdList><ArticleId IdType="pmc">PMC49440</ArticleId><ArticleId IdType="pubmed">1631093</ArticleId></ArticleIdList></Reference><Reference><Citation>Skovronsky DM, Moore DB, Milla ME, Doms RW, Lee VM (2000) Protein kinase C-dependent alpha-secretase competes with beta-secretase for cleavage of amyloid-beta precursor protein in the trans-Golgi network. J Biol Chem 275: 2568&#x2013;2575</Citation><ArticleIdList><ArticleId IdType="pubmed">10644715</ArticleId></ArticleIdList></Reference><Reference><Citation>Slack BE, Ma LK, Seah CC (2001) Constitutive shedding of the amyloid precursor protein ectodomain is up-regulated by tumour necrosis factor-alpha converting enzyme. Biochem J 357: 787&#x2013;794</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1222008</ArticleId><ArticleId IdType="pubmed">11463349</ArticleId></ArticleIdList></Reference><Reference><Citation>Stachel SJ, Coburn CA, Steele TG, Jones KG, Loutzenhiser EF, Gregro AR, Rajapakse HA, Lai MT, Crouthamel MC, Xu M, Tugusheva K, Lineberger JE, Pietrak BL, Espeseth AS, Shi XP, Chen-Dodson E, Holloway MK, Munshi S, Simon AJ, Kuo L et al. (2004) Structure-based design of potent and selective cell-permeable inhibitors of human beta-secretase (BACE-1). J Med Chem 47: 6447&#x2013;6450</Citation><ArticleIdList><ArticleId IdType="pubmed">15588077</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein TD, Anders NJ, DeCarli C, Chan SL, Mattson MP, Johnson JA (2004) Neutralization of transthyretin reverses the neuroprotective effects of secreted amyloid precursor protein (APP) in APPSW mice resulting in tau phosphorylation and loss of hippocampal neurons: support for the amyloid hypothesis. J Neurosci 24: 7707&#x2013;7717</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729623</ArticleId><ArticleId IdType="pubmed">15342738</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor DR, Parkin ET, Cocklin SL, Ault JR, Ashcroft AE, Turner AJ, Hooper NM (2009) Role of ADAMs in the ectodomain shedding and conformational conversion of the prion protein. J Biol Chem 284: 22590&#x2013;22600</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2755666</ArticleId><ArticleId IdType="pubmed">19564338</ArticleId></ArticleIdList></Reference><Reference><Citation>Ullrich S, M&#xfc;nch A, Neumann S, Kremmer E, Tatzelt J, Lichtenthaler SF (2010) The novel membrane protein TMEM59 modulates complex glycosylation, cell surface expression and secretion of the amyloid precursor protein. J Biol Chem 285: 20664&#x2013;20674</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2898310</ArticleId><ArticleId IdType="pubmed">20427278</ArticleId></ArticleIdList></Reference><Reference><Citation>van Tetering G, van Diest P, Verlaan I, van der Wall E, Kopan R, Vooijs M (2009) The metalloprotease ADAM10 is required for notch1 S2 cleavage. J Biol Chem 284: 31018&#x2013;31027</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2781502</ArticleId><ArticleId IdType="pubmed">19726682</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC et al. (1999) Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286: 735&#x2013;741</Citation><ArticleIdList><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Weskamp G, Cai H, Brodie TA, Higashyama S, Manova K, Ludwig T, Blobel CP (2002) Mice lacking the metalloprotease-disintegrin MDC9 (ADAM9) have no evident major abnormalities during development or adult life. Mol Cell Biol 22: 1537&#x2013;1544</Citation><ArticleIdList><ArticleId IdType="pmc">PMC134708</ArticleId><ArticleId IdType="pubmed">11839819</ArticleId></ArticleIdList></Reference><Reference><Citation>Weskamp G, Ford JW, Sturgill J, Martin S, Docherty AJ, Swendeman S, Broadway N, Hartmann D, Saftig P, Umland S, Sehara-Fujisawa A, Black RA, Ludwig A, Becherer JD, Conrad DH, Blobel CP (2006) ADAM10 is a principal &#x2018;sheddase' of the low-affinity immunoglobulin E receptor CD23. Nat Immunol 7: 1293&#x2013;1298</Citation><ArticleIdList><ArticleId IdType="pubmed">17072319</ArticleId></ArticleIdList></Reference><Reference><Citation>Willem M, Garratt AN, Novak B, Citron M, Kaufmann S, Rittger A, DeStrooper B, Saftig P, Birchmeier C, Haass C (2006) Control of peripheral nerve myelination by the beta-secretase BACE1. Science 314: 664&#x2013;666</Citation><ArticleIdList><ArticleId IdType="pubmed">16990514</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20679249</PMID><DateCompleted><Year>2010</Year><Month>09</Month><Day>27</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>107</Volume><Issue>33</Issue><PubDate><Year>2010</Year><Month>Aug</Month><Day>17</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Amyloid beta 42 peptide (Abeta42)-lowering compounds directly bind to Abeta and interfere with amyloid precursor protein (APP) transmembrane dimerization.</ArticleTitle><Pagination><StartPage>14597</StartPage><EndPage>14602</EndPage><MedlinePgn>14597-602</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1003026107</ELocationID><Abstract><AbstractText>Following ectodomain shedding by beta-secretase, successive proteolytic cleavages within the transmembrane sequence (TMS) of the amyloid precursor protein (APP) catalyzed by gamma-secretase result in the release of amyloid-beta (Abeta) peptides of variable length. Abeta peptides with 42 amino acids appear to be the key pathogenic species in Alzheimer's disease, as they are believed to initiate neuronal degeneration. Sulindac sulfide, which is known as a potent gamma-secretase modulator (GSM), selectively reduces Abeta42 production in favor of shorter Abeta species, such as Abeta38. By studying APP-TMS dimerization we previously showed that an attenuated interaction similarly decreased Abeta42 levels and concomitantly increased Abeta38 levels. However, the precise molecular mechanism by which GSMs modulate Abeta production is still unclear. In this study, using a reporter gene-based dimerization assay, we found that APP-TMS dimers are destabilized by sulindac sulfide and related Abeta42-lowering compounds in a concentration-dependent manner. By surface plasmon resonance analysis and NMR spectroscopy, we show that sulindac sulfide and novel sulindac-derived compounds directly bind to the Abeta sequence. Strikingly, the attenuated APP-TMS interaction by GSMs correlated strongly with Abeta42-lowering activity and binding strength to the Abeta sequence. Molecular docking analyses suggest that certain GSMs bind to the GxxxG dimerization motif in the APP-TMS. We conclude that these GSMs decrease Abeta42 levels by modulating APP-TMS interactions. This effect specifically emphasizes the importance of the dimeric APP-TMS as a promising drug target in Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Richter</LastName><ForeName>Luise</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institut f&#xfc;r Chemie und Biochemie, Freie Universit&#xe4;t Berlin, 14195 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munter</LastName><ForeName>Lisa-Marie</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Ness</LastName><ForeName>Julia</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Hildebrand</LastName><ForeName>Peter W</ForeName><Initials>PW</Initials></Author><Author ValidYN="Y"><LastName>Dasari</LastName><ForeName>Muralidhar</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Unterreitmeier</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Bulic</LastName><ForeName>Bruno</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Beyermann</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Gust</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Reif</LastName><ForeName>Bernd</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Weggen</LastName><ForeName>Sascha</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Langosch</LastName><ForeName>Dieter</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Multhaup</LastName><ForeName>Gerd</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>08</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>184SNS8VUH</RegistryNumber><NameOfSubstance UI="D013467">Sulindac</NameOfSubstance></Chemical><Chemical><RegistryNumber>6UVA8S2DEY</RegistryNumber><NameOfSubstance UI="C025462">sulindac sulfide</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016466" MajorTopicYN="N">CHO Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003412" MajorTopicYN="N">Cricetulus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055503" MajorTopicYN="N">Protein Multimerization</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013467" MajorTopicYN="N">Sulindac</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020349" MajorTopicYN="N">Surface Plasmon Resonance</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>2</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20679249</ArticleId><ArticleId IdType="pmc">PMC2930477</ArticleId><ArticleId IdType="doi">10.1073/pnas.1003026107</ArticleId><ArticleId IdType="pii">1003026107</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>De Strooper B, Vassar R, Golde T. The secretases: Enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol. 2010;6:99&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2879045</ArticleId><ArticleId IdType="pubmed">20139999</ArticleId></ArticleIdList></Reference><Reference><Citation>Takami M, et al. Gamma-secretase: Successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. J Neurosci. 2009;29:13042&#x2013;13052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6665297</ArticleId><ArticleId IdType="pubmed">19828817</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res. 2008;192:106&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2601528</ArticleId><ArticleId IdType="pubmed">18359102</ArticleId></ArticleIdList></Reference><Reference><Citation>Munter LM, et al. Aberrant APP processing in hereditary forms of Alzheimer disease caused by APP-FAD mutations can be rescued by mutations in the APP GxxxG motif. J Biol Chem. 2010;285:21636&#x2013;21643.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2898405</ArticleId><ArticleId IdType="pubmed">20452985</ArticleId></ArticleIdList></Reference><Reference><Citation>Munter LM, et al. GxxxG motifs within the amyloid precursor protein transmembrane sequence are critical for the etiology of Abeta42. EMBO J. 2007;26:1702&#x2013;1712.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1829382</ArticleId><ArticleId IdType="pubmed">17332749</ArticleId></ArticleIdList></Reference><Reference><Citation>Beel AJ, Sanders CR. Substrate specificity of gamma-secretase and other intramembrane proteases. Cell Mol Life Sci. 2008;65:1311&#x2013;1334.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2569971</ArticleId><ArticleId IdType="pubmed">18239854</ArticleId></ArticleIdList></Reference><Reference><Citation>Weggen S, et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature. 2001;414:212&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">11700559</ArticleId></ArticleIdList></Reference><Reference><Citation>Kukar T, et al. Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nat Med. 2005;11:545&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pubmed">15834426</ArticleId></ArticleIdList></Reference><Reference><Citation>Weggen S, et al. Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. J Biol Chem. 2003;278:31831&#x2013;31837.</Citation><ArticleIdList><ArticleId IdType="pubmed">12805356</ArticleId></ArticleIdList></Reference><Reference><Citation>Lleo A, et al. Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation. Nat Med. 2004;10:1065&#x2013;1066.</Citation><ArticleIdList><ArticleId IdType="pubmed">15448688</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang SB, Shen TY. Membrane effects of antiinflammatory agents. 2. Interaction of nonsteroidal antiinflammatory drugs with liposome and purple membranes. J Med Chem. 1981;24:1202&#x2013;1211.</Citation><ArticleIdList><ArticleId IdType="pubmed">7328581</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan SS, Shen TY. Membrane effects of antiinflammatory agents. 1. Interaction of sulindac and its metabolites with phospholipid membrane, a magnetic resonance study. J Med Chem. 1981;24:1197&#x2013;1202.</Citation><ArticleIdList><ArticleId IdType="pubmed">6276543</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamerdinger M, Clement AB, Behl C. Effects of sulindac sulfide on the membrane architecture and the activity of gamma-secretase. Neuropharmacology. 2008;54:998&#x2013;1005.</Citation><ArticleIdList><ArticleId IdType="pubmed">18359496</ArticleId></ArticleIdList></Reference><Reference><Citation>Kukar TL, et al. Substrate-targeting gamma-secretase modulators. Nature. 2008;453:925&#x2013;929.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2678541</ArticleId><ArticleId IdType="pubmed">18548070</ArticleId></ArticleIdList></Reference><Reference><Citation>Beel AJ, et al. Non-specificity of binding of gamma-secretase modulators to the amyloid precursor protein. Biochemistry. 2009;48:11837&#x2013;11839.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2794937</ArticleId><ArticleId IdType="pubmed">19928774</ArticleId></ArticleIdList></Reference><Reference><Citation>Langosch D, Brosig B, Kolmar H, Fritz HJ. Dimerisation of the glycophorin A transmembrane segment in membranes probed with the ToxR transcription activator. J Mol Biol. 1996;263:525&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pubmed">8918935</ArticleId></ArticleIdList></Reference><Reference><Citation>Etienne F, Resnick L, Sagher D, Brot N, Weissbach H. Reduction of sulindac to its active metabolite, sulindac sulfide: Assay and role of the methionine sulfoxide reductase system. Biochem Bioph Res Co. 2003;312:1005&#x2013;1010.</Citation><ArticleIdList><ArticleId IdType="pubmed">14651971</ArticleId></ArticleIdList></Reference><Reference><Citation>Czirr E, Weggen S. Gamma-secretase modulation with Abeta42-lowering nonsteroidal anti-inflammatory drugs and derived compounds. Neurodegener Dis. 2006;3:298&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pubmed">17047371</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller O, et al. Identification of potent Ras signaling inhibitors by pathway-selective phenotype-based screening. Angew Chem Int Edit. 2004;43:450&#x2013;454.</Citation><ArticleIdList><ArticleId IdType="pubmed">14735532</ArticleId></ArticleIdList></Reference><Reference><Citation>Czirr E, et al. Insensitivity to Abeta42-lowering nonsteroidal anti-inflammatory drugs and gamma-secretase inhibitors is common among aggressive presenilin-1 mutations. J Biol Chem. 2007;282:24504&#x2013;24513.</Citation><ArticleIdList><ArticleId IdType="pubmed">17573346</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaden D, et al. Homophilic interactions of the amyloid precursor protein (APP) ectodomain are regulated by the loop region and affect beta-secretase cleavage of APP. J Biol Chem. 2008;283:7271&#x2013;7279.</Citation><ArticleIdList><ArticleId IdType="pubmed">18182389</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Ha Y. The X-ray structure of an antiparallel dimer of the human amyloid precursor protein E2 domain. Mol Cell. 2004;15:343&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pubmed">15304215</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber O, Kemler R, Langosch D. Mutations affecting transmembrane segment interactions impair adhesiveness of E-cadherin. J Cell Sci. 1999;112:4415&#x2013;4423.</Citation><ArticleIdList><ArticleId IdType="pubmed">10564659</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendrola JM, Berger MB, King MC, Lemmon MA. The single transmembrane domains of ErbB receptors self-associate in cell membranes. J Biol Chem. 2002;277:4704&#x2013;4712.</Citation><ArticleIdList><ArticleId IdType="pubmed">11741943</ArticleId></ArticleIdList></Reference><Reference><Citation>Vooijs M, Schroeter EH, Pan Y, Blandford M, Kopan R. Ectodomain shedding and intramembrane cleavage of mammalian Notch proteins is not regulated through oligomerization. J Biol Chem. 2004;279:50864&#x2013;50873.</Citation><ArticleIdList><ArticleId IdType="pubmed">15448134</ArticleId></ArticleIdList></Reference><Reference><Citation>Okochi M, et al. Secretion of the Notch-1 Abeta-like peptide during Notch signaling. J Biol Chem. 2006;281:7890&#x2013;7898.</Citation><ArticleIdList><ArticleId IdType="pubmed">16434391</ArticleId></ArticleIdList></Reference><Reference><Citation>Sala Frigerio C, et al. An NSAID-like compound, FT-9, preferentially inhibits gamma-secretase cleavage of the amyloid precursor protein compared to its effect on amyloid precursor-like protein 1. Biochemistry. 2009;48:10894&#x2013;10904.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4489158</ArticleId><ArticleId IdType="pubmed">19821615</ArticleId></ArticleIdList></Reference><Reference><Citation>Waldmann H, et al. Sulindac-derived Ras pathway inhibitors target the Ras-Raf interaction and downstream effectors in the Ras pathway. Angew Chem Int Edit. 2004;43:454&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pubmed">14735533</ArticleId></ArticleIdList></Reference><Reference><Citation>Beyermann M, Fechner K, Furkert J, Krause E, Bienert M. A single-point slight alteration set as a tool for structure-activity relationship studies of ovine corticotropin releasing factor. J Med Chem. 1996;39:3324&#x2013;3330.</Citation><ArticleIdList><ArticleId IdType="pubmed">8765516</ArticleId></ArticleIdList></Reference><Reference><Citation>Harmeier A, et al. Role of amyloid-beta glycine 33 in oligomerization, toxicity, and neuronal plasticity. J Neurosci. 2009;29:7582&#x2013;7590.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6665404</ArticleId><ArticleId IdType="pubmed">19515926</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmechel A, et al. Alzheimer beta-amyloid homodimers facilitate A beta fibrillization and the generation of conformational antibodies. J Biol Chem. 2003;278:35317&#x2013;35324.</Citation><ArticleIdList><ArticleId IdType="pubmed">12840025</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaara M. The outer membrane permeability-increasing action of linear analogues of polymyxin B nonapeptide. Drugs Exp Clin Res. 1991;17:437&#x2013;443.</Citation><ArticleIdList><ArticleId IdType="pubmed">1822436</ArticleId></ArticleIdList></Reference><Reference><Citation>Brockhaus M, et al. Caspase-mediated cleavage is not required for the activity of presenilins in amyloidogenesis and NOTCH signaling. Neuroreport. 1998;9:1481&#x2013;1486.</Citation><ArticleIdList><ArticleId IdType="pubmed">9631452</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20683186</PMID><DateCompleted><Year>2011</Year><Month>01</Month><Day>04</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1546-4156</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>3</Issue><PubDate><Year>2010</Year><Season>Jul-Sep</Season></PubDate></JournalIssue><Title>Alzheimer disease and associated disorders</Title><ISOAbbreviation>Alzheimer Dis Assoc Disord</ISOAbbreviation></Journal><ArticleTitle>Free and cued selective reminding identifies very mild dementia in primary care.</ArticleTitle><Pagination><StartPage>284</StartPage><EndPage>290</EndPage><MedlinePgn>284-90</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/WAD.0b013e3181cfc78b</ELocationID><Abstract><AbstractText>The Free and Cued Selective Reminding Test (FCSRT) is used widely to identify very mild dementia; 3 alternative scoring procedures have been proposed based on free recall, total recall, and cue efficiency. We compared the predictive validity of these scoring procedures for the identification of very mild prevalent dementia (CDR=0.5), of incident dementia, and for distinguishing Alzheimer Disease (AD) and nonAD dementias. We tested 244 elderly African American and White primary care patients at 18 month intervals using a screening neuropsychologic battery that included the FCSRT and a comprehensive diagnostic neuropsychologic battery. Median follow-up was 2.6 years. Dementia diagnoses were assigned using standard criteria without access to the results of the screening battery. There were 50 prevalent and 28 incident dementia cases. At scores selected to provide specificities of 90%, free recall was more sensitive to incident and prevalent dementia than the other 2 measures. Patients with impaired free recall were 15 times more likely to have a prevalent dementia and their risk of future dementia was 4 times higher than patients with intact free recall. Neither race nor education affected prediction although older patients were at increased risk of future dementia. Total recall was more impaired in AD dementia than in nonAD dementias. The results indicate that using the FCSRT, free recall is the best measure for detecting prevalent dementia and predicting future dementia. Total recall impairment supports the diagnosis of AD rather than nonAD dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Grober</LastName><ForeName>Ellen</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York 10462, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanders</LastName><ForeName>Amy E</ForeName><Initials>AE</Initials></Author><Author ValidYN="Y"><LastName>Hall</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Lipton</LastName><ForeName>Richard B</ForeName><Initials>RB</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>KL2 RR025749</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR025750</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>L30 AG032889</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017854</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>TL1 RR025748</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG017854</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003949</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG03949</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>KL2RR025749</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimer Dis Assoc Disord</MedlineTA><NlmUniqueID>8704771</NlmUniqueID><ISSNLinking>0893-0341</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001741" MajorTopicYN="N">Black or African American</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003463" MajorTopicYN="N">Cues</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011320" MajorTopicYN="N">Primary Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044465" MajorTopicYN="N">White People</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>1</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20683186</ArticleId><ArticleId IdType="mid">NIHMS181231</ArticleId><ArticleId IdType="pmc">PMC2929322</ArticleId><ArticleId IdType="doi">10.1097/WAD.0b013e3181cfc78b</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. 4th ed. American Psychiatric Association Press; Washington, D.C.: 1994.</Citation></Reference><Reference><Citation>Ferris SH, Aisen PS, Cummings J, et al. ADCS Prevention Instrument Project: Overview and initial results. Alzheimer's Disease and Associated Disorders, Supplement. 2006</Citation><ArticleIdList><ArticleId IdType="pubmed">17135805</ArticleId></ArticleIdList></Reference><Reference><Citation>Gebner R, Reischies FM, Kage A, Geiselmann B. In an epidemiological sample the apolipoprotein E4 allele is associated to dementia and loss of memory function only in the very old. Neuroscience Letters. 1997;222:29&#x2013;32. al e.</Citation><ArticleIdList><ArticleId IdType="pubmed">9121715</ArticleId></ArticleIdList></Reference><Reference><Citation>Grober E, Buschke H, Crystal H, Bang S, Dresner R. Screening for dementia by memory testing. Neurology. 1988;38(6):900&#x2013;903.</Citation><ArticleIdList><ArticleId IdType="pubmed">3368071</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Smith GE, Ivnik RJ, Kokmen E, Tangalos EG. Memory function in very early Alzheimer's disease. Neurology. 1994 May 1;44(5):867&#x2013;872. 1994.</Citation><ArticleIdList><ArticleId IdType="pubmed">8190289</ArticleId></ArticleIdList></Reference><Reference><Citation>Tounsi H, Deweer B, Ergis A, et al. Sensitivity to Semantic Cuing: An Index of Episodic Memory Dysfunction in Early Alzheimer Disease. Alzheimer Disease and Associated Disorders. 1999;13(1):38&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">10192641</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuokko H, Crockett D. Cued recall and memory disorders in dementia. Journal of Clinical and Experimental Neuropsychology. 1989;11:278&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pubmed">2925836</ArticleId></ArticleIdList></Reference><Reference><Citation>Grober E, Lipton RB, Hall C, Crystal H. Memory impairment on free and cued selective reminding predicts dementia. Neurology. 2000;54(4):827&#x2013;832.</Citation><ArticleIdList><ArticleId IdType="pubmed">10690971</ArticleId></ArticleIdList></Reference><Reference><Citation>Grober E, Kawas C. Learning and retention in preclinical and early Alzheimer's Disease. Psychology and Aging. 1997;12:183&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">9100279</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Smith GE, Ivnik RJ, et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA. 1995 April 26;273(16):1274&#x2013;1278. 1995.</Citation><ArticleIdList><ArticleId IdType="pubmed">7646655</ArticleId></ArticleIdList></Reference><Reference><Citation>Robert PH, Berr C, Volteau M, et al. Neuropsychological performance in mild cognitive impairment with and without apathy. Dementia and Geriatric Cognitive Disorders. 2006;21:192&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pubmed">16424666</ArticleId></ArticleIdList></Reference><Reference><Citation>Grober E, Hall C, Lipton RB, Zonderman A, Resnick S, Kawas C. Memory Impairment, Executive Dysfunction, and Intellectual Decline. Journal of the International Neuropsychological Association. 2008;14:266&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2763488</ArticleId><ArticleId IdType="pubmed">18282324</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarazin M, Berr C, De Rotrou J, et al. Amnestic syndrome of the medial temporal type identifies prodromal AD: A longitudinal study. Neurology. 2007 November 6;69(19):1859&#x2013;1867. 2007.</Citation><ArticleIdList><ArticleId IdType="pubmed">17984454</ArticleId></ArticleIdList></Reference><Reference><Citation>Traykov L, Baudic S, Raoux N, et al. Patterns of memory impairment and perseverative behavior discriminate early Alzheimer's disease from subcortical vascular dementia. Journal of the Neurological Sciences. 2005;229-230:75.</Citation><ArticleIdList><ArticleId IdType="pubmed">15760623</ArticleId></ArticleIdList></Reference><Reference><Citation>Pillon B, Deweer B, Agid Y, Dubois B. Explicit memory in Alzheimer's, Huntington's, and Parkinson's diseases. Arch Neurol. 1993 April 1;50(4):374&#x2013;379. 1993.</Citation><ArticleIdList><ArticleId IdType="pubmed">8460958</ArticleId></ArticleIdList></Reference><Reference><Citation>Grober E, Hall C, Sanders A, Lipton RB. Free and Cued Selective Reminding distinguishes Alzherimer's disease from vascular dementia. Journal of the American Geriatrics Society. 2008;56(5):944&#x2013;946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2735231</ArticleId><ArticleId IdType="pubmed">18454754</ArticleId></ArticleIdList></Reference><Reference><Citation>Buschke H. Cued recall in Amnesia. Journal of Clinical and Experimental Neuropsychology. 1984;6(4):433&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pubmed">6501581</ArticleId></ArticleIdList></Reference><Reference><Citation>Grober E, Buschke H. Genuine memory deficits in dementia. Developmental Neuropsychology. 1987;3:13&#x2013;36.</Citation></Reference><Reference><Citation>Grober E, Merling A, Heimlich T, Lipton RB. Comparison of selective reminding and free and cued selective reminding in the elderly. J Clinical and Experimental Neuropsychology. 1997;19:643&#x2013;654.</Citation><ArticleIdList><ArticleId IdType="pubmed">9408795</ArticleId></ArticleIdList></Reference><Reference><Citation>Buschke H, Sliwinski M, Kuslansky G, Lipton RB. Aging, encoding specificity, and memory change in the Double Memory Test. Neurology. 1995;1:483&#x2013;493.</Citation><ArticleIdList><ArticleId IdType="pubmed">9375233</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivnik RJ, Smith GE, Lucas JA. Free and cued selective reminding test: MOANS norms. Journal of Clinical and Experimental Neuropsychology. 1997;19:676&#x2013;691.</Citation><ArticleIdList><ArticleId IdType="pubmed">9408798</ArticleId></ArticleIdList></Reference><Reference><Citation>Grober E, Hall C, McGinn M, et al. Neuropsychological strategies for detecting early dementia. Journal of the International Neuropsychological Society. 2008;14:130&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2763484</ArticleId><ArticleId IdType="pubmed">18078539</ArticleId></ArticleIdList></Reference><Reference><Citation>Grober E, Hall C, Lipton RB, Teresi J. Primary care screen for early dementia. Journal of the American Geriatrics Society. 2008;56:206&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">18179486</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. The Mini-Mental State: a practical method for grading cognitive state of patients for the clinician. Journal of Psychiatric Research. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. Clinical Dementia Rating: Current version and scoring rules. Neurology. 1993;43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M. Clinical diagnosis of Alzheimer's Disease: Report of the NINCDS-ADRA work group under the auspices of Department of Health and Human Services Task force on Alzheimer's Disease. Neurology. 1984;34:939&#x2013;944. al e.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Chui HC, Victoroff JI, Margolin D, Jagust W, Shankle R, Katzman R. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers. Neurology. 1992 March 1;42(3):473&#x2013;480. 1992.</Citation><ArticleIdList><ArticleId IdType="pubmed">1549205</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG, Perry EK, Perry RH. Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Consortium on Dementia with Lewy bodies. Neurology. 1999;53:902&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="pubmed">10496243</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Boeve BF, Parisi JE, et al. Antemortem diagnosis of frontotemporal lobar degeneration. Annals of Neurology. 2005;57:480&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pubmed">15786453</ArticleId></ArticleIdList></Reference><Reference><Citation>Blessed G, Tomlinson BE, Roth M. The association between quantitative measures and senile changes in the cerebral gray matter of elderly subjects. British Journal of Psychiatry. 1968;114:797&#x2013;811.</Citation><ArticleIdList><ArticleId IdType="pubmed">5662937</ArticleId></ArticleIdList></Reference><Reference><Citation>Grober E, Lipton RB, Katz M, Sliwinski M. Demographic Influences on Free and Cued Selective Reminding Performance in Older Persons. Journal of Clinical and Experimental Neuropsychology. 1998;20:221&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">9777476</ArticleId></ArticleIdList></Reference><Reference><Citation>Paivio A. Imagery and memory. The Cognitive Neurosciences. 1995:977&#x2013;986.</Citation></Reference><Reference><Citation>Cherry KE, Hawley KS, Jackson EM, Volaufova J, Su LJ, Jazwinski SM. Pictorial superiority effects in oldest-old people. Memory. 2008;16(7):728&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2575043</ArticleId><ArticleId IdType="pubmed">18651263</ArticleId></ArticleIdList></Reference><Reference><Citation>Mungas D, Reed BR, Haan MN, Gonzalez H. Spanish and English Neuropsychological Assessment Scales: Relationship to demographics, language, cognition, and independent function. Neuropsychology. 2005;19(4):466&#x2013;475.</Citation><ArticleIdList><ArticleId IdType="pubmed">16060821</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuokko H, Kristjansson E, Miller JA. The neuropsychological detection of dementia: An overview of the neuropsychological component of the Canadian Study of Health and Aging. Journal of Clinican and Experimental Neuropsychology. 1995;13:871&#x2013;879.</Citation><ArticleIdList><ArticleId IdType="pubmed">7650099</ArticleId></ArticleIdList></Reference><Reference><Citation>Buschke H, Kuslansky G, Katz M, et al. Screening for dementia with the Memory Impairment Screen. Neurology. 1999 January 1;52(2):231&#x2013;238. 1999.</Citation><ArticleIdList><ArticleId IdType="pubmed">9932936</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen W. Verbal fluency in aging and dementia. Journal of Clinical Neuropsychology. 1980;2:135&#x2013;146.</Citation></Reference><Reference><Citation>Boustani M, Callahan C, Unverzagt F, et al. Implementing a screening and diagnosis program for dementia in primary care. Journal of General Internal Medicine. 2005;20(7):572&#x2013;577.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1490164</ArticleId><ArticleId IdType="pubmed">16050849</ArticleId></ArticleIdList></Reference><Reference><Citation>Pena-Casanova J, Gramunt-Fombuena N, Quinones-Ubeda S, et al. Spanish Multicenter Normative Studies (NEURONORMA Project): Norms for the Rey-Osterrieth Complex Figure (Copy and Memory), and Free and Cued Selective Reminding Test. Arch Clin Neuropsychol. 2009 June 1;24(4):371&#x2013;393. 2009.</Citation><ArticleIdList><ArticleId IdType="pubmed">19661107</ArticleId></ArticleIdList></Reference><Reference><Citation>Welsh KA, Butters N, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery. Neurology. 1994 April 1;44(4):609&#x2013;614. 1994.</Citation><ArticleIdList><ArticleId IdType="pubmed">8164812</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert M, Moss M, Tanzi R, Jones K. Preclinical prediction of AD using neuropsychological tests. Journal of the International Neuropsychology Society. 2001;7:631&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">11459114</ArticleId></ArticleIdList></Reference><Reference><Citation>Grober E. Nonlinguistic memory in aphasia. Cortex. 1984;20:67&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">6202459</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeman M, Leach L, Kaplan E, Winocur G, Schulman K, Delis D. Clock drawing: A neuropsychological analysis. Oxford University Press; 1994.</Citation></Reference><Reference><Citation>Dartigues JF, Commenges D, Letenneur D, et al. Cognitive predictors of dementia in elderly community residents. Neuroepidemiology. 1997;16(1):29&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">8994938</ArticleId></ArticleIdList></Reference><Reference><Citation>Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. Journal of Psychiatric Research. 1982-1983;17(1):37&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">7183759</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20697030</PMID><DateCompleted><Year>2011</Year><Month>01</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1538-3687</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>12</Issue><PubDate><Year>2010</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Meta-analysis confirms CR1, CLU, and PICALM as alzheimer disease risk loci and reveals interactions with APOE genotypes.</ArticleTitle><Pagination><StartPage>1473</StartPage><EndPage>1484</EndPage><MedlinePgn>1473-84</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/archneurol.2010.201</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To determine whether genotypes at CLU, PICALM, and CR1 confer risk for Alzheimer disease (AD) and whether risk for AD associated with these genes is influenced by apolipoprotein E (APOE) genotypes.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Association study of AD and CLU, PICALM, CR1, and APOE genotypes.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Academic research institutions in the United States, Canada, and Israel.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Seven thousand seventy cases with AD, 3055 with autopsies, and 8169 elderly cognitively normal controls, 1092 with autopsies, from 12 different studies, including white, African American, Israeli-Arab, and Caribbean Hispanic individuals.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Unadjusted, CLU (odds ratio [OR], 0.91; 95% confidence interval [CI], 0.85-0.96 for single-nucleotide polymorphism [SNP] rs11136000), CR1 (OR, 1.14; 95% CI, 1.07-1.22; SNP rs3818361), and PICALM (OR, 0.89; 95% CI, 0.84-0.94, SNP rs3851179) were associated with AD in white individuals. None were significantly associated with AD in the other ethnic groups. APOE &#x3b5;4 was significantly associated with AD (ORs, 1.80-9.05) in all but 1 small white cohort and in the Arab cohort. Adjusting for age, sex, and the presence of at least 1 APOE &#x3b5;4 allele greatly reduced evidence for association with PICALM but not CR1 or CLU. Models with the main SNP effect, presence or absence of APOE &#x3b5;4, and an interaction term showed significant interaction between presence or absence of APOE &#x3b5;4 and PICALM.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We confirm in a completely independent data set that CR1, CLU, and PICALM are AD susceptibility loci in European ancestry populations. Genotypes at PICALM confer risk predominantly in APOE &#x3b5;4-positive subjects. Thus, APOE and PICALM synergistically interact.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jun</LastName><ForeName>Gyungah</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Medicine, Boston University, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naj</LastName><ForeName>Adam C</ForeName><Initials>AC</Initials></Author><Author ValidYN="Y"><LastName>Beecham</LastName><ForeName>Gary W</ForeName><Initials>GW</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Li-San</ForeName><Initials>LS</Initials></Author><Author ValidYN="Y"><LastName>Buros</LastName><ForeName>Jacqueline</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Gallins</LastName><ForeName>Paul J</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>Buxbaum</LastName><ForeName>Joseph D</ForeName><Initials>JD</Initials></Author><Author ValidYN="Y"><LastName>Ertekin-Taner</LastName><ForeName>Nilufer</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Fallin</LastName><ForeName>M Daniele</ForeName><Initials>MD</Initials></Author><Author ValidYN="Y"><LastName>Friedland</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Inzelberg</LastName><ForeName>Rivka</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Kramer</LastName><ForeName>Patricia</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Rogaeva</LastName><ForeName>Ekaterina</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>St George-Hyslop</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><CollectiveName>Alzheimer's Disease Genetics Consortium</CollectiveName></Author><Author ValidYN="Y"><LastName>Cantwell</LastName><ForeName>Laura B</ForeName><Initials>LB</Initials></Author><Author ValidYN="Y"><LastName>Dombroski</LastName><ForeName>Beth A</ForeName><Initials>BA</Initials></Author><Author ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Lunetta</LastName><ForeName>Kathryn L</ForeName><Initials>KL</Initials></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Eden R</ForeName><Initials>ER</Initials></Author><Author ValidYN="Y"><LastName>Montine</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials></Author><Author ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Blacker</LastName><ForeName>Deborah</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Tsuang</LastName><ForeName>Debby W</ForeName><Initials>DW</Initials></Author><Author ValidYN="Y"><LastName>Beekly</LastName><ForeName>Duane</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Cupples</LastName><ForeName>L Adrienne</ForeName><Initials>LA</Initials></Author><Author ValidYN="Y"><LastName>Hakonarson</LastName><ForeName>Hakon</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Kukull</LastName><ForeName>Walter</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Foroud</LastName><ForeName>Tatiana M</ForeName><Initials>TM</Initials></Author><Author ValidYN="Y"><LastName>Haines</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Mayeux</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Farrer</LastName><ForeName>Lindsay A</ForeName><Initials>LA</Initials></Author><Author ValidYN="Y"><LastName>Pericak-Vance</LastName><ForeName>Margaret A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Schellenberg</LastName><ForeName>Gerard D</ForeName><Initials>GD</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG010129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR02777</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013854</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG16574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 CA137788</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG030514</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG05681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG17917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HG006375</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS017950</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>M01 RR000096</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2 AG036528</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG028377</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG08671</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG008671</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC-25195</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG016495</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG10483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG10133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MO1 RR00096</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG009029</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG031581</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UO1 AG16976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016577</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG019085</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032984</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG030146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HG02213</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG008702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR029893</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016575</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC025195</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG016976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG05131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG008051</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG056270</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG020688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH080295</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG10161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG03991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2 AG036535</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG010491</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG08051</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG012300</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01AG06786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG002219</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24-AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2AG036528</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG008017</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG008122</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 CA132378</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC025195</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG033193</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG027841</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG025688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG032990</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG015473</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG026395</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG027944</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG025688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG 027944</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR025777</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG002219</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA129769</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG08122</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG041797</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG010491</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HG002213</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG021547</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005138</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG037212</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 NS054811</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG019757</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG020688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027944</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017173</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG025259</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016582</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016576</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG028383</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG019757</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG026916</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>081864</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>AG021547</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG006786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG005138</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG10129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG16495</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG031287</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>08</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C495242">CLU protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C509991">CR1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051152">Clusterin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034041">Monomeric Clathrin Assembly Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C439003">PICALM protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017463">Receptors, Complement 3b</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Arch Neurol. 2011 Feb;68(2):159</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051152" MajorTopicYN="N">Clusterin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016001" MajorTopicYN="N">Confidence Intervals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015201" MajorTopicYN="N">Meta-Analysis as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034041" MajorTopicYN="N">Monomeric Clathrin Assembly Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017463" MajorTopicYN="N">Receptors, Complement 3b</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044465" MajorTopicYN="N">White People</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Arnold</LastName><ForeName>Steven E</ForeName><Initials>SE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baldwin</LastName><ForeName>Clinton T</ForeName><Initials>CT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barber</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beach</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bigio</LastName><ForeName>Eileen H</ForeName><Initials>EH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bird</LastName><ForeName>Thomas D</ForeName><Initials>TD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boxer</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burke</LastName><ForeName>James R</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cairns</LastName><ForeName>Nigel</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carroll</LastName><ForeName>Steven L</ForeName><Initials>SL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chui</LastName><ForeName>Helena C</ForeName><Initials>HC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clark</LastName><ForeName>David G</ForeName><Initials>DG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cotman</LastName><ForeName>Carl W</ForeName><Initials>CW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cummings</LastName><ForeName>Jeffrey L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Decarli</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Diaz-Arrastia</LastName><ForeName>Ramon</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dick</LastName><ForeName>Malcolm</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ellis</LastName><ForeName>William G</ForeName><Initials>WG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fallon</LastName><ForeName>Kenneth B</ForeName><Initials>KB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farlow</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferris</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frosch</LastName><ForeName>Matthew P</ForeName><Initials>MP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Galasko</LastName><ForeName>Douglas R</ForeName><Initials>DR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gearing</LastName><ForeName>Marla</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Geschwind</LastName><ForeName>Daniel H</ForeName><Initials>DH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ghetti</LastName><ForeName>Bernardino</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gilman</LastName><ForeName>Sid</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Giordani</LastName><ForeName>Bruno</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Glass</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill R</ForeName><Initials>NR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Green</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Growdon</LastName><ForeName>John H</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hamilton</LastName><ForeName>Ronald L</ForeName><Initials>RL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harrell</LastName><ForeName>Lindy E</ForeName><Initials>LE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Head</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Honig</LastName><ForeName>Lawrence S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hulette</LastName><ForeName>Christine M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jicha</LastName><ForeName>Gregory A</ForeName><Initials>GA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jin</LastName><ForeName>Lee-Way</ForeName><Initials>LW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karlawish</LastName><ForeName>Jason</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karydas</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaye</LastName><ForeName>Jeffrey A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koo</LastName><ForeName>Edward H</ForeName><Initials>EH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kowall</LastName><ForeName>Neil W</ForeName><Initials>NW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lah</LastName><ForeName>James J</ForeName><Initials>JJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levey</LastName><ForeName>Allan I</ForeName><Initials>AI</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lieberman</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mack</LastName><ForeName>Wendy J</ForeName><Initials>WJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Markesbery</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marson</LastName><ForeName>Daniel C</ForeName><Initials>DC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martiniuk</LastName><ForeName>Frank</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Masliah</LastName><ForeName>Eliezer</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>McKee</LastName><ForeName>Ann C</ForeName><Initials>AC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mesulam</LastName><ForeName>Marsel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Joshua W</ForeName><Initials>JW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Carol A</ForeName><Initials>CA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parisi</LastName><ForeName>Joseph E</ForeName><Initials>JE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perl</LastName><ForeName>Daniel P</ForeName><Initials>DP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peskind</LastName><ForeName>Elaine</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Poon</LastName><ForeName>Wayne</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quinn</LastName><ForeName>Joseph F</ForeName><Initials>JF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raskind</LastName><ForeName>Murray</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reisberg</LastName><ForeName>Barry</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ringman</LastName><ForeName>John M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roberson</LastName><ForeName>Erik D</ForeName><Initials>ED</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosenberg</LastName><ForeName>Roger N</ForeName><Initials>RN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sano</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seeley</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shelanski</LastName><ForeName>Michael L</ForeName><Initials>ML</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Charles D</ForeName><Initials>CD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spina</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stern</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tanzi</LastName><ForeName>Rudolph E</ForeName><Initials>RE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Troncoso</LastName><ForeName>Juan C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Van Deerlin</LastName><ForeName>Vivianna M</ForeName><Initials>VM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vinters</LastName><ForeName>Harry V</ForeName><Initials>HV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vonsattel</LastName><ForeName>Jean Paul</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weintraub</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Welsh-Bohmer</LastName><ForeName>Kathleen A</ForeName><Initials>KA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Woltjer</LastName><ForeName>Randall L</ForeName><Initials>RL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Younkin</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>12</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20697030</ArticleId><ArticleId IdType="mid">NIHMS272831</ArticleId><ArticleId IdType="pmc">PMC3048805</ArticleId><ArticleId IdType="doi">10.1001/archneurol.2010.201</ArticleId><ArticleId IdType="pii">archneurol.2010.201</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goate A, Chartier-Harlin M-C, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer&#x2019;s disease. Nature. 1991;349:704&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pubmed">1671712</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherrington R, Rogaev EI, Liang Y, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer&#x2019;s disease. Nature. 1995;375:754&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pubmed">7596406</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogaev EI, Sherrington R, Rogaeva EA, et al. Familial Alzheimer&#x2019;s disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer&#x2019;s disease type 3 gene. Nature. 1995;376:775&#x2013;778.</Citation><ArticleIdList><ArticleId IdType="pubmed">7651536</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy-Lahad E, Wasco W, Poorkaj P, et al. Candidate gene for the chromosome 1 familial Alzheimer&#x2019;s disease locus. Science. 1995;269:973&#x2013;977.</Citation><ArticleIdList><ArticleId IdType="pubmed">7638622</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, et al. Gene Dose of Apolipoprotein-E Type-4 Allele and the Risk of Alzheimer&#x2019;s Disease in Late Onset Families. Science. 1993;261:921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Harold D, Abraham R, Hollingworth P, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer&#x2019;s disease. Nat Genet. 2009;41(10):1088&#x2013;U1061.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845877</ArticleId><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Heath S, Even G, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer&#x2019;s disease. Nat Genet. 2009;41(10):1094&#x2013;U1068.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>Saykin A, Shen L, Foroud TM, Potkin SG, Swaminathan S, Kim S, Risacher SL, Nho K, Huentelman MJ, Craig DW, Thompson PM, Stein JL, Moore JH, Farrer LA, Green RC, Bertram L, Jack CR, Weiner MW. Alzheimer&#x2019;s Disease Neuroimaging Initiative ADNI biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans. Alzheimer&#x2019;s and Dementia. 2010;6:265&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2868595</ArticleId><ArticleId IdType="pubmed">20451875</ArticleId></ArticleIdList></Reference><Reference><Citation>McCauley JL, Hahs DW, Jiang L, et al. Combinatorial Mismatch Scan (CMS) for loci associated with dementia in the Amish. BMC Med Genet. 2006;7:19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1448207</ArticleId><ArticleId IdType="pubmed">16515697</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahs DW, McCauley JL, Crunk AE, et al. A genome-wide linkage analysis of dementia in the Amish. American Journal of Medical Genetics Part B Neuropsychiatric Genetics. 2006;141B(2):160&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2613780</ArticleId><ArticleId IdType="pubmed">16389594</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, Barral S, Cheng R, et al. Age-at-onset linkage analysis in Caribbean Hispanics with familial late-onset Alzheimer&#x2019;s disease. Neurogenetics Feb. 2008;9(1):51&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2701253</ArticleId><ArticleId IdType="pubmed">17940814</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawber TR, Kannel WB. The Framingham study. An epidemiological approach to coronary heart disease. Circulation. 1966 Oct;34(4):553&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">5921755</ArticleId></ArticleIdList></Reference><Reference><Citation>Splansky GL, Corey D, Yang Q, et al. The Third Generation Cohort of the National Heart, Lung, and Blood Institute&#x2019;s Framingham Heart Study: design, recruitment, and initial examination. Am J Epidemiol. 2007 Jun 1;165(11):1328&#x2013;1335.</Citation><ArticleIdList><ArticleId IdType="pubmed">17372189</ArticleId></ArticleIdList></Reference><Reference><Citation>Cobb JL, Wolf PA, Au R, White R, D&#x2019;Agostino RB. The effect of education on the incidence of dementia and Alzheimer&#x2019;s disease in the Framingham Study. Neurology Sep. 1995;45(9):1707&#x2013;1712.</Citation><ArticleIdList><ArticleId IdType="pubmed">7675231</ArticleId></ArticleIdList></Reference><Reference><Citation>Green RC, Cupples LA, Go R, et al. Risk of dementia among white and African American relatives of patients with Alzheimer disease. Jama - Journal of the American Medical Association. 2002 January 16;287(3):329&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pubmed">11790212</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijsman EMPN, Choi Y, Rothstein JH, Faber K, Cheng R, Lee JH, Bird T, Bennnett DA, Diaz-Arrastia R, Goate A, Farlow M, Sweet RA, Ghetti B, Foroud T, Mayeux R for The NIA-LOAD/NCRAD Family Study Group. Genome wide association of familial late onset Alzheimer&#x2019;s disease replicates BIN1, and nominates CUGBP2 in interaction with APOE. 2010 submitted.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3040659</ArticleId><ArticleId IdType="pubmed">21379329</ArticleId></ArticleIdList></Reference><Reference><Citation>Coon KD, Myers AJ, Craig DW, et al. A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer&#x2019;s disease. J Clin Psychiatry. 2007;68:613&#x2013;618.</Citation><ArticleIdList><ArticleId IdType="pubmed">17474819</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott WK, Nance MA, Watts RL, et al. Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA. 2001;286:2239&#x2013;2244.</Citation><ArticleIdList><ArticleId IdType="pubmed">11710888</ArticleId></ArticleIdList></Reference><Reference><Citation>Beecham GW, Martin ER, Li YJ, et al. Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease. Am J Hum Genet Jan. 2009;84(1):35&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2668056</ArticleId><ArticleId IdType="pubmed">19118814</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards C. Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease.pa. Annals of Human Genetics. 2010:2010.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2853717</ArticleId><ArticleId IdType="pubmed">20070850</ArticleId></ArticleIdList></Reference><Reference><Citation>Haroutunian V, Perl DP, Purohit DP, et al. Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer disease. Archives of Neurology. 1998 September;55(9):1185&#x2013;1191.</Citation><ArticleIdList><ArticleId IdType="pubmed">9740112</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowirrat A, Friedland RP, Chapman J, Korczyn AD. The very high prevalence of AD in an Arab population is not explained by APOE epsilon 4 allele frequency. Neurology. 2000;55(5):731.</Citation><ArticleIdList><ArticleId IdType="pubmed">10980749</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Bowirrat A, Friedland RP, Waraska K, Korczyn AD, Baldwin CT. Identification of multiple loci for Alzheimer disease in a consanguineous Israeli-Arab community. Hum Molec Genet. 2003;12(4):415&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pubmed">12566388</ArticleId></ArticleIdList></Reference><Reference><Citation>Inzelberg R, Schechtman E, Abuful A, et al. Education effects on cognitive function in a healthy aged Arab population. Int Psychogeriatr Jun. 2007;19(3):593&#x2013;603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3695483</ArticleId><ArticleId IdType="pubmed">17052375</ArticleId></ArticleIdList></Reference><Reference><Citation>IsraeliKorn SD, Masarwa M, Schechtman E, et al. Hypertension Increases the Probability of Alzheimer&#x2019;s Disease and of Mild Cognitive Impairment in an Arab Community in Northern Israel. Neuroepidemiology. 34(2):99&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2855875</ArticleId><ArticleId IdType="pubmed">20016220</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M, Boehnke M, Abecasis GR. Efficient study designs for test of genetic association using sibship data and unrelated cases and controls. Am J Hum Genet. 2006;78:778&#x2013;792.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1474028</ArticleId><ArticleId IdType="pubmed">16642434</ArticleId></ArticleIdList></Reference><Reference><Citation>Pritchard JK, Stephens M, Donnelly PJ. Inference of population structure using multilocus genotype data. Genetics. 2000;155:945&#x2013;959.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1461096</ArticleId><ArticleId IdType="pubmed">10835412</ArticleId></ArticleIdList></Reference><Reference><Citation>Pritchard JK, Stephens M, Rosenberg NA, Donnelly P. Association mapping in structured populations. Am J Hum Genet. 2000;67:170&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1287075</ArticleId><ArticleId IdType="pubmed">10827107</ArticleId></ArticleIdList></Reference><Reference><Citation>Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet. 2006;38:904&#x2013;909.</Citation><ArticleIdList><ArticleId IdType="pubmed">16862161</ArticleId></ArticleIdList></Reference><Reference><Citation>R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing V; Austria: 2009.  URL  http://www.R-project.org.</Citation></Reference><Reference><Citation>Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002 Jun 15;21(11):1539&#x2013;1558.</Citation><ArticleIdList><ArticleId IdType="pubmed">12111919</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003 Sep 6;327(7414):557&#x2013;560.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC192859</ArticleId><ArticleId IdType="pubmed">12958120</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Aisen PS, Beckett LA, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 2010 Jan 19;74(3):201&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2809036</ArticleId><ArticleId IdType="pubmed">20042704</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer PL, Xu H, Woltjer RL, Westaway SK, Clark D, Erten-Lyons D, Kaye JA, Welsh-Bohmer KA, Troncoso JC, Markesbery WR, Petersen RC, Turner RS, Kukull WA, Bennett DA, Galasko D, Morris JC, Ott J. Alzheimer&#x2019;s disease pathology in cognitively healthy elderly: A genome-wide study. Neurobiology of Aging. 2010:2010. (in press)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2990809</ArticleId><ArticleId IdType="pubmed">20452100</ArticleId></ArticleIdList></Reference><Reference><Citation>Feinleib M, Kannel WB, Garrison RJ, McNamara PM, Castelli WP. The Framingham Offspring Study. Design and preliminary data. Prev Med. 1975 Dec;4(4):518&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pubmed">1208363</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: A meta-analysis. JAMA. 1997;278:1349&#x2013;1356.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastor P, Roe CM, Villegas A, et al. Apolipoprotein E epsilon 4 modifies Alzheimer&#x2019;s disease onset in an E280A PS1 kindred. Ann Neurol. 2003;54:163&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">12891668</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijsman EM, Daw E, Yu X, et al. APOE and other loci affect age-at-onset in Alzheimer&#x2019;s disease families with PS2 mutation. Am J Med Genet Neuropsych Genet. (in press)</Citation><ArticleIdList><ArticleId IdType="pubmed">15389756</ArticleId></ArticleIdList></Reference><Reference><Citation>St George-Hyslop P, Crapper McLachlan D, Tuda T, et al. Alzheimer&#x2019;s disease and possible gene interaction. Science. 1994;263:537.</Citation><ArticleIdList><ArticleId IdType="pubmed">8290965</ArticleId></ArticleIdList></Reference><Reference><Citation>Seshadri S, Fitzpatrick AL, Ikram MA, et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA. 2010 May 12;303(18):1832&#x2013;1840.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2989531</ArticleId><ArticleId IdType="pubmed">20460622</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, McKeel DW, Buckles VD, et al. Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging. 2009;30(7):1026&#x2013;1036.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2737680</ArticleId><ArticleId IdType="pubmed">19376612</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18(4):351&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330961</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Arvanitakis Z, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 2006 Jun 27;66(12):1837&#x2013;1844.</Citation><ArticleIdList><ArticleId IdType="pubmed">16801647</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulette CM, Welshbohmer KA, Murray MG, Saunders AM, Mash DC, Mcintyre LM. Neuropathological and neuropsychological changes in &#x201c;normal&#x201d; aging: Evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol. 1998;57(12):1168&#x2013;1174.</Citation><ArticleIdList><ArticleId IdType="pubmed">9862640</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Bienias JL, Evans DA, Wilson RS. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology. 2005;64(5):834&#x2013;841.</Citation><ArticleIdList><ArticleId IdType="pubmed">15753419</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrin RJ, Fagan AM, Holtzman DM. Multimodal techniques for diagnosis and prognosis of Alzheimer&#x2019;s disease. Nature. 2009;461(7266):916&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2810658</ArticleId><ArticleId IdType="pubmed">19829371</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Webster JA, Myers AJ, et al. GAB2 alleles modify Alzheimer&#x2019;s risk in APOE epsilon 4 carriers. Neuron. 2007;54(5):713&#x2013;720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2587162</ArticleId><ArticleId IdType="pubmed">17553421</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrasquillo MM, Zou F, Pankratz VS, et al. Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer&#x2019;s disease. Nat Genet Feb. 2009;41(2):192&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2873177</ArticleId><ArticleId IdType="pubmed">19136949</ArticleId></ArticleIdList></Reference><Reference><Citation>Poduslo SE, Huang R, Huang J, Smith S. Genome screen of late-onset Alzheimer&#x2019;s extended pedigrees identifies TRPC4AP by haplotype analysis. Am J Med Genet B Neuropsychiatr Genet. 2009 Jan 5;150B(1):50&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">18449908</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L, Lange C, Mullin K, et al. Genome-wide association analysis reveals putative Alzheimer&#x2019;s disease susceptibility loci in addition to APOE. Am J Hum Genet Nov. 2008;83(5):623&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2668052</ArticleId><ArticleId IdType="pubmed">18976728</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Wetten S, Li L, et al. Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Archives of Neurology. 2008;65(1):45&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">17998437</ArticleId></ArticleIdList></Reference><Reference><Citation>Feulner TM, Laws SM, Friedrich P, et al. Examination of the current top candidate genes for AD in a genome-wide association study. Mol Psychiatry. 2009 Jan 6;</Citation><ArticleIdList><ArticleId IdType="pubmed">19125160</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20697045</PMID><DateCompleted><Year>2010</Year><Month>09</Month><Day>03</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3687</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>8</Issue><PubDate><Year>2010</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people.</ArticleTitle><Pagination><StartPage>949</StartPage><EndPage>956</EndPage><MedlinePgn>949-56</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/archneurol.2010.179</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To identify biomarker patterns typical for Alzheimer disease (AD) in an independent, unsupervised way, without using information on the clinical diagnosis.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Mixture modeling approach.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Alzheimer's Disease Neuroimaging Initiative database.</AbstractText><AbstractText Label="PATIENTS OR OTHER PARTICIPANTS" NlmCategory="METHODS">Cognitively normal persons, patients with AD, and individuals with mild cognitive impairment.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Cerebrospinal fluid-derived beta-amyloid protein 1-42, total tau protein, and phosphorylated tau(181P) protein concentrations were used as biomarkers on a clinically well-characterized data set. The outcome of the qualification analysis was validated on 2 additional data sets, 1 of which was autopsy confirmed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Using the US Alzheimer's Disease Neuroimaging Initiative data set, a cerebrospinal fluid beta-amyloid protein 1-42/phosphorylated tau(181P) biomarker mixture model identified 1 feature linked to AD, while the other matched the "healthy" status. The AD signature was found in 90%, 72%, and 36% of patients in the AD, mild cognitive impairment, and cognitively normal groups, respectively. The cognitively normal group with the AD signature was enriched in apolipoprotein E epsilon4 allele carriers. Results were validated on 2 other data sets. In 1 study consisting of 68 autopsy-confirmed AD cases, 64 of 68 patients (94% sensitivity) were correctly classified with the AD feature. In another data set with patients (n = 57) with mild cognitive impairment followed up for 5 years, the model showed a sensitivity of 100% in patients progressing to AD.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The mixture modeling approach, totally independent of clinical AD diagnosis, correctly classified patients with AD. The unexpected presence of the AD signature in more than one-third of cognitively normal subjects suggests that AD pathology is active and detectable earlier than has heretofore been envisioned.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>De Meyer</LastName><ForeName>Geert</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Innogenetics, Industriepark Zwijnaarde 7, Box 4, B-9052 Gent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shapiro</LastName><ForeName>Fred</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Vanderstichele</LastName><ForeName>Hugo</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Vanmechelen</LastName><ForeName>Eugeen</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Engelborghs</LastName><ForeName>Sebastiaan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>De Deyn</LastName><ForeName>Peter Paul</ForeName><Initials>PP</Initials></Author><Author ValidYN="Y"><LastName>Coart</LastName><ForeName>Els</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Hansson</LastName><ForeName>Oskar</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Minthon</LastName><ForeName>Lennart</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Leslie</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials></Author><Author ValidYN="Y"><CollectiveName>Alzheimer's Disease Neuroimaging Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Arch Neurol. 2010 Aug;67(8):918-20. doi: 10.1001/archneurol.2010.151.</RefSource><PMID Version="1">20697041</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>J Am Geriatr Soc. 2011 Feb;59(2):377-8. doi: 10.1111/j.1532-5415.2011.03256.x.</RefSource><PMID Version="1">21314665</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015577" MajorTopicYN="Y">Geriatric Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>11</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20697045</ArticleId><ArticleId IdType="mid">NIHMS241490</ArticleId><ArticleId IdType="pmc">PMC2963067</ArticleId><ArticleId IdType="doi">10.1001/archneurol.2010.179</ArticleId><ArticleId IdType="pii">67/8/949</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer&#x2019;s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006;5(3):228&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">16488378</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray S, Britschgi M, Herbert C, et al. Classification and prediction of clinical Alzheimer&#x2019;s diagnosis based on plasma signalling proteins. Nat Med. 2007;13(11):1359&#x2013;1362.</Citation><ArticleIdList><ArticleId IdType="pubmed">17934472</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Korecka M, Clark CM, Lee VM, Trojanowski JQ. Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Discov. 2007;6(4):295&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">17347655</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer&#x2019;s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6(8):734&#x2013;746.</Citation><ArticleIdList><ArticleId IdType="pubmed">17616482</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelborghs S, De Vreese K, Van de Casteele T, et al. Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol Aging. 2008;29:1143&#x2013;1159.</Citation><ArticleIdList><ArticleId IdType="pubmed">17428581</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative. Cerebrospinal fluid biomarker signature in Alzheimer&#x2019;s disease neuroimaging initiative subjects. Ann Neurol. 2009;65(4):403&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson A, Vanderstichele H, Andreasen N, et al. Simultaneous measurement of beta-amyloid(1&#x2013;42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem. 2005;51(2):336&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pubmed">15563479</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderstichele H, Demeyer L, De Roo K, et al. Standardized multiparameter quantification of biomarkers for Alzheimer&#x2019;s disease in cerebrospinal fluid. In: Fisher A, Hanin I, Memo M, Stocchi F, editors. New Trends in Alzheimer and Parkinson Related Disorders: ADPD 2005. Bologna, Italy: Medimond Srl; 2005. pp. 183&#x2013;189.</Citation></Reference><Reference><Citation>R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2007. R Development Core Team.</Citation></Reference><Reference><Citation>Gruen B, Leisch F. Fitting finite mixtures of generalized linear regressions in R. Comput Stat Data Anal. 2007;51(11):5247&#x2013;5252.</Citation></Reference><Reference><Citation>Hastie T, Tibshirani R, Friedman J. The Elements of Statistical Learning. New York, NY: Springer-Verlag; 2001.</Citation></Reference><Reference><Citation>Sing T, Sander O, Beerenwinkel N, Lengauer T. ROCR: visualizing classifier performance in R. Bioinformatics. 2005;21(20):3940&#x2013;3941.</Citation><ArticleIdList><ArticleId IdType="pubmed">16096348</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulstaert F, Blennow K, Ivanoiu A, et al. Improved discrimination of AD patients using beta-amyloid (1&#x2013;42) and tau levels in CSF. Neurology. 1999;52(8):1555&#x2013;1562.</Citation><ArticleIdList><ArticleId IdType="pubmed">10331678</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson C, Blennow K, Almkvist O, et al. Increasing CSF phospho-tau levels during cognitive decline and progression to dementia. Neurobiol Aging. 2008;29(10):1466&#x2013;1473.</Citation><ArticleIdList><ArticleId IdType="pubmed">17512092</ArticleId></ArticleIdList></Reference><Reference><Citation>Bian H, Van Swieten JC, Leight S, et al. CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology. 2008;70(19, pt 2):1827&#x2013;1835.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2707002</ArticleId><ArticleId IdType="pubmed">18458217</ArticleId></ArticleIdList></Reference><Reference><Citation>Skoog I, Davidsson P, Aevarsson O, Vanderstichele H, Vanmechelen E, Blennow K. Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds. Dement Geriatr Cogn Disord. 2003;15(3):169&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">12584433</ArticleId></ArticleIdList></Reference><Reference><Citation>Stomrud E, Hansson O, Blennow K, Minthon L, Londos E. Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly. Dement Geriatr Cogn Disord. 2007;24(2):118&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">17622715</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustafson DR, Skoog I, Rosengren L, Zetterberg H, Blennow K. Cerebrospinal fluid beta-amyloid 1&#x2013;42 concentration may predict cognitive decline in older women. J Neurol Neurosurg Psychiatry. 2007;78(5):461&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2117838</ArticleId><ArticleId IdType="pubmed">17098843</ArticleId></ArticleIdList></Reference><Reference><Citation>Kauwe JS, Cruchaga C, Mayo K, et al. Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition. Proc Natl Acad Sci U S A. 2008;105(23):8050&#x2013;8054.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2430357</ArticleId><ArticleId IdType="pubmed">18541914</ArticleId></ArticleIdList></Reference><Reference><Citation>Engler H, Forsberg A, Almkvist O, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer&#x2019;s disease. Brain. 2006;129(pt 11):2856&#x2013;2866.</Citation><ArticleIdList><ArticleId IdType="pubmed">16854944</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin H, McCulloch CE, Turnbull BW, Slate EH, Clark LC. A latent class mixed model for analysing biomarker trajectories with irregularly scheduled observations. Stat Med. 2000;19(10):1303&#x2013;1318.</Citation><ArticleIdList><ArticleId IdType="pubmed">10814979</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis DG, Schmitt FA, Wekstein DR, Markesbery WR. Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol. 1999;58(4):376&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pubmed">10218633</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006;59(3):512&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">16372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Pike KE, Savage G, Villemagne VL, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer&#x2019;s disease. Brain. 2007;130(pt 11):2837&#x2013;2844.</Citation><ArticleIdList><ArticleId IdType="pubmed">17928318</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Cupples LA, Haines JL, et al. APOE and Alzheimer Disease Meta Analysis Consortium. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. JAMA. 1997;278(16):1349&#x2013;1356.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Peskind ER, Li G, Shofer J, et al. Age and apolipoprotein E*4 allele effects on cerebrospinal fluid &#x3b2;-amyloid 42 in adults with normal cognition. Arch Neurol. 2006;63(7):936&#x2013;939.</Citation><ArticleIdList><ArticleId IdType="pubmed">16831961</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20711477</PMID><DateCompleted><Year>2010</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1545-7885</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>8</Issue><PubDate><Year>2010</Year><Month>Aug</Month><Day>10</Day></PubDate></JournalIssue><Title>PLoS biology</Title><ISOAbbreviation>PLoS Biol</ISOAbbreviation></Journal><ArticleTitle>Widespread protein aggregation as an inherent part of aging in C. elegans.</ArticleTitle><Pagination><StartPage>e1000450</StartPage><MedlinePgn>e1000450</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e1000450</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pbio.1000450</ELocationID><Abstract><AbstractText>Aberrant protein aggregation is a hallmark of many age-related diseases, yet little is known about whether proteins aggregate with age in a non-disease setting. Using a systematic proteomics approach, we identified several hundred proteins that become more insoluble with age in the multicellular organism Caenorhabditis elegans. These proteins are predicted to be significantly enriched in beta-sheets, which promote disease protein aggregation. Strikingly, these insoluble proteins are highly over-represented in aggregates found in human neurodegeneration. We examined several of these proteins in vivo and confirmed their propensity to aggregate with age. Different proteins aggregated in different tissues and cellular compartments. Protein insolubility and aggregation were significantly delayed or even halted by reduced insulin/IGF-1-signaling, which also slows aging. We found a significant overlap between proteins that become insoluble and proteins that influence lifespan and/or polyglutamine-repeat aggregation. Moreover, overexpressing one aggregating protein enhanced polyglutamine-repeat pathology. Together our findings indicate that widespread protein insolubility and aggregation is an inherent part of aging and that it may influence both lifespan and neurodegenerative disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>David</LastName><ForeName>Della C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ollikainen</LastName><ForeName>Noah</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Trinidad</LastName><ForeName>Jonathan C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Cary</LastName><ForeName>Michael P</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Burlingame</LastName><ForeName>Alma L</ForeName><Initials>AL</Initials></Author><Author ValidYN="Y"><LastName>Kenyon</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RR015804</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41RR001614</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG11816</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41 RR001614</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG011816</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NCRR R01416</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG011816</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>08</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Biol</MedlineTA><NlmUniqueID>101183755</NlmUniqueID><ISSNLinking>1544-9173</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D029742">Caenorhabditis elegans Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>PLoS Biol. 2010 Aug 10;8(8):e1000449. doi: 10.1371/journal.pbio.1000449.</RefSource><PMID Version="1">20711479</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017173" MajorTopicYN="N">Caenorhabditis elegans</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029742" MajorTopicYN="N">Caenorhabditis elegans Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006816" MajorTopicYN="N">Huntington Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>2</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>8</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>8</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>8</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20711477</ArticleId><ArticleId IdType="pmc">PMC2919420</ArticleId><ArticleId IdType="doi">10.1371/journal.pbio.1000450</ArticleId><ArticleId IdType="pii">e1000450</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cuervo A. M, Dice J. F. Age-related decline in chaperone-mediated autophagy. J Biol Chem. 2000;275:31505&#x2013;31513.</Citation><ArticleIdList><ArticleId IdType="pubmed">10806201</ArticleId></ArticleIdList></Reference><Reference><Citation>Tonoki A, Kuranaga E, Tomioka T, Hamazaki J, Murata S, et al. Genetic evidence linking age-dependent attenuation of the 26S proteasome with the aging process. Mol Cell Biol. 2009;29:1095&#x2013;1106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2643801</ArticleId><ArticleId IdType="pubmed">19075009</ArticleId></ArticleIdList></Reference><Reference><Citation>Lund J, Tedesco P, Duke K, Wang J, Kim S. K, et al. Transcriptional profile of aging in C. elegans. Curr Biol. 2002;12:1566&#x2013;1573.</Citation><ArticleIdList><ArticleId IdType="pubmed">12372248</ArticleId></ArticleIdList></Reference><Reference><Citation>Poon H. F, Vaishnav R. A, Getchell T. V, Getchell M. L, Butterfield D. A. Quantitative proteomics analysis of differential protein expression and oxidative modification of specific proteins in the brains of old mice. Neurobiol Aging. 2006;27:1010&#x2013;1019.</Citation><ArticleIdList><ArticleId IdType="pubmed">15979213</ArticleId></ArticleIdList></Reference><Reference><Citation>Squier T. C. Oxidative stress and protein aggregation during biological aging. Exp Gerontol. 2001;36:1539&#x2013;1550.</Citation><ArticleIdList><ArticleId IdType="pubmed">11525876</ArticleId></ArticleIdList></Reference><Reference><Citation>Balch W. E, Morimoto R. I, Dillin A, Kelly J. W. Adapting proteostasis for disease intervention. Science. 2008;319:916&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">18276881</ArticleId></ArticleIdList></Reference><Reference><Citation>Morimoto R. I, Cuervo A. M. Protein homeostasis and aging: taking care of proteins from the cradle to the grave. J Gerontol A Biol Sci Med Sci. 2009;64:167&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2655025</ArticleId><ArticleId IdType="pubmed">19228787</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiti F, Webster P, Taddei N, Clark A, Stefani M, et al. Designing conditions for in vitro formation of amyloid protofilaments and fibrils. Proc Natl Acad Sci U S A. 1999;96:3590&#x2013;3594.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22338</ArticleId><ArticleId IdType="pubmed">10097081</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiti F, Dobson C. M. Amyloid formation by globular proteins under native conditions. Nat Chem Biol. 2009;5:15&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">19088715</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldschmidt L, Teng P. K, Riek R, Eisenberg D. Identifying the amylome, proteins capable of forming amyloid-like fibrils. Proc Natl Acad Sci U S A. 2010;107:3487&#x2013;3492.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2840437</ArticleId><ArticleId IdType="pubmed">20133726</ArticleId></ArticleIdList></Reference><Reference><Citation>de Groot N. S, Sabate R, Ventura S. Amyloids in bacterial inclusion bodies. Trends Biochem Sci 2009</Citation><ArticleIdList><ArticleId IdType="pubmed">19647433</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Maji S. K, Sawaya M. R, Eisenberg D, Riek R. Bacterial inclusion bodies contain amyloid-like structure. PLoS Biol. 2008;6:e195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2494559</ArticleId><ArticleId IdType="pubmed">18684013</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaganovich D, Kopito R, Frydman J. Misfolded proteins partition between two distinct quality control compartments. Nature. 2008;454:1088&#x2013;1095.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2746971</ArticleId><ArticleId IdType="pubmed">18756251</ArticleId></ArticleIdList></Reference><Reference><Citation>Salomons F. A, Menendez-Benito V, Bottcher C, McCray B. A, Taylor J. P, et al. Selective accumulation of aggregation-prone proteasome substrates in response to proteotoxic stress. Mol Cell Biol. 2009;29:1774&#x2013;1785.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2655608</ArticleId><ArticleId IdType="pubmed">19158272</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopito R. R. Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol. 2000;10:524&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pubmed">11121744</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao L, Cheng D, Wang J, Duong D. M, Losik T. G, et al. Proteomic characterization of postmortem amyloid plaques isolated by laser capture microdissection. J Biol Chem. 2004;279:37061&#x2013;37068.</Citation><ArticleIdList><ArticleId IdType="pubmed">15220353</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia Q, Liao L, Cheng D, Duong D. M, Gearing M, et al. Proteomic identification of novel proteins associated with Lewy bodies. Front Biosci. 2008;13:3850&#x2013;3856.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2663966</ArticleId><ArticleId IdType="pubmed">18508479</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Woltjer R. L, Cimino P. J, Pan C, Montine K. S, et al. Proteomic analysis of neurofibrillary tangles in Alzheimer disease identifies GAPDH as a detergent-insoluble paired helical filament tau binding protein. Faseb J. 2005;19:869&#x2013;871.</Citation><ArticleIdList><ArticleId IdType="pubmed">15746184</ArticleId></ArticleIdList></Reference><Reference><Citation>Gidalevitz T, Ben-Zvi A, Ho K. H, Brignull H. R, Morimoto R. I. Progressive disruption of cellular protein folding in models of polyglutamine diseases. Science. 2006;311:1471&#x2013;1474.</Citation><ArticleIdList><ArticleId IdType="pubmed">16469881</ArticleId></ArticleIdList></Reference><Reference><Citation>Nollen E. A, Garcia S. M, van Haaften G, Kim S, Chavez A, et al. Genome-wide RNA interference screen identifies previously undescribed regulators of polyglutamine aggregation. Proc Natl Acad Sci U S A. 2004;101:6403&#x2013;6408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC404057</ArticleId><ArticleId IdType="pubmed">15084750</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee V. M, Wang J, Trojanowski J. Q. Purification of paired helical filament tau and normal tau from human brain tissue. Methods Enzymol. 1999;309:81&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">10507018</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawarabayashi T, Younkin L. H, Saido T. C, Shoji M, Ashe K. H, et al. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci. 2001;21:372&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763819</ArticleId><ArticleId IdType="pubmed">11160418</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraemer B. C, Zhang B, Leverenz J. B, Thomas J. H, Trojanowski J. Q, et al. Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy. Proc Natl Acad Sci U S A. 2003;100:9980&#x2013;9985.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC187908</ArticleId><ArticleId IdType="pubmed">12872001</ArticleId></ArticleIdList></Reference><Reference><Citation>Trinidad J. C, Thalhammer A, Specht C. G, Lynn A. J, Baker P. R, et al. Quantitative analysis of synaptic phosphorylation and protein expression. Mol Cell Proteomics. 2008;7:684&#x2013;696.</Citation><ArticleIdList><ArticleId IdType="pubmed">18056256</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruppen I, Grau L, Orenes-Pinero E, Ashman K, Gil M, et al. Differential protein expression profiling by iTRAQ-2DLC-MS/MS of human bladder cancer EJ138 cells transfected with the metastasis suppressor KiSS-1 gene. Mol Cell Proteomics 2010</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2953920</ArticleId><ArticleId IdType="pubmed">20139371</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy J. P, Pinto D. M. Temporal proteomic analysis of IGF-1R signalling in MCF-7 breast adenocarcinoma cells. Proteomics. 2010;10:1847&#x2013;1860.</Citation><ArticleIdList><ArticleId IdType="pubmed">20213678</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross P. L, Huang Y. N, Marchese J. N, Williamson B, Parker K, et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics. 2004;3:1154&#x2013;1169.</Citation><ArticleIdList><ArticleId IdType="pubmed">15385600</ArticleId></ArticleIdList></Reference><Reference><Citation>Doniach T, Hodgkin J. A sex-determining gene, fem-1, required for both male and hermaphrodite development in Caenorhabditis elegans. Dev Biol. 1984;106:223&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pubmed">6541600</ArticleId></ArticleIdList></Reference><Reference><Citation>Andux S, Ellis R. E. Apoptosis maintains oocyte quality in aging Caenorhabditis elegans females. PLoS Genet. 2008;4:e1000295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2585808</ArticleId><ArticleId IdType="pubmed">19057674</ArticleId></ArticleIdList></Reference><Reference><Citation>Salas P. J. Insoluble gamma-tubulin-containing structures are anchored to the apical network of intermediate filaments in polarized CACO-2 epithelial cells. J Cell Biol. 1999;146:645&#x2013;658.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2150552</ArticleId><ArticleId IdType="pubmed">10444072</ArticleId></ArticleIdList></Reference><Reference><Citation>Weis F, Moullintraffort L, Heichette C, Chretien D, Garnier C. The 90-kDa heat shock protein Hsp90 protects tubulin against thermal denaturation. J Biol Chem. 2010;285:9525&#x2013;9534.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2843203</ArticleId><ArticleId IdType="pubmed">20110359</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston J. A, Ward C. L, Kopito R. R. Aggresomes: a cellular response to misfolded proteins. J Cell Biol. 1998;143:1883&#x2013;1898.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2175217</ArticleId><ArticleId IdType="pubmed">9864362</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuret J, Johnson G. S, Cha D, Christenson E. R, DeMaggio A. J, et al. Casein kinase 1 is tightly associated with paired-helical filaments isolated from Alzheimer's disease brain. J Neurochem. 1997;69:2506&#x2013;2515.</Citation><ArticleIdList><ArticleId IdType="pubmed">9375684</ArticleId></ArticleIdList></Reference><Reference><Citation>Kannanayakal T. J, Mendell J. R, Kuret J. Casein kinase 1 alpha associates with the tau-bearing lesions of inclusion body myositis. Neurosci Lett. 2008;431:141&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2359895</ArticleId><ArticleId IdType="pubmed">18191026</ArticleId></ArticleIdList></Reference><Reference><Citation>Motegi F, Sugimoto A. Sequential functioning of the ECT-2 RhoGEF, RHO-1 and CDC-42 establishes cell polarity in Caenorhabditis elegans embryos. Nat Cell Biol. 2006;8:978&#x2013;985.</Citation><ArticleIdList><ArticleId IdType="pubmed">16921365</ArticleId></ArticleIdList></Reference><Reference><Citation>Soto C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nat Rev Neurosci. 2003;4:49&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">12511861</ArticleId></ArticleIdList></Reference><Reference><Citation>Brignull H. R, Morley J. F, Garcia S. M, Morimoto R. I. Modeling polyglutamine pathogenesis in C. elegans. Methods Enzymol. 2006;412:256&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pubmed">17046663</ArticleId></ArticleIdList></Reference><Reference><Citation>Iliev A. I, Ganesan S, Bunt G, Wouters F. S. Removal of pattern-breaking sequences in microtubule binding repeats produces instantaneous tau aggregation and toxicity. J Biol Chem. 2006;281:37195&#x2013;37204.</Citation><ArticleIdList><ArticleId IdType="pubmed">17008320</ArticleId></ArticleIdList></Reference><Reference><Citation>Merzlyak E. M, Goedhart J, Shcherbo D, Bulina M. E, Shcheglov A. S, et al. Bright monomeric red fluorescent protein with an extended fluorescence lifetime. Nat Methods. 2007;4:555&#x2013;557.</Citation><ArticleIdList><ArticleId IdType="pubmed">17572680</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben-Zvi A, Miller E. A, Morimoto R. I. Collapse of proteostasis represents an early molecular event in Caenorhabditis elegans aging. Proc Natl Acad Sci U S A. 2009;106:14914&#x2013;14919.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2736453</ArticleId><ArticleId IdType="pubmed">19706382</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenyon C, Chang J, Gensch E, Rudner A, Tabtiang R. A C. elegans mutant that lives twice as long as wild type. Nature. 1993;366:461&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">8247153</ArticleId></ArticleIdList></Reference><Reference><Citation>Morley J. F, Brignull H. R, Weyers J. J, Morimoto R. I. The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans. Proc Natl Acad Sci U S A. 2002;99:10417&#x2013;10422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC124929</ArticleId><ArticleId IdType="pubmed">12122205</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen E, Bieschke J, Perciavalle R. M, Kelly J. W, Dillin A. Opposing activities protect against age-onset proteotoxicity. Science. 2006;313:1604&#x2013;1610.</Citation><ArticleIdList><ArticleId IdType="pubmed">16902091</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsen P. L, Albert P. S, Riddle D. L. Genes that regulate both development and longevity in Caenorhabditis elegans. Genetics. 1995;139:1567&#x2013;1583.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1206485</ArticleId><ArticleId IdType="pubmed">7789761</ArticleId></ArticleIdList></Reference><Reference><Citation>Gems D, Sutton A. J, Sundermeyer M. L, Albert P. S, King K. V, et al. Two pleiotropic classes of daf-2 mutation affect larval arrest, adult behavior, reproduction and longevity in Caenorhabditis elegans. Genetics. 1998;150:129&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1460297</ArticleId><ArticleId IdType="pubmed">9725835</ArticleId></ArticleIdList></Reference><Reference><Citation>Dillin A, Crawford D. K, Kenyon C. Timing requirements for insulin/IGF-1 signaling in C. elegans. Science. 2002;298:830&#x2013;834.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399591</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw W. M, Luo S, Landis J, Ashraf J, Murphy C. T. The C. elegans TGF-beta Dauer pathway regulates longevity via insulin signaling. Curr Biol. 2007;17:1635&#x2013;1645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3124252</ArticleId><ArticleId IdType="pubmed">17900898</ArticleId></ArticleIdList></Reference><Reference><Citation>Link C. D. Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans. Proc Natl Acad Sci U S A. 1995;92:9368&#x2013;9372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC40986</ArticleId><ArticleId IdType="pubmed">7568134</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaminska M, Havrylenko S, Decottignies P, Le Marechal P, Negrutskii B, et al. Dynamic Organization of Aminoacyl-tRNA Synthetase Complexes in the Cytoplasm of Human Cells. J Biol Chem. 2009;284:13746&#x2013;13754.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2679476</ArticleId><ArticleId IdType="pubmed">19289464</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen D, Huang S. Nucleolar components involved in ribosome biogenesis cycle between the nucleolus and nucleoplasm in interphase cells. J Cell Biol. 2001;153:169&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2185520</ArticleId><ArticleId IdType="pubmed">11285283</ArticleId></ArticleIdList></Reference><Reference><Citation>Garigan D, Hsu A. L, Fraser A. G, Kamath R. S, Ahringer J, et al. Genetic analysis of tissue aging in Caenorhabditis elegans: a role for heat-shock factor and bacterial proliferation. Genetics. 2002;161:1101&#x2013;1112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1462187</ArticleId><ArticleId IdType="pubmed">12136014</ArticleId></ArticleIdList></Reference><Reference><Citation>Herndon L. A, Schmeissner P. J, Dudaronek J. M, Brown P. A, Listner K. M, et al. Stochastic and genetic factors influence tissue-specific decline in ageing C. elegans. Nature. 2002;419:808&#x2013;814.</Citation><ArticleIdList><ArticleId IdType="pubmed">12397350</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Mata R, Gao Y. S, Sztul E. Hassles with taking out the garbage: aggravating aggresomes. Traffic. 2002;3:388&#x2013;396.</Citation><ArticleIdList><ArticleId IdType="pubmed">12010457</ArticleId></ArticleIdList></Reference><Reference><Citation>Scharf A, Rockel T. D, von Mikecz A. Localization of proteasomes and proteasomal proteolysis in the mammalian interphase cell nucleus by systematic application of immunocytochemistry. Histochem Cell Biol. 2007;127:591&#x2013;601.</Citation><ArticleIdList><ArticleId IdType="pubmed">17205305</ArticleId></ArticleIdList></Reference><Reference><Citation>Link C. D. Invertebrate models of Alzheimer's disease. Genes Brain Behav. 2005;4:147&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">15810903</ArticleId></ArticleIdList></Reference><Reference><Citation>Link C. D, Johnson C. J, Fonte V, Paupard M, Hall D. H, et al. Visualization of fibrillar amyloid deposits in living, transgenic Caenorhabditis elegans animals using the sensitive amyloid dye, X-34. Neurobiol Aging. 2001;22:217&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">11182471</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennis G, Jr, Sherman B. T, Hosack D. A, Yang J, Gao W, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003;4:P3.</Citation><ArticleIdList><ArticleId IdType="pubmed">12734009</ArticleId></ArticleIdList></Reference><Reference><Citation>Curran S. P, Ruvkun G. Lifespan regulation by evolutionarily conserved genes essential for viability. PLoS Genet. 2007;3:e56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1847696</ArticleId><ArticleId IdType="pubmed">17411345</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen M, Hsu A. L, Dillin A, Kenyon C. New genes tied to endocrine, metabolic, and dietary regulation of lifespan from a Caenorhabditis elegans genomic RNAi screen. PLoS Genet. 2005;1:119&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1183531</ArticleId><ArticleId IdType="pubmed">16103914</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen M, Taubert S, Crawford D, Libina N, Lee S. J, et al.  Lifespan Extension by Conditions that Inhibit Translation in C. elegans. Aging Cell. 2006 doi: 10.1111/j.1474-9726.2006.00267.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1474-9726.2006.00267.x</ArticleId><ArticleId IdType="pubmed">17266679</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan K. Z, Palter J. E, Rogers A. N, Olsen A, Chen D, et al. Inhibition of mRNA translation extends lifespan in Caenorhabditis elegans. Aging Cell. 2007;6:111&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2745345</ArticleId><ArticleId IdType="pubmed">17266680</ArticleId></ArticleIdList></Reference><Reference><Citation>Copeland J. M, Cho J, Lo T, Jr, Hur J. H, Bahadorani S, et al. Extension of Drosophila life span by RNAi of the mitochondrial respiratory chain. Curr Biol. 2009;19:1591&#x2013;1598.</Citation><ArticleIdList><ArticleId IdType="pubmed">19747824</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuboi D, Qadota H, Kasuya K, Amano M, Kaibuchi K. Isolation of the interacting molecules with GEX-3 by a novel functional screening. Biochem Biophys Res Commun. 2002;292:697&#x2013;701.</Citation><ArticleIdList><ArticleId IdType="pubmed">11922622</ArticleId></ArticleIdList></Reference><Reference><Citation>Soto M. C, Qadota H, Kasuya K, Inoue M, Tsuboi D, et al. The GEX-2 and GEX-3 proteins are required for tissue morphogenesis and cell migrations in C. elegans. Genes Dev. 2002;16:620&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC155352</ArticleId><ArticleId IdType="pubmed">11877381</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin X, Qadota H, Moerman D. G, Williams B. D. C. elegans PAT-6/actopaxin plays a critical role in the assembly of integrin adhesion complexes in vivo. Curr Biol. 2003;13:922&#x2013;932.</Citation><ArticleIdList><ArticleId IdType="pubmed">12781130</ArticleId></ArticleIdList></Reference><Reference><Citation>Deutsch E. W, Lam H, Aebersold R. PeptideAtlas: a resource for target selection for emerging targeted proteomics workflows. EMBO Rep. 2008;9:429&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2373374</ArticleId><ArticleId IdType="pubmed">18451766</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones D. T. Protein secondary structure prediction based on position-specific scoring matrices. J Mol Biol. 1999;292:195&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">10493868</ArticleId></ArticleIdList></Reference><Reference><Citation>Orengo C. A, Michie A. D, Jones S, Jones D. T, Swindells M. B, et al. CATH&#x2013;a hierarchic classification of protein domain structures. Structure. 1997;5:1093&#x2013;1108.</Citation><ArticleIdList><ArticleId IdType="pubmed">9309224</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy C. T, McCarroll S. A, Bargmann C. I, Fraser A, Kamath R. S, et al. Genes that act downstream of DAF-16 to influence the lifespan of Caenorhabditis elegans. Nature. 2003;424:277&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pubmed">12845331</ArticleId></ArticleIdList></Reference><Reference><Citation>Melendez A, Talloczy Z, Seaman M, Eskelinen E. L, Hall D. H, et al. Autophagy genes are essential for dauer development and life-span extension in C. elegans. Science. 2003;301:1387&#x2013;1391.</Citation><ArticleIdList><ArticleId IdType="pubmed">12958363</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S. S, Kennedy S, Tolonen A. C, Ruvkun G. DAF-16 target genes that control C. elegans life-span and metabolism. Science. 2003;300:644&#x2013;647.</Citation><ArticleIdList><ArticleId IdType="pubmed">12690206</ArticleId></ArticleIdList></Reference><Reference><Citation>Henis-Korenblit S, Zhang P, Hansen M, McCormick M, Lee S. J, et al. Insulin/IGF-1 signaling mutants reprogram ER stress response regulators to promote longevity. Proc Natl Acad Sci U S A 2010</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2906894</ArticleId><ArticleId IdType="pubmed">20460307</ArticleId></ArticleIdList></Reference><Reference><Citation>Florez-McClure M. L, Hohsfield L. A, Fonte G, Bealor M. T, Link C. D. Decreased insulin-receptor signaling promotes the autophagic degradation of beta-amyloid peptide in C. elegans. Autophagy. 2007;3:569&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">17675890</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakob U, Gaestel M, Engel K, Buchner J. Small heat shock proteins are molecular chaperones. J Biol Chem. 1993;268:1517&#x2013;1520.</Citation><ArticleIdList><ArticleId IdType="pubmed">8093612</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam S, Geller R, Spiess C, Frydman J. The chaperonin TRiC controls polyglutamine aggregation and toxicity through subunit-specific interactions. Nat Cell Biol. 2006;8:1155&#x2013;1162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2829982</ArticleId><ArticleId IdType="pubmed">16980959</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitamura A, Kubota H, Pack C. G, Matsumoto G, Hirayama S, et al. Cytosolic chaperonin prevents polyglutamine toxicity with altering the aggregation state. Nat Cell Biol. 2006;8:1163&#x2013;1170.</Citation><ArticleIdList><ArticleId IdType="pubmed">16980958</ArticleId></ArticleIdList></Reference><Reference><Citation>Rand J. D, Grant C. M. The thioredoxin system protects ribosomes against stress-induced aggregation. Mol Biol Cell. 2006;17:387&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1345676</ArticleId><ArticleId IdType="pubmed">16251355</ArticleId></ArticleIdList></Reference><Reference><Citation>David D. C, Hauptmann S, Scherping I, Schuessel K, Keil U, et al. Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice. J Biol Chem. 2005;280:23802&#x2013;23814.</Citation><ArticleIdList><ArticleId IdType="pubmed">15831501</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson M. P, Pedersen W. A, Duan W, Culmsee C, Camandola S. Cellular and molecular mechanisms underlying perturbed energy metabolism and neuronal degeneration in Alzheimer's and Parkinson's diseases. Ann N Y Acad Sci. 1999;893:154&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pubmed">10672236</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto M, Rockenstein E, Crews L, Masliah E. Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases. Neuromolecular Med. 2003;4:21&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">14528050</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H. J, Shin S. Y, Choi C, Lee Y. H, Lee S. J. Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors. J Biol Chem. 2002;277:5411&#x2013;5417.</Citation><ArticleIdList><ArticleId IdType="pubmed">11724769</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S, Nollen E. A, Kitagawa K, Bindokas V. P, Morimoto R. I. Polyglutamine protein aggregates are dynamic. Nat Cell Biol. 2002;4:826&#x2013;831.</Citation><ArticleIdList><ArticleId IdType="pubmed">12360295</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabunmi R. P, Wigley W. C, Thomas P. J, DeMartino G. N. Activity and regulation of the centrosome-associated proteasome. J Biol Chem. 2000;275:409&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pubmed">10617632</ArticleId></ArticleIdList></Reference><Reference><Citation>Arrasate M, Mitra S, Schweitzer E. S, Segal M. R, Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature. 2004;431:805&#x2013;810.</Citation><ArticleIdList><ArticleId IdType="pubmed">15483602</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh D. M, Klyubin I, Fadeeva J. V, Cullen W. K, Anwyl R, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiti F, Dobson C. M. Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem. 2006;75:333&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pubmed">16756495</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu S, Wong C. C, Tong E. H, Chung S. S, Yates J. R, 3rd, et al. Phosphorylation by casein kinase 1 regulates tonicity-induced osmotic response element-binding protein/tonicity enhancer-binding protein nucleocytoplasmic trafficking. J Biol Chem. 2008;283:17624&#x2013;17634.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2427355</ArticleId><ArticleId IdType="pubmed">18411282</ArticleId></ArticleIdList></Reference><Reference><Citation>Beyaert R, Vanhaesebroeck B, Declercq W, Van Lint J, Vandenabele P, et al. Casein kinase-1 phosphorylates the p75 tumor necrosis factor receptor and negatively regulates tumor necrosis factor signaling for apoptosis. J Biol Chem. 1995;270:23293&#x2013;23299.</Citation><ArticleIdList><ArticleId IdType="pubmed">7559483</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Qin S, Atangan L. I, Molina Y, Okawa Y, et al. Casein kinase 1alpha interacts with retinoid X receptor and interferes with agonist-induced apoptosis. J Biol Chem. 2004;279:30844&#x2013;30849.</Citation><ArticleIdList><ArticleId IdType="pubmed">15131121</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng P. K, Eisenberg D. Short protein segments can drive a non-fibrillizing protein into the amyloid state. Protein Eng Des Sel. 2009;22:531&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2719503</ArticleId><ArticleId IdType="pubmed">19602569</ArticleId></ArticleIdList></Reference><Reference><Citation>Du H. N, Tang L, Luo X. Y, Li H. T, Hu J, et al. A peptide motif consisting of glycine, alanine, and valine is required for the fibrillization and cytotoxicity of human alpha-synuclein. Biochemistry. 2003;42:8870&#x2013;8878.</Citation><ArticleIdList><ArticleId IdType="pubmed">12873148</ArticleId></ArticleIdList></Reference><Reference><Citation>Lansbury P. T, Jr, Costa P. R, Griffiths J. M, Simon E. J, Auger M, et al. Structural model for the beta-amyloid fibril based on interstrand alignment of an antiparallel-sheet comprising a C-terminal peptide. Nat Struct Biol. 1995;2:990&#x2013;998.</Citation><ArticleIdList><ArticleId IdType="pubmed">7583673</ArticleId></ArticleIdList></Reference><Reference><Citation>Basso M, Samengo G, Nardo G, Massignan T, D'Alessandro G, et al. Characterization of detergent-insoluble proteins in ALS indicates a causal link between nitrative stress and aggregation in pathogenesis. PLoS One. 2009;4:e8130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2780298</ArticleId><ArticleId IdType="pubmed">19956584</ArticleId></ArticleIdList></Reference><Reference><Citation>Krogh A, Larsson B, von Heijne G, Sonnhammer E. L. Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes. J Mol Biol. 2001;305:567&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">11152613</ArticleId></ArticleIdList></Reference><Reference><Citation>Bendtsen J. D, Nielsen H, von Heijne G, Brunak S. Improved prediction of signal peptides: SignalP 3.0. J Mol Biol. 2004;340:783&#x2013;795.</Citation><ArticleIdList><ArticleId IdType="pubmed">15223320</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Godzik A. Cd-hit: a fast program for clustering and comparing large sets of protein or nucleotide sequences. Bioinformatics. 2006;22:1658&#x2013;1659.</Citation><ArticleIdList><ArticleId IdType="pubmed">16731699</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Brien K. P, Remm M, Sonnhammer E. L. Inparanoid: a comprehensive database of eukaryotic orthologs. Nucleic Acids Res. 2005;33:D476&#x2013;480.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC540061</ArticleId><ArticleId IdType="pubmed">15608241</ArticleId></ArticleIdList></Reference><Reference><Citation>Apfeld J, Kenyon C. Regulation of lifespan by sensory perception in Caenorhabditis elegans. Nature. 1999;402:804&#x2013;809.</Citation><ArticleIdList><ArticleId IdType="pubmed">10617200</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20720106</PMID><DateCompleted><Year>2010</Year><Month>09</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>33</Issue><PubDate><Year>2010</Year><Month>Aug</Month><Day>18</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Decreased rhythmic GABAergic septal activity and memory-associated theta oscillations after hippocampal amyloid-beta pathology in the rat.</ArticleTitle><Pagination><StartPage>10991</StartPage><EndPage>11003</EndPage><MedlinePgn>10991-1003</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.6284-09.2010</ELocationID><Abstract><AbstractText>The memory deficits associated with Alzheimer's disease result to a great extent from hippocampal network dysfunction. The coordination of this network relies on theta (symbol) oscillations generated in the medial septum. Here, we investigated in rats the impact of hippocampal amyloid beta (Abeta) injections on the physiological and cognitive functions that depend on the septohippocampal system. Hippocampal Abeta injections progressively impaired behavioral performances, the associated hippocampal theta power, and theta frequency response in a visuospatial recognition test. These alterations were associated with a specific reduction in the firing of the identified rhythmic bursting GABAergic neurons responsible for the propagation of the theta rhythm to the hippocampus, but without loss of medial septal neurons. Such results indicate that hippocampal Abeta treatment leads to a specific functional depression of inhibitory projection neurons of the medial septum, resulting in the functional impairment of the temporal network.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Villette</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Inserm Centre de Psychiatrie et Neurosciences, Unit&#xe9; Mixte de Recherche 894, 75014 Paris, France. vincent.villette@inserm.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poindessous-Jazat</LastName><ForeName>Fr&#xe9;d&#xe9;rique</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Simon</LastName><ForeName>Axelle</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>L&#xe9;na</LastName><ForeName>Cl&#xe9;ment</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Roullot</LastName><ForeName>Elodie</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Bellessort</LastName><ForeName>Brice</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Epelbaum</LastName><ForeName>Jacques</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Dutar</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>St&#xe9;phan</LastName><ForeName>Aline</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>56-12-2</RegistryNumber><NameOfSubstance UI="D005680">gamma-Aminobutyric Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000200" MajorTopicYN="N">Action Potentials</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016657" MajorTopicYN="N">Cerebral Amyloid Angiopathy</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010507" MajorTopicYN="N">Periodicity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021641" MajorTopicYN="N">Recognition, Psychology</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020665" MajorTopicYN="N">Septum of Brain</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013028" MajorTopicYN="N">Space Perception</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013826" MajorTopicYN="Y">Theta Rhythm</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014796" MajorTopicYN="N">Visual Perception</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005680" MajorTopicYN="N">gamma-Aminobutyric Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare that they have no actual or potential conflict of interest, financial or otherwise, related to the present work. The data contained in this work were not submitted elsewhere. Experimental procedures and the manuscript were approved by all authors.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>2</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20720106</ArticleId><ArticleId IdType="pmc">PMC6633464</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.6284-09.2010</ArticleId><ArticleId IdType="pii">30/33/10991</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, et al. Inflammation and Alzheimer's disease. Neurobiol Aging. 2000;21:383&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3887148</ArticleId><ArticleId IdType="pubmed">10858586</ArticleId></ArticleIdList></Reference><Reference><Citation>Alreja M, Wu M, Liu W, Atkins JB, Leranth C, Shanabrough M. Muscarinic tone sustains impulse flow in the septohippocampal GABA but not cholinergic pathway: implications for learning and memory. J Neurosci. 2000;20:8103&#x2013;8110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772717</ArticleId><ArticleId IdType="pubmed">11050132</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambr&#xe9;e O, Touma C, G&#xf6;rtz N, Keyvani K, Paulus W, Palme R, Sachser N. Activity changes and marked stereotypic behavior precede Abeta pathology in TgCRND8 Alzheimer mice. Neurobiol Aging. 2006;27:955&#x2013;964.</Citation><ArticleIdList><ArticleId IdType="pubmed">15993515</ArticleId></ArticleIdList></Reference><Reference><Citation>Apartis E, Poindessous-Jazat FR, Lamour YA, Bassant MH. Loss of rhythmically bursting neurons in rat medial septum following selective lesion of septohippocampal cholinergic system. J Neurophysiol. 1998;79:1633&#x2013;1642.</Citation><ArticleIdList><ArticleId IdType="pubmed">9535934</ArticleId></ArticleIdList></Reference><Reference><Citation>Arkhipov V, Kulesskaja N, Lebedev D. Behavioral perseveration and impairment of long-term memory in rats after intrahippocampal injection of kainic acid in subconvulsive dose. Pharmacol Biochem Behav. 2008;88:299&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">17889287</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassant MH, Jouvenceau A, Apartis E, Poindessous-Jazat F, Dutar P, Billard JM. Immunolesion of the cholinergic basal forebrain: effects on functional properties of hippocampal and septal neurons. Int J Dev Neurosci. 1998;16:613&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pubmed">10198811</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassant MH, Simon A, Poindessous-Jazat F, Csaba Z, Epelbaum J, Dournaud P. Medial septal GABAergic neurons express the somatostatin sst2A receptor: functional consequences on unit firing and hippocampal theta. J Neurosci. 2005;25:2032&#x2013;2041.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6726075</ArticleId><ArticleId IdType="pubmed">15728843</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell KFS, de Kort GJ, Steggerda S, Shigemoto R, Ribeiro-da-Silva A, Cuello AC. Structural involvement of the glutamatergic presynaptic boutons in a transgenic mouse model expressing early onset amyloid pathology. Neurosci Lett. 2003;353:143&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">14664921</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell KFS, Bennett DA, Cuello AC. Paradoxical upregulation of glutamatergic presynaptic boutons during mild cognitive impairment. J Neurosci. 2007;27:10810&#x2013;10817.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672819</ArticleId><ArticleId IdType="pubmed">17913914</ArticleId></ArticleIdList></Reference><Reference><Citation>Bland BH, Oddie SD. Theta band oscillation and synchrony in the hippocampal formation and associated structures: the case for its role in sensorimotor integration. Behav Brain Res. 2001;127:119&#x2013;136. Review.</Citation><ArticleIdList><ArticleId IdType="pubmed">11718888</ArticleId></ArticleIdList></Reference><Reference><Citation>Borhegyi Z, Varga V, Szil&#xe1;gyi N, Fabo D, Freund TF. Phase segregation of medial septal GABAergic neurons during hippocampal theta activity. J Neurosci. 2004;24:8470&#x2013;8479.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729892</ArticleId><ArticleId IdType="pubmed">15456820</ArticleId></ArticleIdList></Reference><Reference><Citation>Brioni JD, Decker MW, Gamboa LP, Izquierdo I, McGaugh JL. Muscimol injections in the medial septum impair spatial learning. Brain Res. 1990;522:227&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">2224525</ArticleId></ArticleIdList></Reference><Reference><Citation>Bullock TH, Buzs&#xe1;ki G, McClune MC. Coherence of compound field potentials reveals discontinuities in the CA1-subiculum of the hippocampus in freely-moving rats. Neuroscience. 1990;38:609&#x2013;619.</Citation><ArticleIdList><ArticleId IdType="pubmed">2270136</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgess N, Barry C, O'Keefe J. An oscillatory interference model of grid cell firing. Hippocampus. 2007;17:801&#x2013;812.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2678278</ArticleId><ArticleId IdType="pubmed">17598147</ArticleId></ArticleIdList></Reference><Reference><Citation>Busche MA, Eichhoff G, Adelsberger H, Abramowski D, Wiederhold KH, Haass C, Staufenbiel M, Konnerth A, Garaschuk O. Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease. Science. 2008;321:1686&#x2013;1689.</Citation><ArticleIdList><ArticleId IdType="pubmed">18802001</ArticleId></ArticleIdList></Reference><Reference><Citation>Buzs&#xe1;ki G. Theta oscillations in the hippocampus. Neuron. 2002;33:325&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pubmed">11832222</ArticleId></ArticleIdList></Reference><Reference><Citation>Buzs&#xe1;ki G, Draguhn A. Neuronal oscillations in cortical networks. Science. 2004;304:1926&#x2013;1929.</Citation><ArticleIdList><ArticleId IdType="pubmed">15218136</ArticleId></ArticleIdList></Reference><Reference><Citation>Canolty RT, Edwards E, Dalal SS, Soltani M, Nagarajan SS, Kirsch HE, Berger MS, Barbaro NM, Knight RT. High gamma power is phase-locked to theta oscillations in human neocortex. Science. 2006;313:1626&#x2013;1628.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2628289</ArticleId><ArticleId IdType="pubmed">16973878</ArticleId></ArticleIdList></Reference><Reference><Citation>Chappell J, McMahan R, Chiba A, Gallagher M. A re-examination of the role of basal forebrain cholinergic neurons in spatial working memory. Neuropharmacology. 1998;37:481&#x2013;487.</Citation><ArticleIdList><ArticleId IdType="pubmed">9704989</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin J, Palop JJ, Puoliv&#xe4;li J, Massaro C, Bien-Ly N, Gerstein H, Scearce-Levie K, Masliah E, Mucke L. Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci. 2005;25:9694&#x2013;9703.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725734</ArticleId><ArticleId IdType="pubmed">16237174</ArticleId></ArticleIdList></Reference><Reference><Citation>Chrobak JJ, Napier TC. Antagonism of GABAergic transmission within the septum disrupts working/episodic memory in the rat. Neuroscience. 1992;47:833&#x2013;841.</Citation><ArticleIdList><ArticleId IdType="pubmed">1579213</ArticleId></ArticleIdList></Reference><Reference><Citation>Chrobak JJ, Stackman RW, Walsh TJ. Intraseptal administration of muscimol produces dose-dependent memory impairments in the rat. Behav Neural Biol. 1989;52:357&#x2013;369.</Citation><ArticleIdList><ArticleId IdType="pubmed">2556105</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke HF, Dalley JW, Crofts HS, Robbins TW, Roberts AC. Cognitive inflexibility after prefrontal serotonin depletion. Science. 2004;304:878&#x2013;880.</Citation><ArticleIdList><ArticleId IdType="pubmed">15131308</ArticleId></ArticleIdList></Reference><Reference><Citation>Colom LV, Casta&#xf1;eda MT, Ba&#xf1;uelos C, Puras G, Garc&#xed;a-Hern&#xe1;ndez A, Hernandez S, Mounsey S, Benavidez J, Lehker C. Medial septal beta-amyloid 1&#x2013;40 injections alter septo-hippocampal anatomy and function. Neurobiol Aging. 2010;31:46&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2810281</ArticleId><ArticleId IdType="pubmed">18547680</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet. 1976;2:1403.</Citation><ArticleIdList><ArticleId IdType="pubmed">63862</ArticleId></ArticleIdList></Reference><Reference><Citation>Dragoi G, Carpi D, Recce M, Csicsvari J, Buzs&#xe1;ki G. Interactions between hippocampus and medial septum during sharp waves and theta oscillation in the behaving rat. J Neurosci. 1999;19:6191&#x2013;6199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6783073</ArticleId><ArticleId IdType="pubmed">10407055</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutar P, Lamour Y, Rascol O, Jobert A. Septo-hippocampal neurons in the rat: further study of their physiological and pharmacological properties. Brain Res. 1986;365:325&#x2013;334.</Citation><ArticleIdList><ArticleId IdType="pubmed">3484996</ArticleId></ArticleIdList></Reference><Reference><Citation>Dwyer TA, Servatius RJ, Pang KC. Noncholinergic lesions of the medial septum impair sequential learning of different spatial locations. J Neurosci. 2007;27:299&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3063940</ArticleId><ArticleId IdType="pubmed">17215389</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekstrom AD, Caplan JB, Ho E, Shattuck K, Fried I, Kahana MJ. Human hippocampal theta activity during virtual navigation. Hippocampus. 2005;15:881&#x2013;889.</Citation><ArticleIdList><ArticleId IdType="pubmed">16114040</ArticleId></ArticleIdList></Reference><Reference><Citation>Faure A, Verret L, Bozon B, El Tannir El Tayara N, Ly M, Kober F, Dhenain M, Rampon C, Delatour B. Impaired neurogenesis, neuronal loss, and brain functional deficits in the APPxPS1-Ki mouse model of Alzheimer's disease. Neurobiol Aging. 2009 doi: 10.1016/j.neurobiolaging.2009.03.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2009.03.009</ArticleId><ArticleId IdType="pubmed">19398247</ArticleId></ArticleIdList></Reference><Reference><Citation>Flood JF, Morley JE, Roberts E. Amnestic effects in mice of four synthetic peptides homologous to amyloid beta protein from patients with Alzheimer disease. Proc Natl Acad Sci U S A. 1991;88:3363&#x2013;3366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC51447</ArticleId><ArticleId IdType="pubmed">2014256</ArticleId></ArticleIdList></Reference><Reference><Citation>Frotscher M, L&#xe9;r&#xe1;nth C. Cholinergic innervation of the rat hippocampus as revealed by choline acetyltransferase immunocytochemistry: a combined light and electron microscopic study. J Comp Neurol. 1985;239:237&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pubmed">4044938</ArticleId></ArticleIdList></Reference><Reference><Citation>Fyhn M, Molden S, Hollup S, Moser MB, Moser E. Hippocampal neurons responding to first-time dislocation of a target object. Neuron. 2002;35:555&#x2013;566.</Citation><ArticleIdList><ArticleId IdType="pubmed">12165476</ArticleId></ArticleIdList></Reference><Reference><Citation>Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, Guido T, Hagopian S, Johnsonwood K, Khan K, Lee M, Leibowitz P, Lieberburg I, Little S, Masliah E, McConlogue L, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature. 1995;373:523&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pubmed">7845465</ArticleId></ArticleIdList></Reference><Reference><Citation>Givens BS, Olton DS. Cholinergic and GABAergic modulation of medial septal area: effect on working memory. Behav Neurosci. 1990;104:849&#x2013;855.</Citation><ArticleIdList><ArticleId IdType="pubmed">2178347</ArticleId></ArticleIdList></Reference><Reference><Citation>Gogol&#xe1;k G, Stumpf C, Petsche H, Sterc J. The firing pattern of septal neurons and the form of the hippocampal theta wave. Brain Res. 1968;7:201&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">5638867</ArticleId></ArticleIdList></Reference><Reference><Citation>Golde TE. The Abeta hypothesis: leading us to rationally-designed therapeutic strategies for the treatment or prevention of Alzheimer disease. Brain Pathol. 2005;15:84&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095797</ArticleId><ArticleId IdType="pubmed">15779241</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorelova N, Reiner PB. Role of the afterhyperpolarization in control of discharge properties of septal cholinergic neurons in vitro. J Neurophysiol. 1996;75:695&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pubmed">8714645</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutagny R, Jackson J, Williams S. Self-generated theta oscillations in the hippocampus. Nat Neurosci. 2009;12:1491&#x2013;1493.</Citation><ArticleIdList><ArticleId IdType="pubmed">19881503</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffith WH, Matthews RT. Electrophysiology of AChE-positive neurons in basal forebrain slices. Neurosci Lett. 1986;71:169&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">3785743</ArticleId></ArticleIdList></Reference><Reference><Citation>Hale G, Good M. Impaired visuospatial recognition memory but normal object novelty detection and relative familiarity judgments in adult mice expressing the APPswe Alzheimer's disease mutation. Behav Neurosci. 2005;119:884&#x2013;891.</Citation><ArticleIdList><ArticleId IdType="pubmed">16187817</ArticleId></ArticleIdList></Reference><Reference><Citation>Hangya B, Borhegyi Z, Szil&#xe1;gyi N, Freund TF, Varga V. GABAergic neurons of the medial septum lead the hippocampal network during theta activity. J Neurosci. 2009;29:8094&#x2013;8102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6666051</ArticleId><ArticleId IdType="pubmed">19553449</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasselmo ME, Wyble BP, Wallenstein GV. Encoding and retrieval of episodic memories: role of cholinergic and GABAergic modulation in the hippocampus. Hippocampus. 1996;6:693&#x2013;708.</Citation><ArticleIdList><ArticleId IdType="pubmed">9034856</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman JM, Zilli EA, Paley AM, Hasselmo ME. Medial prefrontal cortex cells show dynamic modulation with the hippocampal theta rhythm dependent on behavior. Hippocampus. 2005;15:739&#x2013;749.</Citation><ArticleIdList><ArticleId IdType="pubmed">16015622</ArticleId></ArticleIdList></Reference><Reference><Citation>Idrizbegovic E, Bogdanovic N, Willott JF, Canlon B. Age-related increases in calcium-binding protein immunoreactivity in the cochlear nucleus of hearing impaired C57BL/6J mice. Neurobiol Aging. 2004;25:1085&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pubmed">15212833</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarrett JT, Lansbury PT., Jr Seeding &#x201c;one-dimensional crystallization&#x201d; of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell. 1993;73:1055&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pubmed">8513491</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeewajee A, Lever C, Burton S, O'Keefe J, Burgess N. Environmental novelty is signaled by reduction of the hippocampal theta frequency. Hippocampus. 2008;18:340&#x2013;348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2678674</ArticleId><ArticleId IdType="pubmed">18081172</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones MW, Wilson MA. Theta rhythms coordinate hippocampal-prefrontal interactions in a spatial memory task. PLoS Biol. 2005;3:e402.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1283536</ArticleId><ArticleId IdType="pubmed">16279838</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xf6;hler C, Chan-Palay V, Wu JY. Septal neurons containing glutamic acid decarboxylase immunoreactivity project to the hippocampal region in the rat brain. Anat Embryol (Berl) 1984;169:41&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">6721220</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumaran D, Maguire EA. An unexpected sequence of events: mismatch detection in the human hippocampus. PLoS Biol. 2006;4:e424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1661685</ArticleId><ArticleId IdType="pubmed">17132050</ArticleId></ArticleIdList></Reference><Reference><Citation>Lalonde J, Lachance PED, Chaudhuri A. Monocular enucleation induces nuclear localization of calcium/calmodulin-dependent protein kinase IV in cortical interneurons of adult monkey area V1. J Neurosci. 2004;24:554&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729977</ArticleId><ArticleId IdType="pubmed">14724256</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenck-Santini PP, Rivard B, Muller RU, Poucet B. Study of CA1 place cell activity and exploratory behavior following spatial and nonspatial changes in the environment. Hippocampus. 2005;15:356&#x2013;369.</Citation><ArticleIdList><ArticleId IdType="pubmed">15602750</ArticleId></ArticleIdList></Reference><Reference><Citation>Manns JR, Squire LR. Perceptual learning, awareness, and the hippocampus. Hippocampus. 2001;11:776&#x2013;782.</Citation><ArticleIdList><ArticleId IdType="pubmed">11811672</ArticleId></ArticleIdList></Reference><Reference><Citation>Manns JR, Zilli EA, Ong KC, Hasselmo ME, Eichenbaum H. Hippocampal CA1 spiking during encoding and retrieval: relation to theta phase. Neurobiol Learn Mem. 2007;87:9&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">16839788</ArticleId></ArticleIdList></Reference><Reference><Citation>McCartney H, Johnson AD, Weil ZM, Givens B. Theta reset produces optimal conditions for long-term potentiation. Hippocampus. 2004;14:684&#x2013;687.</Citation><ArticleIdList><ArticleId IdType="pubmed">15318327</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A, Koenigsknecht-Talboo J, Holtzman DM, Bacskai BJ, Hyman BT. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature. 2008;451:720&#x2013;724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3264491</ArticleId><ArticleId IdType="pubmed">18256671</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan MA, Schulkin J, LeDoux JE. Ventral medial prefrontal cortex and emotional perseveration: the memory for prior extinction training. Behav Brain Res. 2003;146:121&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">14643465</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormann F, Fell J, Axmacher N, Weber B, Lehnertz K, Elger CE, Fern&#xe1;ndez G. Phase/amplitude reset and theta-gamma interaction in the human medial temporal lobe during a continuous word recognition memory task. Hippocampus. 2005;15:890&#x2013;900.</Citation><ArticleIdList><ArticleId IdType="pubmed">16114010</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagahara AH, McGaugh JL. Muscimol infused into the medial septal area impairs long-term memory but not short-term memory in inhibitory avoidance, water maze place learning and rewarded alternation tasks. Brain Res. 1992;591:54&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">1446233</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, Yoo J, Ho KO, Yu GQ, Kreitzer A, Finkbeiner S, Noebels JL, Mucke L. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse. 2007</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055171</ArticleId><ArticleId IdType="pubmed">17785178</ArticleId></ArticleIdList></Reference><Reference><Citation>Paxinos G, Watson C. The rat brain in stereotaxic coordinates. Ed 2. New York: Academic; 1986.</Citation><ArticleIdList><ArticleId IdType="pubmed">6110810</ArticleId></ArticleIdList></Reference><Reference><Citation>Perkel DH, Gerstein GL, Moore GP. Neuronal spike trains and stochastic point processes. II. Simultaneous spike trains. Biophys J. 1967;7:419&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1368069</ArticleId><ArticleId IdType="pubmed">4292792</ArticleId></ArticleIdList></Reference><Reference><Citation>Petsche H, Stumpf C, Gogolak G. The significance of the rabbit's septum as a relay station between the midbrain and the hippocampus. I. The control of hippocampus arousal activity by the septum cells. Electroencephalogr Clin Neurophysiol. 1962;14:202&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">14038334</ArticleId></ArticleIdList></Reference><Reference><Citation>Peyrache A, Khamassi M, Benchenane K, Wiener SI, Battaglia FP. Replay of rule-learning related neural patterns in the prefrontal cortex during sleep. Nat Neurosci. 2009;12:919&#x2013;926.</Citation><ArticleIdList><ArticleId IdType="pubmed">19483687</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinault D. A novel single-cell staining procedure performed in vivo under electrophysiological control: morpho-functional features of juxtacellularly labeled thalamic cells and other central neurons with biocytin or Neurobiotin. J Neurosci Methods. 1996;65:113&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pubmed">8740589</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramadan W, Eschenko O, Sara SJ. Hippocampal sharp wave/ripples during sleep for consolidation of associative memory. PLoS One. 2009;4:e6697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2725314</ArticleId><ArticleId IdType="pubmed">19693273</ArticleId></ArticleIdList></Reference><Reference><Citation>Richter H, Ambr&#xe9;e O, Lewejohann L, Herring A, Keyvani K, Paulus W, Palme R, Touma C, Sch&#xe4;bitz WR, Sachser N. Wheel-running in a transgenic mouse model of Alzheimer's disease: protection or symptom? Behav Brain Res. 2008;190:74&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">18342378</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheibel AB. The hippocampus: organizational patterns in health and senescence. Mech Ageing Dev. 1979;9:89&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">439952</ArticleId></ArticleIdList></Reference><Reference><Citation>Sederberg PB, Kahana MJ, Howard MW, Donner EJ, Madsen JR. Theta and gamma oscillations during encoding predict subsequent recall. J Neurosci. 2003;23:10809&#x2013;10814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740970</ArticleId><ArticleId IdType="pubmed">14645473</ArticleId></ArticleIdList></Reference><Reference><Citation>Siapas AG, Lubenov EV, Wilson MA. Prefrontal phase locking to hippocampal theta oscillations. Neuron. 2005;46:141&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">15820700</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon AP, Poindessous-Jazat F, Dutar P, Epelbaum J, Bassant MH. Firing properties of anatomically identified neurons in the medial septum of anesthetized and unanesthetized restrained rats. J Neurosci. 2006;26:9038&#x2013;9046.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675331</ArticleId><ArticleId IdType="pubmed">16943562</ArticleId></ArticleIdList></Reference><Reference><Citation>Sirota A, Montgomery S, Fujisawa S, Isomura Y, Zugaro M, Buzs&#xe1;ki G. Entrainment of neocortical neurons and gamma oscillations by the hippocampal theta rhythm. Neuron. 2008;60:683&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2640228</ArticleId><ArticleId IdType="pubmed">19038224</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, Perera GM, DeLaPaz R, Mayeux R, Stern Y. Differential regional dysfunction of the hippocampal formation among elderly with memory decline and Alzheimer's disease. Ann Neurol. 1999;45:466&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pubmed">10211471</ArticleId></ArticleIdList></Reference><Reference><Citation>Sotty F, Danik M, Manseau F, Laplante F, Quirion R, Williams S. Distinct electrophysiological properties of glutamatergic, cholinergic and GABAergic rat septohippocampal neurons: novel implications for hippocampal rhythmicity. J Physiol. 2003;551:927&#x2013;943.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2343277</ArticleId><ArticleId IdType="pubmed">12865506</ArticleId></ArticleIdList></Reference><Reference><Citation>Stepanichev MY, Zdobnova IM, Zarubenko II, Lazareva NA, Gulyaeva NV. Studies of the effects of central administration of beta-amyloid peptide (25&#x2013;35): pathomorphological changes in the Hippocampus and impairment of spatial memory. Neurosci Behav Physiol. 2006;36:101&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">16328175</ArticleId></ArticleIdList></Reference><Reference><Citation>St&#xe9;phan A, Laroche S, Davis S. Generation of aggregated beta-amyloid in the rat hippocampus impairs synaptic transmission and plasticity and causes memory deficits. J Neurosci. 2001;21:5703&#x2013;5714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762634</ArticleId><ArticleId IdType="pubmed">11466442</ArticleId></ArticleIdList></Reference><Reference><Citation>St&#xe9;phan A, Laroche S, Davis S. Learning deficits and dysfunctional synaptic plasticity induced by aggregated amyloid deposits in the dentate gyrus are rescued by chronic treatment with indomethacin. Eur J Neurosci. 2003;17:1921&#x2013;1927.</Citation><ArticleIdList><ArticleId IdType="pubmed">12752791</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart M, Fox SE. Firing relations of medial septal neurons to the hippocampal theta rhythm in urethane anesthetized rats. Exp Brain Res. 1989;77:507&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pubmed">2806444</ArticleId></ArticleIdList></Reference><Reference><Citation>Tort AB, Komorowski RW, Manns JR, Kopell NJ, Eichenbaum H. Theta-gamma coupling increases during the learning of item-context associations. Proc Natl Acad Sci U S A. 2009 doi: 10.1073/pnas.0911331106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0911331106</ArticleId><ArticleId IdType="pmc">PMC2791641</ArticleId><ArticleId IdType="pubmed">19934062</ArticleId></ArticleIdList></Reference><Reference><Citation>T&#xf3;th K, Borhegyi Z, Freund TF. Postsynaptic targets of GABAergic hippocampal neurons in the medial septum-diagonal band of broca complex. J Neurosci. 1993;13:3712&#x2013;3724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6576440</ArticleId><ArticleId IdType="pubmed">7690065</ArticleId></ArticleIdList></Reference><Reference><Citation>T&#xf3;th K, Freund TF, Miles R. Disinhibition of rat hippocampal pyramidal cells by GABAergic afferents from the septum. J Physiol. 1997;500:463&#x2013;474.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1159396</ArticleId><ArticleId IdType="pubmed">9147330</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderwolf CH. Hippocampal electrical activity and voluntary movement in the rat. electroencephalogr Clin Neurophysiol. 1969;26:407&#x2013;418.</Citation><ArticleIdList><ArticleId IdType="pubmed">4183562</ArticleId></ArticleIdList></Reference><Reference><Citation>Varga V, Hangya B, Kr&#xe1;nitz K, Lud&#xe1;nyi A, Zemankovics R, Katona I, Shigemoto R, Freund TF, Borhegyi Z. The presence of pacemaker HCN channels identifies theta rhythmic GABAergic neurons in the medial septum. J Physiol. 2008;586:3893&#x2013;3915.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2538919</ArticleId><ArticleId IdType="pubmed">18565991</ArticleId></ArticleIdList></Reference><Reference><Citation>Vertes RP, Kocsis B. Brainstem-diencephalo-septohippocampal systems controlling the theta rhythm of the hippocampus. Neuroscience. 1997;81:893&#x2013;926.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330355</ArticleId></ArticleIdList></Reference><Reference><Citation>Vertes RP, Hoover WB, Viana Di Prisco G. Theta rhythm of the hippocampus: subcortical control and functional significance. Behav Cogn Neurosci Rev. 2004;3:173&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">15653814</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang PN, Liu HC, Lirng JF, Lin KN, Wu ZA. Accelerated hippocampal atrophy rates in stable and progressive amnestic mild cognitive impairment. Psychiatry Res. 2009;171:221&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">19217759</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang XJ. Pacemaker neurons for the theta rhythm and their synchronization in the septohippocampal reciprocal loop. J Neurophysiol. 2002;87:889&#x2013;900.</Citation><ArticleIdList><ArticleId IdType="pubmed">11826054</ArticleId></ArticleIdList></Reference><Reference><Citation>Weldon DT, Rogers SD, Ghilardi JR, Finke MP, Cleary JP, O'Hare E, Esler WP, Maggio JE, Mantyh PW. Fibrillar beta-amyloid induces microglial phagocytosis, expression of inducible nitric oxide synthase, and loss of a select population of neurons in the rat CNS in vivo. J Neurosci. 1998;18:2161&#x2013;2173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792921</ArticleId><ArticleId IdType="pubmed">9482801</ArticleId></ArticleIdList></Reference><Reference><Citation>Whishaw IQ, Tomie J. Piloting and dead reckoning dissociated by fimbria-fornix lesions in a rat food carrying task. Behav Brain Res. 1997;89:87&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">9475617</ArticleId></ArticleIdList></Reference><Reference><Citation>Winson J. Loss of hippocampal theta rhythm results in spatial memory deficit in the rat. Science. 1978;201:160&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">663646</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20720123</PMID><DateCompleted><Year>2010</Year><Month>09</Month><Day>03</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>33</Issue><PubDate><Year>2010</Year><Month>Aug</Month><Day>18</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>A noncompetitive BACE1 inhibitor TAK-070 ameliorates Abeta pathology and behavioral deficits in a mouse model of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>11157</StartPage><EndPage>11166</EndPage><MedlinePgn>11157-66</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.2884-10.2010</ELocationID><Abstract><AbstractText>We discovered a nonpeptidic compound, TAK-070, that inhibited BACE1, a rate-limiting protease for the generation of Abeta peptides that are considered causative for Alzheimer's disease (AD), in a noncompetitive manner. TAK-070 bound to full-length BACE1, but not to truncated BACE1 lacking the transmembrane domain. Short-term oral administration of TAK-070 decreased the brain levels of soluble Abeta, increased that of neurotrophic sAPPalpha by approximately 20%, and normalized the behavioral impairments in cognitive tests in Tg2576 mice, an APP transgenic mouse model of AD. Six-month chronic treatment decreased cerebral Abeta deposition by approximately 60%, preserving the pharmacological efficacy on soluble Abeta and sAPPalpha levels. These results support the feasibility of BACE1 inhibition with a noncompetitive inhibitor as disease-modifying as well as symptomatic therapy for AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fukumoto</LastName><ForeName>Hiroaki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Yodogawa-ku, Osaka 532-8686, Japan. Fukumoto_Hiroaki@takeda.co.jp</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>Hideki</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Tarui</LastName><ForeName>Naoki</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Matsui</LastName><ForeName>Junji</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Tomita</LastName><ForeName>Taisuke</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Hirode</LastName><ForeName>Mitsuhiro</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Sagayama</LastName><ForeName>Masumi</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Maeda</LastName><ForeName>Ryouta</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Kawamoto</LastName><ForeName>Makiko</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Hirai</LastName><ForeName>Kazuko</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Terauchi</LastName><ForeName>Jun</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Sakura</LastName><ForeName>Yasufumi</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Kakihana</LastName><ForeName>Mitsuru</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kato</LastName><ForeName>Kaneyoshi</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Iwatsubo</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Miyamoto</LastName><ForeName>Masaomi</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C545487">APP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001713">Biphenyl Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009281">Naphthalenes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058255">Protease Nexins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011956">Receptors, Cell Surface</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C551841">TAK-070</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001713" MajorTopicYN="N">Biphenyl Compounds</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009281" MajorTopicYN="N">Naphthalenes</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058255" MajorTopicYN="N">Protease Nexins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011897" MajorTopicYN="N">Random Allocation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011956" MajorTopicYN="N">Receptors, Cell Surface</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021641" MajorTopicYN="N">Recognition, Psychology</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>2</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20720123</ArticleId><ArticleId IdType="pmc">PMC6633483</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2884-10.2010</ArticleId><ArticleId IdType="pii">30/33/11157</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Asami-Odaka A, Ishibashi Y, Kikuchi T, Kitada C, Suzuki N. Long amyloid &#x3b2;-protein secreted from wild-type human neuroblastoma IMR-32 cells. Biochemistry. 1995;34:10272&#x2013;10278.</Citation><ArticleIdList><ArticleId IdType="pubmed">7640283</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Q, Nakajima A, Choi SH, Xiong X, Tang YP. Loss of presenilin function causes Alzheimer's disease-like neurodegeneration in the mouse. J Neurosci Res. 2008;86:1615&#x2013;1625.</Citation><ArticleIdList><ArticleId IdType="pubmed">18189321</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH. Natural oligomers of the amyloid-&#x3b2; protein specifically disrupt cognitive function. Nat Neurosci. 2005;8:79&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">15608634</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole SL, Vassar R. BACE1 structure and function in health and Alzheimer's disease. Curr Alzheimer Res. 2008;5:100&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">18393796</ArticleId></ArticleIdList></Reference><Reference><Citation>Doedens JR, Mahimkar RM, Black RA. TACE/ADAM-17 enzymatic activity is increased in response to cellular stimulation. Biochem Biophys Res Commun. 2003;308:331&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pubmed">12901873</ArticleId></ArticleIdList></Reference><Reference><Citation>Donoviel DB, Hadjantonakis AK, Ikeda M, Zheng H, Hyslop PS, Bernstein A. Mice lacking both presenilin genes exhibit early embryonic patterning defects. Genes Dev. 1999;13:2801&#x2013;2810.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC317124</ArticleId><ArticleId IdType="pubmed">10557208</ArticleId></ArticleIdList></Reference><Reference><Citation>Espeseth AS, Xu M, Huang Q, Coburn CA, Jones KLG, Ferrer M, Zuck PD, Strulovici B, Price EA, Wu G, Wolfe AL, Lineberger JE, Sardana M, Tugusheva K, Pietrak BL, Crouthamel M-C, Lai M-T, Dodson EC, Bazzo R, Shi X-P, et al. Compounds that bind APP and inhibit A&#x3b2; processing in vitro suggest a novel approach to Alzheimer disease therapeutics. J Biol Chem. 2005;280:17792&#x2013;17797.</Citation><ArticleIdList><ArticleId IdType="pubmed">15737955</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukumoto H, Tomita T, Matsunaga H, Ishibashi Y, Saido TC, Iwatsubo T. Primary cultures of neuronal and non-neuronal rat brain cells secrete similar proportions of amyloid &#x3b2; peptides ending at A&#x3b2;40 and A&#x3b2;42. Neuroreport. 1999;10:2965&#x2013;2969.</Citation><ArticleIdList><ArticleId IdType="pubmed">10549806</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukumoto H, Rosene DL, Moss MB, Raju S, Hyman BT, Irizarry MC. &#x3b2;-secretase activity increases with aging in human, monkey, and mouse brain. Am J Pathol. 2004;164:719&#x2013;725.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1602259</ArticleId><ArticleId IdType="pubmed">14742275</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X, Hicks CW, He W, Wong P, Macklin WB, Trapp BD, Yan R. Bace1 modulates myelination in the central and peripheral nervous system. Nat Neurosci. 2006;9:1520&#x2013;1525.</Citation><ArticleIdList><ArticleId IdType="pubmed">17099708</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussain I, Hawkins J, Harrison D, Hille C, Wayne G, Cutler L, Buck T, Walter D, Demont E, Howes C, Naylor A, Jeffrey P, Gonzalez MI, Dingwall C, Michel A, Redshaw S, Davis JB. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases &#x3b2;-cleavage of amyloid precursor protein and amyloid-&#x3b2; production in vivo. J Neurochem. 2007;100:802&#x2013;809.</Citation><ArticleIdList><ArticleId IdType="pubmed">17156133</ArticleId></ArticleIdList></Reference><Reference><Citation>Isacson O, Seo H, Lin L, Albeck D, Granholm AC. Alzheimer's disease and Down's syndrome: roles of APP, trophic factors and ACh. Trends Neurosci. 2002;25:79&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">11814559</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of A&#x3b2;42(43) and A&#x3b2;40 in senile plaques with end-specific A&#x3b2; monoclonals: evidence that an initially deposited species is A&#x3b2;42(43) Neuron. 1994;13:45&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">8043280</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobsen JS, Wu CC, Redwine JM, Comery TA, Arias R, Bowlby M, Martone R, Morrison JH, Pangalos MN, Reinhart PH, Bloom FE. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2006;103:5161&#x2013;5166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1405622</ArticleId><ArticleId IdType="pubmed">16549764</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorissen E, Prox J, Bernreuther C, Weber S, Schwanbeck R, Serneels L, Snellinx A, Craessaerts K, Thathiah A, Tesseur I, Bartsch U, Weskamp G, Blobel CP, Glatzel M, De Strooper B, Saftig P. The disintegrin/metalloproteinase ADAM10 is essential for the establishment of the brain cortex. J Neurosci. 2010;30:4833&#x2013;4844.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2921981</ArticleId><ArticleId IdType="pubmed">20371803</ArticleId></ArticleIdList></Reference><Reference><Citation>Lakshmana MK, Yoon IS, Chen E, Bianchi E, Koo EH, Kang DE. Novel role of RanBP9 in BACE1 processing of amyloid precursor protein and amyloid &#x3b2; peptide generation. J Biol Chem. 2009;284:11863&#x2013;11872.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2673255</ArticleId><ArticleId IdType="pubmed">19251705</ArticleId></ArticleIdList></Reference><Reference><Citation>Marks N, Berg MJ. Neurosecretases provide strategies to treat sporadic and familial Alzheimer disorders. Neurochem Int. 2008;52:184&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">17719698</ArticleId></ArticleIdList></Reference><Reference><Citation>Marlow L, Cain M, Pappolla MA, Sambamurti K. &#x3b2;-Secretase processing of the Alzheimer's amyloid protein precursor (APP) J Mol Neurosci. 2003;20:233&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">14501002</ArticleId></ArticleIdList></Reference><Reference><Citation>McConlogue L, Buttini M, Anderson JP, Brigham EF, Chen KS, Freedman SB, Games D, Johnson-Wood K, Lee M, Zeller M, Liu W, Motter R, Sinha S. Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP transgenic mice. J Biol Chem. 2007;282:26326&#x2013;26334.</Citation><ArticleIdList><ArticleId IdType="pubmed">17616527</ArticleId></ArticleIdList></Reference><Reference><Citation>Obregon DF, Rezai-Zadeh K, Bai Y, Sun N, Hou H, Ehrhart J, Zeng J, Mori T, Arendash GW, Shytle D, Town T, Tan J. ADAM10 activation is required for green tea (-)-epigallocatechin-3-gallate-induced (alpha)-secretase cleavage of amyloid precursor protein. J Biol Chem. 2006;281:16419&#x2013;16427.</Citation><ArticleIdList><ArticleId IdType="pubmed">16624814</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno M, Sametsky EA, Younkin LH, Oakley H, Younkin SG, Citron M, Vassar R, Disterhoft JF. BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. Neuron. 2004;41:27&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">14715132</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno M, Chang L, Tseng W, Oakley H, Citron M, Klein WL, Vassar R, Disterhoft JF. Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1. Eur J Neurosci. 2006;23:251&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">16420434</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno M, Cole SL, Yasvoina M, Zhao J, Citron M, Berry R, Disterhoft JF, Vassar R. BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice. Neurobiol Dis. 2007;26:134&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1876698</ArticleId><ArticleId IdType="pubmed">17258906</ArticleId></ArticleIdList></Reference><Reference><Citation>Postina R. A closer look at &#x3b1;-secretase. Curr Alzheimer Res. 2008;5:179&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pubmed">18393803</ArticleId></ArticleIdList></Reference><Reference><Citation>Sankaranarayanan S, Price EA, Wu G, Crouthamel MC, Shi XP, Tugusheva K, Tyler KX, Kahana J, Ellis J, Jin L, Steele T, Stachel S, Coburn C, Simon AJ. In vivo beta-secretase 1 inhibition leads to brain A&#x3b2; lowering and increased &#x3b1;-secretase processing of amyloid precursor protein without effect on neuregulin-1. J Pharmacol Exp Ther. 2008;324:957&#x2013;969.</Citation><ArticleIdList><ArticleId IdType="pubmed">18156464</ArticleId></ArticleIdList></Reference><Reference><Citation>Sankaranarayanan S, Holahan MA, Colussi D, Crouthamel MC, Devanarayan V, Ellis J, Espeseth A, Gates AT, Graham SL, Gregro AR, Hazuda D, Hochman JH, Holloway K, Jin L, Kahana J, Lai MT, Lineberger J, McGaughey G, Moore KP, Nantermet P, et al. First demonstration of cerebrospinal fluid and plasma A&#x3b2; lowering with oral administration of a &#x3b2;-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates. J Pharmacol Exp Ther. 2009;328:131&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">18854490</ArticleId></ArticleIdList></Reference><Reference><Citation>Saura CA, Choi SY, Beglopoulos V, Malkani S, Zhang D, Shankaranarayana Rao BS, Chattarji S, Kelleher RJ, 3rd, Kandel ER, Duff K, Kirkwood A, Shen J. Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron. 2004;42:23&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">15066262</ArticleId></ArticleIdList></Reference><Reference><Citation>Saura CA, Chen G, Malkani S, Choi SY, Takahashi RH, Zhang D, Gouras GK, Kirkwood A, Morris RG, Shen J. Conditional inactivation of presenilin 1 prevents amyloid accumulation and temporarily rescues contextual and spatial working memory impairments in amyloid precursor protein transgenic mice. J Neurosci. 2005;25:6755&#x2013;6764.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725351</ArticleId><ArticleId IdType="pubmed">16033885</ArticleId></ArticleIdList></Reference><Reference><Citation>Savonenko AV, Melnikova T, Laird FM, Stewart KA, Price DL, Wong PC. Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice. Proc Natl Acad Sci U S A. 2008;105:5585&#x2013;5590.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2291091</ArticleId><ArticleId IdType="pubmed">18385378</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ, Schenk D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol. 2003;43:545&#x2013;584.</Citation><ArticleIdList><ArticleId IdType="pubmed">12415125</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen J, Bronson RT, Chen DF, Xia W, Selkoe DJ, Tonegawa S. Skeletal and CNS defects in Presenilin-1-deficient mice. Cell. 1997;89:629&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">9160754</ArticleId></ArticleIdList></Reference><Reference><Citation>Silvestri R. Boom in the development of non-peptidic &#x3b2;-secretase (BACE1) inhibitors for the treatment of Alzheimer's disease. Med Res Rev. 2009;29:295&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pubmed">18651582</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, Doan M, Dovey HF, Frigon N, Hong J, Jacobson-Croak K, Jewett N, Keim P, Knops J, Lieberburg I, Power M, Tan H, Tatsuno G, Tung J, Schenk D, et al. Purification and cloning of amyloid precursor protein &#x3b2;-secretase from human brain. Nature. 1999;402:537&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pubmed">10591214</ArticleId></ArticleIdList></Reference><Reference><Citation>Stockley JH, O'Neill C. The proteins BACE1 and BACE2 and &#x3b2;-secretase activity in normal and Alzheimer's disease brain. Biochem Soc Trans. 2007;35:574&#x2013;576.</Citation><ArticleIdList><ArticleId IdType="pubmed">17511655</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi Y, Hayashi I, Tominari Y, Rikimaru K, Morohashi Y, Kan T, Natsugari H, Fukuyama T, Tomita T, Iwatsubo T. Sulindac sulfide is a noncompetitive &#x3b3;-secretase inhibitor that preferentially reduces A&#x3b2;42 generation. J Biol Chem. 2003;278:18664&#x2013;18670.</Citation><ArticleIdList><ArticleId IdType="pubmed">12637581</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomita T, Katayama R, Takikawa R, Iwatsubo T. Complex N-glycosylated form of nicastrin is stabilized and selectively bound to presenilin fragments. FEBS Lett. 2002;520:117&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pubmed">12044882</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, et al. &#x3b2;-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286:735&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkitaramani DV, Chin J, Netzer WJ, Gouras GK, Lesne S, Malinow R, Lombroso PJ. &#x3b2;-Amyloid modulation of synaptic transmission and plasticity. J Neurosci. 2007;27:11832&#x2013;11837.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2671021</ArticleId><ArticleId IdType="pubmed">17978019</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Westerman MA, Cooper-Blacketer D, Mariash A, Kotilinek L, Kawarabayashi T, Younkin LH, Carlson GA, Younkin SG, Ashe KH. The relationship between A&#x3b2; and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci. 2002;22:1858&#x2013;1867.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758862</ArticleId><ArticleId IdType="pubmed">11880515</ArticleId></ArticleIdList></Reference><Reference><Citation>Westmeyer GG, Willem M, Lichtenthaler SF, Lurman G, Multhaup G, Assfalg-Machleidt I, Reiss K, Saftig P, Haass C. Dimerization of &#x3b2;-site &#x3b2;-amyloid precursor protein-cleaving enzyme. J Biol Chem. 2004;279:53205&#x2013;53212.</Citation><ArticleIdList><ArticleId IdType="pubmed">15485862</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong PC, Zheng H, Chen H, Becher MW, Sirinathsinghji DJ, Trumbauer ME, Chen HY, Price DL, Van der Ploeg LH, Sisodia SS. Presenilin 1 is required for Notch1 and DII1 expression in the paraxial mesoderm. Nature. 1997;387:288&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pubmed">9153393</ArticleId></ArticleIdList></Reference><Reference><Citation>Zohar O, Pick CG, Cavallaro S, Chapman J, Katzav A, Milman A, Alkon DL. Age-dependent differential expression of BACE splice variants in brain regions of tg2576 mice. Neurobiol Aging. 2005;26:1167&#x2013;1175.</Citation><ArticleIdList><ArticleId IdType="pubmed">15917100</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20720132</PMID><DateCompleted><Year>2010</Year><Month>09</Month><Day>03</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>33</Issue><PubDate><Year>2010</Year><Month>Aug</Month><Day>18</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses.</ArticleTitle><Pagination><StartPage>11246</StartPage><EndPage>11250</EndPage><MedlinePgn>11246-50</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.2488-10.2010</ELocationID><Abstract><AbstractText>Glutamate is the major excitatory neurotransmitter in the brain. The NMDA subtype of glutamate receptors (NMDAR) is known to mediate many physiological neural functions. However, excessive activation of NMDARs contributes to neuronal damage in various acute and chronic neurological disorders. To avoid unwanted adverse side effects, blockade of excessive NMDAR activity must therefore be achieved without affecting its physiological function. Memantine, an adamantane derivative, has been used for the treatment of Alzheimer's disease with an excellent clinical safety profile. We previously showed that memantine preferentially blocked neurotoxicity mediated by excessive NMDAR activity while relatively sparing normal neurotransmission, in part because of its uncompetitive antagonism with a fast off-rate. Here, using rat autaptic hippocampal microcultures, we show that memantine at therapeutic concentrations (1-10 microM) preferentially blocks extrasynaptic rather than synaptic currents mediated by NMDARs in the same neuron. We found that memantine blocks extrasynaptic NMDAR-mediated currents induced by bath application of 100 microM NMDA/10 microM glycine with a twofold higher potency than its blockade of the NMDAR component of evoked EPSCs (EPSCs(NMDAR)); this effect persists under conditions of pathological depolarization in the presence of 1 mm extracellular Mg(2+). Thus, our findings provide the first unequivocal evidence to explain the tolerability of memantine based on differential extrasynaptic/synaptic receptor blockade. At therapeutic concentrations, memantine effectively blocks excessive extrasynaptic NMDAR-mediated currents, while relatively sparing normal synaptic activity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xia</LastName><ForeName>Peng</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Del E. Webb Center for Neuroscience, Aging, and Stem Cell Research, Sanford-Burnham Medical Research Institute, La Jolla, California 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Huei-sheng Vincent</ForeName><Initials>HS</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Dongxian</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Lipton</LastName><ForeName>Stuart A</ForeName><Initials>SA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 EY009024</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EY005477</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HD29587</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 HD029587</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EY05477</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EY09024</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018691">Excitatory Amino Acid Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>W8O17SJF3T</RegistryNumber><NameOfSubstance UI="D008559">Memantine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018691" MajorTopicYN="N">Excitatory Amino Acid Antagonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019706" MajorTopicYN="N">Excitatory Postsynaptic Potentials</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008559" MajorTopicYN="N">Memantine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008564" MajorTopicYN="N">Membrane Potentials</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018408" MajorTopicYN="N">Patch-Clamp Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>2</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20720132</ArticleId><ArticleId IdType="mid">NIHMS229556</ArticleId><ArticleId IdType="pmc">PMC2932667</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2488-10.2010</ArticleId><ArticleId IdType="pii">30/33/11246</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bresink I, Benke TA, Collett VJ, Seal AJ, Parsons CG, Henley JM, Collingridge GL. Effects of memantine on recombinant rat NMDA receptors expressed in HEK 293 cells. Br J Pharmacol. 1996;119:195&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1915856</ArticleId><ArticleId IdType="pubmed">8886398</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HS, Lipton SA. Mechanism of memantine block of NMDA-activated channels in rat retinal ganglion cells: uncompetitive antagonism. J Physiol. 1997;499:27&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1159335</ArticleId><ArticleId IdType="pubmed">9061638</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HS, Lipton SA. Pharmacological implications of two distinct mechanisms of interaction of memantine with N-methyl-d-aspartate-gated channels. J Pharmacol Exp Ther. 2005;314:961&#x2013;971.</Citation><ArticleIdList><ArticleId IdType="pubmed">15901795</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HS, Lipton SA. The chemical biology of clinically tolerated NMDA receptor antagonists. J Neurochem. 2006;97:1611&#x2013;1626.</Citation><ArticleIdList><ArticleId IdType="pubmed">16805772</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HS, Pellegrini JW, Aggarwal SK, Lei SZ, Warach S, Jensen FE, Lipton SA. Open-channel block of N-methyl-d-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J Neurosci. 1992;12:4427&#x2013;4436.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6576016</ArticleId><ArticleId IdType="pubmed">1432103</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HS, Wang YF, Rayudu PV, Edgecomb P, Neill JC, Segal MM, Lipton SA, Jensen FE. Neuroprotective concentrations of the N-methyl-d-aspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation. Neuroscience. 1998;86:1121&#x2013;1132.</Citation><ArticleIdList><ArticleId IdType="pubmed">9697119</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron. 1988;1:623&#x2013;634.</Citation><ArticleIdList><ArticleId IdType="pubmed">2908446</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi DW, Koh JY, Peters S. Pharmacology of glutamate neurotoxicity in cortical cell culture: attenuation by NMDA antagonists. J Neurosci. 1988;8:185&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6569373</ArticleId><ArticleId IdType="pubmed">2892896</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalby NO, Mody I. Activation of NMDA receptors in rat dentate gyrus granule cells by spontaneous and evoked transmitter release. J Neurophysiol. 2003;90:786&#x2013;797.</Citation><ArticleIdList><ArticleId IdType="pubmed">12904493</ArticleId></ArticleIdList></Reference><Reference><Citation>Danysz W, Parsons CG, Quack G. NMDA channel blockers: memantine and amino-aklylcyclohexanes&#x2014;in vivo characterization. Amino Acids. 2000;19:167&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">11026485</ArticleId></ArticleIdList></Reference><Reference><Citation>Dingledine R, Borges K, Bowie D, Traynelis SF. The glutamate receptor ion channels. Pharmacol Rev. 1999;51:7&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">10049997</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardingham GE, Fukunaga Y, Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci. 2002;5:405&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pubmed">11953750</ArticleId></ArticleIdList></Reference><Reference><Citation>Hesselink MB, De Boer BG, Breimer DD, Danysz W. Brain penetration and in vivo recovery of NMDA receptor antagonists amantadine and memantine: a quantitative microdialysis study. Pharm Res. 1999;16:637&#x2013;642.</Citation><ArticleIdList><ArticleId IdType="pubmed">10350004</ArticleId></ArticleIdList></Reference><Reference><Citation>Huettner JE, Bean BP. Block of N-methyl-d-aspartate-activated current by the anticonvulsant MK-801: selective binding to open channels. Proc Natl Acad Sci U S A. 1988;85:1307&#x2013;1311.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC279756</ArticleId><ArticleId IdType="pubmed">2448800</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotermanski SE, Johnson JW. Mg2+ imparts NMDA receptor subtype selectivity to the Alzheimer's drug memantine. J Neurosci. 2009;29:2774&#x2013;2779.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2679254</ArticleId><ArticleId IdType="pubmed">19261873</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xe9;veill&#xe9; F, El Gaamouch F, Gouix E, Lecocq M, Lobner D, Nicole O, Buisson A. Neuronal viability is controlled by a functional relation between synaptic and extrasynaptic NMDA receptors. FASEB J. 2008;22:4258&#x2013;4271.</Citation><ArticleIdList><ArticleId IdType="pubmed">18711223</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipton SA. Prospects for clinically tolerated NMDA antagonists: open-channel blockers and alternative redox states of nitric oxide. Trends Neurosci. 1993;16:527&#x2013;532.</Citation><ArticleIdList><ArticleId IdType="pubmed">7509524</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipton SA. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov. 2006;5:160&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">16424917</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipton SA. Pathologically activated therapeutics for neuroprotection. Nat Rev Neurosci. 2007;8:803&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pubmed">17882256</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipton SA. NMDA receptor activity regulates transcription of antioxidant pathways. Nat Neurosci. 2008;11:381&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pubmed">18368041</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipton SA, Chen HS. Paradigm shift in neuroprotective drug development: clinically tolerated NMDA receptor inhibition by memantine. Cell Death Differ. 2004;11:18&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">14647237</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med. 1994;330:613&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pubmed">7905600</ArticleId></ArticleIdList></Reference><Reference><Citation>MacDonald JF, Bartlett MC, Mody I, Pahapill P, Reynolds JN, Salter MW, Schneiderman JH, Pennefather PS. Actions of ketamine, phencyclidine and MK-801 on NMDA receptor currents in cultured mouse hippocampal neurones. J Physiol. 1991;432:483&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1181337</ArticleId><ArticleId IdType="pubmed">1832184</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer ML, Westbrook GL, Guthrie PB. Voltage-dependent block by Mg2+ of NMDA responses in spinal cord neurones. Nature. 1984;309:261&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">6325946</ArticleId></ArticleIdList></Reference><Reference><Citation>Nowak L, Bregestovski P, Ascher P, Herbet A, Prochiantz A. Magnesium gates glutamate-activated channels in mouse central neurones. Nature. 1984;307:462&#x2013;465.</Citation><ArticleIdList><ArticleId IdType="pubmed">6320006</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamoto S, Pouladi MA, Talantova M, Yao D, Xia P, Ehrnhoefer DE, Zaidi R, Clemente A, Kaul M, Graham RK, Zhang D, Vincent Chen HS, Tong G, Hayden MR, Lipton SA. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat Med. 2009;15:1407&#x2013;1413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2789858</ArticleId><ArticleId IdType="pubmed">19915593</ArticleId></ArticleIdList></Reference><Reference><Citation>Papadia S, Soriano FX, L&#xe9;veill&#xe9; F, Martel MA, Dakin KA, Hansen HH, Kaindl A, Sifringer M, Fowler J, Stefovska V, McKenzie G, Craigon M, Corriveau R, Ghazal P, Horsburgh K, Yankner BA, Wyllie DJ, Ikonomidou C, Hardingham GE. Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses. Nat Neurosci. 2008;11:476&#x2013;487.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2556874</ArticleId><ArticleId IdType="pubmed">18344994</ArticleId></ArticleIdList></Reference><Reference><Citation>Reisberg B, Doody R, St&#xf6;ffler A, Schmitt F, Ferris S, M&#xf6;bius HJ. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348:1333&#x2013;1341.</Citation><ArticleIdList><ArticleId IdType="pubmed">12672860</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogawski MA. Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines. Trends Pharmacol Sci. 1993;14:325&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pubmed">7504360</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogawski MA, Wenk GL. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug Rev. 2003;9:275&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741669</ArticleId><ArticleId IdType="pubmed">14530799</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenmund C, Clements JD, Westbrook GL. Nonuniform probability of glutamate release at a hippocampal synapse. Science. 1993;262:754&#x2013;757.</Citation><ArticleIdList><ArticleId IdType="pubmed">7901909</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothman SM, Olney JW. Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann Neurol. 1986;19:105&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">2421636</ArticleId></ArticleIdList></Reference><Reference><Citation>Segal MM. Epileptiform activity in microcultures containing one excitatory hippocampal neuron. J Neurophysiol. 1991;65:761&#x2013;770.</Citation><ArticleIdList><ArticleId IdType="pubmed">1646871</ArticleId></ArticleIdList></Reference><Reference><Citation>Segal MM, Furshpan EJ. Epileptiform activity in microcultures containing small numbers of hippocampal neurons. J Neurophysiol. 1990;64:1390&#x2013;1399.</Citation><ArticleIdList><ArticleId IdType="pubmed">2283535</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291:317&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">14734594</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas CG, Miller AJ, Westbrook GL. Synaptic and extrasynaptic NMDA receptor NR2 subunits in cultured hippocampal neurons. J Neurophysiol. 2006;95:1727&#x2013;1734.</Citation><ArticleIdList><ArticleId IdType="pubmed">16319212</ArticleId></ArticleIdList></Reference><Reference><Citation>Wesemann W, Sturm G, F&#xfc;nfgeld EW. Distribution of metabolism of the potential anti-parkinson drug memantine in the human. J Neural Transm Suppl. 1980:143&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pubmed">6933219</ArticleId></ArticleIdList></Reference><Reference><Citation>Wrighton DC, Baker EJ, Chen PE, Wyllie DJ. Mg2+ and memantine block of rat recombinant NMDA receptors containing chimeric NR2A/2D subunits expressed in Xenopus laevis oocytes. J Physiol. 2008;586:211&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2375557</ArticleId><ArticleId IdType="pubmed">17962329</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyllie DJ, Chen PE. Taking the time to study competitive antagonism. Br J Pharmacol. 2007;150:541&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2189774</ArticleId><ArticleId IdType="pubmed">17245371</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeevalk GD, Nicklas WJ. Evidence that the loss of the voltage-dependent Mg2+ block at the N-methyl-d-aspartate receptor underlies receptor activation during inhibition of neuronal metabolism. J Neurochem. 1992;59:1211&#x2013;1220.</Citation><ArticleIdList><ArticleId IdType="pubmed">1402878</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20720189</PMID><DateCompleted><Year>2010</Year><Month>10</Month><Day>08</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>75</Volume><Issue>12</Issue><PubDate><Year>2010</Year><Month>Sep</Month><Day>21</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease.</ArticleTitle><Pagination><StartPage>1055</StartPage><EndPage>1061</EndPage><MedlinePgn>1055-61</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0b013e3181f39a78</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Cognitive decline associated with Parkinson disease (PD) is common and highly disabling. Biomarkers that help identify patients at risk for cognitive decline would be useful additions to the clinical management of the disease.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 45 patients with PD were enrolled in this prospective cohort study and had at least 1 yearly longitudinal follow-up evaluation. CSF was collected at baseline and cognition was assessed at baseline and follow-up visits using the Mattis Dementia Rating Scale (DRS-2). CSF was tested for amyloid &#x3b2; 1-42 (A&#x3b2;(1-42)), p-tau(181p), and total tau levels using the Luminex xMAP platform. Mixed linear models were used to test for associations between baseline CSF biomarker levels and change in cognition over time.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Lower baseline CSF A&#x3b2;(1-42) was associated with more rapid cognitive decline. Subjects with CSF A&#x3b2;(1-42) levels &#x2264;192 pg/mL declined an average of 5.85 (95% confidence interval 2.11-9.58, p = 0.002) points per year more rapidly on the DRS-2 than subjects above that cutoff, after adjustment for age, disease duration, and baseline cognitive status. CSF total tau and p-tau(181p) levels were not significantly associated with cognitive decline.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Reduced CSF A&#x3b2;(1-42) was an independent predictor of cognitive decline in patients with PD. This observation is consistent with previous research showing that Alzheimer disease pathology contributes to cognitive impairment in PD. This biomarker may provide clinically useful prognostic information, particularly if combined with other risk factors for cognitive impairment in PD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Siderowf</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, 330 South 9th Street, Second Floor, Philadelphia, PA 19107, USA. andrew.siderowf@uphs.upenn.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>S X</ForeName><Initials>SX</Initials></Author><Author ValidYN="Y"><LastName>Hurtig</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Weintraub</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Duda</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Chen-Plotkin</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>L M</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Van Deerlin</LastName><ForeName>V</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>J Q</ForeName><Initials>JQ</Initials></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>C</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01NS065087</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS44266</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U10 NS0444451</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS053488</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS053488-01</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R43NS0636071</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08AG033101</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 MH067894</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U10 NS044451-023</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NS41265-01</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS053488</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>08</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2010 Sep 21;75(12):1036-7. doi: 10.1212/WNL.0b013e3181f6f272.</RefSource><PMID Version="1">20739641</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>9</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20720189</ArticleId><ArticleId IdType="pmc">PMC2942062</ArticleId><ArticleId IdType="doi">10.1212/WNL.0b013e3181f39a78</ArticleId><ArticleId IdType="pii">WNL.0b013e3181f39a78</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003;60:387&#x2013;392.</Citation><ArticleIdList><ArticleId IdType="pubmed">12633150</ArticleId></ArticleIdList></Reference><Reference><Citation>Cahn DA, Sullivan EV, Shear PK, Pfefferbaum A, Heit G, Silverberg G. Differential contributions of cognitive and motor component processes to physical and instrumental activities of daily living in Parkinson's disease. Arch Clin Neuropsychol 1998;13:575&#x2013;583.</Citation><ArticleIdList><ArticleId IdType="pubmed">14590618</ArticleId></ArticleIdList></Reference><Reference><Citation>Aarsland D, Larsen JP, Karlsen K, Lim NG, Tandberg E. Mental symptoms in Parkinson's disease are important contributors to caregiver distress. Int J Geriatr Psychiatry 1999;14:866&#x2013;874.</Citation><ArticleIdList><ArticleId IdType="pubmed">10521886</ArticleId></ArticleIdList></Reference><Reference><Citation>Buter TC, van den Hout A, Matthews FE, Larsen JP, Brayne C, Aarsland D. Dementia and survival in Parkinson disease: a 12-year population study. Neurology 2008;70:1017&#x2013;1022.</Citation><ArticleIdList><ArticleId IdType="pubmed">18362281</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y, Marder K, Tang MX, Mayeux R. Antecedent clinical features associated with dementia in Parkinson's disease. Neurology 1993;43:1690&#x2013;1692.</Citation><ArticleIdList><ArticleId IdType="pubmed">8414013</ArticleId></ArticleIdList></Reference><Reference><Citation>Uc EY, McDermott MP, Marder KS, et al. Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort. Neurology 2009;73:1469&#x2013;1477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2779004</ArticleId><ArticleId IdType="pubmed">19884574</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009;65:403&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>Emre M, Aarsland D, Brown R, Burn D, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007;22:1689&#x2013;1707.</Citation><ArticleIdList><ArticleId IdType="pubmed">17542011</ArticleId></ArticleIdList></Reference><Reference><Citation>Bibl M, Mollenhauer B, Esselmann H, et al. CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain 2006;129:1177&#x2013;1187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5403412</ArticleId><ArticleId IdType="pubmed">16600985</ArticleId></ArticleIdList></Reference><Reference><Citation>Compta Y, Marti MJ, Ibarretxe-Bilbao N, et al. Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease. Mov Disord 2009;24:2203&#x2013;2210.</Citation><ArticleIdList><ArticleId IdType="pubmed">19795497</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes AJ, Daniel SE, Lees AJ. The clinical features of Parkinson's disease in 100 histologically proven cases. Adv Neurol 1993;60:595&#x2013;599.</Citation><ArticleIdList><ArticleId IdType="pubmed">8420197</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863&#x2013;1872.</Citation><ArticleIdList><ArticleId IdType="pubmed">16237129</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattis S. Dementia Rating Scale. Odessa, FL: Psychological Assessment Resources; 1988.</Citation></Reference><Reference><Citation>Brown GG, Rahill AA, Gorell JM, et al. Validity of the Dementia Rating Scale in assessing cognitive function in Parkinson's disease. J Geriatr Psychiatry Neurol 1999;12:180&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">10616865</ArticleId></ArticleIdList></Reference><Reference><Citation>Llebaria G, Pagonabarraga J, Kulisevsky J, et al. Cut-off score of the Mattis Dementia Rating Scale for screening dementia in Parkinson's disease. Mov Disord 2009;23:1546&#x2013;1550.</Citation><ArticleIdList><ArticleId IdType="pubmed">18546326</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pubmed">6067254</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson A, Vanderstichele H, Andreasen N, et al. Simultaneous measurement of &#x3b2;-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem 2005;51:336&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pubmed">15563479</ArticleId></ArticleIdList></Reference><Reference><Citation>Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982;38:963&#x2013;974.</Citation><ArticleIdList><ArticleId IdType="pubmed">7168798</ArticleId></ArticleIdList></Reference><Reference><Citation>Galasko D, Chang L, Motter R, et al. High cerebrospinal fluid tau and low amyloid &#x3b2;42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 1998;55:937&#x2013;945.</Citation><ArticleIdList><ArticleId IdType="pubmed">9678311</ArticleId></ArticleIdList></Reference><Reference><Citation>Samuels SC, Silverman JM, Marin DB, et al. CSF beta-amyloid, cognition, and APOE genotype in Alzheimer's disease. Neurology 1999;52:547.</Citation><ArticleIdList><ArticleId IdType="pubmed">10025785</ArticleId></ArticleIdList></Reference><Reference><Citation>Kester MI, van der Vlies AE, Blankenstein MA, et al. CSF biomarkers predict rate of cognitive decline in Alzheimer disease. Neurology 2009;73:1353&#x2013;1358.</Citation><ArticleIdList><ArticleId IdType="pubmed">19858456</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Schraen-Maschke S, Richard F, et al. Association of plasma amyloid beta with risk of dementia: the prospective Three-City Study. Neurology 2009;73:847&#x2013;853.</Citation><ArticleIdList><ArticleId IdType="pubmed">19752451</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark CM, Xie S, Chittams J, et al. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol 2003;60:1696&#x2013;1702.</Citation><ArticleIdList><ArticleId IdType="pubmed">14676043</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Korecka M, Clark CM, Lee VM, Trojanowski JQ. Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Discov 2007;6:295&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">17347655</ArticleId></ArticleIdList></Reference><Reference><Citation>Motter R, Vigo-Pelfrey C, Kholodenko D, et al. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 1995;38:643&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pubmed">7574461</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreasen N, Minthon L, Davidsson P, et al. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 2001;58:373&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pubmed">11255440</ArticleId></ArticleIdList></Reference><Reference><Citation>Mollenhauer B, Bibl M, Trenkwalder C, et al. Follow-up investigations in cerebrospinal fluid of patients with dementia with Lewy bodies and Alzheimer's disease. J Neural Transm 2005;112:933&#x2013;948.</Citation><ArticleIdList><ArticleId IdType="pubmed">15937638</ArticleId></ArticleIdList></Reference><Reference><Citation>Mollenhauer B, Trenkwalder C. Neurochemical biomarkers in the differential diagnosis of movement disorders. Mov Disord 2009;24:1411&#x2013;1426.</Citation><ArticleIdList><ArticleId IdType="pubmed">19412961</ArticleId></ArticleIdList></Reference><Reference><Citation>Lippa CF, Duda JE, Grossman M, et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 2007;68:812&#x2013;819.</Citation><ArticleIdList><ArticleId IdType="pubmed">17353469</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Nat Acad Sci USA 1993;90:1977&#x2013;1981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC46003</ArticleId><ArticleId IdType="pubmed">8446617</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X, Chen P, Kaufer DI, Troster AI, Poole C. Apolipoprotein E and dementia in Parkinson disease: a meta-analysis. Arch Neurol 2006;63:189&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">16476806</ArticleId></ArticleIdList></Reference><Reference><Citation>Prince JA, Zetterberg H, Andreasen N, Marcusson J, Blennow K. APOE &#x3b5;4 allele is associated with reduced cerebrospinal fluid levels of A&#x3b2;42. Neurology 2004;62:2116&#x2013;2118.</Citation><ArticleIdList><ArticleId IdType="pubmed">15184629</ArticleId></ArticleIdList></Reference><Reference><Citation>Kester MI, Verwey NA, van Elk EJ, Blankenstein MA, Scheltens P, van der Flier WM. Progression from MCI to AD: predictive value of CSF A&#x3b2;42 is modified by APOE genotype. Neurobiol Aging Epub 2009 Sep 10.</Citation><ArticleIdList><ArticleId IdType="pubmed">19748159</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams-Gray CH, Evans JR, Goris A, et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 2009;132:2958&#x2013;2969.</Citation><ArticleIdList><ArticleId IdType="pubmed">19812213</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustafson DR, Skoog I, Rosengren L, Zetterberg H, Blennow K. Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women. J Neurol Neurosurg Psychiatry 2007;78:461&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2117838</ArticleId><ArticleId IdType="pubmed">17098843</ArticleId></ArticleIdList></Reference><Reference><Citation>El Agnaf OM, Salem SA, Paleologou KE, et al. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J 2006;20:419&#x2013;425.</Citation><ArticleIdList><ArticleId IdType="pubmed">16507759</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20729148</PMID><DateCompleted><Year>2010</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-4465</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>10</Issue><PubDate><Year>2010</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The Lancet. Neurology</Title><ISOAbbreviation>Lancet Neurol</ISOAbbreviation></Journal><ArticleTitle>Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial.</ArticleTitle><Pagination><StartPage>969</StartPage><EndPage>977</EndPage><MedlinePgn>969-77</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1474-4422(10)70194-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Previous studies have suggested that patients with Lewy-body-related dementias might benefit from treatment with the N-methyl D-aspartate receptor antagonist memantine, but further data are needed. Therefore, the efficacy and safety of memantine were investigated in patients with mild to moderate Parkinson's disease dementia (PDD) or dementia with Lewy bodies (DLB).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients (&#x2265;50 years of age) with mild to moderate PDD or DLB were recruited from 30 specialist centres in Austria, France, Germany, the UK, Greece, Italy, Spain, and Turkey. They were randomly assigned to placebo or memantine (20 mg per day) according to a computer-generated list. Patients and all physicians who had contact with them were masked to treatment assignment. No primary endpoint was defined. Safety analyses were done for all patients who took at least one dose of memantine or placebo, and efficacy analyses were done for all patients who had at least one valid postbaseline assessment. This trial is registered with ClinicalTrials.gov, number NCT00855686.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">Of the 199 patients randomly assigned to treatment, 34 with DLB and 62 with PDD were given memantine, and 41 with DLB and 58 with PDD were given placebo. 159 (80%) patients completed the study: 80 in the memantine group and 79 in the placebo group. 93 patients treated with memantine and 97 patients treated with placebo were included in the efficacy analysis. At week 24, patients with DLB who received memantine showed greater improvement according to Alzheimer's disease cooperative study (ADCS)-clinical global impression of change scores than did those who received placebo (mean change from baseline 3&#xb7;3 vs 3&#xb7;9, respectively, difference -0&#xb7;6 [95% CI -1&#xb7;2 to -0&#xb7;1]; p=0&#xb7;023). No significant differences were noted between the two treatments in patients with PDD (3&#xb7;6 with memantine vs 3&#xb7;8 with placebo, -0&#xb7;1 [-0&#xb7;6 to 0&#xb7;3]; p=0&#xb7;576) or in the total population (3&#xb7;5 with memantine vs 3&#xb7;8 with placebo, -0&#xb7;3 [-0&#xb7;7 to 0&#xb7;1]; p=0&#xb7;120). Neuropsychiatric-inventory scores showed significantly greater improvement in the memantine group than in the placebo group (-4&#xb7;3 vs 1&#xb7;7, respectively, -5&#xb7;9 [-11&#xb7;6 to -0&#xb7;2]; p=0&#xb7;041) in patients with DLB, but not in those with PDD (-1&#xb7;6 vs -0&#xb7;1, respectively, -1&#xb7;4 [-5&#xb7;9 to 3&#xb7;0]; p=0&#xb7;522) or in the total patient population (-2&#xb7;6 vs 0&#xb7;4, respectively, -2&#xb7;9 [-6&#xb7;3 to 0&#xb7;5]; p=0&#xb7;092). In most of the cognitive test scores, ADCS-activities of daily living, and Zarit caregiver burden scores, there were no significant differences between the two treatment groups in any of the study populations. The incidence of adverse events and number of discontinuations due to adverse events were similar in the two groups. The most common serious adverse events were stroke (n=3 in memantine group), falls (n=2 in memantine group; n=1 in placebo group), and worsening of dementia (n=2 in memantine group).</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Memantine seems to improve global clinical status and behavioural symptoms of patients with mild to moderate DLB, and might be an option for treatment of these patients.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">Lundbeck.</AbstractText><CopyrightInformation>Copyright &#xa9; 2010 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Emre</LastName><ForeName>Murat</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey. muratemre@superonline.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsolaki</LastName><ForeName>Magda</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Bonuccelli</LastName><ForeName>Ubaldo</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Dest&#xe9;e</LastName><ForeName>Alain</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Tolosa</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Kutzelnigg</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Ceballos-Baumann</LastName><ForeName>Andr&#xe9;s</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Zdravkovic</LastName><ForeName>Slobodan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Bladstr&#xf6;m</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Roy</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><CollectiveName>11018 Study Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00855686</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>08</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Neurol</MedlineTA><NlmUniqueID>101139309</NlmUniqueID><ISSNLinking>1474-4422</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>W8O17SJF3T</RegistryNumber><NameOfSubstance UI="D008559">Memantine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2010 Oct;9(10):943-5. doi: 10.1016/S1474-4422(10)70208-8.</RefSource><PMID Version="1">20729149</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000058" MajorTopicYN="N">Accidental Falls</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N" Type="Geographic">Europe</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D038622" MajorTopicYN="N">Internationality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008559" MajorTopicYN="N">Memantine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012894" MajorTopicYN="N">Sleep Stages</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014421" MajorTopicYN="N" Type="Geographic">Turkey</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Schmitz</LastName><ForeName>Margot</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Poewe</LastName><ForeName>Werner</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Verin</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Destee</LastName><ForeName>Alain</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Damier</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Viallet</LastName><ForeName>Francois</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ceballos-Baumann</LastName><ForeName>Andres</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boehringer</LastName><ForeName>Johannes</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albrecht</LastName><ForeName>Walter</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tsolaki</LastName><ForeName>Magda</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stathis</LastName><ForeName>Pantelis</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mitsikostas</LastName><ForeName>Demos</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bonuccelli</LastName><ForeName>Ubaldo</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albanese</LastName><ForeName>Alberto</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zappia</LastName><ForeName>Mario</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scarpini</LastName><ForeName>Chiara</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tolosa</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buongiorno</LastName><ForeName>Maria Teresa</ForeName><Initials>MT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kulisevsky</LastName><ForeName>Jaume</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vivancos</LastName><ForeName>Francisco</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Linazasoro</LastName><ForeName>Gurutz</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salvador</LastName><ForeName>Carlos</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gil</LastName><ForeName>Eulogio</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Emre</LastName><ForeName>Murat</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cakmur</LastName><ForeName>Raif</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elibol</LastName><ForeName>Bulent</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tokcaer</LastName><ForeName>Ayse Bora</ForeName><Initials>AB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jones</LastName><ForeName>Roy</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barker</LastName><ForeName>Roger</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burn</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Castleton</LastName><ForeName>Beverly</ForeName><Initials>B</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>10</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20729148</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(10)70194-0</ArticleId><ArticleId IdType="pii">S1474-4422(10)70194-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20733075</PMID><DateCompleted><Year>2010</Year><Month>10</Month><Day>07</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>107</Volume><Issue>36</Issue><PubDate><Year>2010</Year><Month>Sep</Month><Day>07</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>{alpha}-Synuclein gene duplication impairs reward learning.</ArticleTitle><Pagination><StartPage>15992</StartPage><EndPage>15994</EndPage><MedlinePgn>15992-4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1006068107</ELocationID><Abstract><AbstractText>alpha-Synuclein (SNCA) plays an important role in the regulation of dopaminergic neurotransmission and neurodegeneration in Parkinson disease. We investigated reward and punishment learning in asymptomatic carriers of a rare SNCA gene duplication who were healthy siblings of patients with Parkinson disease. Results revealed that healthy SNCA duplication carriers displayed impaired reward and intact punishment learning compared with noncarriers. These results demonstrate that a copy number variation of the SNCA gene is associated with selective impairments on reinforcement learning in asymptomatic carriers without the motor symptoms of Parkinson disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>K&#xe9;ri</LastName><ForeName>Szabolcs</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Physiology, University of Szeged, Hungary. szkeri@phys.szote.u-szeged.hu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moustafa</LastName><ForeName>Ahmed A</ForeName><Initials>AA</Initials></Author><Author ValidYN="Y"><LastName>Myers</LastName><ForeName>Catherine E</ForeName><Initials>CE</Initials></Author><Author ValidYN="Y"><LastName>Benedek</LastName><ForeName>Gy&#xf6;rgy</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Gluck</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS047434</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS047434-02</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>08</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020440" MajorTopicYN="Y">Gene Duplication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009042" MajorTopicYN="Y">Motivation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>3</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20733075</ArticleId><ArticleId IdType="pmc">PMC2936644</ArticleId><ArticleId IdType="doi">10.1073/pnas.1006068107</ArticleId><ArticleId IdType="pii">1006068107</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Singleton AB, et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science. 2003;302:841.</Citation><ArticleIdList><ArticleId IdType="pubmed">14593171</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross OA, et al. Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann Neurol. 2008;63:743&#x2013;750.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3850281</ArticleId><ArticleId IdType="pubmed">18571778</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn TB, et al. alpha-Synuclein gene duplication is present in sporadic Parkinson disease. Neurology. 2008;70:43&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">17625105</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishioka K, et al. Expanding the clinical phenotype of SNCA duplication carriers. Mov Disord. 2009;24:1811&#x2013;1819.</Citation><ArticleIdList><ArticleId IdType="pubmed">19562770</ArticleId></ArticleIdList></Reference><Reference><Citation>Oksman M, Tanila H, Yavich L. Brain reward in the absence of alpha-synuclein. Neuroreport. 2006;17:1191&#x2013;1194.</Citation><ArticleIdList><ArticleId IdType="pubmed">16837852</ArticleId></ArticleIdList></Reference><Reference><Citation>Yavich L, et al. Locomotor activity and evoked dopamine release are reduced in mice overexpressing A30P-mutated human alpha-synuclein. Neurobiol Dis. 2005;20:303&#x2013;313.</Citation><ArticleIdList><ArticleId IdType="pubmed">16242637</ArticleId></ArticleIdList></Reference><Reference><Citation>Cools R, et al. Striatal dopamine predicts outcome-specific reversal learning and its sensitivity to dopaminergic drug administration. J Neurosci. 2009;29:1538&#x2013;1543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2940719</ArticleId><ArticleId IdType="pubmed">19193900</ArticleId></ArticleIdList></Reference><Reference><Citation>Delgado MR, Miller MM, Inati S, Phelps EA. An fMRI study of reward-related probability learning. Neuroimage. 2005;24:862&#x2013;873.</Citation><ArticleIdList><ArticleId IdType="pubmed">15652321</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xf3;di N, et al. Reward-learning and the novelty-seeking personality: A between- and within-subjects study of the effects of dopamine agonists on young Parkinson's patients. Brain. 2009;132:2385&#x2013;2395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2766178</ArticleId><ArticleId IdType="pubmed">19416950</ArticleId></ArticleIdList></Reference><Reference><Citation>Frank MJ, Seeberger LC, O'reilly RC. By carrot or by stick: Cognitive reinforcement learning in parkinsonism. Science. 2004;306:1940&#x2013;1943.</Citation><ArticleIdList><ArticleId IdType="pubmed">15528409</ArticleId></ArticleIdList></Reference><Reference><Citation>Cools R, Altamirano L, D'Esposito M. Reversal learning in Parkinson's disease depends on medication status and outcome valence. Neuropsychologia. 2006;44:1663&#x2013;1673.</Citation><ArticleIdList><ArticleId IdType="pubmed">16730032</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsumoto M, Hikosaka O. Two types of dopamine neuron distinctly convey positive and negative motivational signals. Nature. 2009;459:837&#x2013;841.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2739096</ArticleId><ArticleId IdType="pubmed">19448610</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaghloul KA, et al. Human substantia nigra neurons encode unexpected financial rewards. Science. 2009;323:1496&#x2013;1499.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2839450</ArticleId><ArticleId IdType="pubmed">19286561</ArticleId></ArticleIdList></Reference><Reference><Citation>Nemani VM, et al. Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron. 2010;65:66&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3119527</ArticleId><ArticleId IdType="pubmed">20152114</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state.&#x201d; A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D. Wechsler Adult Intelligence Scale&#x2014;Revised Manual. New York: Psychological Corporation; 1981.</Citation></Reference><Reference><Citation>Cirino PT, et al. Measuring socioeconomic status: Reliability and preliminary validity for different approaches. Assessment. 2002;9:145&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pubmed">12066829</ArticleId></ArticleIdList></Reference><Reference><Citation>First MB, Gibbon M, Spitzer RL, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV) Washington, DC: American Psychiatric Press; 1996.</Citation></Reference><Reference><Citation>Fuchs J, et al. Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain. FASEB J. 2008;22:1327&#x2013;1334.</Citation><ArticleIdList><ArticleId IdType="pubmed">18162487</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20739292</PMID><DateCompleted><Year>2011</Year><Month>02</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1083-351X</ISSN><JournalIssue CitedMedium="Internet"><Volume>285</Volume><Issue>47</Issue><PubDate><Year>2010</Year><Month>Nov</Month><Day>19</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Apolipoprotein A-I deficiency increases cerebral amyloid angiopathy and cognitive deficits in APP/PS1DeltaE9 mice.</ArticleTitle><Pagination><StartPage>36945</StartPage><EndPage>36957</EndPage><MedlinePgn>36945-57</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1074/jbc.M110.127738</ELocationID><Abstract><AbstractText>A hallmark of Alzheimer disease (AD) is the deposition of amyloid &#x3b2; (A&#x3b2;) in brain parenchyma and cerebral blood vessels, accompanied by cognitive decline. Previously, we showed that human apolipoprotein A-I (apoA-I) decreases A&#x3b2;(40) aggregation and toxicity. Here we demonstrate that apoA-I in lipidated or non-lipidated form prevents the formation of high molecular weight aggregates of A&#x3b2;(42) and decreases A&#x3b2;(42) toxicity in primary brain cells. To determine the effects of apoA-I on AD phenotype in vivo, we crossed APP/PS1&#x394;E9 to apoA-I(KO) mice. Using a Morris water maze, we demonstrate that the deletion of mouse Apoa-I exacerbates memory deficits in APP/PS1&#x394;E9 mice. Further characterization of APP/PS1&#x394;E9/apoA-I(KO) mice showed that apoA-I deficiency did not affect amyloid precursor protein processing, soluble A&#x3b2; oligomer levels, A&#x3b2; plaque load, or levels of insoluble A&#x3b2; in brain parenchyma. To examine the effect of Apoa-I deletion on cerebral amyloid angiopathy, we measured insoluble A&#x3b2; isolated from cerebral blood vessels. Our data show that in APP/PS1&#x394;E9/apoA-I(KO) mice, insoluble A&#x3b2;(40) is increased more than 10-fold, and A&#x3b2;(42) is increased 1.5-fold. The increased levels of deposited amyloid in the vessels of cortices and hippocampi of APP/PS1&#x394;E9/apoA-I(KO) mice, measured by X-34 staining, confirmed the results. Finally, we demonstrate that lipidated and non-lipidated apoA-I significantly decreased A&#x3b2; toxicity against brain vascular smooth muscle cells. We conclude that lack of apoA-I aggravates the memory deficits in APP/PS1&#x394;E9 mice in parallel to significantly increased cerebral amyloid angiopathy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lefterov</LastName><ForeName>Iliya</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Environmental and Occupational Health, University of Pittsburgh, Pittsburgh, Pennsylvania 15219, USA. iliyal@pitt.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fitz</LastName><ForeName>Nicholas F</ForeName><Initials>NF</Initials></Author><Author ValidYN="Y"><LastName>Cronican</LastName><ForeName>Andrea A</ForeName><Initials>AA</Initials></Author><Author ValidYN="Y"><LastName>Fogg</LastName><ForeName>Allison</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Lefterov</LastName><ForeName>Preslav</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Kodali</LastName><ForeName>Ravindra</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Wetzel</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Koldamova</LastName><ForeName>Radosveta</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG027973</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG031956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG031956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG027973</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>08</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016632">Apolipoprotein A-I</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>97C5T2UQ7J</RegistryNumber><NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016632" MajorTopicYN="N">Apolipoprotein A-I</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016657" MajorTopicYN="N">Cerebral Amyloid Angiopathy</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002784" MajorTopicYN="N">Cholesterol</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004622" MajorTopicYN="N">Embryo, Mammalian</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007124" MajorTopicYN="N">Immunoenzyme Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D032389" MajorTopicYN="N">Myocytes, Smooth Muscle</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017384" MajorTopicYN="N">Sequence Deletion</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>3</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>11</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20739292</ArticleId><ArticleId IdType="pmc">PMC2978623</ArticleId><ArticleId IdType="doi">10.1074/jbc.M110.127738</ArticleId><ArticleId IdType="pii">S0021-9258(20)46843-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alonzo N. C., Hyman B. T., Rebeck G. W., Greenberg S. M. (1998) J. Neuropathol. Exp. Neurol. 57, 353&#x2013;359</Citation><ArticleIdList><ArticleId IdType="pubmed">9600229</ArticleId></ArticleIdList></Reference><Reference><Citation>Bates K. A., Sohrabi H. R., Rodrigues M., Beilby J., Dhaliwal S. S., Taddei K., Criddle A., Wraith M., Howard M., Martins G., Paton A., Mehta P., Foster J. K., Martins I. J., Lautenschlager N. T., Mastaglia F. L., Laws S. M., Gandy S. E., Martins R. N. (2009) J. Alzheimers Dis. 17, 305&#x2013;318</Citation><ArticleIdList><ArticleId IdType="pubmed">19363264</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell R. D., Zlokovic B. V. (2009) Acta Neuropathol. 118, 103&#x2013;113</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2853006</ArticleId><ArticleId IdType="pubmed">19319544</ArticleId></ArticleIdList></Reference><Reference><Citation>Bieschke J., Russ J., Friedrich R. P., Ehrnhoefer D. E., Wobst H., Neugebauer K., Wanker E. E. (2010) Proc. Natl. Acad. Sci. U.S.A. 107, 7710&#x2013;7715</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2867908</ArticleId><ArticleId IdType="pubmed">20385841</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonarek M., Barberger-Gateau P., Letenneur L., Deschamps V., Iron A., Dubroca B., Dartigues J. F. (2000) Neuroepidemiology 19, 141&#x2013;148</Citation><ArticleIdList><ArticleId IdType="pubmed">10705232</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouwman F. H., Schoonenboom N. S., Verwey N. A., van Elk E. J., Kok A., Blankenstein M. A., Scheltens P., van der Flier W. M. (2009) Neurobiol. Aging 30, 1895&#x2013;1901</Citation><ArticleIdList><ArticleId IdType="pubmed">18403055</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos R. B., O'dell M. A., Parsadanian M., Taylor J. W., Harmony J. A., Bales K. R., Paul S. M., Aronow B. J., Holtzman D. M. (2002) Proc. Natl. Acad. Sci. U.S.A. 99, 10843&#x2013;10848</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125060</ArticleId><ArticleId IdType="pubmed">12145324</ArticleId></ArticleIdList></Reference><Reference><Citation>Dietschy J. M., Turley S. D. (2001) Curr. Opin. Lipidol. 12, 105&#x2013;112</Citation><ArticleIdList><ArticleId IdType="pubmed">11264981</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan A. M., Christopher E., Taylor J. W., Parsadanian M., Spinner M., Watson M., Fryer J. D., Wahrle S., Bales K. R., Paul S. M., Holtzman D. M. (2004) Am. J. Pathol. 165, 1413&#x2013;1422</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1618648</ArticleId><ArticleId IdType="pubmed">15466405</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan A. M., Younkin L. H., Morris J. C., Fryer J. D., Cole T. G., Younkin S. G., Holtzman D. M. (2000) Ann. Neurol. 48, 201&#x2013;210</Citation><ArticleIdList><ArticleId IdType="pubmed">10939571</ArticleId></ArticleIdList></Reference><Reference><Citation>Fillit H., Nash D. T., Rundek T., Zuckerman A. (2008) Am. J. Geriatr. Pharmacother. 6, 100&#x2013;118</Citation><ArticleIdList><ArticleId IdType="pubmed">18675769</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitz N. F., Cronican A., Pham T., Fogg A., Fauq A. H., Chapman R., Lefterov I., Koldamova R. (2010) J. Neurosci. 30, 6862&#x2013;6872</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2883862</ArticleId><ArticleId IdType="pubmed">20484628</ArticleId></ArticleIdList></Reference><Reference><Citation>Fryer J. D., Simmons K., Parsadanian M., Bales K. R., Paul S. M., Sullivan P. M., Holtzman D. M. (2005) J. Neurosci. 25, 2803&#x2013;2810</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725147</ArticleId><ArticleId IdType="pubmed">15772340</ArticleId></ArticleIdList></Reference><Reference><Citation>Glabe C. G. (2008) J. Biol. Chem. 283, 29639&#x2013;29643</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2573087</ArticleId><ArticleId IdType="pubmed">18723507</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawkes C. A., McLaurin J. (2009) Proc. Natl. Acad. Sci. U.S.A. 106, 1261&#x2013;1266</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2633563</ArticleId><ArticleId IdType="pubmed">19164591</ArticleId></ArticleIdList></Reference><Reference><Citation>Herzig M. C., Winkler D. T., Burgermeister P., Pfeifer M., Kohler E., Schmidt S. D., Danner S., Abramowski D., St&#xfc;rchler-Pierrat C., B&#xfc;rki K., van Duinen S. G., Maat-Schieman M. L., Staufenbiel M., Mathews P. M., Jucker M. (2004) Nat. Neurosci. 7, 954&#x2013;960</Citation><ArticleIdList><ArticleId IdType="pubmed">15311281</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu M. J., Sheu J. R., Lin C. H., Shen M. Y., Hsu C. Y. (2010) Biochim. Biophys. Acta 1800, 290&#x2013;296</Citation><ArticleIdList><ArticleId IdType="pubmed">19698762</ArticleId></ArticleIdList></Reference><Reference><Citation>Jord&#xe1;n J., Galindo M. F., Miller R. J. (1997) J. Neurochem. 68, 1612&#x2013;1621</Citation><ArticleIdList><ArticleId IdType="pubmed">9084433</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawano M., Kawakami M., Otsuka M., Yashima H., Yaginuma T., Ueki A. (1995) Clin. Chim. Acta 239, 209&#x2013;211</Citation><ArticleIdList><ArticleId IdType="pubmed">8542660</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R., Head E., Thompson J. L., McIntire T. M., Milton S. C., Cotman C. W., Glabe C. G. (2003) Science 300, 486&#x2013;489</Citation><ArticleIdList><ArticleId IdType="pubmed">12702875</ArticleId></ArticleIdList></Reference><Reference><Citation>Kivipelto M., Helkala E. L., H&#xe4;nninen T., Laakso M. P., Hallikainen M., Alhainen K., Soininen H., Tuomilehto J., Nissinen A. (2001) Neurology 56, 1683&#x2013;1689</Citation><ArticleIdList><ArticleId IdType="pubmed">11425934</ArticleId></ArticleIdList></Reference><Reference><Citation>Kivipelto M., Helkala E. L., Laakso M. P., H&#xe4;nninen T., Hallikainen M., Alhainen K., Soininen H., Tuomilehto J., Nissinen A. (2001) BMJ 322, 1447&#x2013;1451</Citation><ArticleIdList><ArticleId IdType="pmc">PMC32306</ArticleId><ArticleId IdType="pubmed">11408299</ArticleId></ArticleIdList></Reference><Reference><Citation>Kivipelto M., Laakso M. P., Tuomilehto J., Nissinen A., Soininen H. (2002) CNS Drugs 16, 435&#x2013;444</Citation><ArticleIdList><ArticleId IdType="pubmed">12056919</ArticleId></ArticleIdList></Reference><Reference><Citation>Kivipelto M., Ngandu T., Fratiglioni L., Viitanen M., K&#xe5;reholt I., Winblad B., Helkala E. L., Tuomilehto J., Soininen H., Nissinen A. (2005) Arch. Neurol. 62, 1556&#x2013;1560</Citation><ArticleIdList><ArticleId IdType="pubmed">16216938</ArticleId></ArticleIdList></Reference><Reference><Citation>Koldamova R., Staufenbiel M., Lefterov I. (2005) J. Biol. Chem. 280, 43224&#x2013;43235</Citation><ArticleIdList><ArticleId IdType="pubmed">16207713</ArticleId></ArticleIdList></Reference><Reference><Citation>Koldamova R. P., Lefterov I. M., Ikonomovic M. D., Skoko J., Lefterov P. I., Isanski B. A., DeKosky S. T., Lazo J. S. (2003) J. Biol. Chem. 278, 13244&#x2013;13256</Citation><ArticleIdList><ArticleId IdType="pubmed">12547833</ArticleId></ArticleIdList></Reference><Reference><Citation>Koldamova R. P., Lefterov I. M., Lefterova M. I., Lazo J. S. (2001) Biochemistry 40, 3553&#x2013;3560</Citation><ArticleIdList><ArticleId IdType="pubmed">11297421</ArticleId></ArticleIdList></Reference><Reference><Citation>Koldamova R. P., Lefterov I. M., Staufenbiel M., Wolfe D., Huang S., Glorioso J. C., Walter M., Roth M. G., Lazo J. S. (2005) J. Biol. Chem. 280, 4079&#x2013;4088</Citation><ArticleIdList><ArticleId IdType="pubmed">15557325</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo Y. M., Emmerling M. R., Bisgaier C. L., Essenburg A. D., Lampert H. C., Drumm D., Roher A. E. (1998) Biochem. Biophys. Res. Commun. 252, 711&#x2013;715</Citation><ArticleIdList><ArticleId IdType="pubmed">9837771</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuriyama M., Takahashi K., Yamano T., Hokezu Y., Togo S., Osame M., Igakura T. (1994) Jpn. J. Psychiatry Neurol. 48, 589&#x2013;593</Citation><ArticleIdList><ArticleId IdType="pubmed">7891423</ArticleId></ArticleIdList></Reference><Reference><Citation>LaDu M. J., Lukens J. R., Reardon C. A., Getz G. S. (1997) J. Neurosci. Res. 49, 9&#x2013;18</Citation><ArticleIdList><ArticleId IdType="pubmed">9211985</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefterov I., Bookout A., Wang Z., Staufenbiel M., Mangelsdorf D., Koldamova R. (2007) Mol. Neurodegener. 2, 20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2214725</ArticleId><ArticleId IdType="pubmed">17953774</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefterov I., Fitz N. F., Cronican A., Lefterov P., Staufenbiel M., Koldamova R. (2009) ASN Neuro. 1, 65&#x2013;76</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2695585</ArticleId><ArticleId IdType="pubmed">19570031</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesser G., Kandiah K., Libow L. S., Likourezos A., Breuer B., Marin D., Mohs R., Haroutunian V., Neufeld R. (2001) Dement. Geriatr. Cogn. Disord. 12, 138&#x2013;145</Citation><ArticleIdList><ArticleId IdType="pubmed">11173887</ArticleId></ArticleIdList></Reference><Reference><Citation>Linsel-Nitschke P., Tall A. R. (2005) Nat. Rev. Drug Discov. 4, 193&#x2013;205</Citation><ArticleIdList><ArticleId IdType="pubmed">15738977</ArticleId></ArticleIdList></Reference><Reference><Citation>Maezawa I., Jin L. W., Woltjer R. L., Maeda N., Martin G. M., Montine T. J., Montine K. S. (2004) J. Neurochem. 91, 1312&#x2013;1321</Citation><ArticleIdList><ArticleId IdType="pubmed">15584908</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsubara E., Soto C., Governale S., Frangione B., Ghiso J. (1996) Biochem. J. 316, 671&#x2013;679</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1217400</ArticleId><ArticleId IdType="pubmed">8687416</ArticleId></ArticleIdList></Reference><Reference><Citation>Merched A., Xia Y., Visvikis S., Serot J. M., Siest G. (2000) Neurobiol. Aging 21, 27&#x2013;30</Citation><ArticleIdList><ArticleId IdType="pubmed">10794845</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Nuallain B., Thakur A. K., Williams A. D., Bhattacharyya A. M., Chen S., Thiagarajan G., Wetzel R. (2006) Methods Enzymol. 413, 34&#x2013;74</Citation><ArticleIdList><ArticleId IdType="pubmed">17046390</ArticleId></ArticleIdList></Reference><Reference><Citation>Panzenboeck U., Balazs Z., Sovic A., Hrzenjak A., Levak-Frank S., Wintersperger A., Malle E., Sattler W. (2002) J. Biol. Chem. 277, 42781&#x2013;42789</Citation><ArticleIdList><ArticleId IdType="pubmed">12202492</ArticleId></ArticleIdList></Reference><Reference><Citation>Paula-Lima A. C., Tricerri M. A., Brito-Moreira J., Bomfim T. R., Oliveira F. F., Magdesian M. H., Grinberg L. T., Panizzutti R., Ferreira S. T. (2009) Int. J. Biochem. Cell Biol. 41, 1361&#x2013;1370</Citation><ArticleIdList><ArticleId IdType="pubmed">19130896</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitas R. E., Boyles J. K., Lee S. H., Hui D., Weisgraber K. H. (1987) J. Biol. Chem. 262, 14352&#x2013;14360</Citation><ArticleIdList><ArticleId IdType="pubmed">3115992</ArticleId></ArticleIdList></Reference><Reference><Citation>Saczynski J. S., White L., Peila R. L., Rodriguez B. L., Launer L. J. (2007) Am. J. Epidemiol. 165, 985&#x2013;992</Citation><ArticleIdList><ArticleId IdType="pubmed">17298957</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe D. J. (2008) Behav. Brain Res. 192, 106&#x2013;113</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2601528</ArticleId><ArticleId IdType="pubmed">18359102</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter W. J., Weisgraber K. H., Huang D. Y., Dong L. M., Salvesen G. S., Pericak-Vance M., Schmechel D., Saunders A. M., Goldgaber D., Roses A. D. (1993) Proc. Natl. Acad. Sci. U.S.A. 90, 8098&#x2013;8102</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47295</ArticleId><ArticleId IdType="pubmed">8367470</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka M., Koyama M., Dhanasekaran P., Nguyen D., Nickel M., Lund-Katz S., Saito H., Phillips M. C. (2008) Biochemistry 47, 2172&#x2013;2180</Citation><ArticleIdList><ArticleId IdType="pubmed">18205410</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahrle S. E., Jiang H., Parsadanian M., Legleiter J., Han X., Fryer J. D., Kowalewski T., Holtzman D. M. (2004) J. Biol. Chem. 279, 40987&#x2013;40993</Citation><ArticleIdList><ArticleId IdType="pubmed">15269217</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiler-G&#xfc;ttler H., Sommerfeldt M., Papandrikopoulou A., Mischek U., Bonitz D., Frey A., Grupe M., Scheerer J., Gassen H. G. (1990) J. Neurochem. 54, 444&#x2013;450</Citation><ArticleIdList><ArticleId IdType="pubmed">2105375</ArticleId></ArticleIdList></Reference><Reference><Citation>Weller R. O., Boche D., Nicoll J. A. (2009) Acta Neuropathol. 118, 87&#x2013;102</Citation><ArticleIdList><ArticleId IdType="pubmed">19234858</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock D. M., Gordon M. N., Morgan D. (2006) Nat. Protoc. 1, 1591&#x2013;1595</Citation><ArticleIdList><ArticleId IdType="pubmed">17406451</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J. W., Breydo L., Isas J. M., Lee J., Kuznetsov Y. G., Langen R., Glabe C. (2010) J. Biol. Chem. 285, 6071&#x2013;6079</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2825401</ArticleId><ArticleId IdType="pubmed">20018889</ArticleId></ArticleIdList></Reference><Reference><Citation>Yvan-Charvet L., Wang N., Tall A. R. (2010) Arterioscler. Thromb. Vasc. Biol. 30, 139&#x2013;143</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2812788</ArticleId><ArticleId IdType="pubmed">19797709</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis T. L., Cao D., Lu H., Mans R. A., Su Y. R., Jungbauer L., Linton M. F., Fazio S., LaDu M. J., Li L. (2010) J. Biol. Chem. 285, 36958&#x2013;36968</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2978624</ArticleId><ArticleId IdType="pubmed">20847045</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20739545</PMID><DateCompleted><Year>2010</Year><Month>09</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>34</Issue><PubDate><Year>2010</Year><Month>Aug</Month><Day>25</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Impaired orthotopic glioma growth and vascularization in transgenic mouse models of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>11251</StartPage><EndPage>11258</EndPage><MedlinePgn>11251-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.2586-10.2010</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is the most common form of dementia among the aging population and is characterized pathologically by the progressive intracerebral accumulation of beta-amyloid (Abeta) peptides and neurofibrillary tangles. The level of proangiogenic growth factors and inflammatory mediators with proangiogenic activity is known to be elevated in AD brains which has led to the supposition that the cerebrovasculature of AD patients is in a proangiogenic state. However, angiogenesis depends on the balance between proangiogenic and antiangiogenic factors and the brains of AD patients also show an accumulation of endostatin and Abeta peptides which have been shown to be antiangiogenic. To determine whether angiogenesis is compromised in the brains of two transgenic mouse models of AD overproducing Abeta peptides (Tg APPsw and Tg PS1/APPsw mice), we assessed the growth and vascularization of orthotopically implanted murine gliomas since they require a high degree of angiogenesis to sustain their growth. Our data reveal that intracranial tumor growth and angiogenesis is significantly reduced in Tg APPsw and Tg PS1/APPsw mice compared with their wild-type littermates. In addition, we show that Abeta inhibits the angiogenesis stimulated by glioma cells when cocultured with human brain microvascular cells on a Matrigel layer. Altogether our data suggest that the brain of transgenic mouse models of AD does not constitute a favorable environment to support neoangiogenesis and may explain why vascular insults synergistically precipitate the cognitive presentation of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Paris</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>The Roskamp Institute, Sarasota, Florida 34243, USA. dparis@rfdn.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ganey</LastName><ForeName>Nowel</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Banasiak</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Laporte</LastName><ForeName>Vincent</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Nikunj</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Mullan</LastName><ForeName>Myles</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Murphy</LastName><ForeName>Susan F</ForeName><Initials>SF</Initials></Author><Author ValidYN="Y"><LastName>Yee</LastName><ForeName>Gi-Taek</ForeName><Initials>GT</Initials></Author><Author ValidYN="Y"><LastName>Bachmeier</LastName><ForeName>Corbin</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Ganey</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Beaulieu-Abdelahad</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Mathura</LastName><ForeName>Venkatarajan S</ForeName><Initials>VS</Initials></Author><Author ValidYN="Y"><LastName>Brem</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Mullan</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG019250</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01A619250</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001932" MajorTopicYN="N">Brain Neoplasms</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="Y">blood supply</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018920" MajorTopicYN="N">Coculture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005910" MajorTopicYN="N">Glioma</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009368" MajorTopicYN="N">Neoplasm Transplantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009389" MajorTopicYN="N">Neovascularization, Pathologic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>2</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20739545</ArticleId><ArticleId IdType="mid">NIHMS230769</ArticleId><ArticleId IdType="pmc">PMC2935547</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2586-10.2010</ArticleId><ArticleId IdType="pii">30/34/11251</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bell RD, Zlokovic BV. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol. 2009;118:103&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2853006</ArticleId><ArticleId IdType="pubmed">19319544</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell RD, Deane R, Chow N, Long X, Sagare A, Singh I, Streb JW, Guo H, Rubio A, Van Nostrand W, Miano JM, Zlokovic BV. SRF and myocardin regulate LRP-mediated amyloid-beta clearance in brain vascular cells. Nat Cell Biol. 2009;11:143&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2654279</ArticleId><ArticleId IdType="pubmed">19098903</ArticleId></ArticleIdList></Reference><Reference><Citation>Biscaro B, Lindvall O, Hock C, Ekdahl CT, Nitsch RM. Abeta immunotherapy protects morphology and survival of adult-born neurons in doubly transgenic APP/PS1 mice. J Neurosci. 2009;29:14108&#x2013;14119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6665051</ArticleId><ArticleId IdType="pubmed">19906959</ArticleId></ArticleIdList></Reference><Reference><Citation>Boscolo E, Folin M, Nico B, Grandi C, Mangieri D, Longo V, Scienza R, Zampieri P, Conconi MT, Parnigotto PP, Ribatti D. Beta amyloid angiogenic activity in vitro and in vivo. Int J Mol Med. 2007;19:581&#x2013;587.</Citation><ArticleIdList><ArticleId IdType="pubmed">17334633</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouras C, K&#xf6;vari E, Herrmann FR, Rivara CB, Bailey TL, von Gunten A, Hof PR, Giannakopoulos P. Stereologic analysis of microvascular morphology in the elderly: Alzheimer disease pathology and cognitive status. J Neuropathol Exp Neurol. 2006;65:235&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pubmed">16651885</ArticleId></ArticleIdList></Reference><Reference><Citation>Breitner JC, Haneuse SJ, Walker R, Dublin S, Crane PK, Gray SL, Larson EB. Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. Neurology. 2009;72:1899&#x2013;1905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2690966</ArticleId><ArticleId IdType="pubmed">19386997</ArticleId></ArticleIdList></Reference><Reference><Citation>Bu&#xe9;e L, Hof PR, Delacourte A. Brain microvascular changes in Alzheimer's disease and other dementias. Ann NY Acad Sci. 1997;826:7&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">9329677</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xfc;rger S, Noack M, Kirazov EP, Naydenov CL, Kouznetsova E, Yafai Y, Schliebs R. Vascular endothelial growth factor (VEGF) affects processing of amyloid precursor protein and beta-amyloidogenesis in brain slice cultures derived from transgenic Tg2576 mouse brain. Int J Dev Neurosci. 2009;27:517&#x2013;523.</Citation><ArticleIdList><ArticleId IdType="pubmed">19589380</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantara S, Donnini S, Morbidelli L, Giachetti A, Schulz R, Memo M, Ziche M. Physiological levels of amyloid peptides stimulate the angiogenic response through FGF-2. FASEB J. 2004;18:1943&#x2013;1945.</Citation><ArticleIdList><ArticleId IdType="pubmed">15448110</ArticleId></ArticleIdList></Reference><Reference><Citation>Carro E, Torres-Aleman I. Serum insulin-like growth factor I in brain function. Keio J Med. 2006;55:59&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">16830417</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow N, Bell RD, Deane R, Streb JW, Chen J, Brooks A, Van Nostrand W, Miano JM, Zlokovic BV. Serum response factor and myocardin mediate arterial hypercontractibility and cerebral blood flow dysregulation in Alzheimer's phenotype. Proc Natl Acad Sci U S A. 2007;104:823&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1783398</ArticleId><ArticleId IdType="pubmed">17215356</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, Zlokovic BV. Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res. 2007;4:191&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pubmed">17430246</ArticleId></ArticleIdList></Reference><Reference><Citation>Deininger MH, Fimmen BA, Thal DR, Schluesener HJ, Meyermann R. Aberrant neuronal and paracellular deposition of endostatin in brains of patients with Alzheimer's Disease. J Neurosci. 2002;22:10621&#x2013;10626.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758461</ArticleId><ArticleId IdType="pubmed">12486154</ArticleId></ArticleIdList></Reference><Reference><Citation>DeSouky AL. The relationship between cancer and Alzheimer's disease. J Am Geriatr Soc. 1992;40:1075.</Citation><ArticleIdList><ArticleId IdType="pubmed">1401685</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnini S, Cantara S, Morbidelli L, Giachetti A, Ziche M. FGF-2 overexpression opposes the beta amyloid toxic injuries to the vascular endothelium. Cell Death Differ. 2006;13:1088&#x2013;1096.</Citation><ArticleIdList><ArticleId IdType="pubmed">16410806</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnini S, Solito R, Cetti E, Corti F, Giachetti A, Carra S, Beltrame M, Cotelli F, Ziche M. Abeta peptides accelerate the senescence of endothelial cells in vitro and in vivo, impairing angiogenesis. FASEB J. 2010;24:2385&#x2013;2395.</Citation><ArticleIdList><ArticleId IdType="pubmed">20207941</ArticleId></ArticleIdList></Reference><Reference><Citation>Drago D, Folin M, Baiguera S, Tognon G, Ricchelli F, Zatta P. Comparative effects of Abeta(1-42)-Al complex from rat and human amyloid on rat endothelial cultures. J Alzheimers Dis. 2007;11:33&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">17361033</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer VW, Siddiqi A, Yusufaly Y. Altered angioarchitecture in selected areas of brains with Alzheimer's disease. Acta Neuropathol (Berl) 1997;79:672&#x2013;679.</Citation><ArticleIdList><ArticleId IdType="pubmed">2360411</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pubmed">8756718</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimura T, Kimura T, Miyakawa T. Morphological changes of blood vessels in the brain with Alzheimer's disease. Jpn J Psychiatry Neurol. 1991;45:661&#x2013;665.</Citation><ArticleIdList><ArticleId IdType="pubmed">1800813</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi S, Sato N, Yamamoto A, Ikegame Y, Nakashima S, Ogihara T, Morishita R. Alzheimer's disease-associated peptide, Amyloid b40, inhibits vascular regeneration with induction of endothelial autophagy. Arterioscler Thromb Vasc Biol. 2009;29:1909&#x2013;1915.</Citation><ArticleIdList><ArticleId IdType="pubmed">19815818</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman LB, Schmeidler J, Lesser GT, Beeri MS, Purohit DP, Grossman HT, Haroutunian V. Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons. Neurology. 2009;72:1720&#x2013;1726.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2683736</ArticleId><ArticleId IdType="pubmed">19228583</ArticleId></ArticleIdList></Reference><Reference><Citation>Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, Wright K, Saad I, Mueller R, Morgan D, Sanders S, Zehr C, O'Campo K, Hardy J, Prada CM, Eckman C, Younkin S, Hsiao K, Duff K. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med. 1998;4:97&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">9427614</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci. 2004;5:347&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pubmed">15100718</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones AR, Overly CC, Sunkin SM. The Allen Brain Atlas: 5 years and beyond. Nat Rev Neurosci. 2009;10:821&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pubmed">19826436</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalaria RN, Cohen DL, Premkumar DR, Nag S, LaManna JC, Lust WD. Vascular endothelial growth factor in Alzheimer's disease and experimental cerebral ischemia. Brain Res Mol Brain Res. 1998;62:101&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">9795165</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur B, Tan C, Brat DJ, Post DE, Van Meir EG. Genetic and hypoxic regulation of angiogenesis in gliomas. J Neurooncol. 2004;70:229&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pubmed">15674480</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci. 2001;21:372&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763819</ArticleId><ArticleId IdType="pubmed">11160418</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawai M, Kalaria RN, Harik SI, Perry G. The relationship of amyloid plaques to cerebral capillaries in Alzheimer's disease. Am J Pathol. 1990;137:1435&#x2013;1446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1877722</ArticleId><ArticleId IdType="pubmed">2260630</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura T, Hashimura T, Miyakawa T. Observations of microvessels in the brain with Alzheimer's disease by the scanning electron microscopy. Jpn J Psychiatry Neurol. 1991;45:671&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">1800815</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitaguchi H, Ihara M, Saiki H, Takahashi R, Tomimoto H. Capillary beds are decreased in Alzheimer's disease, but not in Binswanger's disease. Neurosci Lett. 2007;417:128&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">17403574</ArticleId></ArticleIdList></Reference><Reference><Citation>Kouznetsova E, Klingner M, Sorger D, Sabri O, Grossmann U, Steinbach J, Scheunemann M, Schliebs R. Developmental and amyloid plaque-related changes in cerebral cortical capillaries in transgenic Tg2576 Alzheimer mice. Int J Dev Neurosci. 2006;24:187&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">16423498</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunkel P, Ulbricht U, Bohlen P, Brockmann MA, Fillbrandt R, Stavrou D, Westphal M, Lamszus K. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res. 2001;61:6624&#x2013;6628.</Citation><ArticleIdList><ArticleId IdType="pubmed">11559524</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee GD, Aruna JH, Barrett PM, Lei DL, Ingram DK, Mouton PR. Stereological analysis of microvascular parameters in a double transgenic model of Alzheimer's disease. Brain Res Bull. 2005;65:317&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pubmed">15811597</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefranc F, Mijatovic T, Mathieu V, Rorive S, Decaestecker C, Debeir O, Brotchi J, Van Ham P, Salmon I, Kiss R. Characterization of gastrin-induced proangiogenic effects in vivo in orthotopic U373 experimental human glioblastomas and in vitro in human umbilical vein endothelial cells. Clin Cancer Res. 2004;10:8250&#x2013;8265.</Citation><ArticleIdList><ArticleId IdType="pubmed">15623601</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Lopez C, Dietrich MO, Metzger F, Loetscher H, Torres-Aleman I. Disturbed cross talk between insulin-like growth factor 1 and AMP-activated protein kinase as a possible cause of vascular dysfunction in the amyloid precursor protein/presenilin 2 mouse model of Alzheimer's disease. J Neurosci. 2007;27:824&#x2013;831.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672921</ArticleId><ArticleId IdType="pubmed">17251422</ArticleId></ArticleIdList></Reference><Reference><Citation>Mashayekhi F, Salehin Z. Cerebrospinal fluid nerve growth factor levels in patients with Alzheimer's disease. Ann Saudi Med. 2006;26:278&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6074514</ArticleId><ArticleId IdType="pubmed">16883086</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathieu V, De N&#xe8;ve N, Le Mercier M, Dewelle J, Gaussin JF, Dehoux M, Kiss R, Lefranc F. Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. Neoplasia. 2008;10:1383&#x2013;1392.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2586689</ArticleId><ArticleId IdType="pubmed">19048117</ArticleId></ArticleIdList></Reference><Reference><Citation>McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane Database Syst Rev. 2009;(2):CD003160.</Citation><ArticleIdList><ArticleId IdType="pubmed">19370582</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer EP, Ulmann-Schuler A, Staufenbiel M, Krucker T. Altered morphology and 3D architecture of brain vasculature in a mouse model for Alzheimer's disease. Proc Natl Acad Sci U S A. 2008;105:3587&#x2013;3592.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2265182</ArticleId><ArticleId IdType="pubmed">18305170</ArticleId></ArticleIdList></Reference><Reference><Citation>Narimatsu N, Harada N, Kurihara H, Nakagata N, Sobue K, Okajima K. Donepezil improves cognitive function in mice by increasing the production of insulin-like growth factor-I in the hippocampus. J Pharmacol Exp Ther. 2009;330:2&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">19318594</ArticleId></ArticleIdList></Reference><Reference><Citation>Paris D, Townsend K, Quadros A, Humphrey J, Sun J, Brem S, Wotoczek-Obadia M, DelleDonne A, Patel N, Obregon DF, Crescentini R, Abdullah L, Coppola D, Rojiani AM, Crawford F, Sebti SM, Mullan M. Inhibition of angiogenesis by Abeta peptides. Angiogenesis. 2004a;7:75&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">15302999</ArticleId></ArticleIdList></Reference><Reference><Citation>Paris D, Patel N, DelleDonne A, Quadros A, Smeed R, Mullan M. Impaired angiogenesis in a transgenic mouse model of cerebral amyloidosis. Neurosci Lett. 2004b;366:80&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">15265595</ArticleId></ArticleIdList></Reference><Reference><Citation>Paris D, Ait-Ghezala G, Mathura VS, Patel N, Quadros A, Laporte V, Mullan M. Anti-angiogenic activity of the mutant Dutch A(beta) peptide on human brain microvascular endothelial cells. Brain Res Mol Brain Res. 2005;136:212&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pubmed">15893605</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel NS, Quadros A, Brem S, Wotoczek-Obadia M, Mathura VS, Laporte V, Mullan M, Paris D. Potent anti-angiogenic motifs within the Alzheimer beta-amyloid peptide. Amyloid. 2008;15:5&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">18266117</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel NS, Mathura VS, Bachmeier C, Beaulieu-Abdelahad D, Laporte V, Weeks O, Mullan M, Paris D. Alzheimer's &#x3b2;-amyloid peptide blocks vascular endothelial growth factor mediated signaling via direct interaction with VEGFR-2. J Neurochem. 2010;112:66&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">19818105</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng S, Wuu J, Mufson EJ, Fahnestock M. Increased proNGF levels in subjects with mild cognitive impairment and mild Alzheimer disease. J Neuropathol Exp Neurol. 2004;63:641&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pubmed">15217092</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry G, Smith MA, McCann CE, Siedlak SL, Jones PK, Friedland RP. Cerebrovascular muscle atrophy is a feature of Alzheimer's disease. Brain Res. 1998;791:63&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">9593825</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrovitch H, White LR, Izmirilian G, Ross GW, Havlik RJ, Markesbery W, Nelson J, Davis DG, Hardman J, Foley DJ, Launer LJ. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS, Honolulu-Asia Aging Study. Neurobiol Aging. 2000;21:57&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">10794849</ArticleId></ArticleIdList></Reference><Reference><Citation>Plate KH, Risau W. Angiogenesis in malignant gliomas. Glia. 1995;15:339&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pubmed">8586468</ArticleId></ArticleIdList></Reference><Reference><Citation>Roe CM, Fitzpatrick AL, Xiong C, Sieh W, Kuller L, Miller JP, Williams MM, Kopan R, Behrens MI, Morris JC. Cancer linked to Alzheimer disease but not vascular dementia. Neurology. 2010;74:106&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2809029</ArticleId><ArticleId IdType="pubmed">20032288</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultheiss C, Blechert B, Gaertner FC, Drecoll E, Mueller J, Weber GF, Drzezga A, Essler M. In vivo characterization of endothelial cell activation in a transgenic mouse model of Alzheimer's disease. Angiogenesis. 2006;9:59&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">16821113</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res. 2008;192:10613.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2601528</ArticleId><ArticleId IdType="pubmed">18359102</ArticleId></ArticleIdList></Reference><Reference><Citation>Siedlak SL, Cras P, Kawai M, Richey P, Perry G. Basic fibroblast growth factor binding is a marker for extracellular neurofibrillary tangles in Alzheimer disease. J Histochem Cytochem. 1991;39:899&#x2013;904.</Citation><ArticleIdList><ArticleId IdType="pubmed">1865106</ArticleId></ArticleIdList></Reference><Reference><Citation>Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, Persson G, Od&#xe9;n A, Svanborg A. 15-year longitudinal study of blood pressure and dementia. Lancet. 1996;347:1141&#x2013;1145.</Citation><ArticleIdList><ArticleId IdType="pubmed">8609748</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA. 1997;277:813&#x2013;817.</Citation><ArticleIdList><ArticleId IdType="pubmed">9052711</ArticleId></ArticleIdList></Reference><Reference><Citation>Solito R, Corti F, Fossati S, Mezhericher E, Donnini S, Ghiso J, Giachetti A, Rostagno A, Ziche M. Dutch and Arctic mutant peptides of beta amyloid(1-40) differentially affect the FGF-2 pathway in brain endothelium. Exp Cell Res. 2009;315:385&#x2013;395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2764262</ArticleId><ArticleId IdType="pubmed">19061884</ArticleId></ArticleIdList></Reference><Reference><Citation>Spuch C, Antequera D, Portero A, Orive G, Hern&#xe1;ndez RM, Molina JA, Bermejo-Pareja F, Pedraz JL, Carro E. The effect of encapsulated VEGF-secreting cells on brain amyloid load and behavioral impairment in a mouse model of Alzheimer's disease. Biomaterials. 2010;31:5608&#x2013;5618.</Citation><ArticleIdList><ArticleId IdType="pubmed">20430437</ArticleId></ArticleIdList></Reference><Reference><Citation>Suter OC, Sunthorn T, Kraftsik R, Straubel J, Darekar P, Khalili K, Miklossy J. Cerebral hypoperfusion generates cortical watershed microinfarcts in Alzheimer disease. Stroke. 2002;33:1986&#x2013;1992.</Citation><ArticleIdList><ArticleId IdType="pubmed">12154250</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi D, Sato N, Shimamura M, Kurinami H, Takeda S, Shinohara M, Suzuki S, Kojima M, Ogihara T, Morishita R. Alleviation of Ab-induced cognitive impairment by ultrasound-mediated gene transfer of HGF in a mouse model. Gene Ther. 2008;15:561&#x2013;571.</Citation><ArticleIdList><ArticleId IdType="pubmed">18288214</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarkowski E, Issa R, Sj&#xf6;gren M, Wallin A, Blennow K, Tarkowski A, Kumar P. Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementia. Neurobiol Aging. 2002;23:237&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pubmed">11804709</ArticleId></ArticleIdList></Reference><Reference><Citation>Thirumangalakudi L, Samany PG, Owoso A, Wiskar B, Grammas P. Angiogenic proteins are expressed by brain blood vessels in Alzheimer's disease. J Alzheimers Dis. 2006;10:111&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">16988487</ArticleId></ArticleIdList></Reference><Reference><Citation>Tirumalasetti F, Han L, Birkett DP. The relationship between cancer and Alzheimer's disease. J Am Geriatr Soc. 1991;39:840.</Citation><ArticleIdList><ArticleId IdType="pubmed">2071819</ArticleId></ArticleIdList></Reference><Reference><Citation>Vagnucci AH, Jr, Li WW. Alzheimer's disease and angiogenesis. Lancet. 2003;361:605&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pubmed">12598159</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagemakers M, van der Wal GE, Cuberes R, Alvarez I, Andr&#xe9;s EM, Buxens J, Vela JM, Moorlag H, Mooij JJ, Molema G. COX-2 inhibition combined with radiation reduces orthotopic glioma outgrowth by targeting the tumor vasculature. Transl Oncol. 2009;2:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2647697</ArticleId><ArticleId IdType="pubmed">19252746</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson D, Casta&#xf1;o E, Kokjohn TA, Kuo YM, Lyubchenko Y, Pinsky D, Connolly ES, Jr, Esh C, Luehrs DC, Stine WB, Rowse LM, Emmerling MR, Roher AE. Physicochemical characteristics of soluble oligomeric Abeta and their pathologic role in Alzheimer's disease. Neurol Res. 2005;27:869&#x2013;881.</Citation><ArticleIdList><ArticleId IdType="pubmed">16354549</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z, Guo H, Chow N, Sallstrom J, Bell RD, Deane R, Brooks AI, Kanagala S, Rubio A, Sagare A, Liu D, Li F, Armstrong D, Gasiewicz T, Zidovetzki R, Song X, Hofman F, Zlokovic BV. Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease. Nat Med. 2005;11:959&#x2013;965.</Citation><ArticleIdList><ArticleId IdType="pubmed">16116430</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada M, Sasaki H, Mimori Y, Kasagi F, Sudoh S, Ikeda J, Hosoda Y, Nakamura S, Kodama K. Prevalence and risks of dementia in the Japanese population: RERF's adult health study Hiroshima subjects. Radiation Effects Research Foundation. J Am Geriatr Soc. 1999;47:189&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">9988290</ArticleId></ArticleIdList></Reference><Reference><Citation>Yashin AI, Ukraintseva SV, Akushevich IV, Arbeev KG, Kulminski A, Akushevich L. Trade-off between cancer and aging: What role do other diseases play? Evidence from experimental and human population studies. Mech Ageing Dev. 2009;130:98&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2708086</ArticleId><ArticleId IdType="pubmed">18452970</ArticleId></ArticleIdList></Reference><Reference><Citation>Zagzag D, Zhong H, Scalzitti JM, Laughner E, Simons JW, Semenza GL. Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer. 2000;88:2606&#x2013;2618.</Citation><ArticleIdList><ArticleId IdType="pubmed">10861440</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci. 2005;28:202&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">15808355</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV, Shinia Y, Holtzman D, Ghiso J, Frangione B. Clearance of b-amyloid from brain: transport or metabolism? Nat Med. 2000;6:718&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pubmed">10888893</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20739349</PMID><DateCompleted><Year>2010</Year><Month>11</Month><Day>30</Day></DateCompleted><DateRevised><Year>2010</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>133</Volume><Issue>11</Issue><PubDate><Year>2010</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>Larger temporal volume in elderly with high versus low beta-amyloid deposition.</ArticleTitle><Pagination><StartPage>3349</StartPage><EndPage>3358</EndPage><MedlinePgn>3349-58</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awq187</ELocationID><Abstract><AbstractText>&#x3b2;-Amyloid deposition is one of the main hallmarks of Alzheimer's disease thought to eventually cause neuronal death. Post-mortem and neuroimaging studies have consistently reported cases with documented normal cognition despite high &#x3b2;-amyloid burden. It is of great interest to understand what differentiates these particular subjects from those without &#x3b2;-amyloid deposition or with both &#x3b2;-amyloid deposition and cognitive deficits, i.e. what allows these subjects to resist the damage of the pathological lesions. [&#xb9;&#xb9;C]Pittsburgh compound B positron emission tomography and magnetic resonance brain scans were obtained in 149 participants including healthy controls and patients with subjective cognitive impairment, mild cognitive impairment and Alzheimer's disease. Magnetic resonance data were compared between high versus low-[11C]Pittsburgh compound B cases, and between high-[&#xb9;&#xb9;C]Pittsburgh compound B cases with versus those without cognitive deficits. Larger temporal (including hippocampal) grey matter volume, associated with better episodic memory performance, was found in high- versus low-[&#xb9;&#xb9;C]Pittsburgh compound B healthy controls. The same finding was obtained using different [&#xb9;&#xb9;C]Pittsburgh compound B thresholds, correcting [&#xb9;&#xb9;C]Pittsburgh compound B data for partial averaging, using age, education, Mini-Mental State Examination, apolipoprotein E4 and sex-matched subsamples, and using manual hippocampal delineation instead of voxel-based analysis. By contrast, in participants with subjective cognitive impairment, significant grey matter atrophy was found in high-[&#xb9;&#xb9;C]Pittsburgh compound B cases compared to low-[&#xb9;&#xb9;C]Pittsburgh compound B cases, as well as in high-[&#xb9;&#xb9;C]Pittsburgh compound B cases with subjective cognitive impairment, mild cognitive impairment and Alzheimer's disease compared to high-[&#xb9;&#xb9;C]Pittsburgh compound B healthy controls. Larger grey matter volume in high-[&#xb9;&#xb9;C]Pittsburgh compound B healthy controls may reflect either a tissue reactive response to &#x3b2;-amyloid or a combination of higher 'brain reserve' and under-representation of subjects with standard/low temporal volume in the high-[&#xb9;&#xb9;C]Pittsburgh compound B healthy controls. Our complementary analyses tend to support the latter hypotheses. Overall, our findings suggest that the deleterious effects of &#x3b2;-amyloid on cognition may be delayed in those subjects with larger brain (temporal) volume.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ch&#xe9;telat</LastName><ForeName>Ga&#xeb;l</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine and Centre for PET, Austin Health, 145 Studley Road, Heidelberg, VIC 3084, Australia. chetelat@cyceron.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villemagne</LastName><ForeName>Victor L</ForeName><Initials>VL</Initials></Author><Author ValidYN="Y"><LastName>Pike</LastName><ForeName>Kerryn E</ForeName><Initials>KE</Initials></Author><Author ValidYN="Y"><LastName>Baron</LastName><ForeName>Jean-Claude</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Bourgeat</LastName><ForeName>Pierrick</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Gareth</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Faux</LastName><ForeName>Noel G</ForeName><Initials>NG</Initials></Author><Author ValidYN="Y"><LastName>Ellis</LastName><ForeName>Kathryn A</ForeName><Initials>KA</Initials></Author><Author ValidYN="Y"><LastName>Salvado</LastName><ForeName>Olivier</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Szoeke</LastName><ForeName>Cassandra</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Martins</LastName><ForeName>Ralph N</ForeName><Initials>RN</Initials></Author><Author ValidYN="Y"><LastName>Ames</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Masters</LastName><ForeName>Colin L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Rowe</LastName><ForeName>Christopher C</ForeName><Initials>CC</Initials></Author><Author ValidYN="Y"><CollectiveName>Australian Imaging Biomarkers and Lifestyle Study of Ageing (AIBL) Research Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>08</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009929" MajorTopicYN="N">Organ Size</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20739349</ArticleId><ArticleId IdType="doi">10.1093/brain/awq187</ArticleId><ArticleId IdType="pii">awq187</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20740007</PMID><DateCompleted><Year>2010</Year><Month>09</Month><Day>13</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>466</Volume><Issue>7310</Issue><PubDate><Year>2010</Year><Month>Aug</Month><Day>26</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS.</ArticleTitle><Pagination><StartPage>1069</StartPage><EndPage>1075</EndPage><MedlinePgn>1069-75</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature09320</ELocationID><Abstract><AbstractText>The causes of amyotrophic lateral sclerosis (ALS), a devastating human neurodegenerative disease, are poorly understood, although the protein TDP-43 has been suggested to have a critical role in disease pathogenesis. Here we show that ataxin 2 (ATXN2), a polyglutamine (polyQ) protein mutated in spinocerebellar ataxia type 2, is a potent modifier of TDP-43 toxicity in animal and cellular models. ATXN2 and TDP-43 associate in a complex that depends on RNA. In spinal cord neurons of ALS patients, ATXN2 is abnormally localized; likewise, TDP-43 shows mislocalization in spinocerebellar ataxia type 2. To assess the involvement of ATXN2 in ALS, we analysed the length of the polyQ repeat in the ATXN2 gene in 915 ALS patients. We found that intermediate-length polyQ expansions (27-33 glutamines) in ATXN2 were significantly associated with ALS. These data establish ATXN2 as a relatively common ALS susceptibility gene. Furthermore, these findings indicate that the TDP-43-ATXN2 interaction may be a promising target for therapeutic intervention in ALS and other TDP-43 proteinopathies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Elden</LastName><ForeName>Andrew C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Cell and Developmental Biology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hyung-Jun</ForeName><Initials>HJ</Initials></Author><Author ValidYN="Y"><LastName>Hart</LastName><ForeName>Michael P</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Chen-Plotkin</LastName><ForeName>Alice S</ForeName><Initials>AS</Initials></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Brian S</ForeName><Initials>BS</Initials></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Xiaodong</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Armakola</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Geser</LastName><ForeName>Felix</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Greene</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Min Min</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Padmanabhan</LastName><ForeName>Arun</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Clay-Falcone</LastName><ForeName>Dana</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>McCluskey</LastName><ForeName>Leo</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Elman</LastName><ForeName>Lauren</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Juhr</LastName><ForeName>Denise</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Gruber</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>R&#xfc;b</LastName><ForeName>Udo</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Auburger</LastName><ForeName>Georg</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia M-Y</ForeName><Initials>VM</Initials></Author><Author ValidYN="Y"><LastName>Van Deerlin</LastName><ForeName>Vivianna M</ForeName><Initials>VM</Initials></Author><Author ValidYN="Y"><LastName>Bonini</LastName><ForeName>Nancy M</ForeName><Initials>NM</Initials></Author><Author ValidYN="Y"><LastName>Gitler</LastName><ForeName>Aaron D</ForeName><Initials>AD</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG017586</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R01NS065317-01</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>AG-10124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1DP2OD004417-01</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 AG-033101-01</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS065317</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DP2 OD004417</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG-17586</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG009215</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG-09215</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 AG033101</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000067528">Ataxins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>26700-71-0</RegistryNumber><NameOfSubstance UI="C097188">polyglutamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2010 Aug 26;466(7310):1052-3. doi: 10.1038/4661052a.</RefSource><PMID Version="1">20740002</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Mol Cell Biol. 2019 Feb;20(2):67. doi: 10.1038/s41580-018-0062-6.</RefSource><PMID Version="1">30279566</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000067528" MajorTopicYN="N">Ataxins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004330" MajorTopicYN="N">Drosophila</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020449" MajorTopicYN="N">Repetitive Sequences, Amino Acid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012441" MajorTopicYN="N">Saccharomyces cerevisiae</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>11</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>2</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20740007</ArticleId><ArticleId IdType="mid">NIHMS217752</ArticleId><ArticleId IdType="pmc">PMC2965417</ArticleId><ArticleId IdType="doi">10.1038/nature09320</ArticleId><ArticleId IdType="pii">nature09320</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cleveland DW, Rothstein JD. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci. 2001;2:806&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">11715057</ArticleId></ArticleIdList></Reference><Reference><Citation>Valentine JS, Hart PJ. Misfolded CuZnSOD and amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2003;100:3617&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC152971</ArticleId><ArticleId IdType="pubmed">12655070</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Pesiridis GS, Lee VM, Trojanowski JQ. Mutations in TDP-43 link glycine-rich domain functions to amyotrophic lateral sclerosis. Hum Mol Genet. 2009;18:R156&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2758707</ArticleId><ArticleId IdType="pubmed">19808791</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C, Cleveland DW. Rethinking ALS: the FUS about TDP-43. Cell. 2009;136:1001&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3110083</ArticleId><ArticleId IdType="pubmed">19303844</ArticleId></ArticleIdList></Reference><Reference><Citation>Winton MJ, et al. Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation. J Biol Chem. 2008;283:13302&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2442318</ArticleId><ArticleId IdType="pubmed">18305110</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper AA, et al. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson&#x2019;s models. Science. 2006;313:324&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1983366</ArticleId><ArticleId IdType="pubmed">16794039</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitler AD, et al. Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat Genet. 2009;41:308&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2683786</ArticleId><ArticleId IdType="pubmed">19182805</ArticleId></ArticleIdList></Reference><Reference><Citation>Orr HT, Zoghbi HY. Trinucleotide repeat disorders. Annu Rev Neurosci. 2007;30:575&#x2013;621.</Citation><ArticleIdList><ArticleId IdType="pubmed">17417937</ArticleId></ArticleIdList></Reference><Reference><Citation>Imbert G, et al. Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nat Genet. 1996;14:285&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">8896557</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorenzetti D, Bohlega S, Zoghbi HY. The expansion of the CAG repeat in ataxin-2 is a frequent cause of autosomal dominant spinocerebellar ataxia. Neurology. 1997;49:1009&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">9339681</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulst SM, et al. Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nat Genet. 1996;14:269&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">8896555</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanpei K, et al. Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique, DIRECT. Nat Genet. 1996;14:277&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">8896556</ArticleId></ArticleIdList></Reference><Reference><Citation>Infante J, et al. Spinocerebellar ataxia type 2 with Levodopa-responsive parkinsonism culminating in motor neuron disease. Mov Disord. 2004;19:848&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">15254952</ArticleId></ArticleIdList></Reference><Reference><Citation>Nanetti L, et al. Rare association of motor neuron disease and spinocerebellar ataxia type 2 (SCA2): a new case and review of the literature. J Neurol. 2009</Citation><ArticleIdList><ArticleId IdType="pubmed">19644730</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangus DA, Amrani N, Jacobson A. Pbp1p, a factor interacting with Saccharomyces cerevisiae poly(A)-binding protein, regulates polyadenylation. Mol Cell Biol. 1998;18:7383&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC109320</ArticleId><ArticleId IdType="pubmed">9819425</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchan JR, Muhlrad D, Parker R. P bodies promote stress granule assembly in Saccharomyces cerevisiae. J Cell Biol. 2008;183:441&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2575786</ArticleId><ArticleId IdType="pubmed">18981231</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Ramahi I, et al. dAtaxin-2 mediates expanded Ataxin-1-induced neurodegeneration in a Drosophila model of SCA1. PLoS Genet. 2007;3:e234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2323314</ArticleId><ArticleId IdType="pubmed">18166084</ArticleId></ArticleIdList></Reference><Reference><Citation>Lessing D, Bonini NM. Polyglutamine genes interact to modulate the severity and progression of neurodegeneration in Drosophila. PLoS Biol. 2008;6:e29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2235903</ArticleId><ArticleId IdType="pubmed">18271626</ArticleId></ArticleIdList></Reference><Reference><Citation>Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson&#x2019;s disease. Science. 2002;295:865&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">11823645</ArticleId></ArticleIdList></Reference><Reference><Citation>Warrick JM, et al. Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat Genet. 1999;23:425&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10581028</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E, Baralle FE. Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9. J Biol Chem. 2001;276:36337&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">11470789</ArticleId></ArticleIdList></Reference><Reference><Citation>Lastres-Becker I, Rub U, Auburger G. Spinocerebellar ataxia 2 (SCA2) Cerebellum. 2008;7:115&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">18418684</ArticleId></ArticleIdList></Reference><Reference><Citation>Huynh DP, Yang HT, Vakharia H, Nguyen D, Pulst SM. Expansion of the polyQ repeat in ataxin-2 alters its Golgi localization, disrupts the Golgi complex and causes cell death. Hum Mol Genet. 2003;12:1485&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">12812977</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatraman P, Wetzel R, Tanaka M, Nukina N, Goldberg AL. Eukaryotic proteasomes cannot digest polyglutamine sequences and release them during degradation of polyglutamine-containing proteins. Mol Cell. 2004;14:95&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">15068806</ArticleId></ArticleIdList></Reference><Reference><Citation>Colombrita C, et al. TDP-43 is recruited to stress granules in conditions of oxidative insult. J Neurochem. 2009;111:1051&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">19765185</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonhoff U, et al. Ataxin-2 interacts with the DEAD/H-box RNA helicase DDX6 and interferes with P-bodies and stress granules. Mol Biol Cell. 2007;18:1385&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1838996</ArticleId><ArticleId IdType="pubmed">17392519</ArticleId></ArticleIdList></Reference><Reference><Citation>Freibaum BD, Chitta RK, High AA, Taylor JP. Global Analysis of TDP-43 Interacting Proteins Reveals Strong Association with RNA Splicing and Translation Machinery. J Proteome Res. 9:1104&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2897173</ArticleId><ArticleId IdType="pubmed">20020773</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson M, Llado J, Rothstein JD. Therapeutic developments in the treatment of amyotrophic lateral sclerosis. Expert Opin Investig Drugs. 2002;11:1343&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">12387699</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20798282</PMID><DateCompleted><Year>2010</Year><Month>11</Month><Day>04</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>329</Volume><Issue>5999</Issue><PubDate><Year>2010</Year><Month>Sep</Month><Day>24</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro.</ArticleTitle><Pagination><StartPage>1663</StartPage><EndPage>1667</EndPage><MedlinePgn>1663-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.1195227</ELocationID><Abstract><AbstractText>Presynaptic nerve terminals release neurotransmitters repeatedly, often at high frequency, and in relative isolation from neuronal cell bodies. Repeated release requires cycles of soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE)-complex assembly and disassembly, with continuous generation of reactive SNARE-protein intermediates. Although many forms of neurodegeneration initiate presynaptically, only few pathogenic mechanisms are known, and the functions of presynaptic proteins linked to neurodegeneration, such as &#x3b1;-synuclein, remain unclear. Here, we show that maintenance of continuous presynaptic SNARE-complex assembly required a nonclassical chaperone activity mediated by synucleins. Specifically, &#x3b1;-synuclein directly bound to the SNARE-protein synaptobrevin-2/vesicle-associated membrane protein 2 (VAMP2) and promoted SNARE-complex assembly. Moreover, triple-knockout mice lacking synucleins developed age-dependent neurological impairments, exhibited decreased SNARE-complex assembly, and died prematurely. Thus, synucleins may function to sustain normal SNARE-complex assembly in a presynaptic terminal during aging.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Burr&#xe9;</LastName><ForeName>Jacqueline</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Molecular and Cellular Physiology, and Howard Hughes Medical Institute, Stanford University, 1050 Arastradero Road, Palo Alto, CA 94304-5543, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Manu</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Tsetsenis</LastName><ForeName>Theodoros</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Buchman</LastName><ForeName>Vladimir</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Etherton</LastName><ForeName>Mark R</ForeName><Initials>MR</Initials></Author><Author ValidYN="Y"><LastName>S&#xfc;dhof</LastName><ForeName>Thomas C</ForeName><Initials>TC</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>075615</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>08</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050956">HSP40 Heat-Shock Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050600">SNARE Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497604">SNCA protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497605">Snca protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050988">Vesicle-Associated Membrane Protein 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C088460">cysteine string protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C494808">vesicle-associated membrane protein 2, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="Y">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050956" MajorTopicYN="N">HSP40 Heat-Shock Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008561" MajorTopicYN="N">Membrane Fusion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017729" MajorTopicYN="N">Presynaptic Terminals</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050600" MajorTopicYN="N">SNARE Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050988" MajorTopicYN="N">Vesicle-Associated Membrane Protein 2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">HHMIMS341482</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>11</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>12</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20798282</ArticleId><ArticleId IdType="mid">NIHMS341482</ArticleId><ArticleId IdType="pmc">PMC3235365</ArticleId><ArticleId IdType="doi">10.1126/science.1195227</ArticleId><ArticleId IdType="pii">science.1195227</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Martens S, McMahon HT. Mechanisms of membrane fusion: disparate players and common principles. Nat Rev Mol Cell Biol. 2008;9:543&#x2013;556.</Citation><ArticleIdList><ArticleId IdType="pubmed">18496517</ArticleId></ArticleIdList></Reference><Reference><Citation>Wickner W, Schekman R. Membrane fusion. Nat Struct Mol Biol. 2008;15:658&#x2013;664.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2488960</ArticleId><ArticleId IdType="pubmed">18618939</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xfc;dhof TC, Rothman JE. Membrane fusion: grappling with SNARE and SM proteins. Science. 2009;23:474&#x2013;477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3736821</ArticleId><ArticleId IdType="pubmed">19164740</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer ML, Schulz-Schaeffer WJ. Presynaptic &#x3b1;-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci. 2007;27:1405&#x2013;1410.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673583</ArticleId><ArticleId IdType="pubmed">17287515</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheff SW, Price DA, Schmitt FA, DeKosky ST, Mufson EJ. Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology. 2007;68:1501&#x2013;1508.</Citation><ArticleIdList><ArticleId IdType="pubmed">17470753</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray BC, Siskova Z, Perry VH, O'Connor V. Selective presynaptic degeneration in the synaptopathy associated with ME7-induced hippocampal pathology. Neurobiol Dis. 2009;35:63&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">19362593</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Chacon R, et al. The synaptic vesicle protein CSP&#x3b1; prevents presynaptic degeneration. Neuron. 2004;42:237&#x2013;251.</Citation><ArticleIdList><ArticleId IdType="pubmed">15091340</ArticleId></ArticleIdList></Reference><Reference><Citation>Clayton DF, George JM. The Synucleins: a family of proteins involved in synaptic function, neurodegeneration and disease. Trends Neurosci. 1998;21:249&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">9641537</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymeropoulos MH, et al. Mutation in the &#x3b1;-synuclein gene identified in families with Parkinson's disease. Science. 1997;276:2045&#x2013;2047.</Citation><ArticleIdList><ArticleId IdType="pubmed">9197268</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, et al. &#x3b1;-Synuclein in Lewy bodies. Nature. 1997;388:839&#x2013;840.</Citation><ArticleIdList><ArticleId IdType="pubmed">9278044</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A, Dawson VL, Dawson TM. What causes cell death in Parkinson's disease? Ann Neurol. 2008;64(Suppl 2):S3&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4118469</ArticleId><ArticleId IdType="pubmed">19127586</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad M, Attoub S, Singh MN, Martin FL, El-Agnaf OM. &#x3b3;-Synuclein and the progression of cancer. FASEB J. 2007;21:3419&#x2013;3430.</Citation><ArticleIdList><ArticleId IdType="pubmed">17567567</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S, et al. &#x3b1;-Synuclein produces a long-lasting increase in neurotransmitter release. EMBO J. 2004;23:4506&#x2013;4516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC526467</ArticleId><ArticleId IdType="pubmed">15510220</ArticleId></ArticleIdList></Reference><Reference><Citation>Nemani VM, et al. Increased expression of &#x3b1;-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron. 2010;65:66&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3119527</ArticleId><ArticleId IdType="pubmed">20152114</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandra S, Gallardo G, Fernandez-Chacon R, Schluter OM, S&#xfc;dhof TC. &#x3b1;-synuclein cooperates with CSP&#x3b1; in preventing neurodegeneration. Cell. 2005;123:383&#x2013;396.</Citation><ArticleIdList><ArticleId IdType="pubmed">16269331</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandra S, Chen X, Rizo J, Jahn R, S&#xfc;dhof TC. A broken &#x3b1;-helix in folded &#x3b1;-synuclein. J Biol Chem. 2003;278:15313&#x2013;15318.</Citation><ArticleIdList><ArticleId IdType="pubmed">12586824</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Junco-Clemente P, et al. Cysteine string protein-alpha prevents activity-dependent degeneration in GABAergic synapses. J Neurosci. 2010;30:7377&#x2013;7391.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6632397</ArticleId><ArticleId IdType="pubmed">20505105</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi T, et al. Synaptic vesicle membrane fusion complex: action of clostridial neurotoxins on assembly. EMBO J. 1994;13:5051&#x2013;5061.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC395451</ArticleId><ArticleId IdType="pubmed">7957071</ArticleId></ArticleIdList></Reference><Reference><Citation>Abeliovich A, et al. Mice lacking &#x3b1;-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron. 2000;25:239&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pubmed">10707987</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandra S, et al. Double-knockout mice for &#x3b3;- and &#x3b2;-synucleins: effect on synaptic functions. Proc Nat Acad U S A. 2004;101:14966&#x2013;14971.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC522043</ArticleId><ArticleId IdType="pubmed">15465911</ArticleId></ArticleIdList></Reference><Reference><Citation>Ninkina N, et al. Neurons expressing the highest levels of &#x3b3;-synuclein are unaffected by targeted inactivation of the gene. Mol Cell Biol. 2003;23:8233&#x2013;8245.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC262405</ArticleId><ArticleId IdType="pubmed">14585981</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, et al. &#x3b1;-Synuclein in Lewy bodies. Nature. 1997;388:839&#x2013;840.</Citation><ArticleIdList><ArticleId IdType="pubmed">9278044</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda A, et al. Abnormal accumulation of NACP/&#x3b1;-synuclein in neurodegenerative disorders. Am J Pathol. 1998;152:367&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1857971</ArticleId><ArticleId IdType="pubmed">9466562</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahle PJ, et al. Selective insolubility of &#x3b1;-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am J Pathol. 2001;159:2215&#x2013;2225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850592</ArticleId><ArticleId IdType="pubmed">11733371</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CW, et al. A precipitating role for truncated &#x3b1;-synuclein and the proteasome in &#x3b1;-synuclein aggregation: implications for pathogenesis of Parkinson disease. J Biol Chem. 2005;280:22670&#x2013;22678.</Citation><ArticleIdList><ArticleId IdType="pubmed">15840579</ArticleId></ArticleIdList></Reference><Reference><Citation>Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM. Chaperone suppression of &#x3b1;-synuclein toxicity in a Drosophila model for Parkinson's disease. Science. 2002;295:865&#x2013;868.</Citation><ArticleIdList><ArticleId IdType="pubmed">11823645</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20801717</PMID><DateCompleted><Year>2010</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1474-4465</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>10</Issue><PubDate><Year>2010</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The Lancet. Neurology</Title><ISOAbbreviation>Lancet Neurol</ISOAbbreviation></Journal><ArticleTitle>Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study.</ArticleTitle><Pagination><StartPage>986</StartPage><EndPage>994</EndPage><MedlinePgn>986-94</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1474-4422(10)70197-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease of motor neurons that results in progressive weakness and death from respiratory failure, commonly within about 3 years. Previous studies have shown association of a locus on chromosome 9p with ALS and linkage with ALS-frontotemporal dementia. We aimed to test whether this genomic region is also associated with ALS in an independent set of UK samples, and to identify risk factors associated with ALS in a further genome-wide association study that combined data from the independent analysis with those from other countries.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We collected samples from patients with sporadic ALS from 20 UK hospitals and obtained UK control samples from the control groups of the Depression Case Control study, the Bipolar Affective Case Control Study, and the British 1958 birth cohort DNA collection. Genotyping of DNA in this independent analysis was done with Illumina HumanHap550 BeadChips. We then undertook a joint genome-wide analysis that combined data from the independent set with published data from the UK, USA, Netherlands, Ireland, Italy, France, Sweden, and Belgium. The threshold for significance was p=0&#xb7;05 in the independent analysis, because we were interested in replicating a small number of previously reported associations, whereas the Bonferroni-corrected threshold for significance in the joint analysis was p=2&#xb7;20&#xd7;10(-7)</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">After quality control, samples were available from 599 patients and 4144 control individuals in the independent set. In this analysis, two single nucleotide polymorphisms in a locus on chromosome 9p21.2 were associated with ALS: rs3849942 (p=2&#xb7;22&#xd7;10(-6); odds ratio [OR] 1&#xb7;39, 95% CI 1&#xb7;21-1&#xb7;59) and rs2814707 (p=3&#xb7;32&#xd7;10(-6); 1&#xb7;38, 1&#xb7;20-1&#xb7;58). In the joint analysis, which included samples from 4312 patients with ALS and 8425 control individuals, rs3849942 (p=4&#xb7;64&#xd7;10(-10); OR 1&#xb7;22, 95% CI 1&#xb7;15-1&#xb7;30) and rs2814707 (p=4&#xb7;72&#xd7;10(-10); 1&#xb7;22, 1&#xb7;15-1&#xb7;30) were associated with ALS.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">We have found strong evidence of a genetic association of two single nucleotide polymorphisms on chromosome 9 with sporadic ALS, in line with findings from previous independent GWAS of ALS and linkage studies of ALS-frontotemporal dementia. Our findings together with these earlier findings suggest that genetic variation at this locus on chromosome 9 causes sporadic ALS and familial ALS-frontotemporal dementia. Resequencing studies and then functional analysis should be done to identify the defective gene.</AbstractText><CopyrightInformation>Copyright &#xa9; 2010 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shatunov</LastName><ForeName>Aleksey</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>King's College London, Medical Research Council Centre for Neurodegeneration Research, Department of Clinical Neuroscience, Institute of Psychiatry, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mok</LastName><ForeName>Kin</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Newhouse</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Weale</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Bradley</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Vance</LastName><ForeName>Caroline</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Lauren</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Veldink</LastName><ForeName>Jan H</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>van Es</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>van den Berg</LastName><ForeName>Leonard H</ForeName><Initials>LH</Initials></Author><Author ValidYN="Y"><LastName>Robberecht</LastName><ForeName>Wim</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Van Damme</LastName><ForeName>Philip</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Hardiman</LastName><ForeName>Orla</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Farmer</LastName><ForeName>Anne E</ForeName><Initials>AE</Initials></Author><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>Cathryn M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Butler</LastName><ForeName>Amy W</ForeName><Initials>AW</Initials></Author><Author ValidYN="Y"><LastName>Abel</LastName><ForeName>Olubunmi</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Peter M</ForeName><Initials>PM</Initials></Author><Author ValidYN="Y"><LastName>Fogh</LastName><ForeName>Isabella</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Silani</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Chi&#xf2;</LastName><ForeName>Adriano</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Traynor</LastName><ForeName>Bryan J</ForeName><Initials>BJ</Initials></Author><Author ValidYN="Y"><LastName>Melki</LastName><ForeName>Judith</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Meininger</LastName><ForeName>Vincent</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Landers</LastName><ForeName>John E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>McGuffin</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Glass</LastName><ForeName>Jonathan D</ForeName><Initials>JD</Initials></Author><Author ValidYN="Y"><LastName>Pall</LastName><ForeName>Hardev</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Leigh</LastName><ForeName>P Nigel</ForeName><Initials>PN</Initials></Author><Author ValidYN="Y"><LastName>Hardy</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Robert H</ForeName><Initials>RH</Initials><Suffix>Jr</Suffix></Author><Author ValidYN="Y"><LastName>Powell</LastName><ForeName>John F</ForeName><Initials>JF</Initials></Author><Author ValidYN="Y"><LastName>Orrell</LastName><ForeName>Richard W</ForeName><Initials>RW</Initials></Author><Author ValidYN="Y"><LastName>Morrison</LastName><ForeName>Karen E</ForeName><Initials>KE</Initials></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Pamela J</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Christopher E</ForeName><Initials>CE</Initials></Author><Author ValidYN="Y"><LastName>Al-Chalabi</LastName><ForeName>Ammar</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>089701</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>Z01 AG000949</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0000934</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0600974</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>070122/A/02/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0701420</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0601943</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0701075</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>068545/Z/02</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0900688</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>Z01-AG000949-02</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Neurol</MedlineTA><NlmUniqueID>101139309</NlmUniqueID><ISSNLinking>1474-4422</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Lancet Neurol. 2011 Mar;10(3):205</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2010 Oct;9(10):945-7. doi: 10.1016/S1474-4422(10)70211-8.</RefSource><PMID Version="1">20801719</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002899" MajorTopicYN="N">Chromosomes, Human, Pair 9</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N">Europe</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D038622" MajorTopicYN="N">Internationality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N">United Kingdom</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>10</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20801717</ArticleId><ArticleId IdType="pmc">PMC3257853</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(10)70197-6</ArticleId><ArticleId IdType="pii">S1474-4422(10)70197-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Johnston CA, Stanton BR, Turner MR. Amyotrophic lateral sclerosis in an urban setting: a population based study of inner city London. J Neurol. 2006;253:1642&#x2013;1643.</Citation><ArticleIdList><ArticleId IdType="pubmed">17219036</ArticleId></ArticleIdList></Reference><Reference><Citation>Morita M, Al-Chalabi A, Andersen PM. A locus on chromosome 9p confers susceptibility to amyotrophic lateral sclerosis and frontotemporal dementia. Neurology. 2006;66:839&#x2013;844.</Citation><ArticleIdList><ArticleId IdType="pubmed">16421333</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C, Al-Chalabi A, Ruddy D. Familial amyotrophic lateral sclerosis with frontotemporal dementia is linked to a locus on chromosome 9p13.2-21.3. Brain. 2006;129:868&#x2013;876.</Citation><ArticleIdList><ArticleId IdType="pubmed">16495328</ArticleId></ArticleIdList></Reference><Reference><Citation>Boxer AL, Mackenzie IR, Boeve BF. Clinical, neuroimaging and neuropathological features of a new chromosome 9p-linked FTD-ALS family. J Neurol Neurosurg Psychiatry. 2010 doi: 10.1136/jnnp.2009.204081. published online June 20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2009.204081</ArticleId><ArticleId IdType="pmc">PMC3017222</ArticleId><ArticleId IdType="pubmed">20562461</ArticleId></ArticleIdList></Reference><Reference><Citation>Valdmanis PN, Dupre N, Bouchard JP. Three families with amyotrophic lateral sclerosis and frontotemporal dementia with evidence of linkage to chromosome 9p. Arch Neurol. 2007;64:240&#x2013;245.</Citation><ArticleIdList><ArticleId IdType="pubmed">17296840</ArticleId></ArticleIdList></Reference><Reference><Citation>Gijselinck I, Engelborghs S, Maes G. Identification of 2 loci at chromosomes 9 and 14 in a multiplex family with frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Arch Neurol. 2010;67:606&#x2013;616.</Citation><ArticleIdList><ArticleId IdType="pubmed">20457961</ArticleId></ArticleIdList></Reference><Reference><Citation>Benajiba L, Le Ber I, Camuzat A. TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration. Ann Neurol. 2009;65:470&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pubmed">19350673</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es MA, Veldink JH, Saris CG. Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet. 2009;41:1083&#x2013;1087.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734901</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunckley T, Huentelman MJ, Craig DW. Whole-genome analysis of sporadic amyotrophic lateral sclerosis. N Engl J Med. 2007;357:775&#x2013;788.</Citation><ArticleIdList><ArticleId IdType="pubmed">17671248</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es MA, Van Vught PW, Blauw HM. ITPR2 as a susceptibility gene in sporadic amyotrophic lateral sclerosis: a genome-wide association study. Lancet Neurol. 2007;6:869&#x2013;877.</Citation><ArticleIdList><ArticleId IdType="pubmed">17827064</ArticleId></ArticleIdList></Reference><Reference><Citation>Cronin S, Berger S, Ding J. A genome-wide association study of sporadic ALS in a homogenous Irish population. Hum Mol Genet. 2008;17:768&#x2013;774.</Citation><ArticleIdList><ArticleId IdType="pubmed">18057069</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es MA, van Vught PW, Blauw HM. Genetic variation in DPP6 is associated with susceptibility to amyotrophic lateral sclerosis. Nat Genet. 2008;40:29&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">18084291</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogh I, D'Alfonso S, Gellera C. No association of DPP6 with amyotrophic lateral sclerosis in an Italian population. Neurobiol Aging. 2009 doi: 10.1016/j.neurobiolaging.2009.05.014. published online June 12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2009.05.014</ArticleId><ArticleId IdType="pubmed">19525032</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis CM, Ng MY, Butler AW. Genome-wide association study of major recurrent depression in the UK population. Am J Psychiatry. 2010;167:949&#x2013;957.</Citation><ArticleIdList><ArticleId IdType="pubmed">20516156</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaysina D, Cohen-Woods S, Chow PC. Association of the dystrobrevin binding protein 1 gene (DTNBP1) in a bipolar case-control study (BACCS) Am J Med Genet B Neuropsychiatr Genet. 2009;150B:836&#x2013;844.</Citation><ArticleIdList><ArticleId IdType="pubmed">19089808</ArticleId></ArticleIdList></Reference><Reference><Citation>Landers JE, Melki J, Meininger V. Reduced expression of the kinesin-associated protein 3 (KIFAP3) gene increases survival in sporadic amyotrophic lateral sclerosis. Proc Natl Acad Sci USA. 2009;106:9004&#x2013;9009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2683883</ArticleId><ArticleId IdType="pubmed">19451621</ArticleId></ArticleIdList></Reference><Reference><Citation>Schymick JC, Scholz SW, Fung HC. Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol. 2007;6:322&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pubmed">17362836</ArticleId></ArticleIdList></Reference><Reference><Citation>Wroe R, Wai-Ling Butler A, Andersen PM, Powell JF, Al-Chalabi A. ALSOD: the amyotrophic lateral sclerosis online database. Amyotroph Lateral Scler. 2008;9:249&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">18608099</ArticleId></ArticleIdList></Reference><Reference><Citation>Purcell S, Cherny SS, Sham PC. Genetic power calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics. 2003;19:149&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">12499305</ArticleId></ArticleIdList></Reference><Reference><Citation>Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet. 2006;38:904&#x2013;909.</Citation><ArticleIdList><ArticleId IdType="pubmed">16862161</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson N, Price AL, Reich D. Population structure and eigenanalysis. PLoS Genet. 2006;2:e190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1713260</ArticleId><ArticleId IdType="pubmed">17194218</ArticleId></ArticleIdList></Reference><Reference><Citation>Purcell S, Neale B, Todd-Brown K. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81:559&#x2013;575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1950838</ArticleId><ArticleId IdType="pubmed">17701901</ArticleId></ArticleIdList></Reference><Reference><Citation>Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet. 2009;5:e1000529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2689936</ArticleId><ArticleId IdType="pubmed">19543373</ArticleId></ArticleIdList></Reference><Reference><Citation>International HapMap Consortium The international HapMap project. Nature. 2003;426:789&#x2013;796.</Citation><ArticleIdList><ArticleId IdType="pubmed">14685227</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchini J, Howie B, Myers S, McVean G, Donnelly P. A new multipoint method for genome-wide association studies by imputation of genotypes. Nat Genet. 2007;39:906&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pubmed">17572673</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Fang F, Hanby MF, et al. An estimate of amyotrophic lateral sclerosis heritability using twin data. J Neurol Neurosurg Psychiatry (in press).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2988617</ArticleId><ArticleId IdType="pubmed">20861059</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringholz GM, Appel SH, Bradshaw M, Cooke NA, Mosnik DM, Schulz PE. Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology. 2005;65:586&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pubmed">16116120</ArticleId></ArticleIdList></Reference><Reference><Citation>Lomen-Hoerth C. Characterization of amyotrophic lateral sclerosis and frontotemporal dementia. Dement Geriatr Cogn Disord. 2004;17:337&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pubmed">15178949</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Deerlin VM, Sleiman PM, Martinez-Lage M. Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet. 2010;42:234&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2828525</ArticleId><ArticleId IdType="pubmed">20154673</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson SP, Wang K, Krantz I, Hakonarson H, Goldstein DB. Rare variants create synthetic genome-wide associations. PLoS Biol. 2010;8:e1000294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2811148</ArticleId><ArticleId IdType="pubmed">20126254</ArticleId></ArticleIdList></Reference><Reference><Citation>Laaksovirta H, Peuralinna T, Schymick JC. Chromosome 9p21 in amyotrophic lateral sclerosis in Finland: a genome-wide association study. Lancet Neurol. 2010 doi: 10.1016/S1474-4422(10)70184-8. published online Aug 31.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70184-8</ArticleId><ArticleId IdType="pmc">PMC2965392</ArticleId><ArticleId IdType="pubmed">20801718</ArticleId></ArticleIdList></Reference><Reference><Citation>Beaver JE, Tasan M, Gibbons FD, Tian W, Hughes TR, Roth FP. FuncBase: a resource for quantitative gene function annotation. Bioinformatics. 2010;26:1806&#x2013;1807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2894510</ArticleId><ArticleId IdType="pubmed">20495000</ArticleId></ArticleIdList></Reference><Reference><Citation>Wain LV, Pedroso I, Landers JE. The role of copy number variation in susceptibility to amyotrophic lateral sclerosis: genome-wide association study and comparison with published loci. PLoS ONE. 2009;4:e8175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2780722</ArticleId><ArticleId IdType="pubmed">19997636</ArticleId></ArticleIdList></Reference><Reference><Citation>Cronin S, Blauw HM, Veldink JH. Analysis of genome-wide copy number variation in Irish and Dutch amyotrophic lateral sclerosis populations. Hum Mol Genet. 2008;17:3392&#x2013;3398.</Citation><ArticleIdList><ArticleId IdType="pubmed">18689356</ArticleId></ArticleIdList></Reference><Reference><Citation>Blauw HM, Veldink JH, van Es MA. Copy-number variation in sporadic amyotrophic lateral sclerosis: a genome-wide screen. Lancet Neurol. 2008;7:319&#x2013;326.</Citation><ArticleIdList><ArticleId IdType="pubmed">18313986</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20801718</PMID><DateCompleted><Year>2010</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1474-4465</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>10</Issue><PubDate><Year>2010</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The Lancet. Neurology</Title><ISOAbbreviation>Lancet Neurol</ISOAbbreviation></Journal><ArticleTitle>Chromosome 9p21 in amyotrophic lateral sclerosis in Finland: a genome-wide association study.</ArticleTitle><Pagination><StartPage>978</StartPage><EndPage>985</EndPage><MedlinePgn>978-85</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1474-4422(10)70184-8</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The genetic cause of amyotrophic lateral sclerosis (ALS) is not well understood. Finland is a well suited location for a genome-wide association study of ALS because the incidence of the disease is one of the highest in the world, and because the genetic homogeneity of the Finnish population enhances the ability to detect risk loci. We aimed to identify genetic risk factors for ALS in the Finnish population.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We did a genome-wide association study of Finnish patients with ALS and control individuals by use of Illumina genome-wide genotyping arrays. DNA was collected from patients who attended an ALS specialty clinic that receives referrals from neurologists throughout Finland. Control samples were from a population-based study of elderly Finnish individuals. Patients known to carry D90A alleles of the SOD1 gene (n=40) were included in the final analysis as positive controls to assess whether our genome-wide association study was able to detect an association signal at this locus.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">We obtained samples from 442 patients with ALS and 521 control individuals. After quality control filters were applied, 318&#x2008;167 single nucleotide polymorphisms (SNPs) from 405 people with ALS and 497 control individuals were available for analysis. We identified two association peaks that exceeded genome-wide significance. One was located on chromosome 21q22 (rs13048019, p=2&#xb7;58&#xd7;10(-8)), which corresponds to the autosomal recessive D90A allele of the SOD1 gene. The other was detected in a 232 kb block of linkage disequilibrium (rs3849942, p=9&#xb7;11&#xd7;10(-11)) in a region of chromosome 9p that was previously identified in linkage studies of families with ALS. Within this region, we defined a 42-SNP haplotype that was associated with significantly increased risk of ALS (p=7&#xb7;47&#xd7;10(-33) when people with familial ALS were compared with controls, odds ratio 21&#xb7;0, 95% CI 11&#xb7;2-39&#xb7;1) and which overlapped with an association locus recently reported for frontotemporal dementia. For the 93 patients with familial ALS, the population attributable risk for the chromosome 9p21 locus was 37&#xb7;9% (95% CI 27&#xb7;7-48&#xb7;1) and that for D90A homozygosity was 25&#xb7;5% (16&#xb7;9-34&#xb7;1).</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">The chromosome 9p21 locus is a major cause of familial ALS in the Finnish population. Our data suggest the presence of a founder mutation for chromosome 9p21-linked ALS. Furthermore, the overlap with the risk haplotype recently reported for frontotemporal dementia provides further evidence of a shared genetic cause for these two neurodegenerative diseases.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">National Institutes of Health and National Institute on Aging, Microsoft Research, ALS Association, Helsinki University Central Hospital, Finnish Academy, Finnish Medical Society Duodecim, and Kuopio University.</AbstractText><CopyrightInformation>Copyright &#xa9; 2010 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Laaksovirta</LastName><ForeName>Hannu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Helsinki University Central Hospital and Molecular Neurology Programme, Biomedicum, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peuralinna</LastName><ForeName>Terhi</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Schymick</LastName><ForeName>Jennifer C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Scholz</LastName><ForeName>Sonja W</ForeName><Initials>SW</Initials></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Shaoi-Lin</ForeName><Initials>SL</Initials></Author><Author ValidYN="Y"><LastName>Myllykangas</LastName><ForeName>Liisa</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Sulkava</LastName><ForeName>Raimo</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Jansson</LastName><ForeName>Lilja</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Hernandez</LastName><ForeName>Dena G</ForeName><Initials>DG</Initials></Author><Author ValidYN="Y"><LastName>Gibbs</LastName><ForeName>J Raphael</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Nalls</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Heckerman</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Tienari</LastName><ForeName>Pentti J</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>Traynor</LastName><ForeName>Bryan J</ForeName><Initials>BJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Z01 AG000949</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>ZIA AG000933</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>Z01-AG000949-02</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Neurol</MedlineTA><NlmUniqueID>101139309</NlmUniqueID><ISSNLinking>1474-4422</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2010 Oct;9(10):945-7. doi: 10.1016/S1474-4422(10)70211-8.</RefSource><PMID Version="1">20801719</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002899" MajorTopicYN="N">Chromosomes, Human, Pair 9</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005387" MajorTopicYN="N">Finland</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056426" MajorTopicYN="N">Genetic Loci</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflicts of interest</b>. David Heckerman is Senior Director of the eScience Research Group at Microsoft Research. Hannu Laaksovirta has received payment from Sanofi-Aventis and Rhone-Poulenc Rorer for development of educational presentations including services on speakers&#x2019; bureaus, as well as travel and accommodation expenses from Rhone-Poulenc-Rorer. None of the other authors have any conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>10</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20801718</ArticleId><ArticleId IdType="mid">NIHMS241967</ArticleId><ArticleId IdType="pmc">PMC2965392</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(10)70184-8</ArticleId><ArticleId IdType="pii">S1474-4422(10)70184-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med. 2001;344:1688&#x2013;1700.</Citation><ArticleIdList><ArticleId IdType="pubmed">11386269</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Schymick JC, Restagno G, et al. A two-stage genome-wide association study of sporadic amyotrophic lateral sclerosis. Hum Mol Genet. 2009;18:1524&#x2013;1532.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2664150</ArticleId><ArticleId IdType="pubmed">19193627</ArticleId></ArticleIdList></Reference><Reference><Citation>Schymick JC, Scholz SW, Fung HC, et al. Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol. 2007;6:322&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pubmed">17362836</ArticleId></ArticleIdList></Reference><Reference><Citation>Cronin S, Berger S, Ding J, et al. A genome-wide association study of sporadic ALS in a homogenous Irish population. Hum Mol Genet. 2008;17:768&#x2013;774.</Citation><ArticleIdList><ArticleId IdType="pubmed">18057069</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunckley T, Huentelman MJ, Craig DW, et al. Whole-genome analysis of sporadic amyotrophic lateral sclerosis. N Engl J Med. 2007;357:775&#x2013;788.</Citation><ArticleIdList><ArticleId IdType="pubmed">17671248</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es MA, Van Vught PW, Blauw HM, et al. ITPR2 as a susceptibility gene in sporadic amyotrophic lateral sclerosis: a genome-wide association study. Lancet Neurol. 2007;6:869&#x2013;877.</Citation><ArticleIdList><ArticleId IdType="pubmed">17827064</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es MA, van Vught PW, Blauw HM, et al. Genetic variation in DPP6 is associated with susceptibility to amyotrophic lateral sclerosis. Nat Genet. 2008;40:29&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">18084291</ArticleId></ArticleIdList></Reference><Reference><Citation>Landers JE, Melki J, Meininger V, et al. Reduced expression of the Kinesin-Associated Protein 3 (KIFAP3) gene increases survival in sporadic amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2009;106:9004&#x2013;9009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2683883</ArticleId><ArticleId IdType="pubmed">19451621</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es MA, Veldink JH, Saris CG, et al. Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet. 2009;40:29&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734901</ArticleId></ArticleIdList></Reference><Reference><Citation>Shifman S, Darvasi A. The value of isolated populations. Nat Genet. 2001;28:309&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pubmed">11479587</ArticleId></ArticleIdList></Reference><Reference><Citation>Cronin S, Hardiman O, Traynor BJ. Ethnic variation in the incidence of ALS: a systematic review. Neurology. 2007;68:1002&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pubmed">17389304</ArticleId></ArticleIdList></Reference><Reference><Citation>Murros K, Fogelholm R. Amyotrophic lateral sclerosis in Middle-Finland: an epidemiological study. Acta Neurol Scand. 1983;67:41&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">6601351</ArticleId></ArticleIdList></Reference><Reference><Citation>Kere J. Human population genetics: lessons from Finland. Annu Rev Genomics Hum Genet. 2001;2:103&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">11701645</ArticleId></ArticleIdList></Reference><Reference><Citation>Peltonen L, Jalanko A, Varilo T. Molecular genetics of the Finnish disease heritage. Hum Mol Genet. 1999;8:1913&#x2013;1923.</Citation><ArticleIdList><ArticleId IdType="pubmed">10469845</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen PM, Nilsson P, Ala-Hurula V, et al. Amyotrophic lateral sclerosis associated with homozygosity for an Asp90Ala mutation in CuZn-superoxide dismutase. Nat Genet. 1995;10:61&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">7647793</ArticleId></ArticleIdList></Reference><Reference><Citation>Luty AA, Kwok JB, Thompson EM, et al. Pedigree with frontotemporal lobar degeneration--motor neuron disease and Tar DNA binding protein-43 positive neuropathology: genetic linkage to chromosome 9. BMC Neurol. 2008;8:32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2553097</ArticleId><ArticleId IdType="pubmed">18755042</ArticleId></ArticleIdList></Reference><Reference><Citation>Morita M, Al-Chalabi A, Andersen PM, et al. A locus on chromosome 9p confers susceptibility to ALS and frontotemporal dementia. Neurology. 2006;66:839&#x2013;844.</Citation><ArticleIdList><ArticleId IdType="pubmed">16421333</ArticleId></ArticleIdList></Reference><Reference><Citation>Valdmanis PN, Dupre N, Bouchard JP, et al. Three families with amyotrophic lateral sclerosis and frontotemporal dementia with evidence of linkage to chromosome 9p. Arch Neurol. 2007;64:240&#x2013;245.</Citation><ArticleIdList><ArticleId IdType="pubmed">17296840</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C, Al-Chalabi A, Ruddy D, et al. Familial amyotrophic lateral sclerosis with frontotemporal dementia is linked to a locus on chromosome 9p13.2&#x2013;21.3. Brain. 2006;129:868&#x2013;876.</Citation><ArticleIdList><ArticleId IdType="pubmed">16495328</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Ber I, Camuzat A, Berger E, et al. Chromosome 9p&#x2013;linked families with frontotemporal dementia associated with motor neuron disease. Neurology. 2009;72:1669&#x2013;1676.</Citation><ArticleIdList><ArticleId IdType="pubmed">19433740</ArticleId></ArticleIdList></Reference><Reference><Citation>Boxer AL, Mackenzie IR, Boeve BF, et al. Clinical, neuroimaging and neuropathological features of a new chromosome 9p&#x2013;linked FTD-ALS family. J Neurol Neurosurg Psychiatry. 2010 epub ahead of print.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3017222</ArticleId><ArticleId IdType="pubmed">20562461</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors. J Neurol Sci. 1994;124 Suppl:96&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">7807156</ArticleId></ArticleIdList></Reference><Reference><Citation>Polvikoski T, Sulkava R, Myllykangas L, et al. Prevalence of Alzheimer's disease in very elderly people: a prospective neuropathological study. Neurology. 2001;56:1690&#x2013;1696.</Citation><ArticleIdList><ArticleId IdType="pubmed">11425935</ArticleId></ArticleIdList></Reference><Reference><Citation>Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81:559&#x2013;575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1950838</ArticleId><ArticleId IdType="pubmed">17701901</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">15297300</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter SD. Calculation of attributable risks from epidemiological data. Int J Epidemiol. 1978;7:175&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">681063</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Deerlin VM, Sleiman PM, Martinez-Lage M, et al. Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet. 2010;42:234&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2828525</ArticleId><ArticleId IdType="pubmed">20154673</ArticleId></ArticleIdList></Reference><Reference><Citation>Shatunov A, Mok K, Newhouse S, et al. Chromosome 9p21.2 is the only replicable susceptibility locus for sporadic ALS. Lancet Neurol. 2010</Citation></Reference><Reference><Citation>Anttonen AK, Metzidis A, Avela K, Aula P, Peltonen L. Finnish Disease Database.  [accessed 07/06/2010].  Available from:  www.findis.org.</Citation></Reference><Reference><Citation>Sorenson EJ, Mandrekar J, Crum B, Stevens JC. Effect of referral bias on assessing survival in ALS. Neurology. 2007;68:600&#x2013;602.</Citation><ArticleIdList><ArticleId IdType="pubmed">17310031</ArticleId></ArticleIdList></Reference><Reference><Citation>Luca D, Ringquist S, Klei L, et al. On the Use of General Control Samples for Genome-wide Association Studies: Genetic Matching Highlights Causal Variants. Am J Hum Genet. 2008;82:453&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2427172</ArticleId><ArticleId IdType="pubmed">18252225</ArticleId></ArticleIdList></Reference><Reference><Citation>Ince PG, Lowe J, Shaw PJ. Amyotrophic lateral sclerosis: current issues in classification, pathogenesis and molecular pathology. Neuropathol Appl Neurobiol. 1998;24:104&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">9634206</ArticleId></ArticleIdList></Reference><Reference><Citation>Gislason TB, Sjogren M, Larsson L, Skoog I. The prevalence of frontal variant frontotemporal dementia and the frontal lobe syndrome in a population based sample of 85 year olds. J Neurol Neurosurg Psychiatry. 2003;74:867&#x2013;871.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1738520</ArticleId><ArticleId IdType="pubmed">12810769</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20811458</PMID><DateCompleted><Year>2010</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>467</Volume><Issue>7311</Issue><PubDate><Year>2010</Year><Month>Sep</Month><Day>02</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease.</ArticleTitle><Pagination><StartPage>95</StartPage><EndPage>98</EndPage><MedlinePgn>95-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature09325</ELocationID><Abstract><AbstractText>Accumulation of neurotoxic amyloid-beta is a major hallmark of Alzheimer's disease. Formation of amyloid-beta is catalysed by gamma-secretase, a protease with numerous substrates. Little is known about the molecular mechanisms that confer substrate specificity on this potentially promiscuous enzyme. Knowledge of the mechanisms underlying its selectivity is critical for the development of clinically effective gamma-secretase inhibitors that can reduce amyloid-beta formation without impairing cleavage of other gamma-secretase substrates, especially Notch, which is essential for normal biological functions. Here we report the discovery of a novel gamma-secretase activating protein (GSAP) that drastically and selectively increases amyloid-beta production through a mechanism involving its interactions with both gamma-secretase and its substrate, the amyloid precursor protein carboxy-terminal fragment (APP-CTF). GSAP does not interact with Notch, nor does it affect its cleavage. Recombinant GSAP stimulates amyloid-beta production in vitro. Reducing GSAP concentrations in cell lines decreases amyloid-beta concentrations. Knockdown of GSAP in a mouse model of Alzheimer's disease reduces levels of amyloid-beta and plaque development. GSAP represents a type of gamma-secretase regulator that directs enzyme specificity by interacting with a specific substrate. We demonstrate that imatinib, an anticancer drug previously found to inhibit amyloid-beta formation without affecting Notch cleavage, achieves its amyloid-beta-lowering effect by preventing GSAP interaction with the gamma-secretase substrate, APP-CTF. Thus, GSAP can serve as an amyloid-beta-lowering therapeutic target without affecting other key functions of gamma-secretase.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>He</LastName><ForeName>Gen</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, 1230 York Avenue, New York, New York 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Wenjie</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Peng</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Remmers</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Netzer</LastName><ForeName>William J</ForeName><Initials>WJ</Initials></Author><Author ValidYN="Y"><LastName>Hendrick</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Bettayeb</LastName><ForeName>Karima</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Flajolet</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Gorelick</LastName><ForeName>Fred</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Wennogle</LastName><ForeName>Lawrence P</ForeName><Initials>LP</Initials></Author><Author ValidYN="Y"><LastName>Greengard</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG009464</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 DK007017</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG09464</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001549">Benzamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497762">Notch1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051881">Receptor, Notch1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C552288">gamma-secretase activating protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>8A1O1M485B</RegistryNumber><NameOfSubstance UI="D000068877">Imatinib Mesylate</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2010 Sep 2;467(7311):36-7. doi: 10.1038/467036a.</RefSource><PMID Version="1">20811445</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001549" MajorTopicYN="N">Benzamides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055785" MajorTopicYN="N">Gene Knockdown Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068877" MajorTopicYN="N">Imatinib Mesylate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034622" MajorTopicYN="N">RNA Interference</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051881" MajorTopicYN="N">Receptor, Notch1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>7</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20811458</ArticleId><ArticleId IdType="mid">NIHMS219773</ArticleId><ArticleId IdType="pmc">PMC2936959</ArticleId><ArticleId IdType="doi">10.1038/nature09325</ArticleId><ArticleId IdType="pii">nature09325</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 2001;81:741&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner H, Fluhrer R, Haass C. Intramembrane proteolysis by gamma-secretase. J Biol Chem. 2008;283:29627&#x2013;29631.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2662049</ArticleId><ArticleId IdType="pubmed">18650432</ArticleId></ArticleIdList></Reference><Reference><Citation>Lathia JD, Mattson MP, Cheng A. Notch: from neural development to neurological disorders. J Neurochem. 2008;107:1471&#x2013;1481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4544712</ArticleId><ArticleId IdType="pubmed">19094054</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong GT, Manfra D, Poulet FM, Zhang Q, Josien H, Bara T, Engstrom L, Pinzon-Ortiz M, Fine JS, Lee HJ, Zhang L, Higgins GA, Parker EM. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem. 2004;279:12876&#x2013;12882.</Citation><ArticleIdList><ArticleId IdType="pubmed">14709552</ArticleId></ArticleIdList></Reference><Reference><Citation>Netzer WJ, Dou F, Cai D, Veach D, Jean S, Li Y, Bornmann WG, Clarkson B, Xu H, Greengard P. Gleevec inhibits beta-amyloid production but not Notch cleavage. Proc Natl Acad Sci U S A. 2003;100:12444&#x2013;12449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC218777</ArticleId><ArticleId IdType="pubmed">14523244</ArticleId></ArticleIdList></Reference><Reference><Citation>Placanica L, Tarassishin L, Yang G, Peethumnongsin E, Kim SH, Zheng H, Sisodia SS, Li YM. Pen2 and presenilin-1 modulate the dynamic equilibrium of presenilin-1 and presenilin-2 gamma-secretase complexes. J Biol Chem. 2009;284:2967&#x2013;2977.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2631949</ArticleId><ArticleId IdType="pubmed">19036728</ArticleId></ArticleIdList></Reference><Reference><Citation>Dougan DA, Mogk A, Zeth K, Turgay K, Bukau B. AAA+ proteins and substrate recognition, it all depends on their partner in crime. FEBS Lett. 2002;529:6&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">12354604</ArticleId></ArticleIdList></Reference><Reference><Citation>Visintin R, Prinz S, Amon A. CDC20 and CDH1: a family of substrate-specific activators of APC-dependent proteolysis. Science. 1997;278:460&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pubmed">9334304</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefranc-Jullien S, Sunyach C, Checler F. APP&#x3b5;, the &#x3b5;-secretase-derived N-terminal product of the &#x3b2;-amyloid precursor protein, behaves as a type I protein and undergoes &#x3b1;-, &#x3b2;-, and &#x3b3;-secretase cleavages. J. Neurochem. 2006;97:807&#x2013;817.</Citation><ArticleIdList><ArticleId IdType="pubmed">16524370</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng. 2001;17:157&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">11337275</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es JH, van Gijn ME, Riccio O, van den Born M, Vooijs M, Begthel H, Cozijnsen M, Robine S, Winton DJ, Radtke F, Clevers H. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature. 2005;435:959&#x2013;963.</Citation><ArticleIdList><ArticleId IdType="pubmed">15959515</ArticleId></ArticleIdList></Reference><Reference><Citation>Milano J, McKay J, Dagenais C, Foster-Brown L, Pognan F, Gadient R, Jacobs RT, Zacco A, Greenberg B, Ciaccio PJ. Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol Sci. 2004;82:341&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pubmed">15319485</ArticleId></ArticleIdList></Reference><Reference><Citation>Beel AJ, Sanders CR. Substrate specificity of gamma-secretase and other intramembrane proteases. Cell Mol Life Sci. 2008;65:1311&#x2013;1334.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2569971</ArticleId><ArticleId IdType="pubmed">18239854</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen F, Hasegawa H, Schmitt-Ulms G, Kawarai T, Bohm C, Katayama T, Gu Y, Sanjo N, Glista M, Rogaeva E, Wakutani Y, Pardossi-Piquard R, Ruan X, Tandon A, Checler F, Marambaud P, Hansen K, Westaway D, George-Hyslop P, Fraser P. TMP21 is a presenilin complex component that modulates gamma-secretase but not epsilon-secretase activity. Nature. 2006;440:1208&#x2013;1212.</Citation><ArticleIdList><ArticleId IdType="pubmed">16641999</ArticleId></ArticleIdList></Reference><Reference><Citation>Thathiah A, Spittaels K, Hoffmann M, Staes M, Cohen A, Horr&#xe9; K, Vanbrabant M, Coun F, Baekelandt V, Delacourte A, Fischer DF, Pollet D, De Strooper B, Merchiers P. The orphan G protein-coupled receptor 3 modulates amyloid-beta peptide generation in neurons. Science. 2009;323:946&#x2013;951.</Citation><ArticleIdList><ArticleId IdType="pubmed">19213921</ArticleId></ArticleIdList></Reference><Reference><Citation>Serneels L, Van Biervliet J, Craessaerts K, Dejaegere T, Horr&#xe9; K, Van Houtvin T, Esselmann H, Paul S, Sch&#xe4;fer MK, Berezovska O, Hyman BT, Sprangers B, Sciot R, Moons L, Jucker M, Yang Z, May PC, Karran E, Wiltfang J, D'Hooge R, De Strooper B. gamma-Secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer's disease. Science. 2009;324:639&#x2013;642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2740474</ArticleId><ArticleId IdType="pubmed">19299585</ArticleId></ArticleIdList></Reference><Reference><Citation>Takami M, Nagashima Y, Sano Y, Ishihara S, Morishima-Kawashima M, Funamoto S, Ihara Y. gamma-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. J Neurosci. 2009;29:13042&#x2013;13052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6665297</ArticleId><ArticleId IdType="pubmed">19828817</ArticleId></ArticleIdList></Reference><Reference><Citation>Kume H, Kametani F. Abeta 11-40/42 production without gamma-secretase epsilon-site cleavage. Biochem Biophys Res Commun. 2006;349:1356&#x2013;1360.</Citation><ArticleIdList><ArticleId IdType="pubmed">16979587</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiley JC, Hudson M, Kanning KC, Schecterson LC, Bothwell M. Familial Alzheimer's disease mutations inhibit gamma-secretase-mediated liberation of beta-amyloid precursor protein carboxy-terminal fragment. J Neurochem. 2005;94:1189&#x2013;1201.</Citation><ArticleIdList><ArticleId IdType="pubmed">15992373</ArticleId></ArticleIdList></Reference><Reference><Citation>Bentahir M, Nyabi O, Verhamme J, Tolia A, Horr&#xe9; K, Wiltfang J, Esselmann H, De Strooper B. Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. J Neurochem. 2006;96:732&#x2013;742.</Citation><ArticleIdList><ArticleId IdType="pubmed">16405513</ArticleId></ArticleIdList></Reference><Reference><Citation>Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, Zavitz KH. Tarenflurbil Phase 3 Study Group. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA. 2009;302:2557&#x2013;2564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2902875</ArticleId><ArticleId IdType="pubmed">20009055</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai H, Marbach P, Lemaire M, Hayes M, Elmquist WF. Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol. Exp. Ther. 2003;304:1085&#x2013;1092.</Citation><ArticleIdList><ArticleId IdType="pubmed">12604685</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Luo WJ, Zhang YW, Li YM, Thinakaran G, Greengard P, Xu H. Presenilins and gamma-secretase inhibitors affect intracellular trafficking and cell surface localization of the gamma-secretase complex components. J Biol Chem. 2004;279:40560&#x2013;40566.</Citation><ArticleIdList><ArticleId IdType="pubmed">15247291</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H, Gouras GK, Greenfield JP, Vincent B, Naslund J, Mazzarelli L, Fried G, Jovanovic JN, Seeger M, Relkin NR, Liao F, Checler F, Buxbaum JD, Chait BT, Thinakaran G, Sisodia SS, Wang R, Greengard P, Gandy S. Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides. Nat Med. 1998;4:447&#x2013;451.</Citation><ArticleIdList><ArticleId IdType="pubmed">9546791</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YM, Lai MT, Xu M, Huang Q, DiMuzio-Mower J, Sardana MK, Shi XP, Yin KC, Shafer JA, Gardell SJ. Presenilin 1 is linked with gamma-secretase activity in the detergent solubilized state. Proc Natl Acad Sci U S A. 2000;97:6138&#x2013;6143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18571</ArticleId><ArticleId IdType="pubmed">10801983</ArticleId></ArticleIdList></Reference><Reference><Citation>Seibler J, Kleinridders A, K&#xfc;ter-Luks B, Niehaves S, Br&#xfc;ning JC, Schwenk F. Reversible gene knockdown in mice using a tight, inducible shRNA expression system. Nucleic Acids Res. 2007;35:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1874634</ArticleId><ArticleId IdType="pubmed">17376804</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20826675</PMID><DateCompleted><Year>2010</Year><Month>10</Month><Day>04</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>36</Issue><PubDate><Year>2010</Year><Month>Sep</Month><Day>08</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>NMDA-mediated Ca(2+) influx drives aberrant ryanodine receptor activation in dendrites of young Alzheimer's disease mice.</ArticleTitle><Pagination><StartPage>12128</StartPage><EndPage>12137</EndPage><MedlinePgn>12128-37</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.2474-10.2010</ELocationID><Abstract><AbstractText>Deficits in synaptic function, particularly through NMDA receptors (NMDARs), are linked to late-stage cognitive impairments in Alzheimer's disease (AD). At earlier disease stages, however, there is evidence for altered endoplasmic reticulum (ER) calcium signaling in human cases and in neurons from AD mouse models. Despite the fundamental importance of calcium to synaptic function, neither the extent of ER calcium dysregulation in dendrites nor its interaction with synaptic function in AD pathophysiology is known. Identifying the mechanisms underlying early synaptic calcium dysregulation in AD pathogenesis is likely a key component to understanding, and thereby preventing, the synapse loss and downstream cognitive impairments. Using two-photon calcium imaging, flash photolysis of caged glutamate, and patch-clamp electrophysiology in cortical brain slices, we examined interactions between synaptically and ER-evoked calcium release at glutamatergic synapses in young AD transgenic mice. We found increased ryanodine receptor-evoked calcium signals within dendritic spine heads, dendritic processes, and the soma of pyramidal neurons from 3xTg-AD and TAS/TPM AD mice relative to NonTg controls. In addition, synaptically evoked postsynaptic calcium responses were larger in the AD strains, as were calcium signals generated from NMDAR activation. However, calcium responses triggered by back-propagating action potentials were not different. Concurrent activation of ryanodine receptors (RyRs) with either synaptic or NMDAR stimulation generated a supra-additive calcium response in the AD strains, suggesting an aberrant calcium-induced calcium release (CICR) effect within spines and dendrites. We propose that presenilin-linked disruptions in RyR signaling and subsequent CICR via NMDAR-mediated calcium influx alters synaptic function and serves as an early pathogenic factor in AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goussakov</LastName><ForeName>Ivan</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Rosalind Franklin University of Medicine and Science/The Chicago Medical School, North Chicago, Illinois 60064, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Megan B</ForeName><Initials>MB</Initials></Author><Author ValidYN="Y"><LastName>Stutzmann</LastName><ForeName>Grace E</ForeName><Initials>GE</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG030205</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG030205</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000697">Central Nervous System Stimulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018690">Excitatory Amino Acid Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018691">Excitatory Amino Acid Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019837">Ryanodine Receptor Calcium Release Channel</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>3G6A5W338E</RegistryNumber><NameOfSubstance UI="D002110">Caffeine</NameOfSubstance></Chemical><Chemical><RegistryNumber>6384-92-5</RegistryNumber><NameOfSubstance UI="D016202">N-Methylaspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>9005-49-6</RegistryNumber><NameOfSubstance UI="D006493">Heparin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.2.13</RegistryNumber><NameOfSubstance UI="D011503">Transglutaminases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.2.13</RegistryNumber><NameOfSubstance UI="C105804">transglutaminase 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>J6K4F9V3BA</RegistryNumber><NameOfSubstance UI="D019256">Cadmium Chloride</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019256" MajorTopicYN="N">Cadmium Chloride</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002110" MajorTopicYN="N">Caffeine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000697" MajorTopicYN="N">Central Nervous System Stimulants</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004558" MajorTopicYN="N">Electric Stimulation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004721" MajorTopicYN="N">Endoplasmic Reticulum</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018690" MajorTopicYN="N">Excitatory Amino Acid Agonists</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018691" MajorTopicYN="N">Excitatory Amino Acid Antagonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019706" MajorTopicYN="N">Excitatory Postsynaptic Potentials</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006493" MajorTopicYN="N">Heparin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008564" MajorTopicYN="N">Membrane Potentials</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018613" MajorTopicYN="N">Microscopy, Confocal</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016202" MajorTopicYN="N">N-Methylaspartate</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018408" MajorTopicYN="N">Patch-Clamp Techniques</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017966" MajorTopicYN="N">Pyramidal Cells</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019837" MajorTopicYN="N">Ryanodine Receptor Calcium Release Channel</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011503" MajorTopicYN="N">Transglutaminases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>3</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20826675</ArticleId><ArticleId IdType="mid">NIHMS234055</ArticleId><ArticleId IdType="pmc">PMC2944253</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2474-10.2010</ArticleId><ArticleId IdType="pii">30/36/12128</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Berridge MJ. Calcium microdomains: organization and function. Cell Calcium. 2006;40:405&#x2013;412.</Citation><ArticleIdList><ArticleId IdType="pubmed">17030366</ArticleId></ArticleIdList></Reference><Reference><Citation>Bezprozvanny I, Mattson MP. Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Trends Neurosci. 2008;31:454&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2566585</ArticleId><ArticleId IdType="pubmed">18675468</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouchard R, Pattarini R, Geiger JD. Presence and functional significance of presynaptic ryanodine receptors. Prog Neurobiol. 2003;69:391&#x2013;418.</Citation><ArticleIdList><ArticleId IdType="pubmed">12880633</ArticleId></ArticleIdList></Reference><Reference><Citation>Brennan AR, Dolinsky B, Vu MA, Stanley M, Yeckel MF, Arnsten AF. Blockade of IP3-mediated SK channel signaling in the rat medial prefrontal cortex improves spatial working memory. Learn Mem. 2008;15:93&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2275660</ArticleId><ArticleId IdType="pubmed">18285467</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns A, Jacoby R. Dimebon in Alzheimer's disease: old drug for new indication. Lancet. 2008;372:179&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">18640436</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakroborty S, Goussakov I, Miller MB, Stutzmann GE. Deviant ryanodine receptor-mediated calcium release resets synaptic homeostasis in presymptomatic 3xTg-AD mice. J Neurosci. 2009;29:9458&#x2013;9470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6666542</ArticleId><ArticleId IdType="pubmed">19641109</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung KH, Shineman D, M&#xfc;ller M, C&#xe1;rdenas C, Mei L, Yang J, Tomita T, Iwatsubo T, Lee VM, Foskett JK. Mechanism of Ca2+ disruption in Alzheimer's disease by presenilin regulation of InsP3 receptor channel gating. Neuron. 2008;58:871&#x2013;883.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2495086</ArticleId><ArticleId IdType="pubmed">18579078</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung KH, Mei L, Mak DO, Hayashi I, Iwatsubo T, Kang DE, Foskett JK. Gain-of-function enhancement of IP3 receptor modal gating by familial Alzheimer's disease-linked presenilin mutants in human cells and mouse neurons. Sci Signal. 2010;3:ra22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2898196</ArticleId><ArticleId IdType="pubmed">20332427</ArticleId></ArticleIdList></Reference><Reference><Citation>Collin T, Marty A, Llano I. Presynaptic calcium stores and synaptic transmission. Curr Opin Neurobiol. 2005;15:275&#x2013;281.</Citation><ArticleIdList><ArticleId IdType="pubmed">15919193</ArticleId></ArticleIdList></Reference><Reference><Citation>Demuro A, Parker I, Stutzmann GE. Calcium signaling and amyloid toxicity in Alzheimer's disease. J Biol Chem. 2010;285:12463&#x2013;12468.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2857063</ArticleId><ArticleId IdType="pubmed">20212036</ArticleId></ArticleIdList></Reference><Reference><Citation>Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, Seely L, Hung D. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet. 2008;372:207&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">18640457</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick JS, Hagenston AM, Hertle DN, Gipson KE, Bertetto-D'Angelo L, Yeckel MF. IP3 receptor-dependent Ca2+ waves in pyramidal neuron dendrites propagate through hot spots and cold spots. J Physiol. 2009;587:1439&#x2013;1459.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2678218</ArticleId><ArticleId IdType="pubmed">19204047</ArticleId></ArticleIdList></Reference><Reference><Citation>Harkany T, Hortob&#xe1;gyi T, Sasv&#xe1;ri M, K&#xf3;nya C, Penke B, Luiten PG, Nyakas C. Neuroprotective approaches in experimental models of beta-amyloid neurotoxicity: relevance to Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry. 1999;23:963&#x2013;1008.</Citation><ArticleIdList><ArticleId IdType="pubmed">10621945</ArticleId></ArticleIdList></Reference><Reference><Citation>Hertle DN, Yeckel MF. Distribution of inositol-1,4,5-trisphosphate receptor isotypes and ryanodine receptor isotypes during maturation of the rat hippocampus. Neuroscience. 2007;150:625&#x2013;638.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2238340</ArticleId><ArticleId IdType="pubmed">17981403</ArticleId></ArticleIdList></Reference><Reference><Citation>Howlett DR, Richardson JC, Austin A, Parsons AA, Bate ST, Davies DC, Gonzalez MI. Cognitive correlates of Abeta deposition in male and female mice bearing amyloid precursor protein and presenilin-1 mutant transgenes. Brain Res. 2004;1017:130&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pubmed">15261108</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones VC, McKeown L, Verkhratsky A, Jones OT. LV-pIN-KDEL: a novel lentiviral vector demonstrates the morphology, dynamics and continuity of the endoplasmic reticulum in live neurons. BMC Neurosci. 2008;9:10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2248189</ArticleId><ArticleId IdType="pubmed">18215281</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller DX, Franks KM, Bartol TM, Jr, Sejnowski TJ. Calmodulin activation by calcium transients in the postsynaptic density of dendritic spines. PLoS One. 2008;3:e2045.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2312328</ArticleId><ArticleId IdType="pubmed">18446197</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelliher M, Fastbom J, Cowburn RF, Bonkale W, Ohm TG, Ravid R, Sorrentino V, O'Neill C. Alterations in the ryanodine receptor calcium release channel correlate with Alzheimer's disease neurofibrillary and beta-amyloid pathologies. Neuroscience. 1999;92:499&#x2013;513.</Citation><ArticleIdList><ArticleId IdType="pubmed">10408600</ArticleId></ArticleIdList></Reference><Reference><Citation>Korkotian E, Segal M. Morphological constraints on calcium dependent glutamate receptor trafficking into individual dendritic spine. Cell Calcium. 2007;42:41&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">17187855</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla FM. Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. Nat Rev Neurosci. 2002;3:862&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">12415294</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E. Mechanisms of synaptic dysfunction in Alzheimer's disease. Histol Histopathol. 1995;10:509&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">7599445</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuzaki M, Honkura N, Ellis-Davies GC, Kasai H. Structural basis of long-term potentiation in single dendritic spines. Nature. 2004;429:761&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4158816</ArticleId><ArticleId IdType="pubmed">15190253</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson O, Tu H, Lei T, Bentahir M, de Strooper B, Bezprozvanny I. Familial Alzheimer disease-linked mutations specifically disrupt Ca2+ leak function of presenilin 1. J Clin Invest. 2007;117:1230&#x2013;1239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1847535</ArticleId><ArticleId IdType="pubmed">17431506</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolay NH, Hertle D, Boehmerle W, Heidrich FM, Yeckel M, Ehrlich BE. Inositol 1,4,5 trisphosphate receptor and chromogranin B are concentrated in different regions of the hippocampus. J Neurosci Res. 2007;85:2026&#x2013;2036.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2945619</ArticleId><ArticleId IdType="pubmed">17471556</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Neill C, Cowburn RF, Bonkale WL, Ohm TG, Fastbom J, Carmody M, Kelliher M. Dysfunctional intracellular calcium homoeostasis: a central cause of neurodegeneration in Alzheimer's disease. Biochem Soc Symp. 2001:177&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">11447834</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003;39:409&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabatini BL, Svoboda K. Analysis of calcium channels in single spines using optical fluctuation analysis. Nature. 2000;408:589&#x2013;593.</Citation><ArticleIdList><ArticleId IdType="pubmed">11117746</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeber S, Humeny A, Herkert M, Rau T, Eschenhagen T, Becker CM. Formation of molecular complexes by N-methyl-d-aspartate receptor subunit NR2B and ryanodine receptor 2 in neonatal rat myocard. J Biol Chem. 2004;279:21062&#x2013;21068.</Citation><ArticleIdList><ArticleId IdType="pubmed">15010472</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res. 2008;192:106&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2601528</ArticleId><ArticleId IdType="pubmed">18359102</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloid-&#x3b2; protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci. 2007;27:2866&#x2013;2875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672572</ArticleId><ArticleId IdType="pubmed">17360908</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith IF, Hitt B, Green KN, Oddo S, LaFerla FM. Enhanced caffeine-induced Ca2+ release in the 3xTg-AD mouse model of Alzheimer's disease. J Neurochem. 2005;94:1711&#x2013;1718.</Citation><ArticleIdList><ArticleId IdType="pubmed">16156741</ArticleId></ArticleIdList></Reference><Reference><Citation>Spacek J, Harris KM. Three-dimensional organization of smooth endoplasmic reticulum in hippocampal CA1 dendrites and dendritic spines of the immature and mature rat. J Neurosci. 1997;17:190&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793680</ArticleId><ArticleId IdType="pubmed">8987748</ArticleId></ArticleIdList></Reference><Reference><Citation>Stutzmann GE. The pathogenesis of Alzheimers disease is it a lifelong &#x201c;calciumopathy&#x201d;? Neuroscientist. 2007;13:546&#x2013;559.</Citation><ArticleIdList><ArticleId IdType="pubmed">17901262</ArticleId></ArticleIdList></Reference><Reference><Citation>Stutzmann GE, Parker I. Dynamic multiphoton imaging: a live view from cells to systems. Physiology. 2005;20:15&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">15653835</ArticleId></ArticleIdList></Reference><Reference><Citation>Stutzmann GE, Caccamo A, LaFerla FM, Parker I. Dysregulated IP3 signaling in cortical neurons of knock-in mice expressing an Alzheimer's-linked mutation in presenilin1 results in exaggerated Ca2+ signals and altered membrane excitability. J Neurosci. 2004;24:508&#x2013;513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729995</ArticleId><ArticleId IdType="pubmed">14724250</ArticleId></ArticleIdList></Reference><Reference><Citation>Stutzmann GE, Smith I, Caccamo A, Oddo S, Laferla FM, Parker I. Enhanced ryanodine receptor recruitment contributes to Ca2+ disruptions in young, adult, and aged Alzheimer's disease mice. J Neurosci. 2006;26:5180&#x2013;5189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674246</ArticleId><ArticleId IdType="pubmed">16687509</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu H, Nelson O, Bezprozvanny A, Wang Z, Lee SF, Hao YH, Serneels L, De Strooper B, Yu G, Bezprozvanny I. Presenilins form ER Ca2+ leak channels, a function disrupted by familial Alzheimer's disease-linked mutations. Cell. 2006;126:981&#x2013;993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3241869</ArticleId><ArticleId IdType="pubmed">16959576</ArticleId></ArticleIdList></Reference><Reference><Citation>Verkhratsky A. Physiology and pathophysiology of the calcium store in the endoplasmic reticulum of neurons. Physiol Rev. 2005;85:201&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pubmed">15618481</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamin G. NMDA receptor-dependent signaling pathways that underlie amyloid beta-protein disruption of LTP in the hippocampus. J Neurosci Res. 2009;87:1729&#x2013;1736.</Citation><ArticleIdList><ArticleId IdType="pubmed">19170166</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Wu B, Beglopoulos V, Wines-Samuelson M, Zhang D, Dragatsis I, S&#xfc;dhof TC, Shen J. Presenilins are essential for regulating neurotransmitter release. Nature. 2009;460:632&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2744588</ArticleId><ArticleId IdType="pubmed">19641596</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20833873</PMID><DateCompleted><Year>2011</Year><Month>03</Month><Day>08</Day></DateCompleted><DateRevised><Year>2012</Year><Month>02</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-6860</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2011</Year><Month>Jan</Month></PubDate></JournalIssue><Title>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</Title><ISOAbbreviation>FASEB J</ISOAbbreviation></Journal><ArticleTitle>Mitochondrial &#x3b3;-secretase participates in the metabolism of mitochondria-associated amyloid precursor protein.</ArticleTitle><Pagination><StartPage>78</StartPage><EndPage>88</EndPage><MedlinePgn>78-88</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1096/fj.10-157230</ELocationID><Abstract><AbstractText>Intracellular amyloid-&#x3b2; peptide (A&#x3b2;) has been implicated in the pathogenesis of Alzheimer's disease (AD). Mitochondria were found to be the target both for amyloid precursor protein (APP) that accumulates in the mitochondrial import channels and for A&#x3b2; that interacts with several proteins inside mitochondria and leads to mitochondrial dysfunction. Here, we have studied the role of mitochondrial &#x3b3;-secretase in processing different substrates. We found that a significant proportion of APP is associated with mitochondria in cultured cells and that &#x3b3;-secretase cleaves the shedded C-terminal part of APP identified as C83 associated with the outer membrane of mitochondria (OMM). Moreover, we have established the topology of the C83 in the OMM and found the APP intracellular domain (AICD) to be located inside mitochondria. Our data show for the first time that APP is a substrate for the mitochondrial &#x3b3;-secretase and that AICD is produced inside mitochondria. Thus, we provide a mechanistic view of the mitochondria-associated APP metabolism where AICD, P3 peptide and potentially A&#x3b2; are produced locally and may contribute to mitochondrial dysfunction in AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pavlov</LastName><ForeName>Pavel F</ForeName><Initials>PF</Initials><AffiliationInfo><Affiliation>Karolinska Institutet and Dainippon Sumitomo Pharma Alzheimer Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Huddinge, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiehager</LastName><ForeName>Birgitta</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Sakai</LastName><ForeName>Jun</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Frykman</LastName><ForeName>Susanne</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Behbahani</LastName><ForeName>Homira</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Winblad</LastName><ForeName>Bengt</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Ankarcrona</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>09</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>FASEB J</MedlineTA><NlmUniqueID>8804484</NlmUniqueID><ISSNLinking>0892-6638</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002219">Carbamates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004151">Dipeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C410009">L 685458</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D024101">Mitochondrial Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053766">Presenilin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002219" MajorTopicYN="N">Carbamates</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004151" MajorTopicYN="N">Dipeptides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004622" MajorTopicYN="N">Embryo, Mammalian</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053595" MajorTopicYN="N">Embryonic Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018613" MajorTopicYN="N">Microscopy, Confocal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051336" MajorTopicYN="N">Mitochondrial Membranes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024101" MajorTopicYN="N">Mitochondrial Proteins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053766" MajorTopicYN="N">Presenilin-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013379" MajorTopicYN="N">Substrate Specificity</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20833873</ArticleId><ArticleId IdType="doi">10.1096/fj.10-157230</ArticleId><ArticleId IdType="pii">fj.10-157230</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20837517</PMID><DateCompleted><Year>2010</Year><Month>11</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>107</Volume><Issue>41</Issue><PubDate><Year>2010</Year><Month>Oct</Month><Day>12</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Spatial correlation between brain aerobic glycolysis and amyloid-&#x3b2; (A&#x3b2; ) deposition.</ArticleTitle><Pagination><StartPage>17763</StartPage><EndPage>17767</EndPage><MedlinePgn>17763-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1010461107</ELocationID><Abstract><AbstractText>Amyloid-&#x3b2; (A&#x3b2;) plaque deposition can precede the clinical manifestations of dementia of the Alzheimer type (DAT) by many years and can be associated with changes in brain metabolism. Both the A&#x3b2; plaque deposition and the changes in metabolism appear to be concentrated in the brain's default-mode network. In contrast to prior studies of brain metabolism which viewed brain metabolism from a unitary perspective that equated glucose utilization with oxygen consumption, we here report on regional glucose use apart from that entering oxidative phosphorylation (so-called "aerobic glycolysis"). Using PET, we found that the spatial distribution of aerobic glycolysis in normal young adults correlates spatially with A&#x3b2; deposition in individuals with DAT and cognitively normal participants with elevated A&#x3b2;, suggesting a possible link between regional aerobic glycolysis in young adulthood and later development of Alzheimer pathology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vlassenko</LastName><ForeName>Andrei G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Department of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vaishnavi</LastName><ForeName>S Neil</ForeName><Initials>SN</Initials></Author><Author ValidYN="Y"><LastName>Couture</LastName><ForeName>Lars</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Sacco</LastName><ForeName>Dana</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Shannon</LastName><ForeName>Benjamin J</ForeName><Initials>BJ</Initials></Author><Author ValidYN="Y"><LastName>Mach</LastName><ForeName>Robert H</ForeName><Initials>RH</Initials></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Raichle</LastName><ForeName>Marcus E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Mintun</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG05681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS006833</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F30 NS057901</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS048056</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P20 MH077967</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>09</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>IY9XDZ35W2</RegistryNumber><NameOfSubstance UI="D005947">Glucose</NameOfSubstance></Chemical><Chemical><RegistryNumber>S88TT14065</RegistryNumber><NameOfSubstance UI="D010100">Oxygen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Proc Natl Acad Sci U S A. 2010 Oct 12;107(41):17459-60. doi: 10.1073/pnas.1012684107.</RefSource><PMID Version="1">20921385</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2010 Nov;11(11):729. doi: 10.1038/nrn2937.</RefSource><PMID Version="1">20979317</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006019" MajorTopicYN="N">Glycolysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>9</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20837517</ArticleId><ArticleId IdType="pmc">PMC2955133</ArticleId><ArticleId IdType="doi">10.1073/pnas.1010461107</ArticleId><ArticleId IdType="pii">1010461107</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mattson MP. Pathways towards and away from Alzheimer's disease. Nature. 2004;430:631&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3091392</ArticleId><ArticleId IdType="pubmed">15295589</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulette CM, et al. Neuropathological and neuropsychological changes in &#x201c;normal&#x201d; aging: Evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol. 1998;57:1168&#x2013;1174.</Citation><ArticleIdList><ArticleId IdType="pubmed">9862640</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Price AL. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J Mol Neurosci. 2001;17:101&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">11816784</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006;59:512&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">16372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, et al. [11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894106</ArticleId></ArticleIdList></Reference><Reference><Citation>Raichle ME, et al. A default mode of brain function. Proc Natl Acad Sci USA. 2001;98:676&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC14647</ArticleId><ArticleId IdType="pubmed">11209064</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, et al. Molecular, structural, and functional characterization of Alzheimer's disease: Evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25:7709&#x2013;7717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Raichle ME, Snyder AZ. A default mode of brain function: A brief history of an evolving idea. Neuroimage. 2007;37:1083&#x2013;1090. discussion 1097&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">17719799</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Andrews-Hanna JR, Schacter DL. The brain's default network: Anatomy, function, and relevance to disease. Ann N Y Acad Sci. 2008;1124:1&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">18400922</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaishnavi SN, et al. Regional aerobic glycolysis in the human brain. Proc Natl Acad Sci USA. 2010 10.1079/pnas1010459107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2955101</ArticleId><ArticleId IdType="pubmed">20837536</ArticleId></ArticleIdList></Reference><Reference><Citation>Raichle ME, Posner JB, Plum F. Cerebral blood flow during and after hyperventilation. Arch Neurol. 1970;23:394&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">5471647</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle PJ, et al. Diminished brain glucose metabolism is a significant determinant for falling rates of systemic glucose utilization during sleep in normal humans. J Clin Invest. 1994;93:529&#x2013;535.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC293874</ArticleId><ArticleId IdType="pubmed">8113391</ArticleId></ArticleIdList></Reference><Reference><Citation>Powers WJ, et al. Selective defect of in vivo glycolysis in early Huntington's disease striatum. Proc Natl Acad Sci USA. 2007;104:2945&#x2013;2949.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1797149</ArticleId><ArticleId IdType="pubmed">17299049</ArticleId></ArticleIdList></Reference><Reference><Citation>Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science. 2009;324:1029&#x2013;1033.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2849637</ArticleId><ArticleId IdType="pubmed">19460998</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolanos JP, Delgado-Esteban M, Herrero-Mendez A, Fernandez-Fernandez S, Almeida A. Regulation of glycolysis and pentose-phosphate pathway by nitric oxide: Impact on neuronal survival. Biochim Biophys Acta. 2008;1777(7-8):789&#x2013;793.</Citation><ArticleIdList><ArticleId IdType="pubmed">18455501</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaughn AE, Deshmukh M. Glucose metabolism inhibits apoptosis in neurons and cancer cells by redox inactivation of cytochrome c. Nat Cell Biol. 2008;10:1477&#x2013;1483.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2626347</ArticleId><ArticleId IdType="pubmed">19029908</ArticleId></ArticleIdList></Reference><Reference><Citation>Jolivet R, Magistretti PJ, Weber B. Deciphering neuron-glia compartmentalization in cortical energy metabolism. Front Neuroenergetics. 2009;1:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2715922</ArticleId><ArticleId IdType="pubmed">19636395</ArticleId></ArticleIdList></Reference><Reference><Citation>Minoshima S, Cross DJ, Foster NL, Henry TR, Kuhl DE. Discordance between traditional pathologic and energy metabolic changes in very early Alzheimer's disease. Pathophysiological implications. Ann N Y Acad Sci. 1999;893:350&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pubmed">10672264</ArticleId></ArticleIdList></Reference><Reference><Citation>Minoshima S, Foster NL, Kuhl DE. Posterior cingulate cortex in Alzheimer's disease. Lancet. 1994;344:895.</Citation><ArticleIdList><ArticleId IdType="pubmed">7916431</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen AD, et al. Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: An example of brain reserve. J Neurosci. 2009;29:14770&#x2013;14778.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2810461</ArticleId><ArticleId IdType="pubmed">19940172</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabinovici GD, et al. Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden. Brain. 2010;133:512&#x2013;528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2858015</ArticleId><ArticleId IdType="pubmed">20080878</ArticleId></ArticleIdList></Reference><Reference><Citation>Reivich M, et al. The [18F fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. Circ Res. 1979;44:127&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">363301</ArticleId></ArticleIdList></Reference><Reference><Citation>Phelps ME, et al. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-d-glucose: Validation of method. Ann Neurol. 1979;6:371&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pubmed">117743</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke R, Herholz K, Grond M, Kessler J, Heiss WD. Clinical deterioration in probable Alzheimer's disease correlates with progressive metabolic impairment of association areas. Dementia. 1994;5:36&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">8156085</ArticleId></ArticleIdList></Reference><Reference><Citation>Minoshima S, et al. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol. 1997;42:85&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">9225689</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox PT, Raichle ME, Mintun MA, Dence C. Nonoxidative glucose consumption during focal physiologic neural activity. Science. 1988;241:462&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">3260686</ArticleId></ArticleIdList></Reference><Reference><Citation>Madsen PL, et al. Persistent resetting of the cerebral oxygen/glucose uptake ratio by brain activation: Evidence obtained with the Kety-Schmidt technique. J Cereb Blood Flow Metab. 1995;15:485&#x2013;491.</Citation><ArticleIdList><ArticleId IdType="pubmed">7714007</ArticleId></ArticleIdList></Reference><Reference><Citation>Warburg O. The Metabolism of Tumors. London: Constable &amp; Company; 1939. trans Dickens F.</Citation></Reference><Reference><Citation>Brand KA, Hermfisse U. Aerobic glycolysis by proliferating cells: A protective strategy against reactive oxygen species. FASEB J. 1997;11:388&#x2013;395.</Citation><ArticleIdList><ArticleId IdType="pubmed">9141507</ArticleId></ArticleIdList></Reference><Reference><Citation>Elston GN, Oga T, Fujita I. Spinogenesis and pruning scales across functional hierarchies. J Neurosci. 2009;29:3271&#x2013;3275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6666449</ArticleId><ArticleId IdType="pubmed">19279264</ArticleId></ArticleIdList></Reference><Reference><Citation>Tononi G, Cirelli C. Sleep function and synaptic homeostasis. Sleep Med Rev. 2006;10:49&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">16376591</ArticleId></ArticleIdList></Reference><Reference><Citation>Marder E, Prinz AA. Modeling stability in neuron and network function: The role of activity in homeostasis. Bioessays. 2002;24:1145&#x2013;1154.</Citation><ArticleIdList><ArticleId IdType="pubmed">12447979</ArticleId></ArticleIdList></Reference><Reference><Citation>Altman DI, Perlman JM, Volpe JJ, Powers WJ. Cerebral oxygen metabolism in newborns. Pediatrics. 1993;92:99&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">8516092</ArticleId></ArticleIdList></Reference><Reference><Citation>Powers WJ, Rosenbaum JL, Dence CS, Markham J, Videen TO. Cerebral glucose transport and metabolism in preterm human infants. J Cereb Blood Flow Metab. 1998;18:632&#x2013;638.</Citation><ArticleIdList><ArticleId IdType="pubmed">9626187</ArticleId></ArticleIdList></Reference><Reference><Citation>Settergren G, Lindblad BS, Persson B. Cerebral blood flow and exchange of oxygen, glucose, ketone bodies, lactate, pyruvate and amino acids in infants. Acta Paediatr Scand. 1976;65:343&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pubmed">5840</ArticleId></ArticleIdList></Reference><Reference><Citation>Chugani HT, Phelps ME, Mazziotta JC. Positron emission tomography study of human brain functional development. Ann Neurol. 1987;22:487&#x2013;497.</Citation><ArticleIdList><ArticleId IdType="pubmed">3501693</ArticleId></ArticleIdList></Reference><Reference><Citation>Raichle ME, Mintun MA. Brain work and brain imaging. Annu Rev Neurosci. 2006;29:449&#x2013;476.</Citation><ArticleIdList><ArticleId IdType="pubmed">16776593</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellerin L, Magistretti PJ. Glutamate uptake into astrocytes stimulates aerobic glycolysis: A mechanism coupling neuronal activity to glucose utilization. Proc Natl Acad Sci USA. 1994;91:10625&#x2013;10629.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC45074</ArticleId><ArticleId IdType="pubmed">7938003</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercer RW, Dunham PB. Membrane-bound ATP fuels the Na/K pump. Studies on membrane-bound glycolytic enzymes on inside-out vesicles from human red cell membranes. J Gen Physiol. 1981;78:547&#x2013;568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2228637</ArticleId><ArticleId IdType="pubmed">6273495</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamoto K, Wang W, Rounds J, Chambers EA, Jacobs DO. ATP from glycolysis is required for normal sodium homeostasis in resting fast-twitch rodent skeletal muscle. Am J Physiol Endocrinol Metab. 2001;281:E479&#x2013;E488.</Citation><ArticleIdList><ArticleId IdType="pubmed">11500303</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell JD, Paul RJ. The nature of fuel provision for the Na+,K(+)-ATPase in porcine vascular smooth muscle. J Physiol. 1992;447:67&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1176025</ArticleId><ArticleId IdType="pubmed">1317437</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu K, Aoki C, Elste A, Rogalski-Wilk AA, Siekevitz P. The synthesis of ATP by glycolytic enzymes in the postsynaptic density and the effect of endogenously generated nitric oxide. Proc Natl Acad Sci USA. 1997;94:13273&#x2013;13278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24299</ArticleId><ArticleId IdType="pubmed">9371836</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipton P, Robacker K. Glycolysis and brain function: [K+]o stimulation of protein synthesis and K+ uptake require glycolysis. Fed Proc. 1983;42:2875&#x2013;2880.</Citation><ArticleIdList><ArticleId IdType="pubmed">6136420</ArticleId></ArticleIdList></Reference><Reference><Citation>McGilvery RW, Goldstein GW. Biochemistry: A Functional Approach. Philadelphia: Saunders; 1983.</Citation></Reference><Reference><Citation>Olney JW. Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate. Science. 1969;164:719&#x2013;721.</Citation><ArticleIdList><ArticleId IdType="pubmed">5778021</ArticleId></ArticleIdList></Reference><Reference><Citation>Olney JW. Excitotoxicity, apoptosis and neuropsychiatric disorders. Curr Opin Pharmacol. 2003;3:101&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pubmed">12550750</ArticleId></ArticleIdList></Reference><Reference><Citation>Olney JW, Wozniak DF, Farber NB. Excitotoxic neurodegeneration in Alzheimer disease. New hypothesis and new therapeutic strategies. Arch Neurol. 1997;54:1234&#x2013;1240.</Citation><ArticleIdList><ArticleId IdType="pubmed">9341569</ArticleId></ArticleIdList></Reference><Reference><Citation>Irizarry MC, et al. Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J Neurosci. 1997;17:7053&#x2013;7059.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573263</ArticleId><ArticleId IdType="pubmed">9278541</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Mucke L. Epilepsy and cognitive impairments in Alzheimer disease. Arch Neurol. 2009;66:435&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2812914</ArticleId><ArticleId IdType="pubmed">19204149</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D, et al. Na,K-ATPase activity regulates AMPA receptor turnover through proteasome-mediated proteolysis. J Neurosci. 2009;29:4498&#x2013;4511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2680442</ArticleId><ArticleId IdType="pubmed">19357275</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh H, et al. AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron. 2006;52:831&#x2013;843.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850952</ArticleId><ArticleId IdType="pubmed">17145504</ArticleId></ArticleIdList></Reference><Reference><Citation>Seipp S, Buselmaier W. Isolation of glyceraldehyde 3-phosphate dehydrogenase (Gapdh) cDNA from the distal half of mouse chromosome 16: Further indication of a link between Alzheimer's disease and glycolysis. Neurosci Lett. 1994;182:91&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">7891898</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, et al. Association of late-onset Alzheimer's disease with genetic variation in multiple members of the GAPD gene family. Proc Natl Acad Sci USA. 2004;101:15688&#x2013;15693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC524264</ArticleId><ArticleId IdType="pubmed">15507493</ArticleId></ArticleIdList></Reference><Reference><Citation>Cumming RC, Schubert D. Amyloid-beta induces disulfide bonding and aggregation of GAPDH in Alzheimer's disease. FASEB J. 2005;19:2060&#x2013;2062.</Citation><ArticleIdList><ArticleId IdType="pubmed">16186172</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, et al. Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron. 2008;58:42&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2390913</ArticleId><ArticleId IdType="pubmed">18400162</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, et al. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron. 2005;48:913&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pubmed">16364896</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenetz F, et al. APP processing and synaptic function. Neuron. 2003;37:925&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Plant LD, et al. Amyloid beta peptide as a physiological modulator of neuronal &#x2018;A&#x2019;-type K+ current. Neurobiol Aging. 2006;27:1673&#x2013;1683.</Citation><ArticleIdList><ArticleId IdType="pubmed">16271805</ArticleId></ArticleIdList></Reference><Reference><Citation>Puzzo D, et al. Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. J Neurosci. 2008;28:14537&#x2013;14545.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2673049</ArticleId><ArticleId IdType="pubmed">19118188</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacor PN, et al. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci. 2007;27:796&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672917</ArticleId><ArticleId IdType="pubmed">17251419</ArticleId></ArticleIdList></Reference><Reference><Citation>Freir DB, et al. Abeta oligomers inhibit synapse remodelling necessary for memory consolidation. Neurobiol Aging. 2010 S0 197-4580(10)00030-8[pii] doi: 10:1016/j.neurobiolaging.2010.01.001.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2891223</ArticleId><ArticleId IdType="pubmed">20097446</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP, Magnus T. Ageing and neuronal vulnerability. Nat Rev Neurosci. 2006;7:278&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3710114</ArticleId><ArticleId IdType="pubmed">16552414</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukui H, Moraes CT. The mitochondrial impairment, oxidative stress and neurodegeneration connection: Reality or just an attractive hypothesis? Trends Neurosci. 2008;31:251&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2731695</ArticleId><ArticleId IdType="pubmed">18403030</ArticleId></ArticleIdList></Reference><Reference><Citation>Mej&#xed;as R, et al. Neuroprotection by transgenic expression of glucose-6-phosphate dehydrogenase in dopaminergic nigrostriatal neurons of mice. J Neurosci. 2006;26:4500&#x2013;4508.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674068</ArticleId><ArticleId IdType="pubmed">16641229</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell RL, et al. Increased neuronal glucose-6-phosphate dehydrogenase and sulfhydryl levels indicate reductive compensation to oxidative stress in Alzheimer disease. Arch Biochem Biophys. 1999;370:236&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">10510282</ArticleId></ArticleIdList></Reference><Reference><Citation>Soucek T, Cumming R, Dargusch R, Maher P, Schubert D. The regulation of glucose metabolism by HIF-1 mediates a neuroprotective response to amyloid beta peptide. Neuron. 2003;39:43&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">12848931</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer AM. The activity of the pentose phosphate pathway is increased in response to oxidative stress in Alzheimer's disease. J Neural Transm. 1999;106:317&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pubmed">10392540</ArticleId></ArticleIdList></Reference><Reference><Citation>Vulliamy T, Mason P, Luzzatto L. The molecular basis of glucose-6-phosphate dehydrogenase deficiency. Trends Genet. 1992;8:138&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">1631957</ArticleId></ArticleIdList></Reference><Reference><Citation>Magistretti PJ. Neuron-glia metabolic coupling and plasticity. J Exp Biol. 2006;209:2304&#x2013;2311.</Citation><ArticleIdList><ArticleId IdType="pubmed">16731806</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrero-Mendez A, et al. The bioenergetic and antioxidant status of neurons is controlled by continuous degradation of a key glycolytic enzyme by APC/C-Cdh1. Nat Cell Biol. 2009;11:747&#x2013;752.</Citation><ArticleIdList><ArticleId IdType="pubmed">19448625</ArticleId></ArticleIdList></Reference><Reference><Citation>Allaman I, et al. Amyloid-beta aggregates cause alterations of astrocytic metabolic phenotype: Impact on neuronal viability. J Neurosci. 2010;30:3326&#x2013;3338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6634099</ArticleId><ArticleId IdType="pubmed">20203192</ArticleId></ArticleIdList></Reference><Reference><Citation>Allman J, Hakeem A, Watson K. Two phylogenetic specializations in the human brain. Neuroscientist. 2002;8:335&#x2013;346.</Citation><ArticleIdList><ArticleId IdType="pubmed">12194502</ArticleId></ArticleIdList></Reference><Reference><Citation>Craft S, et al. Memory improvement following induced hyperinsulinemia in Alzheimer's disease. Neurobiol Aging. 1996;17:123&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">8786794</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology. 1993;43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder AZ. Difference image vs ratio image error function forms in PET-PET realignment in quantification of brain function using PET. In: Myer R, Cunningham VJ, Bailey DL, Jones T, editors. Quantification of Brain Function Using PET. San Diego: Academic; 1996. pp. 131&#x2013;137.</Citation></Reference><Reference><Citation>Fagan AM, et al. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease. EMBO Mol Med. 2009;1:371&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2806678</ArticleId><ArticleId IdType="pubmed">20049742</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010;67:122&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2830375</ArticleId><ArticleId IdType="pubmed">20186853</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20837536</PMID><DateCompleted><Year>2010</Year><Month>11</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>107</Volume><Issue>41</Issue><PubDate><Year>2010</Year><Month>Oct</Month><Day>12</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Regional aerobic glycolysis in the human brain.</ArticleTitle><Pagination><StartPage>17757</StartPage><EndPage>17762</EndPage><MedlinePgn>17757-62</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1010459107</ELocationID><Abstract><AbstractText>Aerobic glycolysis is defined as glucose utilization in excess of that used for oxidative phosphorylation despite sufficient oxygen to completely metabolize glucose to carbon dioxide and water. Aerobic glycolysis is present in the normal human brain at rest and increases locally during increased neuronal activity; yet its many biological functions have received scant attention because of a prevailing energy-centric focus on the role of glucose as substrate for oxidative phosphorylation. As an initial step in redressing this neglect, we measured the regional distribution of aerobic glycolysis with positron emission tomography in 33 neurologically normal young adults at rest. We show that the distribution of aerobic glycolysis in the brain is differentially present in previously well-described functional areas. In particular, aerobic glycolysis is significantly elevated in medial and lateral parietal and prefrontal cortices. In contrast, the cerebellum and medial temporal lobes have levels of aerobic glycolysis significantly below the brain mean. The levels of aerobic glycolysis are not strictly related to the levels of brain energy metabolism. For example, sensory cortices exhibit high metabolic rates for glucose and oxygen consumption but low rates of aerobic glycolysis. These striking regional variations in aerobic glycolysis in the normal human brain provide an opportunity to explore how brain systems differentially use the diverse cell biology of glucose in support of their functional specializations in health and disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vaishnavi</LastName><ForeName>S Neil</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>Department of Radiology, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vlassenko</LastName><ForeName>Andrei G</ForeName><Initials>AG</Initials></Author><Author ValidYN="Y"><LastName>Rundle</LastName><ForeName>Melissa M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Snyder</LastName><ForeName>Abraham Z</ForeName><Initials>AZ</Initials></Author><Author ValidYN="Y"><LastName>Mintun</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Raichle</LastName><ForeName>Marcus E</ForeName><Initials>ME</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NS057901</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS048056</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS006833</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F30 NS057901</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS048056</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH077967</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P20 MH077967</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>09</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>IY9XDZ35W2</RegistryNumber><NameOfSubstance UI="D005947">Glucose</NameOfSubstance></Chemical><Chemical><RegistryNumber>S88TT14065</RegistryNumber><NameOfSubstance UI="D010100">Oxygen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Proc Natl Acad Sci U S A. 2010 Oct 12;107(41):17459-60. doi: 10.1073/pnas.1012684107.</RefSource><PMID Version="1">20921385</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2010 Nov;11(11):729. doi: 10.1038/nrn2937.</RefSource><PMID Version="1">20979317</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006019" MajorTopicYN="N">Glycolysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>9</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20837536</ArticleId><ArticleId IdType="pmc">PMC2955101</ArticleId><ArticleId IdType="doi">10.1073/pnas.1010459107</ArticleId><ArticleId IdType="pii">1010459107</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Warburg O, Posener K, Negelein E. Uber den Stoffwechsel der Carcinomzelle. Biochem Z. 1924;152:309&#x2013;344.</Citation></Reference><Reference><Citation>Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol. 1927;8:519&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2140820</ArticleId><ArticleId IdType="pubmed">19872213</ArticleId></ArticleIdList></Reference><Reference><Citation>DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: Metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008;7:11&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">18177721</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell. 2008;134:703&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pubmed">18775299</ArticleId></ArticleIdList></Reference><Reference><Citation>Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science. 2009;324:1029&#x2013;1033.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2849637</ArticleId><ArticleId IdType="pubmed">19460998</ArticleId></ArticleIdList></Reference><Reference><Citation>Raichle ME, Posner JB, Plum F. Cerebral blood flow during and after hyperventilation. Arch Neurol. 1970;23:394&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">5471647</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle PJ, et al. Diminished brain glucose metabolism is a significant determinant for falling rates of systemic glucose utilization during sleep in normal humans. J Clin Invest. 1994;93:529&#x2013;535.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC293874</ArticleId><ArticleId IdType="pubmed">8113391</ArticleId></ArticleIdList></Reference><Reference><Citation>Powers WJ, et al. Selective defect of in vivo glycolysis in early Huntington's disease striatum. Proc Natl Acad Sci USA. 2007;104:2945&#x2013;2949.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1797149</ArticleId><ArticleId IdType="pubmed">17299049</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaughn AE, Deshmukh M. Glucose metabolism inhibits apoptosis in neurons and cancer cells by redox inactivation of cytochrome c. Nat Cell Biol. 2008;10:1477&#x2013;1483.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2626347</ArticleId><ArticleId IdType="pubmed">19029908</ArticleId></ArticleIdList></Reference><Reference><Citation>Settergren G, Lindblad BS, Persson B. Cerebral blood flow and exchange of oxygen, glucose, ketone bodies, lactate, pyruvate and amino acids in infants. Acta Paediatr Scand. 1976;65:343&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pubmed">5840</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox PT, Raichle ME, Mintun MA, Dence C. Nonoxidative glucose consumption during focal physiologic neural activity. Science. 1988;241:462&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">3260686</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlassenko AG, Rundle MM, Mintun MA. Human brain glucose metabolism may evolve during activation: Findings from a modified FDG PET paradigm. Neuroimage. 2006;33:1036&#x2013;1041.</Citation><ArticleIdList><ArticleId IdType="pubmed">17035047</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasischke KA, Vishwasrao HD, Fisher PJ, Zipfel WR, Webb WW. Neural activity triggers neuronal oxidative metabolism followed by astrocytic glycolysis. Science. 2004;305:99&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">15232110</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellerin L, Magistretti PJ. Glutamate uptake into astrocytes stimulates aerobic glycolysis: A mechanism coupling neuronal activity to glucose utilization. Proc Natl Acad Sci USA. 1994;91:10625&#x2013;10629.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC45074</ArticleId><ArticleId IdType="pubmed">7938003</ArticleId></ArticleIdList></Reference><Reference><Citation>McAvoy MP, Ollinger JM, Buckner RL. Cluster size thresholds for assessment of significant activation in fMRI. Neuroimage. 2001;13:S198.</Citation></Reference><Reference><Citation>Forman SD, et al. Improved assessment of significant activation in functional magnetic resonance imaging (fMRI): Use of a cluster-size threshold. Magn Reson Med. 1995;33:636&#x2013;647.</Citation><ArticleIdList><ArticleId IdType="pubmed">7596267</ArticleId></ArticleIdList></Reference><Reference><Citation>Raichle ME, Snyder AZ. A default mode of brain function: A brief history of an evolving idea. Neuroimage. 2007;37:1083&#x2013;1090, discussion 1097&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">17719799</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Andrews-Hanna JR, Schacter DL. The brain's default network: Anatomy, function, and relevance to disease. Ann N Y Acad Sci. 2008;1124:1&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">18400922</ArticleId></ArticleIdList></Reference><Reference><Citation>Braver TS, Barch DM. Extracting core components of cognitive control. Trends Cogn Sci. 2006;10:529&#x2013;532.</Citation><ArticleIdList><ArticleId IdType="pubmed">17071129</ArticleId></ArticleIdList></Reference><Reference><Citation>Dosenbach NU, Fair DA, Cohen AL, Schlaggar BL, Petersen SE. A dual-networks architecture of top-down control. Trends Cogn Sci. 2008;12:99&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3632449</ArticleId><ArticleId IdType="pubmed">18262825</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, Kahn I, Snyder AZ, Raichle ME, Buckner RL. Evidence for a frontoparietal control system revealed by intrinsic functional connectivity. J Neurophysiol. 2008;100:3328&#x2013;3342.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2604839</ArticleId><ArticleId IdType="pubmed">18799601</ArticleId></ArticleIdList></Reference><Reference><Citation>Raichle ME, et al. A default mode of brain function. Proc Natl Acad Sci USA. 2001;98:676&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC14647</ArticleId><ArticleId IdType="pubmed">11209064</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Krasnow B, Reiss AL, Menon V. Functional connectivity in the resting brain: A network analysis of the default mode hypothesis. Proc Natl Acad Sci USA. 2003;100:253&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC140943</ArticleId><ArticleId IdType="pubmed">12506194</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox MD, et al. The human brain is intrinsically organized into dynamic, anticorrelated functional networks. Proc Natl Acad Sci USA. 2005;102:9673&#x2013;9678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1157105</ArticleId><ArticleId IdType="pubmed">15976020</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox MD, Raichle ME. Spontaneous fluctuations in brain activity observed with functional magnetic resonance imaging. Nat Rev Neurosci. 2007;8:700&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pubmed">17704812</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagmann P, et al. Mapping the structural core of human cerebral cortex. PLoS Biol. 2008;6:e159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2443193</ArticleId><ArticleId IdType="pubmed">18597554</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, et al. Cortical hubs revealed by intrinsic functional connectivity: Mapping, assessment of stability, and relation to Alzheimer's disease. J Neurosci. 2009;29:1860&#x2013;1873.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2750039</ArticleId><ArticleId IdType="pubmed">19211893</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, et al. Coherent spontaneous activity identifies a hippocampal-parietal memory network. J Neurophysiol. 2006;96:3517&#x2013;3531.</Citation><ArticleIdList><ArticleId IdType="pubmed">16899645</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellerin L, Magistretti PJ. Excitatory amino acids stimulate aerobic glycolysis in astrocytes via an activation of the Na+/K+ ATPase. Dev Neurosci. 1996;18:336&#x2013;342.</Citation><ArticleIdList><ArticleId IdType="pubmed">8940604</ArticleId></ArticleIdList></Reference><Reference><Citation>Magistretti PJ, Chatton JY. Relationship between L-glutamate-regulated intracellular Na+ dynamics and ATP hydrolysis in astrocytes. J Neural Transm. 2005;112:77&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">15599606</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercer RW, Dunham PB. Membrane-bound ATP fuels the Na/K pump. Studies on membrane-bound glycolytic enzymes on inside-out vesicles from human red cell membranes. J Gen Physiol. 1981;78:547&#x2013;568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2228637</ArticleId><ArticleId IdType="pubmed">6273495</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamoto K, Wang W, Rounds J, Chambers EA, Jacobs DO. ATP from glycolysis is required for normal sodium homeostasis in resting fast-twitch rodent skeletal muscle. Am J Physiol Endocrinol Metab. 2001;281:E479&#x2013;E488.</Citation><ArticleIdList><ArticleId IdType="pubmed">11500303</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell JD, Paul RJ. The nature of fuel provision for the Na+,K(+)-ATPase in porcine vascular smooth muscle. J Physiol. 1992;447:67&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1176025</ArticleId><ArticleId IdType="pubmed">1317437</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu K, Aoki C, Elste A, Rogalski-Wilk AA, Siekevitz P. The synthesis of ATP by glycolytic enzymes in the postsynaptic density and the effect of endogenously generated nitric oxide. Proc Natl Acad Sci USA. 1997;94:13273&#x2013;13278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24299</ArticleId><ArticleId IdType="pubmed">9371836</ArticleId></ArticleIdList></Reference><Reference><Citation>McGilvery RW, Goldstein GW. Biochemistry: A Functional Approach. Philadelphia: Saunders; 1983.</Citation></Reference><Reference><Citation>Azevedo FA, et al. Equal numbers of neuronal and nonneuronal cells make the human brain an isometrically scaled-up primate brain. J Comp Neurol. 2009;513:532&#x2013;541.</Citation><ArticleIdList><ArticleId IdType="pubmed">19226510</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy MB. Signal-processing machines at the postsynaptic density. Science. 2000;290:750&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pubmed">11052931</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy MJ, Ehlers MD. Organelles and trafficking machinery for postsynaptic plasticity. Annu Rev Neurosci. 2006;29:325&#x2013;362.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1876664</ArticleId><ArticleId IdType="pubmed">16776589</ArticleId></ArticleIdList></Reference><Reference><Citation>Marder E, Goaillard JM. Variability, compensation and homeostasis in neuron and network function. Nat Rev Neurosci. 2006;7:563&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pubmed">16791145</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D, et al. Na,K-ATPase activity regulates AMPA receptor turnover through proteasome-mediated proteolysis. J Neurosci. 2009;29:4498&#x2013;4511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2680442</ArticleId><ArticleId IdType="pubmed">19357275</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Okamoto K, Hayashi Y, Sheng M. The importance of dendritic mitochondria in the morphogenesis and plasticity of spines and synapses. Cell. 2004;119:873&#x2013;887.</Citation><ArticleIdList><ArticleId IdType="pubmed">15607982</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng M, Hoogenraad CC. The postsynaptic architecture of excitatory synapses: A more quantitative view. Annu Rev Biochem. 2007;76:1.1&#x2013;1.25.</Citation><ArticleIdList><ArticleId IdType="pubmed">17243894</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Q, Sheng ZH. Mitochondrial transport and docking in axons. Exp Neurol. 2009;218:257&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2710402</ArticleId><ArticleId IdType="pubmed">19341731</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierre K, et al. Linking supply to demand: The neuronal monocarboxylate transporter MCT2 and the alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionic acid receptor GluR2/3 subunit are associated in a common trafficking process. Eur J Neurosci. 2009;29:1951&#x2013;1963.</Citation><ArticleIdList><ArticleId IdType="pubmed">19453627</ArticleId></ArticleIdList></Reference><Reference><Citation>Janni&#xe8;re L, et al. Genetic evidence for a link between glycolysis and DNA replication. PLoS ONE. 2007;2:e447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866360</ArticleId><ArticleId IdType="pubmed">17505547</ArticleId></ArticleIdList></Reference><Reference><Citation>DeBerardinis RJ, et al. Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA. 2007;104:19345&#x2013;19350.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2148292</ArticleId><ArticleId IdType="pubmed">18032601</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaitonde MK, Jones J, Evans G. Metabolism of glucose into glutamate via the hexose monophosphate shunt and its inhibition by 6-aminonicotinamide in rat brain in vivo. Proc R Soc Lond B Biol Sci. 1987;231:71&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">2888118</ArticleId></ArticleIdList></Reference><Reference><Citation>Dringen R, Hoepken HH, Minich T, Ruedig C. Pentose phosphate pathway and NADPH metabolism.Brain Energetics. In: Gibson GE, Dienel GA, editors. Integration of Molecular and Cellular Processes, Handbook of Neurochemistry and Molecular Neurobiology. 3rd Ed. New York: Springer; 2007.</Citation></Reference><Reference><Citation>Herrero-Mendez A, et al. The bioenergetic and antioxidant status of neurons is controlled by continuous degradation of a key glycolytic enzyme by APC/C-Cdh1. Nat Cell Biol. 2009;11:747&#x2013;752.</Citation><ArticleIdList><ArticleId IdType="pubmed">19448625</ArticleId></ArticleIdList></Reference><Reference><Citation>Altman DI, Perlman JM, Volpe JJ, Powers WJ. Cerebral oxygen metabolism in newborns. Pediatrics. 1993;92:99&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">8516092</ArticleId></ArticleIdList></Reference><Reference><Citation>Powers WJ, Rosenbaum JL, Dence CS, Markham J, Videen TO. Cerebral glucose transport and metabolism in preterm human infants. J Cereb Blood Flow Metab. 1998;18:632&#x2013;638.</Citation><ArticleIdList><ArticleId IdType="pubmed">9626187</ArticleId></ArticleIdList></Reference><Reference><Citation>Chugani HT, Phelps ME, Mazziotta JC. Positron emission tomography study of human brain functional development. Ann Neurol. 1987;22:487&#x2013;497.</Citation><ArticleIdList><ArticleId IdType="pubmed">3501693</ArticleId></ArticleIdList></Reference><Reference><Citation>Elston GN, Oga T, Fujita I. Spinogenesis and pruning scales across functional hierarchies. J Neurosci. 2009;29:3271&#x2013;3275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6666449</ArticleId><ArticleId IdType="pubmed">19279264</ArticleId></ArticleIdList></Reference><Reference><Citation>Madsen PL, et al. Persistent resetting of the cerebral oxygen/glucose uptake ratio by brain activation: Evidence obtained with the Kety-Schmidt technique. J Cereb Blood Flow Metab. 1995;15:485&#x2013;491.</Citation><ArticleIdList><ArticleId IdType="pubmed">7714007</ArticleId></ArticleIdList></Reference><Reference><Citation>Tononi G, Cirelli C. Sleep function and synaptic homeostasis. Sleep Med Rev. 2006;10:49&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">16376591</ArticleId></ArticleIdList></Reference><Reference><Citation>Vyazovskiy VV, Cirelli C, Pfister-Genskow M, Faraguna U, Tononi G. Molecular and electrophysiological evidence for net synaptic potentiation in wake and depression in sleep. Nat Neurosci. 2008;11:200&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">18204445</ArticleId></ArticleIdList></Reference><Reference><Citation>Vyazovskiy VV, Cirelli C, Tononi G, Tobler I. Cortical metabolic rates as measured by 2-deoxyglucose-uptake are increased after waking and decreased after sleep in mice. Brain Res Bull. 2008;75:591&#x2013;597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2386085</ArticleId><ArticleId IdType="pubmed">18355635</ArticleId></ArticleIdList></Reference><Reference><Citation>Ido Y, Chang K, Williamson JR. NADH augments blood flow in physiologically activated retina and visual cortex. Proc Natl Acad Sci USA. 2004;101:653&#x2013;658.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC327203</ArticleId><ArticleId IdType="pubmed">14704275</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Vlassenko AG, Rundle MM, Raichle ME. Increased lactate/pyruvate ratio augments blood flow in physiologically activated human brain. Proc Natl Acad Sci USA. 2004;101:659&#x2013;664.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC327204</ArticleId><ArticleId IdType="pubmed">14704276</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlassenko AG, et al. Spatial correlation between brain aerobic glycolysis and A-beta deposition. Proc Natl Acad Sci USA. 2010 10.1073/pnas.1010461107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2955133</ArticleId><ArticleId IdType="pubmed">20837517</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, et al. Molecular, structural, and functional characterization of Alzheimer's disease: Evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25:7709&#x2013;7717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Raichle ME, Martin WR, Herscovitch P, Mintun MA, Markham J. Brain blood flow measured with intravenous H2(15)O. II. Implementation and validation. J Nucl Med. 1983;24:790&#x2013;798.</Citation><ArticleIdList><ArticleId IdType="pubmed">6604140</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Raichle ME, Martin WR, Herscovitch P. Brain oxygen utilization measured with O-15 radiotracers and positron emission tomography. J Nucl Med. 1984;25:177&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610032</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin WR, Powers WJ, Raichle ME. Cerebral blood volume measured with inhaled C15O and positron emission tomography. J Cereb Blood Flow Metab. 1987;7:421&#x2013;426.</Citation><ArticleIdList><ArticleId IdType="pubmed">3497162</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancaster JL, et al. A modality-independent approach to spatial normalization of tomographic images of the human brain. Hum Brain Mapp. 1995;3:209&#x2013;223.</Citation></Reference><Reference><Citation>Van Essen DC. A Population-Average, Landmark- and Surface-based (PALS) atlas of human cerebral cortex. Neuroimage. 2005;28:635&#x2013;662.</Citation><ArticleIdList><ArticleId IdType="pubmed">16172003</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20847045</PMID><DateCompleted><Year>2011</Year><Month>02</Month><Day>28</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1083-351X</ISSN><JournalIssue CitedMedium="Internet"><Volume>285</Volume><Issue>47</Issue><PubDate><Year>2010</Year><Month>Nov</Month><Day>19</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Overexpression of human apolipoprotein A-I preserves cognitive function and attenuates neuroinflammation and cerebral amyloid angiopathy in a mouse model of Alzheimer disease.</ArticleTitle><Pagination><StartPage>36958</StartPage><EndPage>36968</EndPage><MedlinePgn>36958-68</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1074/jbc.M110.127829</ELocationID><Abstract><AbstractText>To date there is no effective therapy for Alzheimer disease (AD). High levels of circulating high density lipoprotein (HDL) and its main protein, apolipoprotein A-I (apoA-I), reduce the risk of cardiovascular disease. Clinical studies show that plasma HDL cholesterol and apoA-I levels are low in patients with AD. To investigate if increasing plasma apoA-I/HDL levels ameliorates AD-like memory deficits and amyloid-&#x3b2; (A&#x3b2;) deposition, we generated a line of triple transgenic (Tg) mice overexpressing mutant forms of amyloid-&#x3b2; precursor protein (APP) and presenilin 1 (PS1) as well as human apoA-I (AI). Here we show that APP/PS1/AI triple Tg mice have a 2-fold increase of plasma HDL cholesterol levels. When tested in the Morris water maze for spatial orientation abilities, whereas APP/PS1 mice develop age-related learning and memory deficits, APP/PS1/AI mice continue to perform normally during aging. Interestingly, no significant differences were found in the total level and deposition of A&#x3b2; in the brains of APP/PS1 and APP/PS1/AI mice, but cerebral amyloid angiopathy was reduced in APP/PS1/AI mice. Also, consistent with the anti-inflammatory properties of apoA-I/HDL, glial activation was reduced in the brain of APP/PS1/AI mice. In addition, A&#x3b2;-induced production of proinflammatory chemokines/cytokines was decreased in mouse organotypic hippocampal slice cultures expressing human apoA-I. Therefore, we conclude that overexpression of human apoA-I in the circulation prevents learning and memory deficits in APP/PS1 mice, partly by attenuating neuroinflammation and cerebral amyloid angiopathy. These findings suggest that elevating plasma apoA-I/HDL levels may be an effective approach to preserve cognitive function in patients with AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>Terry L</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Dongfeng</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Hailin</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Mans</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Yan Ru</ForeName><Initials>YR</Initials></Author><Author ValidYN="Y"><LastName>Jungbauer</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Linton</LastName><ForeName>MacRae F</ForeName><Initials>MF</Initials></Author><Author ValidYN="Y"><LastName>Fazio</LastName><ForeName>Sergio</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>LaDu</LastName><ForeName>Mary Jo</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ling</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG031846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG031846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL086988</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL086988</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG03012801</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL65709</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL065709</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR029879</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1RR029879</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG030128</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>09</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C505693">APOA1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C545487">APP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016632">Apolipoprotein A-I</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058847">Inflammasomes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008074">Lipoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>97C5T2UQ7J</RegistryNumber><NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016632" MajorTopicYN="N">Apolipoprotein A-I</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016657" MajorTopicYN="N">Cerebral Amyloid Angiopathy</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002784" MajorTopicYN="N">Cholesterol</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004622" MajorTopicYN="N">Embryo, Mammalian</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007124" MajorTopicYN="N">Immunoenzyme Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058847" MajorTopicYN="N">Inflammasomes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008074" MajorTopicYN="N">Lipoproteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D032389" MajorTopicYN="N">Myocytes, Smooth Muscle</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017384" MajorTopicYN="N">Sequence Deletion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>3</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>11</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20847045</ArticleId><ArticleId IdType="pmc">PMC2978624</ArticleId><ArticleId IdType="doi">10.1074/jbc.M110.127829</ArticleId><ArticleId IdType="pii">S0021-9258(20)46844-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alzheimer's Association (2010) Alzheimers Dement. 6, 158&#x2013;194</Citation><ArticleIdList><ArticleId IdType="pubmed">20298981</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarmeas N., Luchsinger J. A., Schupf N., Brickman A. M., Cosentino S., Tang M. X., Stern Y. (2009) JAMA 302, 627&#x2013;637</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2765045</ArticleId><ArticleId IdType="pubmed">19671904</ArticleId></ArticleIdList></Reference><Reference><Citation>Naderali E. K., Ratcliffe S. H., Dale M. C. (2009) Am. J. Alzheimers Dis. Other Demen. 24, 445&#x2013;449</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10846277</ArticleId><ArticleId IdType="pubmed">19801534</ArticleId></ArticleIdList></Reference><Reference><Citation>Craft S. (2009) Arch. Neurol. 66, 300&#x2013;305</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2717716</ArticleId><ArticleId IdType="pubmed">19273747</ArticleId></ArticleIdList></Reference><Reference><Citation>Fillit H., Nash D. T., Rundek T., Zuckerman A. (2008) Am. J. Geriatr. Pharmacother. 6, 100&#x2013;118</Citation><ArticleIdList><ArticleId IdType="pubmed">18675769</ArticleId></ArticleIdList></Reference><Reference><Citation>Linsel-Nitschke P., Tall A. R. (2005) Nat. Rev. Drug Discov. 4, 193&#x2013;205</Citation><ArticleIdList><ArticleId IdType="pubmed">15738977</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Rader D. J. (2007) Curr. Opin. Cardiol. 22, 368&#x2013;372</Citation><ArticleIdList><ArticleId IdType="pubmed">17556891</ArticleId></ArticleIdList></Reference><Reference><Citation>Segrest J. P., Anantharamaiah G. M. (1994) Curr. Opin. Cardiol. 9, 404&#x2013;410</Citation><ArticleIdList><ArticleId IdType="pubmed">7919584</ArticleId></ArticleIdList></Reference><Reference><Citation>Barter P. J., Nicholls S., Rye K. A., Anantharamaiah G. M., Navab M., Fogelman A. M. (2004) Circ. Res. 95, 764&#x2013;772</Citation><ArticleIdList><ArticleId IdType="pubmed">15486323</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishiguro H., Yoshida H., Major A. S., Zhu T., Babaev V. R., Linton M. F., Fazio S. (2001) J. Biol. Chem. 276, 36742&#x2013;36748</Citation><ArticleIdList><ArticleId IdType="pubmed">11477092</ArticleId></ArticleIdList></Reference><Reference><Citation>Major A. S., Dove D. E., Ishiguro H., Su Y. R., Brown A. M., Liu L., Carter K. J., Linton M. F., Fazio S. (2001) Arterioscler. Thromb. Vasc. Biol. 21, 1790&#x2013;1795</Citation><ArticleIdList><ArticleId IdType="pubmed">11701467</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y. R., Ishiguro H., Major A. S., Dove D. E., Zhang W., Hasty A. H., Babaev V. R., Linton M. F., Fazio S. (2003) Mol. Ther. 8, 576&#x2013;583</Citation><ArticleIdList><ArticleId IdType="pubmed">14529830</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y. R., Blakemore J. L., Zhang Y., Linton M. F., Fazio S. (2008) Arterioscler. Thromb. Vasc. Biol. 28, 1439&#x2013;1446</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2744493</ArticleId><ArticleId IdType="pubmed">18497309</ArticleId></ArticleIdList></Reference><Reference><Citation>Dietschy J. M., Turley S. D. (2001) Curr. Opin. Lipidol. 12, 105&#x2013;112</Citation><ArticleIdList><ArticleId IdType="pubmed">11264981</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch S., Donarski N., Goetze K., Kreckel M., Stuerenburg H. J., Buhmann C., Beisiegel U. (2001) J. Lipid Res. 42, 1143&#x2013;1151</Citation><ArticleIdList><ArticleId IdType="pubmed">11441143</ArticleId></ArticleIdList></Reference><Reference><Citation>Harr S. D., Uint L., Hollister R., Hyman B. T., Mendez A. J. (1996) J. Neurochem. 66, 2429&#x2013;2435</Citation><ArticleIdList><ArticleId IdType="pubmed">8632166</ArticleId></ArticleIdList></Reference><Reference><Citation>Golabek A., Marques M. A., Lalowski M., Wisniewski T. (1995) Neurosci. Lett. 191, 79&#x2013;82</Citation><ArticleIdList><ArticleId IdType="pubmed">7659297</ArticleId></ArticleIdList></Reference><Reference><Citation>Koudinov A. R., Berezov T. T., Kumar A., Koudinova N. V. (1998) Clin. Chim. Acta. 270, 75&#x2013;84</Citation><ArticleIdList><ArticleId IdType="pubmed">9544446</ArticleId></ArticleIdList></Reference><Reference><Citation>Koldamova R. P., Lefterov I. M., Lefterova M. I., Lazo J. S. (2001) Biochemistry 40, 3553&#x2013;3560</Citation><ArticleIdList><ArticleId IdType="pubmed">11297421</ArticleId></ArticleIdList></Reference><Reference><Citation>Vollbach H., Heun R., Morris C. M., Edwardson J. A., McKeith I. G., Jessen F., Schulz A., Maier W., K&#xf6;lsch H. (2005) Ann. Neurol. 58, 436&#x2013;441</Citation><ArticleIdList><ArticleId IdType="pubmed">16130094</ArticleId></ArticleIdList></Reference><Reference><Citation>Helbecque N., Codron V., Cottel D., Amouyel P. (2008) Dement. Geriatr. Cogn. Disord. 25, 97&#x2013;102</Citation><ArticleIdList><ArticleId IdType="pubmed">18073484</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawano M., Kawakami M., Otsuka M., Yashima H., Yaginuma T., Ueki A. (1995) Clin. Chim. Acta 239, 209&#x2013;211</Citation><ArticleIdList><ArticleId IdType="pubmed">8542660</ArticleId></ArticleIdList></Reference><Reference><Citation>Merched A., Xia Y., Visvikis S., Serot J. M., Siest G. (2000) Neurobiol. Aging. 21, 27&#x2013;30</Citation><ArticleIdList><ArticleId IdType="pubmed">10794845</ArticleId></ArticleIdList></Reference><Reference><Citation>Saczynski J. S., White L., Peila R. L., Rodriguez B. L., Launer L. J. (2007) Am. J. Epidemiol. 165, 985&#x2013;992</Citation><ArticleIdList><ArticleId IdType="pubmed">17298957</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky J. L., Slunt H. H., Ratovitski T., Jenkins N. A., Copeland N. G., Borchelt D. R. (2001) Biomol. Eng. 17, 157&#x2013;165</Citation><ArticleIdList><ArticleId IdType="pubmed">11337275</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky J. L., Fadale D. J., Anderson J., Xu G. M., Gonzales V., Jenkins N. A., Copeland N. G., Lee M. K., Younkin L. H., Wagner S. L., Younkin S. G., Borchelt D. R. (2004) Hum. Mol. Genet. 13, 159&#x2013;170</Citation><ArticleIdList><ArticleId IdType="pubmed">14645205</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin E. M., Ishida B. Y., Clift S. M., Krauss R. M. (1991) Proc. Natl. Acad. Sci. U.S.A. 88, 434&#x2013;438</Citation><ArticleIdList><ArticleId IdType="pmc">PMC50825</ArticleId><ArticleId IdType="pubmed">1703299</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L., Cao D., Garber D. W., Kim H., Fukuchi K. (2003) Am. J. Pathol. 163, 2155&#x2013;2164</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1892402</ArticleId><ArticleId IdType="pubmed">14633589</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L., Cao D., Kim H., Lester R., Fukuchi K. (2006) Ann. Neurol. 60, 729&#x2013;739</Citation><ArticleIdList><ArticleId IdType="pubmed">17192930</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao D., Fukuchi K., Wan H., Kim H., Li L. (2006) Neurobiol. Aging 27, 1632&#x2013;1643</Citation><ArticleIdList><ArticleId IdType="pubmed">16236385</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao D., Lu H., Lewis T. L., Li L. (2007) J. Biol. Chem. 282, 36275&#x2013;36282</Citation><ArticleIdList><ArticleId IdType="pubmed">17942401</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos R. B., Bales K. R., Parsadanian M., O'Dell M. A., Foss E. M., Paul S. M., Holtzman D. M. (2002) J. Neurochem. 81, 229&#x2013;236</Citation><ArticleIdList><ArticleId IdType="pubmed">12064470</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbott C. A., Mackness M. I., Kumar S., Boulton A. J., Durrington P. N. (1995) Arterioscler. Thromb. Vasc. Biol. 15, 1812&#x2013;1818</Citation><ArticleIdList><ArticleId IdType="pubmed">7583560</ArticleId></ArticleIdList></Reference><Reference><Citation>Paragh G., Balla P., Katona E., Seres I., Egerh&#xe1;zi A., Degrell I. (2002) Eur. Arch. Psychiatry Clin. Neurosci. 252, 63&#x2013;67</Citation><ArticleIdList><ArticleId IdType="pubmed">12111338</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapleau C. A., Carlo M. E., Larimore J. L., Pozzo-Miller L. (2008) J. Neurosci. Methods 169, 182&#x2013;190</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2348185</ArticleId><ArticleId IdType="pubmed">18242714</ArticleId></ArticleIdList></Reference><Reference><Citation>Stine W. B., Jr., Dahlgren K. N., Krafft G. A., LaDu M. J. (2003) J. Biol. Chem. 278, 11612&#x2013;11622</Citation><ArticleIdList><ArticleId IdType="pubmed">12499373</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L., Chen J., Mishra V. K., Kurtz J. A., Cao D., Klon A. E., Harvey S. C., Anantharamaiah G. M., Segrest J. P. (2004) J. Mol. Biol. 343, 1293&#x2013;1311</Citation><ArticleIdList><ArticleId IdType="pubmed">15491614</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock D. M., Gordon M. N., Morgan D. (2006) Nat. Protoc. 1, 1591&#x2013;1595</Citation><ArticleIdList><ArticleId IdType="pubmed">17406451</ArticleId></ArticleIdList></Reference><Reference><Citation>Vergnes L., Baroukh N., Ostos M. A., Castro G., Duverger N., Nanjee M. N., Najib J., Fruchart J. C., Miller N. E., Zakin M. M., Ochoa A. (2000) Arterioscler. Thromb. Vasc. Biol. 20, 2267&#x2013;2274</Citation><ArticleIdList><ArticleId IdType="pubmed">11031214</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiserer R. S., Harrison F. E., Syverud D. C., McDonald M. P. (2007) Genes Brain Behav. 6, 54&#x2013;65</Citation><ArticleIdList><ArticleId IdType="pubmed">17233641</ArticleId></ArticleIdList></Reference><Reference><Citation>Navab M., Hama S. Y., Hough G. P., Hedrick C. C., Sorenson R., La Du B. N., Kobashigawa J. A., Fonarow G. C., Berliner J. A., Laks H., Fogelman A. M. (1998) Curr. Opin. Lipidol. 9, 449&#x2013;456</Citation><ArticleIdList><ArticleId IdType="pubmed">9812199</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih D. M., Lusis A. J. (2009) Curr. Opin. Lipidol. 20, 288&#x2013;292</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3869948</ArticleId><ArticleId IdType="pubmed">19474728</ArticleId></ArticleIdList></Reference><Reference><Citation>Durrington P. N., Mackness B., Mackness M. I. (2001) Arterioscler. Thromb. Vasc. Biol. 21, 473&#x2013;480</Citation><ArticleIdList><ArticleId IdType="pubmed">11304460</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackness B., Hunt R., Durrington P. N., Mackness M. I. (1997) Arterioscler. Thromb. Vasc. Biol. 17, 1233&#x2013;1238</Citation><ArticleIdList><ArticleId IdType="pubmed">9261251</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan A. M., Younkin L. H., Morris J. C., Fryer J. D., Cole T. G., Younkin S. G., Holtzman D. M. (2000) Ann. Neurol. 48, 201&#x2013;210</Citation><ArticleIdList><ArticleId IdType="pubmed">10939571</ArticleId></ArticleIdList></Reference><Reference><Citation>Szczepanik A. M., Rampe D., Ringheim G. E. (2001) J. Neurochem. 77, 304&#x2013;317</Citation><ArticleIdList><ArticleId IdType="pubmed">11279286</ArticleId></ArticleIdList></Reference><Reference><Citation>Prat E., Baron P., Meda L., Scarpini E., Galimberti D., Ardolino G., Catania A., Scarlato G. (2000) Neurosci. Lett. 283, 177&#x2013;180</Citation><ArticleIdList><ArticleId IdType="pubmed">10754216</ArticleId></ArticleIdList></Reference><Reference><Citation>Song H., Saito K., Seishima M., Noma A., Urakami K., Nakashima K. (1997) Neurosci Lett. 231, 175&#x2013;178</Citation><ArticleIdList><ArticleId IdType="pubmed">9300650</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitz C., Tang M. X., Luchsinger J., Mayeux R. (2004) Arch. Neurol. 61, 705&#x2013;714</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696387</ArticleId><ArticleId IdType="pubmed">15148148</ArticleId></ArticleIdList></Reference><Reference><Citation>Launer L. J., White L. R., Petrovitch H., Ross G. W., Curb J. D. (2001) Neurology 57, 1447&#x2013;1452</Citation><ArticleIdList><ArticleId IdType="pubmed">11673587</ArticleId></ArticleIdList></Reference><Reference><Citation>Maezawa I., Jin L. W., Woltjer R. L., Maeda N., Martin G. M., Montine T. J., Montine K. S. (2004) J. Neurochem. 91, 1312&#x2013;1321</Citation><ArticleIdList><ArticleId IdType="pubmed">15584908</ArticleId></ArticleIdList></Reference><Reference><Citation>Paula-Lima A. C., Tricerri M. A., Brito-Moreira J., Bomfim T. R., Oliveira F. F., Magdesian M. H., Grinberg L. T., Panizzutti R., Ferreira S. T. (2009) Int. J. Biochem. Cell. Biol. 41, 1361&#x2013;1370</Citation><ArticleIdList><ArticleId IdType="pubmed">19130896</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan A. M., Christopher E., Taylor J. W., Parsadanian M., Spinner M., Watson M., Fryer J. D., Wahrle S., Bales K. R., Paul S. M., Holtzman D. M. (2004) Am. J. Pathol. 165, 1413&#x2013;1422</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1618648</ArticleId><ArticleId IdType="pubmed">15466405</ArticleId></ArticleIdList></Reference><Reference><Citation>Navab M., Ananthramaiah G. M., Reddy S. T., Van Lenten B. J., Ansell B. J., Hama S., Hough G., Bachini E., Grijalva V. R., Wagner A. C., Shaposhnik Z., Fogelman A. M. (2005) Ann. Med. 37, 173&#x2013;178</Citation><ArticleIdList><ArticleId IdType="pubmed">16019715</ArticleId></ArticleIdList></Reference><Reference><Citation>Atzmon G., Gabriely I., Greiner W., Davidson D., Schechter C., Barzilai N. (2002) J. Gerontol. A Biol. Sci. Med. Sci. 57, M712&#x2013;M715</Citation><ArticleIdList><ArticleId IdType="pubmed">12403798</ArticleId></ArticleIdList></Reference><Reference><Citation>Barzilai N., Atzmon G., Derby C. A., Bauman J. M., Lipton R. B. (2006) Neurology 67, 2170&#x2013;2175</Citation><ArticleIdList><ArticleId IdType="pubmed">17190939</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh-Manoux A., Gimeno D., Kivimaki M., Brunner E., Marmot M. G. (2008) Arterioscler. Thromb. Vasc. Biol. 28, 1556&#x2013;1562</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2581752</ArticleId><ArticleId IdType="pubmed">18591462</ArticleId></ArticleIdList></Reference><Reference><Citation>Kontush A., Chapman M. J. (2008) Arterioscler. Thromb. Vasc. Biol. 28, 1418&#x2013;1420</Citation><ArticleIdList><ArticleId IdType="pubmed">18650505</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarmeas N. (2007) Am. J. Epidemiol. 165, 993&#x2013;997</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3627057</ArticleId><ArticleId IdType="pubmed">17298956</ArticleId></ArticleIdList></Reference><Reference><Citation>Eikelenboom P., van Exel E., Hoozemans J. J., Veerhuis R., Rozemuller A. J., van Gool W. A. (2010) Neurodegener Dis. 7, 38&#x2013;41</Citation><ArticleIdList><ArticleId IdType="pubmed">20160456</ArticleId></ArticleIdList></Reference><Reference><Citation>Glass C. K., Saijo K., Winner B., Marchetto M. C., Gage F. H. (2010) Cell 140, 918&#x2013;934</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2873093</ArticleId><ArticleId IdType="pubmed">20303880</ArticleId></ArticleIdList></Reference><Reference><Citation>Buga G. M., Frank J. S., Mottino G. A., Hendizadeh M., Hakhamian A., Tillisch J. H., Reddy S. T., Navab M., Anantharamaiah G. M., Ignarro L. J., Fogelman A. M. (2006) J. Lipid Res. 47, 2148&#x2013;2160</Citation><ArticleIdList><ArticleId IdType="pubmed">16835442</ArticleId></ArticleIdList></Reference><Reference><Citation>Handattu S. P., Garber D. W., Monroe C. E., van Groen T., Kadish I., Nayyar G., Cao D., Palgunachari M. N., Li L., Anantharamaiah G. M. (2009) Neurobiol Dis. 34, 525&#x2013;534</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5558244</ArticleId><ArticleId IdType="pubmed">19344763</ArticleId></ArticleIdList></Reference><Reference><Citation>Yvan-Charvet L., Wang N., Tall A. R. (2010) Arterioscler. Thromb. Vasc. Biol. 30, 139&#x2013;143</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2812788</ArticleId><ArticleId IdType="pubmed">19797709</ArticleId></ArticleIdList></Reference><Reference><Citation>Smoak K. A., Aloor J. J., Madenspacher J., Merrick B. A., Collins J. B., Zhu X., Cavigiolio G., Oda M. N., Parks J. S., Fessler M. B. (2010) Cell. Metab. 11, 493&#x2013;502</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3091482</ArticleId><ArticleId IdType="pubmed">20519121</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes C., Boche D., Wilkinson D., Yadegarfar G., Hopkins V., Bayer A., Jones R. W., Bullock R., Love S., Neal J. W., Zotova E., Nicoll J. A. (2008) Lancet 372, 216&#x2013;223</Citation><ArticleIdList><ArticleId IdType="pubmed">18640458</ArticleId></ArticleIdList></Reference><Reference><Citation>Duffy D., Rader D. J. (2006) Circulation 113, 1140&#x2013;1150</Citation><ArticleIdList><ArticleId IdType="pubmed">16505192</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefterov I., Fitz N. F., Cronican A. A., Fogg A., Lefterov P., Kodali R., Wetzel R., Koldamova R. (2010) J. Biol. Chem. 285, 36945&#x2013;36957</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2978623</ArticleId><ArticleId IdType="pubmed">20739292</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20846908</PMID><DateCompleted><Year>2010</Year><Month>11</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-4465</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>11</Issue><PubDate><Year>2010</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The Lancet. Neurology</Title><ISOAbbreviation>Lancet Neurol</ISOAbbreviation></Journal><ArticleTitle>Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study [corrected].</ArticleTitle><Pagination><StartPage>1070</StartPage><EndPage>1077</EndPage><MedlinePgn>1070-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1474-4422(10)70216-7</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Patients with idiopathic rapid-eye-movement sleep behaviour disorder (IRBD) may develop neurodegenerative conditions associated with substantia nigra dysfunction such as Parkinson's disease. In patients with Parkinson's disease, &#xb9;&#xb2;&#xb3;I-2&#x3b2;-carbomethoxy-3&#x3b2;-(4-iodophenyl)-N-(3-fluoropropyl)-nortropane (&#xb9;&#xb2;&#xb3;I-FP-CIT) SPECT detects striatal dopamine dysfunction resulting from nigral pathology whereas transcranial sonography (TCS) shows increased substantia nigra echogenic size, even before parkinsonism is clinically evident. We postulated that these neuroimaging changes could occur in a proportion of IRBD individuals who might then be at increased risk for development of a neurodegenerative disorder associated with substantia nigra dysfunction.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In our prospective study, we identified patients with IRBD from individuals referred to our sleep disorders centre in Barcelona, Spain. At baseline, we assessed dopamine transporter [corrected] uptake by use of &#xb9;&#xb2;&#xb3;I-FP-CIT SPECT, and estimated echogenicity of the substantia nigra by use of TCS. After a follow-up of 2&#xb7;5 years, participants were clinically assessed to establish whether they had developed neurodegenerative syndromes. Data were compared with those of matched healthy controls.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">43 individuals with IRBD agreed to participate in the study. We found reduced &#xb9;&#xb2;&#xb3;I-FP-CIT binding in the striatum (p=0&#xb7;045) in 17 (40%) of 43 participants compared with 18 controls, and substantia nigra hyperechogenicity in 14 (36%) of 39 participants with IRBD, compared with 16 (11%) of 149 controls (p=0&#xb7;0002). Tracer uptake reduction was more pronounced in the putamen than it was in the caudate nucleus. 27 (63%) participants had reduced &#xb9;&#xb2;&#xb3;I-FP-CIT binding or substantia nigra hyperechogenicity at baseline. Eight (30%) of these participants developed a neurodegenerative disorder (five Parkinson's disease, two dementia with Lewy bodies, and one multiple system atrophy). Individuals with normal neuroimaging results remained disease-free. Sensitivity of combined &#xb9;&#xb2;&#xb3;I-FP-CIT SPECT and TCS to predict conversion to synucleinopathy after 2&#xb7;5 years was 100% and specificity was 55%.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">In patients with IRBD, &#xb9;&#xb2;&#xb3;I-FP-CIT SPECT and TCS can detect subclinical changes much the same as those typically seen in patients with early Parkinson's disease. Decreased striatal &#xb9;&#xb2;&#xb3;I-FP-CIT binding and substantia nigra hyperechogenicity might be useful markers to identify individuals at increased risk for development of synucleinopathies.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">None.</AbstractText><CopyrightInformation>Copyright &#xa9; 2010 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Iranzo</LastName><ForeName>Alex</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Clinic, Networked Biomedical Research Centre for Neurodegenerative Diseases, The August Pi i Sunyer Biomedical Research Institute, Spain. airanzo@clinic.ub.es</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lome&#xf1;a</LastName><ForeName>Francisco</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Stockner</LastName><ForeName>Heike</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Valldeoriola</LastName><ForeName>Francesc</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Vilaseca</LastName><ForeName>Isabel</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Salamero</LastName><ForeName>Manel</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Molinuevo</LastName><ForeName>Jose Luis</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Serradell</LastName><ForeName>Monica</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Duch</LastName><ForeName>Joan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Pav&#xed;a</LastName><ForeName>Javier</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Gallego</LastName><ForeName>Judith</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Seppi</LastName><ForeName>Klaus</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>H&#xf6;gl</LastName><ForeName>Birgit</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Tolosa</LastName><ForeName>Eduard</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Poewe</LastName><ForeName>Werner</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Santamaria</LastName><ForeName>Joan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><CollectiveName>Sleep Innsbruck Barcelona (SINBAR) group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>09</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Neurol</MedlineTA><NlmUniqueID>101139309</NlmUniqueID><ISSNLinking>1474-4422</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050483">Dopamine Plasma Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051843">Synucleins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Lancet Neurol. 2010 Nov;9(11):1045</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2010 Nov;9(11):1040-2. doi: 10.1016/S1474-4422(10)70221-0.</RefSource><PMID Version="1">20869916</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050483" MajorTopicYN="N">Dopamine Plasma Membrane Transport Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020187" MajorTopicYN="N">REM Sleep Behavior Disorder</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013378" MajorTopicYN="N">Substantia Nigra</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051843" MajorTopicYN="N">Synucleins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015899" MajorTopicYN="N">Tomography, Emission-Computed, Single-Photon</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20846908</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(10)70216-7</ArticleId><ArticleId IdType="pii">S1474-4422(10)70216-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20855613</PMID><DateCompleted><Year>2010</Year><Month>11</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>107</Volume><Issue>40</Issue><PubDate><Year>2010</Year><Month>Oct</Month><Day>05</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Soluble amyloid precursor protein (APP) regulates transthyretin and Klotho gene expression without rescuing the essential function of APP.</ArticleTitle><Pagination><StartPage>17362</StartPage><EndPage>17367</EndPage><MedlinePgn>17362-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1012568107</ELocationID><Abstract><AbstractText>Amyloidogenic processing of the amyloid precursor protein (APP) generates a large secreted ectodomain fragment (APPs&#x3b2;), &#x3b2;-amyloid (A&#x3b2;) peptides, and an APP intracellular domain (AICD). Whereas A&#x3b2; is viewed as critical for Alzheimer's disease pathogenesis, the role of other APP processing products remains enigmatic. Of interest, the AICD has been implicated in transcriptional regulation, and N-terminal cleavage of APPs&#x3b2; has been suggested to produce an active fragment that may mediate axonal pruning and neuronal cell death. We previously reported that mice deficient in APP and APP-like protein 2 (APLP2) exhibit early postnatal lethality and neuromuscular synapse defects, whereas mice with neuronal conditional deletion of APP and APLP2 are viable. Using transcriptional profiling, we now identify transthyretin (TTR) and Klotho as APP/APLP2-dependent genes whose expression is decreased in loss-of-function states but increased in gain-of-function states. Significantly, by creating an APP knockin allele that expresses only APPs&#x3b2; protein, we demonstrate that APPs&#x3b2; is not normally cleaved in vivo and is fully capable of mediating the APP-dependent regulation of TTR and Klotho gene expression. Despite being an active regulator of gene expression, APPs&#x3b2; did not rescue the lethality and neuromuscular synapse defects of APP and APLP2 double-KO animals. Our studies identify TTR and Klotho as physiological targets of APP that are regulated by soluble APPs&#x3b2; independent of developmental APP functions. This unexpected APP-mediated signaling pathway may play an important role in maintaining TTR and Klotho levels and their respective functions in A&#x3b2; sequestration and aging.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Hongmei</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Huffington Center on Aging, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Baiping</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zilai</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Qinxi</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Tabuchi</LastName><ForeName>Katsuhiko</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Hammer</LastName><ForeName>Robert E</ForeName><Initials>RE</Initials></Author><Author ValidYN="Y"><LastName>S&#xfc;dhof</LastName><ForeName>Thomas C</ForeName><Initials>TC</Initials></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Hui</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R37 MH052804</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH52804</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>AG033467</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30HD024064</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG032051</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG032051</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG033467</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 HD024064</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>09</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011228">Prealbumin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.31</RegistryNumber><NameOfSubstance UI="D005966">Glucuronidase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.31</RegistryNumber><NameOfSubstance UI="D000090265">Klotho Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):13228</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="Y">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005966" MajorTopicYN="N">Glucuronidase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000090265" MajorTopicYN="N">Klotho Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D046228" MajorTopicYN="N">Microarray Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011228" MajorTopicYN="N">Prealbumin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>4</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20855613</ArticleId><ArticleId IdType="pmc">PMC2951422</ArticleId><ArticleId IdType="doi">10.1073/pnas.1012568107</ArticleId><ArticleId IdType="pii">1012568107</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zheng H, Koo EH. The amyloid precursor protein: Beyond amyloid. Mol Neurodegener. 2006;1:5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1538601</ArticleId><ArticleId IdType="pubmed">16930452</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner PR, O'Connor K, Tate WP, Abraham WC. Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog Neurobiol. 2003;70:1&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">12927332</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolaev A, McLaughlin T, O'Leary DDM, Tessier-Lavigne M. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature. 2009;457:981&#x2013;989.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677572</ArticleId><ArticleId IdType="pubmed">19225519</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao X, S&#xfc;dhof TC. A transcriptionally active complex of APP with Fe65 and histone acetyltransferase Tip60. Science. 2001;293:115&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">11441186</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao X, S&#xfc;dhof TC. Dissection of amyloid-beta precursor protein-dependent transcriptional transactivation. J Biol Chem. 2004;279:24601&#x2013;24611.</Citation><ArticleIdList><ArticleId IdType="pubmed">15044485</ArticleId></ArticleIdList></Reference><Reference><Citation>Baek SH, et al. Exchange of N-CoR corepressor and Tip60 coactivator complexes links gene expression by NF-kappaB and beta-amyloid precursor protein. Cell. 2002;110:55&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">12150997</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HS, et al. C-terminal fragments of amyloid precursor protein exert neurotoxicity by inducing glycogen synthase kinase-3beta expression. FASEB J. 2003;17:1951&#x2013;1953.</Citation><ArticleIdList><ArticleId IdType="pubmed">12923068</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardossi-Piquard R, et al. Presenilin-dependent transcriptional control of the Abeta-degrading enzyme neprilysin by intracellular domains of betaAPP and APLP. Neuron. 2005;46:541&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pubmed">15944124</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YW, et al. Presenilin/gamma-secretase-dependent processing of beta-amyloid precursor protein regulates EGF receptor expression. Proc Natl Acad Sci USA. 2007;104:10613&#x2013;10618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1888796</ArticleId><ArticleId IdType="pubmed">17556541</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, et al. Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1. Neuron. 2007;56:66&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2045076</ArticleId><ArticleId IdType="pubmed">17920016</ArticleId></ArticleIdList></Reference><Reference><Citation>von Rotz RC, et al. The APP intracellular domain forms nuclear multiprotein complexes and regulates the transcription of its own precursor. J Cell Sci. 2004;117:4435&#x2013;4448.</Citation><ArticleIdList><ArticleId IdType="pubmed">15331662</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Z, Cool BH, Martin GM, Hu Q. A dominant role for FE65 (APBB1) in nuclear signaling. J Biol Chem. 2006;281:4207&#x2013;4214.</Citation><ArticleIdList><ArticleId IdType="pubmed">16332686</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert SS, et al. Regulated intramembrane proteolysis of amyloid precursor protein and regulation of expression of putative target genes. EMBO Rep. 2006;7:739&#x2013;745.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1500829</ArticleId><ArticleId IdType="pubmed">16729020</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen AC, Selkoe DJ. Response to: Pardossi-Piquard et al., &#x201c;Presenilin-dependent transcriptional control of the Abeta-degrading enzyme neprilysin by intracellular domains of betaAPP and APLP.&#x201d; Neuron 46:541&#x2013;554. Neuron. 2007;53:479&#x2013;483.</Citation><ArticleIdList><ArticleId IdType="pubmed">17296549</ArticleId></ArticleIdList></Reference><Reference><Citation>Repetto E, Yoon IS, Zheng H, Kang DE. Presenilin 1 regulates epidermal growth factor receptor turnover and signaling in the endosomal-lysosomal pathway. J Biol Chem. 2007;282:31504&#x2013;31516.</Citation><ArticleIdList><ArticleId IdType="pubmed">17716970</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamboli IY, et al. Loss of gamma-secretase function impairs endocytosis of lipoprotein particles and membrane cholesterol homeostasis. J Neurosci. 2008;28:12097&#x2013;12106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6671640</ArticleId><ArticleId IdType="pubmed">19005074</ArticleId></ArticleIdList></Reference><Reference><Citation>Giliberto L, et al. Evidence that the Amyloid beta Precursor Protein-intracellular domain lowers the stress threshold of neurons and has a &#x201c;regulated&#x201d; transcriptional role. Mol Neurodegener. 2008;3:12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2538519</ArticleId><ArticleId IdType="pubmed">18764939</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng H, et al. beta-Amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity. Cell. 1995;81:525&#x2013;531.</Citation><ArticleIdList><ArticleId IdType="pubmed">7758106</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson GR, et al. Age-related cognitive deficits, impaired long-term potentiation and reduction in synaptic marker density in mice lacking the beta-amyloid precursor protein. Neuroscience. 1999;90:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">10188929</ArticleId></ArticleIdList></Reference><Reference><Citation>von Koch CS, et al. Generation of APLP2 KO mice and early postnatal lethality in APLP2/APP double KO mice. Neurobiol Aging. 1997;18:661&#x2013;669.</Citation><ArticleIdList><ArticleId IdType="pubmed">9461064</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P, et al. Defective neuromuscular synapses in mice lacking amyloid precursor protein (APP) and APP-Like protein 2. J Neurosci. 2005;25:1219&#x2013;1225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725967</ArticleId><ArticleId IdType="pubmed">15689559</ArticleId></ArticleIdList></Reference><Reference><Citation>King GD, Scott Turner R. Adaptor protein interactions: Modulators of amyloid precursor protein metabolism and Alzheimer's disease risk? Exp Neurol. 2004;185:208&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pubmed">14736502</ArticleId></ArticleIdList></Reference><Reference><Citation>Ring S, et al. The secreted beta-amyloid precursor protein ectodomain APPs alpha is sufficient to rescue the anatomical, behavioral, and electrophysiological abnormalities of APP-deficient mice. J Neurosci. 2007;27:7817&#x2013;7826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672885</ArticleId><ArticleId IdType="pubmed">17634375</ArticleId></ArticleIdList></Reference><Reference><Citation>Hornsten A, et al. APL-1, a Caenorhabditis elegans protein related to the human beta-amyloid precursor protein, is essential for viability. Proc Natl Acad Sci USA. 2007;104:1971&#x2013;1976.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1794273</ArticleId><ArticleId IdType="pubmed">17267616</ArticleId></ArticleIdList></Reference><Reference><Citation>Koo EH, Squazzo SL, Selkoe DJ, Koo CH. Trafficking of cell-surface amyloid beta-protein precursor. I. Secretion, endocytosis and recycling as detected by labeled monoclonal antibody. J Cell Sci. 1996;109:991&#x2013;998.</Citation><ArticleIdList><ArticleId IdType="pubmed">8743946</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, et al. Presynaptic and postsynaptic interaction of the amyloid precursor protein promotes peripheral and central synaptogenesis. J Neurosci. 2009;29:10788&#x2013;10801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2757256</ArticleId><ArticleId IdType="pubmed">19726636</ArticleId></ArticleIdList></Reference><Reference><Citation>Back S, et al. beta-amyloid precursor protein can be transported independent of any sorting signal to the axonal and dendritic compartment. J Neurosci Res. 2007;85:2580&#x2013;2590.</Citation><ArticleIdList><ArticleId IdType="pubmed">17335075</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein TD, Johnson JA. Lack of neurodegeneration in transgenic mice overexpressing mutant amyloid precursor protein is associated with increased levels of transthyretin and the activation of cell survival pathways. J Neurosci. 2002;22:7380&#x2013;7388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758007</ArticleId><ArticleId IdType="pubmed">12196559</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu ZL, et al. Comparative analysis of cortical gene expression in mouse models of Alzheimer's disease. Neurobiol Aging. 2006;27:377&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pubmed">15927307</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao L, et al. Liver-specific overexpression of the insulin-like growth factor-I enhances somatic growth and partially prevents the effects of growth hormone deficiency. Endocrinology. 2006;147:3877&#x2013;3888.</Citation><ArticleIdList><ArticleId IdType="pubmed">16709615</ArticleId></ArticleIdList></Reference><Reference><Citation>Herms J, et al. Cortical dysplasia resembling human type 2 lissencephaly in mice lacking all three APP family members. EMBO J. 2004;23:4106&#x2013;4115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC524337</ArticleId><ArticleId IdType="pubmed">15385965</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, et al. Genetic dissection of the amyloid precursor protein in developmental function and amyloid pathogenesis. J Biol Chem. 2010 10.1074/jbc.M110.137729.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2945554</ArticleId><ArticleId IdType="pubmed">20693289</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisodia SS. Biomedicine. A cargo receptor mystery APParently solved? Science. 2002;295:805&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pubmed">11823626</ArticleId></ArticleIdList></Reference><Reference><Citation>Kounnas MZ, et al. LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted beta-amyloid precursor protein and mediates its degradation. Cell. 1995;82:331&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pubmed">7543026</ArticleId></ArticleIdList></Reference><Reference><Citation>Santiago-Garc&#xed;a J, Mas-Oliva J, Innerarity TL, Pitas RE. Secreted forms of the amyloid-beta precursor protein are ligands for the class A scavenger receptor. J Biol Chem. 2001;276:30655&#x2013;30661.</Citation><ArticleIdList><ArticleId IdType="pubmed">11389145</ArticleId></ArticleIdList></Reference><Reference><Citation>Caille I, et al. Soluble form of amyloid precursor protein regulates proliferation of progenitors in the adult subventricular zone. Development. 2004;131:2173&#x2013;2181.</Citation><ArticleIdList><ArticleId IdType="pubmed">15073156</ArticleId></ArticleIdList></Reference><Reference><Citation>Young-Pearse TL, Chen AC, Chang R, Marquez C, Selkoe DJ. Secreted APP regulates the function of full-length APP in neurite outgrowth through interaction with integrin beta1. Neural Develop. 2008;3:15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2442059</ArticleId><ArticleId IdType="pubmed">18573216</ArticleId></ArticleIdList></Reference><Reference><Citation>Louren&#xe7;o FC, et al. Netrin-1 interacts with amyloid precursor protein and regulates amyloid-beta production. Cell Death Differ. 2009;16:655&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2757418</ArticleId><ArticleId IdType="pubmed">19148186</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoe HS, et al. Interaction of reelin with amyloid precursor protein promotes neurite outgrowth. J Neurosci. 2009;29:7459&#x2013;7473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2759694</ArticleId><ArticleId IdType="pubmed">19515914</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarzman AL, et al. Transthyretin sequesters amyloid beta protein and prevents amyloid formation. Proc Natl Acad Sci USA. 1994;91:8368&#x2013;8372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC44607</ArticleId><ArticleId IdType="pubmed">8078889</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SH, et al. Accelerated Abeta deposition in APPswe/PS1deltaE9 mice with hemizygous deletions of TTR (transthyretin) J Neurosci. 2007;27:7006&#x2013;7010.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672232</ArticleId><ArticleId IdType="pubmed">17596449</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuro-o M, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997;390:45&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">9363890</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurosu H, et al. Suppression of aging in mice by the hormone Klotho. Science. 2005;309:1829&#x2013;1833.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2536606</ArticleId><ArticleId IdType="pubmed">16123266</ArticleId></ArticleIdList></Reference><Reference><Citation>Imura A, et al. alpha-Klotho as a regulator of calcium homeostasis. Science. 2007;316:1615&#x2013;1618.</Citation><ArticleIdList><ArticleId IdType="pubmed">17569864</ArticleId></ArticleIdList></Reference><Reference><Citation>Buxbaum JN, et al. Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of Abeta toxicity. Proc Natl Acad Sci USA. 2008;105:2681&#x2013;2686.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2268196</ArticleId><ArticleId IdType="pubmed">18272491</ArticleId></ArticleIdList></Reference><Reference><Citation>Serot JM, Christmann D, Dubost T, Couturier M. Cerebrospinal fluid transthyretin: Aging and late onset Alzheimer's disease. J Neurol Neurosurg Psychiatry. 1997;63:506&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2169793</ArticleId><ArticleId IdType="pubmed">9343132</ArticleId></ArticleIdList></Reference><Reference><Citation>Merched A, et al. Apolipoprotein E, transthyretin and actin in the CSF of Alzheimer's patients: Relation with the senile plaques and cytoskeleton biochemistry. FEBS Lett. 1998;425:225&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pubmed">9559653</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmert MR, et al. Soluble derivatives of the beta amyloid protein precursor in cerebrospinal fluid: Alterations in normal aging and in Alzheimer's disease. Neurology. 1990;40:1028&#x2013;1034.</Citation><ArticleIdList><ArticleId IdType="pubmed">2113204</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B, Yang L, Wang Z, Zheng H. Amyloid precursor protein mediates presynaptic localization and activity of the high-affinity choline transporter. Proc Natl Acad Sci USA. 2007;104:14140&#x2013;14145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1955810</ArticleId><ArticleId IdType="pubmed">17709753</ArticleId></ArticleIdList></Reference><Reference><Citation>Tronche F, et al. Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety. Nat Genet. 1999;23:99&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">10471508</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20862329</PMID><DateCompleted><Year>2011</Year><Month>01</Month><Day>04</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1553-7404</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>9</Issue><PubDate><Year>2010</Year><Month>Sep</Month><Day>16</Day></PubDate></JournalIssue><Title>PLoS genetics</Title><ISOAbbreviation>PLoS Genet</ISOAbbreviation></Journal><ArticleTitle>SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>e1001101</StartPage><MedlinePgn>e1001101</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e1001101</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pgen.1001101</ELocationID><Abstract><AbstractText>Alzheimer's Disease (AD) is a complex and multifactorial disease. While large genome-wide association studies have had some success in identifying novel genetic risk factors for AD, case-control studies are less likely to uncover genetic factors that influence progression of disease. An alternative approach to identifying genetic risk for AD is the use of quantitative traits or endophenotypes. The use of endophenotypes has proven to be an effective strategy, implicating genetic risk factors in several diseases, including anemia, osteoporosis and heart disease. In this study we identify a genetic factor associated with the rate of decline in AD patients and present a methodology for identification of other such factors. We have used an established biomarker for AD, cerebrospinal fluid (CSF) tau phosphorylated at threonine 181 (ptau(181)) levels as an endophenotype for AD, identifying a SNP, rs1868402, in the gene encoding the regulatory sub-unit of protein phosphatase B, associated with CSF ptau(181) levels in two independent CSF series (P(combined) = 1.17 x 10(-05)). We show no association of rs1868402 with risk for AD or age at onset, but detected a very significant association with rate of progression of disease that is consistent in two independent series (P(combined) = 1.17 x 10(-05)). Our analyses suggest that genetic variants associated with CSF ptau(181) levels may have a greater impact on rate of progression, while genetic variants such as APOE4, that are associated with CSF A&#x3b2;(42) levels influence risk and onset but not the rate of progression. Our results also suggest that drugs that inhibit or decrease tau phosphorylation may slow cognitive decline in individuals with very mild dementia or delay the appearance of memory problems in elderly individuals with low CSF A&#x3b2;(42) levels. Finally, we believe genome-wide association studies of CSF tau/ptau(181) levels should identify novel genetic variants which will likely influence rate of progression of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cruchaga</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA. cruchagc@psychiatry.wustl.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kauwe</LastName><ForeName>John S K</ForeName><Initials>JS</Initials></Author><Author ValidYN="Y"><LastName>Mayo</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Spiegel</LastName><ForeName>Noah</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Bertelsen</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Nowotny</LastName><ForeName>Petra</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Aarti R</ForeName><Initials>AR</Initials></Author><Author ValidYN="Y"><LastName>Abraham</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Hollingworth</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Harold</LastName><ForeName>Denise</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Owen</LastName><ForeName>Michael M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Julie</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Lovestone</LastName><ForeName>Simon</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Peskind</LastName><ForeName>Elaine R</ForeName><Initials>ER</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ge</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Leverenz</LastName><ForeName>James B</ForeName><Initials>JB</Initials></Author><Author ValidYN="Y"><LastName>Galasko</LastName><ForeName>Douglas</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><CollectiveName>Alzheimer's Disease Neuroimaging Initiative</CollectiveName></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison M</ForeName><Initials>AM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG023185</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG16208</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG05136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG05681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG016208</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0300429</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01AG03991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>09</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Genet</MedlineTA><NlmUniqueID>101239074</NlmUniqueID><ISSNLinking>1553-7390</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010750">Phosphoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.16</RegistryNumber><NameOfSubstance UI="D019703">Calcineurin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.16</RegistryNumber><NameOfSubstance UI="C525676">PPP3R1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019703" MajorTopicYN="N">Calcineurin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010750" MajorTopicYN="N">Phosphoproteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014861" MajorTopicYN="N" Type="Geographic">Washington</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The work presented in this report is also the subject of a pending patent filed by Washington University in St. Louis, Missouri, United States of America, in which Drs. C. Cruchaga, A. M. Goate, D. M. Holtzman and A. Fagan are named as inventors. The patent is currently under option to AstraZeneca Pharmaceuticals, LP. Drs. Goate and Holtzman have acted as consultants for AstraZeneca Pharmaceuticals, LP, in 2008/2009.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>1</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20862329</ArticleId><ArticleId IdType="pmc">PMC2940763</ArticleId><ArticleId IdType="doi">10.1371/journal.pgen.1001101</ArticleId><ArticleId IdType="pii">e1001101</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet. 2009;41:1088&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845877</ArticleId><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Heath S, Even G, Campion D, Sleegers K, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet. 2009;41:1094&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>Chambers JC, Zhang W, Li Y, Sehmi J, Wass MN, et al. Genome-wide association study identifies variants in TMPRSS6 associated with hemoglobin levels. Nat Genet. 2009;41:1170&#x2013;1172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3178047</ArticleId><ArticleId IdType="pubmed">19820698</ArticleId></ArticleIdList></Reference><Reference><Citation>Benyamin B, Ferreira MA, Willemsen G, Gordon S, Middelberg RP, et al. Common variants in TMPRSS6 are associated with iron status and erythrocyte volume. Nat Genet. 2009;41:1173&#x2013;1175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3135421</ArticleId><ArticleId IdType="pubmed">19820699</ArticleId></ArticleIdList></Reference><Reference><Citation>Soranzo N, Spector TD, Mangino M, Kuhnel B, Rendon A, et al. A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet. 2009;41:1182&#x2013;1190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3108459</ArticleId><ArticleId IdType="pubmed">19820697</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganesh SK, Zakai NA, van Rooij FJ, Soranzo N, Smith AV, et al. Multiple loci influence erythrocyte phenotypes in the CHARGE Consortium. Nat Genet. 2009;41:1191&#x2013;1198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2778265</ArticleId><ArticleId IdType="pubmed">19862010</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivadeneira F, Styrkarsdottir U, Estrada K, Halldorsson BV, Hsu YH, et al. Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies. Nat Genet. 2009;41:1199&#x2013;1206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2783489</ArticleId><ArticleId IdType="pubmed">19801982</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen JC, Kiss RS, Pertsemlidis A, Marcel YL, McPherson R, et al. Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science. 2004;305:869&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">15297675</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen JC, Pertsemlidis A, Fahmi S, Esmail S, Vega GL, et al. Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels. Proc Natl Acad Sci U S A. 2006;103:1810&#x2013;1815.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1413637</ArticleId><ArticleId IdType="pubmed">16449388</ArticleId></ArticleIdList></Reference><Reference><Citation>Romeo S, Pennacchio LA, Fu Y, Boerwinkle E, Tybjaerg-Hansen A, et al. Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL. Nat Genet. 2007;39:513&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2762948</ArticleId><ArticleId IdType="pubmed">17322881</ArticleId></ArticleIdList></Reference><Reference><Citation>Romeo S, Yin W, Kozlitina J, Pennacchio LA, Boerwinkle E, et al. Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. J Clin Invest. 2009;119:70&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2613476</ArticleId><ArticleId IdType="pubmed">19075393</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Morris JC. Tangles and plaques in nondemented aging and &#x201c;preclinical&#x201d; Alzheimer's disease. Ann Neurol. 1999;45:358&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">10072051</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Head D, Shah AR, Marcus D, Mintun M, et al. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol. 2009;65:176&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2763631</ArticleId><ArticleId IdType="pubmed">19260027</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006;59:512&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">16372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010;67:122&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2830375</ArticleId><ArticleId IdType="pubmed">20186853</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O, Zetterberg H, Buchhave P, Andreasson U, Londos E, et al. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord. 2007;23:316&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pubmed">17374949</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapaki EN, Paraskevas GP, Tzerakis NG, Sfagos C, Seretis A, et al. Cerebrospinal fluid tau, phospho-tau181 and beta-amyloid1-42 in idiopathic normal pressure hydrocephalus: a discrimination from Alzheimer's disease. Eur J Neurol. 2007;14:168&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pubmed">17250725</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, et al. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64:343&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">17210801</ArticleId></ArticleIdList></Reference><Reference><Citation>Noguchi M, Yoshita M, Matsumoto Y, Ono K, Iwasa K, et al. Decreased beta-amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration. J Neurol Sci. 2005;237:61&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">15992827</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain. 2008;131:1630&#x2013;1645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2408940</ArticleId><ArticleId IdType="pubmed">18339640</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust WJ, Landau SM, Shaw LM, Trojanowski JQ, Koeppe RA, et al. Relationships between biomarkers in aging and dementia. Neurology. 2009;73:1193&#x2013;1199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2764726</ArticleId><ArticleId IdType="pubmed">19822868</ArticleId></ArticleIdList></Reference><Reference><Citation>Hesse C, Rosengren L, Andreasen N, Davidsson P, Vanderstichele H, et al. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett. 2001;297:187&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">11137759</ArticleId></ArticleIdList></Reference><Reference><Citation>Ost M, Nylen K, Csajbok L, Ohrfelt AO, Tullberg M, et al. Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury. Neurology. 2006;67:1600&#x2013;1604.</Citation><ArticleIdList><ArticleId IdType="pubmed">17101890</ArticleId></ArticleIdList></Reference><Reference><Citation>Buerger K, Ewers M, Pirttila T, Zinkowski R, Alafuzoff I, et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain. 2006;129:3035&#x2013;3041.</Citation><ArticleIdList><ArticleId IdType="pubmed">17012293</ArticleId></ArticleIdList></Reference><Reference><Citation>Urakami K, Wada K, Arai H, Sasaki H, Kanai M, et al. Diagnostic significance of tau protein in cerebrospinal fluid from patients with corticobasal degeneration or progressive supranuclear palsy. J Neurol Sci. 2001;183:95&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">11166802</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai H, Morikawa Y, Higuchi M, Matsui T, Clark CM, et al. Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology. Biochem Biophys Res Commun. 1997;236:262&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">9240421</ArticleId></ArticleIdList></Reference><Reference><Citation>Kauwe JS, Cruchaga C, Mayo K, Fenoglio C, Bertelsen S, et al. Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition. Proc Natl Acad Sci U S A. 2008;105:8050&#x2013;8054.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2430357</ArticleId><ArticleId IdType="pubmed">18541914</ArticleId></ArticleIdList></Reference><Reference><Citation>Kauwe JS, Jacquart S, Chakraverty S, Wang J, Mayo K, et al. Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer's disease presenilin 1 mutation. Ann Neurol. 2007;61:446&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">17366635</ArticleId></ArticleIdList></Reference><Reference><Citation>Kauwe JS, Wang J, Mayo K, Morris JC, Fagan AM, et al. Alzheimer's disease risk variants show association with cerebrospinal fluid amyloid beta. Neurogenetics. 2009;10:13&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2726757</ArticleId><ArticleId IdType="pubmed">18813964</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato-Harada R, Okabe S, Umeyama T, Kanai Y, Hirokawa N. Microtubule-associated proteins regulate microtubule function as the track for intracellular membrane organelle transports. Cell Struct Funct. 1996;21:283&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pubmed">9118234</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JZ, Grundke-Iqbal I, Iqbal K. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur J Neurosci. 2007;25:59&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3191918</ArticleId><ArticleId IdType="pubmed">17241267</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires-Jones TL, Stoothoff WH, de Calignon A, Jones PB, Hyman BT. Tau pathophysiology in neurodegeneration: a tangled issue. Trends Neurosci. 2009;32:150&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">19162340</ArticleId></ArticleIdList></Reference><Reference><Citation>Snider BJ, Fagan AM, Roe C, Shah AR, Grant EA, et al. Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch Neurol. 2009;66:638&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2759394</ArticleId><ArticleId IdType="pubmed">19433664</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster JA, Gibbs JR, Clarke J, Ray M, Zhang W, et al. Genetic control of human brain transcript expression in Alzheimer disease. Am J Hum Genet. 2009;84:445&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2667989</ArticleId><ArticleId IdType="pubmed">19361613</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet. 2007;39:17&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">17192785</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu DY, Luo J, Bu F, Song GJ, Zhang LQ, et al. Inhibition of calcineurin by infusion of CsA causes hyperphosphorylation of tau and is accompanied by abnormal behavior in mice. Biol Chem. 2006;387:977&#x2013;983.</Citation><ArticleIdList><ArticleId IdType="pubmed">16913847</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo J, Ma J, Yu DY, Bu F, Zhang W, et al. Infusion of FK506, a specific inhibitor of calcineurin, induces potent tau hyperphosphorylation in mouse brain. Brain Res Bull. 2008;76:464&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pubmed">18534252</ArticleId></ArticleIdList></Reference><Reference><Citation>Garver TD, Kincaid RL, Conn RA, Billingsley ML. Reduction of calcineurin activity in brain by antisense oligonucleotides leads to persistent phosphorylation of tau protein at Thr181 and Thr231. Mol Pharmacol. 1999;55:632&#x2013;641.</Citation><ArticleIdList><ArticleId IdType="pubmed">10101020</ArticleId></ArticleIdList></Reference><Reference><Citation>Ladner CJ, Czech J, Maurice J, Lorens SA, Lee JM. Reduction of calcineurin enzymatic activity in Alzheimer's disease: correlation with neuropathologic changes. J Neuropathol Exp Neurol. 1996;55:924&#x2013;931.</Citation><ArticleIdList><ArticleId IdType="pubmed">8759782</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan AR, Turic D, Jehu L, Hamilton G, Hollingworth P, et al. Association studies of 23 positional/functional candidate genes on chromosome 10 in late-onset Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet. 2007;144B:762&#x2013;770.</Citation><ArticleIdList><ArticleId IdType="pubmed">17373700</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg L, McKeel DW, Jr, Miller JP, Storandt M, Rubin EH, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol. 1998;55:326&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">9520006</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller PY, Janovjak H, Miserez AR, Dobbie Z. Processing of gene expression data generated by quantitative real-time RT-PCR. Biotechniques. 2002;32:1372&#x2013;1374, 1376, 1378&#x2013;1379.</Citation><ArticleIdList><ArticleId IdType="pubmed">12074169</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoothoff WH, Johnson GV. Tau phosphorylation: physiological and pathological consequences. Biochim Biophys Acta. 2005;1739:280&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pubmed">15615646</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuzwa SA, Vocadlo DJ. O-GlcNAc modification and the tauopathies: insights from chemical biology. Curr Alzheimer Res. 2009;6:451&#x2013;454.</Citation><ArticleIdList><ArticleId IdType="pubmed">19874270</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung SH. Aberrant phosphorylation in the pathogenesis of Alzheimer's disease. BMB Rep. 2009;42:467&#x2013;474.</Citation><ArticleIdList><ArticleId IdType="pubmed">19712581</ArticleId></ArticleIdList></Reference><Reference><Citation>Conde L, Vaquerizas JM, Dopazo H, Arbiza L, Reumers J, et al. PupaSuite: finding functional single nucleotide polymorphisms for large-scale genotyping purposes. Nucleic Acids Res. 2006;34:W621&#x2013;625.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1538854</ArticleId><ArticleId IdType="pubmed">16845085</ArticleId></ArticleIdList></Reference><Reference><Citation>Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci U S A. 2003;100:9440&#x2013;9445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC170937</ArticleId><ArticleId IdType="pubmed">12883005</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Myers AJ, Gibbs JR, Webster JA, Rohrer K, Zhao A, et al. A survey of genetic human cortical gene expression. Nat Genet. 2007;39:1494&#x2013;1499.</Citation><ArticleIdList><ArticleId IdType="pubmed">17982457</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20869593</PMID><DateCompleted><Year>2010</Year><Month>10</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>6</Issue><PubDate><Year>2010</Year><Month>Sep</Month><Day>23</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Acetylation of tau inhibits its degradation and contributes to tauopathy.</ArticleTitle><Pagination><StartPage>953</StartPage><EndPage>966</EndPage><MedlinePgn>953-66</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2010.08.044</ELocationID><Abstract><AbstractText>Neurodegenerative tauopathies characterized by hyperphosphorylated tau include frontotemporal dementia and Parkinsonism linked to chromosome 17 (FTDP-17) and Alzheimer's disease (AD). Reducing tau levels improves cognitive function in mouse models of AD and FTDP-17, but the mechanisms regulating the turnover of pathogenic tau are unknown. We found that tau is acetylated and that tau acetylation prevents degradation of phosphorylated tau (p-tau). We generated two antibodies specific for acetylated tau and showed that tau acetylation is elevated in patients at early and moderate Braak stages of tauopathy. Histone acetyltransferase p300 was involved in tau acetylation and the class III protein deacetylase SIRT1 in deacetylation. Deleting SIRT1 enhanced levels of acetylated-tau and pathogenic forms of p-tau, probably by blocking proteasome-mediated degradation. Inhibiting p300 with a small molecule promoted tau deacetylation and eliminated p-tau associated with tauopathy. Modulating tau acetylation could be a new therapeutic strategy to reduce tau-mediated neurodegeneration.</AbstractText><CopyrightInformation>Copyright &#xa9; 2010 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Min</LastName><ForeName>Sang-Won</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Seo-Hyun</ForeName><Initials>SH</Initials></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yungui</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Schroeder</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Haroutunian</LastName><ForeName>Vahram</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Seeley</LastName><ForeName>William W</ForeName><Initials>WW</Initials></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Eric J</ForeName><Initials>EJ</Initials></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Yong</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Masliah</LastName><ForeName>Eliezer</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Mukherjee</LastName><ForeName>Chandrani</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Meyers</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Cole</LastName><ForeName>Philip A</ForeName><Initials>PA</Initials></Author><Author ValidYN="Y"><LastName>Ott</LastName><ForeName>Melanie</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Gan</LastName><ForeName>Li</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG030207</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>C06 RR018928</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG023501-06</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C550547">6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002227">Carbazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011500">Protein Synthesis Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>98600C0908</RegistryNumber><NameOfSubstance UI="D003513">Cycloheximide</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.1.48</RegistryNumber><NameOfSubstance UI="D050880">p300-CBP Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.1.48</RegistryNumber><NameOfSubstance UI="C100367">p300-CBP-associated factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.1.-</RegistryNumber><NameOfSubstance UI="C447939">SIRT1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.1.-</RegistryNumber><NameOfSubstance UI="D056564">Sirtuin 1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Neuron. 2010 Nov 18;68(4):801</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2010 Sep 23;67(6):900-2. doi: 10.1016/j.neuron.2010.09.010.</RefSource><PMID Version="1">20869587</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000107" MajorTopicYN="N">Acetylation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002227" MajorTopicYN="N">Carbazoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003513" MajorTopicYN="N">Cycloheximide</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047468" MajorTopicYN="N">Immunoprecipitation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011500" MajorTopicYN="N">Protein Synthesis Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056564" MajorTopicYN="N">Sirtuin 1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019032" MajorTopicYN="N">Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054875" MajorTopicYN="N">Ubiquitination</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050880" MajorTopicYN="N">p300-CBP Transcription Factors</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>8</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>10</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>9</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20869593</ArticleId><ArticleId IdType="mid">NIHMS261673</ArticleId><ArticleId IdType="pmc">PMC3035103</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2010.08.044</ArticleId><ArticleId IdType="pii">S0896-6273(10)00687-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Amos LA. Microtubule structure and its stabilisation. Org Biomol Chem. 2004;2:2153&#x2013;2160.</Citation><ArticleIdList><ArticleId IdType="pubmed">15280946</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci. 2007;8:663&#x2013;672.</Citation><ArticleIdList><ArticleId IdType="pubmed">17684513</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowers EM, Yan G, Mukherjee C, Orry A, Wang L, Holbert MA, Crump NT, Hazzalin CA, Liszczak G, Yuan H, et al. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chem Biol. 2010;17:471&#x2013;482.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2884008</ArticleId><ArticleId IdType="pubmed">20534345</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol Berl. 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns NJ, Bigio EH, Mackenzie IR, Neumann M, Lee VM, Hatanpaa KJ, White CL, 3rd, Schneider JA, Grinberg LT, Halliday G, et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol. 2007;114:5&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2827877</ArticleId><ArticleId IdType="pubmed">17579875</ArticleId></ArticleIdList></Reference><Reference><Citation>Caron C, Boyault C, Khochbin S. Regulatory cross-talk between lysine acetylation and ubiquitination: role in the control of protein stability. Bioessays. 2005;27:408&#x2013;415.</Citation><ArticleIdList><ArticleId IdType="pubmed">15770681</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Zhou Y, Mueller-Steiner S, Chen LF, Kwon H, Yi S, Mucke L, Gan L. SIRT1 Protects against Microglia-dependent Amyloid-{beta} Toxicity through Inhibiting NF-{kappa}B Signaling. J Biol Chem. 2005;280:40364&#x2013;40374.</Citation><ArticleIdList><ArticleId IdType="pubmed">16183991</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng HL, Mostoslavsky R, Saito S, Manis JP, Gu Y, Patel P, Bronson R, Appella E, Alt FW, Chua KF. Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc Natl Acad Sci USA. 2003;100:10794&#x2013;10799.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC196882</ArticleId><ArticleId IdType="pubmed">12960381</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV, Mann M. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science. 2009;325:834&#x2013;840.</Citation><ArticleIdList><ArticleId IdType="pubmed">19608861</ArticleId></ArticleIdList></Reference><Reference><Citation>Chua KF, Mostoslavsky R, Lombard DB, Pang WW, Saito S, Franco S, Kaushal D, Cheng HL, Fischer MR, Stokes N, et al. Mammalian SIRT1 limits replicative life span in response to chronic genotoxic stress. Cell Metab. 2005;2:67&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">16054100</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen DE, Supinski AM, Bonkowski MS, Donmez G, Guarente LP. Neuronal SIRT1 regulates endocrine and behavioral responses to calorie restriction. Genes Dev. 2009;23:2812&#x2013;2817.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2800085</ArticleId><ArticleId IdType="pubmed">20008932</ArticleId></ArticleIdList></Reference><Reference><Citation>Cripps D, Thomas SN, Jeng Y, Yang F, Davies P, Yang AJ. Alzheimer disease-specific conformation of hyperphosphorylated paired helical filament-Tau is polyubiquitinated through Lys-48, Lys-11, and Lys-6 ubiquitin conjugation. J Biol Chem. 2006;281:10825&#x2013;10838.</Citation><ArticleIdList><ArticleId IdType="pubmed">16443603</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickey CA, Kamal A, Lundgren K, Klosak N, Bailey RM, Dunmore J, Ash P, Shoraka S, Zlatkovic J, Eckman CB, et al. The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J Clin Invest. 2007;117:648&#x2013;658.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1794119</ArticleId><ArticleId IdType="pubmed">17304350</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickey CA, Yue M, Lin WL, Dickson DW, Dunmore JH, Lee WC, Zehr C, West G, Cao S, Clark AM, et al. Deletion of the ubiquitin ligase CHIP leads to the accumulation, but not the aggregation, of both endogenous phospho- and caspase-3-cleaved tau species. J Neurosci. 2006;26:6985&#x2013;6996.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673930</ArticleId><ArticleId IdType="pubmed">16807328</ArticleId></ArticleIdList></Reference><Reference><Citation>Donmez G, Wang D, Cohen DE, Guarente L. SIRT1 suppresses beta-amyloid production by activating the alpha-secretase gene ADAM10. Cell. 2010;142:320&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2911635</ArticleId><ArticleId IdType="pubmed">20655472</ArticleId></ArticleIdList></Reference><Reference><Citation>Gan L, Mucke L. Paths of convergence: sirtuins in aging and neurodegeneration. Neuron. 2008;58:10&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8245119</ArticleId><ArticleId IdType="pubmed">18400158</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge X, Jin Q, Zhang F, Yan T, Zhai Q. PCAF acetylates {beta}-catenin and improves its stability. Mol Biol Cell. 2009;20:419&#x2013;427.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2613091</ArticleId><ArticleId IdType="pubmed">18987336</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodman RH, Smolik S. CBP/p300 in cell growth, transformation, and development. Genes Dev. 2000;14:1553&#x2013;1577.</Citation><ArticleIdList><ArticleId IdType="pubmed">10887150</ArticleId></ArticleIdList></Reference><Reference><Citation>Greiss S, Hall J, Ahmed S, Gartner A. C. elegans SIR-2.1 translocation is linked to a proapoptotic pathway parallel to cep-1/p53 during DNA damage-induced apoptosis. Genes Dev. 2008;22:2831&#x2013;2842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2569882</ArticleId><ArticleId IdType="pubmed">18923081</ArticleId></ArticleIdList></Reference><Reference><Citation>Gronroos E, Hellman U, Heldin CH, Ericsson J. Control of Smad7 stability by competition between acetylation and ubiquitination. Mol Cell. 2002;10:483&#x2013;493.</Citation><ArticleIdList><ArticleId IdType="pubmed">12408818</ArticleId></ArticleIdList></Reference><Reference><Citation>Haigis MC, Guarente LP. Mammalian sirtuins--emerging roles in physiology, aging, and calorie restriction. Genes Dev. 2006;20:2913&#x2013;2921.</Citation><ArticleIdList><ArticleId IdType="pubmed">17079682</ArticleId></ArticleIdList></Reference><Reference><Citation>Hisahara S, Chiba S, Matsumoto H, Tanno M, Yagi H, Shimohama S, Sato M, Horio Y. Histone deacetylase SIRT1 modulates neuronal differentiation by its nuclear translocation. Proc Natl Acad Sci U S A. 2008;105:15599&#x2013;15604.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2563076</ArticleId><ArticleId IdType="pubmed">18829436</ArticleId></ArticleIdList></Reference><Reference><Citation>Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, Yoshida M, Wang XF, Yao TP. HDAC6 is a microtubule-associated deacetylase. Nature. 2002;417:455&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pubmed">12024216</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, Pickering-Brown S, Chakraverty S, Isaacs A, Grover A, et al. Association of missense and 5&#x2032;-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998;393:702&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pubmed">9641683</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito A, Kawaguchi Y, Lai CH, Kovacs JJ, Higashimoto Y, Appella E, Yao TP. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. Embo J. 2002;21:6236&#x2013;6245.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC137207</ArticleId><ArticleId IdType="pubmed">12426395</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Q, Yan T, Ge X, Sun C, Shi X, Zhai Q. Cytoplasm-localized SIRT1 enhances apoptosis. J Cell Physiol. 2007;213:88&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">17516504</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin YH, Jeon EJ, Li QL, Lee YH, Choi JK, Kim WJ, Lee KY, Bae SC. Transforming growth factor-beta stimulates p300-dependent RUNX3 acetylation, which inhibits ubiquitination-mediated degradation. J Biol Chem. 2004;279:29409&#x2013;29417.</Citation><ArticleIdList><ArticleId IdType="pubmed">15138260</ArticleId></ArticleIdList></Reference><Reference><Citation>Julien C, Tremblay C, Emond V, Lebbadi M, Salem N, Jr, Bennett DA, Calon F. Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease. J Neuropathol Exp Neurol. 2009;68:48&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2813570</ArticleId><ArticleId IdType="pubmed">19104446</ArticleId></ArticleIdList></Reference><Reference><Citation>Kar S, Fan J, Smith MJ, Goedert M, Amos LA. Repeat motifs of tau bind to the insides of microtubules in the absence of taxol. EMBO J. 2003;22:70&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC140040</ArticleId><ArticleId IdType="pubmed">12505985</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D, Nguyen MD, Dobbin MM, Fischer A, Sananbenesi F, Rodgers JT, Delalle I, Baur JA, Sui G, Armour SM, et al. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. Embo J. 2007;26:3169&#x2013;3179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1914106</ArticleId><ArticleId IdType="pubmed">17581637</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y, Tanner KG, Denu JM. A continuous, nonradioactive assay for histone acetyltransferases. Anal Biochem. 2000;280:308&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pubmed">10790315</ArticleId></ArticleIdList></Reference><Reference><Citation>Kouzarides T. Acetylation: a regulatory modification to rival phosphorylation? Embo J. 2000;19:1176&#x2013;1179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC305658</ArticleId><ArticleId IdType="pubmed">10716917</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Wang L, Zhao K, Thompson PR, Hwang Y, Marmorstein R, Cole PA. The structural basis of protein acetylation by the p300/CBP transcriptional coactivator. Nature. 2008;451:846&#x2013;850.</Citation><ArticleIdList><ArticleId IdType="pubmed">18273021</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph AC, Kassubek J, Landwehrmeyer BG, Mandelkow E, Mandelkow EM, Burn DJ, Caparros-Lefebvre D, Frey KA, de Yebenes JG, Gasser T, et al. Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. Eur J Neurol. 2009;16:297&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2847416</ArticleId><ArticleId IdType="pubmed">19364361</ArticleId></ArticleIdList></Reference><Reference><Citation>McMillan P, Korvatska E, Poorkaj P, Evstafjeva Z, Robinson L, Greenup L, Leverenz J, Schellenberg GD, D'Souza I. Tau isoform regulation is region- and cell-specific in mouse brain. J Comp Neurol. 2008;511:788&#x2013;803.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845852</ArticleId><ArticleId IdType="pubmed">18925637</ArticleId></ArticleIdList></Reference><Reference><Citation>Michan S, Sinclair D. Sirtuins in mammals: insights into their biological function. Biochem J. 2007;404:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2753453</ArticleId><ArticleId IdType="pubmed">17447894</ArticleId></ArticleIdList></Reference><Reference><Citation>Napper AD, Hixon J, McDonagh T, Keavey K, Pons JF, Barker J, Yau WT, Amouzegh P, Flegg A, Hamelin E, et al. Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1. J Med Chem. 2005;48:8045&#x2013;8054.</Citation><ArticleIdList><ArticleId IdType="pubmed">16335928</ArticleId></ArticleIdList></Reference><Reference><Citation>North BJ, Marshall BL, Borra MT, Denu JM, Verdin E. The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol Cell. 2003;11:437&#x2013;444.</Citation><ArticleIdList><ArticleId IdType="pubmed">12620231</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh YM, Kwon YE, Kim JM, Bae SJ, Lee BK, Yoo SJ, Chung CH, Deshaies RJ, Seol JH. Chfr is linked to tumour metastasis through the downregulation of HDAC1. Nat Cell Biol. 2009;11:295&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pubmed">19182791</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohsawa S, Miura M. Caspase-mediated changes in Sir2alpha during apoptosis. FEBS Lett. 2006;580:5875&#x2013;5879.</Citation><ArticleIdList><ArticleId IdType="pubmed">17027980</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagans S, Pedal A, North BJ, Kaehlcke K, Marshall BL, Dorr A, Hetzer-Egger C, Henklein P, Frye R, McBurney MW, et al. SIRT1 regulates HIV transcription via Tat deacetylation. PLoS Biol. 2005;3:e41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC546329</ArticleId><ArticleId IdType="pubmed">15719057</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrucelli L, Dickson D, Kehoe K, Taylor J, Snyder H, Grover A, De Lucia M, McGowan E, Lewis J, Prihar G, et al. CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum Mol Genet. 2004;13:703&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pubmed">14962978</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke L. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science. 2007;316:750&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pubmed">17478722</ArticleId></ArticleIdList></Reference><Reference><Citation>Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005;309:476&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1574647</ArticleId><ArticleId IdType="pubmed">16020737</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi D, Pop MS, Kulikov R, Love IM, Kung AL, Grossman SR. CBP and p300 are cytoplasmic E4 polyubiquitin ligases for p53. Proc Natl Acad Sci U S A. 2009;106:16275&#x2013;16280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2752525</ArticleId><ArticleId IdType="pubmed">19805293</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimura H, Schwartz D, Gygi SP, Kosik KS. CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival. J Biol Chem. 2004;279:4869&#x2013;4876.</Citation><ArticleIdList><ArticleId IdType="pubmed">14612456</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, Murrell JR, Goedert M, Farlow MR, Klug A, Ghetti B. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci U S A. 1998;95:7737&#x2013;7741.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22742</ArticleId><ArticleId IdType="pubmed">9636220</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan JM, Wong ES, Kirkpatrick DS, Pletnikova O, Ko HS, Tay SP, Ho MW, Troncoso J, Gygi SP, Lee MK, et al. Lysine 63-linked ubiquitination promotes the formation and autophagic clearance of protein inclusions associated with neurodegenerative diseases. Hum Mol Genet. 2008;17:431&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pubmed">17981811</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanno M, Sakamoto J, Miura T, Shimamoto K, Horio Y. Nucleocytoplasmic shuttling of the NAD+-dependent histone deacetylase SIRT1. J Biol Chem. 2007;282:6823&#x2013;6832.</Citation><ArticleIdList><ArticleId IdType="pubmed">17197703</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Loomis PA, Zinkowski RP, Binder LI. A novel tau transcript in cultured human neuroblastoma cells expressing nuclear tau. J Cell Biol. 1993;121:257&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2200092</ArticleId><ArticleId IdType="pubmed">8468346</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang XJ, Seto E. Lysine acetylation: codified crosstalk with other posttranslational modifications. Mol Cell. 2008;31:449&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2551738</ArticleId><ArticleId IdType="pubmed">18722172</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, Lee VM. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53:337&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20881129</PMID><DateCompleted><Year>2010</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>39</Issue><PubDate><Year>2010</Year><Month>Sep</Month><Day>29</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Diabetes-associated SorCS1 regulates Alzheimer's amyloid-beta metabolism: evidence for involvement of SorL1 and the retromer complex.</ArticleTitle><Pagination><StartPage>13110</StartPage><EndPage>13115</EndPage><MedlinePgn>13110-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.3872-10.2010</ELocationID><Abstract><AbstractText>SorCS1 and SorL1/SorLA/LR11 belong to the sortilin family of vacuolar protein sorting-10 (Vps10) domain-containing proteins. Both are genetically associated with Alzheimer's disease (AD), and SORL1 expression is decreased in the brains of patients suffering from AD. SORCS1 is also genetically associated with types 1 and 2 diabetes mellitus (T1DM, T2DM). We have undertaken a study of the possible role(s) for SorCS1 in metabolism of the Alzheimer's amyloid-&#x3b2; peptide (A&#x3b2;) and the A&#x3b2; precursor protein (APP), to test the hypothesis that Sorcs1 deficiency might be a common genetic risk factor underlying the predisposition to AD that is associated with T2DM. Overexpression of SorCS1c&#x3b2;-myc in cultured cells caused a reduction (p = 0.002) in A&#x3b2; generation. Conversely, endogenous murine A&#x3b2;(40) and A&#x3b2;(42) levels were increased (A&#x3b2;(40), p = 0.044; A&#x3b2;(42), p = 0.007) in the brains of female Sorcs1 hypomorphic mice, possibly paralleling the sexual dimorphism that is characteristic of the genetic associations of SORCS1 with AD and DM. Since SorL1 directly interacts with Vps35 to modulate APP metabolism, we investigated the possibility that SorCS1c&#x3b2;-myc interacts with APP, SorL1, and/or Vps35. We readily recovered SorCS1:APP, SorCS1:SorL1, and SorCS1:Vps35 complexes from nontransgenic mouse brain. Notably, total Vps35 protein levels were decreased by 49% (p = 0.009) and total SorL1 protein levels were decreased by 29% (p = 0.003) in the brains of female Sorcs1 hypomorphic mice. From these data, we propose that dysfunction of SorCS1 may contribute to both the APP/A&#x3b2; disturbance underlying AD and the insulin/glucose disturbance underlying DM.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lane</LastName><ForeName>Rachel F</ForeName><Initials>RF</Initials><AffiliationInfo><Affiliation>Department of Neurology and Alzheimer's Disease Research Center, Mount Sinai School of Medicine, New York, New York 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raines</LastName><ForeName>Summer M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Steele</LastName><ForeName>John W</ForeName><Initials>JW</Initials></Author><Author ValidYN="Y"><LastName>Ehrlich</LastName><ForeName>Michelle E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Lah</LastName><ForeName>James A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Small</LastName><ForeName>Scott A</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Tanzi</LastName><ForeName>Rudolph E</ForeName><Initials>RE</Initials></Author><Author ValidYN="Y"><LastName>Attie</LastName><ForeName>Alan D</ForeName><Initials>AD</Initials></Author><Author ValidYN="Y"><LastName>Gandy</LastName><ForeName>Sam</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>I01 BX000348</GrantID><Acronym>BX</Acronym><Agency>BLRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DK058037</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32GM06754</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG008702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5R24 CA095823-04</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01AG10491</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS075685</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005138</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1 S10 RR0 9145-01</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG010491</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R24 CA095823</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DK58037</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D046911">Macromolecular Substances</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026901">Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011956">Receptors, Cell Surface</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011973">Receptors, LDL</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C472780">SORCS1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C491168">Sorl1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C419573">VPS35 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D033921">Vesicular Transport Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D046911" MajorTopicYN="N">Macromolecular Substances</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026901" MajorTopicYN="N">Membrane Transport Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011956" MajorTopicYN="N">Receptors, Cell Surface</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011973" MajorTopicYN="N">Receptors, LDL</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D033921" MajorTopicYN="N">Vesicular Transport Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>3</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20881129</ArticleId><ArticleId IdType="mid">NIHMS240887</ArticleId><ArticleId IdType="pmc">PMC3274732</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.3872-10.2010</ArticleId><ArticleId IdType="pii">30/39/13110</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ali N, Miligan G, Evans WH. G-proteins of rat-liver membranes: subcellular compartmentation and disposition in the plasma membrane. Mol Cell Biochem. 1989;91:75&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">2516242</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen OM, Reiche J, Schmidt V, Gotthardt M, Spoelgen R, Behlke J, von Arnim CA, Breiderhoff T, Jansen P, Wu X, Bales KR, Cappai R, Masters CL, Gliemann J, Mufson EJ, Hyman BT, Paul SM, Nykjaer A, Willnow TE. Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc Natl Acad Sci U S A. 2005;102:13461&#x2013;13466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1224625</ArticleId><ArticleId IdType="pubmed">16174740</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen OM, Schmidt V, Spoelgen R, Gliemann J, Behlke J, Galatis D, McKinstry WJ, Parker MW, Masters CL, Hyman BT, Cappai R, Willnow TE. Molecular dissection of the interaction between amyloid precursor protein and its neuronal trafficking receptor SorLA/LR11. Biochemistry. 2006;45:2618&#x2013;2628.</Citation><ArticleIdList><ArticleId IdType="pubmed">16489755</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen O, Fjorback A, Seaman M, Ilsoe E, Gustafsen C, Willnow T, Madsen P, Nykjaer A. The role of retromer in SorLA dependent APP transport and processing. Alzheimers Dement. 2010;6:S101.</Citation></Reference><Reference><Citation>Buxbaum JD, Gandy SE, Cicchetti P, Ehrlich ME, Czernik AJ, Fracasso RP, Ramabhadran TV, Unterbeck AJ, Greengard P. Processing of Alzheimer beta/A4 amyloid precursor protein: modulation by agents that regulate protein phosphorylation. Proc Natl Acad Sci U S A. 1990;87:6003&#x2013;6006.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC54458</ArticleId><ArticleId IdType="pubmed">2116015</ArticleId></ArticleIdList></Reference><Reference><Citation>Clee SM, Yandell BS, Schueler KM, Rabaglia ME, Richards OC, Raines SM, Kabara EA, Klass DM, Mui ET, Stapleton DS, Gray-Keller MP, Young MB, Stoehr JP, Lan H, Boronenkov I, Raess PW, Flowers MT, Attie AD. Positional cloning of Sorcs1, a type 2 diabetes quantitative trait locus. Nat Genet. 2006;38:688&#x2013;693.</Citation><ArticleIdList><ArticleId IdType="pubmed">16682971</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodson SE, Gearing M, Lippa CF, Montine TJ, Levey AI, Lah JJ. LR11/SorLA expression is reduced in sporadic Alzheimer disease but not in familial Alzheimer disease. J Neuropathol Exp Neurol. 2006;65:866&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2663339</ArticleId><ArticleId IdType="pubmed">16957580</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodson SE, Andersen OM, Karmali V, Fritz JJ, Cheng D, Peng J, Levey AI, Willnow TE, Lah JJ. Loss of LR11/SORLA enhances early pathology in a mouse model of amyloidosis: evidence for a proximal role in Alzheimer's disease. J Neurosci. 2008;28:12877&#x2013;12886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2669320</ArticleId><ArticleId IdType="pubmed">19036982</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandy S. The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease. J Clin Invest. 2005;115:1121&#x2013;1129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1087184</ArticleId><ArticleId IdType="pubmed">15864339</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodarzi MO, Lehman DM, Taylor KD, Guo X, Cui J, Qui&#xf1;ones MJ, Clee SM, Yandell BS, Blangero J, Hsueh WA, Attie AD, Stern MP, Rotter JI. SORCS1: A novel human type 2 diabetes susceptibility gene suggested by the mouse. Diabetes. 2007;56:1922&#x2013;1929.</Citation><ArticleIdList><ArticleId IdType="pubmed">17426289</ArticleId></ArticleIdList></Reference><Reference><Citation>Granhall C, Park HB, Fakhrai-Rad H, Luthman H. High-resolution quantitative trait locus analysis reveals multiple diabetes susceptibility loci mapped to intervals&lt;800 kb in the species-conserved Niddm1i of the GK rat. Genetics. 2006;174:1565&#x2013;1572.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1667097</ArticleId><ArticleId IdType="pubmed">16951059</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermey G, Keat SJ, Madsen P, Jacobsen C, Petersen CM, Gliemann J. Characterization of sorCS1, an alternatively spliced receptor with completely different cytoplasmic domains that mediate different trafficking in cells. J Biol Chem. 2003;278:7390&#x2013;7396.</Citation><ArticleIdList><ArticleId IdType="pubmed">12482870</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang DE, Saitoh T, Chen X, Xia Y, Masliah E, Hansen LA, Thomas RG, Thal LJ, Katzman R. Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), an apolipoprotein E receptor, with late-onset Alzheimer's disease. Neurology. 1997;49:56&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">9222170</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. Age-dependent changes in brain, CSF, and plasma amyloid &#x3b2; protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci. 2001;21:372&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763819</ArticleId><ArticleId IdType="pubmed">11160418</ArticleId></ArticleIdList></Reference><Reference><Citation>Lendon CL, Talbot CJ, Craddock NJ, Han SW, Wragg M, Morris JC, Goate AM. Genetic association studies between dementia of the Alzheimer's type and three receptors for apolipoprotein E in a Caucasian population. Neurosci Lett. 1997;222:187&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">9148246</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang X, Slifer M, Martin ER, Schnetz-Boutaud N, Bartlett J, Anderson B, Z&#xfc;chner S, Gwirtsman H, Gilbert JR, Pericak-Vance MA, Haines JL. Genomic convergence to identify candidate genes for Alzheimer disease on chromosome 10. Hum Mutat. 2009;30:463&#x2013;471.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2713862</ArticleId><ArticleId IdType="pubmed">19241460</ArticleId></ArticleIdList></Reference><Reference><Citation>Lublin AL, Gandy S. Amyloid-beta oligomers: possible roles as key neurotoxins in Alzheimer's disease. Mt Sinai J Med. 2010;77:43&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3306842</ArticleId><ArticleId IdType="pubmed">20101723</ArticleId></ArticleIdList></Reference><Reference><Citation>Messier JM, Shaw LM, Chafel M, Matsudaira P, Mercurio AM. Fimbrin localized to an insoluble cytoskeletal fraction is constitutively phosphorylated on its headpiece domain in adherent macrophages. Cell Motil Cytoskeleton. 1993;25:223&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pubmed">8221900</ArticleId></ArticleIdList></Reference><Reference><Citation>Muhammad A, Flores I, Zhang H, Yu R, Staniszewski A, Planel E, Herman M, Ho L, Kreber R, Honig LS, Ganetzky B, Duff K, Arancio O, Small SA. Retromer deficiency observed in Alzheimer's disease causes hippocampal dysfunction, neurodegeneration, and Abeta accumulation. Proc Natl Acad Sci U S A. 2008;105:7327&#x2013;7332.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2386077</ArticleId><ArticleId IdType="pubmed">18480253</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen MS, Gustafsen C, Madsen P, Nyengaard JR, Hermey G, Bakke O, Mari M, Schu P, Pohlmann R, Dennes A, Petersen CM. Sorting by the cytoplasmic domain of the amyloid precursor protein binding receptor sorLA. Mol Cell Biol. 2007;27:6842&#x2013;6851.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2099242</ArticleId><ArticleId IdType="pubmed">17646382</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen MS, Keat SJ, Hamati JW, Madsen P, Gutzmann JJ, Engelsberg A, Pedersen KM, Gustafsen C, Nykjaer A, Gliemann J, Hermans-Borgmeyer I, Kuhl D, Petersen CM, Hermey G. Different motifs regulate trafficking of SorCS1 isoforms. Traffic. 2008;9:980&#x2013;994.</Citation><ArticleIdList><ArticleId IdType="pubmed">18315530</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyborg AC, Ladd TB, Zwizinski CW, Lah JJ, Golde TE. Sortilin, SorCS1b, and SorLA Vps10p sorting receptors, are novel &#x3b3;-secretase substrates. Mol Neurodegener. 2006;1:3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1513133</ArticleId><ArticleId IdType="pubmed">16930450</ArticleId></ArticleIdList></Reference><Reference><Citation>Offe K, Dodson SE, Shoemaker JT, Fritz JJ, Gearing M, Levey AI, Lah JJ. The lipoprotein receptor LR11 regulates amyloid &#x3b2; production and amyloid precursor protein traffic in endosomal compartments. J Neurosci. 2006;26:1596&#x2013;1603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2638122</ArticleId><ArticleId IdType="pubmed">16452683</ArticleId></ArticleIdList></Reference><Reference><Citation>Paterson AD, Waggott D, Boright AP, Hosseini SM, Shen E, Sylvestre MP, Wong I, Bharaj B, Cleary PA, Lachin JM, Below JE, Nicolae D, Cox NJ, Canty AJ, Sun L, Bull SB, MAGIC (Meta-Analyses of Glucose and Insulin-related traits Consortium) Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group A genome-wide association study identifies a novel major locus for glycemic control in type 1 diabetes. Diabetes. 2010;59:539&#x2013;549.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2809960</ArticleId><ArticleId IdType="pubmed">19875614</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitz C, Tokuhiro S, Clark L, Conrad C, Vonsattel J-P, Lantigua R, Medrano M, Simkin I, Haines J, Pericak-Vance M, Farrer L, Lee J, Rogaeva E, St George Hyslop P, Mayeux R. SorCS1 alters APP processing and variants may increase Alzheimer's disease risk. Alzheimers Dement. 2010 in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3086759</ArticleId><ArticleId IdType="pubmed">21280075</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogaeva E, Meng Y, Lee JH, Gu Y, Kawarai T, Zou F, Katayama T, Baldwin CT, Cheng R, Hasegawa H, Chen F, Shibata N, Lunetta KL, Pardossi-Piquard R, Bohm C, Wakutani Y, Cupples LA, Cuenco KT, Green RC, Pinessi L, et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet. 2007;39:168&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2657343</ArticleId><ArticleId IdType="pubmed">17220890</ArticleId></ArticleIdList></Reference><Reference><Citation>Sager KL, Wuu J, Leurgans SE, Rees HD, Gearing M, Mufson EJ, Levey AI, Lah JJ. Neuronal LR11/sorLA expression is reduced in mild cognitive impairment. Ann Neurol. 2007;62:640&#x2013;647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2669325</ArticleId><ArticleId IdType="pubmed">17721864</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 1993;43:1467&#x2013;1472.</Citation><ArticleIdList><ArticleId IdType="pubmed">8350998</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherzer CR, Offe K, Gearing M, Rees HD, Fang G, Heilman CJ, Schaller C, Bujo H, Levey AI, Lah JJ. Loss of apolipoprotein E receptor LR11 in Alzheimer disease. Arch Neurol. 2004;61:1200&#x2013;1205.</Citation><ArticleIdList><ArticleId IdType="pubmed">15313836</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt V, Sporbert A, Rohe M, Reimer T, Rehm A, Andersen OM, Willnow TE. sorLA/LR11 regulates processing of amyloid precursor protein via interaction with adaptors GGA and PACS-1. J Biol Chem. 2007;282:32956&#x2013;32964.</Citation><ArticleIdList><ArticleId IdType="pubmed">17855360</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, Gandy S. Sorting through the cell biology of Alzheimer's disease: intracellular pathways to pathogenesis. Neuron. 2006;52:15&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4820242</ArticleId><ArticleId IdType="pubmed">17015224</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, Kent K, Pierce A, Leung C, Kang MS, Okada H, Honig L, Vonsattel JP, Kim TW. Model-guided microarray implicates the retromer complex in Alzheimer's disease. Ann Neurol. 2005;58:909&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">16315276</ArticleId></ArticleIdList></Reference><Reference><Citation>Spoelgen R, von Arnim CA, Thomas AV, Peltan ID, Koker M, Deng A, Irizarry MC, Andersen OM, Willnow TE, Hyman BT. Interaction of the cytosolic domains of sorLA/LR11 with the amyloid precursor protein (APP) and the &#x3b2;-secretase &#x3b2;-site APP-cleaving enzyme. J Neurosci. 2006;26:418&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674411</ArticleId><ArticleId IdType="pubmed">16407538</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20889584</PMID><DateCompleted><Year>2011</Year><Month>01</Month><Day>07</Day></DateCompleted><DateRevised><Year>2010</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>133</Volume><Issue>Pt 12</Issue><PubDate><Year>2010</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>Concerted changes in transcripts in the prefrontal cortex precede neuropathology in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>3699</StartPage><EndPage>3723</EndPage><MedlinePgn>3699-723</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awq258</ELocationID><Abstract><AbstractText>Using the Braak staging for neurofibrillary changes as an objective indicator of the progression of Alzheimer's disease, we have performed a systematic search for global gene expression changes in the prefrontal cortex during the course of Alzheimer's disease. In the prefrontal cortex, senile plaques and neurofibrillary changes start to appear around Braak stage III, allowing for the detection of changes in gene expression before, during and after the onset of Alzheimer's disease neuropathology. Two distinct patterns of tightly co-regulated groups of genes were observed: (i) an increase in expression in early Braak stages, followed by a decline in expression in later stages (the UPDOWN clusters; containing 865 genes) and (ii) a decrease in expression in early Braak stages, followed by an increase in expression in later stages (the DOWNUP clusters; containing 983 genes). The most profound changes in gene expression were detected between Braak stages II and III, just before or at the onset of plaque pathology and neurofibrillary changes in the prefrontal cortex. We also observed an increase in intracellular beta amyloid staining from Braak stages I to III and a clear decrease in Braak stages IV to VI. These data suggest a link between specific gene expression clusters and Alzheimer's disease-associated neuropathology in the prefrontal cortex. Gene ontology over-representation and functional gene network analyses indicate an increase in synaptic activity and changes in plasticity during the very early pre-symptomatic stage of the disease. In later Braak stages, the decreased expression of these genes suggests a reduction in synaptic activity that coincides with the appearance of plaque pathology and neurofibrillary changes and the clinical diagnosis of mild cognitive impairment. The interaction of the ApoE genotype with the expression levels of the genes in the UPDOWN and DOWNUP clusters demonstrates that the accelerating role of ApoE-&#x3b5;4 in the progression of Alzheimer's disease is reflected in the temporal changes in gene expression presented here. Since the UPDOWN cluster contains several genes involved in amyloid precursor protein processing and beta amyloid clearance that increase in expression in parallel with increased intracellular beta amyloid load, just before the onset of plaque pathology in the prefrontal cortex, we hypothesize that the temporally orchestrated increase in genes involved in synaptic activity represents a coping mechanism against increased soluble beta amyloid levels. As these gene expression changes occur before the appearance of Alzheimer's disease-associated neuropathology, they provide an excellent starting point for the identification of new targets for the development of therapeutic strategies aimed at the prevention of Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bossers</LastName><ForeName>Koen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Neuroregeneration Group, Netherlands Institute for Neuroscience, Amsterdam, The Netherlands. k.bossers@nin.knaw.nl</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wirz</LastName><ForeName>Kerstin T S</ForeName><Initials>KT</Initials></Author><Author ValidYN="Y"><LastName>Meerhoff</LastName><ForeName>Gideon F</ForeName><Initials>GF</Initials></Author><Author ValidYN="Y"><LastName>Essing</LastName><ForeName>Anke H W</ForeName><Initials>AH</Initials></Author><Author ValidYN="Y"><LastName>van Dongen</LastName><ForeName>Jeroen W</ForeName><Initials>JW</Initials></Author><Author ValidYN="Y"><LastName>Houba</LastName><ForeName>Pieter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Kruse</LastName><ForeName>Chris G</ForeName><Initials>CG</Initials></Author><Author ValidYN="Y"><LastName>Verhaagen</LastName><ForeName>Joost</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Swaab</LastName><ForeName>Dick F</ForeName><Initials>DF</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>63231-63-0</RegistryNumber><NameOfSubstance UI="D012313">RNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.1.-</RegistryNumber><NameOfSubstance UI="D037761">Sirtuins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D046228" MajorTopicYN="N">Microarray Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005810" MajorTopicYN="N">Multigene Family</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009693" MajorTopicYN="N">Nucleic Acid Hybridization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012313" MajorTopicYN="N">RNA</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D037761" MajorTopicYN="N">Sirtuins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20889584</ArticleId><ArticleId IdType="doi">10.1093/brain/awq258</ArticleId><ArticleId IdType="pii">awq258</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20926834</PMID><DateCompleted><Year>2011</Year><Month>02</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>2</Volume><Issue>52</Issue><PubDate><Year>2010</Year><Month>Oct</Month><Day>06</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>PGC-1&#x3b1;, a potential therapeutic target for early intervention in Parkinson's disease.</ArticleTitle><Pagination><StartPage>52ra73</StartPage><MedlinePgn>52ra73</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.3001059</ELocationID><Abstract><AbstractText>Parkinson's disease affects 5 million people worldwide, but the molecular mechanisms underlying its pathogenesis are still unclear. Here, we report a genome-wide meta-analysis of gene sets (groups of genes that encode the same biological pathway or process) in 410 samples from patients with symptomatic Parkinson's and subclinical disease and healthy controls. We analyzed 6.8 million raw data points from nine genome-wide expression studies, and 185 laser-captured human dopaminergic neuron and substantia nigra transcriptomes, followed by two-stage replication on three platforms. We found 10 gene sets with previously unknown associations with Parkinson's disease. These gene sets pinpoint defects in mitochondrial electron transport, glucose utilization, and glucose sensing and reveal that they occur early in disease pathogenesis. Genes controlling cellular bioenergetics that are expressed in response to peroxisome proliferator-activated receptor &#x3b3; coactivator-1&#x3b1; (PGC-1&#x3b1;) are underexpressed in Parkinson's disease patients. Activation of PGC-1&#x3b1; results in increased expression of nuclear-encoded subunits of the mitochondrial respiratory chain and blocks the dopaminergic neuron loss induced by mutant &#x3b1;-synuclein or the pesticide rotenone in cellular disease models. Our systems biology analysis of Parkinson's disease identifies PGC-1&#x3b1; as a potential therapeutic target for early intervention.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Bin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Laboratory for Neurogenomics, Center for Neurologic Diseases, Harvard Medical School and Brigham and Women's Hospital, 65 Landsdowne Street, Suite 307A, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Zhixiang</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Locascio</LastName><ForeName>Joseph J</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>Lesniak</LastName><ForeName>Kristen A</ForeName><Initials>KA</Initials></Author><Author ValidYN="Y"><LastName>Roderick</LastName><ForeName>Sarah S</ForeName><Initials>SS</Initials></Author><Author ValidYN="Y"><LastName>Watt</LastName><ForeName>Marla L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Eklund</LastName><ForeName>Aron C</ForeName><Initials>AC</Initials></Author><Author ValidYN="Y"><LastName>Zhang-James</LastName><ForeName>Yanli</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Peter D</ForeName><Initials>PD</Initials></Author><Author ValidYN="Y"><LastName>Hauser</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Gr&#xfc;nblatt</LastName><ForeName>Edna</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Moran</LastName><ForeName>Linda B</ForeName><Initials>LB</Initials></Author><Author ValidYN="Y"><LastName>Mandel</LastName><ForeName>Silvia A</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Riederer</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Renee M</ForeName><Initials>RM</Initials></Author><Author ValidYN="Y"><LastName>Federoff</LastName><ForeName>Howard J</ForeName><Initials>HJ</Initials></Author><Author ValidYN="Y"><LastName>W&#xfc;llner</LastName><ForeName>Ullrich</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Papapetropoulos</LastName><ForeName>Spyridon</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Youdim</LastName><ForeName>Moussa B</ForeName><Initials>MB</Initials></Author><Author ValidYN="Y"><LastName>Cantuti-Castelvetri</LastName><ForeName>Ippolita</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>Anne B</ForeName><Initials>AB</Initials></Author><Author ValidYN="Y"><LastName>Vance</LastName><ForeName>Jeffery M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Richard L</ForeName><Initials>RL</Initials></Author><Author ValidYN="Y"><LastName>Hedreen</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Adler</LastName><ForeName>Charles H</ForeName><Initials>CH</Initials></Author><Author ValidYN="Y"><LastName>Beach</LastName><ForeName>Thomas G</ForeName><Initials>TG</Initials></Author><Author ValidYN="Y"><LastName>Graeber</LastName><ForeName>Manuel B</ForeName><Initials>MB</Initials></Author><Author ValidYN="Y"><LastName>Middleton</LastName><ForeName>Frank A</ForeName><Initials>FA</Initials></Author><Author ValidYN="Y"><LastName>Rochet</LastName><ForeName>Jean-Christophe</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Scherzer</LastName><ForeName>Clemens R</ForeName><Initials>CR</Initials></Author><Author ValidYN="Y"><CollectiveName>Global PD Gene Expression (GPEX) Consortium</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>GEO</DataBankName><AccessionNumberList><AccessionNumber>GSE20141</AccessionNumber><AccessionNumber>GSE20146</AccessionNumber><AccessionNumber>GSE20153</AccessionNumber><AccessionNumber>GSE20159</AccessionNumber><AccessionNumber>GSE20163</AccessionNumber><AccessionNumber>GSE20164</AccessionNumber><AccessionNumber>GSE20168</AccessionNumber><AccessionNumber>GSE20291</AccessionNumber><AccessionNumber>GSE20292</AccessionNumber><AccessionNumber>GSE20314</AccessionNumber><AccessionNumber>GSE20333</AccessionNumber><AccessionNumber>GSE24378</AccessionNumber><AccessionNumber>GSE6613</AccessionNumber><AccessionNumber>GSE7621</AccessionNumber><AccessionNumber>GSE8397</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>P01 NS058793</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS064155</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AG19610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R24MH068855</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NS049221</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 AG024816</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21NS060227</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NS064155</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01NS058793</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS060227</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08AG024816</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R24 MH068855</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS049221</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006360">Heat-Shock Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C486497">PPARGC1A protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071248">Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019295" MajorTopicYN="N">Computational Biology</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D030541" MajorTopicYN="N">Databases, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042241" MajorTopicYN="Y">Early Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="Y">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006360" MajorTopicYN="Y">Heat-Shock Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071248" MajorTopicYN="N">Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014157" MajorTopicYN="Y">Transcription Factors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests:</b> S.P. holds stock in Allergan Inc. and Biogen Idec Inc. C.R.S. has received consulting fees from Link Medicine Corp. and the Michael J. Fox Foundation. He is a scientific collaborator of DiaGenic in a study entirely funded by the Michael J. Fox Foundation and has received speaking fees from the International Movement Disorders Society, as well as being listed as co-inventor on a U.S. patent held by Brigham and Women&#x2019;s Hospital relating to diagnostics for neurodegenerative diseases. None of the other authors have any competing interests to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>10</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>7</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20926834</ArticleId><ArticleId IdType="mid">NIHMS293172</ArticleId><ArticleId IdType="pmc">PMC3129986</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.3001059</ArticleId><ArticleId IdType="pii">2/52/52ra73</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dhillon AS, Tarbutton GL, Levin JL, Plotkin GM, Lowry LK, Nalbone JT, Shepherd S. Pesticide/environmental exposures and Parkinson&#x2019;s disease in East Texas. J Agromedicine. 2008;13:37.</Citation><ArticleIdList><ArticleId IdType="pubmed">19042691</ArticleId></ArticleIdList></Reference><Reference><Citation>Chade AR, Kasten M, Tanner CM. Nongenetic causes of Parkinson&#x2019;s disease. J Neural Transm. 2006;(Suppl):147.</Citation><ArticleIdList><ArticleId IdType="pubmed">17017522</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, Kim JH, Miller GW, Yagi T, Matsuno-Yagi A, Greenamyre JT. Mechanism of toxicity in rotenone models of Parkinson&#x2019;s disease. J Neurosci. 2003 Nov 26;23:10756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740985</ArticleId><ArticleId IdType="pubmed">14645467</ArticleId></ArticleIdList></Reference><Reference><Citation>Park HJ, Kim HJ, Park HK, Chung JH. Protective effect of histamine H2 receptor antagonist ranitidine against rotenone-induced apoptosis. Neurotoxicology. 2009 Nov;30:1114.</Citation><ArticleIdList><ArticleId IdType="pubmed">19723537</ArticleId></ArticleIdList></Reference><Reference><Citation>Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson&#x2019;s disease. Nat Neurosci. 2000 Dec;3:1301.</Citation><ArticleIdList><ArticleId IdType="pubmed">11100151</ArticleId></ArticleIdList></Reference><Reference><Citation>Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983 Feb 25;219:979.</Citation><ArticleIdList><ArticleId IdType="pubmed">6823561</ArticleId></ArticleIdList></Reference><Reference><Citation>Henchcliffe C, Beal MF. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol. 2008 Nov;4:600.</Citation><ArticleIdList><ArticleId IdType="pubmed">18978800</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J, Lee SB, Lee S, Kim Y, Song S, Kim S, Bae E, Kim J, Shong M, Kim JM, Chung J. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature. 2006 Jun 29;441:1157.</Citation><ArticleIdList><ArticleId IdType="pubmed">16672980</ArticleId></ArticleIdList></Reference><Reference><Citation>Greene JC, Whitworth AJ, Kuo I, Andrews LA, Feany MB, Pallanck LJ. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc Natl Acad Sci U S A. 2003 Apr 1;100:4078.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC153051</ArticleId><ArticleId IdType="pubmed">12642658</ArticleId></ArticleIdList></Reference><Reference><Citation>Devi L, Raghavendran V, Prabhu BM, Avadhani NG, Anandatheerthavarada HK. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem. 2008 Apr 4;283:9089.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2431021</ArticleId><ArticleId IdType="pubmed">18245082</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy S, Wolman L. Ultrastructural observations in Parkinsonism. J Pathol. 1969 Sep;99:39.</Citation><ArticleIdList><ArticleId IdType="pubmed">5359222</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherzer CR, Offe K, Gearing M, Rees HD, Fang G, Heilman CJ, Schaller C, Bujo H, Levey AI, Lah JJ. Loss of apolipoprotein E receptor LR11 in Alzheimer disease. Arch Neurol. 2004 Aug;61:1200.</Citation><ArticleIdList><ArticleId IdType="pubmed">15313836</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherzer CR. Chipping away at diagnostics for neurodegenerative diseases. Neurobiol Dis. 2009 Mar 10;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2753504</ArticleId><ArticleId IdType="pubmed">19285134</ArticleId></ArticleIdList></Reference><Reference><Citation>Schadt EE, Lamb J, Yang X, Zhu J, Edwards S, Guhathakurta D, Sieberts SK, Monks S, Reitman M, Zhang C, Lum PY, Leonardson A, Thieringer R, Metzger JM, Yang L, Castle J, Zhu H, Kash SF, Drake TA, Sachs A, Lusis AJ. An integrative genomics approach to infer causal associations between gene expression and disease. Nat Genet. 2005 Jul;37:710.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2841396</ArticleId><ArticleId IdType="pubmed">15965475</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherzer CR, Eklund AC, Morse LJ, Liao Z, Locascio JJ, Fefer D, Schwarzschild MA, Schlossmacher MG, Hauser MA, Vance JM, Sudarsky LR, Standaert DG, Growdon JH, Jensen RV, Gullans SR. Molecular markers of early Parkinson&#x2019;s disease based on gene expression in blood. Proc Natl Acad Sci U S A. 2007 Jan 16;104:955.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1766335</ArticleId><ArticleId IdType="pubmed">17215369</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherzer CR, Grass JA, Liao Z, Pepivani I, Zheng B, Eklund AC, Ney PA, Ng J, McGoldrick M, Mollenhauer B, Bresnick EH, Schlossmacher MG. GATA transcription factors directly regulate the Parkinson&#x2019;s disease-linked gene alpha-synuclein. Proc Natl Acad Sci U S A. 2008 Aug 5;105:10907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2504800</ArticleId><ArticleId IdType="pubmed">18669654</ArticleId></ArticleIdList></Reference><Reference><Citation>Grunblatt E, Mandel S, Jacob-Hirsch J, Zeligson S, Amariglo N, Rechavi G, Li J, Ravid R, Roggendorf W, Riederer P, Youdim MB. Gene expression profiling of parkinsonian substantia substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J Neural Transm. 2004;111:1543&#x2013;1573.</Citation><ArticleIdList><ArticleId IdType="pubmed">15455214</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauser MA, Li YJ, Xu H, Noureddine MA, Shao YS, Gullans SR, Scherzer CR, Jensen RV, McLaurin AC, Gibson JR, Scott BL, Jewett RM, Stenger JE, Schmechel DE, Hulette CM, Vance JM. Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism. Arch Neurol. 2005;62:917&#x2013;921.</Citation><ArticleIdList><ArticleId IdType="pubmed">15956162</ArticleId></ArticleIdList></Reference><Reference><Citation>Moran LB, Duke DC, Deprez M, Dexter DT, Pearce RK, Graeber MB. Whole genome expression profiling of the medial and lateral substantia nigra in Parkinson&#x2019;s disease. Neurogenetics. 2006;7:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">16344956</ArticleId></ArticleIdList></Reference><Reference><Citation>Papapetropoulos S, Ffrench-Mullen J, McCorquodale D, Qin Y, Pablo J, Mash DC. Multiregional gene expression profiling identifies MRPS6 as a possible candidate gene for Parkinson&#x2019;s disease. Gene Expr. 2006;13:205&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6032441</ArticleId><ArticleId IdType="pubmed">17193926</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantuti-Castelvetri I, Keller-McGandy C, Bouzou B, Asteris G, Clark TW, Frosch MP, Standaert DG. Effects of gender on nigral gene expression and Parkinson disease. Neurobiol Dis. 2007;26:606&#x2013;614.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2435483</ArticleId><ArticleId IdType="pubmed">17412603</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, James M, Middleton FA, Davis RL. Transcriptional analysis of multiple brain regions in Parkinson&#x2019;s disease supports the involvement of specific protein processing, energy metabolism, and signaling pathways, and suggests novel disease mechanisms. Am J Med Genet B Neuropsychiatr Genet. 2005;137B:5&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">15965975</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogt IR, Lees AJ, Evert BO, Klockgether T, Bonin M, Wullner U. Transcriptional changes in multiple system atrophy and Parkinson&#x2019;s disease putamen. Exp Neurol. 2006;199:465&#x2013;478.</Citation><ArticleIdList><ArticleId IdType="pubmed">16626704</ArticleId></ArticleIdList></Reference><Reference><Citation>Simunovic F, Yi M, Wang Y, Macey L, Brown LT, Krichevsky AM, Andersen SL, Stephens RM, Benes FM, Sonntag KC. Gene expression profiling of substantia nigra dopamine neurons: Further insights into Parkinson&#x2019;s disease pathology. Brain. 2009;132:1795&#x2013;1809.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2724914</ArticleId><ArticleId IdType="pubmed">19052140</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005 Oct 25;102:15545.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1239896</ArticleId><ArticleId IdType="pubmed">16199517</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Kuehn H, Gould J, Tamayo P, Mesirov JP. GSEA-P: a desktop application for Gene Set Enrichment Analysis. Bioinformatics. 2007 Dec 1;23:3251.</Citation><ArticleIdList><ArticleId IdType="pubmed">17644558</ArticleId></ArticleIdList></Reference><Reference><Citation>Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E, Houstis N, Daly MJ, Patterson N, Mesirov JP, Golub TR, Tamayo P, Spiegelman B, Lander ES, Hirschhorn JN, Altshuler D, Groop LC. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003 Jul;34:267.</Citation><ArticleIdList><ArticleId IdType="pubmed">12808457</ArticleId></ArticleIdList></Reference><Reference><Citation>Blyth CR. On Simpson&#x2019;s Paradox and the Sure-Thing Principle. Journal of the American Statistical Association. 1972;67:364.</Citation></Reference><Reference><Citation>Thomassen M, Tan Q, Kruse TA. Gene expression meta-analysis identifies chromosomal regions and candidate genes involved in breast cancer metastasis. Breast Cancer Res Treat. 2009 Jan;113:239.</Citation><ArticleIdList><ArticleId IdType="pubmed">18293085</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedges LV, Vevea JL. Fixed- and random-effects models in meta-analysis. Psychological Methods. 1998;3:486.</Citation></Reference><Reference><Citation>Jellinger KA. A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders. Biochim Biophys Acta. 2009 Jul;1792:730.</Citation><ArticleIdList><ArticleId IdType="pubmed">18718530</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW, Fujishiro H, DelleDonne A, Menke J, Ahmed Z, Klos KJ, Josephs KA, Frigerio R, Burnett M, Parisi JE, Ahlskog JE. Evidence that incidental Lewy body disease is pre-symptomatic Parkinson&#x2019;s disease. Acta Neuropathol. 2008 Apr;115:437.</Citation><ArticleIdList><ArticleId IdType="pubmed">18264713</ArticleId></ArticleIdList></Reference><Reference><Citation>DelleDonne A, Klos KJ, Fujishiro H, Ahmed Z, Parisi JE, Josephs KA, Frigerio R, Burnett M, Wszolek ZK, Uitti RJ, Ahlskog JE, Dickson DW. Incidental Lewy body disease and preclinical Parkinson disease. Arch Neurol. 2008 Aug;65:1074.</Citation><ArticleIdList><ArticleId IdType="pubmed">18695057</ArticleId></ArticleIdList></Reference><Reference><Citation>Beach TG, Adler CH, Sue LI, Peirce JB, Bachalakuri J, Dalsing-Hernandez JE, Lue LF, Caviness JN, Connor DJ, Sabbagh MN, Walker DG. Reduced striatal tyrosine hydroxylase in incidental Lewy body disease. Acta Neuropathol. 2008 Apr;115:445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2724592</ArticleId><ArticleId IdType="pubmed">17985144</ArticleId></ArticleIdList></Reference><Reference><Citation>Fearnley JM, Lees AJ. Ageing and Parkinson&#x2019;s disease: substantia nigra regional selectivity. Brain. 1991 Oct;114(Pt 5):2283.</Citation><ArticleIdList><ArticleId IdType="pubmed">1933245</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson&#x2019;s disease. Neurobiol Aging. 2003 Mar-Apr;24:197.</Citation><ArticleIdList><ArticleId IdType="pubmed">12498954</ArticleId></ArticleIdList></Reference><Reference><Citation>Savica R, Rocca WA, Ahlskog JE. When does Parkinson disease start? Arch Neurol. Jul;67:798.</Citation><ArticleIdList><ArticleId IdType="pubmed">20625084</ArticleId></ArticleIdList></Reference><Reference><Citation>Forno L. Concentric hyalin intraneuronal inclusions of Lewy type in the brains of elderly persons (50 incidental cases): relationship to parkinsonism. J Am Geriatr Soc. 1969;17:557.</Citation><ArticleIdList><ArticleId IdType="pubmed">4182529</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross GW, Petrovitch H, Abbott RD, Nelson J, Markesbery W, Davis D, Hardman J, Launer L, Masaki K, Tanner CM, White LR. Parkinsonian signs and substantia nigra neuron density in decendents elders without PD. Ann Neurol. 2004 Oct;56:532.</Citation><ArticleIdList><ArticleId IdType="pubmed">15389895</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger KA. Critical evaluation of the Braak staging scheme for Parkinson&#x2019;s disease. Ann Neurol. Apr;67:550.</Citation><ArticleIdList><ArticleId IdType="pubmed">20437592</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K. Invited Article: Nervous system pathology in sporadic Parkinson disease. Neurology. 2008 May 13;70:1916.</Citation><ArticleIdList><ArticleId IdType="pubmed">18474848</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke RE, Dauer WT, Vonsattel JP. A critical evaluation of the Braak staging scheme for Parkinson&#x2019;s disease. Ann Neurol. 2008 Nov;64:485.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2605160</ArticleId><ArticleId IdType="pubmed">19067353</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW, Uchikado H, Fujishiro H, Tsuboi Y. Evidence in favor of Braak staging of Parkinson&#x2019;s disease. Mov Disord. 25(Suppl 1):S78.</Citation><ArticleIdList><ArticleId IdType="pubmed">20187227</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalfo E, Portero-Otin M, Ayala V, Martinez A, Pamplona R, Ferrer I. Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J Neuropathol Exp Neurol. 2005 Sep;64:816.</Citation><ArticleIdList><ArticleId IdType="pubmed">16141792</ArticleId></ArticleIdList></Reference><Reference><Citation>Dexter DT, Sian J, Rose S, Hindmarsh JG, Mann VM, Cooper JM, Wells FR, Daniel SE, Lees AJ, Schapira AH, et al. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann Neurol. 1994 Jan;35:38.</Citation><ArticleIdList><ArticleId IdType="pubmed">8285590</ArticleId></ArticleIdList></Reference><Reference><Citation>Haas RH, Nasirian F, Nakano K, Ward D, Pay M, Hill R, Shults CW. Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson&#x2019;s disease. Ann Neurol. 1995 Jun;37:714.</Citation><ArticleIdList><ArticleId IdType="pubmed">7778844</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbanti P, Fabbrini G, Ricci A, Cerbo R, Bronzetti E, Caronti B, Calderaro C, Felici L, Stocchi F, Meco G, Amenta F, Lenzi GL. Increased expression of dopamine receptors on lymphocytes in Parkinson&#x2019;s disease. Mov Disord. 1999 Sep;14:764.</Citation><ArticleIdList><ArticleId IdType="pubmed">10495037</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherzer CR, Feany MB. Yeast genetics targets lipids in Parkinson&#x2019;s disease. Trends Genet. 2004 Jul;20:273.</Citation><ArticleIdList><ArticleId IdType="pubmed">15219388</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowen BC, Block RE, Sanchez-Ramos J, Pattany PM, Lampman DA, Murdoch JB, Quencer RM. Proton MR spectroscopy of the brain in 14 patients with Parkinson disease. AJNR Am J Neuroradiol. 1995 Jan;16:61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8337695</ArticleId><ArticleId IdType="pubmed">7900603</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu MT, Taylor-Robinson SD, Chaudhuri KR, Bell JD, Labbe C, Cunningham VJ, Koepp MJ, Hammers A, Morris RG, Turjanski N, Brooks DJ. Cortical dysfunction in non-demented Parkinson&#x2019;s disease patients: a combined (31)P-MRS and (18)FDG-PET study. Brain. 2000 Feb;123(Pt 2):340.</Citation><ArticleIdList><ArticleId IdType="pubmed">10648441</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin J, Handschin C, Spiegelman BM. Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab. 2005 Jun;1:361.</Citation><ArticleIdList><ArticleId IdType="pubmed">16054085</ArticleId></ArticleIdList></Reference><Reference><Citation>Arany Z, He H, Lin J, Hoyer K, Handschin C, Toka O, Ahmad F, Matsui T, Chin S, Wu PH, Rybkin, Shelton JM, Manieri M, Cinti S, Schoen FJ, Bassel-Duby R, Rosenzweig A, Ingwall JS, Spiegelman BM. Transcriptional coactivator PGC-1 alpha controls the energy state and contractile function of cardiac muscle. Cell Metab. 2005 Apr;1:259.</Citation><ArticleIdList><ArticleId IdType="pubmed">16054070</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohas LM, St-Pierre J, Uldry M, Jager S, Handschin C, Spiegelman BM. A fundamental system of cellular energy homeostasis regulated by PGC-1alpha. Proc Natl Acad Sci U S A. 2007 May 8;104:7933.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1876550</ArticleId><ArticleId IdType="pubmed">17470778</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper AA, Gitler AD, Cashikar A, Haynes CM, Hill KJ, Bhullar B, Liu K, Xu K, Strathearn KE, Liu F, Cao S, Caldwell KA, Caldwell GA, Marsischky G, Kolodner RD, Labaer J, Rochet JC, Bonini NM, Lindquist S. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson&#x2019;s models. Science. 2006 Jul 21;313:324.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1983366</ArticleId><ArticleId IdType="pubmed">16794039</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F, Nguyen JL, Hulleman JD, Li L, Rochet JC. Mechanisms of DJ-1 neuroprotection in a cellular model of Parkinson&#x2019;s disease. J Neurochem. 2008 Jun;105:2435.</Citation><ArticleIdList><ArticleId IdType="pubmed">18331584</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitler AD, Chesi A, Geddie ML, Strathearn KE, Hamamichi S, Hill KJ, Caldwell KA, Caldwell GA, Cooper AA, Rochet JC, Lindquist S. Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat Genet. 2009 Mar;41:308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2683786</ArticleId><ArticleId IdType="pubmed">19182805</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F, Hindupur J, Nguyen JL, Ruf KJ, Zhu J, Schieler JL, Bonham CC, Wood KV, Davisson VJ, Rochet JC. Methionine sulfoxide reductase A protects dopaminergic cells from Parkinson&#x2019;s disease-related insults. Free Radic Biol Med. 2008 Aug 1;45:242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2518045</ArticleId><ArticleId IdType="pubmed">18456002</ArticleId></ArticleIdList></Reference><Reference><Citation>Berridge MV, Tan AS. Characterization of the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction. Arch Biochem Biophys. 1993 Jun;303:474.</Citation><ArticleIdList><ArticleId IdType="pubmed">8390225</ArticleId></ArticleIdList></Reference><Reference><Citation>Przedborski S, Tieu K, Perier C, Vila M. MPTP as a mitochondrial neurotoxic model of Parkinson&#x2019;s disease. J Bioenerg Biomembr. 2004 Aug;36:375.</Citation><ArticleIdList><ArticleId IdType="pubmed">15377875</ArticleId></ArticleIdList></Reference><Reference><Citation>St-Pierre J, Drori S, Uldry M, Silvaggi JM, Rhee J, Jager S, Handschin C, Zheng K, Lin J, Yang W, Simon DK, Bachoo R, Spiegelman BM. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell. 2006 Oct 20;127:397.</Citation><ArticleIdList><ArticleId IdType="pubmed">17055439</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva RM, Ries V, Oo TF, Yarygina O, Jackson-Lewis V, Ryu EJ, Lu PD, Marciniak SJ, Ron D, Przedborski S, Kholodilov N, Greene LA, Burke RE. CHOP/GADD153 is a mediator of apoptotic death in substantia nigra dopamine neurons in an in vivo neurotoxin model of parkinsonism. J Neurochem. 2005 Nov;95:974.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3082498</ArticleId><ArticleId IdType="pubmed">16135078</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker WD, Jr, Parks JK, Swerdlow RH. Complex I deficiency in Parkinson&#x2019;s disease frontal cortex. Brain Res. 2008 Jan 16;1189:215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2295283</ArticleId><ArticleId IdType="pubmed">18061150</ArticleId></ArticleIdList></Reference><Reference><Citation>Keeney PM, Xie J, Capaldi RA, Bennett JP., Jr Parkinson&#x2019;s disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J Neurosci. 2006 May 10;26:5256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674236</ArticleId><ArticleId IdType="pubmed">16687518</ArticleId></ArticleIdList></Reference><Reference><Citation>Morais VA, De Strooper B. Mitochondria dysfunction and neurodegenerative disorders: cause or consequence. J Alzheimers Dis. 20(Suppl 2):S255.</Citation><ArticleIdList><ArticleId IdType="pubmed">20463408</ArticleId></ArticleIdList></Reference><Reference><Citation>Geisler S, Holmstrom KM, Skujat D, Fiesel FC, Rothfuss OC, Kahle PJ, Springer W. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat Cell Biol. Feb;12:119.</Citation><ArticleIdList><ArticleId IdType="pubmed">20098416</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JY, Zhang J. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5:R80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC545600</ArticleId><ArticleId IdType="pubmed">15461798</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20929727</PMID><DateCompleted><Year>2010</Year><Month>12</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>330</Volume><Issue>6007</Issue><PubDate><Year>2010</Year><Month>Nov</Month><Day>19</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Gamma-secretase gene mutations in familial acne inversa.</ArticleTitle><Pagination><StartPage>1065</StartPage><MedlinePgn>1065</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.1196284</ELocationID><Abstract><AbstractText>Acne inversa (AI), also known as hidradenitis suppurativa, is a chronic, recurrent, inflammatory disease of hair follicles that often runs in families. We studied six Chinese families with features of AI as well as additional skin lesions on back, face, nape, and waist and found independent loss-of-function mutations in PSENEN, PSEN1, or NCSTN, the genes encoding essential components of the &#x3b3;-secretase multiprotein complex. Our results identify the &#x3b3;-secretase component genes as the culprits for a subset of familial AI, implicate the &#x3b3;-secretase-Notch pathway in the molecular pathogenesis of AI, and demonstrate that familial AI can be an allelic disorder of early-onset familial Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Baoxi</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Peking Union Medical College Hospital, Chinese Academy of Medical Sciences-Peking Union Medical College (CAMS-PUMC), Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Wei</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Wen</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Jing</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Bin</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Bo</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Donglai</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Lv</LastName><ForeName>Dan</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Yaran</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Qu</LastName><ForeName>Tao</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Min</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Miao</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Yan</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xue</ForeName><Initials>X</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C469349">PSENEN protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C413604">nicastrin protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Science. 2010 Nov 19;330(6007):1055-6. doi: 10.1126/science.1198668.</RefSource><PMID Version="1">21097925</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>J R Coll Physicians Edinb. 2011 Mar;41(1):29. doi: 10.4997/JRCPE.2011.108.</RefSource><PMID Version="1">21365064</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044466" MajorTopicYN="N">Asian People</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002888" MajorTopicYN="N">Chromosomes, Human, Pair 19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004252" MajorTopicYN="N">DNA Mutational Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017497" MajorTopicYN="N">Hidradenitis Suppurativa</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20929727</ArticleId><ArticleId IdType="doi">10.1126/science.1196284</ArticleId><ArticleId IdType="pii">science.1196284</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20935652</PMID><DateCompleted><Year>2010</Year><Month>11</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>01</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1548-7105</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>11</Issue><PubDate><Year>2010</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Nature methods</Title><ISOAbbreviation>Nat Methods</ISOAbbreviation></Journal><ArticleTitle>Specific gene transfer to neurons, endothelial cells and hematopoietic progenitors with lentiviral vectors.</ArticleTitle><Pagination><StartPage>929</StartPage><EndPage>935</EndPage><MedlinePgn>929-35</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nmeth.1514</ELocationID><Abstract><AbstractText>We present a flexible and highly specific targeting method for lentiviral vectors based on single-chain antibodies recognizing cell-surface antigens. We generated lentiviral vectors specific for human CD105(+) endothelial cells, human CD133(+) hematopoietic progenitors and mouse GluA-expressing neurons. Lentiviral vectors specific for CD105 or for CD20 transduced their target cells as efficiently as VSV-G pseudotyped vectors but discriminated between endothelial cells and lymphocytes in mixed cultures. CD133-targeted vectors transduced CD133(+) cultured hematopoietic progenitor cells more efficiently than VSV-G pseudotyped vectors, resulting in stable long-term transduction. Lentiviral vectors targeted to the glutamate receptor subunits GluA2 and GluA4 exhibited more than 94% specificity for neurons in cerebellar cultures and when injected into the adult mouse brain. We observed neuron-specific gene modification upon transfer of the Cre recombinase gene into the hippocampus of reporter mice. This approach allowed targeted gene transfer to many cell types of interest with an unprecedented degree of specificity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Anliker</LastName><ForeName>Brigitte</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Medical Biotechnology, Paul-Ehrlich-Institut, Langen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abel</LastName><ForeName>Tobias</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Kneissl</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Hlavaty</LastName><ForeName>Juraj</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Caputi</LastName><ForeName>Antonio</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Brynza</LastName><ForeName>Julia</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Irene C</ForeName><Initials>IC</Initials></Author><Author ValidYN="Y"><LastName>M&#xfc;nch</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Author><Author ValidYN="Y"><LastName>Petznek</LastName><ForeName>Helga</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Kontermann</LastName><ForeName>Roland E</ForeName><Initials>RE</Initials></Author><Author ValidYN="Y"><LastName>Koehl</LastName><ForeName>Ulrike</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Johnston</LastName><ForeName>Ian C D</ForeName><Initials>IC</Initials></Author><Author ValidYN="Y"><LastName>Kein&#xe4;nen</LastName><ForeName>Kari</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>Ulrike C</ForeName><Initials>UC</Initials></Author><Author ValidYN="Y"><LastName>Hohenadl</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Monyer</LastName><ForeName>Hannah</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Cichutek</LastName><ForeName>Klaus</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Buchholz</LastName><ForeName>Christian J</ForeName><Initials>CJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>10</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Methods</MedlineTA><NlmUniqueID>101215604</NlmUniqueID><ISSNLinking>1548-7091</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071916">AC133 Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015703">Antigens, CD</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018951">Antigens, CD20</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006023">Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606023">PROM1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606024">Prom1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018091">Receptors, AMPA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000071916" MajorTopicYN="N">AC133 Antigen</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015703" MajorTopicYN="N">Antigens, CD</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018951" MajorTopicYN="N">Antigens, CD20</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042783" MajorTopicYN="N">Endothelial Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018014" MajorTopicYN="Y">Gene Transfer Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005822" MajorTopicYN="Y">Genetic Vectors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006023" MajorTopicYN="N">Glycoproteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006412" MajorTopicYN="N">Hematopoietic Stem Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016086" MajorTopicYN="N">Lentivirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018091" MajorTopicYN="N">Receptors, AMPA</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>7</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20935652</ArticleId><ArticleId IdType="doi">10.1038/nmeth.1514</ArticleId><ArticleId IdType="pii">nmeth.1514</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2004 Apr 30;317(2):515-21</Citation><ArticleIdList><ArticleId IdType="pubmed">15063787</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Gene Ther. 2005 Nov;12(11):900-12</Citation><ArticleIdList><ArticleId IdType="pubmed">15905858</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 1994 Nov 4;79(3):497-506</Citation><ArticleIdList><ArticleId IdType="pubmed">7954815</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Top Microbiol Immunol. 2009;329:13-30</Citation><ArticleIdList><ArticleId IdType="pubmed">19198560</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Protoc. 2006;1(6):3166-73</Citation><ArticleIdList><ArticleId IdType="pubmed">17406580</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2005 Mar;11(3):346-52</Citation><ArticleIdList><ArticleId IdType="pubmed">15711560</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Genet. 2009 Aug;10(8):578-85</Citation><ArticleIdList><ArticleId IdType="pubmed">19609263</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2004 Nov 18;432(7015):396-401</Citation><ArticleIdList><ArticleId IdType="pubmed">15549107</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Ther. 2010 Jul;18(7):1310-7</Citation><ArticleIdList><ArticleId IdType="pubmed">20372106</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Gene Ther. 2006 Jan;17(1):1-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16409120</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 1999 Jan;21(1):70-1</Citation><ArticleIdList><ArticleId IdType="pubmed">9916792</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gene Med. 2008 Mar;10(3):242-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18074400</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Biochem. 2000 Mar;267(5):1382-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10691975</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Haematol. 2004 Jan;124(1):72-9</Citation><ArticleIdList><ArticleId IdType="pubmed">14675410</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pathol. 2008 Jan;214(1):3-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18067118</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1995 Dec;69(12):7541-7</Citation><ArticleIdList><ArticleId IdType="pubmed">7494260</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Gene Ther. 2008 Dec;8(6):449-60</Citation><ArticleIdList><ArticleId IdType="pubmed">19075628</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Death Differ. 1998 Oct;5(10):858-66</Citation><ArticleIdList><ArticleId IdType="pubmed">10203685</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Biochem Cell Biol. 2005 Apr;37(4):715-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15694831</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3571-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11248119</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Biotechnol. 2009 May;27(5):259-65</Citation><ArticleIdList><ArticleId IdType="pubmed">19327858</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2002 Dec 20;277(51):49662-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12393905</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Gene Ther. 2008 Dec;8(6):483-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19075631</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Biotechnol. 2007 Jul;36(3):184-204</Citation><ArticleIdList><ArticleId IdType="pubmed">17873406</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neurobiol. 1998 Apr;54(5):581-618</Citation><ArticleIdList><ArticleId IdType="pubmed">9550192</ArticleId></ArticleIdList></Reference><Reference><Citation>Gene Ther. 2009 May;16(5):700-5</Citation><ArticleIdList><ArticleId IdType="pubmed">19212424</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Tissue Res. 2006 Nov;326(2):447-55</Citation><ArticleIdList><ArticleId IdType="pubmed">16896950</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Cell Res. 1997 Nov 1;236(2):404-11</Citation><ArticleIdList><ArticleId IdType="pubmed">9367624</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2007 Feb 15;53(4):591-604</Citation><ArticleIdList><ArticleId IdType="pubmed">17296559</ArticleId></ArticleIdList></Reference><Reference><Citation>Gene Ther. 2009 Apr;16(4):476-82</Citation><ArticleIdList><ArticleId IdType="pubmed">19242525</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Ther. 2008 Aug;16(8):1427-36</Citation><ArticleIdList><ArticleId IdType="pubmed">18578012</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Gene Ther. 2002 May 1;13(7):803-13</Citation><ArticleIdList><ArticleId IdType="pubmed">11975847</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2009 Nov 6;326(5954):805-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19892968</ArticleId></ArticleIdList></Reference><Reference><Citation>Gene Ther. 2007 Sep;14(18):1330-43</Citation><ArticleIdList><ArticleId IdType="pubmed">17611586</ArticleId></ArticleIdList></Reference><Reference><Citation>J Transl Med. 2004 Jun 11;2(1):18</Citation><ArticleIdList><ArticleId IdType="pubmed">15193152</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Biotechnol. 2005 Feb;23(2):209-14</Citation><ArticleIdList><ArticleId IdType="pubmed">15685166</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11479-84</Citation><ArticleIdList><ArticleId IdType="pubmed">16864770</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Biol. 2004 Oct 25;167(2):377-88</Citation><ArticleIdList><ArticleId IdType="pubmed">15504916</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20944075</PMID><DateCompleted><Year>2010</Year><Month>11</Month><Day>08</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>75</Volume><Issue>16</Issue><PubDate><Year>2010</Year><Month>Oct</Month><Day>19</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Physical activity predicts gray matter volume in late adulthood: the Cardiovascular Health Study.</ArticleTitle><Pagination><StartPage>1415</StartPage><EndPage>1422</EndPage><MedlinePgn>1415-22</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0b013e3181f88359</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Physical activity (PA) has been hypothesized to spare gray matter volume in late adulthood, but longitudinal data testing an association has been lacking. Here we tested whether PA would be associated with greater gray matter volume after a 9-year follow-up, a threshold could be identified for the amount of walking necessary to spare gray matter volume, and greater gray matter volume associated with PA would be associated with a reduced risk for cognitive impairment 13 years after the PA evaluation.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In 299 adults (mean age 78 years) from the Cardiovascular Health Cognition Study, we examined the association between gray matter volume, PA, and cognitive impairment. Physical activity was quantified as the number of blocks walked over 1 week. High-resolution brain scans were acquired 9 years after the PA assessment on cognitively normal adults. White matter hyperintensities, ventricular grade, and other health variables at baseline were used as covariates. Clinical adjudication for cognitive impairment occurred 13 years after baseline.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Walking amounts ranged from 0 to 300 blocks (mean 56.3; SD 69.7). Greater PA predicted greater volumes of frontal, occipital, entorhinal, and hippocampal regions 9 years later. Walking 72 blocks was necessary to detect increased gray matter volume but walking more than 72 blocks did not spare additional volume. Greater gray matter volume with PA reduced the risk for cognitive impairment 2-fold.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Greater amounts of walking are associated with greater gray matter volume, which is in turn associated with a reduced risk of cognitive impairment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Erickson</LastName><ForeName>K I</ForeName><Initials>KI</Initials><AffiliationInfo><Affiliation>Department of Psychology, University of Pittsburgh, PA, USA. kiericks@pitt.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raji</LastName><ForeName>C A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>O L</ForeName><Initials>OL</Initials></Author><Author ValidYN="Y"><LastName>Becker</LastName><ForeName>J T</ForeName><Initials>JT</Initials></Author><Author ValidYN="Y"><LastName>Rosano</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Newman</LastName><ForeName>A B</ForeName><Initials>AB</Initials></Author><Author ValidYN="Y"><LastName>Gach</LastName><ForeName>H M</ForeName><Initials>HM</Initials></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>P M</ForeName><Initials>PM</Initials></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>A J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Kuller</LastName><ForeName>L H</ForeName><Initials>LH</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>N01-HC-85085</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL080295</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30-AG-024827</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-HC-85086</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG-027058</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-HC-85082</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG020098</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG-023629</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-HC-85084</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG024827</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG-15928</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-HC-85081</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL-075366</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-HC-35129</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC-55222</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-HC-85083</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-HC-75150</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-HC-85080</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC-15103</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG-20098</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-HC-45133</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-HC-85079</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>10</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008609" MajorTopicYN="N">Mental Status Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>10</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>10</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>11</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>10</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20944075</ArticleId><ArticleId IdType="pmc">PMC3039208</ArticleId><ArticleId IdType="doi">10.1212/WNL.0b013e3181f88359</ArticleId><ArticleId IdType="pii">WNL.0b013e3181f88359</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Raz N, Lindenberger U, Rodrigue KM, et al. Regional brain changes in aging healthy adults: general trends, individual differences and modifiers. Cereb Cortex 2005;15:1676&#x2013;1689.</Citation><ArticleIdList><ArticleId IdType="pubmed">15703252</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer AF, Erickson KI. Capitalizing on cortical plasticity: influence of physical activity on cognition and brain function. Trends Cogn Sci 2007;11:342&#x2013;348.</Citation><ArticleIdList><ArticleId IdType="pubmed">17629545</ArticleId></ArticleIdList></Reference><Reference><Citation>Hillman CH, Erickson KI, Kramer AF. Be smart, exercise your heart: exercise effects on brain and cognition. Nat Rev Neurosci 2008;9:58&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">18094706</ArticleId></ArticleIdList></Reference><Reference><Citation>Colcombe SJ, Erickson KI, Raz N, et al. Aerobic fitness reduces brain tissue loss in aging humans. J Gerontol A Biol Sci Med Sci 2003;58:176&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">12586857</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns JM, Cronk BB, Anderson HS, et al. Cardiorespiratory fitness and brain atrophy in early Alzheimer's disease. Neurology 2008;71:210&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2657657</ArticleId><ArticleId IdType="pubmed">18625967</ArticleId></ArticleIdList></Reference><Reference><Citation>Honea RA, Thomas GP, Harsha A, et al. Cardiorespiratory fitness and preserved medial temporal lobe volume in Alzheimer's disease. Alzheimer Dis Assoc Disord 2009;23:188&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2760037</ArticleId><ArticleId IdType="pubmed">19812458</ArticleId></ArticleIdList></Reference><Reference><Citation>Erickson KI, Prakash RS, Voss MW, et al. Aerobic fitness is associated with hippocampal volume in elderly humans. Hippocampus 2009;19:1030&#x2013;1039.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3072565</ArticleId><ArticleId IdType="pubmed">19123237</ArticleId></ArticleIdList></Reference><Reference><Citation>Colcombe SJ, Erickson KI, Scalf PE, et al. Aerobic exercise training increases brain volume in aging humans: evidence from a randomized clinical trial. J Gerontol A Biol Sci Med Sci 2006;61:1166&#x2013;1170.</Citation><ArticleIdList><ArticleId IdType="pubmed">17167157</ArticleId></ArticleIdList></Reference><Reference><Citation>Andel R, Crowe M, Pederson NL, Fratiglioni L, Johansson B, Gatz M. Physical exercise at midlife and risk of dementia three decades later: a population-based study of Swedish twins. J Gerontol A Biol Sci Med Sci 2008;63:62&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">18245762</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes DE, Yaffe K, Satariano WA, Tager IB. A longitudinal study of cardiorespiratory fitness and cognitive function in healthy older adults. J Am Geriatr Soc 2003;51:459&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">12657064</ArticleId></ArticleIdList></Reference><Reference><Citation>Dik M, Deeg DJ, Visser M, Jonker C. Early life physical activity and cognition at old age. J Clin Exp Neuropsychol 2003;25:643&#x2013;653.</Citation><ArticleIdList><ArticleId IdType="pubmed">12815502</ArticleId></ArticleIdList></Reference><Reference><Citation>Larson EB, Wang L, Bowen JD, et al. Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older. Ann Intern Med 2006;144:73&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">16418406</ArticleId></ArticleIdList></Reference><Reference><Citation>Podewils LJ, Guallar E, Kuller LH, et al. Physical activity, APOE genotype, and dementia risk: findings from the Cardiovascular Health Cognition Study. Am J Epidemiol 2005;161:639&#x2013;651.</Citation><ArticleIdList><ArticleId IdType="pubmed">15781953</ArticleId></ArticleIdList></Reference><Reference><Citation>Weuve J, Kang JH, Manson JE, et al. Physical activity, including walking, and cognitive function in older women. JAMA 2004;292:1454&#x2013;1461.</Citation><ArticleIdList><ArticleId IdType="pubmed">15383516</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe K, Barnes D, Nevitt M, Lui LY, Covinsky K. A prospective study of physical activity and cognitive decline in elderly women: women who walk. Arch Intern Med 2001;161:1703&#x2013;1708.</Citation><ArticleIdList><ArticleId IdType="pubmed">11485502</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarmeas N, Luchsinger JA, Schupf N, et al. Physical activity, diet, and risk of Alzheimer disease. JAMA 2009;302:627&#x2013;637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2765045</ArticleId><ArticleId IdType="pubmed">19671904</ArticleId></ArticleIdList></Reference><Reference><Citation>Geda YE, Roberts RO, Knopman DS, et al. Physical exercise, aging, and mild cognitive impairment: a population-based study. Arch Neurol 2010;67:80&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2919839</ArticleId><ArticleId IdType="pubmed">20065133</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe K, Fiocco AJ, Lindquist K, et al. Predictors of maintaining cognitive function in older adults: the Health ABC Study. Neurology 2009;72:2029&#x2013;2035.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2692177</ArticleId><ArticleId IdType="pubmed">19506226</ArticleId></ArticleIdList></Reference><Reference><Citation>Erickson KI, Kramer AF. Exercise effects on cognitive and neural plasticity in older adults. Br J Sports Med 2009;43:22&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2853472</ArticleId><ArticleId IdType="pubmed">18927158</ArticleId></ArticleIdList></Reference><Reference><Citation>Fried LP, Borhani NO, Enright P, et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol 1991;1:263&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pubmed">1669507</ArticleId></ArticleIdList></Reference><Reference><Citation>Tell GS, Fried LP, Hermanson B, Manolio TA, Newman AB, Borhani NO. Recruitment of adults 65 years and older as participants in the Cardiovascular Health Study. Ann Epidemiol 1993;3:358&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pubmed">8275211</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Jagust WJ, DeKosky ST, et al. Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study. Arch Neurol 2003;60:1385&#x2013;1389.</Citation><ArticleIdList><ArticleId IdType="pubmed">14568808</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky S. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1131&#x2013;1132.</Citation><ArticleIdList><ArticleId IdType="pubmed">11342677</ArticleId></ArticleIdList></Reference><Reference><Citation>McPhillips JB, Pellettera KM, Barrett-Conner E, Wingard DL, Criqui MH. Exercise patterns in a population of older adults. Am J Prev Med 1989;5:65&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">2730794</ArticleId></ArticleIdList></Reference><Reference><Citation>Siscovick DS, Fried LP, Mittelmark M, et al. Exercise intensity and subclinical cardiovascular disease in the elderly. Am J Epidemiol 1997;145:977&#x2013;986.</Citation><ArticleIdList><ArticleId IdType="pubmed">9169906</ArticleId></ArticleIdList></Reference><Reference><Citation>Longsreth WT, Manolio TA, Arnold A, et al. Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people: The Cardiovascular Health Study. Stroke 1996;27:1274&#x2013;1282.</Citation><ArticleIdList><ArticleId IdType="pubmed">8711786</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner JA, Friston KJ. Voxel-based morphometry: the methods. Neuroimage 2001;14:1238&#x2013;1241.</Citation><ArticleIdList><ArticleId IdType="pubmed">11707080</ArticleId></ArticleIdList></Reference><Reference><Citation>Good CD, Johnsrude IS, Ashburner J, et al. A voxel-based morphometric study of ageing in 465 normal adult human brains. Neuroimage 2001;14:21&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">11525331</ArticleId></ArticleIdList></Reference><Reference><Citation>Mechelli A, Price CJ, Friston KJ, Ashburner J. Voxel-based morphometry of the human brain: methods and applications. Curr Med Imaging Rev 2005;11:1&#x2013;9.</Citation></Reference><Reference><Citation>Smith SM, Jenkinson M, Woolrich MW, et al. Advances in functional and structural MR image analysis and implementation as FSL. NeuroImage 2004;23:208&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pubmed">15501092</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith S. Fast robust automated brain extraction. Hum Brain Mapp 2002;17:143&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871816</ArticleId><ArticleId IdType="pubmed">12391568</ArticleId></ArticleIdList></Reference><Reference><Citation>Spears JR, Greer PJ, Ziolko SK, et al. Evaluation of an age-specific neurological template. Annual meeting of the Organization of Human Brain Mapping; Toronto, Canada; June 2005.</Citation></Reference><Reference><Citation>Wen W, Sachdev PS, Chen X, Anstey K. Gray matter reduction is correlated with white matter hyperintensity volume: a voxel-based morphometric study in a large epidemiological sample. NeuroImage 2006;29:1031&#x2013;1039.</Citation><ArticleIdList><ArticleId IdType="pubmed">16253521</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Praag H, Kempermann G, Gage FH. Running increases cell proliferation and neurogenesis in the adult mouse dentate gyrus. Nat Neuroscience 1999;2:266&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pubmed">10195220</ArticleId></ArticleIdList></Reference><Reference><Citation>Black JE, Isaacs KR, Anderson BJ, Alcantara AA, Greenough WT. Learning causes synaptogenesis, whereas motor activity causes angiogenesis, in cerebellar cortex of adult rats. Proc Natl Acad Sci USA 1990;87:5568&#x2013;5572.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC54366</ArticleId><ArticleId IdType="pubmed">1695380</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichol KE, Poon WW, Parachikova AI, Cribbs DH, Glabe CG, Cotman CW. Exercise alters the immune profile in Tg2576 Alzheimer mice toward a response coincident with improved cognitive performance and decreased amyloid. J Neuroinflammation 2008;5:13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2329612</ArticleId><ArticleId IdType="pubmed">18400101</ArticleId></ArticleIdList></Reference><Reference><Citation>Leem YH, Lim HJ, Shim SB, Cho JY, Kim BS, Han PL. Repression of tau hyperphosphorylation by chronic endurance exercise in aged transgenic mouse model of tauopathies. J Neurosci Res 2009;87:2561&#x2013;2570.</Citation><ArticleIdList><ArticleId IdType="pubmed">19360903</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichol KE, Parachikova AI, Cotman CW. Three weeks of running wheel exposure improves cognitive performance in the aged Tg2576 mouse. Behav Brain Res 2007;184:124&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2215770</ArticleId><ArticleId IdType="pubmed">17698211</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20956308</PMID><DateCompleted><Year>2010</Year><Month>11</Month><Day>30</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>107</Volume><Issue>44</Issue><PubDate><Year>2010</Year><Month>Nov</Month><Day>02</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Genetic reduction of striatal-enriched tyrosine phosphatase (STEP) reverses cognitive and cellular deficits in an Alzheimer's disease mouse model.</ArticleTitle><Pagination><StartPage>19014</StartPage><EndPage>19019</EndPage><MedlinePgn>19014-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1013543107</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is a progressive and incurable neurodegenerative disorder. Early in the pathophysiology of AD, synaptic function is disrupted by soluble A&#x3b2; oligomers, possibly through A&#x3b2;-mediated internalization of NMDA receptors. Striatal-enriched phosphatase (STEP) is a tyrosine phosphatase that regulates the internalization of NMDA receptors. Recent work shows that STEP is elevated in the prefrontal cortex of human AD patients and in animal models of AD. Here, we use genetic manipulations to reduce STEP activity in a triple transgenic AD mouse model and show that a decrease in STEP levels reverses cognitive and cellular deficits observed in these mice. Our results suggest that STEP inhibitors may prove therapeutic for this devastating disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yongfang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Child Study Center, Yale University School of Medicine, New Haven, CT 06520, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurup</LastName><ForeName>Pradeep</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Jian</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Carty</LastName><ForeName>Nikisha</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Fernandez</LastName><ForeName>Stephanie M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Nygaard</LastName><ForeName>Haakon B</ForeName><Initials>HB</Initials></Author><Author ValidYN="Y"><LastName>Pittenger</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Greengard</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Strittmatter</LastName><ForeName>Stephen M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Nairn</LastName><ForeName>Angus C</ForeName><Initials>AC</Initials></Author><Author ValidYN="Y"><LastName>Lombroso</LastName><ForeName>Paul J</ForeName><Initials>PJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R37 NS033020</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG009464</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS042304</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS42304</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH52711</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K02 MH001527</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 MH081190</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG034924</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS39962</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG09464</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS039962</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH052711</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH081190</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH01527</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>10</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C545487">APP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.48</RegistryNumber><NameOfSubstance UI="D054558">Protein Tyrosine Phosphatases, Non-Receptor</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.48</RegistryNumber><NameOfSubstance UI="C082101">Ptpn5 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054558" MajorTopicYN="N">Protein Tyrosine Phosphatases, Non-Receptor</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>5</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20956308</ArticleId><ArticleId IdType="pmc">PMC2973892</ArticleId><ArticleId IdType="doi">10.1073/pnas.1013543107</ArticleId><ArticleId IdType="pii">1013543107</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8:101&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkitaramani DV, et al. Beta-amyloid modulation of synaptic transmission and plasticity. J Neurosci. 2007;27:11832&#x2013;11837.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2671021</ArticleId><ArticleId IdType="pubmed">17978019</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res. 2008;192:106&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2601528</ArticleId><ArticleId IdType="pubmed">18359102</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, et al. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation. J Neurosci. 2000;20:4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobsen JS, et al. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA. 2006;103:5161&#x2013;5166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1405622</ArticleId><ArticleId IdType="pubmed">16549764</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, et al. Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacor PN, et al. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci. 2007;27:796&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672917</ArticleId><ArticleId IdType="pubmed">17251419</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, et al. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci. 2007;27:2866&#x2013;2875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672572</ArticleId><ArticleId IdType="pubmed">17360908</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008;14:837&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman PF, et al. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci. 1999;2:271&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pubmed">10195221</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: Intracellular Abeta and synaptic dysfunction. Neuron. 2003;39:409&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Boulanger LM, et al. Cellular and molecular characterization of a brain-enriched protein tyrosine phosphatase. J Neurosci. 1995;15:1532&#x2013;1544.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577844</ArticleId><ArticleId IdType="pubmed">7869116</ArticleId></ArticleIdList></Reference><Reference><Citation>Goebel-Goody SM, Davies KD, Alvestad Linger RM, Freund RK, Browning MD. Phospho-regulation of synaptic and extrasynaptic N-methyl-d-aspartate receptors in adult hippocampal slices. Neuroscience. 2009;158:1446&#x2013;1459.</Citation><ArticleIdList><ArticleId IdType="pubmed">19041929</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, et al. Extrasynaptic NMDA receptors couple preferentially to excitotoxicity via calpain-mediated cleavage of STEP. J Neurosci. 2009;29:9330&#x2013;9343.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2737362</ArticleId><ArticleId IdType="pubmed">19625523</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder EM, et al. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci. 2005;8:1051&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pubmed">16025111</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelkey KA, et al. Tyrosine phosphatase STEP is a tonic brake on induction of long-term potentiation. Neuron. 2002;34:127&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">11931747</ArticleId></ArticleIdList></Reference><Reference><Citation>Braithwaite SP, et al. Regulation of NMDA receptor trafficking and function by striatal-enriched tyrosine phosphatase (STEP) Eur J Neurosci. 2006;23:2847&#x2013;2856.</Citation><ArticleIdList><ArticleId IdType="pubmed">16819973</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen TH, Liu J, Lombroso PJ. Striatal enriched phosphatase 61 dephosphorylates Fyn at phosphotyrosine 420. J Biol Chem. 2002;277:24274&#x2013;24279.</Citation><ArticleIdList><ArticleId IdType="pubmed">11983687</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul S, Nairn AC, Wang P, Lombroso PJ. NMDA-mediated activation of the tyrosine phosphatase STEP regulates the duration of ERK signaling. Nat Neurosci. 2003;6:34&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">12483215</ArticleId></ArticleIdList></Reference><Reference><Citation>Braithwaite SP, Paul S, Nairn AC, Lombroso PJ. Synaptic plasticity: One STEP at a time. Trends Neurosci. 2006;29:452&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1630769</ArticleId><ArticleId IdType="pubmed">16806510</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin J, et al. Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci. 2005;25:9694&#x2013;9703.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725734</ArticleId><ArticleId IdType="pubmed">16237174</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurup P, et al. Abeta-mediated NMDA receptor endocytosis in Alzheimer's disease involves ubiquitination of the tyrosine phosphatase STEP61. J Neurosci. 2010;30:5948&#x2013;5957.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2868326</ArticleId><ArticleId IdType="pubmed">20427654</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkitaramani DV, et al. Knockout of striatal enriched protein tyrosine phosphatase in mice results in increased ERK1/2 phosphorylation. Synapse. 2009;63:69&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2706508</ArticleId><ArticleId IdType="pubmed">18932218</ArticleId></ArticleIdList></Reference><Reference><Citation>Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron. 2005;45:675&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pubmed">15748844</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll JC, et al. Progesterone and estrogen regulate Alzheimer-like neuropathology in female 3xTg-AD mice. J Neurosci. 2007;27:13357&#x2013;13365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673397</ArticleId><ArticleId IdType="pubmed">18045930</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez SM, et al. Estradiol-induced enhancement of object memory consolidation involves hippocampal extracellular signal-regulated kinase activation and membrane-bound estrogen receptors. J Neurosci. 2008;28:8660&#x2013;8667.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2693006</ArticleId><ArticleId IdType="pubmed">18753366</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh Y, et al. Extracellular signal-regulated kinase 2 (ERK2) knockdown mice show deficits in long-term memory; ERK2 has a specific function in learning and memory. J Neurosci. 2007;27:10765&#x2013;10776.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672813</ArticleId><ArticleId IdType="pubmed">17913910</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant SG, et al. Impaired long-term potentiation, spatial learning, and hippocampal development in fyn mutant mice. Science. 1992;258:1903&#x2013;1910.</Citation><ArticleIdList><ArticleId IdType="pubmed">1361685</ArticleId></ArticleIdList></Reference><Reference><Citation>Laur&#xe9;n J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature. 2009;457:1128&#x2013;1132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2748841</ArticleId><ArticleId IdType="pubmed">19242475</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20962290</PMID><DateCompleted><Year>2010</Year><Month>12</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>75</Volume><Issue>20</Issue><PubDate><Year>2010</Year><Month>Nov</Month><Day>16</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Detection of elevated levels of &#x3b1;-synuclein oligomers in CSF from patients with Parkinson disease.</ArticleTitle><Pagination><StartPage>1766</StartPage><EndPage>1772</EndPage><MedlinePgn>1766-72</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0b013e3181fd613b</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">To date, there is no accepted clinical diagnostic test for Parkinson disease (PD) that is based on biochemical analysis of blood or CSF. The discovery of mutations in the SNCA gene encoding &#x3b1;-synuclein in familial parkinsonism and the accumulation of &#x3b1;-synuclein in the PD brain suggested a critical role for this protein in PD etiology.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We investigated total and &#x3b1;-synuclein oligomers levels in CSF from patients clinically diagnosed with PD, progressive supranuclear palsy (PSP), or Alzheimer disease (AD), and age-matched controls, using ELISA developed in our laboratory.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The levels of &#x3b1;-synuclein oligomers and oligomers/total-&#x3b1;-synuclein ratio in CSF were higher in the PD group (n = 32; p &lt; 0.0001, Mann-Whitney U test) compared to the control group (n = 28). The area under the receiver operating characteristic curve (AUC) indicated a sensitivity of 75.0% and a specificity of 87.5%, with an AUC of 0.859 for increased CSF &#x3b1;-synuclein oligomers in clinically diagnosed PD cases. However, when the CSF oligomers/total-&#x3b1;-synuclein ratio was analyzed, it provided an even greater sensitivity of 89.3% and specificity of 90.6%, with an AUC of 0.948. In another cross-sectional pilot study, we confirmed that the levels of CSF &#x3b1;-synuclein oligomers were higher in patients with PD (n = 25) compared to patients with PSP (n = 18; p &lt; 0.05) or AD (n = 35; p &lt; 0.001) or control subjects (n = 43; p &lt; 0.05).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our results demonstrate that levels of &#x3b1;-synuclein oligomers in CSF and the oligomers/total-&#x3b1;-synuclein ratio can be useful biomarkers for diagnosis and early detection of PD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tokuda</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kyoto Prefectural University of Medicine, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qureshi</LastName><ForeName>M M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Ardah</LastName><ForeName>M T</ForeName><Initials>MT</Initials></Author><Author ValidYN="Y"><LastName>Varghese</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Shehab</LastName><ForeName>S A S</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Kasai</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Ishigami</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Tamaoka</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Nakagawa</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>El-Agnaf</LastName><ForeName>O M A</ForeName><Initials>OM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>10</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2010 Nov 16;75(20):1760-1. doi: 10.1212/WNL.0b013e3181fd6393.</RefSource><PMID Version="1">20962288</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2011 Aug 2;77(5):510; author reply 510-1. doi: 10.1212/WNL.0b013e318219dd92.</RefSource><PMID Version="1">21810701</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013494" MajorTopicYN="N">Supranuclear Palsy, Progressive</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20962290</ArticleId><ArticleId IdType="doi">10.1212/WNL.0b013e3181fd613b</ArticleId><ArticleId IdType="pii">WNL.0b013e3181fd613b</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20966215</PMID><DateCompleted><Year>2010</Year><Month>12</Month><Day>14</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>330</Volume><Issue>6006</Issue><PubDate><Year>2010</Year><Month>Nov</Month><Day>12</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis.</ArticleTitle><Pagination><StartPage>980</StartPage><EndPage>982</EndPage><MedlinePgn>980-2</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.1194516</ELocationID><Abstract><AbstractText>The intracerebral injection of &#x3b2;-amyloid-containing brain extracts can induce cerebral &#x3b2;-amyloidosis and associated pathologies in susceptible hosts. We found that intraperitoneal inoculation with &#x3b2;-amyloid-rich extracts induced &#x3b2;-amyloidosis in the brains of &#x3b2;-amyloid precursor protein transgenic mice after prolonged incubation times.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Eisele</LastName><ForeName>Yvonne S</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie-Institute for Clinical Brain Research, University of T&#xfc;bingen, D-72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oberm&#xfc;ller</LastName><ForeName>Ulrike</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Heilbronner</LastName><ForeName>G&#xf6;tz</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Baumann</LastName><ForeName>Frank</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Kaeser</LastName><ForeName>Stephan A</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Wolburg</LastName><ForeName>Hartwig</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Lary C</ForeName><Initials>LC</Initials></Author><Author ValidYN="Y"><LastName>Staufenbiel</LastName><ForeName>Matthias</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Heikenwalder</LastName><ForeName>Mathias</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Jucker</LastName><ForeName>Mathias</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P51 RR000165</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RR-00165</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>10</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011328">Prions</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C538248">Amyloid angiopathy</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Science. 2010 Nov 12;330(6006):918-9. doi: 10.1126/science.1198314.</RefSource><PMID Version="1">21071652</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016657" MajorTopicYN="N">Cerebral Amyloid Angiopathy</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007274" MajorTopicYN="N">Injections, Intraperitoneal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011328" MajorTopicYN="N">Prions</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017510" MajorTopicYN="N">Protein Folding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>12</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20966215</ArticleId><ArticleId IdType="mid">NIHMS338781</ArticleId><ArticleId IdType="pmc">PMC3233904</ArticleId><ArticleId IdType="doi">10.1126/science.1194516</ArticleId><ArticleId IdType="pii">science.1194516</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Meyer-L&#xfc;hmann M, et al. Science. 2006;131:1781.</Citation><ArticleIdList><ArticleId IdType="pubmed">16990547</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisele YS, et al. Proc Natl Acad Sci USA. 2009;106:12926.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2722323</ArticleId><ArticleId IdType="pubmed">19622727</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusiner SB. Prion Biology and Diseases. 2. Cold Spring Harbor Laboratory Press; Cold Spring Harbor, NY: 2004.</Citation></Reference><Reference><Citation>Kimberlin RH, Walker CA. J Comp Path. 1978;88:39.</Citation><ArticleIdList><ArticleId IdType="pubmed">563870</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturchler-Pierrat C, et al. Proc Natl Acad Sci USA. 1997;94:13287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24301</ArticleId><ArticleId IdType="pubmed">9371838</ArticleId></ArticleIdList></Reference><Reference><Citation>Calhoun ME, et al. Proc Natl Acad Sci USA. 1999;96:14088.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24195</ArticleId><ArticleId IdType="pubmed">10570203</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguzzi A, Sigurdson C, Heikenw&#xe4;lder M. Annu Rev Pathol Mech Dis. 2008;3:11.</Citation><ArticleIdList><ArticleId IdType="pubmed">18233951</ArticleId></ArticleIdList></Reference><Reference><Citation>Heikenwalder M, et al. Science. 2005;307:1107.</Citation><ArticleIdList><ArticleId IdType="pubmed">15661974</ArticleId></ArticleIdList></Reference><Reference><Citation>Bremer J, et al. PloS One. 2009;4:e7160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2744926</ArticleId><ArticleId IdType="pubmed">19779609</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. Science. 2002;297:353.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorandt M, Mintun MA, Head D, Morris JC. Arch Neurol. 2009;66:1476.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2796577</ArticleId><ArticleId IdType="pubmed">20008651</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, et al. Arch Neurol. 2009;66:1469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2798814</ArticleId><ArticleId IdType="pubmed">20008650</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang-Nunes SX, et al. Brain Pathol. 2006;16:30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095991</ArticleId><ArticleId IdType="pubmed">16612980</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker LC, LeVine H, 3rd, Mattson MP, Jucker M. Trends Neurosci. 2006;29:438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10725716</ArticleId><ArticleId IdType="pubmed">16806508</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguzzi A, Rajendran L. Neuron. 2009;64:783.</Citation><ArticleIdList><ArticleId IdType="pubmed">20064386</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20981092</PMID><DateCompleted><Year>2010</Year><Month>12</Month><Day>14</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>467</Volume><Issue>7319</Issue><PubDate><Year>2010</Year><Month>Oct</Month><Day>28</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>A map of human genome variation from population-scale sequencing.</ArticleTitle><Pagination><StartPage>1061</StartPage><EndPage>1073</EndPage><MedlinePgn>1061-73</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature09534</ELocationID><Abstract><AbstractText>The 1000 Genomes Project aims to provide a deep characterization of human genome sequence variation as a foundation for investigating the relationship between genotype and phenotype. Here we present results of the pilot phase of the project, designed to develop and compare different strategies for genome-wide sequencing with high-throughput platforms. We undertook three projects: low-coverage whole-genome sequencing of 179 individuals from four populations; high-coverage sequencing of two mother-father-child trios; and exon-targeted sequencing of 697 individuals from seven populations. We describe the location, allele frequency and local haplotype structure of approximately 15 million single nucleotide polymorphisms, 1 million short insertions and deletions, and 20,000 structural variants, most of which were previously undescribed. We show that, because we have catalogued the vast majority of common variation, over 95% of the currently accessible variants found in any individual are present in this data set. On average, each person is found to carry approximately 250 to 300 loss-of-function variants in annotated genes and 50 to 100 variants previously implicated in inherited disorders. We demonstrate how these results can be used to inform association and functional studies. From the two trios, we directly estimate the rate of de novo germline base substitution mutations to be approximately 10(-8) per base pair per generation. We explore the data with regard to signatures of natural selection, and identify a marked reduction of genetic variation in the neighbourhood of genes, due to selection at linked sites. These methods and public data will support the next phase of human genetic research.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><CollectiveName>1000 Genomes Project Consortium</CollectiveName></Author><Author ValidYN="Y"><LastName>Abecasis</LastName><ForeName>Gon&#xe7;alo R</ForeName><Initials>GR</Initials></Author><Author ValidYN="Y"><LastName>Altshuler</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Auton</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Brooks</LastName><ForeName>Lisa D</ForeName><Initials>LD</Initials></Author><Author ValidYN="Y"><LastName>Durbin</LastName><ForeName>Richard M</ForeName><Initials>RM</Initials></Author><Author ValidYN="Y"><LastName>Gibbs</LastName><ForeName>Richard A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Hurles</LastName><ForeName>Matt E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>McVean</LastName><ForeName>Gil A</ForeName><Initials>GA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01HG5208</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>075491</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U54 HG002750</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM059290</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>077014</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>WT086084/Z/08/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>077009</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01HG4960</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>077192</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 HG004960</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH084698</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HG005208</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>WT081407/Z/06/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>01MH84698</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01GM72861</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 HG003067</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U41 HG002371</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HG004333</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 HG002371</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41HG2371</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HG002651</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HG004719</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41 HG004222</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01HG4333</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01HG3698</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM072861</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2 HG005552</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54HG2757</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>WT089088/Z/09/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U54 HG002757</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>089088</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01GM59290</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01HG5210</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U41HG4568</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HG005211</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HG005214</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>WT075491/Z/04</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 HG003229</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41 HG002371</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007753</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 HG003273</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0801823</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>WT085532AIA</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U01HG5211</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54HG3079</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01HG5214</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U41 HG004568</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RG/09/012/28096</GrantID><Acronym>BHF_</Acronym><Agency>British Heart Foundation</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U54HG2750</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>089062</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HG005210</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HG003698</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2HG5552</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01HG4120</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01HG5209</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>089061</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>086084</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>01HG3229</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54HG3067</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41HG4221</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HG002510</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>081407</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>085532</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>N01 HG062088</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HG005209</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 HG005201</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50HG2357</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AA022707</GrantID><Acronym>AA</Acronym><Agency>NIAAA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41 HG004221</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 HG004120</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41HG4222</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10RR025056</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01HG2651</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01HG4719</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 HG002357</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0801823(89305)</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U54HG3273</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004272">DNA, Mitochondrial</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Nature. 2011 May 26;473(7348):544</RefSource><Note>Xue, Yali [added]; Cartwright, Reed A [added]; Altshuler, David L [corrected to Altshuler, David]; Kebbel, Andrew [corrected to Keebler, Jonathan]; Koko-Gonzales, Paula [corrected to Kokko-Gonzales, Paula]; Nickerson, Debbie A [corrected to Nickerson, Debo</Note></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2010 Oct 28;467(7319):1050-1. doi: 10.1038/4671050a.</RefSource><PMID Version="1">20981085</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Genet. 2010 Dec;11(12):814. doi: 10.1038/nrg2906.</RefSource><PMID Version="1">21063440</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D002138" MajorTopicYN="N">Calibration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D041322" MajorTopicYN="N">Chromosomes, Human, Y</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019295" MajorTopicYN="N">Computational Biology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004252" MajorTopicYN="N">DNA Mutational Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004272" MajorTopicYN="N">DNA, Mitochondrial</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019143" MajorTopicYN="N">Evolution, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056726" MajorTopicYN="N">Genetic Association Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005828" MajorTopicYN="N">Genetics, Population</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015894" MajorTopicYN="N">Genome, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D023281" MajorTopicYN="N">Genomics</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006239" MajorTopicYN="N">Haplotypes</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011995" MajorTopicYN="N">Recombination, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018401" MajorTopicYN="N">Sample Size</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012641" MajorTopicYN="N">Selection, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016415" MajorTopicYN="N">Sequence Alignment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017422" MajorTopicYN="N">Sequence Analysis, DNA</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">UKMS34220</OtherID><InvestigatorList><Investigator ValidYN="Y"><LastName>Altshuler</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Durbin</LastName><ForeName>Richard M</ForeName><Initials>RM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abecasis</LastName><ForeName>Gon&#xe7;alo R</ForeName><Initials>GR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bentley</LastName><ForeName>David R</ForeName><Initials>DR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chakravarti</LastName><ForeName>Aravinda</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clark</LastName><ForeName>Andrew G</ForeName><Initials>AG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Collins</LastName><ForeName>Francis S</ForeName><Initials>FS</Initials></Investigator><Investigator ValidYN="Y"><LastName>De La Vega</LastName><ForeName>Francisco M</ForeName><Initials>FM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donnelly</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Egholm</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flicek</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gabriel</LastName><ForeName>Stacey B</ForeName><Initials>SB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gibbs</LastName><ForeName>Richard A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Knoppers</LastName><ForeName>Bartha M</ForeName><Initials>BM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lander</LastName><ForeName>Eric S</ForeName><Initials>ES</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lehrach</LastName><ForeName>Hans</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mardis</LastName><ForeName>Elaine R</ForeName><Initials>ER</Initials></Investigator><Investigator ValidYN="Y"><LastName>McVean</LastName><ForeName>Gil A</ForeName><Initials>GA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nickerson</LastName><ForeName>Deborah A</ForeName><Initials>DA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peltonen</LastName><ForeName>Leena</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schafer</LastName><ForeName>Alan J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sherry</LastName><ForeName>Stephen T</ForeName><Initials>ST</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Jun</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilson</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gibbs</LastName><ForeName>Richard A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deiros</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Metzker</LastName><ForeName>Mike</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Muzny</LastName><ForeName>Donna</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reid</LastName><ForeName>Jeff</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wheeler</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Jun</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Jingxiang</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jian</LastName><ForeName>Min</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Guoqing</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Ruiqiang</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liang</LastName><ForeName>Huiqing</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tian</LastName><ForeName>Geng</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Bo</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Jian</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Wei</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yang</LastName><ForeName>Huanming</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xiuqing</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zheng</LastName><ForeName>Huisong</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lander</LastName><ForeName>Eric S</ForeName><Initials>ES</Initials></Investigator><Investigator ValidYN="Y"><LastName>Altshuler</LastName><ForeName>David L</ForeName><Initials>DL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ambrogio</LastName><ForeName>Lauren</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bloom</LastName><ForeName>Toby</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cibulskis</LastName><ForeName>Kristian</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fennell</LastName><ForeName>Tim J</ForeName><Initials>TJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gabriel</LastName><ForeName>Stacey B</ForeName><Initials>SB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jaffe</LastName><ForeName>David B</ForeName><Initials>DB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shefler</LastName><ForeName>Erica</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sougnez</LastName><ForeName>Carrie L</ForeName><Initials>CL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bentley</LastName><ForeName>David R</ForeName><Initials>DR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gormley</LastName><ForeName>Niall</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Humphray</LastName><ForeName>Sean</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kingsbury</LastName><ForeName>Zoya</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kokko-Gonzales</LastName><ForeName>Paula</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stone</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>McKernan</LastName><ForeName>Kevin J</ForeName><Initials>KJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Costa</LastName><ForeName>Gina L</ForeName><Initials>GL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ichikawa</LastName><ForeName>Jeffry K</ForeName><Initials>JK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Clarence C</ForeName><Initials>CC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sudbrak</LastName><ForeName>Ralf</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lehrach</LastName><ForeName>Hans</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borodina</LastName><ForeName>Tatiana A</ForeName><Initials>TA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dahl</LastName><ForeName>Andreas</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davydov</LastName><ForeName>Alexey N</ForeName><Initials>AN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marquardt</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mertes</LastName><ForeName>Florian</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nietfeld</LastName><ForeName>Wilfiried</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosenstiel</LastName><ForeName>Philip</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schreiber</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Soldatov</LastName><ForeName>Aleksey V</ForeName><Initials>AV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Timmermann</LastName><ForeName>Bernd</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tolzmann</LastName><ForeName>Marius</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Egholm</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Affourtit</LastName><ForeName>Jason</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ashworth</LastName><ForeName>Dana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Attiya</LastName><ForeName>Said</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bachorski</LastName><ForeName>Melissa</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buglione</LastName><ForeName>Eli</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burke</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caprio</LastName><ForeName>Amanda</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Celone</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clark</LastName><ForeName>Shauna</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Conners</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Desany</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gu</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guccione</LastName><ForeName>Lorri</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kao</LastName><ForeName>Kalvin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kebbler</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Knowlton</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Labrecque</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>McDade</LastName><ForeName>Louise</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mealmaker</LastName><ForeName>Craig</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Minderman</LastName><ForeName>Melissa</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nawrocki</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Niazi</LastName><ForeName>Faheem</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pareja</LastName><ForeName>Kristen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramenani</LastName><ForeName>Ravi</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Riches</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Song</LastName><ForeName>Wanmin</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turcotte</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Shally</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mardis</LastName><ForeName>Elaine R</ForeName><Initials>ER</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilson</LastName><ForeName>Richard K</ForeName><Initials>RK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dooling</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fulton</LastName><ForeName>Lucinda</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fulton</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weinstock</LastName><ForeName>George</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Durbin</LastName><ForeName>Richard M</ForeName><Initials>RM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burton</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carter</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Churcher</LastName><ForeName>Carol</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coffey</LastName><ForeName>Alison</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cox</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Palotie</LastName><ForeName>Aarno</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quail</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Skelly</LastName><ForeName>Tom</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stalker</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Swerdlow</LastName><ForeName>Harold P</ForeName><Initials>HP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turner</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Witte</LastName><ForeName>Anniek</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Giles</LastName><ForeName>Shane</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gibbs</LastName><ForeName>Richard A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wheeler</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bainbridge</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Challis</LastName><ForeName>Danny</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sabo</LastName><ForeName>Aniko</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yu</LastName><ForeName>Fuli</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yu</LastName><ForeName>Jin</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Jun</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fang</LastName><ForeName>Xiaodong</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guo</LastName><ForeName>Xiaosen</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Ruiqiang</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Yingrui</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Luo</LastName><ForeName>Ruibang</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tai</LastName><ForeName>Shuaishuai</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wu</LastName><ForeName>Honglong</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zheng</LastName><ForeName>Hancheng</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zheng</LastName><ForeName>Xiaole</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yan</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Guoqing</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Jian</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yang</LastName><ForeName>Huanming</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marth</LastName><ForeName>Gabor T</ForeName><Initials>GT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garrison</LastName><ForeName>Erik P</ForeName><Initials>EP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huang</LastName><ForeName>Weichun</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Indap</LastName><ForeName>Amit</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kural</LastName><ForeName>Deniz</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Wan-Ping</ForeName><Initials>WP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leong</LastName><ForeName>Wen Fung</ForeName><Initials>WF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quinlan</LastName><ForeName>Aaron R</ForeName><Initials>AR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stewart</LastName><ForeName>Chip</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stromberg</LastName><ForeName>Michael P</ForeName><Initials>MP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ward</LastName><ForeName>Alistair N</ForeName><Initials>AN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wu</LastName><ForeName>Jiantao</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mills</LastName><ForeName>Ryan E</ForeName><Initials>RE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shi</LastName><ForeName>Xinghua</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Daly</LastName><ForeName>Mark J</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>DePristo</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Altshuler</LastName><ForeName>David L</ForeName><Initials>DL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ball</LastName><ForeName>Aaron D</ForeName><Initials>AD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Banks</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bloom</LastName><ForeName>Toby</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Browning</LastName><ForeName>Brian L</ForeName><Initials>BL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cibulskis</LastName><ForeName>Kristian</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fennell</LastName><ForeName>Tim J</ForeName><Initials>TJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garimella</LastName><ForeName>Kiran V</ForeName><Initials>KV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grossman</LastName><ForeName>Sharon R</ForeName><Initials>SR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Handsaker</LastName><ForeName>Robert E</ForeName><Initials>RE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hanna</LastName><ForeName>Matt</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hartl</LastName><ForeName>Chris</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jaffe</LastName><ForeName>David B</ForeName><Initials>DB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kernytsky</LastName><ForeName>Andrew M</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Korn</LastName><ForeName>Joshua M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Heng</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maguire</LastName><ForeName>Jared R</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCarroll</LastName><ForeName>Steven A</ForeName><Initials>SA</Initials></Investigator><Investigator ValidYN="Y"><LastName>McKenna</LastName><ForeName>Aaron</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nemesh</LastName><ForeName>James C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Philippakis</LastName><ForeName>Anthony A</ForeName><Initials>AA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Poplin</LastName><ForeName>Ryan E</ForeName><Initials>RE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Price</LastName><ForeName>Alkes</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rivas</LastName><ForeName>Manuel A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sabeti</LastName><ForeName>Pardis C</ForeName><Initials>PC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schaffner</LastName><ForeName>Stephen F</ForeName><Initials>SF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shefler</LastName><ForeName>Erica</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shlyakhter</LastName><ForeName>Ilya A</ForeName><Initials>IA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cooper</LastName><ForeName>David N</ForeName><Initials>DN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ball</LastName><ForeName>Edward V</ForeName><Initials>EV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mort</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Phillips</LastName><ForeName>Andrew D</ForeName><Initials>AD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stenson</LastName><ForeName>Peter D</ForeName><Initials>PD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sebat</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Makarov</LastName><ForeName>Vladimir</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ye</LastName><ForeName>Kenny</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yoon</LastName><ForeName>Seungtai C</ForeName><Initials>SC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bustamante</LastName><ForeName>Carlos D</ForeName><Initials>CD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clark</LastName><ForeName>Andrew G</ForeName><Initials>AG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boyko</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Degenhardt</LastName><ForeName>Jeremiah</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gravel</LastName><ForeName>Simon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gutenkunst</LastName><ForeName>Ryan N</ForeName><Initials>RN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaganovich</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Keinan</LastName><ForeName>Alon</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lacroute</LastName><ForeName>Phil</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ma</LastName><ForeName>Xin</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reynolds</LastName><ForeName>Andy</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clarke</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flicek</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cunningham</LastName><ForeName>Fiona</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Herrero</LastName><ForeName>Javier</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Keenen</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kulesha</LastName><ForeName>Eugene</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leinonen</LastName><ForeName>Rasko</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>McLaren</LastName><ForeName>William M</ForeName><Initials>WM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Radhakrishnan</LastName><ForeName>Rajesh</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Richard E</ForeName><Initials>RE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zalunin</LastName><ForeName>Vadim</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zheng-Bradley</LastName><ForeName>Xiangqun</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Korbel</LastName><ForeName>Jan O</ForeName><Initials>JO</Initials></Investigator><Investigator ValidYN="Y"><LastName>St&#xfc;tz</LastName><ForeName>Adrian M</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Humphray</LastName><ForeName>Sean</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bauer</LastName><ForeName>Markus</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cheetham</LastName><ForeName>R Keira</ForeName><Initials>RK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cox</LastName><ForeName>Tony</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eberle</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>James</LastName><ForeName>Terena</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kahn</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Murray</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chakravarti</LastName><ForeName>Aravinda</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ye</LastName><ForeName>Kai</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>De La Vega</LastName><ForeName>Francisco M</ForeName><Initials>FM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fu</LastName><ForeName>Yutao</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hyland</LastName><ForeName>Fiona C L</ForeName><Initials>FC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Manning</LastName><ForeName>Jonathan M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>McLaughlin</LastName><ForeName>Stephen F</ForeName><Initials>SF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peckham</LastName><ForeName>Heather E</ForeName><Initials>HE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sakarya</LastName><ForeName>Onur</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sun</LastName><ForeName>Yongming A</ForeName><Initials>YA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tsung</LastName><ForeName>Eric F</ForeName><Initials>EF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Batzer</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Konkel</LastName><ForeName>Miriam K</ForeName><Initials>MK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walker</LastName><ForeName>Jerilyn A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sudbrak</LastName><ForeName>Ralf</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albrecht</LastName><ForeName>Marcus W</ForeName><Initials>MW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Amstislavskiy</LastName><ForeName>Vyacheslav S</ForeName><Initials>VS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Herwig</LastName><ForeName>Ralf</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parkhomchuk</LastName><ForeName>Dimitri V</ForeName><Initials>DV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sherry</LastName><ForeName>Stephen T</ForeName><Initials>ST</Initials></Investigator><Investigator ValidYN="Y"><LastName>Agarwala</LastName><ForeName>Richa</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khouri</LastName><ForeName>Hoda M</ForeName><Initials>HM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morgulis</LastName><ForeName>Aleksandr O</ForeName><Initials>AO</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paschall</LastName><ForeName>Justin E</ForeName><Initials>JE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Phan</LastName><ForeName>Lon D</ForeName><Initials>LD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rotmistrovsky</LastName><ForeName>Kirill E</ForeName><Initials>KE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sanders</LastName><ForeName>Robert D</ForeName><Initials>RD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shumway</LastName><ForeName>Martin F</ForeName><Initials>MF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xiao</LastName><ForeName>Chunlin</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>McVean</LastName><ForeName>Gil A</ForeName><Initials>GA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Auton</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Iqbal</LastName><ForeName>Zamin</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lunter</LastName><ForeName>Gerton</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marchini</LastName><ForeName>Jonathan L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moutsianas</LastName><ForeName>Loukas</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Myers</LastName><ForeName>Simon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tumian</LastName><ForeName>Afidalina</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Desany</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Knight</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Winer</LastName><ForeName>Roger</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Craig</LastName><ForeName>David W</ForeName><Initials>DW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beckstrom-Sternberg</LastName><ForeName>Steve M</ForeName><Initials>SM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Christoforides</LastName><ForeName>Alexis</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kurdoglu</LastName><ForeName>Ahmet A</ForeName><Initials>AA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pearson</LastName><ForeName>John V</ForeName><Initials>JV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sinari</LastName><ForeName>Shripad A</ForeName><Initials>SA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tembe</LastName><ForeName>Waibhav D</ForeName><Initials>WD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haussler</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hinrichs</LastName><ForeName>Angie S</ForeName><Initials>AS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Katzman</LastName><ForeName>Sol J</ForeName><Initials>SJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kern</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuhn</LastName><ForeName>Robert M</ForeName><Initials>RM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Przeworski</LastName><ForeName>Molly</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hernandez</LastName><ForeName>Ryan D</ForeName><Initials>RD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Howie</LastName><ForeName>Bryan</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kelley</LastName><ForeName>Joanna L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Melton</LastName><ForeName>S Cord</ForeName><Initials>SC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abecasis</LastName><ForeName>Gon&#xe7;alo R</ForeName><Initials>GR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Yun</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderson</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blackwell</LastName><ForeName>Tom</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Wei</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cookson</LastName><ForeName>William O</ForeName><Initials>WO</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ding</LastName><ForeName>Jun</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kang</LastName><ForeName>Hyun Min</ForeName><Initials>HM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lathrop</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liang</LastName><ForeName>Liming</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moffatt</LastName><ForeName>Miriam F</ForeName><Initials>MF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scheet</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sidore</LastName><ForeName>Carlo</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Snyder</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhan</LastName><ForeName>Xiaowei</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Z&#xf6;llner</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Awadalla</LastName><ForeName>Philip</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Casals</LastName><ForeName>Ferran</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Idaghdour</LastName><ForeName>Youssef</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Keebler</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stone</LastName><ForeName>Eric A</ForeName><Initials>EA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zilversmit</LastName><ForeName>Martine</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jorde</LastName><ForeName>Lynn</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xing</LastName><ForeName>Jinchuan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eichler</LastName><ForeName>Evan E</ForeName><Initials>EE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aksay</LastName><ForeName>Gozde</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alkan</LastName><ForeName>Can</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hajirasouliha</LastName><ForeName>Iman</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hormozdiari</LastName><ForeName>Fereydoun</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kidd</LastName><ForeName>Jeffrey M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sahinalp</LastName><ForeName>S Cenk</ForeName><Initials>SC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sudmant</LastName><ForeName>Peter H</ForeName><Initials>PH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mardis</LastName><ForeName>Elaine R</ForeName><Initials>ER</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Ken</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chinwalla</LastName><ForeName>Asif</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ding</LastName><ForeName>Li</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koboldt</LastName><ForeName>Daniel C</ForeName><Initials>DC</Initials></Investigator><Investigator ValidYN="Y"><LastName>McLellan</LastName><ForeName>Mike D</ForeName><Initials>MD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dooling</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weinstock</LastName><ForeName>George</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wallis</LastName><ForeName>John W</ForeName><Initials>JW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wendl</LastName><ForeName>Michael C</ForeName><Initials>MC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhang</LastName><ForeName>Qunyuan</ForeName><Initials>Q</Initials></Investigator><Investigator ValidYN="Y"><LastName>Durbin</LastName><ForeName>Richard M</ForeName><Initials>RM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albers</LastName><ForeName>Cornelis A</ForeName><Initials>CA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ayub</LastName><ForeName>Qasim</ForeName><Initials>Q</Initials></Investigator><Investigator ValidYN="Y"><LastName>Balasubramaniam</LastName><ForeName>Senduran</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barrett</LastName><ForeName>Jeffrey C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carter</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Conrad</LastName><ForeName>Donald F</ForeName><Initials>DF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Danecek</LastName><ForeName>Petr</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dermitzakis</LastName><ForeName>Emmanouil T</ForeName><Initials>ET</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hu</LastName><ForeName>Min</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huang</LastName><ForeName>Ni</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hurles</LastName><ForeName>Matt E</ForeName><Initials>ME</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jin</LastName><ForeName>Hanjun</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jostins</LastName><ForeName>Luke</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Keane</LastName><ForeName>Thomas M</ForeName><Initials>TM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Le</LastName><ForeName>Si Quang</ForeName><Initials>SQ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lindsay</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Long</LastName><ForeName>Quan</ForeName><Initials>Q</Initials></Investigator><Investigator ValidYN="Y"><LastName>MacArthur</LastName><ForeName>Daniel G</ForeName><Initials>DG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montgomery</LastName><ForeName>Stephen B</ForeName><Initials>SB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parts</LastName><ForeName>Leopold</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stalker</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tyler-Smith</LastName><ForeName>Chris</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walter</LastName><ForeName>Klaudia</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yujun</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gerstein</LastName><ForeName>Mark B</ForeName><Initials>MB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Snyder</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abyzov</LastName><ForeName>Alexej</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Balasubramanian</LastName><ForeName>Suganthi</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bjornson</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Du</LastName><ForeName>Jiang</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grubert</LastName><ForeName>Fabian</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Habegger</LastName><ForeName>Lukas</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haraksingh</LastName><ForeName>Rajini</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jee</LastName><ForeName>Justin</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khurana</LastName><ForeName>Ekta</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lam</LastName><ForeName>Hugo Y K</ForeName><Initials>HY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leng</LastName><ForeName>Jing</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mu</LastName><ForeName>Xinmeng Jasmine</ForeName><Initials>XJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Urban</LastName><ForeName>Alexander E</ForeName><Initials>AE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zhengdong</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Yingrui</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Luo</LastName><ForeName>Ruibang</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marth</LastName><ForeName>Gabor T</ForeName><Initials>GT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garrison</LastName><ForeName>Erik P</ForeName><Initials>EP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kural</LastName><ForeName>Deniz</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quinlan</LastName><ForeName>Aaron R</ForeName><Initials>AR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stewart</LastName><ForeName>Chip</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stromberg</LastName><ForeName>Michael P</ForeName><Initials>MP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ward</LastName><ForeName>Alistair N</ForeName><Initials>AN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wu</LastName><ForeName>Jiantao</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mills</LastName><ForeName>Ryan E</ForeName><Initials>RE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shi</LastName><ForeName>Xinghua</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCarroll</LastName><ForeName>Steven A</ForeName><Initials>SA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Banks</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>DePristo</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Handsaker</LastName><ForeName>Robert E</ForeName><Initials>RE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hartl</LastName><ForeName>Chris</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Korn</LastName><ForeName>Joshua M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Heng</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nemesh</LastName><ForeName>James C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sebat</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Makarov</LastName><ForeName>Vladimir</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ye</LastName><ForeName>Kenny</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yoon</LastName><ForeName>Seungtai C</ForeName><Initials>SC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Degenhardt</LastName><ForeName>Jeremiah</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaganovich</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clarke</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Richard E</ForeName><Initials>RE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zheng-Bradley</LastName><ForeName>Xiangqun</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Korbel</LastName><ForeName>Jan O</ForeName><Initials>JO</Initials></Investigator><Investigator ValidYN="Y"><LastName>Humphray</LastName><ForeName>Sean</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cheetham</LastName><ForeName>R Keira</ForeName><Initials>RK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eberle</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kahn</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Murray</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ye</LastName><ForeName>Kai</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>De La Vega</LastName><ForeName>Francisco M</ForeName><Initials>FM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fu</LastName><ForeName>Yutao</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peckham</LastName><ForeName>Heather E</ForeName><Initials>HE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sun</LastName><ForeName>Yongming A</ForeName><Initials>YA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Batzer</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Konkel</LastName><ForeName>Miriam K</ForeName><Initials>MK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walker</LastName><ForeName>Jerilyn A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xiao</LastName><ForeName>Chunlin</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Iqbal</LastName><ForeName>Zamin</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Desany</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blackwell</LastName><ForeName>Tom</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Snyder</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xing</LastName><ForeName>Jinchuan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eichler</LastName><ForeName>Evan E</ForeName><Initials>EE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aksay</LastName><ForeName>Gozde</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alkan</LastName><ForeName>Can</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hajirasouliha</LastName><ForeName>Iman</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hormozdiari</LastName><ForeName>Fereydoun</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kidd</LastName><ForeName>Jeffrey M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Ken</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chinwalla</LastName><ForeName>Asif</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ding</LastName><ForeName>Li</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>McLellan</LastName><ForeName>Mike D</ForeName><Initials>MD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wallis</LastName><ForeName>John W</ForeName><Initials>JW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hurles</LastName><ForeName>Matt E</ForeName><Initials>ME</Initials></Investigator><Investigator ValidYN="Y"><LastName>Conrad</LastName><ForeName>Donald F</ForeName><Initials>DF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walter</LastName><ForeName>Klaudia</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yujun</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gerstein</LastName><ForeName>Mark B</ForeName><Initials>MB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Snyder</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abyzov</LastName><ForeName>Alexej</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Du</LastName><ForeName>Jiang</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grubert</LastName><ForeName>Fabian</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haraksingh</LastName><ForeName>Rajini</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jee</LastName><ForeName>Justin</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khurana</LastName><ForeName>Ekta</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lam</LastName><ForeName>Hugo Y K</ForeName><Initials>HY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leng</LastName><ForeName>Jing</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mu</LastName><ForeName>Xinmeng Jasmine</ForeName><Initials>XJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Urban</LastName><ForeName>Alexander E</ForeName><Initials>AE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zhengdong</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gibbs</LastName><ForeName>Richard A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bainbridge</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Challis</LastName><ForeName>Danny</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coafra</LastName><ForeName>Cristian</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dinh</LastName><ForeName>Huyen</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kovar</LastName><ForeName>Christie</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Sandy</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Muzny</LastName><ForeName>Donna</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nazareth</LastName><ForeName>Lynne</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reid</LastName><ForeName>Jeff</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sabo</LastName><ForeName>Aniko</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yu</LastName><ForeName>Fuli</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yu</LastName><ForeName>Jin</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marth</LastName><ForeName>Gabor T</ForeName><Initials>GT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garrison</LastName><ForeName>Erik P</ForeName><Initials>EP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Indap</LastName><ForeName>Amit</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leong</LastName><ForeName>Wen Fung</ForeName><Initials>WF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quinlan</LastName><ForeName>Aaron R</ForeName><Initials>AR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stewart</LastName><ForeName>Chip</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ward</LastName><ForeName>Alistair N</ForeName><Initials>AN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wu</LastName><ForeName>Jiantao</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cibulskis</LastName><ForeName>Kristian</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fennell</LastName><ForeName>Tim J</ForeName><Initials>TJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gabriel</LastName><ForeName>Stacey B</ForeName><Initials>SB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garimella</LastName><ForeName>Kiran V</ForeName><Initials>KV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hartl</LastName><ForeName>Chris</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shefler</LastName><ForeName>Erica</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sougnez</LastName><ForeName>Carrie L</ForeName><Initials>CL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilkinson</LastName><ForeName>Jane</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clark</LastName><ForeName>Andrew G</ForeName><Initials>AG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gravel</LastName><ForeName>Simon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grubert</LastName><ForeName>Fabian</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clarke</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flicek</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Richard E</ForeName><Initials>RE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zheng-Bradley</LastName><ForeName>Xiangqun</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sherry</LastName><ForeName>Stephen T</ForeName><Initials>ST</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khouri</LastName><ForeName>Hoda M</ForeName><Initials>HM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paschall</LastName><ForeName>Justin E</ForeName><Initials>JE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shumway</LastName><ForeName>Martin F</ForeName><Initials>MF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xiao</LastName><ForeName>Chunlin</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>McVean</LastName><ForeName>Gil A</ForeName><Initials>GA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Katzman</LastName><ForeName>Sol J</ForeName><Initials>SJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abecasis</LastName><ForeName>Gon&#xe7;alo R</ForeName><Initials>GR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mardis</LastName><ForeName>Elaine R</ForeName><Initials>ER</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dooling</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fulton</LastName><ForeName>Lucinda</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fulton</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koboldt</LastName><ForeName>Daniel C</ForeName><Initials>DC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Durbin</LastName><ForeName>Richard M</ForeName><Initials>RM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Balasubramaniam</LastName><ForeName>Senduran</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coffey</LastName><ForeName>Allison</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Keane</LastName><ForeName>Thomas M</ForeName><Initials>TM</Initials></Investigator><Investigator ValidYN="Y"><LastName>MacArthur</LastName><ForeName>Daniel G</ForeName><Initials>DG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Palotie</LastName><ForeName>Aarno</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scott</LastName><ForeName>Carol</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stalker</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tyler-Smith</LastName><ForeName>Chris</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gerstein</LastName><ForeName>Mark B</ForeName><Initials>MB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Balasubramanian</LastName><ForeName>Suganthi</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chakravarti</LastName><ForeName>Aravinda</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Knoppers</LastName><ForeName>Bartha M</ForeName><Initials>BM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abecasis</LastName><ForeName>Gon&#xe7;alo R</ForeName><Initials>GR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bustamante</LastName><ForeName>Carlos D</ForeName><Initials>CD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gharani</LastName><ForeName>Neda</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gibbs</LastName><ForeName>Richard A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jorde</LastName><ForeName>Lynn</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaye</LastName><ForeName>Jane S</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kent</LastName><ForeName>Alastair</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Taosha</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>McGuire</LastName><ForeName>Amy L</ForeName><Initials>AL</Initials></Investigator><Investigator ValidYN="Y"><LastName>McVean</LastName><ForeName>Gil A</ForeName><Initials>GA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ossorio</LastName><ForeName>Pilar N</ForeName><Initials>PN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rotimi</LastName><ForeName>Charles N</ForeName><Initials>CN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Su</LastName><ForeName>Yeyang</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toji</LastName><ForeName>Lorraine H</ForeName><Initials>LH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tyler-Smith</LastName><ForeName>Chris</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brooks</LastName><ForeName>Lisa D</ForeName><Initials>LD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Felsenfeld</LastName><ForeName>Adam L</ForeName><Initials>AL</Initials></Investigator><Investigator ValidYN="Y"><LastName>McEwen</LastName><ForeName>Jean E</ForeName><Initials>JE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abdallah</LastName><ForeName>Assya</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Juenger</LastName><ForeName>Christopher R</ForeName><Initials>CR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clemm</LastName><ForeName>Nicholas C</ForeName><Initials>NC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Collins</LastName><ForeName>Francis S</ForeName><Initials>FS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duncanson</LastName><ForeName>Audrey</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Green</LastName><ForeName>Eric D</ForeName><Initials>ED</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guyer</LastName><ForeName>Mark S</ForeName><Initials>MS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peterson</LastName><ForeName>Jane L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schafer</LastName><ForeName>Alan J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xue</LastName><ForeName>Yali</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cartwright</LastName><ForeName>Reed A</ForeName><Initials>RA</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20981092</ArticleId><ArticleId IdType="mid">UKMS34220</ArticleId><ArticleId IdType="pmc">PMC3042601</ArticleId><ArticleId IdType="doi">10.1038/nature09534</ArticleId><ArticleId IdType="pii">nature09534</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>The International Human Genome Sequencing Consortium Finishing the euchromatic sequence of the human genome. Nature. 2004;431:931&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">15496913</ArticleId></ArticleIdList></Reference><Reference><Citation>Sachidanandam R, et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature. 2001;409:928&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">11237013</ArticleId></ArticleIdList></Reference><Reference><Citation>The International HapMap Consortium A haplotype map of the human genome. Nature. 2005;437:1299&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1880871</ArticleId><ArticleId IdType="pubmed">16255080</ArticleId></ArticleIdList></Reference><Reference><Citation>The International HapMap Consortium A second generation human haplotype map of over 3.1 million SNPs. Nature. 2007;449:851&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2689609</ArticleId><ArticleId IdType="pubmed">17943122</ArticleId></ArticleIdList></Reference><Reference><Citation>NHGRI Office of Population Genomics A catalog of published genome-wide association studies. 2010</Citation></Reference><Reference><Citation>Craddock N, et al. Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature. 2010;464:713&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2892339</ArticleId><ArticleId IdType="pubmed">20360734</ArticleId></ArticleIdList></Reference><Reference><Citation>Manolio TA, et al. Finding the missing heritability of complex diseases. Nature. 2009;461:747&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2831613</ArticleId><ArticleId IdType="pubmed">19812666</ArticleId></ArticleIdList></Reference><Reference><Citation>Nejentsev S, Walker N, Riches D, Egholm M, Todd JA. Rare variants of IFIH1, a gene implicated in antiviral responses, protect against type 1 diabetes. Science. 2009;324:387&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2707798</ArticleId><ArticleId IdType="pubmed">19264985</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen JC, Boerwinkle E, Mosley TH, Jr., Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">16554528</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy S, et al. The diploid genome sequence of an individual human. PLoS Biol. 2007;5:e254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1964779</ArticleId><ArticleId IdType="pubmed">17803354</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheeler DA, et al. The complete genome of an individual by massively parallel DNA sequencing. Nature. 2008;452:872&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">18421352</ArticleId></ArticleIdList></Reference><Reference><Citation>Bentley DR, et al. Accurate whole human genome sequencing using reversible terminator chemistry. Nature. 2008;456:53&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2581791</ArticleId><ArticleId IdType="pubmed">18987734</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, et al. The diploid genome sequence of an Asian individual. Nature. 2008;456:60&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2716080</ArticleId><ArticleId IdType="pubmed">18987735</ArticleId></ArticleIdList></Reference><Reference><Citation>The International HapMap 3 Consortium Integrating common and rare genetic variation in diverse human populations. Nature. 2010 In press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3173859</ArticleId><ArticleId IdType="pubmed">20811451</ArticleId></ArticleIdList></Reference><Reference><Citation>Liti G, et al. Population genomics of domestic and wild yeasts. Nature. 2009;458:337&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2659681</ArticleId><ArticleId IdType="pubmed">19212322</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Willer C, Sanna S, Abecasis G. Genotype imputation. Annu Rev Genomics Hum Genet. 2009;10:387&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2925172</ArticleId><ArticleId IdType="pubmed">19715440</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009;25:2078&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2723002</ArticleId><ArticleId IdType="pubmed">19505943</ArticleId></ArticleIdList></Reference><Reference><Citation>Albers C, et al. Dindel: Accurate indel calls from short read data. Genome Res. 2010 submitted.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3106329</ArticleId><ArticleId IdType="pubmed">20980555</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam HY, et al. Nucleotide-resolution analysis of structural variants using BreakSeq and a breakpoint library. Nat Biotechnol. 2010;28:47&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2951730</ArticleId><ArticleId IdType="pubmed">20037582</ArticleId></ArticleIdList></Reference><Reference><Citation>Conrad DF, et al. Origins and functional impact of copy number variation in the human genome. Nature. 2010;464:704&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3330748</ArticleId><ArticleId IdType="pubmed">19812545</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin JA, et al. Investigation of heteroplasmy in the human mitochondrial DNA control region: a synthesis of observations from more than 5000 global population samples. J Mol Evol. 2009;68:516&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">19407924</ArticleId></ArticleIdList></Reference><Reference><Citation>Balaresque P, et al. A predominantly neolithic origin for European paternal lineages. PLoS Biol. 2010;8:e1000285.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2799514</ArticleId><ArticleId IdType="pubmed">20087410</ArticleId></ArticleIdList></Reference><Reference><Citation>Wendl MC, Wilson RK. The theory of discovering rare variants via DNA sequencing. BMC Genomics. 2009;10:485.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2778663</ArticleId><ArticleId IdType="pubmed">19843339</ArticleId></ArticleIdList></Reference><Reference><Citation>Quang LS, Li H, Durbin R. QCALL: A genealogical method for variant detection and genotyping from low coverage sequence data in population samples. Genome Res. submitted.</Citation></Reference><Reference><Citation>Seattle SNPs NHLBI Program for Genomic Applications. 2010 SeattleSNPs.</Citation></Reference><Reference><Citation>Xing J, et al. Mobile elements create structural variation: analysis of a complete human genome. Genome Res. 2009;19:1516&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2752133</ArticleId><ArticleId IdType="pubmed">19439515</ArticleId></ArticleIdList></Reference><Reference><Citation>Stranger BE, et al. Population genomics of human gene expression. Nat Genet. 2007;39:1217&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2683249</ArticleId><ArticleId IdType="pubmed">17873874</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR. MaCH: Using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genet. Epi. 2010;32:1&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3175618</ArticleId><ArticleId IdType="pubmed">21058334</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchini J, Howie B. Genotype imputation for genome-wide association studies. Nat Rev Genet. 2010;11:499&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pubmed">20517342</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixon AL, et al. A genome-wide association study of global gene expression. Nature Genetics. 2007;39:1202&#x2013;07.</Citation><ArticleIdList><ArticleId IdType="pubmed">17873877</ArticleId></ArticleIdList></Reference><Reference><Citation>Genovese G. Association of Trypanolytic ApoL1 Variants with Kidney Disease in African-Americans. Science. 2010</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2980843</ArticleId><ArticleId IdType="pubmed">20647424</ArticleId></ArticleIdList></Reference><Reference><Citation>Nachman MW, Crowell SL. Estimate of the mutation rate per nucleotide in humans. Genetics. 2000;156:297&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1461236</ArticleId><ArticleId IdType="pubmed">10978293</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondrashov AS. Direct estimates of human per nucleotide mutation rates at 20 loci causing Mendelian diseases. Hum Mutat. 2003;21:12&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">12497628</ArticleId></ArticleIdList></Reference><Reference><Citation>Roach JC, et al. Analysis of genetic inheritance in a family quartet by whole-genome sequencing. Science. 2010;328:636&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3037280</ArticleId><ArticleId IdType="pubmed">20220176</ArticleId></ArticleIdList></Reference><Reference><Citation>Charlesworth B, Morgan MT, Charlesworth D. The effect of deleterious mutations on neutral molecular variation. Genetics. 1993;134:1289&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1205596</ArticleId><ArticleId IdType="pubmed">8375663</ArticleId></ArticleIdList></Reference><Reference><Citation>Maynard Smith J, Haigh J. The hitch-hiking effect of a favourable gene. Genet Res. 1974;23:23&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">4407212</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai JJ, Macpherson JM, Sella G, Petrov DA. Pervasive hitchhiking at coding and regulatory sites in humans. PLoS Genet. 2009;5:e1000336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2613029</ArticleId><ArticleId IdType="pubmed">19148272</ArticleId></ArticleIdList></Reference><Reference><Citation>Voight BF, Kudaravalli S, Wen X, Pritchard JK. A map of recent positive selection in the human genome. PLoS Biol. 2006;4:e72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1382018</ArticleId><ArticleId IdType="pubmed">16494531</ArticleId></ArticleIdList></Reference><Reference><Citation>Barreiro LB, Laval G, Quach H, Patin E, Quintana-Murci L. Natural selection has driven population differentiation in modern humans. Nat Genet. 2008;40:340&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">18246066</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamason RL, et al. SLC24A5, a putative cation exchanger, affects pigmentation in zebrafish and humans. Science. 2005;310:1782&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">16357253</ArticleId></ArticleIdList></Reference><Reference><Citation>Tournamille C, Colin Y, Cartron JP, Le Van Kim C. Disruption of a GATA motif in the Duffy gene promoter abolishes erythroid gene expression in Duffy-negative individuals. Nat Genet. 1995;10:224&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">7663520</ArticleId></ArticleIdList></Reference><Reference><Citation>Myers S, et al. Drive against hotspot motifs in primates implicates the PRDM9 gene in meiotic recombination. Science. 2010;327:876&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3828505</ArticleId><ArticleId IdType="pubmed">20044541</ArticleId></ArticleIdList></Reference><Reference><Citation>Myers S, Freeman C, Auton A, Donnelly P, McVean G. A common sequence motif associated with recombination hot spots and genome instability in humans. Nat Genet. 2008;40:1124&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19165926</ArticleId></ArticleIdList></Reference><Reference><Citation>Baudat F, et al. PRDM9 is a major determinant of meiotic recombination hotspots in humans and mice. Science. 2010;327:836&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4295902</ArticleId><ArticleId IdType="pubmed">20044539</ArticleId></ArticleIdList></Reference><Reference><Citation>Parvanov ED, Petkov PM, Paigen K. Prdm9 controls activation of mammalian recombination hotspots. Science. 2010;327:835.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2821451</ArticleId><ArticleId IdType="pubmed">20044538</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu JZ, et al. Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nat Genet. 2010;42:436&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3612983</ArticleId><ArticleId IdType="pubmed">20418889</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanna S, et al. Variants within the immunoregulatory CBLB gene are associated with multiple sclerosis. Nat Genet. 2010;42:495&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3786343</ArticleId><ArticleId IdType="pubmed">20453840</ArticleId></ArticleIdList></Reference><Reference><Citation>Musunuru K, Kathiresan S. Exome Sequencing Identifies ANGPTL3 as a Cause of Familial Combined Hypolipidemia. New Engl. J. Med. In review.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3008575</ArticleId><ArticleId IdType="pubmed">20942659</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewing AD, Kazazian HH., Jr. High-throughput sequencing reveals extensive variation in human-specific L1 content in individual human genomes. Genome Res. 2010</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2928504</ArticleId><ArticleId IdType="pubmed">20488934</ArticleId></ArticleIdList></Reference><Reference><Citation>Mills RE, et al. An initial map of insertion and deletion (INDEL) variation in the human genome. Genome Res. 2006;16:1182&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1557762</ArticleId><ArticleId IdType="pubmed">16902084</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">2105469</PMID><DateCompleted><Year>1990</Year><Month>03</Month><Day>05</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-0836</ISSN><JournalIssue CitedMedium="Print"><Volume>343</Volume><Issue>6257</Issue><PubDate><Year>1990</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Inhibition of neurite polarity by tau antisense oligonucleotides in primary cerebellar neurons.</ArticleTitle><Pagination><StartPage>461</StartPage><EndPage>463</EndPage><MedlinePgn>461-3</MedlinePgn></Pagination><Abstract><AbstractText>Neurons in culture can have fundamentally distinct morphologies which permit their cytological identification and the recognition of their neurites as axons or dendrites. Microtubules may have a role in determining morphology by the selective stabilization of spatially distinct microtubule subsets. The plasticity of a neurite correlates inversely with the stability of its component microtubules: microtubules in growth cones are very dynamic, and in initial neurites there is continuous incorporation of labelled subunits, whereas in mature neurites, microtubules are highly stabilized. The binding of microtubule-associated proteins to the microtubules very probably contributes to this stability. Cerebellar neurons in dissociated culture initially extend exploratory neurites and, after a relatively constant interval, become polarized. Polarity becomes evident when a single neurite exceeds the others in length. These stable neurites cease to undergo the retractions and extensions characteristic of initial neurites and assume many features of axons and dendrites. We have now studied the role of the neuronal microtubule-associate protein tau in neurite polarization by selectively inhibiting tau expression by the addition of antisense oligonucleotides to the culture media. Although the extension of initial exploratory neurites occurred normally, neurite asymmetry was inhibited by the failure to elaborate an axon.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Caceres</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kosik</LastName><ForeName>K S</ForeName><Initials>KS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008869">Microtubule-Associated Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009841">Oligonucleotides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016376">Oligonucleotides, Antisense</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-49-2</RegistryNumber><NameOfSubstance UI="D004247">DNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002531" MajorTopicYN="N">Cerebellum</DescriptorName><QualifierName UI="Q000196" MajorTopicYN="N">embryology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008869" MajorTopicYN="N">Microtubule-Associated Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009841" MajorTopicYN="N">Oligonucleotides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016376" MajorTopicYN="N">Oligonucleotides, Antisense</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1990</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1990</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1990</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2105469</ArticleId><ArticleId IdType="doi">10.1038/343461a0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21059989</PMID><DateCompleted><Year>2011</Year><Month>05</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1538-3687</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>3</Issue><PubDate><Year>2011</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Identification of novel loci for Alzheimer disease and replication of CLU, PICALM, and BIN1 in Caribbean Hispanic individuals.</ArticleTitle><Pagination><StartPage>320</StartPage><EndPage>328</EndPage><MedlinePgn>320-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/archneurol.2010.292</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To identify novel loci for late-onset Alzheimer disease (LOAD) in Caribbean Hispanic individuals and to replicate the findings in a publicly available data set from the National Institute on Aging Late-Onset Alzheimer's Disease Family Study.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Nested case-control genome-wide association study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">The Washington Heights-Inwood Columbia Aging Project and the Estudio Familiar de Influencia Genetica de Alzheimer study.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Five hundred forty-nine affected and 544 unaffected individuals of Caribbean Hispanic ancestry.</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="METHODS">The Illumina HumanHap 650Y chip for genotyping.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURE" NlmCategory="METHODS">Clinical diagnosis or pathologically confirmed diagnosis of LOAD.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The strongest support for allelic association was for rs9945493 on 18q23 (P=1.7&#xd7;10(-7)), but 22 additional single-nucleotide polymorphisms (SNPs) had a P value less than 9&#xd7;10(-6) under 3 different analyses: unadjusted and stratified by the presence or absence of the APOE &#x3b5;4 allele. Of these SNPs, 5 SNPs (rs4669573 and rs10197851 on 2p25.1; rs11711889 on 3q25.2; rs1117750 on 7p21.1; and rs7908652 on 10q23.1) were associated with LOAD in an independent cohort from the National Institute on Aging Late-Onset Alzheimer's Disease Family Study. We also replicated genetic associations for CLU, PICALM, and BIN1.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our genome-wide search of Caribbean Hispanic individuals identified several novel genetic variants associated with LOAD and replicated these associations in a white cohort. We also replicated associations in CLU, PICALM, and BIN1 in the Caribbean Hispanic cohort.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Joseph H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer&#x2019;s Disease and the Aging Brain, Gertrude H Sergievsky Center, 630 W 168th St, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Rong</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Barral</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Reitz</LastName><ForeName>Christiane</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Medrano</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Lantigua</LastName><ForeName>Rafael</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Jim&#xe9;nez-Velazquez</LastName><ForeName>Ivonne Z</ForeName><Initials>IZ</Initials></Author><Author ValidYN="Y"><LastName>Rogaeva</LastName><ForeName>Ekaterina</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>St George-Hyslop</LastName><ForeName>Peter H</ForeName><Initials>PH</Initials></Author><Author ValidYN="Y"><LastName>Mayeux</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>CAPMC</Acronym><Agency> CIHR</Agency><Country>Canada</Country></Grant><Grant><GrantID>P01 AG007232</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23AG034550</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG015473</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37-AG15473</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG037212</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG036040</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>081864</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG034550</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>P01-AG07232</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>11</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C101410">BIN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C495242">CLU protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051152">Clusterin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034041">Monomeric Clathrin Assembly Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C439003">PICALM protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D025521">Tumor Suppressor Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D048868" MajorTopicYN="N">Adaptor Proteins, Signal Transducing</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044383" MajorTopicYN="N">Black People</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017691" MajorTopicYN="N" Type="Geographic">Caribbean Region</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051152" MajorTopicYN="N">Clusterin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003627" MajorTopicYN="N">Data Interpretation, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006630" MajorTopicYN="N">Hispanic or Latino</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034041" MajorTopicYN="N">Monomeric Clathrin Assembly Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009687" MajorTopicYN="N">Nuclear Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D025521" MajorTopicYN="N">Tumor Suppressor Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044465" MajorTopicYN="N">White People</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>11</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>11</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>1</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21059989</ArticleId><ArticleId IdType="mid">NIHMS349814</ArticleId><ArticleId IdType="pmc">PMC3268783</ArticleId><ArticleId IdType="doi">10.1001/archneurol.2010.292</ArticleId><ArticleId IdType="pii">archneurol.2010.292</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abraham R, Moskvina V, Sims R, et al. A genome-wide association study for late-onset Alzheimer&#x2019;s disease using DNA pooling. BMC Med Genomics. 2008;1:44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2570675</ArticleId><ArticleId IdType="pubmed">18823527</ArticleId></ArticleIdList></Reference><Reference><Citation>Beecham GW, Martin ER, Li YJ, et al. Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease. Am J Hum Genet. 2009;84(1):35&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2668056</ArticleId><ArticleId IdType="pubmed">19118814</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L, Lange C, Mullin K, et al. Genome-wide association analysis reveals putative Alzheimer&#x2019;s disease susceptibility loci in addition to APOE. Am J Hum Genet. 2008;83(5):623&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2668052</ArticleId><ArticleId IdType="pubmed">18976728</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrasquillo MM, Zou F, Pankratz VS, et al. Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer&#x2019;s disease. Nat Genet. 2009;41(2):192&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2873177</ArticleId><ArticleId IdType="pubmed">19136949</ArticleId></ArticleIdList></Reference><Reference><Citation>Coon KD, Myers AJ, Craig DW, et al. A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer&#x2019;s disease. J Clin Psychiatry. 2007;68(4):613&#x2013;618.</Citation><ArticleIdList><ArticleId IdType="pubmed">17474819</ArticleId></ArticleIdList></Reference><Reference><Citation>Feulner TM, Laws SM, Friedrich P, et al. Examination of the current top candidate genes for AD in a genome-wide association study. Mol Psychiatry. 2010;15(7):756&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">19125160</ArticleId></ArticleIdList></Reference><Reference><Citation>Harold D, Abraham R, Hollingworth P, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer&#x2019;s disease. Nat Genet. 2009;41(10):1088&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845877</ArticleId><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinzen EL, Need AC, Hayden KM, et al. Genome-wide scan of copy number variation in late-onset Alzheimer&#x2019;s disease [published online September 11, 2009] J Alzheimers Dis</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2883723</ArticleId><ArticleId IdType="pubmed">20061627</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Heath S, Even G, et al. European Alzheimer&#x2019;s Disease Initiative Investigators. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer&#x2019;s disease. Nat Genet. 2009;41(10):1094&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Wetten S, Li L, et al. Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch Neurol. 2008;65(1):45&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">17998437</ArticleId></ArticleIdList></Reference><Reference><Citation>Poduslo SE, Huang R, Huang J, Smith S. Genome screen of late-onset Alzheimer&#x2019;s extended pedigrees identifies TRPC4AP by haplotype analysis. Am J Med Genet B Neuropsychiatr Genet. 2009;150B(1):50&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">18449908</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Webster JA, Myers AJ, et al. GAB2 alleles modify Alzheimer&#x2019;s risk in APOE epsilon4 carriers. Neuron. 2007;54(5):713&#x2013;720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2587162</ArticleId><ArticleId IdType="pubmed">17553421</ArticleId></ArticleIdList></Reference><Reference><Citation>Seshadri S, Fitzpatrick AL, Ikram MA, et al. CHARGE Consortium; GERAD1 Consortium; EADI1 Consortium. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA. 2010;303(18):1832&#x2013;1840.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2989531</ArticleId><ArticleId IdType="pubmed">20460622</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouwers N, Sleegers K, Van Broeckhoven C. Molecular genetics of Alzheimer&#x2019;s disease: an update. Ann Med. 2008;40(8):562&#x2013;583.</Citation><ArticleIdList><ArticleId IdType="pubmed">18608129</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleegers K, Lambert JC, Bertram L, Cruts M, Amouyel P, Van Broeckhoven C. The pursuit of susceptibility genes for Alzheimer&#x2019;s disease: progress and prospects. Trends Genet. 2010;26(2):84&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">20080314</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogaeva E, Meng Y, Lee JH, et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet. 2007;39(2):168&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2657343</ArticleId><ArticleId IdType="pubmed">17220890</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitz C, Cheng R, Rogaeva E, et al. Meta-analysis of the association between variants in SORL1 and Alzheimer disease. Arch Neurol. 2011;68(1):99&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3086666</ArticleId><ArticleId IdType="pubmed">21220680</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatz M, Reynolds CA, Fratiglioni L, et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry. 2006;63(2):168&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">16461860</ArticleId></ArticleIdList></Reference><Reference><Citation>Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. Nature. 2009;461(7265):747&#x2013;753.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2831613</ArticleId><ArticleId IdType="pubmed">19812666</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy MI. Exploring the unknown: assumptions about allelic architecture and strategies for susceptibility variant discovery. Genome Med. 2009;1(7):66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2717392</ArticleId><ArticleId IdType="pubmed">19591663</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang MX, Stern Y, Marder K, et al. The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA. 1998;279(10):751&#x2013;755.</Citation><ArticleIdList><ArticleId IdType="pubmed">9508150</ArticleId></ArticleIdList></Reference><Reference><Citation>Romas SN, Santana V, Williamson J, et al. Familial Alzheimer disease among Caribbean Hispanics: a reexamination of its association with APOE. Arch Neurol. 2002;59(1):87&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">11790235</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y, Andrews H, Pittman J, et al. Diagnosis of dementia in a heterogeneous population: development of a neuropsychological paradigm-based diagnosis of dementia and quantified correction for the effects of education. Arch Neurol. 1992;49(5):453&#x2013;460.</Citation><ArticleIdList><ArticleId IdType="pubmed">1580806</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan E, Goodglass H, Weintraub S. Boston Naming Test. Philadelphia, PA: Lea &amp; Febiger; 1983.</Citation></Reference><Reference><Citation>Benton A. FAS Test. In: Spreen O, Benton A, editors. Neurosensory Center Comprehensive Examination for Aphasia. Victoria, BC, Canada: University of Victoria; 1967.</Citation></Reference><Reference><Citation>Goodglass H, Kaplan E. The Assessment of Aphasia and Related Disorders. 2nd ed. Philadelphia, PA: Lea &amp; Febiger; 1983.</Citation></Reference><Reference><Citation>Wechsler D. WAIS-R Manual. New York, NY: The Psychological Corp; 1981.</Citation></Reference><Reference><Citation>Mattis S. Mental status examination for organic mental syndrome in the elderly patient. In: Bellak L, Karasu T, editors. Geriatric Psychiatry. New York, NY: Grune &amp; Statton; 1976.</Citation></Reference><Reference><Citation>Rosen W. The Rosen Drawing Test. Bronx, NY: Veterans Administration Medical Center; 1981.</Citation></Reference><Reference><Citation>Benton AL. The Benton Visual Retention Test. New York, NY: The Psychological Corp; 1955.</Citation></Reference><Reference><Citation>Buschke H, Fuld PA. Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology. 1974;24(11):1019&#x2013;1025.</Citation><ArticleIdList><ArticleId IdType="pubmed">4473151</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34(7):939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartl DL, Clark AG. Principles of Population Genetics. 4th ed. Sunderland, MA: Sinauer Associates; 2007.</Citation></Reference><Reference><Citation>Pritchard JK, Stephens M, Donnelly P. Inference of population structure using multilocus genotype data. Genetics. 2000;155(2):945&#x2013;959.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1461096</ArticleId><ArticleId IdType="pubmed">10835412</ArticleId></ArticleIdList></Reference><Reference><Citation>Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81(3):559&#x2013;575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1950838</ArticleId><ArticleId IdType="pubmed">17701901</ArticleId></ArticleIdList></Reference><Reference><Citation>Pacini A, Toscano A, Cesati V, et al. NAPOR-3 RNA binding protein is required for apoptosis in hippocampus. Brain Res Mol Brain Res. 2005;140(1&#x2013;2):34&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">16095752</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamide K, Kokubo Y, Yang J, et al. Hypertension susceptibility genes on chromosome 2p24&#x2013;p25 in a general Japanese population. J Hypertens. 2005;23(5):955&#x2013;960.</Citation><ArticleIdList><ArticleId IdType="pubmed">15834280</ArticleId></ArticleIdList></Reference><Reference><Citation>Grupe A, Li Y, Rowland C, et al. A scan of chromosome 10 identifies a novel locus showing strong association with late-onset Alzheimer disease. Am J Hum Genet. 2006;78(1):78&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1380225</ArticleId><ArticleId IdType="pubmed">16385451</ArticleId></ArticleIdList></Reference><Reference><Citation>Tycko B, Feng L, Nguyen L, et al. Polymorphisms in the human apolipoprotein-J/clusterin gene: ethnic variation and distribution in Alzheimer&#x2019;s disease. Hum Genet. 1996;98(4):430&#x2013;436.</Citation><ArticleIdList><ArticleId IdType="pubmed">8792817</ArticleId></ArticleIdList></Reference><Reference><Citation>Bushlin I, Petralia RS, Wu F, et al. Clathrin assembly protein AP180 and CALM differentially control axogenesis and dendrite outgrowth in embryonic hippocampal neurons. J Neurosci. 2008;28(41):10257&#x2013;10271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2581865</ArticleId><ArticleId IdType="pubmed">18842885</ArticleId></ArticleIdList></Reference><Reference><Citation>Harel A, Wu F, Mattson MP, Morris CM, Yao PJ. Evidence for CALM in directing VAMP2 trafficking. Traffic. 2008;9(3):417&#x2013;429.</Citation><ArticleIdList><ArticleId IdType="pubmed">18182011</ArticleId></ArticleIdList></Reference><Reference><Citation>Luchsinger JA, Reitz C, Honig LS, Tang MX, Shea S, Mayeux R. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology. 2005;65(4):545&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1619350</ArticleId><ArticleId IdType="pubmed">16116114</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen NL. Reaching the limits of genome-wide significance in Alzheimer disease: back to the environment. JAMA. 2010;303(18):1864&#x2013;1865.</Citation><ArticleIdList><ArticleId IdType="pubmed">20460629</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">2110384</PMID><DateCompleted><Year>1990</Year><Month>06</Month><Day>07</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0036-8075</ISSN><JournalIssue CitedMedium="Print"><Volume>248</Volume><Issue>4956</Issue><PubDate><Year>1990</Year><Month>May</Month><Day>11</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Protease nexin-II (amyloid beta-protein precursor): a platelet alpha-granule protein.</ArticleTitle><Pagination><StartPage>745</StartPage><EndPage>748</EndPage><MedlinePgn>745-8</MedlinePgn></Pagination><Abstract><AbstractText>Protease nexin-II (PN-II) [amyloid beta-protein precursor (APP)] and the amyloid beta-protein are major constituents of neuritic plaques and cerebrovascular deposits in individuals with Alzheimer's disease and Down syndrome. Both the brain and the circulation have been implicated as sources of these molecules, although they have not been detected in blood. Human platelets have now been found to contain relatively large amounts of PN-II/APP. Platelet PN-II/APP was localized in platelet alpha-granules and was secreted upon platelet activation. Because PN-II/APP is a potent protease inhibitor and possesses growth factor activity, these results implicate PN-II/APP in wound repair. In certain disease states, alterations in platelet release and processing and clearance of PN-II/APP and its derived fragments could lead to pathological accumulation of these proteins.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Van Nostrand</LastName><ForeName>W E</ForeName><Initials>WE</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Molecular Genetics, University of California, Irvine 92717.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmaier</LastName><ForeName>A H</ForeName><Initials>AH</Initials></Author><Author ValidYN="Y"><LastName>Farrow</LastName><ForeName>J S</ForeName><Initials>JS</Initials></Author><Author ValidYN="Y"><LastName>Cunningham</LastName><ForeName>D D</ForeName><Initials>DD</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>GM-31609</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL01615</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL35553</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015849">Plasminogen Inactivators</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011498">Protein Precursors</NameOfSubstance></Chemical><Chemical><RegistryNumber>62229-50-9</RegistryNumber><NameOfSubstance UI="D004815">Epidermal Growth Factor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001792" MajorTopicYN="N">Blood Platelets</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002458" MajorTopicYN="N">Cell Fractionation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003594" MajorTopicYN="N">Cytoplasmic Granules</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004815" MajorTopicYN="N">Epidermal Growth Factor</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015151" MajorTopicYN="N">Immunoblotting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015849" MajorTopicYN="N">Plasminogen Inactivators</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015539" MajorTopicYN="N">Platelet Activation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011498" MajorTopicYN="N">Protein Precursors</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1990</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1990</Year><Month>5</Month><Day>11</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1990</Year><Month>5</Month><Day>11</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2110384</ArticleId><ArticleId IdType="doi">10.1126/science.2110384</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21113149</PMID><DateCompleted><Year>2011</Year><Month>02</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>469</Volume><Issue>7328</Issue><PubDate><Year>2011</Year><Month>Jan</Month><Day>06</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Reversing EphB2 depletion rescues cognitive functions in Alzheimer model.</ArticleTitle><Pagination><StartPage>47</StartPage><EndPage>52</EndPage><MedlinePgn>47-52</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature09635</ELocationID><Abstract><AbstractText>Amyloid-&#x3b2; oligomers may cause cognitive deficits in Alzheimer's disease by impairing neuronal NMDA-type glutamate receptors, whose function is regulated by the receptor tyrosine kinase EphB2. Here we show that amyloid-&#x3b2; oligomers bind to the fibronectin repeats domain of EphB2 and trigger EphB2 degradation in the proteasome. To determine the pathogenic importance of EphB2 depletions in Alzheimer's disease and related models, we used lentiviral constructs to reduce or increase neuronal expression of EphB2 in memory centres of the mouse brain. In nontransgenic mice, knockdown of EphB2 mediated by short hairpin RNA reduced NMDA receptor currents and impaired long-term potentiation in the dentate gyrus, which are important for memory formation. Increasing EphB2 expression in the dentate gyrus of human amyloid precursor protein transgenic mice reversed deficits in NMDA receptor-dependent long-term potentiation and memory impairments. Thus, depletion of EphB2 is critical in amyloid-&#x3b2;-induced neuronal dysfunction. Increasing EphB2 levels or function could be beneficial in Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ciss&#xe9;</LastName><ForeName>Moustapha</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, California 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halabisky</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Harris</LastName><ForeName>Julie</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Devidze</LastName><ForeName>Nino</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Dubal</LastName><ForeName>Dena B</ForeName><Initials>DB</Initials></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Binggui</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Orr</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Lotz</LastName><ForeName>Gregor</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Daniel H</ForeName><Initials>DH</Initials></Author><Author ValidYN="Y"><LastName>Hamto</LastName><ForeName>Patricia</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Kaitlyn</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Gui-Qiu</ForeName><Initials>GQ</Initials></Author><Author ValidYN="Y"><LastName>Mucke</LastName><ForeName>Lennart</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG011385</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS041787</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 AG039220</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS041787</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RR18928-01</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG011385</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG022074</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG022074</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG011385</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>C06 RR018928</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>11</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D036183">Receptor, EphB2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.25.1</RegistryNumber><NameOfSubstance UI="D046988">Proteasome Endopeptidase Complex</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2011 Jan 6;469(7328):44-5. doi: 10.1038/469044a.</RefSource><PMID Version="1">21209657</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2011 Feb;7(2):62. doi: 10.1038/nrneurol.2010.204.</RefSource><PMID Version="1">21391318</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018891" MajorTopicYN="N">Dentate Gyrus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017774" MajorTopicYN="N">Long-Term Potentiation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D046988" MajorTopicYN="N">Proteasome Endopeptidase Complex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036183" MajorTopicYN="N">Receptor, EphB2</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>11</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>11</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>11</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>2</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>7</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21113149</ArticleId><ArticleId IdType="mid">NIHMS264862</ArticleId><ArticleId IdType="pmc">PMC3030448</ArticleId><ArticleId IdType="doi">10.1038/nature09635</ArticleId><ArticleId IdType="pii">nature09635</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron. 2004;44:181&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">15450169</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, et al. Amyloid-&#x3b2; protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nature Med. 2008;14:837&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenetz F, et al. APP processing and synaptic function. Neuron. 2003;37:925&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Malenka RC, Bear MF. LTP and LTD: an embarrassment of riches. Neuron. 2004;44:5&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">15450156</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonomovic MD, et al. Distribution of glutamate receptor subunit NMDAR1 in the hippocampus of normal elderly and patients with Alzheimer's disease. Exp. Neurol. 1999;160:194&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">10630204</ArticleId></ArticleIdList></Reference><Reference><Citation>Sze C, Bi H, Kleinschmidt-DeMasters BK, Filley CM, Martin LJ. N-Methyl-D-aspartate receptor subunit proteins and their phosphorylation status are altered selectively in Alzheimer's disease. J. Neurol. Sci. 2001;182:151&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">11137521</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, et al. Vulnerability of dentate granule cells to disruption of Arc expression in human amyloid precursor protein transgenic mice. J. Neurosci. 2005;25:9686&#x2013;9693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725729</ArticleId><ArticleId IdType="pubmed">16237173</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron. 2007;55:697&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055171</ArticleId><ArticleId IdType="pubmed">17785178</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon AM, et al. Early changes in hippocampal Eph receptors precede the onset of memory decline in mouse models of Alzheimer's disease. J. Alzheimers Dis. 2009;17:773&#x2013;786.</Citation><ArticleIdList><ArticleId IdType="pubmed">19542617</ArticleId></ArticleIdList></Reference><Reference><Citation>Henderson JT, et al. The receptor tyrosine kinase EphB2 regulates NMDA-dependent synaptic function. Neuron. 2001;32:1041&#x2013;1056.</Citation><ArticleIdList><ArticleId IdType="pubmed">11754836</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalva MB, et al. EphB receptors interact with NMDA receptors and regulate excitatory synapse formation. Cell. 2000;103:945&#x2013;956.</Citation><ArticleIdList><ArticleId IdType="pubmed">11136979</ArticleId></ArticleIdList></Reference><Reference><Citation>Takasu MA, Dalva MB, Zigmond RE, Greenberg ME. Modulation of NMDA receptor-dependent calcium influx and gene expression through EphB receptors. Science. 2002;295:491&#x2013;495.</Citation><ArticleIdList><ArticleId IdType="pubmed">11799243</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Fu AK, Ip NY. Bidirectional signaling of ErbB and Eph receptors at synapses. Neuron Glia Biol. 2008;4:211&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">19785921</ArticleId></ArticleIdList></Reference><Reference><Citation>Grunwald IC, et al. Kinase-independent requirement of EphB2 receptors in hippocampal synaptic plasticity. Neuron. 2001;32:1027&#x2013;1040.</Citation><ArticleIdList><ArticleId IdType="pubmed">11754835</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleischmann A, et al. Impaired long-term memory and NR2A-type NMDA receptor-dependent synaptic plasticity in mice lacking c-Fos in the CNS. J. Neurosci. 2003;23:9116&#x2013;9122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740829</ArticleId><ArticleId IdType="pubmed">14534245</ArticleId></ArticleIdList></Reference><Reference><Citation>Litterst C, et al. Ligand binding and calcium influx induce distinct ectodomain/&#x3b3;-secretase-processing pathways of EphB2 receptor. J. Biol. Chem. 2007;282:16155&#x2013;16163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4005067</ArticleId><ArticleId IdType="pubmed">17428795</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakabayashi K, Honer WG, Masliah E. Synapse alterations in the hippocampalentorhinal formation in Alzheimer's disease with and without Lewy body disease. Brain Res. 1994;667:24&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">7895080</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheff SW, Price DA. Alzheimer's disease-related alterations in synaptic density: neocortex and hippocampus. J. Alzheimers Dis. 2006;9:101&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pubmed">16914849</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller-Steiner S, et al. Anti-amyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease. Neuron. 2006;51:703&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pubmed">16982417</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun B, et al. Imbalance between GABAergic and glutamatergic transmissions impairs adult neurogenesis in an animal model of Alzheimer's disease. Cell Stem Cell. 2009;5:624&#x2013;633.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2823799</ArticleId><ArticleId IdType="pubmed">19951690</ArticleId></ArticleIdList></Reference><Reference><Citation>Shemer I, et al. Non-fibrillar &#x3b2;-amyloid abates spike-timing-dependent synaptic potentiation at excitatory synapses in layer 2/3 of the neocortex by targeting postsynaptic AMPA receptors. Eur. J. Neurosci. 2006;23:2035&#x2013;2047.</Citation><ArticleIdList><ArticleId IdType="pubmed">16630051</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashe KH, Zahs KR. Probing the biology of Alzheimer's disease in mice. Neuron. 2010;66:631&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2956420</ArticleId><ArticleId IdType="pubmed">20547123</ArticleId></ArticleIdList></Reference><Reference><Citation>Colino A, Malenka RC. Mechanisms underlying induction of long-term potentiation in rat medial and lateral perforant paths in vitro. J. Neurophysiol. 1993;69:1150&#x2013;1159.</Citation><ArticleIdList><ArticleId IdType="pubmed">8492154</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris JA, et al. Many neuronal and behavioral impairments in transgenic mouse models of Alzheimer's disease are independent of caspase cleavage of the amyloid precursor protein. J. Neurosci. 2010;30:372&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3064502</ArticleId><ArticleId IdType="pubmed">20053918</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Mejia RO, et al. Phospholipase A2 reduction ameliorates cognitve deficits in mouse model of Alzheimer's disease. Nature Neurosci. 2008;11:1311&#x2013;1318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2597064</ArticleId><ArticleId IdType="pubmed">18931664</ArticleId></ArticleIdList></Reference><Reference><Citation>Meilandt WJ, et al. Enkephalin elevations contribute to neuronal and behavioral impairments in a transgenic mouse model of Alzheimer's disease. J. Neurosci. 2008;28:5007&#x2013;5017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3315282</ArticleId><ArticleId IdType="pubmed">18463254</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, et al. Reducing endogenous tau ameliorates amyloid b-induced deficits in an Alzheimer's disease mouse model. Science. 2007;316:750&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pubmed">17478722</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen PV, Abel T, Kandel ER, Bourtchouladze R. Strain-dependent differences in LTP and hippocampus-dependent memory in inbred mice. Learn. Mem. 2000;7:170&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC311331</ArticleId><ArticleId IdType="pubmed">10837506</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakajima R, et al. Comprehensive behavioral phenotyping of calpastatin-knockout mice. Mol. Brain. 2008;1:7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2561015</ArticleId><ArticleId IdType="pubmed">18803809</ArticleId></ArticleIdList></Reference><Reference><Citation>Potter MC, et al. Reduction of endogenous kynurenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior. Neuropsychopharmacology. 2010;35:1734&#x2013;1742.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3055476</ArticleId><ArticleId IdType="pubmed">20336058</ArticleId></ArticleIdList></Reference><Reference><Citation>Terashima A, et al. An essential role for PICK1 in NMDA receptor-dependent bidirectional synaptic plasticity. Neuron. 2008;57:872&#x2013;882.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2336895</ArticleId><ArticleId IdType="pubmed">18367088</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder EM, et al. Regulation of NMDA receptor trafficking by amyloid-&#x3b2;. Nature Neurosci. 2005;8:1051&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pubmed">16025111</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurup P, et al. A&#x3b2;-mediated NMDA receptor endocytosis in Alzheimer's disease involves ubiquitination of the tyrosine phosphatase STEP61. J. Neurosci. 2010;30:5948&#x2013;5957.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2868326</ArticleId><ArticleId IdType="pubmed">20427654</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonifazi P, et al. GABAergic hub neurons orchestrate synchrony in developing hippocampal networks. Science. 2009;326:1419&#x2013;1424.</Citation><ArticleIdList><ArticleId IdType="pubmed">19965761</ArticleId></ArticleIdList></Reference><Reference><Citation>Han JH, et al. Selective erasure of a fear memory. Science. 2009;323:1492&#x2013;1496.</Citation><ArticleIdList><ArticleId IdType="pubmed">19286560</ArticleId></ArticleIdList></Reference><Reference><Citation>Li CY, Poo MM, Dan Y. Burst spiking of a single cortical neuron modifies global brain state. Science. 2009;324:643&#x2013;646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2913066</ArticleId><ArticleId IdType="pubmed">19407203</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockenstein EM, et al. Levels and alternative splicing of amyloid &#x3b2; protein precursor (APP) transcripts in brains of transgenic mice and humans with Alzheimer's disease. J. Biol. Chem. 1995;270:28257&#x2013;28267.</Citation><ArticleIdList><ArticleId IdType="pubmed">7499323</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, et al. High-level neuronal expression of Ab1&#x2013;42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 2000;20:4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Koo EH, Squazzo SL. Evidence that production and release of amyloid &#x3b2;-protein involves the endocytic pathway. J. Biol. Chem. 1994;269:17386&#x2013;17389.</Citation><ArticleIdList><ArticleId IdType="pubmed">8021238</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, et al. Naturally secreted oligomers of amyloid b protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Franklin KBJ, Paxinos G. The Mouse Brain in Stereotaxic Coordinates. Academic; 1997.</Citation></Reference><Reference><Citation>Xia Z, Dudek H, Miranti CK, Greenberg ME. Calcium influx via the NMDA receptor induces immediate early gene transcription by a MAP kinase/ERK-dependent mechanism. J. Neurosci. 1996;16:5425&#x2013;5436.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578897</ArticleId><ArticleId IdType="pubmed">8757255</ArticleId></ArticleIdList></Reference><Reference><Citation>Laur&#xe9;n J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-&#x3b2; oligomers. Nature. 2009;457:1128&#x2013;1132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2748841</ArticleId><ArticleId IdType="pubmed">19242475</ArticleId></ArticleIdList></Reference><Reference><Citation>Alfa Cisse M, et al. M1 and M3 muscarinic receptors control physiological processing of cellular prion by modulating Alzheimer's disease AM17 phosphorylation and activity. J. Neurosci. 2007;27:4083&#x2013;4092.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672535</ArticleId><ArticleId IdType="pubmed">17428986</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J, Rush A, Rowan MJ, Anwyl R. NMDA receptor- and metabotropic glutamate receptor-dependent synaptic plasticity induced by high frequency stimulation in the rat dentate gyrus in vitro. J. Physiol. (Lond.) 2001;533:745&#x2013;755.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2278668</ArticleId><ArticleId IdType="pubmed">11410631</ArticleId></ArticleIdList></Reference><Reference><Citation>Raber J, et al. Hypothalamic-pituitary-adrenal function in Apoe&#x2212;/&#x2212; mice: possible role in behavioral and metabolic alterations. J. Neurosci. 2000;20:2064&#x2013;2071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772921</ArticleId><ArticleId IdType="pubmed">10684907</ArticleId></ArticleIdList></Reference><Reference><Citation>Raber J, LeFevour A, Buttini M, Mucke L. Androgens protect against Apolipoprotein E4-induced cognitive deficits. J. Neurosci. 2002;22:5204&#x2013;5209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757715</ArticleId><ArticleId IdType="pubmed">12077215</ArticleId></ArticleIdList></Reference><Reference><Citation>Dere E, Huston JP, De Souza Silva MA. Episodic-like memory in mice: simultaneous assessment of object, place and temporal order memory. Brain Res. Protoc. 2005;16:10&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">16185914</ArticleId></ArticleIdList></Reference><Reference><Citation>Benice T, Rizk A, Kohama S, Pfankuch T, Raber J. Sex-differences in age-related cognitive decline in C57BL/6J mice associated with increased brain microtubule-associated protein 2 and synaptophysin immunoreactivity. Neuroscience. 2006;137:413&#x2013;423.</Citation><ArticleIdList><ArticleId IdType="pubmed">16330151</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson-Wood K, et al. Amyloid precursor protein processing and Ab42 deposition in a transgenic mouse model of Alzheimer disease. Proc. Natl Acad. Sci. USA. 94:1550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19829</ArticleId><ArticleId IdType="pubmed">9037091</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21115476</PMID><DateCompleted><Year>2011</Year><Month>03</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1083-351X</ISSN><JournalIssue CitedMedium="Internet"><Volume>286</Volume><Issue>5</Issue><PubDate><Year>2011</Year><Month>Feb</Month><Day>04</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Activation of D1/D5 dopamine receptors protects neurons from synapse dysfunction induced by amyloid-beta oligomers.</ArticleTitle><Pagination><StartPage>3270</StartPage><EndPage>3276</EndPage><MedlinePgn>3270-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1074/jbc.M110.177790</ELocationID><Abstract><AbstractText>Soluble oligomers of the amyloid-&#x3b2; peptide (A&#x3b2;Os) accumulate in the brains of Alzheimer disease (AD) patients and are implicated in synapse failure and early memory loss in AD. A&#x3b2;Os have been shown to impact synapse function by inhibiting long term potentiation, facilitating the induction of long term depression and inducing internalization of both AMPA and NMDA glutamate receptors, critical players in plasticity mechanisms. Because activation of dopamine D1/D5 receptors plays important roles in memory circuits by increasing the insertion of AMPA and NMDA receptors at synapses, we hypothesized that selective activation of D1/D5 receptors could protect synapses from the deleterious action of A&#x3b2;Os. We show that SKF81297, a selective D1/D5 receptor agonist, prevented the reduction in surface levels of AMPA and NMDA receptors induced by A&#x3b2;Os in hippocampal neurons in culture. Protection by SKF81297 was abrogated by the specific D1/D5 antagonist, SCH23390. Levels of AMPA receptor subunit GluR1 phosphorylated at Ser(845), which regulates AMPA receptor association with the plasma membrane, were reduced in a calcineurin-dependent manner in the presence of A&#x3b2;Os, and treatment with SKF81297 prevented this reduction. Establishing the functional relevance of these findings, SKF81297 blocked the impairment of long term potentiation induced by A&#x3b2;Os in hippocampal slices. Results suggest that D1/D5 receptors may be relevant targets for development of novel pharmacological approaches to prevent synapse failure in AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>J&#xfc;rgensen</LastName><ForeName>Sofia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Medical Biochemistry, Federal University of Rio de Janeiro, Rio de Janeiro RJ 1944-590, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antonio</LastName><ForeName>Leandro L</ForeName><Initials>LL</Initials></Author><Author ValidYN="Y"><LastName>Mussi</LastName><ForeName>Gabriela E A</ForeName><Initials>GE</Initials></Author><Author ValidYN="Y"><LastName>Brito-Moreira</LastName><ForeName>Jordano</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Bomfim</LastName><ForeName>Theresa R</ForeName><Initials>TR</Initials></Author><Author ValidYN="Y"><LastName>De Felice</LastName><ForeName>Fernanda G</ForeName><Initials>FG</Initials></Author><Author ValidYN="Y"><LastName>Garrido-Sanabria</LastName><ForeName>Emilio R</ForeName><Initials>ER</Initials></Author><Author ValidYN="Y"><LastName>Cavalheiro</LastName><ForeName>&#xc9;sper A</ForeName><Initials>&#xc9;A</Initials></Author><Author ValidYN="Y"><LastName>Ferreira</LastName><ForeName>Sergio T</ForeName><Initials>ST</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>SC1 NS063950</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>3SC1NS063950-03S1</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5SC1NS063950-04</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>11</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001552">Benzazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020011">Protective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018091">Receptors, AMPA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017447">Receptors, Dopamine D1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>137750-35-7</RegistryNumber><NameOfSubstance UI="D050641">Receptors, Dopamine D5</NameOfSubstance></Chemical><Chemical><RegistryNumber>71636-61-8</RegistryNumber><NameOfSubstance UI="C067113">SK&amp;F 81297</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001552" MajorTopicYN="N">Benzazepines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="Y">Neurons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020011" MajorTopicYN="N">Protective Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018091" MajorTopicYN="N">Receptors, AMPA</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017447" MajorTopicYN="N">Receptors, Dopamine D1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050641" MajorTopicYN="N">Receptors, Dopamine D5</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>12</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>12</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>2</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21115476</ArticleId><ArticleId IdType="pmc">PMC3030332</ArticleId><ArticleId IdType="doi">10.1074/jbc.M110.177790</ArticleId><ArticleId IdType="pii">S0021-9258(20)54032-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brookmeyer R., Johnson E., Ziegler-Graham K., Arrighi H. M. (2007) Alzheimers Dement 3, 186&#x2013;191</Citation><ArticleIdList><ArticleId IdType="pubmed">19595937</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalaria R. N., Maestre G. E., Arizaga R., Friedland R. P., Galasko D., Hall K., Luchsinger J. A., Ogunniyi A., Perry E. K., Potocnik F., Prince M., Stewart R., Wimo A., Zhang Z. X., Antuono P. (2008) Lancet Neurol. 7, 812&#x2013;826</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2860610</ArticleId><ArticleId IdType="pubmed">18667359</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C., Selkoe D. J. (2007) Nat. Rev. Mol. Cell Biol. 8, 101&#x2013;112</Citation><ArticleIdList><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert M. P., Barlow A. K., Chromy B. A., Edwards C., Freed R., Liosatos M., Morgan T. E., Rozovsky I., Trommer B., Viola K. L., Wals P., Zhang C., Finch C. E., Krafft G. A., Klein W. L. (1998) Proc. Natl. Acad. Sci. U.S.A. 95, 6448&#x2013;6453</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira S. T., Vieira M. N., De Felice F. G. (2007) IUBMB life 59, 332&#x2013;345</Citation><ArticleIdList><ArticleId IdType="pubmed">17505973</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh D. M., Klyubin I., Fadeeva J. V., Cullen W. K., Anwyl R., Wolfe M. S., Rowan M. J., Selkoe D. J. (2002) Nature 416, 535&#x2013;539</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend M., Shankar G. M., Mehta T., Walsh D. M., Selkoe D. J. (2006) J. Physiol. 572, 477&#x2013;492</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1779683</ArticleId><ArticleId IdType="pubmed">16469784</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S., Hong S., Shepardson N. E., Walsh D. M., Shankar G. M., Selkoe D. (2009) Neuron 62, 788&#x2013;801</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2702854</ArticleId><ArticleId IdType="pubmed">19555648</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar G. M., Li S., Mehta T. H., Garcia-Munoz A., Shepardson N. E., Smith I., Brett F. M., Farrell M. A., Rowan M. J., Lemere C. A., Regan C. M., Walsh D. M., Sabatini B. L., Selkoe D. J. (2008) Nat. Med. 14, 837&#x2013;842</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W. Q., Santini F., Breese R., Ross D., Zhang X. D., Stone D. J., Ferrer M., Townsend M., Wolfe A. L., Seager M. A., Kinney G. G., Shughrue P. J., Ray W. J. (2010) J. Biol. Chem. 285, 7619&#x2013;7632</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2844209</ArticleId><ArticleId IdType="pubmed">20032460</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh H., Boehm J., Sato C., Iwatsubo T., Tomita T., Sisodia S., Malinow R. (2006) Neuron 52, 831&#x2013;843</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850952</ArticleId><ArticleId IdType="pubmed">17145504</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida C. G., Tampellini D., Takahashi R. H., Greengard P., Lin M. T., Snyder E. M., Gouras G. K. (2005) Neurobiol. Dis. 20, 187&#x2013;198</Citation><ArticleIdList><ArticleId IdType="pubmed">16242627</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder E. M., Nong Y., Almeida C. G., Paul S., Moran T., Choi E. Y., Nairn A. C., Salter M. W., Lombroso P. J., Gouras G. K., Greengard P. (2005) Nat. Neurosci. 8, 1051&#x2013;1058</Citation><ArticleIdList><ArticleId IdType="pubmed">16025111</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacor P. N., Buniel M. C., Furlow P. W., Clemente A. S., Velasco P. T., Wood M., Viola K. L., Klein W. L. (2007) J. Neurosci. 27, 796&#x2013;807</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672917</ArticleId><ArticleId IdType="pubmed">17251419</ArticleId></ArticleIdList></Reference><Reference><Citation>Knobloch M., Farinelli M., Konietzko U., Nitsch R. M., Mansuy I. M. (2007) J. Neurosci. 27, 7648&#x2013;7653</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672892</ArticleId><ArticleId IdType="pubmed">17634359</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu H. Y., Hudry E., Hashimoto T., Kuchibhotla K., Rozkalne A., Fan Z., Spires-Jones T., Xie H., Arbel-Ornath M., Grosskreutz C. L., Bacskai B. J., Hyman B. T. (2010) J. Neurosci. 30, 2636&#x2013;2649</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2841957</ArticleId><ArticleId IdType="pubmed">20164348</ArticleId></ArticleIdList></Reference><Reference><Citation>Missale C., Nash S. R., Robinson S. W., Jaber M., Caron M. G. (1998) Physiol. Rev. 78, 189&#x2013;225</Citation><ArticleIdList><ArticleId IdType="pubmed">9457173</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalley J. W., Everitt B. J. (2009) Semin. Cell Dev. Biol. 20, 403&#x2013;410</Citation><ArticleIdList><ArticleId IdType="pubmed">19560045</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao C., Sun X., Wolf M. E. (2006) J. Neurochem. 98, 1664&#x2013;1677</Citation><ArticleIdList><ArticleId IdType="pubmed">16800848</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith W. B., Starck S. R., Roberts R. W., Schuman E. M. (2005) Neuron 45, 765&#x2013;779</Citation><ArticleIdList><ArticleId IdType="pubmed">15748851</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepherd J. D., Huganir R. L. (2007) Annu. Rev. Cell Dev. Biol. 23, 613&#x2013;643</Citation><ArticleIdList><ArticleId IdType="pubmed">17506699</ArticleId></ArticleIdList></Reference><Reference><Citation>Brewer G. J., Torricelli J. R., Evege E. K., Price P. J. (1993) J. Neurosci. Res. 35, 567&#x2013;576</Citation><ArticleIdList><ArticleId IdType="pubmed">8377226</ArticleId></ArticleIdList></Reference><Reference><Citation>Paula-Lima A. C., Tricerri M. A., Brito-Moreira J., Bomfim T. R., Oliveira F. F., Magdesian M. H., Grinberg L. T., Panizzutti R., Ferreira S. T. (2009) Int. J. Biochem. Cell Biol. 41, 1361&#x2013;1370</Citation><ArticleIdList><ArticleId IdType="pubmed">19130896</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuitino L., Godoy J. A., Far&#xed;as G. G., Couve A., Bonansco C., Fuenzalida M., Inestrosa N. C. (2010) J. Neurosci. 30, 8411&#x2013;8420</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6634644</ArticleId><ArticleId IdType="pubmed">20573888</ArticleId></ArticleIdList></Reference><Reference><Citation>Glynn M. W., McAllister A. K. (2006) Nat. Protocols 1, 1287&#x2013;1296</Citation><ArticleIdList><ArticleId IdType="pubmed">17406413</ArticleId></ArticleIdList></Reference><Reference><Citation>Abramoff M. D., Magalhaes P. J., Ram S. J. (2004) Biophoton. Int. 11, 36&#x2013;42</Citation></Reference><Reference><Citation>De Felice F. G., Velasco P. T., Lambert M. P., Viola K., Fernandez S. J., Ferreira S. T., Klein W. L. (2007) J. Biol. Chem. 282, 11590&#x2013;11601</Citation><ArticleIdList><ArticleId IdType="pubmed">17308309</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanabria E. R., Pereira M. F., Dolnikoff M. S., Andrade I. S., Ferreira A. T., Cavalheiro E. A., Fernandes M. J. (2002) Brain Res. Bull. 59, 47&#x2013;51</Citation><ArticleIdList><ArticleId IdType="pubmed">12372548</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitolo O. V., Sant'Angelo A., Costanzo V., Battaglia F., Arancio O., Shelanski M. (2002) Proc. Natl. Acad. Sci. U.S.A. 99, 13217&#x2013;13221</Citation><ArticleIdList><ArticleId IdType="pmc">PMC130613</ArticleId><ArticleId IdType="pubmed">12244210</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamin G. (2009) J. Neurosci. Res. 87, 1729&#x2013;1736</Citation><ArticleIdList><ArticleId IdType="pubmed">19170166</ArticleId></ArticleIdList></Reference><Reference><Citation>Parameshwaran K., Dhanasekaran M., Suppiramaniam V. (2008) Exp. Neurol. 210, 7&#x2013;13</Citation><ArticleIdList><ArticleId IdType="pubmed">18053990</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf M. E., Mangiavacchi S., Sun X. (2003) Ann. N. Y. Acad. Sci. 1003, 241&#x2013;249</Citation><ArticleIdList><ArticleId IdType="pubmed">14684450</ArticleId></ArticleIdList></Reference><Reference><Citation>Roselli F., Tirard M., Lu J., Hutzler P., Lamberti P., Livrea P., Morabito M., Almeida O. F. (2005) J. Neurosci. 25, 11061&#x2013;11070</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725651</ArticleId><ArticleId IdType="pubmed">16319306</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuda R. P., Ikonomovic M. D., Sheffield R., Rubin R. T., Wolfe B. B., Armstrong D. M. (1995) Brain Res. 678, 161&#x2013;167</Citation><ArticleIdList><ArticleId IdType="pubmed">7542540</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonomovic M. D., Mizukami K., Warde D., Sheffield R., Hamilton R., Wenthold R. J., Armstrong D. M. (1999) Exp. Neurol. 160, 194&#x2013;204</Citation><ArticleIdList><ArticleId IdType="pubmed">10630204</ArticleId></ArticleIdList></Reference><Reference><Citation>Malenka R. C., Bear M. F. (2004) Neuron 44, 5&#x2013;21</Citation><ArticleIdList><ArticleId IdType="pubmed">15450156</ArticleId></ArticleIdList></Reference><Reference><Citation>Castner S. A., Williams G. V. (2007) Brain Cognition 63, 94&#x2013;122</Citation><ArticleIdList><ArticleId IdType="pubmed">17204357</ArticleId></ArticleIdList></Reference><Reference><Citation>Missale C., Fiorentini C., Busi C., Collo G., Spano P. F. (2006) Curr. Top. Med. Chem. 6, 801&#x2013;808</Citation><ArticleIdList><ArticleId IdType="pubmed">16719818</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen B. S., Roche K. W. (2007) Neuropharmacology 53, 362&#x2013;368</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2001266</ArticleId><ArticleId IdType="pubmed">17644144</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder G. L., Fienberg A. A., Huganir R. L., Greengard P. (1998) J. Neurosci. 18, 10297&#x2013;10303</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793330</ArticleId><ArticleId IdType="pubmed">9852567</ArticleId></ArticleIdList></Reference><Reference><Citation>Granado N., Ortiz O., Su&#xe1;rez L. M., Mart&#xed;n E. D., Ce&#xf1;a V., Sol&#xed;s J. M., Moratalla R. (2008) Cereb. Cortex 18, 1&#x2013;12</Citation><ArticleIdList><ArticleId IdType="pubmed">17395606</ArticleId></ArticleIdList></Reference><Reference><Citation>Malenka R. C. (2003) Ann. N. Y. Acad. Sci. 1003, 1&#x2013;11</Citation><ArticleIdList><ArticleId IdType="pubmed">14684431</ArticleId></ArticleIdList></Reference><Reference><Citation>Park M., Penick E. C., Edwards J. G., Kauer J. A., Ehlers M. D. (2004) Science 305, 1972&#x2013;1975</Citation><ArticleIdList><ArticleId IdType="pubmed">15448273</ArticleId></ArticleIdList></Reference><Reference><Citation>Groc L., Choquet D. (2006) Cell Tiss. Res. 326, 423&#x2013;438</Citation><ArticleIdList><ArticleId IdType="pubmed">16847641</ArticleId></ArticleIdList></Reference><Reference><Citation>Bredt D. S., Nicoll R. A. (2003) Neuron 40, 361&#x2013;379</Citation><ArticleIdList><ArticleId IdType="pubmed">14556714</ArticleId></ArticleIdList></Reference><Reference><Citation>Song I., Huganir R. L. (2002) Trends Neurosci. 25, 578&#x2013;588</Citation><ArticleIdList><ArticleId IdType="pubmed">12392933</ArticleId></ArticleIdList></Reference><Reference><Citation>He K., Song L., Cummings L. W., Goldman J., Huganir R. L., Lee H. K. (2009) Proc. Natl. Acad. Sci. U.S.A. 106, 20033&#x2013;20038</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2785287</ArticleId><ArticleId IdType="pubmed">19892736</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H. K., Takamiya K., He K., Song L., Huganir R. L. (2010) J. Neurophysiol. 103, 479&#x2013;489</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2807233</ArticleId><ArticleId IdType="pubmed">19906877</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H. K., Takamiya K., Han J. S., Man H., Kim C. H., Rumbaugh G., Yu S., Ding L., He C., Petralia R. S., Wenthold R. J., Gallagher M., Huganir R. L. (2003) Cell 112, 631&#x2013;643</Citation><ArticleIdList><ArticleId IdType="pubmed">12628184</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerpa W., Far&#xed;as G. G., Godoy J. A., Fuenzalida M., Bonansco C., Inestrosa N. C. (2010) Mol. Neurodegen. 5, 3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2823745</ArticleId><ArticleId IdType="pubmed">20205789</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H. K. (2006) Pharmacol. Ther. 112, 810&#x2013;832</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2748765</ArticleId><ArticleId IdType="pubmed">16904750</ArticleId></ArticleIdList></Reference><Reference><Citation>Greengard P., Allen P. B., Nairn A. C. (1999) Neuron 23, 435&#x2013;447</Citation><ArticleIdList><ArticleId IdType="pubmed">10433257</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Q. S., Wei W. Z., Shimahara T., Xie C. W. (2002) Neurobiol. Learn. Mem. 77, 354&#x2013;371</Citation><ArticleIdList><ArticleId IdType="pubmed">11991763</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao S. Z., Lu W., Lee H. K., Huganir R. L., Wolf M. E. (2002) J. Neurochem. 81, 984&#x2013;992</Citation><ArticleIdList><ArticleId IdType="pubmed">12065610</ArticleId></ArticleIdList></Reference><Reference><Citation>Mockett B. G., Gu&#xe9;vremont D., Williams J. M., Abraham W. C. (2007) J. Neurosci. 27, 2918&#x2013;2926</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672564</ArticleId><ArticleId IdType="pubmed">17360914</ArticleId></ArticleIdList></Reference><Reference><Citation>Decker H., Lo K. Y., Unger S. M., Ferreira S. T., Silverman M. A. (2010) J. Neurosci. 30, 9166&#x2013;9171</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6632489</ArticleId><ArticleId IdType="pubmed">20610750</ArticleId></ArticleIdList></Reference><Reference><Citation>Rui Y., Gu J., Yu K., Hartzell H. C., Zheng J. Q. (2010) Mol. Brain 3, 10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2853530</ArticleId><ArticleId IdType="pubmed">20346152</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y., Wang X. B., Frerking M., Zhou Q. (2008) Proc. Natl. Acad. Sci. U.S.A. 105, 11388&#x2013;11393</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2496888</ArticleId><ArticleId IdType="pubmed">18682558</ArticleId></ArticleIdList></Reference><Reference><Citation>Man H. Y., Sekine-Aizawa Y., Huganir R. L. (2007) Proc. Natl. Acad. Sci. U.S.A. 104, 3579&#x2013;3584</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1805611</ArticleId><ArticleId IdType="pubmed">17360685</ArticleId></ArticleIdList></Reference><Reference><Citation>de Keyser J., De Backer J. P., Vauquelin G., Ebinger G. (1990) Brain Res. 528, 308&#x2013;310</Citation><ArticleIdList><ArticleId IdType="pubmed">2148706</ArticleId></ArticleIdList></Reference><Reference><Citation>van Praag H., Kempermann G., Gage F. H. (2000) Nat. Rev. Neurosci. 1, 191&#x2013;198</Citation><ArticleIdList><ArticleId IdType="pubmed">11257907</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaeffer E. L., Novaes B. A., da Silva E. R., Skaf H. D., Mendes-Neto A. G. (2009) Prog. Neuropsychopharmacol. Biol. Psychiatry 33, 1087&#x2013;1102</Citation><ArticleIdList><ArticleId IdType="pubmed">19596396</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">2111583</PMID><DateCompleted><Year>1990</Year><Month>06</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0036-8075</ISSN><JournalIssue CitedMedium="Print"><Volume>248</Volume><Issue>4959</Issue><PubDate><Year>1990</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Cleavage of amyloid beta peptide during constitutive processing of its precursor.</ArticleTitle><Pagination><StartPage>1122</StartPage><EndPage>1124</EndPage><MedlinePgn>1122-4</MedlinePgn></Pagination><Abstract><AbstractText>The amyloid beta peptide (A beta P) is a small fragment of the much larger, broadly distributed amyloid precursor protein (APP). Abundant A beta P deposition in the brains of patients with Alzheimer's disease suggests that altered APP processing may represent a key pathogenic event. Direct protein structural analyses showed that constitutive processing in human embryonic kidney 293 cells cleaves APP in the interior of the A beta P, thus preventing A beta P deposition. A deficiency of this processing event may ultimately prove to be the etiological event in Alzheimer's disease that gives rise to senile plaque formation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Esch</LastName><ForeName>F S</ForeName><Initials>FS</Initials><AffiliationInfo><Affiliation>Athena Neurosciences, Incorporated, South San Francisco, CA 94080.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keim</LastName><ForeName>P S</ForeName><Initials>PS</Initials></Author><Author ValidYN="Y"><LastName>Beattie</LastName><ForeName>E C</ForeName><Initials>EC</Initials></Author><Author ValidYN="Y"><LastName>Blacher</LastName><ForeName>R W</ForeName><Initials>RW</Initials></Author><Author ValidYN="Y"><LastName>Culwell</LastName><ForeName>A R</ForeName><Initials>AR</Initials></Author><Author ValidYN="Y"><LastName>Oltersdorf</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>McClure</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Ward</LastName><ForeName>P J</ForeName><Initials>PJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011498">Protein Precursors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011498" MajorTopicYN="N">Protein Precursors</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011499" MajorTopicYN="N">Protein Processing, Post-Translational</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1990</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1990</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1990</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2111583</ArticleId><ArticleId IdType="doi">10.1126/science.2111583</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21136067</PMID><DateCompleted><Year>2011</Year><Month>06</Month><Day>14</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-0533</ISSN><JournalIssue CitedMedium="Internet"><Volume>121</Volume><Issue>3</Issue><PubDate><Year>2011</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Acta neuropathologica</Title><ISOAbbreviation>Acta Neuropathol</ISOAbbreviation></Journal><ArticleTitle>In vivo multiphoton imaging reveals gradual growth of newborn amyloid plaques over weeks.</ArticleTitle><Pagination><StartPage>327</StartPage><EndPage>335</EndPage><MedlinePgn>327-35</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00401-010-0787-6</ELocationID><Abstract><AbstractText>The kinetics of amyloid plaque formation and growth as one of the characteristic hallmarks of Alzheimer's disease (AD) are fundamental issues in AD research. Especially the question how fast amyloid plaques grow to their final size after they are born remains controversial. By long-term two-photon in vivo imaging we monitored individual methoxy-X04-stained amyloid plaques over 6 weeks in 12 and 18 months old Tg2576 mice. We found that in 12 months old mice, newly appearing amyloid plaques were initially small in volume and subsequently grew over time. The growth rate of plaques was inversely proportional to their volume; thus amyloid plaques that were already present at the first imaging time point grew over time but slower compared to new plaques. Additionally, we analyzed 18 months old Tg2576 mice in which we neither found newly appearing plaques nor a significant growth of pre-existing plaques over 6 weeks of imaging. In conclusion, newly appearing amyloid plaques are initially small in size but grow over time until plaque growth can not be detected anymore in aged mice. These results suggest that drugs that target plaque formation should be most effective early in the disease, when plaques are growing.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Burgold</LastName><ForeName>Steffen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center of Neuropathology and Prion Research, Ludwig Maximilians Universit&#xe4;t, Feodor-Lynen-Strasse 23, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bittner</LastName><ForeName>Tobias</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Dorostkar</LastName><ForeName>Mario M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Kieser</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Fuhrmann</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Mitteregger</LastName><ForeName>Gerda</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Kretzschmar</LastName><ForeName>Hans</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Boris</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Herms</LastName><ForeName>Jochen</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>12</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Acta Neuropathol</MedlineTA><NlmUniqueID>0412041</NlmUniqueID><ISSNLinking>0001-6322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName><QualifierName UI="Q000254" MajorTopicYN="Y">growth &amp; development</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036641" MajorTopicYN="N">Microscopy, Fluorescence, Multiphoton</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>11</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>11</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>12</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21136067</ArticleId><ArticleId IdType="pmc">PMC3038220</ArticleId><ArticleId IdType="doi">10.1007/s00401-010-0787-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bittner T, Fuhrmann M, Burgold S, et al. gamma-Secretase inhibition reduces spine density in vivo via an amyloid precursor protein-dependent pathway. J Neurosci. 2009;29:10405&#x2013;10409. doi: 10.1523/JNEUROSCI.2288-09.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2288-09.2009</ArticleId><ArticleId IdType="pmc">PMC6665795</ArticleId><ArticleId IdType="pubmed">19692615</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolmont T, Haiss F, Eicke D, et al. Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. J Neurosci. 2008;28:4283&#x2013;4292. doi: 10.1523/JNEUROSCI.4814-07.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4814-07.2008</ArticleId><ArticleId IdType="pmc">PMC3844768</ArticleId><ArticleId IdType="pubmed">18417708</ArticleId></ArticleIdList></Reference><Reference><Citation>Christie RH, Bacskai BJ, Zipfel WR, et al. Growth arrest of individual senile plaques in a model of Alzheimer&#x2019;s disease observed by in vivo multiphoton microscopy. J Neurosci. 2001;21:858&#x2013;864.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762315</ArticleId><ArticleId IdType="pubmed">11157072</ArticleId></ArticleIdList></Reference><Reference><Citation>Esler WP, Stimson ER, Ghilardi JR, et al. In vitro growth of Alzheimer&#x2019;s disease beta-amyloid plaques displays first-order kinetics. Biochemistry. 1996;35:749&#x2013;757. doi: 10.1021/bi951685w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi951685w</ArticleId><ArticleId IdType="pubmed">8547255</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng G, Mellor RH, Bernstein M, et al. Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. Neuron. 2000;28:41&#x2013;51. doi: 10.1016/S0896-6273(00)00084-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)00084-2</ArticleId><ArticleId IdType="pubmed">11086982</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuhrmann M, Bittner T, Jung CKE, et al. Microglial CX3CR1 knockout prevents neuron loss in a mouse model of Alzheimer&#x2019;s disease. Nat Neurosci. 2010;13:411&#x2013;413. doi: 10.1038/nn.2511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2511</ArticleId><ArticleId IdType="pmc">PMC4072212</ArticleId><ArticleId IdType="pubmed">20305648</ArticleId></ArticleIdList></Reference><Reference><Citation>Grutzendler J, Helmin K, Tsai J, Gan WB. Various dendritic abnormalities are associated with fibrillar amyloid deposits in Alzheimer&#x2019;s disease. Ann NY Acad Sci. 2007;1097:30&#x2013;39. doi: 10.1196/annals.1379.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1196/annals.1379.003</ArticleId><ArticleId IdType="pubmed">17413007</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtmaat A, Bonhoeffer T, Chow DK, et al. Long-term, high-resolution imaging in the mouse neocortex through a chronic cranial window. Nat Protocols. 2009;4:1128&#x2013;1144. doi: 10.1038/nprot.2009.89.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2009.89</ArticleId><ArticleId IdType="pmc">PMC3072839</ArticleId><ArticleId IdType="pubmed">19617885</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, Chapman P, Nilsen S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99&#x2013;102. doi: 10.1126/science.274.5284.99.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.274.5284.99</ArticleId><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh H, Boehm J, Sato C, et al. AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron. 2006;52:831&#x2013;843. doi: 10.1016/j.neuron.2006.10.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2006.10.035</ArticleId><ArticleId IdType="pmc">PMC1850952</ArticleId><ArticleId IdType="pubmed">17145504</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarrett JT, Lansbury PT. Seeding one-dimensional crystallization of amyloid&#x2013;&#x2013;a pathogenic mechanism in Alzheimer&#x2019;s disease and scrapie. Cell. 1993;73:1055&#x2013;1058. doi: 10.1016/0092-8674(93)90635-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(93)90635-4</ArticleId><ArticleId IdType="pubmed">8513491</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadir A, Almkvist O, Forsberg A et al (2010) Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer&#x2019;s disease. Neurobiol Aging. doi:10.1016/j.neurobiolaging.2010.06.015</Citation><ArticleIdList><ArticleId IdType="pubmed">20688420</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Bacskai BJ, Mathis CA, et al. Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J Neuropathol Exp Neurol. 2002;61:797&#x2013;805.</Citation><ArticleIdList><ArticleId IdType="pubmed">12230326</ArticleId></ArticleIdList></Reference><Reference><Citation>Knafo S, Alonso-Nanclares L, Gonzalez-Soriano J, et al. Widespread changes in dendritic spines in a model of Alzheimer&#x2019;s disease. Cereb Cortex. 2009;19:586&#x2013;592. doi: 10.1093/cercor/bhn111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/bhn111</ArticleId><ArticleId IdType="pubmed">18632740</ArticleId></ArticleIdList></Reference><Reference><Citation>Koffie RM, Meyer-Luehmann M, Hashimoto T, et al. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci USA. 2009;106:4012&#x2013;4017. doi: 10.1073/pnas.0811698106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0811698106</ArticleId><ArticleId IdType="pmc">PMC2656196</ArticleId><ArticleId IdType="pubmed">19228947</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, Spires-Jones TL, Prada C, et al. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer&#x2019;s disease. Nature. 2008;451:720&#x2013;724. doi: 10.1038/nature06616.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature06616</ArticleId><ArticleId IdType="pmc">PMC3264491</ArticleId><ArticleId IdType="pubmed">18256671</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Li SM, Mehta TH, et al. Amyloid-beta protein dimers isolated directly from Alzheimer&#x2019;s brains impair synaptic plasticity and memory. Nat Med. 2008;14:837&#x2013;842. doi: 10.1038/nm1782.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1782</ArticleId><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder EM, Nong Y, Almeida CG, et al. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci. 2005;8:1051&#x2013;1058. doi: 10.1038/nn1503.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1503</ArticleId><ArticleId IdType="pubmed">16025111</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires TL, Meyer-Luehmann M, Stern EA, et al. Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J Neurosci. 2005;25:7278&#x2013;7287. doi: 10.1523/JNEUROSCI.1879-05.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1879-05.2005</ArticleId><ArticleId IdType="pmc">PMC1820616</ArticleId><ArticleId IdType="pubmed">16079410</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires-Jones TL, Meyer-Luehmann M, Osetek JD, et al. Impaired spine stability underlies plaque-related spine loss in an Alzheimer&#x2019;s disease mouse model. Am J Pathol. 2007;171:1304&#x2013;1311. doi: 10.2353/ajpath.2007.070055.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2007.070055</ArticleId><ArticleId IdType="pmc">PMC1988879</ArticleId><ArticleId IdType="pubmed">17717139</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai J, Grutzendler J, Duff K, Gan WB. Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. Nat Neurosci. 2004;7:1181&#x2013;1183. doi: 10.1038/nn1335.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1335</ArticleId><ArticleId IdType="pubmed">15475950</ArticleId></ArticleIdList></Reference><Reference><Citation>Wadell H. Volume, shape, and roundness of quartz particles. J Geol. 1935;43:250&#x2013;280. doi: 10.1086/624298.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/624298</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei W, Nguyen LN, Kessels HW, et al. Amyloid beta from axons and dendrites reduces local spine number and plasticity. Nat Neurosci. 2010;13:190&#x2013;196. doi: 10.1038/nn.2476.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2476</ArticleId><ArticleId IdType="pmc">PMC3310198</ArticleId><ArticleId IdType="pubmed">20037574</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan P, Bero AW, Cirrito JR, et al. Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice. J Neurosci. 2009;29:10706&#x2013;10714. doi: 10.1523/JNEUROSCI.2637-09.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2637-09.2009</ArticleId><ArticleId IdType="pmc">PMC2756291</ArticleId><ArticleId IdType="pubmed">19710322</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21147781</PMID><DateCompleted><Year>2011</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1083-351X</ISSN><JournalIssue CitedMedium="Internet"><Volume>286</Volume><Issue>8</Issue><PubDate><Year>2011</Year><Month>Feb</Month><Day>25</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Rho kinase II phosphorylation of the lipoprotein receptor LR11/SORLA alters amyloid-beta production.</ArticleTitle><Pagination><StartPage>6117</StartPage><EndPage>6127</EndPage><MedlinePgn>6117-27</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1074/jbc.M110.167239</ELocationID><Abstract><AbstractText>LR11, also known as SorLA, is a mosaic low-density lipoprotein receptor that exerts multiple influences on Alzheimer disease susceptibility. LR11 interacts with the amyloid-&#x3b2; precursor protein (APP) and regulates APP traffic and processing to amyloid-&#x3b2; peptide (A&#x3b2;). The functional domains of LR11 suggest that it can act as a cell surface receptor and as an intracellular sorting receptor for trans-Golgi network to endosome traffic. We show that LR11 over-expressed in HEK293 cells is radiolabeled following incubation of cells with [(32)P(i)]orthophosphate. Liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) was used to discover putative LR11 interacting kinases. Rho-associated coiled-coil containing protein kinase (ROCK) 2 was identified as a binding partner and a candidate kinase acting on LR11. LR11 and ROCK2 co-immunoprecipitate from post-mortem human brain tissue and drug inhibition of ROCK activity reduces LR11 phosphorylation in vivo. Targeted knockdown of ROCK2 with siRNA decreased LR11 ectodomain shedding while simultaneously increasing intracellular LR11 protein level. Site-directed mutagenesis of serine 2206 in the LR11 cytoplasmic tail reduced LR11 shedding, decreased LR11 phosphorylation in vitro, and abrogated LR11 mediated A&#x3b2; reduction. These findings provide direct evidence that LR11 is phosphorylated in vivo and indicate that ROCK2 phosphorylation of LR11 may enhance LR11 mediated processing of APP and amyloid production.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Herskowitz</LastName><ForeName>Jeremy H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Neurology, the Center for Neurodegenerative Diseases, Emory University School of Medicine, Atlanta, Georgia 30322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seyfried</LastName><ForeName>Nicholas T</ForeName><Initials>NT</Initials></Author><Author ValidYN="Y"><LastName>Gearing</LastName><ForeName>Marla</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kahn</LastName><ForeName>Richard A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Junmin</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Levey</LastName><ForeName>Allan I</ForeName><Initials>AI</Initials></Author><Author ValidYN="Y"><LastName>Lah</LastName><ForeName>James J</ForeName><Initials>JJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01GM067226</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 NS007480-07</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 AG032848</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01AG1449</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM067226</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 NS007480</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS055077</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS055077</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32AG032848-02</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG025688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG025688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>12</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026502">LDL-Receptor Related Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026901">Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C102582">SORL1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C515852">ROCK2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D054460">rho-Associated Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055785" MajorTopicYN="N">Gene Knockdown Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026502" MajorTopicYN="N">LDL-Receptor Related Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D026901" MajorTopicYN="N">Membrane Transport Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054460" MajorTopicYN="N">rho-Associated Kinases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>2</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21147781</ArticleId><ArticleId IdType="pmc">PMC3057792</ArticleId><ArticleId IdType="doi">10.1074/jbc.M110.167239</ArticleId><ArticleId IdType="pii">S0021-9258(20)51987-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Motoi Y., Aizawa T., Haga S., Nakamura S., Namba Y., Ikeda K. (1999) Brain Res. 833, 209&#x2013;215</Citation><ArticleIdList><ArticleId IdType="pubmed">10375696</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobsen L., Madsen P., Moestrup S. K., Lund A. H., Tommerup N., Nykjaer A., Sottrup-Jensen L., Gliemann J., Petersen C. M. (1996) J. Biol. Chem. 271, 31379&#x2013;31383</Citation><ArticleIdList><ArticleId IdType="pubmed">8940146</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherzer C. R., Offe K., Gearing M., Rees H. D., Fang G., Heilman C. J., Schaller C., Bujo H., Levey A. I., Lah J. J. (2004) Arch. Neurol. 61, 1200&#x2013;1205</Citation><ArticleIdList><ArticleId IdType="pubmed">15313836</ArticleId></ArticleIdList></Reference><Reference><Citation>Offe K., Dodson S. E., Shoemaker J. T., Fritz J. J., Gearing M., Levey A. I., Lah J. J. (2006) J. Neurosci. 26, 1596&#x2013;1603</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2638122</ArticleId><ArticleId IdType="pubmed">16452683</ArticleId></ArticleIdList></Reference><Reference><Citation>Sager K. L., Wuu J., Leurgans S. E., Rees H. D., Gearing M., Mufson E. J., Levey A. I., Lah J. J. (2007) Ann. Neurol. 62, 640&#x2013;647</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2669325</ArticleId><ArticleId IdType="pubmed">17721864</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogaeva E., Meng Y., Lee J. H., Gu Y., Kawarai T., Zou F., Katayama T., Baldwin C. T., Cheng R., Hasegawa H., Chen F., Shibata N., Lunetta K. L., Pardossi-Piquard R., Bohm C., Wakutani Y., Cupples L. A., Cuenco K. T., Green R. C., Pinessi L., Rainero I., Sorbi S., Bruni A., Duara R., Friedland R. P., Inzelberg R., Hampe W., Bujo H., Song Y. Q., Andersen O. M., Willnow T. E., Graff-Radford N., Petersen R. C., Dickson D., Der S. D., Fraser P. E., Schmitt-Ulms G., Younkin S., Mayeux R., Farrer L. A., St George-Hyslop P. (2007) Nat. Genet. 39, 168&#x2013;177</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2657343</ArticleId><ArticleId IdType="pubmed">17220890</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisodia S. S. (1992) Proc. Natl. Acad. Sci. U.S.A. 89, 6075&#x2013;6079</Citation><ArticleIdList><ArticleId IdType="pmc">PMC49440</ArticleId><ArticleId IdType="pubmed">1631093</ArticleId></ArticleIdList></Reference><Reference><Citation>Koo E. H., Squazzo S. L. (1994) J. Biol. Chem. 269, 17386&#x2013;17389</Citation><ArticleIdList><ArticleId IdType="pubmed">8021238</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartmann T., Bieger S. C., Br&#xfc;hl B., Tienari P. J., Ida N., Allsop D., Roberts G. W., Masters C. L., Dotti C. G., Unsicker K., Beyreuther K. (1997) Nat. Med. 3, 1016&#x2013;1020</Citation><ArticleIdList><ArticleId IdType="pubmed">9288729</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H., Sweeney D., Wang R., Thinakaran G., Lo A. C., Sisodia S. S., Greengard P., Gandy S. (1997) Proc. Natl. Acad. Sci. U.S.A. 94, 3748&#x2013;3752</Citation><ArticleIdList><ArticleId IdType="pmc">PMC20512</ArticleId><ArticleId IdType="pubmed">9108049</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen O. M., Reiche J., Schmidt V., Gotthardt M., Spoelgen R., Behlke J., von Arnim C. A., Breiderhoff T., Jansen P., Wu X., Bales K. R., Cappai R., Masters C. L., Gliemann J., Mufson E. J., Hyman B. T., Paul S. M., Nykjaer A., Willnow T. E. (2005) Proc. Natl. Acad. Sci. U.S.A. 102, 13461&#x2013;13466</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1224625</ArticleId><ArticleId IdType="pubmed">16174740</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodson S. E., Andersen O. M., Karmali V., Fritz J. J., Cheng D., Peng J., Levey A. I., Willnow T. E., Lah J. J. (2008) J. Neurosci. 28, 12877&#x2013;12886</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2669320</ArticleId><ArticleId IdType="pubmed">19036982</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohe M., Carlo A. S., Breyhan H., Sporbert A., Militz D., Schmidt V., Wozny C., Harmeier A., Erdmann B., Bales K. R., Wolf S., Kempermann G., Paul S. M., Schmitz D., Bayer T. A., Willnow T. E., Andersen O. M. (2008) J. Biol. Chem. 283, 14826&#x2013;14834</Citation><ArticleIdList><ArticleId IdType="pubmed">18362153</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobsen L., Madsen P., Nielsen M. S., Geraerts W. P., Gliemann J., Smit A. B., Petersen C. M. (2002) FEBS Lett. 511, 155&#x2013;158</Citation><ArticleIdList><ArticleId IdType="pubmed">11821067</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobsen L., Madsen P., Jacobsen C., Nielsen M. S., Gliemann J., Petersen C. M. (2001) J. Biol. Chem. 276, 22788&#x2013;22796</Citation><ArticleIdList><ArticleId IdType="pubmed">11294867</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen M. S., Madsen P., Christensen E. I., Nykjaer A., Gliemann J., Kasper D., Pohlmann R., Petersen C. M. (2001) EMBO J. 20, 2180&#x2013;2190</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125444</ArticleId><ArticleId IdType="pubmed">11331584</ArticleId></ArticleIdList></Reference><Reference><Citation>Puertollano R., Aguilar R. C., Gorshkova I., Crouch R. J., Bonifacino J. S. (2001) Science 292, 1712&#x2013;1716</Citation><ArticleIdList><ArticleId IdType="pubmed">11387475</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y., Doray B., Poussu A., Lehto V. P., Kornfeld S. (2001) Science 292, 1716&#x2013;1718</Citation><ArticleIdList><ArticleId IdType="pubmed">11387476</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen M. S., Gustafsen C., Madsen P., Nyengaard J. R., Hermey G., Bakke O., Mari M., Schu P., Pohlmann R., Dennes A., Petersen C. M. (2007) Mol. Cell Biol. 27, 6842&#x2013;6851</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2099242</ArticleId><ArticleId IdType="pubmed">17646382</ArticleId></ArticleIdList></Reference><Reference><Citation>Cramer J. F., Gustafsen C., Behrens M. A., Oliveira C. L., Pedersen J. S., Madsen P., Petersen C. M., Thirup S. S. Traffic 11, 259&#x2013;273</Citation><ArticleIdList><ArticleId IdType="pubmed">20015111</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu P., Duong D. M., Peng J. (2010) J. Proteome Res. 8, 3944&#x2013;3950</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2749476</ArticleId><ArticleId IdType="pubmed">19566079</ArticleId></ArticleIdList></Reference><Reference><Citation>Eng J., McCormack A. L., Yates J. R., 3rd. (1994) J. Am. Soc. Mass Spectrom. 5, 976&#x2013;989</Citation><ArticleIdList><ArticleId IdType="pubmed">24226387</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampe W., Riedel I. B., Lintzel J., Bader C. O., Franke I., Schaller H. C. (2000) J. Cell Sci. 113, 4475&#x2013;4485</Citation><ArticleIdList><ArticleId IdType="pubmed">11082041</ArticleId></ArticleIdList></Reference><Reference><Citation>Kubo T., Yamaguchi A., Iwata N., Yamashita T. (2008) Ther. Clin. Risk Manag. 4, 605&#x2013;615</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2500253</ArticleId><ArticleId IdType="pubmed">18827856</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmandke A., Strittmatter S. M. (2007) Neuroscientist 13, 454&#x2013;469</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2849133</ArticleId><ArticleId IdType="pubmed">17901255</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagawa O., Fujisawa K., Ishizaki T., Saito Y., Nakao K., Narumiya S. (1996) FEBS Lett. 392, 189&#x2013;193</Citation><ArticleIdList><ArticleId IdType="pubmed">8772201</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto R., Nakamura Y., Kosako H., Amano M., Kaibuchi K., Inagaki M., Takeda M. (1999) Biochem. Biophys. Res. Commun. 263, 575&#x2013;579</Citation><ArticleIdList><ArticleId IdType="pubmed">10491334</ArticleId></ArticleIdList></Reference><Reference><Citation>Riento K., Ridley A. J. (2003) Nat. Rev. Mol. Cell Biol. 4, 446&#x2013;456</Citation><ArticleIdList><ArticleId IdType="pubmed">12778124</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikenoya M., Hidaka H., Hosoya T., Suzuki M., Yamamoto N., Sasaki Y. (2002) J. Neurochem. 81, 9&#x2013;16</Citation><ArticleIdList><ArticleId IdType="pubmed">12067241</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki Y., Suzuki M., Hidaka H. (2002) Pharmacol. Ther. 93, 225&#x2013;232</Citation><ArticleIdList><ArticleId IdType="pubmed">12191614</ArticleId></ArticleIdList></Reference><Reference><Citation>Herskowitz J. H., Seyfried N. T., Duong D. M., Xia Q., Rees H., Gearing M., Peng J., Lah J., Levey A. (2010) J. Proteome Res. 9, 6368&#x2013;6379</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2997170</ArticleId><ArticleId IdType="pubmed">20886841</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia Q., Cheng D., Duong D. M., Gearing M., Lah J. J., Levey A. I., Peng J. (2008) J. Proteome Res. 7, 2845&#x2013;2851</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2663965</ArticleId><ArticleId IdType="pubmed">18510355</ArticleId></ArticleIdList></Reference><Reference><Citation>Schilling O., Barre O., Huesgen P. F., Overall C. M. (2010) Nat. Methods 7, 508&#x2013;511</Citation><ArticleIdList><ArticleId IdType="pubmed">20526347</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue Y., Zhou F., Zhu M., Ahmed K., Chen G., Yao X. (2005) Nucleic Acids Res. 33, W184&#x2013;187</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1160154</ArticleId><ArticleId IdType="pubmed">15980451</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F. F., Xue Y., Chen G. L., Yao X. (2004) Biochem. Biophys. Res. Commun. 325, 1443&#x2013;1448</Citation><ArticleIdList><ArticleId IdType="pubmed">15555589</ArticleId></ArticleIdList></Reference><Reference><Citation>Spoelgen R., von Arnim C. A., Thomas A. V., Peltan I. D., Koker M., Deng A., Irizarry M. C., Andersen O. M., Willnow T. E., Hyman B. T. (2006) J. Neurosci. 26, 418&#x2013;428</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674411</ArticleId><ArticleId IdType="pubmed">16407538</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung T., Manser E., Tan L., Lim L. (1995) J. Biol. Chem. 270, 29051&#x2013;29054</Citation><ArticleIdList><ArticleId IdType="pubmed">7493923</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsui T., Amano M., Yamamoto T., Chihara K., Nakafuku M., Ito M., Nakano T., Okawa K., Iwamatsu A., Kaibuchi K. (1996) EMBO J. 15, 2208&#x2013;2216</Citation><ArticleIdList><ArticleId IdType="pmc">PMC450144</ArticleId><ArticleId IdType="pubmed">8641286</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung A. Y., Selkoe D. J. (1994) EMBO J. 13, 534&#x2013;542</Citation><ArticleIdList><ArticleId IdType="pmc">PMC394842</ArticleId><ArticleId IdType="pubmed">8313898</ArticleId></ArticleIdList></Reference><Reference><Citation>Amano M., Kaneko T., Maeda A., Nakayama M., Ito M., Yamauchi T., Goto H., Fukata Y., Oshiro N., Shinohara A., Iwamatsu A., Kaibuchi K. (2003) J. Neurochem. 87, 780&#x2013;790</Citation><ArticleIdList><ArticleId IdType="pubmed">14535960</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawano Y., Fukata Y., Oshiro N., Amano M., Nakamura T., Ito M., Matsumura F., Inagaki M., Kaibuchi K. (1999) J. Cell Biol. 147, 1023&#x2013;1038</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2169354</ArticleId><ArticleId IdType="pubmed">10579722</ArticleId></ArticleIdList></Reference><Reference><Citation>Goto H., Kosako H., Tanabe K., Yanagida M., Sakurai M., Amano M., Kaibuchi K., Inagaki M. (1998) J. Biol. Chem. 273, 11728&#x2013;11736</Citation><ArticleIdList><ArticleId IdType="pubmed">9565595</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneko T., Amano M., Maeda A., Goto H., Takahashi K., Ito M., Kaibuchi K. (2000) Biochem. Biophys. Res. Commun. 273, 110&#x2013;116</Citation><ArticleIdList><ArticleId IdType="pubmed">10873572</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohashi K., Nagata K., Maekawa M., Ishizaki T., Narumiya S., Mizuno K. (2000) J. Biol. Chem. 275, 3577&#x2013;3582</Citation><ArticleIdList><ArticleId IdType="pubmed">10652353</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukata Y., Oshiro N., Kinoshita N., Kawano Y., Matsuoka Y., Bennett V., Matsuura Y., Kaibuchi K. (1999) J. Cell Biol. 145, 347&#x2013;361</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2133101</ArticleId><ArticleId IdType="pubmed">10209029</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosako H., Amano M., Yanagida M., Tanabe K., Nishi Y., Kaibuchi K., Inagaki M. (1997) J. Biol. Chem. 272, 10333&#x2013;10336</Citation><ArticleIdList><ArticleId IdType="pubmed">9099667</ArticleId></ArticleIdList></Reference><Reference><Citation>Arimura N., Inagaki N., Chihara K., M&#xe9;nager C., Nakamura N., Amano M., Iwamatsu A., Goshima Y., Kaibuchi K. (2000) J. Biol. Chem. 275, 23973&#x2013;23980</Citation><ArticleIdList><ArticleId IdType="pubmed">10818093</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsui T., Maeda M., Doi Y., Yonemura S., Amano M., Kaibuchi K., Tsukita S. (1998) J. Cell Biol. 140, 647&#x2013;657</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2140160</ArticleId><ArticleId IdType="pubmed">9456324</ArticleId></ArticleIdList></Reference><Reference><Citation>Amano M., Ito M., Kimura K., Fukata Y., Chihara K., Nakano T., Matsuura Y., Kaibuchi K. (1996) J. Biol. Chem. 271, 20246&#x2013;20249</Citation><ArticleIdList><ArticleId IdType="pubmed">8702756</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki Y. (2003) J. Pharmacol. Sci. 93, 35&#x2013;40</Citation><ArticleIdList><ArticleId IdType="pubmed">14501149</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagumo H., Ikenoya M., Sakurada K., Furuya K., Ikuhara T., Hiraoka H., Sasaki Y. (2001) Biochem. Biophys. Res. Commun. 280, 605&#x2013;609</Citation><ArticleIdList><ArticleId IdType="pubmed">11162562</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang J. H., Jiang Y., Toita R., Oishi J., Kawamura K., Han A., Mori T., Niidome T., Ishida M., Tatematsu K., Tanizawa K., Katayama Y. (2007) Biochimie 89, 39&#x2013;47</Citation><ArticleIdList><ArticleId IdType="pubmed">16996192</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashida K., Bartlett A. H., Chen Y., Park P. W. Anat. Rec. 293, 925&#x2013;937</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4621804</ArticleId><ArticleId IdType="pubmed">20503387</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xed;az-Rodr&#xed;guez E., Montero J. C., Espar&#xed;s-Ogando A., Yuste L., Pandiella A. (2002) Mol. Biol. Cell 13, 2031&#x2013;2044</Citation><ArticleIdList><ArticleId IdType="pmc">PMC117622</ArticleId><ArticleId IdType="pubmed">12058067</ArticleId></ArticleIdList></Reference><Reference><Citation>Taira K., Bujo H., Hirayama S., Yamazaki H., Kanaki T., Takahashi K., Ishii I., Miida T., Schneider W. J., Saito Y. (2001) Arterioscler. Thromb. Vasc. Biol. 21, 1501&#x2013;1506</Citation><ArticleIdList><ArticleId IdType="pubmed">11557679</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyborg A. C., Ladd T. B., Zwizinski C. W., Lah J. J., Golde T. E. (2006) Mol. Neurodegener. 1, 3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1513133</ArticleId><ArticleId IdType="pubmed">16930450</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xf6;hm C., Seibel N. M., Henkel B., Steiner H., Haass C., Hampe W. (2006) J. Biol. Chem. 281, 14547&#x2013;14553</Citation><ArticleIdList><ArticleId IdType="pubmed">16531402</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y., Su Y., Li B., Liu F., Ryder J. W., Wu X., Gonzalez-DeWhitt P. A., Gelfanova V., Hale J. E., May P. C., Paul S. M., Ni B. (2003) Science 302, 1215&#x2013;1217</Citation><ArticleIdList><ArticleId IdType="pubmed">14615541</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedrini S., Carter T. L., Prendergast G., Petanceska S., Ehrlich M. E., Gandy S. (2005) PLoS Med. 2, e18</Citation><ArticleIdList><ArticleId IdType="pmc">PMC543463</ArticleId><ArticleId IdType="pubmed">15647781</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21149712</PMID><DateCompleted><Year>2011</Year><Month>03</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>107</Volume><Issue>52</Issue><PubDate><Year>2010</Year><Month>Dec</Month><Day>28</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>CBP gene transfer increases BDNF levels and ameliorates learning and memory deficits in a mouse model of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>22687</StartPage><EndPage>22692</EndPage><MedlinePgn>22687-92</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1012851108</ELocationID><Abstract><AbstractText>Cognitive dysfunction and memory loss are common features of Alzheimer's disease (AD). Abnormalities in the expression profile of immediate early genes that play a critical role in memory formation, such as the cAMP-response element binding protein (CREB), have been reported in the brains of AD patients. Here we show that amyloid-&#x3b2; (A&#x3b2;) accumulation, which plays a primary role in the cognitive deficits of AD, interferes with CREB activity. We further show that restoring CREB function via brain viral delivery of the CREB-binding protein (CBP) improves learning and memory deficits in an animal model of AD. Notably, such improvements occur without changes in A&#x3b2; and tau pathology, and instead are linked to an increased level of brain-derived neurotrophic factor. The resulting data suggest that A&#x3b2;-induced learning and memory deficits are mediated by alterations in CREB function, based on the finding that restoring CREB activity by directly modulating CBP levels in the brains of adult mice is sufficient to ameliorate learning and memory. Therefore, increasing CBP expression in adult brains may be a valid therapeutic approach not only for AD, but also for various brain disorders characterized by alterations in immediate early genes, further supporting the concept that viral vector delivery may be a viable therapeutic approach in neurodegenerative diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Caccamo</LastName><ForeName>Antonella</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Physiology, and Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center, San Antonio, TX 78229, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maldonado</LastName><ForeName>Monica A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Bokov</LastName><ForeName>Alex F</ForeName><Initials>AF</Initials></Author><Author ValidYN="Y"><LastName>Majumder</LastName><ForeName>Smita</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Oddo</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R00 AG029729</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00-AG29729-4</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>12</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019208">Brain-Derived Neurotrophic Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017362">Cyclic AMP Response Element-Binding Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.1.48</RegistryNumber><NameOfSubstance UI="D050882">CREB-Binding Protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019208" MajorTopicYN="N">Brain-Derived Neurotrophic Factor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016466" MajorTopicYN="N">CHO Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050882" MajorTopicYN="N">CREB-Binding Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003412" MajorTopicYN="N">Cricetulus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017362" MajorTopicYN="N">Cyclic AMP Response Element-Binding Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018014" MajorTopicYN="N">Gene Transfer Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015316" MajorTopicYN="N">Genetic Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007859" MajorTopicYN="N">Learning Disabilities</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016086" MajorTopicYN="N">Lentivirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>3</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>6</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21149712</ArticleId><ArticleId IdType="pmc">PMC3012497</ArticleId><ArticleId IdType="doi">10.1073/pnas.1012851108</ArticleId><ArticleId IdType="pii">1012851108</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med. 2010;362:329&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">20107219</ArticleId></ArticleIdList></Reference><Reference><Citation>Crews L, Masliah E. Molecular mechanisms of neurodegeneration in Alzheimer's disease. Hum Mol Genet. 2010;19(R1):R12&#x2013;R20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2875049</ArticleId><ArticleId IdType="pubmed">20413653</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder EM, et al. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci. 2005;8:1051&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pubmed">16025111</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Mucke L. Amyloid-beta&#x2013;induced neuronal dysfunction in Alzheimer's disease: From synapses toward neural networks. Nat Neurosci. 2010;13:812&#x2013;818.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3072750</ArticleId><ArticleId IdType="pubmed">20581818</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickey CA, et al. Selectively reduced expression of synaptic plasticity-related genes in amyloid precursor protein + presenilin-1 transgenic mice. J Neurosci. 2003;23:5219&#x2013;5226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741153</ArticleId><ArticleId IdType="pubmed">12832546</ArticleId></ArticleIdList></Reference><Reference><Citation>Caccamo A, Majumder S, Richardson A, Strong R, Oddo S. Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: Effects on cognitive impairments. J Biol Chem. 2010;285:13107&#x2013;13120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2857107</ArticleId><ArticleId IdType="pubmed">20178983</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma QL, et al. Evidence of Abeta- and transgene-dependent defects in ERK-CREB signaling in Alzheimer's models. J Neurochem. 2007;103:1594&#x2013;1607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2527620</ArticleId><ArticleId IdType="pubmed">17760871</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, et al. Vulnerability of dentate granule cells to disruption of arc expression in human amyloid precursor protein transgenic mice. J Neurosci. 2005;25:9686&#x2013;9693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725729</ArticleId><ArticleId IdType="pubmed">16237173</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, et al. Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease&#x2013;related cognitive deficits. Proc Natl Acad Sci USA. 2003;100:9572&#x2013;9577.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC170959</ArticleId><ArticleId IdType="pubmed">12881482</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanahan A, Worley P. Immediate-early genes and synaptic function. Neurobiol Learn Mem. 1998;70:37&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">9753585</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitolo OV, et al. Amyloid beta-peptide inhibition of the PKA/CREB pathway and long-term potentiation: Reversibility by drugs that enhance cAMP signaling. Proc Natl Acad Sci USA. 2002;99:13217&#x2013;13221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC130613</ArticleId><ArticleId IdType="pubmed">12244210</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong L, Thornton PL, Balazs R, Cotman CW. Beta -amyloid(1&#x2013;42) impairs activity-dependent cAMP-response element&#x2013;binding protein signaling in neurons at concentrations in which cell survival Is not compromised. J Biol Chem. 2001;276:17301&#x2013;17306.</Citation><ArticleIdList><ArticleId IdType="pubmed">11278679</ArticleId></ArticleIdList></Reference><Reference><Citation>Espa&#xf1;a J, et al. beta-Amyloid disrupts activity-dependent gene transcription required for memory through the CREB coactivator CRTC1. J Neurosci. 2010;30:9402&#x2013;9410.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6632424</ArticleId><ArticleId IdType="pubmed">20631169</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodman RH, Smolik S. CBP/p300 in cell growth, transformation, and development. Genes Dev. 2000;14:1553&#x2013;1577.</Citation><ArticleIdList><ArticleId IdType="pubmed">10887150</ArticleId></ArticleIdList></Reference><Reference><Citation>Vo N, Goodman RH. CREB-binding protein and p300 in transcriptional regulation. J Biol Chem. 2001;276:13505&#x2013;13508.</Citation><ArticleIdList><ArticleId IdType="pubmed">11279224</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis YI, Stephanou A, Latchman DS. CREB-binding protein activation by presenilin 1 but not by its M146L mutant. Neuroreport. 2006;17:917&#x2013;921.</Citation><ArticleIdList><ArticleId IdType="pubmed">16738488</ArticleId></ArticleIdList></Reference><Reference><Citation>Marambaud P, et al. A CBP-binding transcriptional repressor produced by the PS1/epsilon-cleavage of N-cadherin is inhibited by PS1 FAD mutations. Cell. 2003;114:635&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pubmed">13678586</ArticleId></ArticleIdList></Reference><Reference><Citation>Saura CA, et al. Loss of presenilin functon causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron. 2004;42:23&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">15066262</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YS, Silva AJ. The molecular and cellular biology of enhanced cognition. Nat Rev Neurosci. 2009;10:126&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2664745</ArticleId><ArticleId IdType="pubmed">19153576</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, et al. Blocking Abeta42 accumulation delays the onset and progression of tau pathology via the C terminus of heat shock protein 70&#x2013;interacting protein: A mechanistic link between Abeta and tau pathology. J Neurosci. 2008;28:12163&#x2013;12175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6671718</ArticleId><ArticleId IdType="pubmed">19020010</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: Intracellular Abeta and synaptic dysfunction. Neuron. 2003;39:409&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron. 2004;43:321&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pubmed">15294141</ArticleId></ArticleIdList></Reference><Reference><Citation>Koo EH, Squazzo SL. Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J Biol Chem. 1994;269:17386&#x2013;17389.</Citation><ArticleIdList><ArticleId IdType="pubmed">8021238</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleary JP, et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci. 2005;8:79&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">15608634</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, et al. The carboxy-terminal fragment of inhibitor-2 of protein phosphatase-2A induces Alzheimer disease pathology and cognitive impairment. FASEB J. 2010;24:4420&#x2013;4432.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3229424</ArticleId><ArticleId IdType="pubmed">20651003</ArticleId></ArticleIdList></Reference><Reference><Citation>Cowansage KK, LeDoux JE, Monfils MH. Brain-derived neurotrophic factor: a dynamic gatekeeper of neural plasticity. Curr Mol Pharmacol. 2010;3:12&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">20030625</ArticleId></ArticleIdList></Reference><Reference><Citation>Hock C, Heese K, Hulette C, Rosenberg C, Otten U. Region-specific neurotrophin imbalances in Alzheimer disease: Decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. Arch Neurol. 2000;57:846&#x2013;851.</Citation><ArticleIdList><ArticleId IdType="pubmed">10867782</ArticleId></ArticleIdList></Reference><Reference><Citation>Connor B, et al. Brain-derived neurotrophic factor is reduced in Alzheimer's disease. Brain Res Mol Brain Res. 1997;49:71&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">9387865</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng S, et al. Decreased brain-derived neurotrophic factor depends on amyloid aggregation state in transgenic mouse models of Alzheimer's disease. J Neurosci. 2009;29:9321&#x2013;9329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3411546</ArticleId><ArticleId IdType="pubmed">19625522</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu F, et al. Brain-derived neurotrophic factor rapidly increases NMDA receptor channel activity through Fyn-mediated phosphorylation. Brain Res. 2006;1121:22&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">17045972</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, et al. Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron. 2009;62:788&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2702854</ArticleId><ArticleId IdType="pubmed">19555648</ArticleId></ArticleIdList></Reference><Reference><Citation>Garzon DJ, Fahnestock M. Oligomeric amyloid decreases basal levels of brain-derived neurotrophic factor (BDNF) mRNA via specific down-regulation of BDNF transcripts IV and V in differentiated human neuroblastoma cells. J Neurosci. 2007;27:2628&#x2013;2635.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672502</ArticleId><ArticleId IdType="pubmed">17344400</ArticleId></ArticleIdList></Reference><Reference><Citation>Fahnestock M, et al. BDNF increases with behavioral enrichment and an antioxidant diet in the aged dog. Neurobiol Aging. 2010 in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2935515</ArticleId><ArticleId IdType="pubmed">20447733</ArticleId></ArticleIdList></Reference><Reference><Citation>Neeper SA, G&#xf3;mez-Pinilla F, Choi J, Cotman CW. Physical activity increases mRNA for brain-derived neurotrophic factor and nerve growth factor in rat brain. Brain Res. 1996;726:49&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">8836544</ArticleId></ArticleIdList></Reference><Reference><Citation>Blurton-Jones M, et al. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc Natl Acad Sci USA. 2009;106:13594&#x2013;13599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2715325</ArticleId><ArticleId IdType="pubmed">19633196</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagahara AH, et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med. 2009;15:331&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2838375</ArticleId><ArticleId IdType="pubmed">19198615</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouaux C, Loeffler JP, Boutillier AL. Targeting CREB-binding protein (CBP) loss of function as a therapeutic strategy in neurological disorders. Biochem Pharmacol. 2004;68:1157&#x2013;1164.</Citation><ArticleIdList><ArticleId IdType="pubmed">15313413</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21149866</PMID><DateCompleted><Year>2011</Year><Month>01</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>134</Volume><Issue>Pt 1</Issue><PubDate><Year>2011</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease.</ArticleTitle><Pagination><StartPage>301</StartPage><EndPage>317</EndPage><MedlinePgn>301-17</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awq349</ELocationID><Abstract><AbstractText>The accumulation of &#x3b2;-amyloid in the brain is an early event in Alzheimer's disease. This study presents the first patient with Alzheimer's disease who underwent positron emission tomography imaging with the amyloid tracer, Pittsburgh Compound B to visualize fibrillar &#x3b2;-amyloid in the brain. Here we relate the clinical progression, amyloid and functional brain positron emission tomography imaging with molecular neuropathological alterations at autopsy to gain new insight into the relationship between &#x3b2;-amyloid accumulation, inflammatory processes and the cholinergic neurotransmitter system in Alzheimer's disease brain. The patient underwent positron emission tomography studies with (18)F-fluorodeoxyglucose three times (at ages 53, 56 and 58 years) and twice with Pittsburgh Compound B (at ages 56 and 58 years), prior to death at 61 years of age. The patient showed a pronounced decline in cerebral glucose metabolism and cognition during disease progression, while Pittsburgh Compound B retention remained high and stable at follow-up. Neuropathological examination of the brain at autopsy confirmed the clinical diagnosis of pure Alzheimer's disease. A comprehensive neuropathological investigation was performed in nine brain regions to measure the regional distribution of &#x3b2;-amyloid, neurofibrillary tangles and the levels of binding of (3)H-nicotine and (125)I-&#x3b1;-bungarotoxin to neuronal nicotinic acetylcholine receptor subtypes, (3)H-L-deprenyl to activated astrocytes and (3)H-PK11195 to microglia, as well as butyrylcholinesterase activity. Regional in vivo (11)C-Pittsburgh Compound B-positron emission tomography retention positively correlated with (3)H-Pittsburgh Compound B binding, total insoluble &#x3b2;-amyloid, and &#x3b2;-amyloid plaque distribution, but not with the number of neurofibrillary tangles measured at autopsy. There was a negative correlation between regional fibrillar &#x3b2;-amyloid and levels of (3)H-nicotine binding. In addition, a positive correlation was found between regional (11)C-Pittsburgh Compound B positron emission tomography retention and (3)H-Pittsburgh Compound B binding with the number of glial fibrillary acidic protein immunoreactive cells, but not with (3)H-L-deprenyl and (3)H-PK-11195 binding. In summary, high (11)C-Pittsburgh Compound B positron emission tomography retention significantly correlates with both fibrillar &#x3b2;-amyloid and losses of neuronal nicotinic acetylcholine receptor subtypes at autopsy, suggesting a closer involvement of &#x3b2;-amyloid pathology with neuronal nicotinic acetylcholine receptor subtypes than with inflammatory processes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kadir</LastName><ForeName>Ahmadul</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden. agneta.k.nordberg@ki.se</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marutle</LastName><ForeName>Amelia</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Gonzalez</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Sch&#xf6;ll</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Almkvist</LastName><ForeName>Ove</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Mousavi</LastName><ForeName>Malahat</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Mustafiz</LastName><ForeName>Tamanna</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Darreh-Shori</LastName><ForeName>Taher</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Nennesmo</LastName><ForeName>Inger</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Nordberg</LastName><ForeName>Agneta</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>12</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="Y">Aniline Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="Y">Thiazoles</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>12</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21149866</ArticleId><ArticleId IdType="pmc">PMC3009843</ArticleId><ArticleId IdType="doi">10.1093/brain/awq349</ArticleId><ArticleId IdType="pii">awq349</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alafuzoff I, Pikkarainen M, Al-Sarraj S, Arzberger T, Bell J, Bodi I, et al. Interlaboratory comparison of assessments of Alzheimer disease-related lesions: a study of the BrainNet Europe Consortium. J Neuropathol Exp Neurol. 2006;65:740&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">16896308</ArticleId></ArticleIdList></Reference><Reference><Citation>Almkvist O, Tallberg IM. Cognitive decline from estimated premorbid status predicts neurodegeneration in Alzheimer&#x2019;s disease. Neuropsychology. 2009;23:117&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">19210039</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson JL, Thurfjell L. Implementation and validation of a fully automatic system for intra- and interindividual registration of PET brain scans. J Comput Assist Tomogr. 1997;21:136&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">9022786</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacskai BJ, Frosch MP, Freeman SH, Raymond SB, Augustinack JC, Johnson KA, et al. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol. 2007;64:431&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">17353389</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergman I, Blomberg M, Almkvist O. The importance of impaired physical health and age in normal cognitive aging. Scand J Psychol. 2007;48:115&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">17430364</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6:131&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">20157306</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, de Vos RA, Jansen EN, Bratzke H, Braak E. Neuropathological hallmarks of Alzheimer&#x2019;s and Parkinson&#x2019;s diseases. Prog Brain Res. 1998;117:267&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">9932414</ArticleId></ArticleIdList></Reference><Reference><Citation>Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE, et al. In-vivo measurement of activated microglia in dementia. Lancet. 2001;358:461&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">11513911</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns NJ, Ikonomovic MD, Benzinger T, Storandt M, Fagan AM, Shah A, et al. Absence of PIttsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease. Arch Neurol. 2009;66:1557&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2796200</ArticleId><ArticleId IdType="pubmed">20008664</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter SF, Sch&#xf6;ll M, Almkvist O, Wall A, Engler H, L&#xe5;ngstr&#xf6;m B, et al. Investigating astrocytes with 11C-deuterium deprenyl in mild cognitive impairment and mild Alzheimer&#x2019;s - a multi-tracer positron emission tomography paradigm. The abstract/poster (poster number P4-089) was presented in the Hot Topics session in Alzheimer's Association International Conference on Alzheimer's Disease 2010 (AAICAD), July 10&#x2013;15, Honolulu, Hawaii. 2010</Citation></Reference><Reference><Citation>Clifford PM, Siu G, Kosciuk M, Levin EC, Venkataraman V, D&#x2019;Andrea MR, et al. Alpha7 nicotinic acetylcholine receptor expression by vascular smooth muscle cells facilitates the deposition of Abeta peptides and promotes cerebrovascular amyloid angiopathy. Brain Res. 2008;1234:158&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">18708033</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings BJ, Pike CJ, Shankle R, Cotman CW. Beta-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer&#x2019;s disease. Neurobiol Aging. 1996;17:921&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">9363804</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Andrea MR, Nagele RG, Wang HY, Peterson PA, Lee DH. Evidence that neurones accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer&#x2019;s disease. Histopathology. 2001;38:120&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">11207825</ArticleId></ArticleIdList></Reference><Reference><Citation>Darreh-Shori T, Brimijoin S, Kadir A, Almkvist O, Nordberg A. Differential CSF butyrylcholinesterase levels in Alzheimer&#x2019;s disease patients with the ApoE epsilon4 allele, in relation to cognitive function and cerebral glucose metabolism. Neurobiol Dis. 2006;24:326&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">16973370</ArticleId></ArticleIdList></Reference><Reference><Citation>Darreh-Shori T, Forsberg A, Modiri N, Andreasen N, Blennow K, Kamil C, et al. Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer&#x2019;s disease in the brain in vivo. Neurobiol Aging. 2010 Advance Access published on June 8, 2010, doi:10.1016/j.neurobiolaging.2010.04.028.</Citation><ArticleIdList><ArticleId IdType="pubmed">20538374</ArticleId></ArticleIdList></Reference><Reference><Citation>Darreh-Shori T, Modiri N, Blennow K, Baza S, Kamil C, Ahmed H, et al. The apolipoprotein E varepsilon4 allele plays pathological roles in AD through high protein expression and interaction with butyrylcholinesterase. Neurobiol Aging. 2009 doi:10.1016/j.neurobiolaging.2009.07.015, (published online 25 August 2009)</Citation><ArticleIdList><ArticleId IdType="pubmed">19713000</ArticleId></ArticleIdList></Reference><Reference><Citation>Debruyne JC, Versijpt J, Van Laere KJ, De Vos F, Keppens J, Strijckmans K, et al. PET visualization of microglia in multiple sclerosis patients using [11C]PK11195. Eur J Neurol. 2003;10:257&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">12752399</ArticleId></ArticleIdList></Reference><Reference><Citation>Dineley KT, Bell KA, Bui D, Sweatt JD. beta -Amyloid peptide activates alpha 7 nicotinic acetylcholine receptors expressed in Xenopus oocytes. J Biol Chem. 2002;277:25056&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">11983690</ArticleId></ArticleIdList></Reference><Reference><Citation>Diorio D, Welner SA, Butterworth RF, Meaney MJ, Suranyi-Cadotte BE. Peripheral benzodiazepine binding sites in Alzheimer&#x2019;s disease frontal and temporal cortex. Neurobiol Aging. 1991;12:255&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">1652108</ArticleId></ArticleIdList></Reference><Reference><Citation>Dougherty JJ, Wu J, Nichols RA. Beta-amyloid regulation of presynaptic nicotinic receptors in rat hippocampus and neocortex. J Neurosci. 2003;23:6740&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740736</ArticleId><ArticleId IdType="pubmed">12890766</ArticleId></ArticleIdList></Reference><Reference><Citation>Edison P, Archer HA, Gerhard A, Hinz R, Pavese N, Turkheimer FE, et al. Microglia, amyloid, and cognition in Alzheimer&#x2019;s disease: An [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol Dis. 2008;32:412&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">18786637</ArticleId></ArticleIdList></Reference><Reference><Citation>Edison P, Archer HA, Hinz R, Hammers A, Pavese N, Tai YF, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology. 2007;68:501&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17065593</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellis RJ, Olichney JM, Thal LJ, Mirra SS, Morris JC, Beekly D, et al. Cerebral amyloid angiopathy in the brains of patients with Alzheimer&#x2019;s disease: the CERAD experience, Part XV. Neurology. 1996;46:1592&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">8649554</ArticleId></ArticleIdList></Reference><Reference><Citation>Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer&#x2019;s disease. Brain. 2006;129:2856&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">16854944</ArticleId></ArticleIdList></Reference><Reference><Citation>Engler H, Lundberg PO, Ekbom K, Nennesmo I, Nilsson A, Bergstrom M, et al. Multitracer study with positron emission tomography in Creutzfeldt-Jakob disease. Eur J Nucl Med Mol Imaging. 2003;30:85&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">12483414</ArticleId></ArticleIdList></Reference><Reference><Citation>Esiri MM. Pro: can neuropathology really confirm the exact diagnosis? Alzheimers Res Ther. 2010;2:10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2876787</ArticleId><ArticleId IdType="pubmed">20497619</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsberg A, Almkvist O, Engler H, Wall A, Langstrom B, Nordberg A. High PIB retention in Alzheimer&#x2019;s disease is an early event with complex relationship with CSF biomarkers and functional parameters. Curr Alzheimer Res. 2010;7:56&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">20205671</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging. 2008;29:1456&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">17499392</ArticleId></ArticleIdList></Reference><Reference><Citation>Frisoni GB, Fox NC, Jack CR, Jr, Scheltens P, Thompson PM. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol. 2010;6:67&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2938772</ArticleId><ArticleId IdType="pubmed">20139996</ArticleId></ArticleIdList></Reference><Reference><Citation>Furst AJ, Rabinovici GD, Rostomian AH, Steed T, Alkalay A, Racine C, et al. Cognition, glucose metabolism and amyloid burden in Alzheimer&#x2019;s disease. Neurobiol Aging. 2010 Advance Access published on April 22, 2010, doi:10.1016/j.neurobiolaging.2010.03.011.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2920373</ArticleId><ArticleId IdType="pubmed">20417582</ArticleId></ArticleIdList></Reference><Reference><Citation>Geula C, Mesulam MM. Cholinesterases and the pathology of Alzheimer disease. Alzheimer Dis Assoc Disord. 1995;9 (Suppl 2):23&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">8534419</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan ZZ, Miao H, Tian JY, Unger C, Nordberg A, Zhang X. Suppressed expression of nicotinic acetylcholine receptors by nanomolar beta-amyloid peptides in PC12 cells. J Neural Transm. 2001;108:1417&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">11810405</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellstrom-Lindahl E, Mousavi M, Ravid R, Nordberg A. Reduced levels of Abeta 40 and Abeta 42 in brains of smoking controls and Alzheimer&#x2019;s patients. Neurobiol Dis. 2004;15:351&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">15006705</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer&#x2019;s disease. Brain. 2008;131:1630&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2408940</ArticleId><ArticleId IdType="pubmed">18339640</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonomovic MD, Wecker L, Abrahamson EE, Wuu J, Counts SE, Ginsberg SD, et al. Cortical alpha7 nicotinic acetylcholine receptor and beta-amyloid levels in early Alzheimer disease. Arch Neurol. 2009;66:646&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2841566</ArticleId><ArticleId IdType="pubmed">19433665</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingelsson M, Fukumoto H, Newell KL, Growdon JH, Hedley-Whyte ET, Frosch MP, et al. Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology. 2004;62:925&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">15037694</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer&#x2019;s disease: implications for sequence of pathological events in Alzheimer&#x2019;s disease. Brain. 2009;132:1355&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677798</ArticleId><ArticleId IdType="pubmed">19339253</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger KA. Con: can neuropathology really confirm the exact diagnosis? Alzheimers Res Ther. 2010;2:11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2876788</ArticleId><ArticleId IdType="pubmed">20497615</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Gregas M, Becker JA, Kinnecom C, Salat DH, Moran EK, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol. 2007;62:229&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">17683091</ArticleId></ArticleIdList></Reference><Reference><Citation>Jossan SS, Gillberg PG, d&#x2019;Argy R, Aquilonius SM, Langstrom B, Halldin C, et al. Quantitative localization of human brain monoamine oxidase B by large section autoradiography using L-[3H]deprenyl. Brain Res. 1991a;547:69&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">1907217</ArticleId></ArticleIdList></Reference><Reference><Citation>Jossan SS, Gillberg PG, Gottfries CG, Karlsson I, Oreland L. Monoamine oxidase B in brains from patients with Alzheimer&#x2019;s disease: a biochemical and autoradiographical study. Neuroscience. 1991b;45:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">1754059</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadir A, Almkvist O, Forsberg A, Wall A, Engler H, Langstrom B, et al. Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer&#x2019;s disease. Neurobiol Aging. 2010 Advance Access published on August 3, 2010, doi:10.1016/j.neurobiolaging.2010.06.015.</Citation><ArticleIdList><ArticleId IdType="pubmed">20688420</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadir A, Almkvist O, Wall A, Langstrom B, Nordberg A. PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer&#x2019;s disease. Psychopharmacology. 2006;188:509&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">16832659</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer&#x2019;s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Lopresti BJ, Ikonomovic MD, Lefterov IM, Koldamova RP, Abrahamson EE, et al. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer&#x2019;s disease brain but not in transgenic mouse brain. J Neurosci. 2005;25:10598&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725842</ArticleId><ArticleId IdType="pubmed">16291932</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumlien E, Hilton-Brown P, Spannare B, Gillberg PG. In vitro quantitative autoradiography of [3H]-L-deprenyl and [3H]-PK 11195 binding sites in human epileptic hippocampus. Epilepsia. 1992;33:610&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">1321029</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee DH, Wang HY. Differential physiologic responses of alpha7 nicotinic acetylcholine receptors to beta-amyloid1-40 and beta-amyloid1-42. J Neurobiol. 2003;55:25&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">12605456</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmann DJ, Nagy Z, Litchfield S, Borja MC, Smith AD. Association of butyrylcholinesterase K variant with cholinesterase-positive neuritic plaques in the temporal cortex in late-onset Alzheimer&#x2019;s disease. Hum Genet. 2000;106:447&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">10830913</ArticleId></ArticleIdList></Reference><Reference><Citation>Leinonen V, Alafuzoff I, Aalto S, Suotunen T, Savolainen S, Nagren K, et al. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol. 2008;65:1304&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">18695050</ArticleId></ArticleIdList></Reference><Reference><Citation>Lilja AM, Porras O, Storelli E, Nordberg A, Marutle A. Functional interactions of fibrillar and oligomeric amyloid &#x3b2; with alpha 7 nicotinic receptors in Alzheimer&#x2019;s disease. doi:10.3233/j. Alzheimer's Dis.2010-101242; In press.</Citation><ArticleIdList><ArticleId IdType="pubmed">21116052</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Ford B, Mann MA, Fischbach GD. Neuregulins increase alpha7 nicotinic acetylcholine receptors and enhance excitatory synaptic transmission in GABAergic interneurons of the hippocampus. J Neurosci. 2001;21:5660&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762647</ArticleId><ArticleId IdType="pubmed">11466437</ArticleId></ArticleIdList></Reference><Reference><Citation>Lockhart A, Lamb JR, Osredkar T, Sue LI, Joyce JN, Ye L, et al. PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. Brain. 2007;130:2607&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">17698496</ArticleId></ArticleIdList></Reference><Reference><Citation>Ly JV, Donnan GA, Villemagne VL, Zavala JA, Ma H, O&#x2019;Keefe G, et al. 11C-PIB binding is increased in patients with cerebral amyloid angiopathy-related hemorrhage. Neurology. 2010;74:487&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">20142615</ArticleId></ArticleIdList></Reference><Reference><Citation>Marutle A, Warpman U, Bogdanovic N, Nordberg A. Regional distribution of subtypes of nicotinic receptors in human brain and effect of aging studied by (+/-)-[3H]epibatidine. Brain Res. 1998;801:143&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9729344</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem. 2003;46:2740&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">12801237</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP. Pathways towards and away from Alzheimer&#x2019;s disease. Nature. 2004;430:631&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3091392</ArticleId><ArticleId IdType="pubmed">15295589</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, McGeer EG, Yasojima K. Alzheimer disease and neuroinflammation. J Neural Transm Suppl. 2000;59:53&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">10961418</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2018;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34:939&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Gearing M, McKeel DW, Jr, Crain BJ, Hughes JP, van Belle G, et al. Interlaboratory comparison of neuropathology assessments in Alzheimer&#x2019;s disease: a study of the Consortium to Establish a Registry for Alzheimer&#x2019;s Disease (CERAD) J Neuropathol Exp Neurol. 1994;53:303&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">8176413</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The Consortium to Establish a Registry for Alzheimer&#x2019;s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer&#x2019;s disease. Neurology. 1991;41:479&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagele RG, D&#x2018;Andrea MR, Anderson WJ, Wang HY. Intracellular accumulation of beta-amyloid(1-42) in neurons is facilitated by the alpha 7 nicotinic acetylcholine receptor in Alzheimer&#x2019;s disease. Neuroscience. 2002;110:199&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">11958863</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordberg A. Nicotinic receptor abnormalities of Alzheimer&#x2019;s disease: therapeutic implications. Biol Psychiatry. 2001;49:200&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">11230871</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordberg A, Rinne JO, Kadir A, Langstrom B. The use of PET in Alzheimer disease. Nat Rev Neurol. 2010;6:78&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">20139997</ArticleId></ArticleIdList></Reference><Reference><Citation>Okello A, Edison P, Archer HA, Turkheimer FE, Kennedy J, Bullock R, et al. Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology. 2009;72:56&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2817573</ArticleId><ArticleId IdType="pubmed">19122031</ArticleId></ArticleIdList></Reference><Reference><Citation>Paterson D, Nordberg A. Neuronal nicotinic receptors in the human brain. Prog Neurobiol. 2000;61:75&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">10759066</ArticleId></ArticleIdList></Reference><Reference><Citation>Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab. 1983;3:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">6822610</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry EK, Perry RH, Blessed G, Tomlinson BE. Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol. 1978;4:273&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">703927</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeifer LA, White LR, Ross GW, Petrovitch H, Launer LJ. Cerebral amyloid angiopathy and cognitive function: the HAAS autopsy study. Neurology. 2002;58:1629&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">12058090</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, McKeel DW, Jr, Buckles VD, Roe CM, Xiong C, Grundman M, et al. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging. 2009;30:1026&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2737680</ArticleId><ArticleId IdType="pubmed">19376612</ArticleId></ArticleIdList></Reference><Reference><Citation>Saura J, Luque JM, Cesura AM, Da Prada M, Chan-Palay V, Huber G, et al. Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography. Neuroscience. 1994;62:15&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">7816197</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheinin NM, Aalto S, Koikkalainen J, Lotjonen J, Karrasch M, Kemppainen N, et al. Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls. Neurology. 2009;73:1186&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">19726751</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, et al. Atrophy of medial temporal lobes on MRI in &#x201c;probable&#x201d; Alzheimer&#x2019;s disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry. 1992;55:967&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1015202</ArticleId><ArticleId IdType="pubmed">1431963</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;ll M, Almkvist O, Axelman K, Stefanova E, Wall A, Westman E, et al. Glucose metabolism and PIB binding in carriers of a His163Tyr presenilin 1 mutation. Neurobiol Aging. 2009 Advance Access published on September 29, 2009, doi:10.1016/j.neurobiolaging.2009.08.016.</Citation><ArticleIdList><ArticleId IdType="pubmed">19796846</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson JE, Ince PG, Lace G, Forster G, Shaw PJ, Matthews F, et al. Astrocyte phenotype in relation to Alzheimer-type pathology in the ageing brain. Neurobiol Aging. 2010;31:578&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">18586353</ArticleId></ArticleIdList></Reference><Reference><Citation>Svedberg MM, Hall H, Hellstrom-Lindahl E, Estrada S, Guan Z, Nordberg A, et al. [(11)C]PIB-amyloid binding and levels of Abeta40 and Abeta42 in postmortem brain tissue from Alzheimer patients. Neurochem Int. 2009;54:347&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">19162107</ArticleId></ArticleIdList></Reference><Reference><Citation>Talairach J, Tournoux P. Co-planar Stereotaxic Atlas of the Human Brain. New York: Thieme Medical; 1988.</Citation></Reference><Reference><Citation>Tampellini D, Gouras GK. Synapses, synaptic activity and intraneuronal abeta in Alzheimer&#x2019;s disease. Front Aging Neurosci. 2010;2:1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2912028</ArticleId><ArticleId IdType="pubmed">20725518</ArticleId></ArticleIdList></Reference><Reference><Citation>Tasker A, Perry EK, Ballard CG. Butyrylcholinesterase: impact on symptoms and progression of cognitive impairment. Expert Rev Neurother. 2005;5:101&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">15853480</ArticleId></ArticleIdList></Reference><Reference><Citation>Teaktong T, Graham A, Court J, Perry R, Jaros E, Johnson M, et al. Alzheimer&#x2019;s disease is associated with a selective increase in alpha7 nicotinic acetylcholine receptor immunoreactivity in astrocytes. Glia. 2003;41:207&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">12509811</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pubmed">12084879</ArticleId></ArticleIdList></Reference><Reference><Citation>Thangavel R, Van Hoesen GW, Zaheer A. The abnormally phosphorylated tau lesion of early Alzheimer&#x2019;s disease. Neurochem Res. 2009;34:118&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">18437565</ArticleId></ArticleIdList></Reference><Reference><Citation>Vas A, Shchukin Y, Karrenbauer VD, Cselenyi Z, Kostulas K, Hillert J, et al. Functional neuroimaging in multiple sclerosis with radiolabelled glia markers: preliminary comparative PET studies with [11C]vinpocetine and [11C]PK11195 in patients. J Neurol Sci. 2008;264:9&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">17727889</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiley CA, Lopresti BJ, Venneti S, Price J, Klunk WE, DeKosky ST, et al. Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. Arch Neurol. 2009;66:60&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2666881</ArticleId><ArticleId IdType="pubmed">19139300</ArticleId></ArticleIdList></Reference><Reference><Citation>von Gunten A, Kovari E, Bussiere T, Rivara CB, Gold G, Bouras C, et al. Cognitive impact of neuronal pathology in the entorhinal cortex and CA1 field in Alzheimer&#x2019;s disease. Neurobiol Aging. 2006;27:270&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">16399212</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaguchi H, Hirai S, Morimatsu M, Shoji M, Nakazato Y. Diffuse type of senile plaques in the cerebellum of Alzheimer-type dementia demonstrated by beta protein immunostain. Acta Neuropathol. 1989;77:314&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">2466390</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu WF, Guan ZZ, Bogdanovic N, Nordberg A. High selective expression of alpha7 nicotinic receptors on astrocytes in the brains of patients with sporadic Alzheimer&#x2019;s disease and patients carrying Swedish APP 670/671 mutation: a possible association with neuritic plaques. Exp Neurol. 2005;192:215&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">15698636</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu SG, Sheng JG, Jones RA, Brewer MM, Zhou XQ, Mrak RE, et al. Increased interleukin-1beta converting enzyme expression and activity in Alzheimer disease. J Neuropathol Exp Neurol. 1999;58:582&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">10374748</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21151119</PMID><DateCompleted><Year>2011</Year><Month>02</Month><Day>03</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2011</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Caspase-3 triggers early synaptic dysfunction in a mouse model of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>69</StartPage><EndPage>76</EndPage><MedlinePgn>69-76</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nn.2709</ELocationID><Abstract><AbstractText>Synaptic loss is the best pathological correlate of the cognitive decline in Alzheimer's disease; however, the molecular mechanisms underlying synaptic failure are unknown. We found a non-apoptotic baseline caspase-3 activity in hippocampal dendritic spines and an enhancement of this activity at the onset of memory decline in the Tg2576-APPswe mouse model of Alzheimer's disease. In spines, caspase-3 activated calcineurin, which in turn triggered dephosphorylation and removal of the GluR1 subunit of AMPA-type receptor from postsynaptic sites. These molecular modifications led to alterations of glutamatergic synaptic transmission and plasticity and correlated with spine degeneration and a deficit in hippocampal-dependent memory. Notably, pharmacological inhibition of caspase-3 activity in Tg2576 mice rescued the observed Alzheimer-like phenotypes. Our results identify a previously unknown caspase-3-dependent mechanism that drives synaptic failure and contributes to cognitive dysfunction in Alzheimer's disease. These findings indicate that caspase-3 is a potential target for pharmacological therapy during early disease stages.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>D'Amelio</LastName><ForeName>Marcello</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Dulbecco Telethon Institute at the Laboratory of Molecular Neuroembryology, Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS) Fondazione Santa Lucia, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cavallucci</LastName><ForeName>Virve</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Middei</LastName><ForeName>Silvia</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Marchetti</LastName><ForeName>Cristina</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Pacioni</LastName><ForeName>Simone</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Ferri</LastName><ForeName>Alberto</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Diamantini</LastName><ForeName>Adamo</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>De Zio</LastName><ForeName>Daniela</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Carrara</LastName><ForeName>Paolo</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Battistini</LastName><ForeName>Luca</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Moreno</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Bacci</LastName><ForeName>Alberto</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Ammassari-Teule</LastName><ForeName>Martine</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Marie</LastName><ForeName>H&#xe9;l&#xe8;ne</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Cecconi</LastName><ForeName>Francesco</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>TCR04004</GrantID><Acronym>TI_</Acronym><Agency>Telethon</Agency><Country>Italy</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>12</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061945">Caspase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004151">Dipeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C419410">N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009842">Oligopeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018091">Receptors, AMPA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C110772">benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone</NameOfSubstance></Chemical><Chemical><RegistryNumber>25513-46-6</RegistryNumber><NameOfSubstance UI="D011099">Polyglutamic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.16</RegistryNumber><NameOfSubstance UI="D019703">Calcineurin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="C505409">Casp3 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D053148">Caspase 3</NameOfSubstance></Chemical><Chemical><RegistryNumber>TFZ3H25BS1</RegistryNumber><NameOfSubstance UI="C097222">glutamate receptor ionotropic, AMPA 1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2011 Feb;12(2):66. doi: 10.1038/nrn2983.</RefSource><PMID Version="1">21309097</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019703" MajorTopicYN="N">Calcineurin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053148" MajorTopicYN="N">Caspase 3</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061945" MajorTopicYN="N">Caspase Inhibitors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049229" MajorTopicYN="N">Dendritic Spines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004151" MajorTopicYN="N">Dipeptides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D036881" MajorTopicYN="N">Long-Term Synaptic Depression</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009842" MajorTopicYN="N">Oligopeptides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011099" MajorTopicYN="N">Polyglutamic Acid</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018091" MajorTopicYN="N">Receptors, AMPA</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21151119</ArticleId><ArticleId IdType="doi">10.1038/nn.2709</ArticleId><ArticleId IdType="pii">nn.2709</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Neurosci. 2002 Mar 1;22(5):1858-67</Citation><ArticleIdList><ArticleId IdType="pubmed">11880515</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Pathol. 2008 Nov;173(5):1488-95</Citation><ArticleIdList><ArticleId IdType="pubmed">18818379</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2006 Dec 21;52(6):1061-72</Citation><ArticleIdList><ArticleId IdType="pubmed">17178408</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2009 Aug 13;4(8):e6634</Citation><ArticleIdList><ArticleId IdType="pubmed">19675677</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 1999 Apr 30;97(3):395-406</Citation><ArticleIdList><ArticleId IdType="pubmed">10319819</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2000 Aug;75(2):606-13</Citation><ArticleIdList><ArticleId IdType="pubmed">10899935</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2005 Mar 3;45(5):741-52</Citation><ArticleIdList><ArticleId IdType="pubmed">15748849</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Neurosci. 2008;31:47-67</Citation><ArticleIdList><ArticleId IdType="pubmed">18284372</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Neurol. 1998 Sep;153(1):35-48</Citation><ArticleIdList><ArticleId IdType="pubmed">9743565</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2004 Jul 30;305(5684):626-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15286356</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2009 Jul;118(1):167-79</Citation><ArticleIdList><ArticleId IdType="pubmed">19390859</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2000 Aug 17;343(7):450-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10944562</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2000 Dec 21-28;408(6815):979-82</Citation><ArticleIdList><ArticleId IdType="pubmed">11140685</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Pathol. 1999 Nov;155(5):1459-66</Citation><ArticleIdList><ArticleId IdType="pubmed">10550301</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Neurosci. 2006 Jan;23(1):129-40</Citation><ArticleIdList><ArticleId IdType="pubmed">16420423</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 1998 Nov;21(5):1151-62</Citation><ArticleIdList><ArticleId IdType="pubmed">9856470</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 1998 Aug 7;94(3):325-37</Citation><ArticleIdList><ArticleId IdType="pubmed">9708735</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2006 Mar 28;103(13):5161-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16549764</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Neurosci. 1992 Apr;106(2):274-85</Citation><ArticleIdList><ArticleId IdType="pubmed">1590953</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2007 May 1;68(18):1501-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17470753</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1997 Oct 17;278(5337):412-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9334292</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 1990 Jun 22;114(1):11-6</Citation><ArticleIdList><ArticleId IdType="pubmed">2199862</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Biochem Biophys. 2000 Jul 15;379(2):337-43</Citation><ArticleIdList><ArticleId IdType="pubmed">10898953</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Dis. 2005 Nov;20(2):187-98</Citation><ArticleIdList><ArticleId IdType="pubmed">16242627</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropathol Exp Neurol. 1997 Sep;56(9):965-73</Citation><ArticleIdList><ArticleId IdType="pubmed">9291938</ArticleId></ArticleIdList></Reference><Reference><Citation>Mech Ageing Dev. 2000 Oct 20;119(1-2):63-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11040402</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 1998 Aug 7;94(3):339-52</Citation><ArticleIdList><ArticleId IdType="pubmed">9708736</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mol Genet. 2006 May 1;15(9):1437-49</Citation><ArticleIdList><ArticleId IdType="pubmed">16551656</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurochem Int. 2004 Feb;44(3):125-31</Citation><ArticleIdList><ArticleId IdType="pubmed">14568554</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2000 Dec 21-28;408(6815):975-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11140684</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Neurosci. 2002;25:103-26</Citation><ArticleIdList><ArticleId IdType="pubmed">12052905</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2004 Apr 7;24(14):3592-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15071107</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Chem. 2006 Jun 29;49(13):3763-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16789732</ArticleId></ArticleIdList></Reference><Reference><Citation>Hippocampus. 2004;14(3):301-10</Citation><ArticleIdList><ArticleId IdType="pubmed">15132429</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2010 May 28;141(5):859-71</Citation><ArticleIdList><ArticleId IdType="pubmed">20510932</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 1997 Nov 14;91(4):443-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9390553</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1996 Nov 28;384(6607):368-72</Citation><ArticleIdList><ArticleId IdType="pubmed">8934524</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2008 Jul;4(4):265-70</Citation><ArticleIdList><ArticleId IdType="pubmed">18631977</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 1998 Sep 18;94(6):727-37</Citation><ArticleIdList><ArticleId IdType="pubmed">9753320</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2009 Apr 3;324(5923):102-5</Citation><ArticleIdList><ArticleId IdType="pubmed">19342591</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Biochem. 1998 Jun 15;254(3):439-59</Citation><ArticleIdList><ArticleId IdType="pubmed">9688254</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1996 Oct 4;274(5284):99-102</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2009 Jun 25;62(6):788-801</Citation><ArticleIdList><ArticleId IdType="pubmed">19555648</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Dis. 2003 Aug;13(3):246-53</Citation><ArticleIdList><ArticleId IdType="pubmed">12901839</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2001 Jan 15;21(2):372-81</Citation><ArticleIdList><ArticleId IdType="pubmed">11160418</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 1999 Mar;2(3):271-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10195221</ArticleId></ArticleIdList></Reference><Reference><Citation>Cytometry. 1998 Jan 1;31(1):1-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9450519</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 2000 Jun;57(6):808-13</Citation><ArticleIdList><ArticleId IdType="pubmed">10867777</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2006 Dec 7;52(5):831-43</Citation><ArticleIdList><ArticleId IdType="pubmed">17145504</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21159959</PMID><DateCompleted><Year>2011</Year><Month>02</Month><Day>09</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>50</Issue><PubDate><Year>2010</Year><Month>Dec</Month><Day>15</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Diffusion tensor tractography reveals abnormal topological organization in structural cortical networks in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>16876</StartPage><EndPage>16885</EndPage><MedlinePgn>16876-85</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.4136-10.2010</ELocationID><Abstract><AbstractText>Recent research on Alzheimer's disease (AD) has shown that the decline of cognitive and memory functions is accompanied by a disrupted neuronal connectivity characterized by white matter (WM) degeneration. However, changes in the topological organization of WM structural network in AD remain largely unknown. Here, we used diffusion tensor image tractography to construct the human brain WM networks of 25 AD patients and 30 age- and sex-matched healthy controls, followed by a graph theoretical analysis. We found that both AD patients and controls had a small-world topology in WM network, suggesting an optimal balance between structurally segregated and integrative organization. More important, the AD patients exhibited increased shortest path length and decreased global efficiency in WM network compared with controls, implying abnormal topological organization. Furthermore, we showed that the WM network contained highly connected hub regions that were predominately located in the precuneus, cingulate cortex, and dorsolateral prefrontal cortex, which was consistent with the previous diffusion-MRI studies. Specifically, AD patients were found to have reduced nodal efficiency predominantly located in the frontal regions. Finally, we showed that the alterations of various network properties were significantly correlated with the behavior performances. Together, the present study demonstrated for the first time that the Alzheimer's brain was associated with disrupted topological organization in the large-scale WM structural networks, thus providing the structural evidence for abnormalities of systematic integrity in this disease. This work could also have implications for understanding how the abnormalities of structural connectivity in AD underlie behavioral deficits in the patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lo</LastName><ForeName>Chun-Yi</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>Department of Biomedical Imaging and Radiological Sciences, National Yang-Ming University, Taipei 11221, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Pei-Ning</ForeName><Initials>PN</Initials></Author><Author ValidYN="Y"><LastName>Chou</LastName><ForeName>Kun-Hsien</ForeName><Initials>KH</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jinhui</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Yong</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Ching-Po</ForeName><Initials>CP</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056324" MajorTopicYN="N">Diffusion Tensor Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008959" MajorTopicYN="N">Models, Neurological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015233" MajorTopicYN="N">Models, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009413" MajorTopicYN="N">Nerve Fibers, Myelinated</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011597" MajorTopicYN="N">Psychomotor Performance</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>2</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>6</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21159959</ArticleId><ArticleId IdType="pmc">PMC6634928</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.4136-10.2010</ArticleId><ArticleId IdType="pii">30/50/16876</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Achard S, Bullmore E. Efficiency and cost of economical brain functional networks. PLoS Comput Biol. 2007;3:e17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1794324</ArticleId><ArticleId IdType="pubmed">17274684</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert R, Barabasi A. Statistical mechanics of complex networks. Rev Mod Phys. 2002;74:47&#x2013;97.</Citation></Reference><Reference><Citation>Arnold SE, Hyman BT, Van Hoesen GW. Neuropathologic changes of the temporal pole in Alzheimer's disease and Pick's disease. Arch Neurol. 1994;51:145&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">8304839</ArticleId></ArticleIdList></Reference><Reference><Citation>Baddeley A. Working memory: looking back and looking forward. Nat Rev Neurosci. 2003;4:829&#x2013;839.</Citation><ArticleIdList><ArticleId IdType="pubmed">14523382</ArticleId></ArticleIdList></Reference><Reference><Citation>Basser PJ, Pierpaoli C. Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI. J Magn Reson B. 1996;111:209&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pubmed">8661285</ArticleId></ArticleIdList></Reference><Reference><Citation>Basser PJ, Mattiello J, LeBihan D. MR diffusion tensor spectroscopy and imaging. Biophys J. 1994;66:259&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1275686</ArticleId><ArticleId IdType="pubmed">8130344</ArticleId></ArticleIdList></Reference><Reference><Citation>Beaulieu C. The basis of anisotropic water diffusion in the nervous system&#x2014;a technical review. NMR Biomed. 2002;15:435&#x2013;455.</Citation><ArticleIdList><ArticleId IdType="pubmed">12489094</ArticleId></ArticleIdList></Reference><Reference><Citation>Behrens TE, Johansen-Berg H, Woolrich MW, Smith SM, Wheeler-Kingshott CA, Boulby PA, Barker GJ, Sillery EL, Sheehan K, Ciccarelli O, Thompson AJ, Brady JM, Matthews PM. Non-invasive mapping of connections between human thalamus and cortex using diffusion imaging. Nat Neurosci. 2003;6:750&#x2013;757.</Citation><ArticleIdList><ArticleId IdType="pubmed">12808459</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozzali M, Falini A, Franceschi M, Cercignani M, Zuffi M, Scotti G, Comi G, Filippi M. White matter damage in Alzheimer's disease assessed in vivo using diffusion tensor magnetic resonance imaging. J Neurol Neurosurg Psychiatry. 2002;72:742&#x2013;746.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1737921</ArticleId><ArticleId IdType="pubmed">12023417</ArticleId></ArticleIdList></Reference><Reference><Citation>Brun A, Englund E. Brain changes in dementia of Alzheimer's type relevant to new imaging diagnostic methods. Prog Neuropsychopharmacol Biol Psychiatry. 1986;10:297&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">3492011</ArticleId></ArticleIdList></Reference><Reference><Citation>Bullmore E, Sporns O. Complex brain networks: graph theoretical analysis of structural and functional systems. Nat Rev Neurosci. 2009;10:186&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">19190637</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SJ, Lim KO, Monteiro I, Reisberg B. Diffusion tensor imaging of frontal white matter microstructure in early Alzheimer's disease: a preliminary study. J Geriatr Psychiatry Neurol. 2005;18:12&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">15681623</ArticleId></ArticleIdList></Reference><Reference><Citation>Damoiseaux JS, Greicius MD. Greater than the sum of its parts: a review of studies combining structural connectivity and resting-state functional connectivity. Brain Struct Funct. 2009;213:525&#x2013;533.</Citation><ArticleIdList><ArticleId IdType="pubmed">19565262</ArticleId></ArticleIdList></Reference><Reference><Citation>de Haan W, Pijnenburg YAL, Strijers RLM, van der Made Y, van der Flier WM, Scheltens P, Stam CJ. Functional neural network analysis in frontotemporal dementia and Alzheimer's disease using EEG and graph theory. BMC Neurosci. 2009;10:101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2736175</ArticleId><ArticleId IdType="pubmed">19698093</ArticleId></ArticleIdList></Reference><Reference><Citation>Delbeuck X, Van der Linden M, Collette F. Alzheimer's disease as a disconnection syndrome? Neuropsychol Rev. 2003;13:79&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">12887040</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupont S. Investigating temporal pole function by functional imaging. Epileptic Disord. 2002;4(Suppl 1):S17&#x2013;S22.</Citation><ArticleIdList><ArticleId IdType="pubmed">12424086</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state.&#x201d; A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Galton CJ, Gomez-Anson B, Antoun N, Scheltens P, Patterson K, Graves M, Sahakian BJ, Hodges JR. Temporal lobe rating scale: application to Alzheimer's disease and frontotemporal dementia. J Neurol Neurosurg Psychiatry. 2001;70:165&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1737195</ArticleId><ArticleId IdType="pubmed">11160463</ArticleId></ArticleIdList></Reference><Reference><Citation>Genovese CR, Lazar NA, Nichols T. Thresholding of statistical maps in functional neuroimaging using the false discovery rate. Neuroimage. 2002;15:870&#x2013;878.</Citation><ArticleIdList><ArticleId IdType="pubmed">11906227</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong G, Rosa-Neto P, Carbonell F, Chen ZJ, He Y, Evans AC. Age- and gender-related differences in the cortical anatomical network. J Neurosci. 2009a;29:15684&#x2013;15693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2831804</ArticleId><ArticleId IdType="pubmed">20016083</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong G, He Y, Concha L, Lebel C, Gross DW, Evans AC, Beaulieu C. Mapping anatomical connectivity patterns of human cerebral cortex using in vivo diffusion tensor imaging tractography. Cereb Cortex. 2009b;19:524&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2722790</ArticleId><ArticleId IdType="pubmed">18567609</ArticleId></ArticleIdList></Reference><Reference><Citation>Grady CL, Furey ML, Pietrini P, Horwitz B, Rapoport SI. Altered brain functional connectivity and impaired short-term memory in Alzheimer's disease. Brain. 2001;124:739&#x2013;756.</Citation><ArticleIdList><ArticleId IdType="pubmed">11287374</ArticleId></ArticleIdList></Reference><Reference><Citation>Grady CL, McIntosh AR, Beig S, Keightley ML, Burian H, Black SE. Evidence from functional neuroimaging of a compensatory prefrontal network in Alzheimer's disease. J Neurosci. 2003;23:986&#x2013;993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741917</ArticleId><ArticleId IdType="pubmed">12574428</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagmann P, Kurant M, Gigandet X, Thiran P, Wedeen VJ, Meuli R, Thiran JP. Mapping human whole-brain structural networks with diffusion MRI. PLoS ONE. 2007;2:e597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1895920</ArticleId><ArticleId IdType="pubmed">17611629</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagmann P, Cammoun L, Gigandet X, Meuli R, Honey CJ, Wedeen VJ, Sporns O. Mapping the structural core of human cerebral cortex. PLoS Biol. 2008;6:e159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2443193</ArticleId><ArticleId IdType="pubmed">18597554</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayasaka S, Laurienti PJ. Comparison of characteristics between region-and voxel-based network analyses in resting-state fMRI data. Neuroimage. 2010;50:499&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2824075</ArticleId><ArticleId IdType="pubmed">20026219</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y, Evans A. Graph theoretical modeling of brain connectivity. Curr Opin Neurol. 2010;23:341&#x2013;350.</Citation><ArticleIdList><ArticleId IdType="pubmed">20581686</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y, Chen Z, Evans A. Structural insights into aberrant topological patterns of large-scale cortical networks in Alzheimer's disease. J Neurosci. 2008;28:4756&#x2013;4766.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6670444</ArticleId><ArticleId IdType="pubmed">18448652</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y, Dagher A, Chen Z, Charil A, Zijdenbos A, Worsley K, Evans A. Impaired small-world efficiency in structural cortical networks in multiple sclerosis associated with white matter lesion load. Brain. 2009;132:3366&#x2013;3379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2792366</ArticleId><ArticleId IdType="pubmed">19439423</ArticleId></ArticleIdList></Reference><Reference><Citation>Honea RA, Swerdlow RH, Vidoni ED, Goodwin J, Burns JM. Reduced gray matter volume in normal adults with a maternal family history of Alzheimer disease. Neurology. 2010;74:113&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2809030</ArticleId><ArticleId IdType="pubmed">20065246</ArticleId></ArticleIdList></Reference><Reference><Citation>Honey CJ, Sporns O, Cammoun L, Gigandet X, Thiran JP, Meuli R, Hagmann P. Predicting human resting-state functional connectivity from structural connectivity. Proc Natl Acad Sci U S A. 2009;106:2035&#x2013;2040.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2634800</ArticleId><ArticleId IdType="pubmed">19188601</ArticleId></ArticleIdList></Reference><Reference><Citation>Horwitz B, Grady CL, Schlageter NL, Duara R, Rapoport SI. Intercorrelations of regional cerebral glucose metabolic rates in Alzheimer's disease. Brain Res. 1987;407:294&#x2013;306.</Citation><ArticleIdList><ArticleId IdType="pubmed">3494486</ArticleId></ArticleIdList></Reference><Reference><Citation>Houenou J, Wessa M, Douaud G, Leboyer M, Chanraud S, Perrin M, Poupon C, Martinot JL, Paillere-Martinot ML. Increased white matter connectivity in euthymic bipolar patients: diffusion tensor tractography between the subgenual cingulate and the amygdalo-hippocampal complex. Mol Psychiatry. 2007;12:1001&#x2013;1010.</Citation><ArticleIdList><ArticleId IdType="pubmed">17471288</ArticleId></ArticleIdList></Reference><Reference><Citation>Humphries MD, Gurney K, Prescott TJ. The brainstem reticular formation is a small-world, not scale-free, network. Proc Biol Sci. 2006;273:503&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1560205</ArticleId><ArticleId IdType="pubmed">16615219</ArticleId></ArticleIdList></Reference><Reference><Citation>Iturria-Medina Y, Sotero RC, Canales-Rodr&#xed;guez EJ, Alem&#xe1;n-G&#xf3;mez Y, Melie-Garc&#xed;a L. Studying the human brain anatomical network via diffusion-weighted MRI and graph theory. Neuroimage. 2008;40:1064&#x2013;1076.</Citation><ArticleIdList><ArticleId IdType="pubmed">18272400</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiuchi K, Morikawa M, Taoka T, Nagashima T, Yamauchi T, Makinodan M, Norimoto K, Hashimoto K, Kosaka J, Inoue Y, Inoue M, Kichikawa K, Kishimoto T. Abnormalities of the uncinate fasciculus and posterior cingulate fasciculus in mild cognitive impairment and early Alzheimer's disease: a diffusion tensor tractography study. Brain Res. 2009;1287:184&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pubmed">19559010</ArticleId></ArticleIdList></Reference><Reference><Citation>Latora V, Marchiori M. Economic small-world behavior in weighted networks. Eur Phys J B Condens Matter Complex Syst. 2003;32:249&#x2013;263.</Citation></Reference><Reference><Citation>Lekeu F, Van der Linden M, Chicherio C, Collette F, Degueldre C, Franck G, Moonen G, Salmon E. Brain correlates of performance in a free/cued recall task with semantic encoding in Alzheimer disease. Alzheimer Dis Assoc Disord. 2003;17:35&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">12621318</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Liu Y, Li J, Qin W, Li K, Yu C, Jiang T. Brain anatomical network and intelligence. PLoS Comput Biol. 2009;5:e1000395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2683575</ArticleId><ArticleId IdType="pubmed">19492086</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin KN, Liu HC, Wang PN, Liao YC. Early detection of memory impairment: the use of the 12-item selective reminding test in Taiwan. Paper presented at The 10th International Conference on Alzheimer's Disease and Related Disorders; July; Madrid. 2006.</Citation></Reference><Reference><Citation>Maslov S, Sneppen K. Specificity and stability in topology of protein networks. Science. 2002;296:910&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pubmed">11988575</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesulam MM. From sensation to cognition. Brain. 1998;121:1013&#x2013;1052.</Citation><ArticleIdList><ArticleId IdType="pubmed">9648540</ArticleId></ArticleIdList></Reference><Reference><Citation>Minati L, Grisoli M, Bruzzone MG. MR spectroscopy, functional MRI, and diffusion-tensor imaging in the aging brain: a conceptual review. J Geriatr Psychiatry Neurol. 2007;20:3&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">17341766</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori S, van Zijl PC. Fiber tracking: principles and strategies&#x2014;a technical review. NMR Biomed. 2002;15:468&#x2013;480.</Citation><ArticleIdList><ArticleId IdType="pubmed">12489096</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori S, Crain BJ, Chacko VP, van Zijl PC. Three-dimensional tracking of axonal projections in the brain by magnetic resonance imaging. Ann Neurol. 1999;45:265&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pubmed">9989633</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Naggara O, Oppenheim C, Rieu D, Raoux N, Rodrigo S, Dalla Barba G, Meder JF. Diffusion tensor imaging in early Alzheimer's disease. Psychiatry Res. 2006;146:243&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">16520023</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman MEJ. The structure and function of complex networks. SIAM Rev. 2003;45:167&#x2013;256.</Citation></Reference><Reference><Citation>Olson IR, Plotzker A, Ezzyat Y. The enigmatic temporal pole: a review of findings on social and emotional processing. Brain. 2007;130:1718&#x2013;1731.</Citation><ArticleIdList><ArticleId IdType="pubmed">17392317</ArticleId></ArticleIdList></Reference><Reference><Citation>Onnela JP, Saram&#xe4;ki J, Kert&#xe9;sz J, Kaski K. Intensity and coherence of motifs in weighted complex networks. Phys Rev E Stat Nonlin Soft Matter Phys. 2005;71 065103.</Citation><ArticleIdList><ArticleId IdType="pubmed">16089800</ArticleId></ArticleIdList></Reference><Reference><Citation>Osterrieth PA. Le test de copie d'une figure complexe: contribution &#xe0; l'&#xe9;tude de la perception et de la m&#xe9;moire. Arch Psychol. 1944;30:286&#x2013;356.</Citation></Reference><Reference><Citation>Pievani M, Agosta F, Pagani E, Canu E, Sala S, Absinta M, Geroldi C, Ganzola R, Frisoni GB, Filippi M. Assessment of white matter tract damage in mild cognitive impairment and Alzheimer's disease. Hum Brain Mapp. 2010;31:1862&#x2013;1875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6870900</ArticleId><ArticleId IdType="pubmed">20162601</ArticleId></ArticleIdList></Reference><Reference><Citation>Rose SE, Chen F, Chalk JB, Zelaya FO, Strugnell WE, Benson M, Semple J, Doddrell DM. Loss of connectivity in Alzheimer's disease: an evaluation of white matter tract integrity with colour coded MR diffusion tensor imaging. J Neurol Neurosurg Psychiatry. 2000;69:528&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1737121</ArticleId><ArticleId IdType="pubmed">10990518</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002;298:789&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Shu N, Liu Y, Li J, Li Y, Yu C, Jiang T. Altered anatomical network in early blindness revealed by diffusion tensor tractography. PLoS ONE. 2009;4:e7228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2747271</ArticleId><ArticleId IdType="pubmed">19784379</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SM. Fast robust automated brain extraction. Hum Brain Mapp. 2002;17:143&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871816</ArticleId><ArticleId IdType="pubmed">12391568</ArticleId></ArticleIdList></Reference><Reference><Citation>Sporns O, Zwi JD. The small world of the cerebral cortex. Neuroinformatics. 2004;2:145&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pubmed">15319512</ArticleId></ArticleIdList></Reference><Reference><Citation>Sporns O, Tononi G, Edelman GM. Theoretical neuroanatomy: relating anatomical and functional connectivity in graphs and cortical connection matrices. Cereb Cortex. 2000;10:127&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pubmed">10667981</ArticleId></ArticleIdList></Reference><Reference><Citation>Sporns O, Tononi G, K&#xf6;tter R. The human connectome: a structural description of the human brain. PLoS Comput Biol. 2005;1:e42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1239902</ArticleId><ArticleId IdType="pubmed">16201007</ArticleId></ArticleIdList></Reference><Reference><Citation>Stam CJ, Jones BF, Nolte G, Breakspear M, Scheltens P. Small-world networks and functional connectivity in Alzheimer's disease. Cereb Cortex. 2007;17:92&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">16452642</ArticleId></ArticleIdList></Reference><Reference><Citation>Stam CJ, de Haan W, Daffertshofer A, Jones BF, Manshanden I, van Cappellen van Walsum AM, Montez T, Verbunt JPA, de Munck JC, van Dijk BW, Berendse HW, Scheltens P. Graph theoretical analysis of magnetoencephalographic functional connectivity in Alzheimer's disease. Brain. 2009;132:213&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">18952674</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuss DT, Alexander MP. Executive functions and the frontal lobes: a conceptual view. Psychol Res. 2000;63:289&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">11004882</ArticleId></ArticleIdList></Reference><Reference><Citation>Supekar K, Menon V, Rubin D, Musen M, Greicius MD. Network analysis of intrinsic functional brain connectivity in Alzheimer's disease. PLoS Comput Biol. 2008;4:e1000100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2435273</ArticleId><ArticleId IdType="pubmed">18584043</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuch DS, Wedeen VJ, Dale AM, George JS, Belliveau JW. Conductivity tensor mapping of the human brain using diffusion tensor MRI. Proc Natl Acad Sci U S A. 2001;98:11697&#x2013;11701.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC58792</ArticleId><ArticleId IdType="pubmed">11573005</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, Mazoyer B, Joliot M. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002;15:273&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">11771995</ArticleId></ArticleIdList></Reference><Reference><Citation>Ukmar M, Makuc E, Onor ML, Garbin G, Trevisiol M, Cova MA. Evaluation of white matter damage in patients with Alzheimer's disease and in patients with mild cognitive impairment by using diffusion tensor imaging. Radiol Med. 2008;113:915&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pubmed">18618077</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Wang L, Zang Y, Yang H, Tang H, Gong Q, Chen Z, Zhu C, He Y. Parcellation-dependent small-world brain functional networks: a resting-state fMRI study. Hum Brain Mapp. 2009;30:1511&#x2013;1523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6870680</ArticleId><ArticleId IdType="pubmed">18649353</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K, Liang M, Wang L, Tian L, Zhang X, Li K, Jiang T. Altered functional connectivity in early Alzheimer's disease: a resting-state fMRI study. Hum Brain Mapp. 2007;28:967&#x2013;978.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871392</ArticleId><ArticleId IdType="pubmed">17133390</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts DJ, Strogatz SH. Collective dynamics of &#x2018;small-world&#x2019; networks. Nature. 1998;393:440&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pubmed">9623998</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie S, Xiao JX, Gong GL, Zang YF, Wang YH, Wu HK, Jiang XX. Voxel-based detection of white matter abnormalities in mild Alzheimer disease. Neurology. 2006;66:1845&#x2013;1849.</Citation><ArticleIdList><ArticleId IdType="pubmed">16801648</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan C, Gong G, Wang J, Wang D, Liu D, Zhu C, Chen ZJ, Evans A, Zang Y, He Y. Sex- and brain size-related small-world structural cortical networks in young adults: a DTI tractography study. Cereb Cortex. 2010 doi: 10.1093/cercor/bhq111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/bhq111</ArticleId><ArticleId IdType="pubmed">20562318</ArticleId></ArticleIdList></Reference><Reference><Citation>Zalesky A, Fornito A, Harding IH, Cocchi L, Y&#xfc;cel M, Pantelis C, Bullmore ET. Whole-brain anatomical networks: does the choice of nodes matter? Neuroimage. 2010;50:970&#x2013;983.</Citation><ArticleIdList><ArticleId IdType="pubmed">20035887</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21159973</PMID><DateCompleted><Year>2011</Year><Month>02</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>50</Issue><PubDate><Year>2010</Year><Month>Dec</Month><Day>15</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>APOE4 allele disrupts resting state fMRI connectivity in the absence of amyloid plaques or decreased CSF A&#x3b2;42.</ArticleTitle><Pagination><StartPage>17035</StartPage><EndPage>17040</EndPage><MedlinePgn>17035-40</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.3987-10.2010</ELocationID><Abstract><AbstractText>Identifying high-risk populations is an important component of disease prevention strategies. One approach for identifying at-risk populations for Alzheimer's disease (AD) is examining neuroimaging parameters that differ between patients, including functional connections known to be disrupted within the default-mode network. We have previously shown these same disruptions in cognitively normal elderly who have amyloid-&#x3b2; (A&#x3b2;) plaques [detected using Pittsburgh Compound B (PIB) PET imaging], suggesting neuronal toxicity of plaques. Here we sought to determine if pathological effects of apolipoprotein E &#x3b5;4 (APOE4) genotype could be seen independent of A&#x3b2; plaque toxicity by examining resting state fMRI functional connectivity (fcMRI) in participants without preclinical fibrillar amyloid deposition (PIB-). Cognitively normal participants enrolled in longitudinal studies (n = 100, mean age = 62) who were PIB- were categorized into those with and without an APOE4 allele and studied using fcMRI. APOE4 allele carriers (E4+) differed significantly from E4- in functional connectivity of the precuneus to several regions previously defined as having abnormal connectivity in a group of AD participants. These effects were observed before any manifestations of cognitive changes and in the absence of brain fibrillar A&#x3b2; plaque deposition, suggesting that early manifestations of a genetic effect can be detected using fcMRI and that these changes may antedate the pathological effects of fibrillar amyloid plaque toxicity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sheline</LastName><ForeName>Yvette I</ForeName><Initials>YI</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, The Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri 63110, USA. yvette@npg.wustl.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Snyder</LastName><ForeName>Abraham Z</ForeName><Initials>AZ</Initials></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>Joseph L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Zhizi</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>D'Angelo</LastName><ForeName>Gina</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Collin</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Dixit</LastName><ForeName>Sachin</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Benzinger</LastName><ForeName>Tammie</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Mintun</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 NS006833</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01AG03991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS048056</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG05681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01AG026275</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 MH079510</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24MHO79510</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30NS048056</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30NS06833</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009434" MajorTopicYN="N">Neural Pathways</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>2</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>6</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21159973</ArticleId><ArticleId IdType="mid">NIHMS257894</ArticleId><ArticleId IdType="pmc">PMC3023180</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.3987-10.2010</ArticleId><ArticleId IdType="pii">30/50/17035</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet. 2006;368:387&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">16876668</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, Sheline YI, Klunk WE, Mathis CA, Morris JC, Mintun MA. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25:7709&#x2013;7717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns NJ, Ikonomovic MD, Benzinger T, Storandt M, Fagan AM, Shah A, Reinwald LT, Carter D, Felton A, Holtzman DM, Mintun MA, Klunk WE, Morris JC. Absence of Pittsburgh Compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease. Arch Neurol. 2009;66:1557&#x2013;1562.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2796200</ArticleId><ArticleId IdType="pubmed">20008664</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmichael ST, Price JL. Connectional networks within the orbital and medial prefrontal cortex of macaque monkeys. J Comp Neurol. 1996;371:179&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">8835726</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, Deane R, Fagan AM, Spinner ML, Parsadanian M, Finn MB, Jiang H, Prior JL, Sagare A, Bales KR, Paul SM, Zlokovic BV, Piwnica-Worms D, Holtzman DM. P-glycoprotein deficiency at the blood&#x2013;brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest. 2005;115:3285&#x2013;3290.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1257538</ArticleId><ArticleId IdType="pubmed">16239972</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC, Jr, Rimmler JB, Locke PA, Conneally PM, Schmader KE. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet. 1994;7:180&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">7920638</ArticleId></ArticleIdList></Reference><Reference><Citation>Daselaar SM, Prince SE, Cabeza R. When less means more: deactivations during encoding that predict subsequent memory. Neuroimage. 2004;23:921&#x2013;927.</Citation><ArticleIdList><ArticleId IdType="pubmed">15528092</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, Holtzman DM, Zlokovic BV. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest. 2008;118:4002&#x2013;4013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2582453</ArticleId><ArticleId IdType="pubmed">19033669</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong LM, Wilson C, Wardell MR, Simmons T, Mahley RW, Weisgraber KH, Agard DA. (1994) Human apolipoprotein E: role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms. J Biol Chem. 1994;269:22358&#x2013;22365.</Citation><ArticleIdList><ArticleId IdType="pubmed">8071364</ArticleId></ArticleIdList></Reference><Reference><Citation>Drzezga A, Grimmer T, Henriksen G, M&#xfc;hlau M, Perneczky R, Miederer I, Praus C, Sorg C, Wohlschl&#xe4;ger A, Riemenschneider M, Wester HJ, Foerstl H, Schwaiger M, Kurz A. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology. 2009;72:1487&#x2013;1494.</Citation><ArticleIdList><ArticleId IdType="pubmed">19339712</ArticleId></ArticleIdList></Reference><Reference><Citation>Filippini N, MacIntosh BJ, Hough MG, Goodwin GM, Frisoni GB, Smith SM, Matthews PM, Beckmann CF, Mackay CE. Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele. Proc Natl Acad Sci U S A. 2009;106:7209&#x2013;7214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2678478</ArticleId><ArticleId IdType="pubmed">19357304</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher AS, Sherzai A, Taylor C, Langbaum JB, Chen K, Buxton RB. Resting-state BOLD networks versus task-associated functional MRI for distinguishing Alzheimer's disease risk groups. Neuroimage. 2009;47:1678&#x2013;1690.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2722694</ArticleId><ArticleId IdType="pubmed">19539034</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox MD, Raichle ME. Spontaneous fluctuations in brain activity observed with functional magnetic resonance imaging. Nat Rev Neurosci. 2007;8:700&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pubmed">17704812</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox MD, Zhang D, Snyder AZ, Raichle ME. The global signal and observed anticorrelated resting state brain networks. J Neurophysiol. 2009;101:3270&#x2013;3283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2694109</ArticleId><ArticleId IdType="pubmed">19339462</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Menon V. Default-mode activity during a passive sensory task: uncoupled from deactivation but impacting activation. J Cogn Neurosci. 2004;16:1484&#x2013;1492.</Citation><ArticleIdList><ArticleId IdType="pubmed">15601513</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagmann P, Cammoun L, Gigandet X, Meuli R, Honey CJ, Wedeen VJ, Sporns O. Mapping the structural core of human cerebral cortex. PLoS Biol. 2008;6:e159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2443193</ArticleId><ArticleId IdType="pubmed">18597554</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris FM, Brecht WJ, Xu Q, Tesseur I, Kekonius L, Wyss-Coray T, Fish JD, Masliah E, Hopkins PC, Scearce-Levie K, Weisgraber KH, Mucke L, Mahley RW, Huang Y. Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc Natl Acad Sci U S A. 2003;100:10966&#x2013;10971.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC196910</ArticleId><ArticleId IdType="pubmed">12939405</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatters DM, Zhong N, Rutenber E, Weisgraber KH. Amino-terminal domain stability mediates apolipoprotein E aggregation into neurotoxic fibrils. J Mol Biol. 2006;361:932&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">16890957</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedden T, Van Dijk KR, Becker JA, Mehta A, Sperling RA, Johnson KA, Buckner RL. Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. J Neurosci. 2009;29:12686&#x2013;12694.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2808119</ArticleId><ArticleId IdType="pubmed">19812343</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. Neuron. 2009;63:287&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3044446</ArticleId><ArticleId IdType="pubmed">19679070</ArticleId></ArticleIdList></Reference><Reference><Citation>Lustig C, Snyder AZ, Bhakta M, O'Brien KC, McAvoy M, Raichle ME, Morris JC, Buckner RL. Functional deactivations: change with age and dementia of the Alzheimer type. Proc Natl Acad Sci U S A. 2003;100:14504&#x2013;14509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC283621</ArticleId><ArticleId IdType="pubmed">14608034</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, Klunk WE, Mathis CA, DeKosky ST, Morris JC. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894106</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, Mintun MA. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010;67:122&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2830375</ArticleId><ArticleId IdType="pubmed">20186853</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrella JR, Wang L, Krishnan S, Slavin MJ, Prince SE, Tran TT, Doraiswamy PM. Cortical deactivation in mild cognitive impairment: high-field-strength functional MR imaging. Radiology. 2007;245:224&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pubmed">17885190</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Morris JC. Tangles and plaques in nondemented aging and &#x201d;preclinical&#x201c; Alzheimer's disease. Ann Neurol. 1999;45:358&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">10072051</ArticleId></ArticleIdList></Reference><Reference><Citation>Raichle ME, MacLeod AM, Snyder AZ, Powers WJ, Gusnard DA, Shulman GL. A default mode of brain function. Proc Natl Acad Sci U S A. 2001;98:676&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC14647</ArticleId><ArticleId IdType="pubmed">11209064</ArticleId></ArticleIdList></Reference><Reference><Citation>Rebeck GW, Reiter JS, Strickland DK, Hyman BT. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron. 1993;11:575&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">8398148</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, Ayutyanont N, Keppler J, Reeder SA, Langbaum JB, Alexander GE, Klunk WE, Mathis CA, Price JC, Aizenstein HJ, DeKosky ST, Caselli RJ. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A. 2009;106:6820&#x2013;6825.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2665196</ArticleId><ArticleId IdType="pubmed">19346482</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheline YI, Raichle ME, Snyder AZ, Morris JC, Head D, Wang S, Mintun MA. Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Biol Psychiatry. 2010;67:584&#x2013;587.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2829379</ArticleId><ArticleId IdType="pubmed">19833321</ArticleId></ArticleIdList></Reference><Reference><Citation>Shulman GL, Fiez JA, Corbetta M, Buckner RL, Miezin FM, Riachle ME, Petersen SE. Common blood flow changes across visual tasks. II. Decreases in cerebral cortex. J Cogn Neurosci. 1997;9:648&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pubmed">23965122</ArticleId></ArticleIdList></Reference><Reference><Citation>Small GW, Siddarth P, Burggren AC, Kepe V, Ercoli LM, Miller KJ, Lavretsky H, Thompson PM, Cole GM, Huang SC, Phelps ME, Bookheimer SY, Barrio JR. Influence of cognitive status, age, and APOE-4 genetic risk on brain FDDNP positron-emission tomography imaging in persons without dementia. Arch Gen Psychiatry. 2009;66:81&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2693405</ArticleId><ArticleId IdType="pubmed">19124691</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Laviolette PS, O'Keefe K, O'Brien J, Rentz DM, Pihlajamaki M, Marshall G, Hyman BT, Selkoe DJ, Hedden T, Buckner RL, Becker JA, Johnson KA. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron. 2009;63:178&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2738994</ArticleId><ArticleId IdType="pubmed">19640477</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter WJ, Roses AD. Apolipoprotein E and Alzheimer's disease. Annu Rev Neurosci. 1996;19:53&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">8833436</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiraboschi P, Hansen LA, Masliah E, Alford M, Thal LJ, Corey-Bloom J. Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease. Neurology. 2004;62:1977&#x2013;1983.</Citation><ArticleIdList><ArticleId IdType="pubmed">15184600</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, Snyder AZ, Fox MD, Shannon BJ, Andrews JR, Raichle ME, Buckner RL. Coherent spontaneous activity identifies a hippocampal-parietal memory network. J Neurophysiol. 2006;96:3517&#x2013;3531.</Citation><ArticleIdList><ArticleId IdType="pubmed">16899645</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisniewski T, Casta&#xf1;o EM, Golabek A, Vogel T, Frangione B. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am J Pathol. 1994;145:1030&#x2013;1035.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1887417</ArticleId><ArticleId IdType="pubmed">7977635</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolk DA, Dickerson BC the Alzheimer's Disease Neuroimaging Initiative. Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's disease. Proc Natl Acad Sci U S A. 2010;107:10256&#x2013;10261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2890481</ArticleId><ArticleId IdType="pubmed">20479234</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Q, Bernardo A, Walker D, Kanegawa T, Mahley RW, Huang Y. Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus. J Neurosci. 2006;26:4985&#x2013;4994.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674234</ArticleId><ArticleId IdType="pubmed">16687490</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong N, Weisgraber KH. Understanding the basis for the association of apoE4 with Alzheimer's disease: opening the door for therapeutic approaches. Curr Alzheimer Res. 2009;6:415&#x2013;418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2810311</ArticleId><ArticleId IdType="pubmed">19874264</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21172610</PMID><DateCompleted><Year>2011</Year><Month>01</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>6</Issue><PubDate><Year>2010</Year><Month>Dec</Month><Day>22</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration.</ArticleTitle><Pagination><StartPage>1067</StartPage><EndPage>1081</EndPage><MedlinePgn>1067-81</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2010.11.030</ELocationID><Abstract><AbstractText>The microtubule-associated protein tau accumulates in Alzheimer's and other fatal dementias, which manifest when forebrain neurons die. Recent advances in understanding these disorders indicate that brain dysfunction precedes neurodegeneration, but the role of tau is unclear. Here, we show that early tau-related deficits develop not from the loss of synapses or neurons, but rather as a result of synaptic abnormalities caused by the accumulation of hyperphosphorylated tau within intact dendritic spines, where it disrupts synaptic function by impairing glutamate receptor trafficking or synaptic anchoring. Mutagenesis of 14 disease-associated serine and threonine amino acid residues to create pseudohyperphosphorylated tau caused tau mislocalization while creation of phosphorylation-deficient tau blocked the mistargeting of tau to dendritic spines. Thus, tau phosphorylation plays a critical role in mediating tau mislocalization and subsequent synaptic impairment. These data establish that the locus of early synaptic malfunction caused by tau resides in dendritic spines.</AbstractText><CopyrightInformation>Copyright &#xa9; 2010 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hoover</LastName><ForeName>Brian R</ForeName><Initials>BR</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Minnesota, Minneapolis, MN 55455, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reed</LastName><ForeName>Miranda N</ForeName><Initials>MN</Initials></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Jianjun</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Penrod</LastName><ForeName>Rachel D</ForeName><Initials>RD</Initials></Author><Author ValidYN="Y"><LastName>Kotilinek</LastName><ForeName>Linda A</ForeName><Initials>LA</Initials></Author><Author ValidYN="Y"><LastName>Grant</LastName><ForeName>Marianne K</ForeName><Initials>MK</Initials></Author><Author ValidYN="Y"><LastName>Pitstick</LastName><ForeName>Rose</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Carlson</LastName><ForeName>George A</ForeName><Initials>GA</Initials></Author><Author ValidYN="Y"><LastName>Lanier</LastName><ForeName>Lorene M</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Li-Lian</ForeName><Initials>LL</Initials></Author><Author ValidYN="Y"><LastName>Ashe</LastName><ForeName>Karen H</ForeName><Initials>KH</Initials></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Dezhi</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K02 DA025048</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS049178</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA077598</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-NS049178</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K02-DA025048</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS063214</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 DA022616-02</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DA020582</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-NS063214</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 DA007234</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-DA020582</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32-DA007234</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA77598</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG026252</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-AG026252</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 DA022616</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS049129</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-NS049129</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049229" MajorTopicYN="N">Dendritic Spines</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>11</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>1</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>12</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21172610</ArticleId><ArticleId IdType="mid">NIHMS254011</ArticleId><ArticleId IdType="pmc">PMC3026458</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2010.11.030</ArticleId><ArticleId IdType="pii">S0896-6273(10)00972-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arvanitakis Z, Witte RJ, Dickson DW, Tsuboi Y, Uitti RJ, Slowinski J, Hutton ML, Lin S-C, Boeve BF, Cheshire WP, Pooley RA, Liss JM, Caviness JN, Strongosky AJ, Wszolek ZK. Clinical-pathologic study of biomarkers in FTDP-17 (PPND family with N279K tau mutation) Parkinsonism Relat. Disord. 2007;13:230&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">17196872</ArticleId></ArticleIdList></Reference><Reference><Citation>Avila J, Lucas JJ, Perez M, Hernandez F. Role of tau protein in both physiological and pathological conditions. Physiol. Rev. 2004;84:361&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">15044677</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertrand J, Plouffe V, Senechal P, Leclerc N. The pattern of human tau phosphorylation is the result of priming and feedback events in primary hippocampal neurons. Neuroscience. 2010;168:323&#x2013;334.</Citation><ArticleIdList><ArticleId IdType="pubmed">20394726</ArticleId></ArticleIdList></Reference><Reference><Citation>Boekhoorn K, Terwel D, Biemans B, Borghgraef P, Wiegert O, Ramakers GJA, de Vos K, Krugers H, Tomiyama T, Mori H, Joels M, van Leuven F, Lucassen PJ. Improved long-term potentiation and memory in young tau-P301L transgenic mice before onset of hyperphosphorylation and tauopathy. J. Neurosci. 2006;26:3514&#x2013;3523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673867</ArticleId><ArticleId IdType="pubmed">16571759</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandt R, Hundelt M, Shahani N. Tau alteration and neuronal degeneration in tauopathies: mechanisms and models. Biochim. Biophys. Acta. 2005;1739:331&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pubmed">15615650</ArticleId></ArticleIdList></Reference><Reference><Citation>Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Rev. 2000;33:95&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">10967355</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng D, Hoogenraad CC, Rush J, Ramm E, Schlager MA, Duong DM, Xu P, Wijayawardana SR, Hanfelt J, Nakagawa T, Sheng M, Peng J. Relative and absolute quantification of postsynaptic density proteome isolated from rat forebrain and cerebellum. Mol. Cell. Proteomics. 2006;5:1158&#x2013;1170.</Citation><ArticleIdList><ArticleId IdType="pubmed">16507876</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies CA, Mann DM, Sumpter PQ, Yates PO. A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer&#x2019;s disease. J. Neurol. Sci. 1987;78:151&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">3572454</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixit R, Ross JL, Goldman YE, Holzbaur ELF. Differential regulation of dynein and kinesin motor proteins by tau. Science. 2008;319:1086&#x2013;1089.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2866193</ArticleId><ArticleId IdType="pubmed">18202255</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckermann K, Mocanu M-M, Khlistunova I, Biernat J, Nissen A, Hofmann A, Schonig K, Bujard H, Haemisch A, Mandelkow E, Zhou L, Rune G, Mandelkow E-M. The &#x3b2;-propensity of tau determines aggregation and synaptic loss in inducible mouse models of tauopathy. J. Biol. Chem. 2007;282:31755&#x2013;31765.</Citation><ArticleIdList><ArticleId IdType="pubmed">17716969</ArticleId></ArticleIdList></Reference><Reference><Citation>Fifkova E, Delay RJ. Cytoplasmic actin in neuronal processes as a possible mediator of synaptic plasticity. J. Cell Biol. 1982;95:345&#x2013;350.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2112353</ArticleId><ArticleId IdType="pubmed">6890558</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer M, Kaech S, Wagner U, Brinkhaus H, Matus A. Glutamate receptors regulate actin-based plasticity in dendritic spines. Nat. Neurosci. 2000;3:887&#x2013;894.</Citation><ArticleIdList><ArticleId IdType="pubmed">10966619</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuhrmann M, Mitteregger G, Kretzschmar H, Herms J. Dendritic pathology in prion disease starts at the synaptic spine. J. Neurosci. 2007;27:6224&#x2013;6233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672160</ArticleId><ArticleId IdType="pubmed">17553995</ArticleId></ArticleIdList></Reference><Reference><Citation>Fulga TA, Elson-Schwab I, Khurana V, Steinhilb ML, Spires TL, Hyman BT, Feany MB. Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo. Nat. Cell Biol. 2007;9:139&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pubmed">17187063</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, Petrucelli L. The role of tau in neurodegeneration. Mol. Neurodegener. 2009;4:13&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2663562</ArticleId><ArticleId IdType="pubmed">19284597</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong C-X, Liu F, Grundke-Iqbal I, Iqbal K. Post-translational modifications of tau protein in Alzheimer&#x2019;s disease. J. Neural Transm. 2005;112:813&#x2013;838.</Citation><ArticleIdList><ArticleId IdType="pubmed">15517432</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu J, Firestein BL, Zheng JQ. Microtubules in dendritic spine development. J. Neurosci. 2008;28:12120&#x2013;12124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2605155</ArticleId><ArticleId IdType="pubmed">19005076</ArticleId></ArticleIdList></Reference><Reference><Citation>He HJ, Wang XS, Pan R, Want DL, Liu MN, He RQ. The proline-rich domain of tau plays a role in interactions with actin. BMC Cell Biol. 2009;10:81&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2784441</ArticleId><ArticleId IdType="pubmed">19895707</ArticleId></ArticleIdList></Reference><Reference><Citation>Hering H, Sheng M. Dendritic spines: structure, dynamics and regulation. Nat. Rev. Neurosci. 2001;2:880&#x2013;888.</Citation><ArticleIdList><ArticleId IdType="pubmed">11733795</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, Sisodia S, Malinow R. AMPAR removal underlies A&#x3b2;-induced synaptic depression and dendritic spine loss. Neuron. 2006;52:831&#x2013;843.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850952</ArticleId><ArticleId IdType="pubmed">17145504</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X, Viesselmann C, Nam S, Merriam E, Dent EW. Activity-dependent dynamic microtubule invasion of dendritic spines. J. Neurosci. 2008;28:13094&#x2013;13105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6671621</ArticleId><ArticleId IdType="pubmed">19052200</ArticleId></ArticleIdList></Reference><Reference><Citation>Isaac JTR, Nicoll RA, Malenka RC. Evidence for silent synapses: implications for the expression of LTP. Neuron. 1995;15:427&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pubmed">7646894</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, Eersel Jv, Wolfing H, Chieng BC, Christie MJ, Napier IA, Eckert A, Staufenbiel M, Hardeman E, Gotz J. Dendritic function of tau mediates amyloid-&#x3b2; toxicity in Alzheimer&#x2019;s disease mouse models. Cell. 2010;142:387&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pubmed">20655099</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaworski J, Kapitein LC, Gouveia SM, Dortland BR, Wulf PS, Grigoriev I, Camera P, Spangler SA, Di Stefano P, Demmers J, Krugers H, Defilippi P, Akhmanova A, Hoogenraad CC. Dynamic microtubules regulate dendritic spine morphology and synaptic plasticity. Neuron. 2009;61:85&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">19146815</ArticleId></ArticleIdList></Reference><Reference><Citation>Knobloch M, Mansuy IM. Dendritic spine loss and synaptic alterations in Alzheimer&#x2019;s disease. Mol. Neurobiol. 2008;37:73&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">18438727</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer ML, Schulz-Schaeffer WJ. Presynaptic &#x3b1;-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J. Neurosci. 2007;27:1405&#x2013;1410.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673583</ArticleId><ArticleId IdType="pubmed">17287515</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao D, Hessler NA, Malinow R. Activation of postsynaptically silent synapses during pairing-induced LTP in CA1 region of hippocampus slice. Nature. 1995;375:400&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">7760933</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao D, Zhang X, O&#x2019;Brien R, Ehlers MD, Huganir RL. Regulation of morphological postsynaptic silent synapses in developing hippocampal neurons. Nat. Neurosci. 1999;2:37&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">10195178</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao D, Lin H, Law PY, Loh HH. Mu-opioid receptors modulate the stability of dendritic spines. Proc. Natl. Acad. Sci. U.S.A. 2005;102:1725&#x2013;1730.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC545084</ArticleId><ArticleId IdType="pubmed">15659552</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin H, Huganir R, Liao D. Temporal dynamics of NMDA receptor-induced changes in spine morphology and AMPA receptor recruitment to spines. Biochem. Biophys. Res. Commun. 2004;316:501&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pubmed">15020245</ArticleId></ArticleIdList></Reference><Reference><Citation>Luna-Munoz J, Chavez-Macias L, Garcia-Sierra F, Mena R. Earliest stages of tau conformational changes are related to the appearance of a sequence of specific phospho-dependent tau epitopes in Alzheimer&#x2019;s disease. J. Alzheimers Dis. 2007;12:365&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pubmed">18198423</ArticleId></ArticleIdList></Reference><Reference><Citation>Malinow R, Malenka RC. AMPA receptor trafficking and synaptic plasticity. Annu. Rev. Neurosci. 2002;25:103&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">12052905</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandelkow E-M, Stamer K, Vogel R, Thies E, Mandelkow E. Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol. Aging. 2003;24:1079&#x2013;1085.</Citation><ArticleIdList><ArticleId IdType="pubmed">14643379</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Mallory M, Alford M, DeTeresa R, Hansen LA, McKeel DW, Jr, Morris JC. Altered expression of synaptic proteins occurs early during progression of Alzheimer&#x2019;s disease. Neurology. 2001;56:127&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">11148253</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurage C-A, Sergeant N, Ruchoux M-M, Hauw J-J, Delacourte A. Phosphorylated serine 199 of microtubule-associated protein tau is a neuronal epitope abundantly expressed in youth and an early marker of tau pathology. Acta Neuropathol. 2003;105:89&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">12536218</ArticleId></ArticleIdList></Reference><Reference><Citation>McKinney RA, Capogna M, Durr R, Gahwiler BH, Thompson SM. Miniature synaptic events maintain dendritic spines via AMPA receptor activation. Nat. Neurosci. 1999;2:44&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">10195179</ArticleId></ArticleIdList></Reference><Reference><Citation>McKinney RA. Excitatory amino acid involvement in dendritic spine formation, maintenance and remodeling. J. Physiol. (London) 2010;588:107&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2821552</ArticleId><ArticleId IdType="pubmed">19933758</ArticleId></ArticleIdList></Reference><Reference><Citation>Newpher TM, Ehlers MD. Glutamate receptor dynamics in dendritic microdomains. Neuron. 2008;58:472&#x2013;497.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2572138</ArticleId><ArticleId IdType="pubmed">18498731</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Vasilevko V, Caccamo A, Kitazawa M, Cribbs DH, LaFerla FM. Reduction of soluble A&#x3b2; and tau, but not soluble A&#x3b2; alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J. Biol. Chem. 2006;281:39413&#x2013;39423.</Citation><ArticleIdList><ArticleId IdType="pubmed">17056594</ArticleId></ArticleIdList></Reference><Reference><Citation>Papasozomenos SCh, Binder LI. Phosphorylation determines two distinct species of tau in the central nervous system. Cell Motil. Cytoskeleton. 1987;8:210&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">2446784</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrie EC, Cross DJ, Galasko D, Schellenberg GD, Raskind MA, Peskind ER, Minoshima S. Preclinical evidence of Alzheimer changes: Convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings. Arch. Neurol. 2009;66:632&#x2013;637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2718788</ArticleId><ArticleId IdType="pubmed">19433663</ArticleId></ArticleIdList></Reference><Reference><Citation>Polydoro M, Acker CM, Duff K, Castillo PE, Davies P. Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. J. Neurosci. 2009;29:10741&#x2013;10749.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2760256</ArticleId><ArticleId IdType="pubmed">19710325</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramsden M, Kotilinek L, Forster C, Paulson J, McGowan E, SantaCruz K, Guimaraes A, Yue M, Lewis J, Carlson G, Hutton M, Ashe KH. Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L) J. Neurosci. 2005;25:10637&#x2013;10647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725849</ArticleId><ArticleId IdType="pubmed">16291936</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards DA, Mateos JM, Hugel S, de Paola V, Caroni P, Gahwiler BH, McKinney RA. Glutamate induces the rapid formation of spine head protrusions in hippocampal slice cultures. Proc. Natl. Acad. Sci. USA. 2005;102:6166&#x2013;6171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC556130</ArticleId><ArticleId IdType="pubmed">15831587</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocher AB, Crimins JL, Amatrudo JM, Kinson MS, Todd-Brown MA, Lewis J, Luebke JI. Structural and functional changes in tau mutant mice neurons are not linked to the presence of NFTs. Exp. Neurol. 2010;223:385&#x2013;393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2864360</ArticleId><ArticleId IdType="pubmed">19665462</ArticleId></ArticleIdList></Reference><Reference><Citation>SantaCruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, Forster C, Yue M, Orne J, Janus C, Mariash A, Kuskowski M, Hyman B, Hutton M, Ashe KH. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005;309:476&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1574647</ArticleId><ArticleId IdType="pubmed">16020737</ArticleId></ArticleIdList></Reference><Reference><Citation>Sdrulla AD, Linden DJ. Double dissociation between long-term depression and dendritic spine morphology in cerebellar Purkinje cells. Nat. Neurosci. 2007;10:546&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pubmed">17435753</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe D. Alzheimer&#x2019;s disease is a synaptic failure. Science. 2002;298:789&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahani N, Subramaniam S, Wolf T, Tackenberg C, Brandt R. Tau aggregation and progressive neuronal degeneration in the absence of changes in spine density and morphology after targeted expression of Alzheimer&#x2019;s disease-relevant tau constructs in organotypic hippocampal slices. J. Neurosci. 2006;26:6103&#x2013;6114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675219</ArticleId><ArticleId IdType="pubmed">16738255</ArticleId></ArticleIdList></Reference><Reference><Citation>Shemer I, Holmgren C, Min R, Fulop L, Zilberter M, Sousa KM, Farkas T, Hartig W, Penke B, Burnashev N, Tanila H, Zilberter Y, Harkany T. Non-fibrillar &#x3b2;-amyloid abates spike-timing-dependent synaptic potentiation at excitatory synapses in layer 2/3 of the neocortex by targeting postsynaptic AMPA receptors. Eur. J. Neurosci. 2006;23:2035&#x2013;2047.</Citation><ArticleIdList><ArticleId IdType="pubmed">16630051</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith DL, Pozueta J, Gong B, Arancio O, Shelanski M. Reversal of long-term dendritic spine alterations in Alzheimer disease models. Proc. Natl. Acad. Sci. U.S.A. 2009;106:16877&#x2013;16882.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2743726</ArticleId><ArticleId IdType="pubmed">19805389</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinhilb ML, Dias-Santagata D, Mulkearns EE, Shulman JM, Biernat J, Mandelkow E-M, Feany MB. S/P and T/P phosphorylation is critical for tau neurotoxicity in Drosophila. J. Neurosci. Res. 2007a;85:1271&#x2013;1278.</Citation><ArticleIdList><ArticleId IdType="pubmed">17335084</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinhilb ML, Dias-Santagata D, Fulga TA, Felch DL, Feany MB. Tau phosphorylation sites work in concert to promote neurotoxicity in vivo. Mol. Biol. Cell. 2007b;18:5060&#x2013;5068.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2096612</ArticleId><ArticleId IdType="pubmed">17928404</ArticleId></ArticleIdList></Reference><Reference><Citation>Strasser GA, Rahim NA, VanderWaal KE, Gertler FB, Lanier LM. Arp2/3 is a negative regulator of growth cone translocation. Neuron. 2004;43:81&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">15233919</ArticleId></ArticleIdList></Reference><Reference><Citation>Tackenberg C, Brandt R. Divergent pathways mediate spine alterations and cell death induced by amyloid-&#x3b2;, wild-type tau, and R406W tau. J. Neurosci. 2009;29:14439&#x2013;14450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6665808</ArticleId><ArticleId IdType="pubmed">19923278</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. Physical basis of cognitive alterations in Alzheimer&#x2019;s disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 1991;30:572&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X-b, Yang Y, Zhou Q. Independent expression of synaptic and morphological plasticity associated with long-term depression. J. Neurosci. 2007;27:12419&#x2013;12429.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673249</ArticleId><ArticleId IdType="pubmed">17989307</ArticleId></ArticleIdList></Reference><Reference><Citation>Westerman MA, Cooper-Blacketer D, Mariash A, Kotilinek L, Kawarabayashi T, Younkin LH, Carlson GA, Younkin SG, Ashe KH. The relationship between A&#x3b2; and memory in the Tg2576 mouse model of Alzheimer&#x2019;s disease. J. Neurosci. 2002;22:1858&#x2013;1867.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758862</ArticleId><ArticleId IdType="pubmed">11880515</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfer DP, Madani R, Valenti P, Lipp HP. Extended analysis of path data from mutant mice using the public domain software Wintrack. Physiol. Behav. 2001;73:745&#x2013;753.</Citation><ArticleIdList><ArticleId IdType="pubmed">11566208</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, Higuchi M, Zhang B, Huang S-M, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, Lee VM-Y. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53:337&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Zempel H, Thies E, Mandelkow E, Mandelkow E-M. A&#x3b2; oligomers cause localized Ca2+ elevation, missorting of endogenous tau into dendrites, tau phosphorylation, and destruction of microtubules and spines. J. Neurosci. 2010;30:11938&#x2013;11950.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6633549</ArticleId><ArticleId IdType="pubmed">20826658</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21178097</PMID><DateCompleted><Year>2011</Year><Month>02</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>76</Volume><Issue>3</Issue><PubDate><Year>2011</Year><Month>Jan</Month><Day>18</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Report of the task force on designing clinical trials in early (predementia) AD.</ArticleTitle><Pagination><StartPage>280</StartPage><EndPage>286</EndPage><MedlinePgn>280-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0b013e318207b1b9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">A large number of promising candidate disease-modifying treatments for Alzheimer disease (AD) continue to advance into phase II and phase III testing. However, most completed trials have failed to demonstrate efficacy, and there is growing concern that methodologic difficulties may contribute to these clinical trial failures. The optimal time to intervene with such treatments is probably in the years prior to the onset of dementia, before the neuropathology has progressed to the advanced stage corresponding to clinical dementia.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">An international task force of individuals from academia, industry, nonprofit foundations, and regulatory agencies was convened to discuss optimal trial design in early (predementia) AD.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">General consensus was reached on key principles involving the scope of the AD diagnosis, the selection of subjects for trials, outcome measures, and analytical methods.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">A consensus has been achieved in support of the testing of candidate treatments in the early (predementia) AD population.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aisen</LastName><ForeName>P S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, UCSD, 9500 Gilman Drive M/C 0949, La Jolla, CA 92093, USA paisen@ucsd.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andrieu</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Sampaio</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Carrillo</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Khachaturian</LastName><ForeName>Z S</ForeName><Initials>ZS</Initials></Author><Author ValidYN="Y"><LastName>Dubois</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Feldman</LastName><ForeName>H H</ForeName><Initials>HH</Initials></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>R C</ForeName><Initials>RC</Initials></Author><Author ValidYN="Y"><LastName>Siemers</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Doody</LastName><ForeName>R S</ForeName><Initials>RS</Initials></Author><Author ValidYN="Y"><LastName>Hendrix</LastName><ForeName>S B</ForeName><Initials>SB</Initials></Author><Author ValidYN="Y"><LastName>Grundman</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>L S</ForeName><Initials>LS</Initials></Author><Author ValidYN="Y"><LastName>Schindler</LastName><ForeName>R J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Salmon</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Potter</LastName><ForeName>W Z</ForeName><Initials>WZ</Initials></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>R G</ForeName><Initials>RG</Initials></Author><Author ValidYN="Y"><LastName>Salmon</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Donohue</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Bednar</LastName><ForeName>M M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Touchon</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Vellas</LastName><ForeName>B</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>12</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058227">Amyloidogenic Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007189">Indans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018697">Nootropic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010880">Piperidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>1406-18-4</RegistryNumber><NameOfSubstance UI="D014810">Vitamin E</NameOfSubstance></Chemical><Chemical><RegistryNumber>8SSC91326P</RegistryNumber><NameOfSubstance UI="D000077265">Donepezil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D026683" MajorTopicYN="N">Advisory Committees</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058227" MajorTopicYN="N">Amyloidogenic Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D032921" MajorTopicYN="N">Consensus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077265" MajorTopicYN="N">Donepezil</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004345" MajorTopicYN="N">Drug Industry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042241" MajorTopicYN="N">Early Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N" Type="Geographic">Europe</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007189" MajorTopicYN="N">Indans</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007391" MajorTopicYN="N">International Cooperation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018697" MajorTopicYN="N">Nootropic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018579" MajorTopicYN="N">Patient Selection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014486" MajorTopicYN="N">United States Food and Drug Administration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014810" MajorTopicYN="N">Vitamin E</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>1</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21178097</ArticleId><ArticleId IdType="pmc">PMC3034393</ArticleId><ArticleId IdType="doi">10.1212/WNL.0b013e318207b1b9</ArticleId><ArticleId IdType="pii">WNL.0b013e318207b1b9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Katzman R. The prevalence and malignancy of Alzheimer disease: a major killer [editorial]. Arch Neurol 1976; 33: 217&#x2013;218</Citation><ArticleIdList><ArticleId IdType="pubmed">1259639</ArticleId></ArticleIdList></Reference><Reference><Citation>2009 Alzheimer's disease facts and figures Alzheimers Dement 2009; 5: 234&#x2013;270</Citation><ArticleIdList><ArticleId IdType="pubmed">19426951</ArticleId></ArticleIdList></Reference><Reference><Citation>Rafii MS, Aisen PS. Recent developments in Alzheimer's disease therapeutics. BMC Med 2009; 7: 7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2649159</ArticleId><ArticleId IdType="pubmed">19228370</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes C, Boche D, Wilkinson D, et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008; 372: 216&#x2013;223</Citation><ArticleIdList><ArticleId IdType="pubmed">18640458</ArticleId></ArticleIdList></Reference><Reference><Citation>Aisen PS. Alzheimer's disease therapeutic research: the path forward. Alzheimers Res Ther 2009; 1: 2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2719107</ArticleId><ArticleId IdType="pubmed">19674435</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrieu S, Coley N, Aisen P, et al. Methodological issues in primary prevention trials for neurodegenerative dementia. J Alzheimers Dis 2009; 16: 235&#x2013;270</Citation><ArticleIdList><ArticleId IdType="pubmed">19221415</ArticleId></ArticleIdList></Reference><Reference><Citation>Vellas B, Andrieu S, Sampaio C, Coley N, Wilcock G. Endpoints for trials in Alzheimer's disease: a European Task Force consensus. Lancet Neurol 2008; 7: 436&#x2013;450</Citation><ArticleIdList><ArticleId IdType="pubmed">18420157</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56: 303&#x2013;308</Citation><ArticleIdList><ArticleId IdType="pubmed">10190820</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005; 352: 2379&#x2013;2388</Citation><ArticleIdList><ArticleId IdType="pubmed">15829527</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman HH, Ferris S, Winblad B, et al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol 2007; 6: 501&#x2013;512</Citation><ArticleIdList><ArticleId IdType="pubmed">17509485</ArticleId></ArticleIdList></Reference><Reference><Citation>Winblad B, Gauthier S, Scinto L, et al. Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology 2008; 70: 2024&#x2013;2035</Citation><ArticleIdList><ArticleId IdType="pubmed">18322263</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal LJ, Ferris SH, Kirby L, et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 2005; 30: 1204&#x2013;1215</Citation><ArticleIdList><ArticleId IdType="pubmed">15742005</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Aisen PS, Beckett LA, et al. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology 2010; 74: 201&#x2013;209</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2809036</ArticleId><ArticleId IdType="pubmed">20042704</ArticleId></ArticleIdList></Reference><Reference><Citation>Visser PJ, Verhey F, Knol DL, et al. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol 2009; 8: 619&#x2013;627</Citation><ArticleIdList><ArticleId IdType="pubmed">19523877</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6: 734&#x2013;746</Citation><ArticleIdList><ArticleId IdType="pubmed">17616482</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher A, Grundman M, Jack CR, Jr, et al. Sex, apolipoprotein E epsilon 4 status, and hippocampal volume in mild cognitive impairment. Arch Neurol 2005; 62: 953&#x2013;957</Citation><ArticleIdList><ArticleId IdType="pubmed">15956166</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Lowe VJ, Weigand SD, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009; 132: 1355&#x2013;1365</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677798</ArticleId><ArticleId IdType="pubmed">19339253</ArticleId></ArticleIdList></Reference><Reference><Citation>Langbaum JB, Chen K, Lee W, et al. Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Neuroimage 2009; 45: 1107&#x2013;1116</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2886795</ArticleId><ArticleId IdType="pubmed">19349228</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009; 65: 403&#x2013;413</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 2007; 64: 343&#x2013;349</Citation><ArticleIdList><ArticleId IdType="pubmed">17210801</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Zetterberg H, Hansson O, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009; 302: 385&#x2013;393</Citation><ArticleIdList><ArticleId IdType="pubmed">19622817</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006; 59: 512&#x2013;519</Citation><ArticleIdList><ArticleId IdType="pubmed">16372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006; 5: 228&#x2013;234</Citation><ArticleIdList><ArticleId IdType="pubmed">16488378</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinne JO, Brooks DJ, Rossor MN, et al. (11)C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. Epub 2010.</Citation><ArticleIdList><ArticleId IdType="pubmed">20189881</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohs RC, Knopman D, Petersen RC, et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: Additions to the Alzheimer's disease assessment scale that broaden its scope. Alzheimer Dis Assoc Disord 1997; 11 (suppl 2): S13&#x2013;S21</Citation><ArticleIdList><ArticleId IdType="pubmed">9236948</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43: 2412&#x2013;2414</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Aisen PS, Beckett LA, et al. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology 2010; 74: 201&#x2013;209</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2809036</ArticleId><ArticleId IdType="pubmed">20042704</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC. Alzheimer's disease: progress in prediction. Lancet Neurol 2010; 9: 4&#x2013;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3098141</ArticleId><ArticleId IdType="pubmed">20083022</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21193246</PMID><DateCompleted><Year>2012</Year><Month>04</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1558-1497</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>2</Issue><PubDate><Year>2012</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Neurobiology of aging</Title><ISOAbbreviation>Neurobiol Aging</ISOAbbreviation></Journal><ArticleTitle>Duplication of amyloid precursor protein (APP), but not prion protein (PRNP) gene is a significant cause of early onset dementia in a large UK series.</ArticleTitle><Pagination><StartPage>426.e13</StartPage><EndPage>426.e4.26E21</EndPage><MedlinePgn>426.e13-21</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neurobiolaging.2010.10.010</ELocationID><Abstract><AbstractText>Amyloid precursor protein gene (APP) duplications have been identified in screens of selected probands with early onset familial Alzheimer's disease (FAD). A causal role for copy number variation (CNV) in the prion protein gene (PRNP) in prion dementias is not known. We aimed to determine the prevalence of copy number variation in APP and PRNP in a large referral series, test a screening method for detection of the same, and expand knowledge of clinical phenotype. We used a 3-tiered screening assay for APP and PRNP duplication (exonic real-time quantitative polymerase chain reaction [exon-qPCR], fluorescent microsatellite quantitative PCR [fm-q-PCR], and Illumina array [Illumina Inc., San Diego, CA, USA]) for analysis of a heterogeneous referral series comprising 1531 probands. Five of 1531 probands screened showed APP duplication, a similar prevalence to APP missense mutation. Real-time quantitative PCR and fluorescent microsatellite quantitative PCR were similar individually but are theoretically complementary; we used Illumina arrays as our reference assay. Two of 5 probands were from an autosomal dominant early onset Alzheimer's disease (familial Alzheimer's disease) pedigree. One extensive, noncontiguous duplication on chromosome 21 was consistent with an unbalanced translocation not including the Down's syndrome critical region. Seizures were prominent in the other typical APP duplications. A range of imaging, neuropsychological, cerebrospinal fluid, and pathological findings are reported that extend the known phenotype. APP but not PRNP duplication is a significant cause of early onset dementia in the UK. The recognized phenotype may be expanded to include the possibility of early seizures and apparently sporadic disease which, in part, may be due to different mutational mechanisms. The pros and cons of our screening method are discussed.</AbstractText><CopyrightInformation>Copyright &#xa9; 2012 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McNaughton</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>MRC Prion Unit, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knight</LastName><ForeName>William</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Guerreiro</LastName><ForeName>Rita</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Natalie</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Lowe</LastName><ForeName>Jessica</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Poulter</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Nicholl</LastName><ForeName>David J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Hardy</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Revesz</LastName><ForeName>Tamas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Lowe</LastName><ForeName>James</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Rossor</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Collinge</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Mead</LastName><ForeName>Simon</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0900421</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_U123160657</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_U123160651</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0701075</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>Z01 AG000950</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>Z01 AG000950-06</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>12</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Aging</MedlineTA><NlmUniqueID>8100437</NlmUniqueID><ISSNLinking>0197-4580</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C545487">APP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011328">Prions</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015984" MajorTopicYN="N">Causality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020440" MajorTopicYN="N">Gene Duplication</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011328" MajorTopicYN="N">Prions</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N">United Kingdom</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>6</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>1</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>2</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21193246</ArticleId><ArticleId IdType="pmc">PMC3657692</ArticleId><ArticleId IdType="doi">10.1016/j.neurobiolaging.2010.10.010</ArticleId><ArticleId IdType="pii">S0197-4580(10)00443-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Blom E.S., Viswanathan J., Kilander L., Helisalmi S., Soininen H., Lannfelt L., Ingelsson M., Glaser A., Hiltunen M. Low prevalence of APP duplications in Swedish and Finnish patients with early-onset Alzheimer's disease. Eur. J. Hum. Genet. 2008;16:171&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pubmed">18043715</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns A., Iliffe S. Alzheimer's disease. BMJ. 2009;338:b75.</Citation><ArticleIdList><ArticleId IdType="pubmed">19196745</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabrejo L., Guyant-Marechal L., Laquerriere A., Vercelletto M., De la Fourniere F., Thomas-Anterion C., Verny C., Letournel F., Pasquier F., Vital A., Checler F., Frebourg T., Campion D., Hannequin D. Phenotype associated with APP duplication in five families. Brain. 2006;129:2966&#x2013;2976.</Citation><ArticleIdList><ArticleId IdType="pubmed">16959815</ArticleId></ArticleIdList></Reference><Reference><Citation>Collinge J. Prion diseases of humans and animals: their causes and molecular basis. Annu. Rev. Neurosci. 2001;24:519&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pubmed">11283320</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins S.J., Schuur M., Coun A.B., Lewis V., Klug G.M., McGlade A., van Oosterhout A., Breedveld G., Oostra B.A., Masters C., Duijn C.M. No evidence for prion protein gene locus multiplication in Creutzfeldt-Jakob Disease. Neurosci. Lett. 2010;472:16&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">20105449</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer M., Rulicke T., Raeber A., Sailer A., Moser M., Oesch B., Brandner S., Aguzzi A., Weissmann C. Prion protein (PrP) with amino-proximal deletions restoring susceptibility of PrP knockout mice to scrapie. EMBO J. 1996;15:1255&#x2013;1264.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC450028</ArticleId><ArticleId IdType="pubmed">8635458</ArticleId></ArticleIdList></Reference><Reference><Citation>Guyant-Marechal L., Berger E., Laquerriere A., Rovelet-Lecrux A., Viennet G., Frebourg T., Rumbach L., Campion D., Hannequin D. Intrafamilial Diversity of Phenotype Associated with App Duplication. Neurology. 2008;71:1925&#x2013;1926.</Citation><ArticleIdList><ArticleId IdType="pubmed">19047566</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J., Orr H. The genetics of neurodegenerative diseases. J. Neurochem. 2006;97:1690&#x2013;1699.</Citation><ArticleIdList><ArticleId IdType="pubmed">16805777</ArticleId></ArticleIdList></Reference><Reference><Citation>Hendriks L., van Duijn C.M., Cras P., Cruts M., van Hul W., van Harskamp F., Warren A., McInnis M.G., Antonarakis S.E., Martin J.J., Hofman A., van Broeckhoven C. Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the b-amyloid precursor protein gene. Nat. Genet. 1992;1:218&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">1303239</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasuga K., Shimohata T., Nishimura A., Shiga A., Mizuguchi T., Tokunaga J., Ohno T., Miyashita A., Kuwano R., Matsumoto N., Onodera O., Nishizawa M., Ikeuchi T. Identification of independent APP locus duplication in Japanese patients with early-onset Alzheimer disease. J. Neurol. Neurosurg. Psychiatry. 2009;80:1050&#x2013;1052.</Citation><ArticleIdList><ArticleId IdType="pubmed">19684239</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarroll S.A., Altshuler D.M. Copy-number variation and association studies of human disease. Nat. Genet. 2007;39:S37&#x2013;S42.</Citation><ArticleIdList><ArticleId IdType="pubmed">17597780</ArticleId></ArticleIdList></Reference><Reference><Citation>Menendez M. Down syndrome, Alzheimer's disease and seizures. Brain Dev. 2005;27:246&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pubmed">15862185</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoll A.J., Collinge J. Preventing prion pathogenicity by targeting the cellular prion protein. Infect. Disord. Drug Targets. 2009;9:48&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">19200015</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahmani Z., Blouin J.L., Creaugoldberg N., Watkins P.C., Mattei J.F., Poissonnier M., Prieur M., Chettouh Z., Nicole A., Aurias A., Sinet P.M., Delabar J.M. Critical Role of the D21S55 Region on Chromosome-21 in the Pathogenesis of Down Syndrome. Proc. Natl. Acad. Sci. U. S. A. 1989;86:5958&#x2013;5962.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC297750</ArticleId><ArticleId IdType="pubmed">2527368</ArticleId></ArticleIdList></Reference><Reference><Citation>Raux G., Guyant-Marechal L., Martin C., Bou J., Penet C., Brice A., Hannequin D., Frebourg T., Campion D. Molecular diagnosis of autosomal dominant early onset Alzheimer's disease: an update. J. Med. Genet. 2005;42:793&#x2013;795.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1735922</ArticleId><ArticleId IdType="pubmed">16033913</ArticleId></ArticleIdList></Reference><Reference><Citation>Remes A.M., Finnila S., Mononen H., Tuominen H., Takalo R., Herva R., Majamaa K. Hereditary dementia with intracerebral hemorrhages and cerebral amyloid angiopathy. Neurology. 2004;63:234&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pubmed">15277614</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovelet-Lecrux A., Frebourg T., Tuominen H., Majamaa K., Campion D., Remes A.M. APP locus duplication in a Finnish family with dementia and intracerebral haemorrhage. J. Neurol. Neurosurg. Psychiatry. 2007;78:1158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2117532</ArticleId><ArticleId IdType="pubmed">17442758</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovelet-Lecrux A., Hannequin D., Raux G., Le Meur N., Laquerriere A., Vital A., Dumanchin C., Feuillette S., Brice A., Vercelletto M., Dubas F., Frebourg T., Campion D. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat. Genet. 2006;38:24&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">16369530</ArticleId></ArticleIdList></Reference><Reference><Citation>Salloway S., Sperling R., Gilman S., Fox N.C., Blennow K., Raskind M., Sabbagh M., Honig L.S., Doody R., van Dyck C.H., Mulnard R., Barakos J., Gregg K.M., Liu E., Lieberburg I., Schenk D., Black R., Grundman M. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2009;73:2061&#x2013;2070.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2790221</ArticleId><ArticleId IdType="pubmed">19923550</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleegers K., Brouwers N., Gijselinck I., Theuns J., Goossens D., Wauters J., Del Favero J., Cruts M., van Duijn C.M., van Broeckhoven C. APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy. Brain. 2006;129:2977&#x2013;2983.</Citation><ArticleIdList><ArticleId IdType="pubmed">16921174</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallin A.K., Blennow K., Andreasen N., Minthon L. CSF biomarkers for Alzheimer's disease: Levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival. Dement. Geriatr. Cogn. Disord. 2006;21:131&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">16391474</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21209097</PMID><DateCompleted><Year>2011</Year><Month>05</Month><Day>11</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1083-351X</ISSN><JournalIssue CitedMedium="Internet"><Volume>286</Volume><Issue>10</Issue><PubDate><Year>2011</Year><Month>Mar</Month><Day>11</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Inhibition of beta-secretase in vivo via antibody binding to unique loops (D and F) of BACE1.</ArticleTitle><Pagination><StartPage>8677</StartPage><EndPage>8687</EndPage><MedlinePgn>8677-8687</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1074/jbc.M110.194860</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0021-9258(20)54007-6</ELocationID><Abstract><AbstractText>&#x3b2;-Secretase (BACE1) is an attractive drug target for Alzheimer disease. However, the design of clinical useful inhibitors targeting its active site has been extremely challenging. To identify alternative drug targeting sites we have generated a panel of BACE1 monoclonal antibodies (mAbs) that interfere with BACE1 activity in various assays and determined their binding epitopes. mAb 1A11 inhibited BACE1 in vitro using a large APP sequence based substrate (IC(50) &#x223c;0.76 nm), in primary neurons (EC(50) &#x223c;1.8 nm), and in mouse brain after stereotactic injection. Paradoxically, mAb 1A11 increased BACE1 activity in vitro when a short synthetic peptide was used as substrate, indicating that mAb 1A11 does not occupy the active-site. Epitope mapping revealed that mAb 1A11 binds to adjacent loops D and F, which together with nearby helix A, distinguishes BACE1 from other aspartyl proteases. Interestingly, mutagenesis of loop F and helix A decreased or increased BACE1 activity, identifying them as enzymatic regulatory elements and as potential alternative sites for inhibitor design. In contrast, mAb 5G7 was a potent BACE1 inhibitor in cell-free enzymatic assays (IC(50) &#x223c;0.47 nm) but displayed no inhibitory effect in primary neurons. Its epitope, a surface helix 299-312, is inaccessible in membrane-anchored BACE1. Remarkably, mutagenesis of helix 299-312 strongly reduced BACE1 ectodomain shedding, suggesting that this helix plays a role in BACE1 cellular biology. In conclusion, this study generated highly selective and potent BACE1 inhibitory mAbs, which recognize unique structural and functional elements in BACE1, and uncovered interesting alternative sites on BACE1 that could become targets for drug development.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Lujia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>From the Department of Molecular and Developmental Genetics, VIB and; the Center for Human Genetics, KULeuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ch&#xe1;vez-Guti&#xe9;rrez</LastName><ForeName>Lucia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>From the Department of Molecular and Developmental Genetics, VIB and; the Center for Human Genetics, KULeuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bockstael</LastName><ForeName>Katrijn</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>From the Department of Molecular and Developmental Genetics, VIB and; the Center for Human Genetics, KULeuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sannerud</LastName><ForeName>Ragna</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>From the Department of Molecular and Developmental Genetics, VIB and; the Center for Human Genetics, KULeuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Annaert</LastName><ForeName>Wim</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>From the Department of Molecular and Developmental Genetics, VIB and; the Center for Human Genetics, KULeuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>May</LastName><ForeName>Patrick C</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>the Neuroscience Discovery Research, Lilly Research Laboratories, Eli Lilly and Co., Indianapolis, Indiana 46285, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karran</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Johnson and Johnson Pharmaceutical Research and Development, 2340 Beerse, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Strooper</LastName><ForeName>Bart</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>From the Department of Molecular and Developmental Genetics, VIB and; the Center for Human Genetics, KULeuven, 3000 Leuven, Belgium,. Electronic address: Bart.DeStrooper@cme.vib-kuleuven.be.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>01</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058846">Antibodies, Monoclonal, Murine-Derived</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058846" MajorTopicYN="N">Antibodies, Monoclonal, Murine-Derived</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016296" MajorTopicYN="N">Mutagenesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017433" MajorTopicYN="N">Protein Structure, Secondary</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>3</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21209097</ArticleId><ArticleId IdType="pmc">PMC3048749</ArticleId><ArticleId IdType="doi">10.1074/jbc.M110.194860</ArticleId><ArticleId IdType="pii">S0021-9258(20)54007-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardy J., Selkoe D. J. (2002) Science 297, 353&#x2013;356</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Golde T. E., Dickson D., Hutton M. (2006) Curr. Alzheimer Res. 3, 421&#x2013;430</Citation><ArticleIdList><ArticleId IdType="pubmed">17168641</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe D. J. (2001) Physiol. Rev. 81, 741&#x2013;766</Citation><ArticleIdList><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussain I., Powell D., Howlett D. R., Tew D. G., Meek T. D., Chapman C., Gloger I. S., Murphy K. E., Southan C. D., Ryan D. M., Smith T. S., Simmons D. L., Walsh F. S., Dingwall C., Christie G. (1999) Mol. Cell Neurosci. 14, 419&#x2013;427</Citation><ArticleIdList><ArticleId IdType="pubmed">10656250</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha S., Anderson J. P., Barbour R., Basi G. S., Caccavello R., Davis D., Doan M., Dovey H. F., Frigon N., Hong J., Jacobson-Croak K., Jewett N., Keim P., Knops J., Lieberburg I., Power M., Tan H., Tatsuno G., Tung J., Schenk D., Seubert P., Suomensaari S. M., Wang S., Walker D., Zhao J., McConlogue L., John V. (1999) Nature 402, 537&#x2013;540</Citation><ArticleIdList><ArticleId IdType="pubmed">10591214</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R., Bennett B. D., Babu-Khan S., Kahn S., Mendiaz E. A., Denis P., Teplow D. B., Ross S., Amarante P., Loeloff R., Luo Y., Fisher S., Fuller J., Edenson S., Lile J., Jarosinski M. A., Biere A. L., Curran E., Burgess T., Louis J. C., Collins F., Treanor J., Rogers G., Citron M. (1999) Science 286, 735&#x2013;741</Citation><ArticleIdList><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan R., Bienkowski M. J., Shuck M. E., Miao H., Tory M. C., Pauley A. M., Brashier J. R., Stratman N. C., Mathews W. R., Buhl A. E., Carter D. B., Tomasselli A. G., Parodi L. A., Heinrikson R. L., Gurney M. E. (1999) Nature 402, 533&#x2013;537</Citation><ArticleIdList><ArticleId IdType="pubmed">10591213</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin X., Koelsch G., Wu S., Downs D., Dashti A., Tang J. (2000) Proc. Natl. Acad. Sci. U.S.A. 97, 1456&#x2013;1460</Citation><ArticleIdList><ArticleId IdType="pmc">PMC26455</ArticleId><ArticleId IdType="pubmed">10677483</ArticleId></ArticleIdList></Reference><Reference><Citation>Costantini C., Ko M. H., Jonas M. C., Puglielli L. (2007) Biochem. J. 407, 383&#x2013;395</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2275071</ArticleId><ArticleId IdType="pubmed">17425515</ArticleId></ArticleIdList></Reference><Reference><Citation>Charlwood J., Dingwall C., Matico R., Hussain I., Johanson K., Moore S., Powell D. J., Skehel J. M., Ratcliffe S., Clarke B., Trill J., Sweitzer S., Camilleri P. (2001) J. Biol. Chem. 276, 16739&#x2013;16748</Citation><ArticleIdList><ArticleId IdType="pubmed">11278492</ArticleId></ArticleIdList></Reference><Reference><Citation>Creemers J. W., Ines Dominguez D., Plets E., Serneels L., Taylor N. A., Multhaup G., Craessaerts K., Annaert W., De Strooper B. (2001) J. Biol. Chem. 276, 4211&#x2013;4217</Citation><ArticleIdList><ArticleId IdType="pubmed">11071887</ArticleId></ArticleIdList></Reference><Reference><Citation>Huse J. T., Pijak D. S., Leslie G. J., Lee V. M., Doms R. W. (2000) J. Biol. Chem. 275, 33729&#x2013;33737</Citation><ArticleIdList><ArticleId IdType="pubmed">10924510</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter J., Fluhrer R., Hartung B., Willem M., Kaether C., Capell A., Lammich S., Multhaup G., Haass C. (2001) J. Biol. Chem. 276, 14634&#x2013;14641</Citation><ArticleIdList><ArticleId IdType="pubmed">11278841</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan R., Han P., Miao H., Greengard P., Xu H. (2001) J. Biol. Chem. 276, 36788&#x2013;36796</Citation><ArticleIdList><ArticleId IdType="pubmed">11466313</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajendran L., Honsho M., Zahn T. R., Keller P., Geiger K. D., Verkade P., Simons K. (2006) Proc. Natl. Acad. Sci. U.S.A. 103, 11172&#x2013;11177</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1544060</ArticleId><ArticleId IdType="pubmed">16837572</ArticleId></ArticleIdList></Reference><Reference><Citation>Koo E. H., Squazzo S. L. (1994) J. Biol. Chem. 269, 17386&#x2013;17389</Citation><ArticleIdList><ArticleId IdType="pubmed">8021238</ArticleId></ArticleIdList></Reference><Reference><Citation>Carey R. M., Balcz B. A., Lopez-Coviella I., Slack B. E. (2005) BMC Cell Biol. 6, 30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1208872</ArticleId><ArticleId IdType="pubmed">16095541</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai H., Wang Y., McCarthy D., Wen H., Borchelt D. R., Price D. L., Wong P. C. (2001) Nat. Neurosci. 4, 233&#x2013;234</Citation><ArticleIdList><ArticleId IdType="pubmed">11224536</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y., Bolon B., Kahn S., Bennett B. D., Babu-Khan S., Denis P., Fan W., Kha H., Zhang J., Gong Y., Martin L., Louis J. C., Yan Q., Richards W. G., Citron M., Vassar R. (2001) Nat. Neurosci. 4, 231&#x2013;232</Citation><ArticleIdList><ArticleId IdType="pubmed">11224535</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberds S. L., Anderson J., Basi G., Bienkowski M. J., Branstetter D. G., Chen K. S., Freedman S. B., Frigon N. L., Games D., Hu K., Johnson-Wood K., Kappenman K. E., Kawabe T. T., Kola I., Kuehn R., Lee M., Liu W., Motter R., Nichols N. F., Power M., Robertson D. W., Schenk D., Schoor M., Shopp G. M., Shuck M. E., Sinha S., Svensson K. A., Tatsuno G., Tintrup H., Wijsman J., Wright S., McConlogue L. (2001) Hum. Mol. Genet 10, 1317&#x2013;1324</Citation><ArticleIdList><ArticleId IdType="pubmed">11406613</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominguez D., Tournoy J., Hartmann D., Huth T., Cryns K., Deforce S., Serneels L., Camacho I. E., Marjaux E., Craessaerts K., Roebroek A. J., Schwake M., D'Hooge R., Bach P., Kalinke U., Moechars D., Alzheimer C., Reiss K., Saftig P., De Strooper B. (2005) J. Biol. Chem. 280, 30797&#x2013;30806</Citation><ArticleIdList><ArticleId IdType="pubmed">15987683</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X., Hicks C. W., He W., Wong P., Macklin W. B., Trapp B. D., Yan R. (2006) Nat. Neurosci. 9, 1520&#x2013;1525</Citation><ArticleIdList><ArticleId IdType="pubmed">17099708</ArticleId></ArticleIdList></Reference><Reference><Citation>Willem M., Garratt A. N., Novak B., Citron M., Kaufmann S., Rittger A., DeStrooper B., Saftig P., Birchmeier C., Haass C. (2006) Science 314, 664&#x2013;666</Citation><ArticleIdList><ArticleId IdType="pubmed">16990514</ArticleId></ArticleIdList></Reference><Reference><Citation>Savonenko A. V., Melnikova T., Laird F. M., Stewart K. A., Price D. L., Wong P. C. (2008) Proc. Natl. Acad. Sci. U.S.A. 105, 5585&#x2013;5590</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2291091</ArticleId><ArticleId IdType="pubmed">18385378</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer O., Marr R. A., Rockenstein E., Crews L., Coufal N. G., Gage F. H., Verma I. M., Masliah E. (2005) Nat. Neurosci. 8, 1343&#x2013;1349</Citation><ArticleIdList><ArticleId IdType="pubmed">16136043</ArticleId></ArticleIdList></Reference><Reference><Citation>McConlogue L., Buttini M., Anderson J. P., Brigham E. F., Chen K. S., Freedman S. B., Games D., Johnson-Wood K., Lee M., Zeller M., Liu W., Motter R., Sinha S. (2007) J. Biol. Chem. 282, 26326&#x2013;26334</Citation><ArticleIdList><ArticleId IdType="pubmed">17616527</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong L., Koelsch G., Lin X., Wu S., Terzyan S., Ghosh A. K., Zhang X. C., Tang J. (2000) Science 290, 150&#x2013;153</Citation><ArticleIdList><ArticleId IdType="pubmed">11021803</ArticleId></ArticleIdList></Reference><Reference><Citation>Silvestri R. (2009) Med. Res. Rev. 29, 295&#x2013;338</Citation><ArticleIdList><ArticleId IdType="pubmed">18651582</ArticleId></ArticleIdList></Reference><Reference><Citation>Erlanson D. A., McDowell R. S., O'Brien T. (2004) J. Med. Chem. 47, 3463&#x2013;3482</Citation><ArticleIdList><ArticleId IdType="pubmed">15214773</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner R. T., 3rd, Loy J. A., Nguyen C., Devasamudram T., Ghosh A. K., Koelsch G., Tang J. (2002) Biochemistry 41, 8742&#x2013;8746</Citation><ArticleIdList><ArticleId IdType="pubmed">12093293</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner R. T., 3rd, Koelsch G., Hong L., Castanheira P., Ermolieff J., Ghosh A. K., Tang J. (2001) Biochemistry 40, 10001&#x2013;10006</Citation><ArticleIdList><ArticleId IdType="pubmed">11513577</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahar Doan K. M., Humphreys J. E., Webster L. O., Wring S. A., Shampine L. J., Serabjit-Singh C. J., Adkison K. K., Polli J. W. (2002) J. Pharmacol. Exp. Ther. 303, 1029&#x2013;1037</Citation><ArticleIdList><ArticleId IdType="pubmed">12438524</ArticleId></ArticleIdList></Reference><Reference><Citation>Meredith J. E., Jr., Thompson L. A., Toyn J. H., Marcin L., Barten D. M., Marcinkeviciene J., Kopcho L., Kim Y., Lin A., Guss V., Burton C., Iben L., Polson C., Cantone J., Ford M., Drexler D., Fiedler T., Lentz K. A., Grace J. E., Jr., Kolb J., Corsa J., Pierdomenico M., Jones K., Olson R. E., Macor J. E., Albright C. F. (2008) J. Pharmacol. Exp. Ther. 326, 502&#x2013;513</Citation><ArticleIdList><ArticleId IdType="pubmed">18499745</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong L., Tang J. (2004) Biochemistry 43, 4689&#x2013;4695</Citation><ArticleIdList><ArticleId IdType="pubmed">15096037</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong L., Turner R. T., 3rd, Koelsch G., Shin D., Ghosh A. K., Tang J. (2002) Biochemistry 41, 10963&#x2013;10967</Citation><ArticleIdList><ArticleId IdType="pubmed">12206667</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel S., Vuillard L., Cleasby A., Murray C. W., Yon J. (2004) J. Mol. Biol. 343, 407&#x2013;416</Citation><ArticleIdList><ArticleId IdType="pubmed">15451669</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner R. T., 3rd, Hong L., Koelsch G., Ghosh A. K., Tang J. (2005) Biochemistry 44, 105&#x2013;112</Citation><ArticleIdList><ArticleId IdType="pubmed">15628850</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorfe A. A., Caflisch A. (2005) Structure 13, 1487&#x2013;1498</Citation><ArticleIdList><ArticleId IdType="pubmed">16216580</ArticleId></ArticleIdList></Reference><Reference><Citation>Binder L. I., Frankfurter A., Rebhun L. I. (1986) Ann. N.Y. Acad. Sci. 466, 145&#x2013;166</Citation><ArticleIdList><ArticleId IdType="pubmed">3089105</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H. C., Chai X., Mosior M., Kohn W., Boggs L. N., Erickson J. A., McClure D. B., Yeh W. K., Zhang L., Gonzalez-DeWhitt P., Mayer J. P., Martin J. A., Hu J., Chen S. H., Bueno A. B., Little S. P., McCarthy J. R., May P. C. (2004) J. Neurochem. 91, 1249&#x2013;1259</Citation><ArticleIdList><ArticleId IdType="pubmed">15584902</ArticleId></ArticleIdList></Reference><Reference><Citation>Annaert W. G., Levesque L., Craessaerts K., Dierinck I., Snellings G., Westaway D., George-Hyslop P. S., Cordell B., Fraser P., De Strooper B. (1999) J. Cell Biol. 147, 277&#x2013;294</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2174229</ArticleId><ArticleId IdType="pubmed">10525535</ArticleId></ArticleIdList></Reference><Reference><Citation>Annaert W. G., Esselens C., Baert V., Boeve C., Snellings G., Cupers P., Craessaerts K., De Strooper B. (2001) Neuron 32, 579&#x2013;589</Citation><ArticleIdList><ArticleId IdType="pubmed">11719200</ArticleId></ArticleIdList></Reference><Reference><Citation>Herzig M. C., Winkler D. T., Burgermeister P., Pfeifer M., Kohler E., Schmidt S. D., Danner S., Abramowski D., St&#xfc;rchler-Pierrat C., B&#xfc;rki K., van Duinen S. G., Maat-Schieman M. L., Staufenbiel M., Mathews P. M., Jucker M. (2004) Nat. Neurosci. 7, 954&#x2013;960</Citation><ArticleIdList><ArticleId IdType="pubmed">15311281</ArticleId></ArticleIdList></Reference><Reference><Citation>Stachel S. J., Coburn C. A., Steele T. G., Jones K. G., Loutzenhiser E. F., Gregro A. R., Rajapakse H. A., Lai M. T., Crouthamel M. C., Xu M., Tugusheva K., Lineberger J. E., Pietrak B. L., Espeseth A. S., Shi X. P., Chen-Dodson E., Holloway M. K., Munshi S., Simon A. J., Kuo L., Vacca J. P. (2004) J. Med. Chem. 47, 6447&#x2013;6450</Citation><ArticleIdList><ArticleId IdType="pubmed">15588077</ArticleId></ArticleIdList></Reference><Reference><Citation>Checler F. (1995) J. Neurochem. 65, 1431&#x2013;1444</Citation><ArticleIdList><ArticleId IdType="pubmed">7561836</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussain I., Hawkins J., Harrison D., Hille C., Wayne G., Cutler L., Buck T., Walter D., Demont E., Howes C., Naylor A., Jeffrey P., Gonzalez M. I., Dingwall C., Michel A., Redshaw S., Davis J. B. (2007) J. Neurochem. 100, 802&#x2013;809</Citation><ArticleIdList><ArticleId IdType="pubmed">17156133</ArticleId></ArticleIdList></Reference><Reference><Citation>Sankaranarayanan S., Price E. A., Wu G., Crouthamel M. C., Shi X. P., Tugusheva K., Tyler K. X., Kahana J., Ellis J., Jin L., Steele T., Stachel S., Coburn C., Simon A. J. (2008) J. Pharmacol. Exp. Ther. 324, 957&#x2013;969</Citation><ArticleIdList><ArticleId IdType="pubmed">18156464</ArticleId></ArticleIdList></Reference><Reference><Citation>Simons M., de Strooper B., Multhaup G., Tienari P. J., Dotti C. G., Beyreuther K. (1996) J. Neurosci. 16, 899&#x2013;908</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578819</ArticleId><ArticleId IdType="pubmed">8558258</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimberly W. T., Zheng J. B., Town T., Flavell R. A., Selkoe D. J. (2005) J. Neurosci. 25, 5533&#x2013;5543</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6724978</ArticleId><ArticleId IdType="pubmed">15944381</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoey S. E., Williams R. J., Perkinton M. S. (2009) J. Neurosci. 29, 4442&#x2013;4460</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6665739</ArticleId><ArticleId IdType="pubmed">19357271</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y. H., Chen Z., Purcell R. H., Emerson S. U. (2007) Immunol. Cell Biol. 85, 73&#x2013;78</Citation><ArticleIdList><ArticleId IdType="pubmed">17130902</ArticleId></ArticleIdList></Reference><Reference><Citation>Thornton J. M., Edwards M. S., Taylor W. R., Barlow D. J. (1986) EMBO J. 5, 409&#x2013;413</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1166746</ArticleId><ArticleId IdType="pubmed">2423325</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussain I., Hawkins J., Shikotra A., Riddell D. R., Faller A., Dingwall C. (2003) J. Biol. Chem. 278, 36264&#x2013;36268</Citation><ArticleIdList><ArticleId IdType="pubmed">12857759</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang W. P., Downs D., Huang X. P., Da H., Fung K. M., Tang J. (2007) FASEB J. 21, 3184&#x2013;3196</Citation><ArticleIdList><ArticleId IdType="pubmed">17494994</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajendran L., Schneider A., Schlechtingen G., Weidlich S., Ries J., Braxmeier T., Schwille P., Schulz J. B., Schroeder C., Simons M., Jennings G., Kn&#xf6;lker H. J., Simons K. (2008) Science 320, 520&#x2013;523</Citation><ArticleIdList><ArticleId IdType="pubmed">18436784</ArticleId></ArticleIdList></Reference><Reference><Citation>Kouzarides T. (2000) EMBO J. 19, 1176&#x2013;1179</Citation><ArticleIdList><ArticleId IdType="pmc">PMC305658</ArticleId><ArticleId IdType="pubmed">10716917</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjannet S., Elagoz A., Wickham L., Mamarbachi M., Munzer J. S., Basak A., Lazure C., Cromlish J. A., Sisodia S., Checler F., Chr&#xe9;tien M., Seidah N. G. (2001) J. Biol. Chem. 276, 10879&#x2013;10887</Citation><ArticleIdList><ArticleId IdType="pubmed">11152688</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukumoto H., Takahashi H., Tarui N., Matsui J., Tomita T., Hirode M., Sagayama M., Maeda R., Kawamoto M., Hirai K., Terauchi J., Sakura Y., Kakihana M., Kato K., Iwatsubo T., Miyamoto M. (2010) J. Neurosci. 30, 11157&#x2013;11166</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6633483</ArticleId><ArticleId IdType="pubmed">20720123</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos R. B., Bales K. R., Cummins D. J., Dodart J. C., Paul S. M., Holtzman D. M. (2001) Proc. Natl. Acad. Sci. U.S.A. 98, 8850&#x2013;8855</Citation><ArticleIdList><ArticleId IdType="pmc">PMC37524</ArticleId><ArticleId IdType="pubmed">11438712</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohajeri M. H., Gaugler M. N., Martinez J., Tracy J., Li H., Crameri A., Kuehnle K., Wollmer M. A., Nitsch R. M. (2004) Neurodegener Dis. 1, 160&#x2013;167</Citation><ArticleIdList><ArticleId IdType="pubmed">16908985</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel M. M., Goyal B. R., Bhadada S. V., Bhatt J. S., Amin A. F. (2009) CNS Drugs 23, 35&#x2013;58</Citation><ArticleIdList><ArticleId IdType="pubmed">19062774</ArticleId></ArticleIdList></Reference><Reference><Citation>Alam M. I., Beg S., Samad A., Baboota S., Kohli K., Ali J., Ahuja A., Akbar M. (2010) Eur. J. Pharm. Sci. 40, 385&#x2013;403</Citation><ArticleIdList><ArticleId IdType="pubmed">20497904</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21209194</PMID><DateCompleted><Year>2011</Year><Month>02</Month><Day>04</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>1</Issue><PubDate><Year>2011</Year><Month>Jan</Month><Day>05</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Knockout of Zn transporters Zip-1 and Zip-3 attenuates seizure-induced CA1 neurodegeneration.</ArticleTitle><Pagination><StartPage>97</StartPage><EndPage>104</EndPage><MedlinePgn>97-104</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.5162-10.2011</ELocationID><Abstract><AbstractText>CA1 pyramidal neurons are the final integrators of information flow leaving the hippocampus, yet are singularly vulnerable to activity-dependent cell death. Zinc (Zn) entry into cells may add to this vulnerability. Here, we find that Slc39a1 and Slc39a3, members of the Zip (Zrt/Irt-like protein) plasmalemmal Zn transporter family, are predominantly expressed in the hippocampus. We examined Zip-1,3-deficient mice to investigate their role in neurodegeneration following intense synaptic activation. When isolated by blockade of NMDA receptors and voltage-gated calcium channels, the absence of both transporters slowed passive Zn uptake into CA1 neurons measured with intracellular fluorescent Zn dyes. In vivo CA1 cell damage following kainic acid exposure was greatly attenuated. Consistent with the hypothesis that Zn entry contributes to neurodegeneration, Znt-3-deficient mice lacking synaptic Zn also show less hippocampal cell damage following kainic acid injection. Zip transporters may provide selective therapeutic targets to protect these neurons from early Zn-induced neurodegeneration following injury.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Qian</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Kaiping</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Yoo</LastName><ForeName>Jong</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Tim T</ForeName><Initials>TT</Initials></Author><Author ValidYN="Y"><LastName>Andrews</LastName><ForeName>Glen</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Noebels</LastName><ForeName>Jeffrey L</ForeName><Initials>JL</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS029709</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS 29709</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D027682">Cation Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018690">Excitatory Amino Acid Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005452">Fluoresceins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C409466">NR1 NMDA receptor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009930">Organic Chemicals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C485744">Slc39a1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498426">Slc39a3 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C485184">enhanced green fluorescent protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C435731">fluoro jade</NameOfSubstance></Chemical><Chemical><RegistryNumber>147336-22-9</RegistryNumber><NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>J41CSQ7QDS</RegistryNumber><NameOfSubstance UI="D015032">Zinc</NameOfSubstance></Chemical><Chemical><RegistryNumber>SIV03811UC</RegistryNumber><NameOfSubstance UI="D007608">Kainic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056547" MajorTopicYN="N">CA1 Region, Hippocampal</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D027682" MajorTopicYN="N">Cation Transport Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004569" MajorTopicYN="N">Electroencephalography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018690" MajorTopicYN="N">Excitatory Amino Acid Agonists</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005452" MajorTopicYN="N">Fluoresceins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015967" MajorTopicYN="N">Gene Expression Regulation, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049452" MajorTopicYN="N">Green Fluorescent Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007608" MajorTopicYN="N">Kainic Acid</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009930" MajorTopicYN="N">Organic Chemicals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018408" MajorTopicYN="N">Patch-Clamp Techniques</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012640" MajorTopicYN="N">Seizures</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014741" MajorTopicYN="N">Video Recording</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015032" MajorTopicYN="N">Zinc</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>7</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21209194</ArticleId><ArticleId IdType="mid">NIHMS262001</ArticleId><ArticleId IdType="pmc">PMC3078714</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.5162-10.2011</ArticleId><ArticleId IdType="pii">31/1/97</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bancila V, Nikonenko I, Dunant Y, Bloc A. Zinc inhibits glutamate release via activation of pre-synaptic K channels and reduces ischaemic damage in rat hippocampus. J Neurochem. 2004;90:1243&#x2013;1250.</Citation><ArticleIdList><ArticleId IdType="pubmed">15312179</ArticleId></ArticleIdList></Reference><Reference><Citation>Belloni-Olivi L, Marshall C, Laal B, Andrews GK, Bressler J. Localization of zip1 and zip4 mRNA in the adult rat brain. J Neurosci Res. 2009;87:3221&#x2013;3230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2810118</ArticleId><ArticleId IdType="pubmed">19530166</ArticleId></ArticleIdList></Reference><Reference><Citation>Besancon E, Guo S, Lok J, Tymianski M, Lo EH. Beyond NMDA and AMPA glutamate receptors: emerging mechanisms for ionic imbalance and cell death in stroke. Trends Pharmacol Sci. 2008;29:268&#x2013;275.</Citation><ArticleIdList><ArticleId IdType="pubmed">18384889</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldi M, Lariccia V, Marzaioli V, Cavaccini A, Curia G, Viggiano D, Canzoniero LM, di Renzo G, Avoli M, Annunziato L. Zn(2+) slows down Ca(V)3.3 gating kinetics: implications for thalamocortical activity. J Neurophysiol. 2007;98:2274&#x2013;2284.</Citation><ArticleIdList><ArticleId IdType="pubmed">17699699</ArticleId></ArticleIdList></Reference><Reference><Citation>Colvin RA, Fontaine CP, Laskowski M, Thomas D. Zn2+ transporters and Zn2+ homeostasis in neurons. Eur J Pharmacol. 2003;479:171&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">14612148</ArticleId></ArticleIdList></Reference><Reference><Citation>C&#xf4;t&#xe9; A, Chiasson M, Peralta MR, 3rd, Lafortune K, Pellegrini L, T&#xf3;th K. Cell type-specific action of seizure-induced intracellular zinc accumulation in the rat hippocampus. J Physiol. 2005;566:821&#x2013;837.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1464793</ArticleId><ArticleId IdType="pubmed">15919712</ArticleId></ArticleIdList></Reference><Reference><Citation>Dom&#xed;nguez MI, Blasco-Ib&#xe1;&#xf1;ez JM, Crespo C, Marqu&#xe9;s-Mar&#xed; AI, Mart&#xed;nez-Guijarro FJ. Zinc chelation during nonlesioning overexcitation results in neuronal death in the mouse hippocampus. Neuroscience. 2003;116:791&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pubmed">12573720</ArticleId></ArticleIdList></Reference><Reference><Citation>Dom&#xed;nguez MI, Blasco-Ib&#xe1;&#xf1;ez JM, Crespo C, Nacher J, Marqu&#xe9;s-Mar&#xed; AI, Mart&#xed;nez-Guijarro FJ. Neural overexcitation and implication of NMDA and AMPA receptors in a mouse model of temporal lobe epilepsy implying zinc chelation. Epilepsia. 2006;47:887&#x2013;899.</Citation><ArticleIdList><ArticleId IdType="pubmed">16686654</ArticleId></ArticleIdList></Reference><Reference><Citation>Dufner-Beattie J, Langmade SJ, Wang F, Eide D, Andrews GK. Structure, function, and regulation of a subfamily of mouse zinc transporter genes. J Biol Chem. 2003;278:50142&#x2013;50150.</Citation><ArticleIdList><ArticleId IdType="pubmed">14525987</ArticleId></ArticleIdList></Reference><Reference><Citation>Dufner-Beattie J, Huang ZL, Geiser J, Xu W, Andrews GK. Mouse ZIP1 and ZIP3 genes together are essential for adaptation to dietary zinc deficiency during pregnancy. Genesis. 2006;44:239&#x2013;251.</Citation><ArticleIdList><ArticleId IdType="pubmed">16652366</ArticleId></ArticleIdList></Reference><Reference><Citation>Emmetsberger J, Mirrione MM, Zhou C, Fernandez-Monreal M, Siddiq MM, Ji K, Tsirka SE. Tissue plasminogen activator alters intracellular sequestration of zinc through interaction with the transporter ZIP4. J Neurosci. 2010;30:6538&#x2013;6547.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2872103</ArticleId><ArticleId IdType="pubmed">20463217</ArticleId></ArticleIdList></Reference><Reference><Citation>Frederickson CJ, Koh JY, Bush AI. The neurobiology of zinc in health and disease. Nat Rev Neurosci. 2005;6:449&#x2013;462.</Citation><ArticleIdList><ArticleId IdType="pubmed">15891778</ArticleId></ArticleIdList></Reference><Reference><Citation>Frederickson CJ, Giblin LJ, 3rd, Balaji RV, Rengarajan B, Masalha R, Frederickson CJ, Zeng Y, Lopez EV, Koh JY, Chorin U, Besser L, Hershfinkel M, Li Y, Thompson RB, Krezel A. Synaptic release of zinc from brain slices: factors governing release, imaging, and accurate calculation of concentration. J Neurosci Methods. 2006;154:19&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">16460810</ArticleId></ArticleIdList></Reference><Reference><Citation>Freund WD, Reddig S. AMPA/Zn(2+)-induced neurotoxicity in rat primary cortical cultures: involvement of L-type calcium channels. Brain Res. 1994;654:257&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">7527288</ArticleId></ArticleIdList></Reference><Reference><Citation>Grooms SY, Opitz T, Bennett MV, Zukin RS. Status epilepticus decreases glutamate receptor 2 mRNA and protein expression in hippocampal pyramidal cells before neuronal death. Proc Natl Acad Sci U S A. 2000;97:3631&#x2013;3636.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16291</ArticleId><ArticleId IdType="pubmed">10725374</ArticleId></ArticleIdList></Reference><Reference><Citation>Hershfinkel M, Kandler K, Knoch ME, Dagan-Rabin M, Aras MA, Abramovitch-Dahan C, Sekler I, Aizenman E. Intracellular zinc inhibits KCC2 transporter activity. Nat Neurosci. 2009;12:725&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2737597</ArticleId><ArticleId IdType="pubmed">19430470</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirzel K, M&#xfc;ller U, Latal AT, H&#xfc;lsmann S, Grudzinska J, Seeliger MW, Betz H, Laube B. Hyperekplexia phenotype of glycine receptor alpha1 subunit mutant mice identifies Zn(2+) as an essential endogenous modulator of glycinergic neurotransmission. Neuron. 2006;52:679&#x2013;690.</Citation><ArticleIdList><ArticleId IdType="pubmed">17114051</ArticleId></ArticleIdList></Reference><Reference><Citation>Kambe T, Yamaguchi-Iwai Y, Sasaki R, Nagao M. Overview of mammalian zinc transporters. Cell Mol Life Sci. 2004;61:49&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11138893</ArticleId><ArticleId IdType="pubmed">14704853</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh JY, Suh SW, Gwag BJ, He YY, Hsu CY, Choi DW. The role of zinc in selective neuronal death after transient global cerebral ischemia. Science. 1996;272:1013&#x2013;1016.</Citation><ArticleIdList><ArticleId IdType="pubmed">8638123</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwak S, Weiss JH. Calcium-permeable AMPA channels in neurodegenerative disease and ischemia. Curr Opin Neurobiol. 2006;16:281&#x2013;287.</Citation><ArticleIdList><ArticleId IdType="pubmed">16698262</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavoie N, Peralta MR, 3rd, Chiasson M, Lafortune K, Pellegrini L, Seress L, T&#xf3;th K. Extracellular chelation of zinc does not affect hippocampal excitability and seizure-induced cell death in rats. J Physiol. 2007;578:275&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2075111</ArticleId><ArticleId IdType="pubmed">17095563</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JY, Cole TB, Palmiter RD, Koh JY. Accumulation of zinc in degenerating hippocampal neurons of ZnT3-null mice after seizures: evidence against synaptic vesicle origin. J Neurosci. 2000;20:RC79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772632</ArticleId><ArticleId IdType="pubmed">10807937</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JY, Kim JH, Palmiter RD, Koh JY. Zinc released from metallothionein-iii may contribute to hippocampal CA1 and thalamic neuronal death following acute brain injury. Exp Neurol. 2003;184:337&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pubmed">14637104</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu SJ, Zukin RS. Ca2+-permeable AMPA receptors in synaptic plasticity and neuronal death. Trends Neurosci. 2007;30:126&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">17275103</ArticleId></ArticleIdList></Reference><Reference><Citation>Moln&#xe1;r P, Nadler JV. Synaptically-released zinc inhibits N-methyl-D-aspartate receptor activation at recurrent mossy fiber synapses. Brain Res. 2001;910:205&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">11489274</ArticleId></ArticleIdList></Reference><Reference><Citation>Noh KM, Yokota H, Mashiko T, Castillo PE, Zukin RS, Bennett MV. Blockade of calcium-permeable AMPA receptors protects hippocampal neurons against global ischemia-induced death. Proc Natl Acad Sci U S A. 2005;102:12230&#x2013;12235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1189338</ArticleId><ArticleId IdType="pubmed">16093311</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian J, Noebels JL. Visualization of transmitter release with zinc fluorescence detection at the mouse hippocampal mossy fibre synapse. J Physiol. 2005;566:747&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1464795</ArticleId><ArticleId IdType="pubmed">15919713</ArticleId></ArticleIdList></Reference><Reference><Citation>Sensi SL, Canzoniero LM, Yu SP, Ying HS, Koh JY, Kerchner GA, Choi DW. Measurement of intracellular free zinc in living cortical neurons: routes of entry. J Neurosci. 1997;17:9554&#x2013;9564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573416</ArticleId><ArticleId IdType="pubmed">9391010</ArticleId></ArticleIdList></Reference><Reference><Citation>Sensi SL, Yin HZ, Carriedo SG, Rao SS, Weiss JH. Preferential Zn2+ influx through Ca2+-permeable AMPA/kainate channels triggers prolonged mitochondrial superoxide production. Proc Natl Acad Sci U S A. 1999;96:2414&#x2013;2419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC26798</ArticleId><ArticleId IdType="pubmed">10051656</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda A, Tamano H, Nagayoshi A, Yamada K, Oku N. Increase in hippocampal cell death after treatment with kainate in zinc deficiency. Neurochem Int. 2005;47:539&#x2013;544.</Citation><ArticleIdList><ArticleId IdType="pubmed">16169125</ArticleId></ArticleIdList></Reference><Reference><Citation>Traboulsie A, Chemin J, Chevalier M, Quignard JF, Nargeot J, Lory P. Subunit-specific modulation of T-type calcium channels by zinc. J Physiol. 2007;578:159&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2075129</ArticleId><ArticleId IdType="pubmed">17082234</ArticleId></ArticleIdList></Reference><Reference><Citation>Villmann C, Becker CM. On the hypes and falls in neuroprotection: targeting the NMDA receptor. Neuroscientist. 2007;13:594&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pubmed">17911221</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogt K, Mellor J, Tong G, Nicoll R. The actions of synaptically released zinc at hippocampal mossy fiber synapses. Neuron. 2000;26:187&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pubmed">10798403</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss JH, Sensi SL, Koh JY. Zn(2+): a novel ionic mediator of neural injury in brain disease. Trends Pharmacol Sci. 2000;21:395&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pubmed">11050320</ArticleId></ArticleIdList></Reference><Reference><Citation>Wenthold RJ, Petralia RS, Blahos J, II, Niedzielski AS. Evidence for multiple AMPA receptor complexes in hippocampal CA1/CA2 neurons. J Neurosci. 1996;16:1982&#x2013;1989.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578515</ArticleId><ArticleId IdType="pubmed">8604042</ArticleId></ArticleIdList></Reference><Reference><Citation>Westbrook GL, Mayer ML. Micromolar concentrations of Zn2+ antagonize NMDA and GABA responses of hippocampal neurons. Nature. 1987;328:640&#x2013;643.</Citation><ArticleIdList><ArticleId IdType="pubmed">3039375</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin HZ, Sensi SL, Ogoshi F, Weiss JH. Blockade of Ca2+-permeable AMPA/kainate channels decreases oxygen-glucose deprivation-induced Zn2+ accumulation and neuronal loss in hippocampal pyramidal neurons. J Neurosci. 2002;22:1273&#x2013;1279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757569</ArticleId><ArticleId IdType="pubmed">11850455</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21209202</PMID><DateCompleted><Year>2011</Year><Month>02</Month><Day>04</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>1</Issue><PubDate><Year>2011</Year><Month>Jan</Month><Day>05</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Phosphodiesterase-4D knock-out and RNA interference-mediated knock-down enhance memory and increase hippocampal neurogenesis via increased cAMP signaling.</ArticleTitle><Pagination><StartPage>172</StartPage><EndPage>183</EndPage><MedlinePgn>172-83</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.5236-10.2011</ELocationID><Abstract><AbstractText>Phosphodiesterase-4 (PDE4) plays an important role in mediating memory via the control of intracellular cAMP signaling; inhibition of PDE4 enhances memory. However, development of PDE4 inhibitors as memory enhancers has been hampered by their major side effect of emesis. PDE4 has four subtypes (PDE4A-D) consisting of 25 splice variants. Mice deficient in PDE4D displayed memory enhancement in radial arm maze, water maze, and object recognition tests. These effects were mimicked by repeated treatment with rolipram in wild-type mice. In addition, similarly as rolipram-treated wild-type mice, PDE4D-deficient mice also displayed increased hippocampal neurogenesis and phosphorylated cAMP response element-binding protein (pCREB). Furthermore, microinfusion of lentiviral vectors that contained microRNAs (miRNAs) targeting long-form PDE4D isoforms into bilateral dentate gyri of the mouse hippocampus downregulated PDE4D4 and PDE4D5, enhanced memory, and increased hippocampal neurogenesis and pCREB. Finally, while rolipram and PDE4D deficiency shortened &#x3b1;2 adrenergic receptor-mediated anesthesia, a surrogate measure of emesis, miRNA-mediated PDE4D knock-down in the hippocampus did not. The present results suggest that PDE4D, in particular long-form PDE4D, plays a critical role in the mediation of memory and hippocampal neurogenesis, which are mediated by cAMP/CREB signaling; reduced expression of PDE4D, or at least PDE4D4 and PDE4D5, in the hippocampus enhances memory but appears not to cause emesis. These novel findings will aid in the development of PDE4 subtype- or variant-selective inhibitors for treatment of disorders involving impaired cognition, including Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yun-Feng</ForeName><Initials>YF</Initials><AffiliationInfo><Affiliation>Department of Behavioral Medicine and Psychiatry, West Virginia University Health Sciences Center, Morgantown, West Virginia 26506, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Yu-Fang</ForeName><Initials>YF</Initials></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Ying</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Conti</LastName><ForeName>Marco</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Steven P</ForeName><Initials>SP</Initials></Author><Author ValidYN="Y"><LastName>O'Donnell</LastName><ForeName>James M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Han-Ting</ForeName><Initials>HT</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R21 AG031687</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH040697</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH051175</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH051175</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG031687</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058988">Phosphodiesterase 4 Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D055748">SOXB1 Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C527783">Sox2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C485184">enhanced green fluorescent protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>147336-22-9</RegistryNumber><NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>E0399OZS9N</RegistryNumber><NameOfSubstance UI="D000242">Cyclic AMP</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.1.48</RegistryNumber><NameOfSubstance UI="D050882">CREB-Binding Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.4.17</RegistryNumber><NameOfSubstance UI="D054703">Cyclic Nucleotide Phosphodiesterases, Type 4</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.4.17</RegistryNumber><NameOfSubstance UI="C531980">PDE4D protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>G34N38R2N1</RegistryNumber><NameOfSubstance UI="D001973">Bromodeoxyuridine</NameOfSubstance></Chemical><Chemical><RegistryNumber>K676NL63N7</RegistryNumber><NameOfSubstance UI="D020889">Rolipram</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001362" MajorTopicYN="N">Avoidance Learning</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001973" MajorTopicYN="N">Bromodeoxyuridine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050882" MajorTopicYN="N">CREB-Binding Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000242" MajorTopicYN="N">Cyclic AMP</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054703" MajorTopicYN="N">Cyclic Nucleotide Phosphodiesterases, Type 4</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005106" MajorTopicYN="N">Exploratory Behavior</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049452" MajorTopicYN="N">Green Fluorescent Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008813" MajorTopicYN="N">Mice, Inbred ICR</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055495" MajorTopicYN="N">Neurogenesis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058988" MajorTopicYN="N">Phosphodiesterase 4 Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034622" MajorTopicYN="N">RNA Interference</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021641" MajorTopicYN="N">Recognition, Psychology</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020889" MajorTopicYN="N">Rolipram</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055748" MajorTopicYN="N">SOXB1 Transcription Factors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>7</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21209202</ArticleId><ArticleId IdType="mid">NIHMS262002</ArticleId><ArticleId IdType="pmc">PMC3079568</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.5236-10.2011</ArticleId><ArticleId IdType="pii">31/1/172</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abel T, Kandel E. Positive and negative regulatory mechanisms that mediate long-term memory storage. Brain Res Brain Res Rev. 1998;26:360&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pubmed">9651552</ArticleId></ArticleIdList></Reference><Reference><Citation>Baillie GS, MacKenzie SJ, McPhee I, Houslay MD. Sub-family selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the activity of PDE4 cyclic AMP-specific phosphodiesterases. Br J Pharmacol. 2000;131:811&#x2013;819.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1572393</ArticleId><ArticleId IdType="pubmed">11030732</ArticleId></ArticleIdList></Reference><Reference><Citation>Barad M, Bourtchouladze R, Winder DG, Golan H, Kandel E. Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory. Proc Natl Acad Sci U S A. 1998;95:15020&#x2013;15025.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24568</ArticleId><ArticleId IdType="pubmed">9844008</ArticleId></ArticleIdList></Reference><Reference><Citation>Barco A, Pittenger C, Kandel ER. CREB, memory enhancement and the treatment of memory disorders: promises, pitfalls and prospects. Expert Opin Ther Targets. 2003;7:101&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pubmed">12556206</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolger GB, McPhee I, Houslay MD. Alternative splicing of cAMP-specific phosphodiesterase mRNA transcripts: characterization of a novel tissue-specific isoform, RNPDE4A8. J Biol Chem. 1996;271:1065&#x2013;1071.</Citation><ArticleIdList><ArticleId IdType="pubmed">8557632</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolger GB, Erdogan S, Jones RE, Loughney K, Scotland G, Hoffmann R, Wilkinson I, Farrell C, Houslay MD. Characterization of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene. Biochem J. 1997;328:539&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1218953</ArticleId><ArticleId IdType="pubmed">9371713</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourtchouladze R, Lidge R, Catapano R, Stanley J, Gossweiler S, Romashko D, Scott R, Tully T. A mouse model of Rubinstein-Taybi syndrome: defective long-term memory is ameliorated by inhibitors of phosphodiesterase 4. Proc Natl Acad Sci U S A. 2003;100:10518&#x2013;10522.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC193593</ArticleId><ArticleId IdType="pubmed">12930888</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyes BE, Kim SU, Lee V, Sung SC. Immunohistochemical colocalization of S-100&#x3b2; and the glial fibrillary acidic protein in rat brain. Neuroscience. 1986;17:857&#x2013;865.</Citation><ArticleIdList><ArticleId IdType="pubmed">2422599</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruel-Jungerman E, Laroche S, Rampon C. New neurons in the dentate gyrus are involved in the expression of enhanced long-term memory following environmental enrichment. Eur J Neurosci. 2005;21:513&#x2013;521.</Citation><ArticleIdList><ArticleId IdType="pubmed">15673450</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgin AB, Magnusson OT, Singh J, Witte P, Staker BL, Bjornsson JM, Thorsteinsdottir M, Hrafnsdottir S, Hagen T, Kiselyov AS, Stewart LJ, Gurney ME. Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety. Nat Biotechnol. 2010;28:63&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">20037581</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandrasekaran A, Toh KY, Low SH, Tay SK, Brenner S, Goh DL. Identification and characterization of novel mouse PDE4D isoforms: molecular cloning, subcellular distribution and detection of isoform-specific intracellular localization signals. Cell Signal. 2008;20:139&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pubmed">18006274</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherry JA, Davis RL. Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement, and affect. J Comp Neurol. 1999;407:287&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">10213096</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung YF, Kan Z, Garrett-Engele P, Gall I, Murdoch H, Baillie GS, Camargo LM, Johnson JM, Houslay MD, Castle JC. PDE4B5, a novel, super-short, brain-specific cAMP phosphodiesterase-4 variant whose isoform-specifying N-terminal region is identical to that of cAMP phosphodiesterase-4D6 (PDE4D6) J Pharmacol Exp Ther. 2007;322:600&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pubmed">17519386</ArticleId></ArticleIdList></Reference><Reference><Citation>Conti M, Richter W, Mehats C, Livera G, Park JY, Jin C. Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J Biol Chem. 2003;278:5493&#x2013;5496.</Citation><ArticleIdList><ArticleId IdType="pubmed">12493749</ArticleId></ArticleIdList></Reference><Reference><Citation>Cullen BR. RNAi the natural way. Nat Genet. 2005;37:1163&#x2013;1165.</Citation><ArticleIdList><ArticleId IdType="pubmed">16254559</ArticleId></ArticleIdList></Reference><Reference><Citation>de Lima MN, Laranja DC, Bromberg E, Roesler R, Schr&#xf6;der N. Pre- or post-training administration of the NMDA receptor blocker MK-801 impairs object recognition memory in rats. Behav Brain Res. 2005;156:139&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">15474658</ArticleId></ArticleIdList></Reference><Reference><Citation>Dlaboga D, Hajjhussein H, O'Donnell JM. Regulation of phosphodiesterase-4 (PDE4) expression in mouse brain by repeated antidepressant treatment: comparison with rolipram. Brain Res. 2006;1096:104&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">16730340</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Sa C, Eisch AJ, Bolger GB, Duman RS. Differential expression and regulation of the cAMP-selective phosphodiesterase type 4A splice variants in rat brain by chronic antidepressant administration. Eur J Neurosci. 2005;22:1463&#x2013;1475.</Citation><ArticleIdList><ArticleId IdType="pubmed">16190900</ArticleId></ArticleIdList></Reference><Reference><Citation>Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, Naldini L. A third-generation lentivirus vector with a conditional packaging system. J Virol. 1998;72:8463&#x2013;8471.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC110254</ArticleId><ArticleId IdType="pubmed">9765382</ArticleId></ArticleIdList></Reference><Reference><Citation>Duman RS, Malberg J, Nakagawa S. Regulation of adult neurogenesis by psychotropic drugs and stress. J Pharmacol Exp Ther. 2001;299:401&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="pubmed">11602648</ArticleId></ArticleIdList></Reference><Reference><Citation>Dyke HJ, Montana JG. Update on the therapeutic potential of PDE4 inhibitors. Expert Opin Investig Drugs. 2002;11:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">11772317</ArticleId></ArticleIdList></Reference><Reference><Citation>Egawa T, Mishima K, Matsumoto Y, Iwasaki K, Iwasaki K, Fujiwara M. Rolipram and its optical isomers, phosphodiesterase 4 inhibitors, attenuated the scopolamine-induced impairments of learning and memory in rats. Jpn J Pharmacol. 1997;75:275&#x2013;281.</Citation><ArticleIdList><ArticleId IdType="pubmed">9434259</ArticleId></ArticleIdList></Reference><Reference><Citation>Encinas JM, Vaahtokari A, Enikolopov G. Fluoxetine targets early progenitor cells in the adult brain. Proc Natl Acad Sci U S A. 2006;103:8233&#x2013;8238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1461404</ArticleId><ArticleId IdType="pubmed">16702546</ArticleId></ArticleIdList></Reference><Reference><Citation>Episkopou V. SOX2 functions in adult neural stem cells. Trends Neurosci. 2005;28:219&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">15866195</ArticleId></ArticleIdList></Reference><Reference><Citation>Epp JR, Spritzer MD, Galea LA. Hippocampus-dependent learning promotes survival of new neurons in the dentate gyrus at a specific time during cell maturation. Neuroscience. 2007;149:273&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">17900815</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujioka T, Fujioka A, Duman RS. Activation of cAMP signaling facilitates the morphological maturation of newborn neurons in adult hippocampus. J Neurosci. 2004;24:319&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729999</ArticleId><ArticleId IdType="pubmed">14724230</ArticleId></ArticleIdList></Reference><Reference><Citation>Giorgi M, Modica A, Pompili A, Pacitti C, Gasbarri A. The induction of cyclic nucleotide phosphodiesterase 4 gene (PDE4D) impairs memory in a water maze task. Behav Brain Res. 2004;154:99&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">15302115</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould E, Beylin A, Tanapat P, Reeves A, Shors TJ. Learning enhances adult neurogenesis in the hippocampal formation. Nat Neurosci. 1999;2:260&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">10195219</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham V, Khudyakov J, Ellis P, Pevny L. SOX2 functions to maintain neural progenitor identity. Neuron. 2003;39:749&#x2013;765.</Citation><ArticleIdList><ArticleId IdType="pubmed">12948443</ArticleId></ArticleIdList></Reference><Reference><Citation>Grillo CA, Tamashiro KL, Piroli GG, Melhorn S, Gass JT, Newsom RJ, Reznikov LR, Smith A, Wilson SP, Sakai RR, Reagan LP. Lentivirus-mediated downregulation of hypothalamic insulin receptor expression. Physiol Behav. 2007;92:691&#x2013;701.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2129218</ArticleId><ArticleId IdType="pubmed">17585961</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen G, Jin S, Umetsu DT, Conti M. Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D. Proc Natl Acad Sci U S A. 2000;97:6751&#x2013;6756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18727</ArticleId><ArticleId IdType="pubmed">10841571</ArticleId></ArticleIdList></Reference><Reference><Citation>Houslay MD. PDE4 cAMP-specific phosphodiesterases. Prog Nucleic Acid Res Mol Biol. 2001;69:249&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pubmed">11550796</ArticleId></ArticleIdList></Reference><Reference><Citation>Houslay MD. Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown. Trends Biochem Sci. 2010;35:91&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">19864144</ArticleId></ArticleIdList></Reference><Reference><Citation>Houslay MD, Baillie GS, Maurice DH. cAMP-Specific phosphodiesterase-4 enzymes in the cardiovascular system: a molecular toolbox for generating compartmentalized cAMP signaling. Circ Res. 2007;100:950&#x2013;966.</Citation><ArticleIdList><ArticleId IdType="pubmed">17431197</ArticleId></ArticleIdList></Reference><Reference><Citation>Huston E, Lumb S, Russell A, Catterall C, Ross AH, Steele MR, Bolger GB, Perry MJ, Owens RJ, Houslay MD. Molecular cloning and transient expression in COS7 cells of a novel human PDE4B cAMP-specific phosphodiesterase, HSPDE4B3. Biochem J. 1997;328:549&#x2013;558.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1218954</ArticleId><ArticleId IdType="pubmed">9371714</ArticleId></ArticleIdList></Reference><Reference><Citation>Imanishi T, Sawa A, Ichimaru Y, Miyashiro M, Kato S, Yamamoto T, Ueki S. Ameliorating effects of rolipram on experimentally induced impairments of learning and memory in rodents. Eur J Pharmacol. 1997;321:273&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pubmed">9085037</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin SL, Richard FJ, Kuo WP, D'Ercole AJ, Conti M. Impaired growth and fertility of cAMP-specific phosphodiesterase PDE4D-deficient mice. Proc Natl Acad Sci U S A. 1999;96:11998&#x2013;12003.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18401</ArticleId><ArticleId IdType="pubmed">10518565</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston LA, Erdogan S, Cheung YF, Sullivan M, Barber R, Lynch MJ, Baillie GS, Van Heeke G, Adams DR, Huston E, Houslay MD. Expression, intracellular distribution and basis for lack of catalytic activity of the PDE4A7 isoform encoded by the human PDE4A cAMP-specific phosphodiesterase gene. Biochem J. 2004;380:371&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1224194</ArticleId><ArticleId IdType="pubmed">15025561</ArticleId></ArticleIdList></Reference><Reference><Citation>Kempermann G, Gast D, Kronenberg G, Yamaguchi M, Gage FH. Early determination and long-term persistence of adult-generated new neurons in the hippocampus of mice. Development. 2003;130:391&#x2013;399.</Citation><ArticleIdList><ArticleId IdType="pubmed">12466205</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolosionek E, Savai R, Ghofrani HA, Weissmann N, Guenther A, Grimminger F, Seeger W, Banat GA, Schermuly RT, Pullamsetti SS. Expression and activity of phosphodiesterase isoforms during epithelial mesenchymal transition: the role of phosphodiesterase 4. Mol Biol Cell. 2009;20:4751&#x2013;4765.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2777105</ArticleId><ArticleId IdType="pubmed">19759179</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Huston E, Lynch MJ, Houslay MD, Baillie GS. Phosphodiesterase-4 influences the PKA phosphorylation status and membrane translocation of G-protein receptor kinase 2 (GRK2) in HEK-293beta2 cells and cardiac myocytes. Biochem J. 2006;394:427&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1408673</ArticleId><ArticleId IdType="pubmed">16356165</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YF, Huang Y, Amsdell SL, Xiao L, O'Donnell JM, Zhang HT. Antidepressant- and anxiolytic-like effects of the phosphodiesterase-4 (PDE4) inhibitor rolipram on behavior depend on cyclic AMP-response element binding protein (CREB)-mediated neurogenesis in the hippocampus. Neuropsychopharmacology. 2009;34:2404&#x2013;2419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2743762</ArticleId><ArticleId IdType="pubmed">19516250</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynch MJ, Baillie GS, Mohamed A, Li X, Maisonneuve C, Klussmann E, van Heeke G, Houslay MD. RNA silencing identifies PDE4D5 as the functionally relevant cAMP phosphodiesterase interacting with beta arrestin to control the protein kinase A/AKAP79-mediated switching of the beta2-adrenergic receptor to activation of ERK in HEK293B2 cells. J Biol Chem. 2005;280:33178&#x2013;33189.</Citation><ArticleIdList><ArticleId IdType="pubmed">16030021</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynex CN, Li Z, Chen ML, Toh KY, Low RW, Goh DL, Tay SK. Identification and molecular characterization of a novel PDE4D11 cAMP-specific phosphodiesterase isoform. Cell Signal. 2008;20:2247&#x2013;2255.</Citation><ArticleIdList><ArticleId IdType="pubmed">18804162</ArticleId></ArticleIdList></Reference><Reference><Citation>MacKenzie SJ, Houslay MD. Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element-binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells. Biochem J. 2000;347:571&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1220991</ArticleId><ArticleId IdType="pubmed">10749688</ArticleId></ArticleIdList></Reference><Reference><Citation>Malberg JE, Eisch AJ, Nestler EJ, Duman RS. Chronic antidepressant treatment increases neurogenesis in adult hippocampus. J Neurosci. 2000;20:9104&#x2013;9110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6773038</ArticleId><ArticleId IdType="pubmed">11124987</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurice T, Privat A. SA4503, a novel cognitive enhancer with &#x3c3;1 receptor agonist properties, facilitates NMDA receptor-dependent learning in mice. Eur J Pharmacol. 1997;328:9&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">9203561</ArticleId></ArticleIdList></Reference><Reference><Citation>McPhee I, Cochran S, Houslay MD. The novel long PDE4A10 cyclic AMP phosphodiesterase shows a pattern of expression within brain that is distinct from the long PDE4A5 and short PDE4A1 isoforms. Cell Signal. 2001;13:911&#x2013;918.</Citation><ArticleIdList><ArticleId IdType="pubmed">11728831</ArticleId></ArticleIdList></Reference><Reference><Citation>Millar JK, Pickard BS, Mackie S, James R, Christie S, Buchanan SR, Malloy MP, Chubb JE, Huston E, Baillie GS, Thomson PA, Hill EV, Brandon NJ, Rain JC, Camargo LM, Whiting PJ, Houslay MD, Blackwood DH, Muir WJ, Porteous DJ. DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling. Science. 2005;310:1187&#x2013;1191.</Citation><ArticleIdList><ArticleId IdType="pubmed">16293762</ArticleId></ArticleIdList></Reference><Reference><Citation>Mir&#xf3; X, P&#xe9;rez-Torres S, Puigdom&#xe8;nech P, Palacios JM, Mengod G. Differential distribution of PDE4D splice variant mRNAs in rat brain suggests association with specific pathways and presynaptical localization. Synapse. 2002;45:259&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pubmed">12125047</ArticleId></ArticleIdList></Reference><Reference><Citation>Monti B, Berteotti C, Contestabile A. Subchronic rolipram delivery activates hippocampal CREB and Arc, enhances retention and slows down extinction of conditioned fear. Neuropsychopharmacology. 2006;31:278&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pubmed">15988467</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris RG, Garrud P, Rawlins JN, O'Keefe J. Place navigation impaired in rats with hippocampal lesions. Nature. 1982;297:681&#x2013;683.</Citation><ArticleIdList><ArticleId IdType="pubmed">7088155</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullen R, Buck CR, Smith AM. NeuN, a neuronal specific nuclear protein in vertebrates. Development. 1992;116:201&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">1483388</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagawa S, Kim JE, Lee R, Malberg JE, Chen J, Steffen C, Zhang YJ, Nestler EJ, Duman RS. Regulation of neurogenesis in adult mouse hippocampus by cAMP and the cAMP response element-binding protein. J Neurosci. 2002a;22:3673&#x2013;3682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758358</ArticleId><ArticleId IdType="pubmed">11978843</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagawa S, Kim JE, Lee R, Chen J, Fujioka T, Malberg J, Tsuji S, Duman RS. Localization of phosphorylated cAMP response element binding protein in immature neurons of adult hippocampus. J Neurosci. 2002b;22:9868&#x2013;9876.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757843</ArticleId><ArticleId IdType="pubmed">12427843</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#xe9;moz G, Zhang R, Sette C, Conti M. Identification of cyclic AMP-phosphodiesterase variants from the PDE4D gene expressed in human peripheral mononuclear cells. FEBS Lett. 1996;384:97&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8797812</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Donnell JM, Zhang HT. Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4) Trends Pharmacol Sci. 2004;25:158&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">15019272</ArticleId></ArticleIdList></Reference><Reference><Citation>Otmakhov N, Khibnik L, Otmakhova N, Carpenter S, Riahi S, Asrican B, Lisman J. Forskolin-induced LTP in the CA1 hippocampal region is NMDA receptor dependent. J Neurophysiol. 2004;91:1955&#x2013;1962.</Citation><ArticleIdList><ArticleId IdType="pubmed">14702333</ArticleId></ArticleIdList></Reference><Reference><Citation>Paxinos G, Franklin KBJ. Ed 2. San Diego: Academic; 2001. The mouse brain in stereotaxic coordinates.</Citation></Reference><Reference><Citation>P&#xe9;rez-Torres S, Mir&#xf3; X, Palacios JM, Cort&#xe9;s R, Puigdom&#xe9;nech P, Mengod G. Phosphodiesterase type 4 isozymes expression in human brain examined by in situ hybridization histochemistry and [3H]rolipram binding autoradiography: comparison with monkey and rat brain. J Chem Neuroanat. 2000;20:349&#x2013;374.</Citation><ArticleIdList><ArticleId IdType="pubmed">11207431</ArticleId></ArticleIdList></Reference><Reference><Citation>Remondes M, Schuman EM. Role for a cortical input to hippocampal area CA1 in the consolidation of a long-term memory. Nature. 2004;431:699&#x2013;703.</Citation><ArticleIdList><ArticleId IdType="pubmed">15470431</ArticleId></ArticleIdList></Reference><Reference><Citation>Richter W, Jin SL, Conti M. Splice variants of the cyclic nucleotide phosphodiesterase PDE4D are differentially expressed and regulated in rat tissue. Biochem J. 2005;388:803&#x2013;811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1183459</ArticleId><ArticleId IdType="pubmed">15717866</ArticleId></ArticleIdList></Reference><Reference><Citation>Robichaud A, Savoie C, Stamatiou PB, Tattersall FD, Chan CC. PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway. Neuropharmacology. 2001;40:262&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pubmed">11114405</ArticleId></ArticleIdList></Reference><Reference><Citation>Robichaud A, Savoie C, Stamatiou PB, Lachance N, Jolicoeur P, Rasori R, Chan CC. Assessing the emetic potential of PDE4 inhibitors in rats. Br J Pharmacol. 2002a;135:113&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1573119</ArticleId><ArticleId IdType="pubmed">11786486</ArticleId></ArticleIdList></Reference><Reference><Citation>Robichaud A, Stamatiou PB, Jin SL, Lachance N, MacDonald D, Lalibert&#xe9; F, Liu S, Huang Z, Conti M, Chan CC. Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest. 2002b;110:1045&#x2013;1052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC151147</ArticleId><ArticleId IdType="pubmed">12370283</ArticleId></ArticleIdList></Reference><Reference><Citation>Romano A, Delorenzi A, Pedreira ME, Tomsic D, Maldonado H. Acute administration of a permeant analog of cAMP and a phosphodiesterase inhibitor improve long-term habituation in the crab Chasmagnathus. Behav Brain Res. 1996;75:119&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pubmed">8800648</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutten K, Misner DL, Works M, Blokland A, Novak TJ, Santarelli L, Wallace TL. Enhanced long-term potentiation and impaired learning in phosphodiesterase 4D-knockout (PDE4D) mice. Eur J Neurosci. 2008;28:625&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pubmed">18702734</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki T, Kitagawa K, Omura-Matsuoka E, Todo K, Terasaki Y, Sugiura S, Hatazawa J, Yagita Y, Hori M. The phosphodiesterase inhibitor rolipram promotes survival of newborn hippocampal neurons after ischemia. Stroke. 2007;38:1597&#x2013;1605.</Citation><ArticleIdList><ArticleId IdType="pubmed">17379823</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt HD, Duman RS. The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. Behav Pharmacol. 2007;18:391&#x2013;418.</Citation><ArticleIdList><ArticleId IdType="pubmed">17762509</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider HH. Brain cAMP response to phosphodiesterase inhibitors in rats killed by microwave irradiation or decapitation. Biochem Pharmacol. 1984;33:1690&#x2013;1693.</Citation><ArticleIdList><ArticleId IdType="pubmed">6203537</ArticleId></ArticleIdList></Reference><Reference><Citation>Schratt GM, Tuebing F, Nigh EA, Kane CG, Sabatini ME, Kiebler M, Greenberg ME. A brain-specific microRNA regulates dendritic spine development. Nature. 2006;439:283&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">16421561</ArticleId></ArticleIdList></Reference><Reference><Citation>Shors TJ, Miesegaes G, Beylin A, Zhao M, Rydel T, Gould E. Neurogenesis in the adult is involved in the formation of trace memories. Nature. 2001;410:372&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pubmed">11268214</ArticleId></ArticleIdList></Reference><Reference><Citation>Siuciak JA, McCarthy SA, Chapin DS, Martin AN. Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-4B (PDE4B) enzyme. Psychopharmacology. 2008;197:115&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">18060387</ArticleId></ArticleIdList></Reference><Reference><Citation>Stegmeier F, Hu G, Rickles RJ, Hannon GJ, Elledge SJ. A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. Proc Natl Acad Sci U S A. 2005;102:13212&#x2013;13217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1196357</ArticleId><ArticleId IdType="pubmed">16141338</ArticleId></ArticleIdList></Reference><Reference><Citation>van Praag H, Schinder AF, Christie BR, Toni N, Palmer TD, Gage FH. Functional neurogenesis in the adult hippocampus. Nature. 2002;415:1030&#x2013;1034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9284568</ArticleId><ArticleId IdType="pubmed">11875571</ArticleId></ArticleIdList></Reference><Reference><Citation>Villiger JW, Dunn AJ. Phosphodiesterase inhibitors facilitate memory for passive avoidance conditioning. Behav Neural Biol. 1981;31:354&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pubmed">6164361</ArticleId></ArticleIdList></Reference><Reference><Citation>Zala D, Bensadoun JC, Pereira de Almeida L, Leavitt BR, Gutekunst CA, Aebischer P, Hayden MR, D&#xe9;glon N. Long-term lentiviral-mediated expression of ciliary neurotrophic factor in the striatum of Huntington's disease transgenic mice. Exp Neurol. 2004;185:26&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">14697316</ArticleId></ArticleIdList></Reference><Reference><Citation>Zentilin L, Giacca M. In vivo transfer and expression of genes coding for short interfering RNAs. Curr Pharm Biotechnol. 2004;5:341&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pubmed">15320764</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeringue HC, Constantine-Paton M. Post-transcriptional gene silencing in neurons. Curr Opin Neurobiol. 2004;14:654&#x2013;659.</Citation><ArticleIdList><ArticleId IdType="pubmed">15464901</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang HT. Cyclic AMP-specific phosphodiesterase-4 as a target for the development of antidepressant drugs. Curr Pharm Des. 2009;15:1688&#x2013;1698.</Citation><ArticleIdList><ArticleId IdType="pubmed">19442182</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang HT, O'Donnell JM. Effects of rolipram on scopolamine-induced impairment of working and reference memory in the radial-arm maze tests in rats. Psychopharmacology. 2000;150:311&#x2013;316.</Citation><ArticleIdList><ArticleId IdType="pubmed">10923759</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang HT, Crissman AM, Dorairaj NR, Chandler LJ, O'Donnell JM. Inhibition of cyclic AMP phosphodiesterase (PDE4) reverses memory deficits associated with NMDA receptor antagonism. Neuropsychopharmacology. 2000;23:198&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">10882846</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang HT, Huang Y, Jin SL, Frith SA, Suvarna N, Conti M, O'Donnell JM. Antidepressant-like Profile and Reduced Sensitivity to Rolipram in Mice Deficient in the PDE4D Phosphodiesterase Enzyme. Neuropsychopharmacology. 2002;27:587&#x2013;595.</Citation><ArticleIdList><ArticleId IdType="pubmed">12377395</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang HT, Zhao Y, Huang Y, Dorairaj NR, Chandler LJ, O'Donnell JM. Inhibition of the phosphodiesterase 4 (PDE4) enzyme reverses memory deficits produced by infusion of the MEK inhibitor U0126 into the CA1 subregion of the rat hippocampus. Neuropsychopharmacology. 2004;29:1432&#x2013;1439.</Citation><ArticleIdList><ArticleId IdType="pubmed">15114341</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang HT, Huang Y, Suvarna NU, Deng C, Crissman AM, Hopper AT, De Vivo M, Rose GM, O'Donnell JM. Effects of the novel PDE4 inhibitors MEM1018 and MEM1091 on memory in the radial-arm maze and inhibitory avoidance tests in rats. Psychopharmacology. 2005;179:613&#x2013;619.</Citation><ArticleIdList><ArticleId IdType="pubmed">15672274</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang HT, Huang Y, Masood A, Stolinski LR, Li Y, Zhang L, Dlaboga D, Jin SL, Conti M, O'Donnell JM. Anxiogenic-like behavioral phenotype of mice deficient in phosphodiesterase 4B (PDE4B) Neuropsychopharmacology. 2008;33:1611&#x2013;1623.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2728355</ArticleId><ArticleId IdType="pubmed">17700644</ArticleId></ArticleIdList></Reference><Reference><Citation>Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, Naldini L, Trono D. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol. 1998;72:9873&#x2013;9880.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC110499</ArticleId><ArticleId IdType="pubmed">9811723</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21215375</PMID><DateCompleted><Year>2011</Year><Month>01</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>144</Volume><Issue>1</Issue><PubDate><Year>2011</Year><Month>Jan</Month><Day>07</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>Identification of candidate IgG biomarkers for Alzheimer's disease via combinatorial library screening.</ArticleTitle><Pagination><StartPage>132</StartPage><EndPage>142</EndPage><MedlinePgn>132-42</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2010.11.054</ELocationID><Abstract><AbstractText>The adaptive immune system is thought to be a rich source of protein biomarkers, but diagnostically useful antibodies remain unknown for a large number of diseases. This is, in part, because the antigens that trigger an immune response in many diseases remain unknown. We present here a general and unbiased approach to the identification of diagnostically useful antibodies that avoids the requirement for antigen identification. This method involves the comparative screening of combinatorial libraries of unnatural, synthetic molecules against serum samples obtained from cases and controls. Molecules that retain far more IgG antibodies from the case samples than the controls are identified and subsequently tested as capture agents for diagnostically useful antibodies. The utility of this method is demonstrated using a mouse model for multiple sclerosis and via the identification of two candidate IgG biomarkers for Alzheimer's disease.</AbstractText><CopyrightInformation>Copyright &#xc2;&#xa9; 2011 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reddy</LastName><ForeName>M Muralidhar</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Opko Health Laboratories, Jupiter, FL 33458, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Rosemary</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Johnnie</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Connell</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Gocke</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Hynan</LastName><ForeName>Linda</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>German</LastName><ForeName>Dwight</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Kodadek</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>N01-HV-28185</GrantID><Acronym>HV</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG12300</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DP1 OD000663</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG012300</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DP1OD000663</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HV028185</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019151">Peptide Library</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Cell. 2011 Jan 7;144(1):13-5. doi: 10.1016/j.cell.2010.12.022.</RefSource><PMID Version="1">21215365</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Biomark Med. 2011 Apr;5(2):202.</RefSource><PMID Version="1">21612119</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="Y">Antibodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004681" MajorTopicYN="N">Encephalomyelitis, Autoimmune, Experimental</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="Y">Immunoglobulin G</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019151" MajorTopicYN="Y">Peptide Library</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>2</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>8</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>1</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21215375</ArticleId><ArticleId IdType="mid">NIHMS257732</ArticleId><ArticleId IdType="pmc">PMC3066439</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2010.11.054</ArticleId><ArticleId IdType="pii">S0092-8674(10)01376-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alluri PG, Reddy MM, Bacchawat-Sikder K, Olivos HJ, Kodadek T. Isolation of protein ligands from large peptoid libraries. J Amer Chem Soc. 2003;125:13995&#x2013;14004.</Citation><ArticleIdList><ArticleId IdType="pubmed">14611236</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson KS, LaBaer J. The sentinel within: Exploiting the immune system for cancer biomarkers. J Proteome Res. 2005;4:1123&#x2013;1133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2522321</ArticleId><ArticleId IdType="pubmed">16083262</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6:131&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">20157306</ArticleId></ArticleIdList></Reference><Reference><Citation>Fatham CG, Soares L, Chan SM, Utz PJ. An array of possibilities for the study of autoimmunity. Nature. 2005;435:605&#x2013;611.</Citation><ArticleIdList><ArticleId IdType="pubmed">15931213</ArticleId></ArticleIdList></Reference><Reference><Citation>Figliozzi GM, Goldsmith R, Ng SC, Banville SC, Zuckermann RN. Synthesis of N-substituted glycine peptoid libraries. Methods Enzymol. 1996;267:437&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pubmed">8743331</ArticleId></ArticleIdList></Reference><Reference><Citation>Frulloni L, Lunardi C, Simone R, Dolcino M, Scattolini C, Falconi M, Benini L, Vantini I, Corrocher R, Puccetti A. Identification of a novel antibody associated with autoimmune pancreatitis. The New England journal of medicine. 2009;361:2135&#x2013;2142.</Citation><ArticleIdList><ArticleId IdType="pubmed">19940298</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Archives of neurology. 1999;56:33&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">9923759</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson DS, Banha J, Penque D, Costa L, Conrads TP, Cahill DJ, O'Brien JK, Rooney ME. Diagnostic and prognostic biomarker discovery strategies for autoimmune disorders. J Proteomics. 2010;73:1045&#x2013;1060.</Citation><ArticleIdList><ArticleId IdType="pubmed">19995622</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J, Herholz K, Bokde AL, Jessen F, Hoessler YC, et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov. 2010;9:560&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pubmed">20592748</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauser SL. Multiple lessons for multiple sclerosis. N Eng J Med. 2008;359:1838&#x2013;1841.</Citation><ArticleIdList><ArticleId IdType="pubmed">18946071</ArticleId></ArticleIdList></Reference><Reference><Citation>Hudson ME, Pozdnyakova I, Haines K, Mor G, Snyder M. Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays. Proc Natl Acad Sci U S A. 2007;104:17494&#x2013;17499.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2077284</ArticleId><ArticleId IdType="pubmed">17954908</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanter JL, Narayana S, Ho PP, Catz I, Warren KG, Sobel RA, Steinman L, Robinson WH. Lipid microarrays identify key mediators of autoimmune brain inflammation. Nature medicine. 2006;12:138&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">16341241</ArticleId></ArticleIdList></Reference><Reference><Citation>Knittelfelder R, Riemer AB, Jensen-Jarolim E. Mimotope vaccination--from allergy to cancer. Expert Opin Biol Ther. 2009;9:493&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3049225</ArticleId><ArticleId IdType="pubmed">19344285</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu K, Wakeland EK. Delineation of the pathogenesis of systemic lupus erythematosus by using murine models. Adv Exp Med Biol. 2001;490:1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">11505967</ArticleId></ArticleIdList></Reference><Reference><Citation>Lueking A, Possling A, Huber O, Beveridge A, Horn M, Eickoff H, Schuchardt J, Lehrach H, Cahill DJ. A non-redundant human protein chip for antibody screening and serum profiling. Mol Cell Proteomics. 2003;2:1342&#x2013;1349.</Citation><ArticleIdList><ArticleId IdType="pubmed">14517340</ArticleId></ArticleIdList></Reference><Reference><Citation>McFarland HF, Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol. 2007;8:913&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">17712344</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Olivos HJ, P.G. A, Reddy MM, Saloney D, Kodadek T. Microwave-assisted solid phase synthesis of peptoids. Org Lett. 2002;4:4057&#x2013;4059.</Citation><ArticleIdList><ArticleId IdType="pubmed">12423085</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff DF. Lessons from controversy: Ovarian cancer screening and serum proteomics. J of the NCI. 2005;97:315&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">15713968</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy MM, Kodadek T. Protein &#x201c;fingerprinting&#x201d; in complex mixtures with peptoid microarrays. Proc Natl Acad Sci U S A. 2005;102:12672&#x2013;12677.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1200257</ArticleId><ArticleId IdType="pubmed">16123137</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson WH, DiGennaro C, Hueber W, Haab B, Kamachi M, Dean E, Fournel S, Fong D, Genovese MC, de Vegvar H, et al. Antigen arrays for multiplex characterization of autoantibody responses. Nature Med. 2002a;8:295&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">11875502</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson WH, Steinman L, Utz PJ. Protein and peptide array analysis of autoimmune disease. Biotechniques. 2002b Dec.(Suppl.):66&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">12514932</ArticleId></ArticleIdList></Reference><Reference><Citation>Saah AJ, Hoover DR. &#x201c;Sensitivity&#x201d; and &#x201c;specificity&#x201d; reconsidered: the meaning of these terms in analytical and diagnostic settings. Ann Intern Med. 1997;126:91&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">8992938</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon RJ, Kania RS, Zuckermann RN, Huebner VD, Jewell DA, Banville S, Ng S, Wang L, Rosenberg S, Marlowe CK, et al. Peptoids: a modular approach to drug discovery. Proc Natl Acad Sci U S A. 1992;89:9367&#x2013;9371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC50132</ArticleId><ArticleId IdType="pubmed">1409642</ArticleId></ArticleIdList></Reference><Reference><Citation>Steller S, Angenendt P, Cahill DJ, Heuberger S, Lehrach H, Kreutzberger J. Bacterial protein microarrays for identification of new potential diagnostic markers for Neisseria meningitidis infections. Proteomics. 2005;5:2048&#x2013;2055.</Citation><ArticleIdList><ArticleId IdType="pubmed">15852346</ArticleId></ArticleIdList></Reference><Reference><Citation>Thambisetty M, Simmons A, Velayudhan L, Hye A, Campbell J, Zhang Y, Wahlund LO, Westman E, Kinsey A, Guntert A, et al. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry. 2010;67:739&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3111021</ArticleId><ArticleId IdType="pubmed">20603455</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Yu J-Q, Sreekumar A, Varambally S, Shen R, Giachero D, Mehra R, Montie JE, Pienta KJ, Sanda MG, et al. Autoantibody signatures in prostate cancer. New England J Med. 2005;355:16&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">16177248</ArticleId></ArticleIdList></Reference><Reference><Citation>Weksler ME, Relkin N, Turkenich R, LaRusse S, Zhou L, Szabo P. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp Gerontol. 2002;37:943&#x2013;948.</Citation><ArticleIdList><ArticleId IdType="pubmed">12086704</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21228171</PMID><DateCompleted><Year>2011</Year><Month>02</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>2</Issue><PubDate><Year>2011</Year><Month>Jan</Month><Day>12</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Long-term in vivo imaging of &#x3b2;-amyloid plaque appearance and growth in a mouse model of cerebral &#x3b2;-amyloidosis.</ArticleTitle><Pagination><StartPage>624</StartPage><EndPage>629</EndPage><MedlinePgn>624-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.5147-10.2011</ELocationID><Abstract><AbstractText>Extracellular deposition of the amyloid-&#x3b2; peptide (A&#x3b2;) in the brain parenchyma is a hallmark lesion of Alzheimer's disease (AD) and a predictive marker for the progression of preclinical to symptomatic AD. Here, we used multiphoton in vivo imaging to study A&#x3b2; plaque formation in the brains of 3- to 4-month-old APPPS1 transgenic mice over a period of 6 months. A novel head fixation system provided robust and efficient long-term tracking of single plaques over time. Results revealed an estimated rate of 35 newly formed plaques per cubic millimeter of neocortical volume per week at 4-5 months of age. At later time points (i.e., in the presence of increasing cerebral &#x3b2;-amyloidosis), the number of newly formed plaques decreased. On average, both newly formed and existing plaques grew at a similar growth rate of 0.3 &#x3bc;m (radius) per week. A solid knowledge of the dynamics of cerebral &#x3b2;-amyloidosis in mouse models provides a powerful tool to monitor preclinical A&#x3b2; targeting therapeutic strategies and eases the interpretation of diagnostic amyloid imaging in humans.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hefendehl</LastName><ForeName>Jasmin K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wegenast-Braun</LastName><ForeName>Bettina M</ForeName><Initials>BM</Initials></Author><Author ValidYN="Y"><LastName>Liebig</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Eicke</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Milford</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Calhoun</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Kohsaka</LastName><ForeName>Shinichi</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Eichner</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Jucker</LastName><ForeName>Mathias</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>147336-22-9</RegistryNumber><NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="N">Amyloidosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005911" MajorTopicYN="N">Gliosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049452" MajorTopicYN="N">Green Fluorescent Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D036641" MajorTopicYN="N">Microscopy, Fluorescence, Multiphoton</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013194" MajorTopicYN="N">Staining and Labeling</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>7</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21228171</ArticleId><ArticleId IdType="pmc">PMC6623424</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.5147-10.2011</ArticleId><ArticleId IdType="pii">31/2/624</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andr&#xe4; K, Abramowski D, Duke M, Probst A, Wiederhold KH, B&#xfc;rki K, Goedert M, Sommer B, Staufenbiel M. Expression of APP in transgenic mice: a comparison of neuron-specific promoters. Neurobiol Aging. 1996;17:183&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">8744399</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolmont T, Haiss F, Eicke D, Radde R, Mathis CA, Klunk WE, Kohsaka S, Jucker M, Calhoun ME. Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. J Neurosci. 2008;28:4283&#x2013;4292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3844768</ArticleId><ArticleId IdType="pubmed">18417708</ArticleId></ArticleIdList></Reference><Reference><Citation>Christie RH, Bacskai BJ, Zipfel WR, Williams RM, Kajdasz ST, Webb WW, Hyman BT. Growth arrest of individual senile plaques in a model of Alzheimer's disease observed by in vivo multiphoton microscopy. J Neurosci. 2001;21:858&#x2013;864.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762315</ArticleId><ArticleId IdType="pubmed">11157072</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong J, Revilla-Sanchez R, Moss S, Haydon PG. Multiphoton in vivo imaging of amyloid in animal models of Alzheimer&#x2018;s disease. Neuropharmacology. 2010;59:268&#x2013;275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3117428</ArticleId><ArticleId IdType="pubmed">20398680</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Helmchen F, Denk W. Deep tissue two-photon microscopy. Nat Methods. 2005;2:932&#x2013;940.</Citation><ArticleIdList><ArticleId IdType="pubmed">16299478</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirasawa T, Ohsawa K, Imai Y, Ondo Y, Akazawa C, Uchino S, Kohsaka S. Visualization of microglia in living tissues using Iba1-EGFP transgenic mice. J Neurosci Res. 2005;81:357&#x2013;362.</Citation><ArticleIdList><ArticleId IdType="pubmed">15948177</ArticleId></ArticleIdList></Reference><Reference><Citation>Jucker M. The benefits and limitations of animal models for translational research in neurodegenerative diseases. Nat Med. 2010;16:1210&#x2013;1214.</Citation><ArticleIdList><ArticleId IdType="pubmed">21052075</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Bacskai BJ, Mathis CA, Kajdasz ST, McLellan ME, Frosch MP, Debnath ML, Holt DP, Wang Y, Hyman BT. Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J Neuropathol Exp Neurol. 2002;61:797&#x2013;805.</Citation><ArticleIdList><ArticleId IdType="pubmed">12230326</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Lopresti BJ, Ikonomovic MD, Lefterov IM, Koldamova RP, Abrahamson EE, Debnath ML, Holt DP, Huang GF, Shao L, DeKosky ST, Price JC, Mathis CA. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-&#x3b2; in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci. 2005;25:10598&#x2013;10606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725842</ArticleId><ArticleId IdType="pubmed">16291932</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A, Koenigsknecht-Talboo J, Holtzman DM, Bacskai BJ, Hyman BT. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature. 2008;451:720&#x2013;724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3264491</ArticleId><ArticleId IdType="pubmed">18256671</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM, Fagan AM, Holtzman DM, Mintun MA. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol. 2009;66:1469&#x2013;1475.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2798814</ArticleId><ArticleId IdType="pubmed">20008650</ArticleId></ArticleIdList></Reference><Reference><Citation>Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L, Calhoun ME, J&#xe4;ggi F, Wolburg H, Gengler S, Haass C, Ghetti B, Czech C, H&#xf6;lscher C, Mathews PM, Jucker M. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 2006;7:940&#x2013;946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1559665</ArticleId><ArticleId IdType="pubmed">16906128</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires TL, Meyer-Luehmann M, Stern EA, McLean PJ, Skoch J, Nguyen PT, Bacskai BJ, Hyman BT. Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J Neurosci. 2005;25:7278&#x2013;7287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1820616</ArticleId><ArticleId IdType="pubmed">16079410</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner MW, Aisen PS, Jack CR, Jr, Jagust WJ, Trojanowski JQ, Shaw L, Saykin AJ, Morris JC, Cairns N, Beckett LA, Toga A, Green R, Walter S, Soares H, Snyder P, Siemers E, Potter W, Cole PE, Schmidt M. The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement. 2010;6:202&#x2013;211.e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2927112</ArticleId><ArticleId IdType="pubmed">20451868</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu HT, Pan F, Yang G, Gan WB. Choice of cranial window type for in vivo imaging affects dendritic spine turnover in the cortex. Nat Neurosci. 2007;10:549&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="pubmed">17417634</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan P, Bero AW, Cirrito JR, Xiao Q, Hu X, Wang Y, Gonzales E, Holtzman DM, Lee JM. Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice. J Neurosci. 2009;29:10706&#x2013;10714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2756291</ArticleId><ArticleId IdType="pubmed">19710322</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang G, Pan F, Parkhurst CN, Grutzendler J, Gan WB. Thinned-skull cranial window technique for long-term imaging of the cortex in live mice. Nat Protoc. 2010;5:201&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4690457</ArticleId><ArticleId IdType="pubmed">20134419</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21228179</PMID><DateCompleted><Year>2011</Year><Month>02</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>2</Issue><PubDate><Year>2011</Year><Month>Jan</Month><Day>12</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Amyloid-&#x3b2;/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>700</StartPage><EndPage>711</EndPage><MedlinePgn>700-11</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.4152-10.2011</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD), the most common neurodegenerative disorder, is a growing public health problem and still lacks effective treatments. Recent evidence suggests that microtubule-associated protein tau may mediate amyloid-&#x3b2; peptide (A&#x3b2;) toxicity by modulating the tyrosine kinase Fyn. We showed previously that tau reduction prevents, and Fyn overexpression exacerbates, cognitive deficits in human amyloid precursor protein (hAPP) transgenic mice overexpressing A&#x3b2;. However, the mechanisms by which A&#x3b2;, tau, and Fyn cooperate in AD-related pathogenesis remain to be fully elucidated. Here we examined the synaptic and network effects of this pathogenic triad. Tau reduction prevented cognitive decline induced by synergistic effects of A&#x3b2; and Fyn. Tau reduction also prevented synaptic transmission and plasticity deficits in hAPP mice. Using electroencephalography to examine network effects, we found that tau reduction prevented spontaneous epileptiform activity in multiple lines of hAPP mice. Tau reduction also reduced the severity of spontaneous and chemically induced seizures in mice overexpressing both A&#x3b2; and Fyn. To better understand these protective effects, we recorded whole-cell currents in acute hippocampal slices from hAPP mice with and without tau. hAPP mice with tau had increased spontaneous and evoked excitatory currents, reduced inhibitory currents, and NMDA receptor dysfunction. Tau reduction increased inhibitory currents and normalized excitation/inhibition balance and NMDA receptor-mediated currents in hAPP mice. Our results indicate that A&#x3b2;, tau, and Fyn jointly impair synaptic and network function and suggest that disrupting the copathogenic relationship between these factors could be of therapeutic benefit.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Roberson</LastName><ForeName>Erik D</ForeName><Initials>ED</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, California 94158, USA. eroberson@uab.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halabisky</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Yoo</LastName><ForeName>Jong W</ForeName><Initials>JW</Initials></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Jinghua</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Chin</LastName><ForeName>Jeannie</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Fengrong</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Tiffany</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Hamto</LastName><ForeName>Patricia</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Devidze</LastName><ForeName>Nino</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Gui-Qiu</ForeName><Initials>GQ</Initials></Author><Author ValidYN="Y"><LastName>Palop</LastName><ForeName>Jorge J</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>Noebels</LastName><ForeName>Jeffrey L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Mucke</LastName><ForeName>Lennart</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NS29709</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS041787</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS041787</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RR018928</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS054811</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG022074</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS029709</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>C06 RR018928</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG022074</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 NS054811</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.2</RegistryNumber><NameOfSubstance UI="C494960">Fyn protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.2</RegistryNumber><NameOfSubstance UI="D051076">Proto-Oncogene Proteins c-fyn</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004569" MajorTopicYN="N">Electroencephalography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008817" MajorTopicYN="N">Mice, Mutant Strains</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051076" MajorTopicYN="N">Proto-Oncogene Proteins c-fyn</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012640" MajorTopicYN="N">Seizures</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013045" MajorTopicYN="N">Species Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>7</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21228179</ArticleId><ArticleId IdType="mid">NIHMS279180</ArticleId><ArticleId IdType="pmc">PMC3325794</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.4152-10.2011</ArticleId><ArticleId IdType="pii">31/2/700</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Busche MA, Eichhoff G, Adelsberger H, Abramowski D, Wiederhold KH, Haass C, Staufenbiel M, Konnerth A, Garaschuk O. Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease. Science. 2008;321:1686&#x2013;1689.</Citation><ArticleIdList><ArticleId IdType="pubmed">18802001</ArticleId></ArticleIdList></Reference><Reference><Citation>Cain DP, Grant SG, Saucier D, Hargreaves EL, Kandel ER. Fyn tyrosine kinase is required for normal amygdala kindling. Epilepsy Res. 1995;22:107&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pubmed">8777897</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlson GA, Borchelt DR, Dake A, Turner S, Danielson V, Coffin JD, Eckman C, Meiners J, Nilsen SP, Younkin SG, Hsiao KK. Genetic modification of the phenotypes produced by amyloid precursor protein overexpression in transgenic mice. Hum Mol Genet. 1997;6:1951&#x2013;1959.</Citation><ArticleIdList><ArticleId IdType="pubmed">9302276</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman PF, White GL, Jones MW, Cooper-Blacketer D, Marshall VJ, Irizarry M, Younkin L, Good MA, Bliss TV, Hyman BT, Younkin SG, Hsiao KK. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci. 1999;2:271&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pubmed">10195221</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin J, Palop JJ, Yu GQ, Kojima N, Masliah E, Mucke L. Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice. J Neurosci. 2004;24:4692&#x2013;4697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729387</ArticleId><ArticleId IdType="pubmed">15140940</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin J, Palop JJ, Puoliv&#xe4;li J, Massaro C, Bien-Ly N, Gerstein H, Scearce-Levie K, Masliah E, Mucke L. Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci. 2005;25:9694&#x2013;9703.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725734</ArticleId><ArticleId IdType="pubmed">16237174</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson HN, Ferreira A, Eyster MV, Ghoshal N, Binder LI, Vitek MP. Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. J Cell Sci. 2001;114:1179&#x2013;1187.</Citation><ArticleIdList><ArticleId IdType="pubmed">11228161</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson HN, Cantillana V, Jansen M, Wang H, Vitek MP, Wilcock DM, Lynch JR, Laskowitz DT. Loss of tau elicits axonal degeneration in a mouse model of Alzheimer's disease. Neuroscience. 2010;169:516&#x2013;531.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2900546</ArticleId><ArticleId IdType="pubmed">20434528</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Vecchio RA, Gold LH, Novick SJ, Wong G, Hyde LA. Increased seizure threshold and severity in young transgenic CRND8 mice. Neurosci Lett. 2004;367:164&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pubmed">15331144</ArticleId></ArticleIdList></Reference><Reference><Citation>Farris W, Sch&#xfc;tz SG, Cirrito JR, Shankar GM, Sun X, George A, Leissring MA, Walsh DM, Qiu WQ, Holtzman DM, Selkoe DJ. Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy. Am J Pathol. 2007;171:241&#x2013;251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1941603</ArticleId><ArticleId IdType="pubmed">17591969</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM AN1792(QS-21)-201 Study Team. Clinical effects of A&#x3b2; immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64:1553&#x2013;1562.</Citation><ArticleIdList><ArticleId IdType="pubmed">15883316</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez de Barreda E, P&#xe9;rez M, G&#xf3;mez Ramos P, de Cristobal J, Mart&#xed;n-Maestro P, Mor&#xe1;n A, Dawson HN, Vitek MP, Lucas JJ, Hern&#xe1;ndez F, Avila J. Tau-knockout mice show reduced GSK3-induced hippocampal degeneration and learning deficits. Neurobiol Dis. 2010;37:622&#x2013;629.</Citation><ArticleIdList><ArticleId IdType="pubmed">20004245</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;tz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301L tau transgenic mice induced by A&#x3b2;42 fibrils. Science. 2001;293:1491&#x2013;1495.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520988</ArticleId></ArticleIdList></Reference><Reference><Citation>Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, Zavitz KH Tarenflurbil Phase 3 Study Group. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA. 2009;302:2557&#x2013;2564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2902875</ArticleId><ArticleId IdType="pubmed">20009055</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, Caliendo J, Hentati A, Kwon YW, Deng HX, Chen WJ, Zhai P, Sufit RL, Siddique T. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science. 1994;264:1772&#x2013;1775.</Citation><ArticleIdList><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutnick MJ, Connors BW, Prince DA. Mechanisms of neocortical epileptogenesis in vitro. J Neurophysiol. 1982;48:1321&#x2013;1335.</Citation><ArticleIdList><ArticleId IdType="pubmed">7153795</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Mandelkow E. Fyn-tau-amyloid: a toxic triad. Cell. 2010;142:356&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pubmed">20691893</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris JA, Devidze N, Halabisky B, Lo I, Thwin MT, Yu GQ, Bredesen DE, Masliah E, Mucke L. Many neuronal and behavioral impairments in transgenic mouse models of Alzheimer's disease are independent of caspase cleavage of the amyloid precursor protein. J Neurosci. 2010;30:372&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3064502</ArticleId><ArticleId IdType="pubmed">20053918</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinemann U, Beck H, Dreier JP, Ficker E, Stabel J, Zhang CL. The dentate gyrus as a regulated gate for the propagation of epileptiform activity. Epilepsy Res Suppl. 1992;7:273&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pubmed">1334666</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooper C, Killick R, Lovestone S. The GSK3 hypothesis of Alzheimer's disease. J Neurochem. 2008;104:1433&#x2013;1439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3073119</ArticleId><ArticleId IdType="pubmed">18088381</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K, Kholodenko D, Malenka RC, Nicoll RA, Mucke L. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci U S A. 1999;96:3228&#x2013;3233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15924</ArticleId><ArticleId IdType="pubmed">10077666</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao KK, Borchelt DR, Olson K, Johannsdottir R, Kitt C, Yunis W, Xu S, Eckman C, Younkin S, Price D, Iadecola C, Clark HB, Carlson G. Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron. 1995;15:1203&#x2013;1218.</Citation><ArticleIdList><ArticleId IdType="pubmed">7576662</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, W&#xf6;lfing H, Chieng BC, Christie MJ, Napier IA, Eckert A, Staufenbiel M, Hardeman E, G&#xf6;tz J. Dendritic function of tau mediates amyloid-&#x3b2; toxicity in Alzheimer's disease mouse models. Cell. 2010;142:387&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pubmed">20655099</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R. APP processing and synaptic function. Neuron. 2003;37:925&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasugai M, Akaike K, Imamura S, Matsukubo H, Tojo H, Nakamura M, Tanaka S, Sano A. Differences in two mice strains on kainic acid-induced amygdalar seizures. Biochem Biophys Res Commun. 2007;357:1078&#x2013;1083.</Citation><ArticleIdList><ArticleId IdType="pubmed">17467670</ArticleId></ArticleIdList></Reference><Reference><Citation>King ME, Kan HM, Baas PW, Erisir A, Glabe CG, Bloom GS. Tau-dependent microtubule disassembly initiated by prefibrillar &#x3b2;-amyloid. J Cell Biol. 2006;175:541&#x2013;546.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2064590</ArticleId><ArticleId IdType="pubmed">17101697</ArticleId></ArticleIdList></Reference><Reference><Citation>Kojima N, Wang J, Mansuy IM, Grant SG, Mayford M, Kandel ER. Rescuing impairment of long-term potentiation in fyn-deficient mice by introducing Fyn transgene. Proc Natl Acad Sci U S A. 1997;94:4761&#x2013;4765.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC20798</ArticleId><ArticleId IdType="pubmed">9114065</ArticleId></ArticleIdList></Reference><Reference><Citation>Kojima N, Ishibashi H, Obata K, Kandel ER. Higher seizure susceptibility and enhanced tyrosine phosphorylation on N-methyl-d-aspartate receptor subunit 2B in fyn transgenic mice. Learn Mem. 1998;5:429&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC311255</ArticleId><ArticleId IdType="pubmed">10489260</ArticleId></ArticleIdList></Reference><Reference><Citation>Korn SJ, Giacchino JL, Chamberlin NL, Dingledine R. Epileptiform burst activity induced by potassium in the hippocampus and its regulation by GABA-mediated inhibition. J Neurophysiol. 1987;57:325&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pubmed">3559679</ArticleId></ArticleIdList></Reference><Reference><Citation>Krezowski J, Knudson D, Ebeling C, Pitstick R, Giri RK, Schenk D, Westaway D, Younkin L, Younkin SG, Ashe KH, Carlson GA. Identification of loci determining susceptibility to the lethal effects of amyloid precursor protein transgene overexpression. Hum Mol Genet. 2004;13:1989&#x2013;1997.</Citation><ArticleIdList><ArticleId IdType="pubmed">15254013</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar-Singh S, Dewachter I, Moechars D, L&#xfc;bke U, De Jonghe C, Ceuterick C, Checler F, Naidu A, Cordell B, Cras P, Van Broeckhoven C, Van Leuven F. Behavioral disturbances without amyloid deposits in mice overexpressing human amyloid precursor protein with Flemish (A692G) or Dutch (E693Q) mutation. Neurobiol Dis. 2000;7:9&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">10671319</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla FM, Tinkle BT, Bieberich CJ, Haudenschild CC, Jay G. The Alzheimer's A&#x3b2; peptide induces neurodegeneration and apoptotic cell death in transgenic mice. Nat Genet. 1995;9:21&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">7704018</ArticleId></ArticleIdList></Reference><Reference><Citation>Lalonde R, Dumont M, Staufenbiel M, Strazielle C. Neurobehavioral characterization of APP23 transgenic mice with the SHIRPA primary screen. Behav Brain Res. 2005;157:91&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">15617775</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL. Diffusible, nonfibrillar ligands derived from A&#x3b2;1&#x2013;42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A. 1998;95:6448&#x2013;6453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee G, Newman ST, Gard DL, Band H, Panchamoorthy G. Tau interacts with src-family non-receptor tyrosine kinases. J Cell Sci. 1998;111:3167&#x2013;3177.</Citation><ArticleIdList><ArticleId IdType="pubmed">9763511</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee G, Thangavel R, Sharma VM, Litersky JM, Bhaskar K, Fang SM, Do LH, Andreadis A, Van Hoesen G, Ksiezak-Reding H. Phosphorylation of tau by fyn: implications for Alzheimer's disease. J Neurosci. 2004;24:2304&#x2013;2312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730442</ArticleId><ArticleId IdType="pubmed">14999081</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, Yen SH, Sahara N, Skipper L, Yager D, Eckman C, Hardy J, Hutton M, McGowan E. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science. 2001;293:1487&#x2013;1491.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520987</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Hong S, Shepardson NE, Walsh DM, Shankar GM, Selkoe D. Soluble oligomers of amyloid &#x3b2; protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron. 2009;62:788&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2702854</ArticleId><ArticleId IdType="pubmed">19555648</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu T, Perry G, Chan HW, Verdile G, Martins RN, Smith MA, Atwood CS. Amyloid-&#x3b2;-induced toxicity of primary neurons is dependent upon differentiation-associated increases in tau and cyclin-dependent kinase 5 expression. J Neurochem. 2004;88:554&#x2013;563.</Citation><ArticleIdList><ArticleId IdType="pubmed">14720205</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf6;scher W, H&#xf6;nack D, Fassbender CP, Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. III. Pentylenetetrazole seizure models. Epilepsy Res. 1991;8:171&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">1907909</ArticleId></ArticleIdList></Reference><Reference><Citation>Lothman EW, Stringer JL, Bertram EH. The dentate gyrus as a control point for seizures in the hippocampus and beyond. Epilepsy Res Suppl. 1992;7:301&#x2013;313.</Citation><ArticleIdList><ArticleId IdType="pubmed">1334669</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, 2nd, Wenzel HJ, Robbins CA, Sosunov AA, Schwartzkroin PA. Mouse strain differences in kainic acid sensitivity, seizure behavior, mortality, and hippocampal pathology. Neuroscience. 2003;122:551&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pubmed">14614919</ArticleId></ArticleIdList></Reference><Reference><Citation>Minkeviciene R, Rheims S, Dobszay MB, Zilberter M, Hartikainen J, F&#xfc;l&#xf6;p L, Penke B, Zilberter Y, Harkany T, Pitk&#xe4;nen A, Tanila H. Amyloid &#x3b2;-induced neuronal hyperexcitability triggers progressive epilepsy. J Neurosci. 2009;29:3453&#x2013;3462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6665248</ArticleId><ArticleId IdType="pubmed">19295151</ArticleId></ArticleIdList></Reference><Reference><Citation>Moechars D, Dewachter I, Lorent K, Revers&#xe9; D, Baekelandt V, Naidu A, Tesseur I, Spittaels K, Haute CV, Checler F, Godaux E, Cordell B, Van Leuven F. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem. 1999;274:6483&#x2013;6492.</Citation><ArticleIdList><ArticleId IdType="pubmed">10037741</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L. High-level neuronal expression of A&#x3b2;1&#x2013;42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci. 2000;20:4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular A&#x3b2; and synaptic dysfunction. Neuron. 2003;39:409&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Pacheco CD, Elrick MJ, Lieberman AP. Tau deletion exacerbates the phenotype of Niemann-Pick type C mice and implicates autophagy in pathogenesis. Hum Mol Genet. 2009;18:956&#x2013;965.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2646181</ArticleId><ArticleId IdType="pubmed">19074461</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Mucke L. Epilepsy and cognitive impairments in Alzheimer disease. Arch Neurol. 2009;66:435&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2812914</ArticleId><ArticleId IdType="pubmed">19204149</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Mucke L. Amyloid-&#x3b2;-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat Neurosci. 2010;13:812&#x2013;818.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3072750</ArticleId><ArticleId IdType="pubmed">20581818</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, Yoo J, Ho KO, Yu GQ, Kreitzer A, Finkbeiner S, Noebels JL, Mucke L. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron. 2007;55:697&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055171</ArticleId><ArticleId IdType="pubmed">17785178</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Mucke L, Roberson ED. Quantifying biomarkers of cognitive dysfunction and neuronal network hyperexcitability in mouse models of Alzheimer's disease: depletion of calcium-dependent proteins and inhibitory hippocampal remodeling. Methods Mol Biol. 2011;670:245&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8153735</ArticleId><ArticleId IdType="pubmed">20967595</ArticleId></ArticleIdList></Reference><Reference><Citation>Park SY, Ferreira A. The generation of a 17 kDa neurotoxic fragment: an alternative mechanism by which tau mediates &#x3b2;-amyloid-induced neurodegeneration. J Neurosci. 2005;25:5365&#x2013;5375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1352316</ArticleId><ArticleId IdType="pubmed">15930385</ArticleId></ArticleIdList></Reference><Reference><Citation>Racine RJ. Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr Clin Neurophysiol. 1972;32:281&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pubmed">4110397</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapoport M, Dawson HN, Binder LI, Vitek MP, Ferreira A. Tau is essential to &#x3b2;-amyloid-induced neurotoxicity. Proc Natl Acad Sci U S A. 2002;99:6364&#x2013;6369.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC122954</ArticleId><ArticleId IdType="pubmed">11959919</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, Hesse JH, Rose KD, Slama H, Johnson JK, Yaffe K, Forman MS, Miller CA, Trojanowski JQ, Kramer JH, Miller BL. Frontotemporal dementia progresses to death faster than Alzheimer disease. Neurology. 2005;65:719&#x2013;725.</Citation><ArticleIdList><ArticleId IdType="pubmed">16157905</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke L. Reducing endogenous tau ameliorates amyloid &#x3b2;-induced deficits in an Alzheimer's disease mouse model. Science. 2007;316:750&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pubmed">17478722</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockenstein E, Mallory M, Mante M, Sisk A, Masliaha E. Early formation of mature amyloid-&#x3b2; protein deposits in a mutant APP transgenic model depends on levels of A&#x3b2;1&#x2013;42. J Neurosci Res. 2001;66:573&#x2013;582.</Citation><ArticleIdList><ArticleId IdType="pubmed">11746377</ArticleId></ArticleIdList></Reference><Reference><Citation>Salter MW, Kalia LV. Src kinases: A hub for NMDA receptor regulation. Nat Rev Neurosci. 2004;5:317&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pubmed">15034556</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002;298:789&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloid-&#x3b2; protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci. 2007;27:2866&#x2013;2875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672572</ArticleId><ArticleId IdType="pubmed">17360908</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun B, Zhou Y, Halabisky B, Lo I, Cho SH, Mueller-Steiner S, Devidze N, Wang X, Grubb A, Gan L. Cystatin C-cathepsin B axis regulates amyloid beta levels and associated neuronal deficits in an animal model of Alzheimer's disease. Neuron. 2008;60:247&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2755563</ArticleId><ArticleId IdType="pubmed">18957217</ArticleId></ArticleIdList></Reference><Reference><Citation>Tallent MK, Siggins GR. Somatostatin acts in CA1 and CA3 to reduce hippocampal epileptiform activity. J Neurophysiol. 1999;81:1626&#x2013;1635.</Citation><ArticleIdList><ArticleId IdType="pubmed">10200199</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE, Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell. 2005;120:545&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">15734686</ArticleId></ArticleIdList></Reference><Reference><Citation>Tucker KL, Meyer M, Barde YA. Neurotrophins are required for nerve growth during development. Nat Neurosci. 2001;4:29&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">11135642</ArticleId></ArticleIdList></Reference><Reference><Citation>Vezzani A, Sperk G, Colmers WF. Neuropeptide Y: emerging evidence for a functional role in seizure modulation. Trends Neurosci. 1999;22:25&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">10088996</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogt DL, Thomas D, Galvan V, Bredesen DE, Lamb BT, Pimplikar SW. Abnormal neuronal networks and seizure susceptibility in mice overexpressing the APP intracellular domain. Neurobiol Aging. 2009 doi: 10.1016/j.neurobiolaging.2009.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2009.09.002</ArticleId><ArticleId IdType="pmc">PMC2889215</ArticleId><ArticleId IdType="pubmed">19828212</ArticleId></ArticleIdList></Reference><Reference><Citation>Vossel KA, Zhang K, Brodbeck J, Daub AC, Sharma P, Finkbeiner S, Cui B, Mucke L. Tau reduction prevents A&#x3b2;-induced defects in axonal transport. Science. 2010;330:198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3024010</ArticleId><ArticleId IdType="pubmed">20829454</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. Naturally secreted oligomers of amyloid &#x3b2; protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh JS, Welch HG, Larson EB. Survival of outpatients with Alzheimer-type dementia. Ann Intern Med. 1990;113:429&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pubmed">2386336</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson R, Scales T, Clark BR, Gibb G, Reynolds CH, Kellie S, Bird IN, Varndell IM, Sheppard PW, Everall I, Anderton BH. Rapid tyrosine phosphorylation of neuronal proteins including tau and focal adhesion kinase in response to amyloid-&#x3b2; peptide exposure: Involvement of Src family protein kinases. J Neurosci. 2002;22:10&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757621</ArticleId><ArticleId IdType="pubmed">11756483</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson TL, Bruijn LI, Zhu Q, Anderson KL, Anderson SD, Julien JP, Cleveland DW. Absence of neurofilaments reduces the selective vulnerability of motor neurons and slows disease caused by a familial amyotrophic lateral sclerosis-linked superoxide dismutase 1 mutant. Proc Natl Acad Sci U S A. 1998;95:9631&#x2013;9636.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC21390</ArticleId><ArticleId IdType="pubmed">9689132</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan A, Kumar A, Peterhoff C, Duff K, Nixon RA. Axonal transport rates in vivo are unaffected by tau deletion or overexpression in mice. J Neurosci. 2008;28:1682&#x2013;1687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2814454</ArticleId><ArticleId IdType="pubmed">18272688</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21258327</PMID><DateCompleted><Year>2011</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>3</Issue><PubDate><Year>2011</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Labile or stable: opposing consequences for memory when reactivated during waking and sleep.</ArticleTitle><Pagination><StartPage>381</StartPage><EndPage>386</EndPage><MedlinePgn>381-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nn.2744</ELocationID><Abstract><AbstractText>Memory consolidation is a dynamic process. Reconsolidation theory assumes that reactivation during wakefulness transiently destabilizes memories, requiring them to reconsolidate in order to persist. Memory reactivation also occurs during slow-wave sleep (SWS) and is assumed to underlie the consolidating effect of sleep. Here, we tested whether the same principle of transient destabilization applies to memory reactivation during SWS. We reactivated memories in humans by presenting associated odor cues either during SWS or wakefulness. Reactivation was followed by an interference task to probe memory stability. As we expected, reactivation during waking destabilized memories. In contrast, reactivation during SWS immediately stabilized memories, thereby directly increasing their resistance to interference. Functional magnetic resonance imaging revealed that reactivation during SWS mainly activated hippocampal and posterior cortical regions, whereas reactivation during wakefulness primarily activated prefrontal cortical areas. Our results show that reactivation of memory serves distinct functions depending on the brain state of wakefulness or sleep.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Diekelmann</LastName><ForeName>Susanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of L&#xfc;beck, Department of Neuroendocrinology, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>B&#xfc;chel</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Born</LastName><ForeName>Jan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Rasch</LastName><ForeName>Bj&#xf6;rn</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>01</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Neurosci. 2011 Mar;14(3):272-4. doi: 10.1038/nn0311-272.</RefSource><PMID Version="1">21346743</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D003463" MajorTopicYN="N">Cues</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009812" MajorTopicYN="N">Odorants</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012890" MajorTopicYN="N">Sleep</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014851" MajorTopicYN="N">Wakefulness</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21258327</ArticleId><ArticleId IdType="doi">10.1038/nn.2744</ArticleId><ArticleId IdType="pii">nn.2744</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Trends Neurosci. 2003 Feb;26(2):65-72</Citation><ArticleIdList><ArticleId IdType="pubmed">12536129</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Rev. 1995 Jul;102(3):419-457</Citation><ArticleIdList><ArticleId IdType="pubmed">7624455</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2009 Oct 21;4(10):e7519</Citation><ArticleIdList><ArticleId IdType="pubmed">19844577</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2003 Nov 13;40(4):695-701</Citation><ArticleIdList><ArticleId IdType="pubmed">14622575</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18778-83</Citation><ArticleIdList><ArticleId IdType="pubmed">18000060</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):756-61</Citation><ArticleIdList><ArticleId IdType="pubmed">16407110</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Neurosci. 2005 Jan;28(1):51-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15626497</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2010 Jan 7;463(7277):49-53</Citation><ArticleIdList><ArticleId IdType="pubmed">20010606</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Clin Neurosci. 2001 Jun;55(3):305-10</Citation><ArticleIdList><ArticleId IdType="pubmed">11422885</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2004 Jul 1;430(6995):78-81</Citation><ArticleIdList><ArticleId IdType="pubmed">15184907</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2009 Nov 20;326(5956):1079</Citation><ArticleIdList><ArticleId IdType="pubmed">19965421</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2010 Feb;11(2):114-26</Citation><ArticleIdList><ArticleId IdType="pubmed">20046194</ArticleId></ArticleIdList></Reference><Reference><Citation>Learn Mem. 2000 Mar-Apr;7(2):73-84</Citation><ArticleIdList><ArticleId IdType="pubmed">10753974</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2003 Oct 9;425(6958):616-20</Citation><ArticleIdList><ArticleId IdType="pubmed">14534587</ArticleId></ArticleIdList></Reference><Reference><Citation>Learn Mem. 2007 Apr 10;14(4):295-303</Citation><ArticleIdList><ArticleId IdType="pubmed">17522018</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2006 May 4;50(3):479-89</Citation><ArticleIdList><ArticleId IdType="pubmed">16675401</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1968 May 3;160(3827):554-5</Citation><ArticleIdList><ArticleId IdType="pubmed">5689415</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2002 Sep 15;22(18):8305-11</Citation><ArticleIdList><ArticleId IdType="pubmed">12223585</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2007 Nov 16;318(5853):1147-50</Citation><ArticleIdList><ArticleId IdType="pubmed">18006749</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2000 Jan 14;287(5451):248-51</Citation><ArticleIdList><ArticleId IdType="pubmed">10634773</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2002 Oct 24;36(3):521-5</Citation><ArticleIdList><ArticleId IdType="pubmed">12408853</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2006 Apr;9(4):478-80</Citation><ArticleIdList><ArticleId IdType="pubmed">16531998</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2000 Aug 17;406(6797):722-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10963596</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2007 May;10(5):540-2</Citation><ArticleIdList><ArticleId IdType="pubmed">17453055</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 1999 Oct;23(7):1285-317</Citation><ArticleIdList><ArticleId IdType="pubmed">10581649</ArticleId></ArticleIdList></Reference><Reference><Citation>Am Psychol. 1999 Mar;54(3):182-203</Citation><ArticleIdList><ArticleId IdType="pubmed">10199218</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2008 Feb 15;319(5865):966-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18276894</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Learn Mem. 2009 Jan;91(1):50-7</Citation><ArticleIdList><ArticleId IdType="pubmed">18854218</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2009 Mar;10(3):224-34</Citation><ArticleIdList><ArticleId IdType="pubmed">19229241</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2007 Apr 6;316(5821):76-82</Citation><ArticleIdList><ArticleId IdType="pubmed">17412951</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1994 Jul 29;265(5172):676-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8036517</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Neurosci. 2000 Oct;23(10):475-83</Citation><ArticleIdList><ArticleId IdType="pubmed">11006464</ArticleId></ArticleIdList></Reference><Reference><Citation>Philos Trans R Soc Lond B Biol Sci. 2005 Apr 29;360(1456):781-95</Citation><ArticleIdList><ArticleId IdType="pubmed">15937012</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Psychol. 2004;55:51-86</Citation><ArticleIdList><ArticleId IdType="pubmed">14744210</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Learn Mem. 2009 Oct;92(3):327-34</Citation><ArticleIdList><ArticleId IdType="pubmed">19348959</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2007 Mar 9;315(5817):1426-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17347444</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sleep Res. 1998;7 Suppl 1:17-23</Citation><ArticleIdList><ArticleId IdType="pubmed">9682189</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2003 Aug;4(8):637-48</Citation><ArticleIdList><ArticleId IdType="pubmed">12894239</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2003 Jun 19;38(6):863-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12818173</ArticleId></ArticleIdList></Reference><Reference><Citation>Learn Mem. 2007 Jan 03;14(1-2):47-53</Citation><ArticleIdList><ArticleId IdType="pubmed">17202429</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Cogn Sci. 2008 Jan;12(1):24-30</Citation><ArticleIdList><ArticleId IdType="pubmed">18069046</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurophysiol. 2000 Jan;83(1):537-51</Citation><ArticleIdList><ArticleId IdType="pubmed">10634894</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Neurosci. 2009 Aug;32(8):413-20</Citation><ArticleIdList><ArticleId IdType="pubmed">19640595</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2007 Apr;10(4):414-6</Citation><ArticleIdList><ArticleId IdType="pubmed">17351634</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Neurobiol. 2007 Dec;17(6):698-703</Citation><ArticleIdList><ArticleId IdType="pubmed">18222688</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2007 Jan;10(1):100-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17173043</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2004 Oct 28;44(3):535-45</Citation><ArticleIdList><ArticleId IdType="pubmed">15504332</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2010 Apr;13(4):501-6</Citation><ArticleIdList><ArticleId IdType="pubmed">20190745</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21258392</PMID><DateCompleted><Year>2011</Year><Month>03</Month><Day>04</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1755-4349</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>2</Issue><PubDate><Year>2011</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Nature chemistry</Title><ISOAbbreviation>Nat Chem</ISOAbbreviation></Journal><ArticleTitle>Ion mobility-mass spectrometry reveals a conformational conversion from random assembly to &#x3b2;-sheet in amyloid fibril formation.</ArticleTitle><Pagination><StartPage>172</StartPage><EndPage>177</EndPage><MedlinePgn>172-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nchem.945</ELocationID><Abstract><AbstractText>Amyloid cascades that lead to peptide &#x3b2;-sheet fibrils and plaques are central to many important diseases. Recently, intermediate assemblies of these cascades were identified as the toxic agents that interact with cellular machinery. The location and cause of the transformation from a natively unstructured assembly to the &#x3b2;-sheet oligomers found in all fibrils is important in understanding disease onset and the development of therapeutic agents. Largely, research on this early oligomeric region was unsuccessful because all the traditional techniques measure only the average oligomer properties of the ensemble. We utilized ion-mobility methods to deduce the peptide self-assembly mechanism and examined a series of amyloid-forming peptides clipped from larger peptides or proteins associated with disease. We provide unambiguous evidence for structural transitions in each of these fibril-forming peptide systems and establish the potential of this method for the development of therapeutic agents and drug evaluation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bleiholder</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Chemistry and Biochemistry, University of California, Santa Barbara, California 93106-9510, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dupuis</LastName><ForeName>Nicholas F</ForeName><Initials>NF</Initials></Author><Author ValidYN="Y"><LastName>Wyttenbach</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Bowers</LastName><ForeName>Michael T</ForeName><Initials>MT</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG027818</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>12</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Chem</MedlineTA><NlmUniqueID>101499734</NlmUniqueID><ISSNLinking>1755-4330</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013058" MajorTopicYN="N">Mass Spectrometry</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017433" MajorTopicYN="Y">Protein Structure, Secondary</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>5</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>11</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>8</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21258392</ArticleId><ArticleId IdType="mid">NIHMS252059</ArticleId><ArticleId IdType="pmc">PMC3073516</ArticleId><ArticleId IdType="doi">10.1038/nchem.945</ArticleId><ArticleId IdType="pii">nchem.945</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gleiter R, Werz DB, Rausch BJ. A world beyond hydrogen bonds? - Chalcogen-Chalcogen interactions yielding tubular structures. Chem. Eur. J. 2003;9:2676&#x2013;2683.</Citation><ArticleIdList><ArticleId IdType="pubmed">12772282</ArticleId></ArticleIdList></Reference><Reference><Citation>Bong DT, Clark TD, Granja JR, Ghadiri MR. Self-Assembling Organic Nanotubes. Angew. Chem. Int. Ed. 2001;40:988&#x2013;1011.</Citation><ArticleIdList><ArticleId IdType="pubmed">11268062</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamley IW. Peptide fibrillization. Angew. Chem. Int. Ed. 2007;46:8128&#x2013;8147.</Citation><ArticleIdList><ArticleId IdType="pubmed">17935097</ArticleId></ArticleIdList></Reference><Reference><Citation>Couet J, Samuel JD, Kopyshev A, Santer S, Biesalski M. Peptide-Polymer Hybrid Nanotubes. Angew. Chem. Int. Ed. 2005;44:3297&#x2013;3301.</Citation><ArticleIdList><ArticleId IdType="pubmed">15830332</ArticleId></ArticleIdList></Reference><Reference><Citation>Unwin N. Acetylcholine receptor channel imaged in the open state. Nature. 1995;373:37&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">7800037</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghadiri MR, Granja JR, Milligan RA, McRee DE, Khazanovich N. Self-assembling organic nanotubes based on a cyclic peptide architecture. Nature. 1993;366:324&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pubmed">8247126</ArticleId></ArticleIdList></Reference><Reference><Citation>Lear JD, Wasserman ZR, DeGrado WF. Synthetic amphiphilic peptide models for protein ion channels. Science. 1988;240:1177&#x2013;1181.</Citation><ArticleIdList><ArticleId IdType="pubmed">2453923</ArticleId></ArticleIdList></Reference><Reference><Citation>Fowler DM, Koulov AV, Balch WE, Kelly JW. Functional amyloid &#x2013; from bacteria to humans. Trends Biochem. Sci. 2007;32:217&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">17412596</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawaya MR, et al. Atomic structures of amyloid cross-&#x3b2; spines reveal varied steric zippers. Nature. 2007;447:453&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">17468747</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson R, et al. Structure of the cross-&#x3b2; spine of amyloid-like fibrils. Nature. 2005;435:773&#x2013;778.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1479801</ArticleId><ArticleId IdType="pubmed">15944695</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartgerink JD, Clark TD, Ghadiri MR. Peptide nanotubes and beyond. Chem. Eur. J. 1998;4:1367&#x2013;1372.</Citation></Reference><Reference><Citation>Sipe JD, Cohen AS. Review: History of the Amyloid Fibril. J. Struct. Biol. 2000;130:88&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">10940217</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiti F, Dobson CM. Amyloid formation by globular proteins under native conditions. Nat. Chem. Biol. 2008;5:15&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">19088715</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson R, Eisenberg D. Recent atomic models of amyloid fibril structure. Curr. Opin. Struct. Biol. 2006;16:260&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">16563741</ArticleId></ArticleIdList></Reference><Reference><Citation>Luhrs T, et al. 3D structure of Alzheimer&#x2019;s amyloid-beta(1-42) fibrils. Proc. Natl. Acad. Sci. USA. 2005;102(48):17342&#x2013;17347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1297669</ArticleId><ArticleId IdType="pubmed">16293696</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris AM, Watzky MA, Finke RG. Protein aggregation kinetics, mechanism, and curve-fitting: A review of the literature. Biochim. Biophys. Acta. 2009;1794:375&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pubmed">19071235</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenberg D, et al. The structural biology of protein aggregation diseases: Fundamental questions and some answers. Acc. Chem. Res. 2006;39(9):568&#x2013;575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3017558</ArticleId><ArticleId IdType="pubmed">16981672</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer&#x2019;s amyloid &#x3b2;-peptide. Nat. Rev. Mol. Cell Biol. 2007;8:101&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrnhoefer DE, et al. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat. Struct. Bio. 2008;15:558&#x2013;566.</Citation><ArticleIdList><ArticleId IdType="pubmed">18511942</ArticleId></ArticleIdList></Reference><Reference><Citation>Kodali R, Wetzel R. Polymorphism in the intermediates and products of amyloid assembly. Curr. Opin. Struct. Biol. 2007;17:48&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">17251001</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, et al. Diffusible, nonfibrillar ligands derived from A&#x3b2;1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA. 1998;95:6448&#x2013;6453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirkitadze MD, Bitan G, Teplow DB. Paradigm shifts in Alzheimer&#x2019;s disease and other neurodegenerative disorders: The emerging role of oligomeric assemblies. J. Neurosci. Res. 2002;69:567&#x2013;577.</Citation><ArticleIdList><ArticleId IdType="pubmed">12210822</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernstein SL, et al. Amyloid-&#x3b2; protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer&#x2019;s disease. Nat. Chem. 2009;1:326&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2918915</ArticleId><ArticleId IdType="pubmed">20703363</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, et al. Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis. Science. 2003;300:486&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">12702875</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucciantini M, et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature. 2002;416:507&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932737</ArticleId></ArticleIdList></Reference><Reference><Citation>Glabe CG. Conformation-dependent antibodies target diseases of protein misfolding. Trends Biochem. Sci. 2004;29:542&#x2013;547.</Citation><ArticleIdList><ArticleId IdType="pubmed">15450609</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis NF, Wu C, Shea JE, Bowers MT. Human Islet Amyloid Polypeptide Monomers Form Ordered &#x3b2;-hairpins: A Possible Amyloidogenic Conformation. J. Am. Chem. Soc. 2009;131:18283&#x2013;18292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2810149</ArticleId><ArticleId IdType="pubmed">19950949</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, et al. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol. Neurodegen. 2007;2(18)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2100048</ArticleId><ArticleId IdType="pubmed">17897471</ArticleId></ArticleIdList></Reference><Reference><Citation>Larson JL, Ko E, Miranker AD. Direct measurement of islet amyloid polypeptide fibrillogenesis by mass spectrometry. Protein Sci. 2000;9(2):427&#x2013;431.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2144543</ArticleId><ArticleId IdType="pubmed">10716196</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith RD, Lightwahl KJ, Winger BE, Loo JA. Preservation of Noncovalent Associations in Electrospray Ionization Mass-Spectrometry - Multiply Charged Polypeptide and Protein Dimers. Org Mass Spectrom. 1992;27(7):811&#x2013;821.</Citation></Reference><Reference><Citation>Lightwahl KJ, Schwartz BL, Smith RD. Observation of the Noncovalent Quaternary Associations of Proteins by Electrospray-Ionization Mass-Spectrometry. J. Am. Chem. Soc. 1994;116(12):5271&#x2013;5278.</Citation></Reference><Reference><Citation>Smith RD, Lightwahl KJ. The Observation of Noncovalent Interactions in Solution by Electrospray-Ionization Mass-Spectrometry - Promise, Pitfalls and Prognosis. Biol Mass Spectrom. 1993;22(9):493&#x2013;501.</Citation></Reference><Reference><Citation>Nettleton EJ, et al. Characterization of the oligomeric states of insulin in self-assembly and amyloid formation by mass spectrometry. Biophys. J. 2000;79:1053&#x2013;1065.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1301001</ArticleId><ArticleId IdType="pubmed">10920035</ArticleId></ArticleIdList></Reference><Reference><Citation>Caddy GL, Robinson CV. Insights into amyloid fibril formation from mass spectrometry. Protein Pept. Lett. 2006;13:255&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">16515453</ArticleId></ArticleIdList></Reference><Reference><Citation>Loo JA. Studying noncovalent protein complexes by electrospray ionization mass spectrometry. Mass Spectrom Rev. 1997;16(1):1&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">9414489</ArticleId></ArticleIdList></Reference><Reference><Citation>von Helden G, Gotts NG, Bowers MT. Experimental Evidence for the Formation of Fullerenes by Collisional Heating of Carbon Rings in the Gas Phase. Nature. 1993;363:60&#x2013;63.</Citation></Reference><Reference><Citation>von Helden G, Wyttenbach T, Bowers MT. Conformation of Macromolecules in the Gas Phase: Use of Matrix-Assisted Laser Desorption Methods in Ion Chromatography. Science. 1995;267:1483&#x2013;1485.</Citation><ArticleIdList><ArticleId IdType="pubmed">17743549</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowers MT, Kemper PR, von Helden G, van Koppen PAM. Gas-Phase Ion Chromatography - Transition-Metal State Selection and Carbon Cluster Formation. Science. 1993;260(5113):1446&#x2013;1451.</Citation><ArticleIdList><ArticleId IdType="pubmed">17739800</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruotolo BT, et al. Evidence for Macromolecular Protein Rings in the absence of bulk water. Science. 2005;310:1658&#x2013;1661.</Citation><ArticleIdList><ArticleId IdType="pubmed">16293722</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith GD, Griffin JF. Conformation of [Leu5] Enkephalin from X-ray Diffraction: Features Important for Recognition at Opiate Receptor. Science. 1978;199:1214&#x2013;1216.</Citation><ArticleIdList><ArticleId IdType="pubmed">204006</ArticleId></ArticleIdList></Reference><Reference><Citation>Deschamps JR, George C, Flippen-Anderson JL. Structural studies of opioid peptides: A review of recent progress in x-ray diffraction studies. Biopolymers. 1996;40:121&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">8541444</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21270887</PMID><DateCompleted><Year>2011</Year><Month>02</Month><Day>01</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>469</Volume><Issue>7331</Issue><PubDate><Year>2011</Year><Month>Jan</Month><Day>27</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>A critical role for IGF-II in memory consolidation and enhancement.</ArticleTitle><Pagination><StartPage>491</StartPage><EndPage>497</EndPage><MedlinePgn>491-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature09667</ELocationID><Abstract><AbstractText>We report that, in the rat, administering insulin-like growth factor II (IGF-II, also known as IGF2) significantly enhances memory retention and prevents forgetting. Inhibitory avoidance learning leads to an increase in hippocampal expression of IGF-II, which requires the transcription factor CCAAT enhancer binding protein &#x3b2; and is essential for memory consolidation. Furthermore, injections of recombinant IGF-II into the hippocampus after either training or memory retrieval significantly enhance memory retention and prevent forgetting. To be effective, IGF-II needs to be administered within a sensitive period of memory consolidation. IGF-II-dependent memory enhancement requires IGF-II receptors, new protein synthesis, the function of activity-regulated cytoskeletal-associated protein and glycogen-synthase kinase 3 (GSK3). Moreover, it correlates with a significant activation of synaptic GSK3&#x3b2; and increased expression of GluR1 (also known as GRIA1) &#x3b1;-amino-3-hydroxy-5-methyl-4-isoxasolepropionic acid receptor subunits. In hippocampal slices, IGF-II promotes IGF-II receptor-dependent, persistent long-term potentiation after weak synaptic stimulation. Thus, IGF-II may represent a novel target for cognitive enhancement therapies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Dillon Y</ForeName><Initials>DY</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mount Sinai School of Medicine, New York, New York 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stern</LastName><ForeName>Sarah A</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Garcia-Osta</LastName><ForeName>Ana</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Saunier-Rebori</LastName><ForeName>Bernadette</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Pollonini</LastName><ForeName>Gabriella</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Bambah-Mukku</LastName><ForeName>Dhananjay</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Blitzer</LastName><ForeName>Robert D</ForeName><Initials>RD</Initials></Author><Author ValidYN="Y"><LastName>Alberini</LastName><ForeName>Cristina M</ForeName><Initials>CM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01-MH065635</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH074736</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-GM054508</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH065635</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 MH087004</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 DA029298</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-MH074736</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32-MH087004</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31-MH816213</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21-DA29298</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM054508</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022782">CCAAT-Enhancer-Binding Protein-beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>67763-97-7</RegistryNumber><NameOfSubstance UI="D007335">Insulin-Like Growth Factor II</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2011 Jan 27;469(7331):474-5. doi: 10.1038/469474a.</RefSource><PMID Version="1">21270879</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2011 Mar;12(3):122. doi: 10.1038/nrn2997.</RefSource><PMID Version="1">21433324</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D022782" MajorTopicYN="N">CCAAT-Enhancer-Binding Protein-beta</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007335" MajorTopicYN="N">Insulin-Like Growth Factor II</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017774" MajorTopicYN="N">Long-Term Potentiation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020318" MajorTopicYN="N">Rats, Long-Evans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>11</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>1</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21270887</ArticleId><ArticleId IdType="mid">NIHMS252661</ArticleId><ArticleId IdType="pmc">PMC3908455</ArticleId><ArticleId IdType="doi">10.1038/nature09667</ArticleId><ArticleId IdType="pii">nature09667</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>McGaugh JL. Memory--a century of consolidation. Science. 2000;287:248&#x2013;251.</Citation><ArticleIdList><ArticleId IdType="pubmed">10634773</ArticleId></ArticleIdList></Reference><Reference><Citation>Alberini CM. Transcription factors in long-term memory and synaptic plasticity. Physiol. Rev. 2009;89:121&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3883056</ArticleId><ArticleId IdType="pubmed">19126756</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandel ER. The molecular biology of memory storage: A dialog between genes and synapses. Biosci. Rep. 2001;21:565&#x2013;611.</Citation><ArticleIdList><ArticleId IdType="pubmed">12168768</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva AJ, Kogan JH, Frankland PW, Kida S. Creb and memory. Annu. Rev. Neurosci. 1998;21:127&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pubmed">9530494</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailey CH, Kandel ER. Structural changes accompanying memory storage. Annu. Rev. Physiol. 1993;55:397&#x2013;426.</Citation><ArticleIdList><ArticleId IdType="pubmed">8466181</ArticleId></ArticleIdList></Reference><Reference><Citation>Kida S, et al. Creb required for the stability of new and reactivated fear memories. Nat. Neurosci. 2002;5:348&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">11889468</ArticleId></ArticleIdList></Reference><Reference><Citation>Milekic MH, Pollonini G, Alberini CM. Temporal requirement of c/ebpbeta in the amygdala following reactivation but not acquisition of inhibitory avoidance. Learn. Mem. 2007;14:504&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1934346</ArticleId><ArticleId IdType="pubmed">17644752</ArticleId></ArticleIdList></Reference><Reference><Citation>Nader K, Schafe GE, Le Doux JE. Fear memories require protein synthesis in the amygdala for reconsolidation after retrieval. Nature. 2000;406:722&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pubmed">10963596</ArticleId></ArticleIdList></Reference><Reference><Citation>Shamblott MJ, Leung S, Greene MW, Chen TT. Characterization of a teleost insulin-like growth factor ii (igf-ii) gene: Evidence for promoter ccaat/enhancer-binding protein (c/ebp) sites, and the presence of hepatic c/ebp. Mol. Mar. Biol. Biotechnol. 1998;7:181&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">9701612</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo VC, Gluckman PD, Feldman EL, Werther GA. The insulin-like growth factor system and its pleiotropic functions in brain. Endocr. Rev. 2005;26:916&#x2013;943.</Citation><ArticleIdList><ArticleId IdType="pubmed">16131630</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawkes C, Kar S. The insulin-like growth factor-ii/mannose-6-phosphate receptor: Structure, distribution and function in the central nervous system. Brain Res. Brain Res. Rev. 2004;44:117&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">15003389</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitraki E, Bozas E, Philippidis H, Stylianopoulou F. Aging-related changes in igf-ii and c-fos gene expression in the rat brain. Int. J. Dev. Neurosci. 1993;11:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">7683839</ArticleId></ArticleIdList></Reference><Reference><Citation>Kar S, Chabot JG, Quirion R. Quantitative autoradiographic localization of [125i]insulin-like growth factor i, [125i]insulin-like growth factor ii, and [125i]insulin receptor binding sites in developing and adult rat brain. J. Comp. Neurol. 1993;333:375&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pubmed">8349849</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Osta A, et al. Musk expressed in the brain mediates cholinergic responses, synaptic plasticity, and memory formation. J. Neurosci. 2006;26:7919&#x2013;7932.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674217</ArticleId><ArticleId IdType="pubmed">16870737</ArticleId></ArticleIdList></Reference><Reference><Citation>Taubenfeld SM, Milekic MH, Monti B, Alberini CM. The consolidation of new but not reactivated memory requires hippocampal c/ebpbeta. Nat. Neurosci. 2001;4:813&#x2013;818.</Citation><ArticleIdList><ArticleId IdType="pubmed">11477427</ArticleId></ArticleIdList></Reference><Reference><Citation>Muravieva EV, Alberini CM. Limited efficacy of propranolol on the reconsolidation of fear memories. Learn. Mem. 2010;17:306&#x2013;313.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2884288</ArticleId><ArticleId IdType="pubmed">20516209</ArticleId></ArticleIdList></Reference><Reference><Citation>Tronel S, Alberini CM. Persistent disruption of a traumatic memory by postretrieval inactivation of glucocorticoid receptors in the amygdala. Biol. Psychiatry. 2007;62:33&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1978220</ArticleId><ArticleId IdType="pubmed">17207472</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsankova NM, Kumar A, Nestler EJ. Histone modifications at gene promoter regions in rat hippocampus after acute and chronic electroconvulsive seizures. J. Neurosci. 2004;24:5603&#x2013;5610.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729334</ArticleId><ArticleId IdType="pubmed">15201333</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsokas P, et al. Local protein synthesis mediates a rapid increase in dendritic elongation factor 1a after induction of late long-term potentiation. J. Neurosci. 2005;25:5833&#x2013;5843.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6724870</ArticleId><ArticleId IdType="pubmed">15958750</ArticleId></ArticleIdList></Reference><Reference><Citation>Taubenfeld SM, et al. Fornix-dependent induction of hippocampal ccaat enhancer-binding protein [beta] and [delta] co-localizes with phosphorylated camp response element-binding protein and accompanies long-term memory consolidation. J. Neurosci. 2001;21:84&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762431</ArticleId><ArticleId IdType="pubmed">11150323</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang KC, et al. Post-training amygdaloid lesions impair retention of an inhibitory avoidance response. Behav. Brain. Res. 1982;4:237&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">7059379</ArticleId></ArticleIdList></Reference><Reference><Citation>Alberini CM. Mechanisms of memory stabilization: Are consolidation and reconsolidation similar or distinct processes? Trends Neurosci. 2005;28:51&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">15626497</ArticleId></ArticleIdList></Reference><Reference><Citation>Nader K, Schafe GE, LeDoux JE. The labile nature of consolidation theory. Nat. Rev. Neurosci. 2000;1:216&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pubmed">11257912</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenberg M, Dudai Y. Reconsolidation of fresh, remote, and extinguished fear memory in medaka: Old fears don&#x2019;t die. Eur. J. Neurosci. 2004;20:3397&#x2013;3403.</Citation><ArticleIdList><ArticleId IdType="pubmed">15610172</ArticleId></ArticleIdList></Reference><Reference><Citation>Milekic MH, Alberini CM. Temporally graded requirement for protein synthesis following memory reactivation. Neuron. 2002;36:521&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pubmed">12408853</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki A, et al. Memory reconsolidation and extinction have distinct temporal and biochemical signatures. J. Neurosci. 2004;24:4787&#x2013;4795.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729467</ArticleId><ArticleId IdType="pubmed">15152039</ArticleId></ArticleIdList></Reference><Reference><Citation>Litvin OO, Anokhin KV. Mechanisms of memory reorganization during retrieval of acquired behavioral experience in chicks: The effects of protein synthesis inhibition in the brain. Neurosci. Behav. Physiol. 2000;30:671&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pubmed">11127794</ArticleId></ArticleIdList></Reference><Reference><Citation>Debiec J, LeDoux JE, Nader K. Cellular and systems reconsolidation in the hippocampus. Neuron. 2002;36:527&#x2013;538.</Citation><ArticleIdList><ArticleId IdType="pubmed">12408854</ArticleId></ArticleIdList></Reference><Reference><Citation>Nissley SP, Rechler MM. Somatomedin/insulin-like growth factor tissue receptors. Clin. Endocrinol. Metab. 1984;13:43&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">6202447</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramham CR, Worley PF, Moore MJ, Guzowski JF. The immediate early gene arc/arg3.1: Regulation, mechanisms, and function. J. Neurosci. 2008;28:11760&#x2013;11767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2615463</ArticleId><ArticleId IdType="pubmed">19005037</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitlock JR, Heynen AJ, Shuler MG, Bear MF. Learning induces long-term potentiation in the hippocampus. Science. 2006;313:1093&#x2013;1097.</Citation><ArticleIdList><ArticleId IdType="pubmed">16931756</ArticleId></ArticleIdList></Reference><Reference><Citation>Slipczuk L, et al. Bdnf activates mtor to regulate glur1 expression required for memory formation. PLoS One. 2009;4:e6007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2695538</ArticleId><ArticleId IdType="pubmed">19547753</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessels HW, Malinow R. Synaptic ampa receptor plasticity and behavior. Neuron. 2009;61:340&#x2013;350.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3917551</ArticleId><ArticleId IdType="pubmed">19217372</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei J, Liu W, Yan Z. Regulation of ampa receptor trafficking and function by glycogen synthase kinase 3. J. Biol. Chem. 285:26369&#x2013;26376.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2924064</ArticleId><ArticleId IdType="pubmed">20584904</ArticleId></ArticleIdList></Reference><Reference><Citation>Scalia P, et al. Regulation of the akt/glycogen synthase kinase-3 axis by insulin-like growth factor-ii via activation of the human insulin receptor isoform-a. J. Cell Biochem. 2001;82:610&#x2013;618.</Citation><ArticleIdList><ArticleId IdType="pubmed">11500939</ArticleId></ArticleIdList></Reference><Reference><Citation>Dajani R, et al. Crystal structure of glycogen synthase kinase 3 beta: Structural basis for phosphate-primed substrate specificity and autoinhibition. Cell. 2001;105:721&#x2013;732.</Citation><ArticleIdList><ArticleId IdType="pubmed">11440715</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooke SF, Bliss TV. Plasticity in the human central nervous system. Brain. 2006;129:1659&#x2013;1673.</Citation><ArticleIdList><ArticleId IdType="pubmed">16672292</ArticleId></ArticleIdList></Reference><Reference><Citation>Alberini CM, Milekic MH, Tronel S. Mechanisms of memory stabilization and de-stabilization. Cell Mol. Life Sci. 2006;63:999&#x2013;1008.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11136347</ArticleId><ArticleId IdType="pubmed">16596332</ArticleId></ArticleIdList></Reference><Reference><Citation>Milner B, Squire LR, Kandel ER. Cognitive neuroscience and the study of memory. Neuron. 1998;20:445&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pubmed">9539121</ArticleId></ArticleIdList></Reference><Reference><Citation>Maviel T, Durkin TP, Menzaghi F, Bontempi B. Sites of neocortical reorganization critical for remote spatial memory. Science. 2004;305:96&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">15232109</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadel L, Land C. Memory traces revisited. Nat. Rev. Neurosci. 2000;1:209&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">11257909</ArticleId></ArticleIdList></Reference><Reference><Citation>Elizalde PV, et al. Involvement of insulin-like growth factors-i and -ii and their receptors in medroxyprogesterone acetate-induced growth of mouse mammary adenocarcinomas. J. Steroid Biochem. Mol. Biol. 1998;67:305&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pubmed">9883987</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzowski JF, et al. Inhibition of activity-dependent arc protein expression in the rat hippocampus impairs the maintenance of long-term potentiation and the consolidation of long-term memory. J. Neurosci. 2000;20:3993&#x2013;4001.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772617</ArticleId><ArticleId IdType="pubmed">10818134</ArticleId></ArticleIdList></Reference><Reference><Citation>Pietrzkowski Z, et al. Inhibition of cellular proliferation by peptide analogues of insulin-like growth factor 1. Cancer Res. 1992;52:6447&#x2013;6451.</Citation><ArticleIdList><ArticleId IdType="pubmed">1423292</ArticleId></ArticleIdList></Reference><Reference><Citation>Quesada A, Micevych PE. Estrogen interacts with the igf-1 system to protect nigrostriatal dopamine and maintain motoric behavior after 6-hydroxdopamine lesions. J. Neurosci. Res. 2004;75:107&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">14689453</ArticleId></ArticleIdList></Reference><Reference><Citation>Milekic MH, Brown SD, Castellini C, Alberini CM. Persistent disruption of an established morphine conditioned place preference. J. Neurosci. 2006;26:3010&#x2013;3020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673959</ArticleId><ArticleId IdType="pubmed">16540579</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu CM, et al. Glycogen synthase kinase 3beta in the nucleus accumbens core mediates cocaine-induced behavioral sensitization. J. Neurochem. 2009;111:1357&#x2013;1368.</Citation><ArticleIdList><ArticleId IdType="pubmed">19799712</ArticleId></ArticleIdList></Reference><Reference><Citation>Elkobi A, et al. Erk-dependent psd-95 induction in the gustatory cortex is necessary for taste learning, but not retrieval. Nat. Neurosci. 2008;11:1149&#x2013;1151.</Citation><ArticleIdList><ArticleId IdType="pubmed">18776894</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo JH, Chen TT. Ccaat/enhancer binding protein beta2 is involved in growth hormone-regulated insulin-like growth factor-ii gene expression in the liver of rainbow trout (oncorhynchus mykiss) Endocrinology. 151:2128&#x2013;2139.</Citation><ArticleIdList><ArticleId IdType="pubmed">20228168</ArticleId></ArticleIdList></Reference><Reference><Citation>van Dijk MA, Rodenburg RJ, Holthuizen P, Sussenbach JS. The liver-specific promoter of the human insulin-like growth factor ii gene is activated by ccaat/enhancer binding protein (c/ebp) Nucleic Acids Res. 1992;20:3099&#x2013;3104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC312444</ArticleId><ArticleId IdType="pubmed">1620607</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21273426</PMID><DateCompleted><Year>2011</Year><Month>03</Month><Day>30</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>4</Issue><PubDate><Year>2011</Year><Month>Jan</Month><Day>26</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Crystal structure of the amyloid-&#x3b2; p3 fragment provides a model for oligomer formation in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1419</StartPage><EndPage>1426</EndPage><MedlinePgn>1419-26</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.4259-10.2011</ELocationID><Abstract><AbstractText>Alzheimer's disease is a progressive neurodegenerative disorder associated with the presence of amyloid-&#x3b2; (A&#x3b2;) peptide fibrillar plaques in the brain. However, current evidence suggests that soluble nonfibrillar A&#x3b2; oligomers may be the major drivers of A&#x3b2;-mediated synaptic dysfunction. Structural information on these A&#x3b2; species has been very limited because of their noncrystalline and unstable nature. Here, we describe a crystal structure of amylogenic residues 18-41 of the A&#x3b2; peptide (equivalent to the p3 &#x3b1;/&#x3b3;-secretase fragment of amyloid precursor protein) presented within the CDR3 loop region of a shark Ig new antigen receptor (IgNAR) single variable domain antibody. The predominant oligomeric species is a tightly associated A&#x3b2; dimer, with paired dimers forming a tetramer in the crystal caged within four IgNAR domains, preventing uncontrolled amyloid formation. Our structure correlates with independently observed features of small nonfibrillar A&#x3b2; oligomers and reveals conserved elements consistent with residues and motifs predicted as critical in A&#x3b2; folding and oligomerization, thus potentially providing a model system for nonfibrillar oligomer formation in Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Streltsov</LastName><ForeName>Victor A</ForeName><Initials>VA</Initials><AffiliationInfo><Affiliation>Commonwealth Scientific and Industrial Research Organization, Parkville, Victoria 3052, Australia. victor.streltsov@csiro.au</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Varghese</LastName><ForeName>Joseph N</ForeName><Initials>JN</Initials></Author><Author ValidYN="Y"><LastName>Masters</LastName><ForeName>Colin L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Nuttall</LastName><ForeName>Stewart D</ForeName><Initials>SD</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007135">Immunoglobulin Variable Region</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011946">Receptors, Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018360" MajorTopicYN="N">Crystallography, X-Ray</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007135" MajorTopicYN="N">Immunoglobulin Variable Region</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055503" MajorTopicYN="N">Protein Multimerization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020836" MajorTopicYN="N">Protein Structure, Quaternary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017433" MajorTopicYN="N">Protein Structure, Secondary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011946" MajorTopicYN="N">Receptors, Antigen</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012754" MajorTopicYN="N">Sharks</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>7</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21273426</ArticleId><ArticleId IdType="pmc">PMC6623621</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.4259-10.2011</ArticleId><ArticleId IdType="pii">31/4/1419</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Barghorn S, Nimmrich V, Striebinger A, Krantz C, Keller P, Janson B, Bahr M, Schmidt M, Bitner RS, Harlan J, Barlow E, Ebert U, Hillen H. Globular amyloid &#x3b2;-peptide oligomer&#x2014;a homogenous and stable neuropathological protein in Alzheimer's disease. J Neurochem. 2005;95:834&#x2013;847.</Citation><ArticleIdList><ArticleId IdType="pubmed">16135089</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnham KJ, Cappai R, Beyreuther K, Masters CL, Hill AF. Delineating common molecular mechanisms in Alzheimer's and prion diseases. Trends Biochem Sci. 2006;31:465&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pubmed">16820299</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumketner A, Krone MG, Shea JE. Role of the familial Dutch mutation E22Q in the folding and aggregation of the 15&#x2013;28 fragment of the Alzheimer amyloid-&#x3b2; protein. Proc Natl Acad Sci U S A. 2008;105:6027&#x2013;6032.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2329720</ArticleId><ArticleId IdType="pubmed">18408165</ArticleId></ArticleIdList></Reference><Reference><Citation>Betts V, Leissring MA, Dolios G, Wang R, Selkoe DJ, Walsh DM. Aggregation and catabolism of disease-associated intra-A&#x3b2; mutations: reduced proteolysis of A&#x3b2;A21G by neprilysin. Neurobiol Dis. 2008;31:442&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3160758</ArticleId><ArticleId IdType="pubmed">18602473</ArticleId></ArticleIdList></Reference><Reference><Citation>Br&#xfc;nger AT. Free R value: a novel statistical quantity for assessing the accuracy of crystal structures. Nature. 1992;355:472&#x2013;475.</Citation><ArticleIdList><ArticleId IdType="pubmed">18481394</ArticleId></ArticleIdList></Reference><Reference><Citation>Caine J, Volitakis I, Cherny R, Varghese J, Macreadie I. A&#x3b2; produced as a fusion to maltose binding protein can be readily purified and stably associates with copper and zinc. Protein Pept Lett. 2007;14:83&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">17266654</ArticleId></ArticleIdList></Reference><Reference><Citation>Chimon S, Ishii Y. Capturing intermediate structures of Alzheimer's &#x3b2;-amyloid, A&#x3b2;(1&#x2013;40), by solid-state NMR spectroscopy. J Am Chem Soc. 2005;127:13472&#x2013;13473.</Citation><ArticleIdList><ArticleId IdType="pubmed">16190691</ArticleId></ArticleIdList></Reference><Reference><Citation>Chimon S, Shaibat MA, Jones CR, Calero DC, Aizezi B, Ishii Y. Evidence of fibril-like &#x3b2;-sheet structures in a neurotoxic amyloid intermediate of Alzheimer's &#x3b2;-amyloid. Nat Struct Mol Biol. 2007;14:1157&#x2013;1164.</Citation><ArticleIdList><ArticleId IdType="pubmed">18059284</ArticleId></ArticleIdList></Reference><Reference><Citation>DeLano WL. The PyMOL molecular graphics system. San Carlos, CA: DeLano Scientific; 2002.</Citation></Reference><Reference><Citation>Egnaczyk GF, Greis KD, Stimson ER, Maggio JE. Photoaffinity cross-linking of Alzheimer's disease amyloid fibrils reveals interstrand contact regions between assembled &#x3b2;-amyloid peptide subunits. Biochemistry. 2001;40:11706&#x2013;11714.</Citation><ArticleIdList><ArticleId IdType="pubmed">11570871</ArticleId></ArticleIdList></Reference><Reference><Citation>Gardberg AS, Dice LT, Ou S, Rich RL, Helmbrecht E, Ko J, Wetzel R, Myszka DG, Patterson PH, Dealwis C. Molecular basis for passive immunotherapy of Alzheimer's disease. Proc Natl Acad Sci U S A. 2007;104:15659&#x2013;15664.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1994138</ArticleId><ArticleId IdType="pubmed">17895381</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant MA, Lazo ND, Lomakin A, Condron MM, Arai H, Yamin G, Rigby AC, Teplow DB. Familial Alzheimer's disease mutations alter the stability of the amyloid &#x3b2;-protein monomer folding nucleus. Proc Natl Acad Sci U S A. 2007;104:16522&#x2013;16527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2034231</ArticleId><ArticleId IdType="pubmed">17940047</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimaldi M, Scrima M, Esposito C, Vitiello G, Ramunno A, Limongelli V, D'Errico G, Novellino E, D'Ursi AM. Membrane charge dependent states of the &#x3b2;-amyloid fragment A&#x3b2;(16&#x2013;35) with differently charged micelle aggregates. Biochim Biophys Acta. 2010;1798:660&#x2013;671.</Citation><ArticleIdList><ArticleId IdType="pubmed">20045392</ArticleId></ArticleIdList></Reference><Reference><Citation>Harada T, Kuroda R. CD measurements of &#x3b2;-amyloid (1&#x2013;40) and (1&#x2013;42) in the condensed phase. Biopolymers. 2011;95:127&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">20872872</ArticleId></ArticleIdList></Reference><Reference><Citation>Henderson KA, Streltsov VA, Coley AM, Dolezal O, Hudson PJ, Batchelor AH, Gupta A, Bai T, Murphy VJ, Anders RF, Foley M, Nuttall SD. Structure of an IgNAR-AMA1 complex: targeting a conserved hydrophobic cleft broadens malarial strain recognition. Structure. 2007;15:1452&#x2013;1466.</Citation><ArticleIdList><ArticleId IdType="pubmed">17997971</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins LS, Murphy GM, Jr, Forno LS, Catalano R, Cordell B. P3 &#x3b2;-amyloid peptide has a unique and potentially pathogenic immunohistochemical profile in Alzheimer's disease brain. Am J Pathol. 1996;149:585&#x2013;596.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1865300</ArticleId><ArticleId IdType="pubmed">8701997</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou L, Shao H, Zhang Y, Li H, Menon NK, Neuhaus EB, Brewer JM, Byeon IJ, Ray DG, Vitek MP, Iwashita T, Makula RA, Przybyla AB, Zagorski MG. Solution NMR studies of the A&#x3b2;(1&#x2013;40) and A&#x3b2;(1&#x2013;42) peptides establish that the Met35 oxidation state affects the mechanism of amyloid formation. J Am Chem Soc. 2004;126:1992&#x2013;2005.</Citation><ArticleIdList><ArticleId IdType="pubmed">14971932</ArticleId></ArticleIdList></Reference><Reference><Citation>Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph. 1996;14:33&#x2013;38. 27&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">8744570</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang H, Arce FT, Ramachandran S, Capone R, Azimova R, Kagan BL, Nussinov R, Lal R. Truncated &#x3b2;-amyloid peptide channels provide an alternative mechanism for Alzheimer's disease and Down syndrome. Proc Natl Acad Sci U S A. 2010;107:6538&#x2013;6543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2851998</ArticleId><ArticleId IdType="pubmed">20308552</ArticleId></ArticleIdList></Reference><Reference><Citation>Kajava AV, Squire JM, Parry DA. &#x3b2;-Structures in fibrous proteins. Adv Protein Chem. 2006;73:1&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">17190609</ArticleId></ArticleIdList></Reference><Reference><Citation>Kienlen-Campard P, Tasiaux B, Van Hees J, Li M, Huysseune S, Sato T, Fei JZ, Aimoto S, Courtoy PJ, Smith SO, Constantinescu SN, Octave JN. Amyloidogenic processing but not amyloid precursor protein (APP) intracellular C-terminal domain production requires a precisely oriented APP dimer assembled by transmembrane GXXXG motifs. J Biol Chem. 2008;283:7733&#x2013;7744.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2702479</ArticleId><ArticleId IdType="pubmed">18201969</ArticleId></ArticleIdList></Reference><Reference><Citation>Lalowski M, Golabek A, Lemere CA, Selkoe DJ, Wisniewski HM, Beavis RC, Frangione B, Wisniewski T. The &#x201c;nonamyloidogenic&#x201d; p3 fragment (amyloid &#x3b2;17&#x2013;42) is a major constituent of Down's syndrome cerebellar preamyloid. J Biol Chem. 1996;271:33623&#x2013;33631.</Citation><ArticleIdList><ArticleId IdType="pubmed">8969231</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawrence MC, Colman PM. Shape complementarity at protein/protein interfaces. J Mol Biol. 1993;234:946&#x2013;950.</Citation><ArticleIdList><ArticleId IdType="pubmed">8263940</ArticleId></ArticleIdList></Reference><Reference><Citation>Losic D, Martin LL, Mechler A, Aguilar MI, Small DH. High resolution scanning tunnelling microscopy of the &#x3b2;-amyloid protein (A&#x3b2;1&#x2013;40) of Alzheimer's disease suggests a novel mechanism of oligomer assembly. J Struct Biol. 2006;155:104&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pubmed">16650774</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xfc;hrs T, Ritter C, Adrian M, Riek-Loher D, Bohrmann B, D&#xf6;beli H, Schubert D, Riek R. 3D structure of Alzheimer's amyloid-&#x3b2;(1&#x2013;42) fibrils. Proc Natl Acad Sci U S A. 2005;102:17342&#x2013;17347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1297669</ArticleId><ArticleId IdType="pubmed">16293696</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynn DG, Meredith SC. Review: model peptides and the physicochemical approach to &#x3b2;-amyloids. J Struct Biol. 2000;130:153&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pubmed">10940223</ArticleId></ArticleIdList></Reference><Reference><Citation>Malinchik SB, Inouye H, Szumowski KE, Kirschner DA. Structural analysis of Alzheimer's &#x3b2;(1&#x2013;40) amyloid: protofilament assembly of tubular fibrils. Biophys J. 1998;74:537&#x2013;545.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1299406</ArticleId><ArticleId IdType="pubmed">9449354</ArticleId></ArticleIdList></Reference><Reference><Citation>Mastrangelo IA, Ahmed M, Sato T, Liu W, Wang C, Hough P, Smith SO. High-resolution atomic force microscopy of soluble A&#x3b2;42 oligomers. J Mol Biol. 2006;358:106&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">16499926</ArticleId></ArticleIdList></Reference><Reference><Citation>McRee DE. XtalView/Xfit&#x2014;a versatile program for manipulating atomic coordinates and electron density. J Struct Biol. 1999;125:156&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">10222271</ArticleId></ArticleIdList></Reference><Reference><Citation>Miles LA, Wun KS, Crespi GA, Fodero-Tavoletti MT, Galatis D, Bagley CJ, Beyreuther K, Masters CL, Cappai R, McKinstry WJ, Barnham KJ, Parker MW. Amyloid-&#x3b2;-anti-amyloid-&#x3b2; complex structure reveals an extended conformation in the immunodominant B-cell epitope. J Mol Biol. 2008;377:181&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">18237744</ArticleId></ArticleIdList></Reference><Reference><Citation>Munter LM, Voigt P, Harmeier A, Kaden D, Gottschalk KE, Weise C, Pipkorn R, Schaefer M, Langosch D, Multhaup G. GxxxG motifs within the amyloid precursor protein transmembrane sequence are critical for the etiology of A&#x3b2;42. EMBO J. 2007;26:1702&#x2013;1712.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1829382</ArticleId><ArticleId IdType="pubmed">17332749</ArticleId></ArticleIdList></Reference><Reference><Citation>Murshudov GN, Vagin AA, Dodson EJ. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr. 1997;53:240&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pubmed">15299926</ArticleId></ArticleIdList></Reference><Reference><Citation>Nag S, Chen J, Irudayaraj J, Maiti S. Measurement of the attachment and assembly of small amyloid-&#x3b2; oligomers on live cell membranes at physiological concentrations using single-molecule tools. Biophys J. 2010;99:1969&#x2013;1975.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2941002</ArticleId><ArticleId IdType="pubmed">20858443</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson R, Eisenberg D. Recent atomic models of amyloid fibril structure. Curr Opin Struct Biol. 2006;16:260&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">16563741</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuttall SD, Irving RA, Hudson PJ. Immunoglobulin VH domains and beyond: design and selection of single-domain binding and targeting reagents. Curr Pharm Biotechnol. 2000;1:253&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">11469383</ArticleId></ArticleIdList></Reference><Reference><Citation>Otwinowski Z, Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997;276:307&#x2013;326.</Citation><ArticleIdList><ArticleId IdType="pubmed">27754618</ArticleId></ArticleIdList></Reference><Reference><Citation>Paravastu AK, Qahwash I, Leapman RD, Meredith SC, Tycko R. Seeded growth of &#x3b2;-amyloid fibrils from Alzheimer's brain-derived fibrils produces a distinct fibril structure. Proc Natl Acad Sci U S A. 2009;106:7443&#x2013;7448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2678625</ArticleId><ArticleId IdType="pubmed">19376973</ArticleId></ArticleIdList></Reference><Reference><Citation>Petkova AT, Ishii Y, Balbach JJ, Antzutkin ON, Leapman RD, Delaglio F, Tycko R. A structural model for Alzheimer's &#x3b2;-amyloid fibrils based on experimental constraints from solid state NMR. Proc Natl Acad Sci U S A. 2002;99:16742&#x2013;16747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC139214</ArticleId><ArticleId IdType="pubmed">12481027</ArticleId></ArticleIdList></Reference><Reference><Citation>Petkova AT, Leapman RD, Guo Z, Yau WM, Mattson MP, Tycko R. Self-propagating, molecular-level polymorphism in Alzheimer's &#x3b2;-amyloid fibrils. Science. 2005;307:262&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">15653506</ArticleId></ArticleIdList></Reference><Reference><Citation>Petkova AT, Yau WM, Tycko R. Experimental constraints on quaternary structure in Alzheimer's &#x3b2;-amyloid fibrils. Biochemistry. 2006;45:498&#x2013;512.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1435828</ArticleId><ArticleId IdType="pubmed">16401079</ArticleId></ArticleIdList></Reference><Reference><Citation>Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med. 2010;362:329&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">20107219</ArticleId></ArticleIdList></Reference><Reference><Citation>Rand RP. Structural studies by X-ray diffraction of model lipid-protein membranes of serum albumin-lecithin-cardiolipin. Biochim Biophys Acta. 1971;241:823&#x2013;834.</Citation><ArticleIdList><ArticleId IdType="pubmed">5168601</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauk A. Why is the amyloid &#x3b2; peptide of Alzheimer's disease neurotoxic? Dalton Trans. 2008;10:1273&#x2013;1282.</Citation><ArticleIdList><ArticleId IdType="pubmed">18305836</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan DA, Narrow WC, Federoff HJ, Bowers WJ. An improved method for generating consistent soluble amyloid-beta oligomer preparations for in vitro neurotoxicity studies. J Neurosci Methods. 2010;190:171&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2902796</ArticleId><ArticleId IdType="pubmed">20452375</ArticleId></ArticleIdList></Reference><Reference><Citation>Sachse C, F&#xe4;ndrich M, Grigorieff N. Paired &#x3b2;-sheet structure of an A&#x3b2;(1&#x2013;40) amyloid fibril revealed by electron microscopy. Proc Natl Acad Sci U S A. 2008;105:7462&#x2013;7466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2396686</ArticleId><ArticleId IdType="pubmed">18483195</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato T, Kienlen-Campard P, Ahmed M, Liu W, Li H, Elliott JI, Aimoto S, Constantinescu SN, Octave JN, Smith SO. Inhibitors of amyloid toxicity based on &#x3b2;-sheet packing of A&#x3b2;40 and A&#x3b2;42. Biochemistry. 2006;45:5503&#x2013;5516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2593882</ArticleId><ArticleId IdType="pubmed">16634632</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawaya MR, Sambashivan S, Nelson R, Ivanova MI, Sievers SA, Apostol MI, Thompson MJ, Balbirnie M, Wiltzius JJ, McFarlane HT, Madsen A&#xd8;, Riekel C, Eisenberg D. Atomic structures of amyloid cross-&#x3b2; spines reveal varied steric zippers. Nature. 2007;447:453&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">17468747</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmechel A, Zentgraf H, Scheuermann S, Fritz G, Pipkorn R, Reed J, Beyreuther K, Bayer TA, Multhaup G. Alzheimer &#x3b2;-amyloid homodimers facilitate A&#x3b2; fibrillization and the generation of conformational antibodies. J Biol Chem. 2003;278:35317&#x2013;35324.</Citation><ArticleIdList><ArticleId IdType="pubmed">12840025</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ. Amyloid-&#x3b2; protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008;14:837&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Y, Joachimiak A, Rosner MR, Tang WJ. Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism. Nature. 2006;443:870&#x2013;874.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3366509</ArticleId><ArticleId IdType="pubmed">17051221</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorimachi K, Craik DJ, Lloyd EJ, Beyreuther K, Masters CL. Identification of a &#x3b2;-turn in the tertiary structure of a peptide fragment of the Alzheimer amyloid protein. Biochem Int. 1990;22:447&#x2013;454.</Citation><ArticleIdList><ArticleId IdType="pubmed">2076103</ArticleId></ArticleIdList></Reference><Reference><Citation>Soscia SJ, Kirby JE, Washicosky KJ, Tucker SM, Ingelsson M, Hyman B, Burton MA, Goldstein LE, Duong S, Tanzi RE, Moir RD. The Alzheimer's disease-associated amyloid &#x3b2;-protein is an antimicrobial peptide. PLoS One. 2010;5:e9505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2831066</ArticleId><ArticleId IdType="pubmed">20209079</ArticleId></ArticleIdList></Reference><Reference><Citation>Streltsov V. X-ray absorption and diffraction studies of the metal binding sites in amyloid &#x3b2;-peptide. Eur Biophys J. 2008;37:257&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">18004559</ArticleId></ArticleIdList></Reference><Reference><Citation>Streltsov VA, Varghese JN, Carmichael JA, Irving RA, Hudson PJ, Nuttall SD. Structural evidence for evolution of shark Ig new antigen receptor variable domain antibodies from a cell-surface receptor. Proc Natl Acad Sci U S A. 2004;101:12444&#x2013;12449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC515081</ArticleId><ArticleId IdType="pubmed">15304650</ArticleId></ArticleIdList></Reference><Reference><Citation>Streltsov VA, Titmuss SJ, Epa VC, Barnham KJ, Masters CL, Varghese JN. The structure of the amyloid-&#x3b2; peptide high-affinity copper II binding site in Alzheimer disease. Biophys J. 2008;95:3447&#x2013;3456.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2547438</ArticleId><ArticleId IdType="pubmed">18599641</ArticleId></ArticleIdList></Reference><Reference><Citation>Takano K, Endo S, Mukaiyama A, Chon H, Matsumura H, Koga Y, Kanaya S. Structure of amyloid-&#x3b2; fragments in aqueous environments. FEBS J. 2006;273:150&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">16367755</ArticleId></ArticleIdList></Reference><Reference><Citation>Tycko R. Solid-state nuclear magnetic resonance techniques for structural studies of amyloid fibrils. Methods Enzymol. 2001;339:390&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pubmed">11462823</ArticleId></ArticleIdList></Reference><Reference><Citation>Urbanc B, Betnel M, Cruz L, Bitan G, Teplow DB. Elucidation of amyloid &#x3b2;-protein oligomerization mechanisms: discrete molecular dynamics study. J Am Chem Soc. 2010;132:4266&#x2013;4280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5767167</ArticleId><ArticleId IdType="pubmed">20218566</ArticleId></ArticleIdList></Reference><Reference><Citation>Vagin A, Teplyakov A. MOLREP: an automated program for molecular replacement. J Appl Crystallogr. 1997;30:1022&#x2013;1025.</Citation></Reference><Reference><Citation>Walsh DM, Selkoe DJ. A&#x3b2; oligomers&#x2014;a decade of discovery. J Neurochem. 2007;101:1172&#x2013;1184.</Citation><ArticleIdList><ArticleId IdType="pubmed">17286590</ArticleId></ArticleIdList></Reference><Reference><Citation>Winn MD, Isupov MN, Murshudov GN. Use of TLS parameters to model anisotropic displacements in macromolecular refinement. Acta Crystallogr D Biol Crystallogr. 2001;57:122&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">11134934</ArticleId></ArticleIdList></Reference><Reference><Citation>Wurth C, Guimard NK, Hecht MH. Mutations that reduce aggregation of the Alzheimer's A&#x3b2;42 peptide: an unbiased search for the sequence determinants of A&#x3b2; amyloidogenesis. J Mol Biol. 2002;319:1279&#x2013;1290.</Citation><ArticleIdList><ArticleId IdType="pubmed">12079364</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoda M, Miura T, Takeuchi H. Non-electrostatic binding and self-association of amyloid &#x3b2;-peptide on the surface of tightly packed phosphatidylcholine membranes. Biochem Biophys Res Commun. 2008;376:56&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">18755140</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu L, Edalji R, Harlan JE, Holzman TF, Lopez AP, Labkovsky B, Hillen H, Barghorn S, Ebert U, Richardson PL, Miesbauer L, Solomon L, Bartley D, Walter K, Johnson RW, Hajduk PJ, Olejniczak ET. Structural characterization of a soluble amyloid &#x3b2;-peptide oligomer. Biochemistry. 2009;48:1870&#x2013;1877.</Citation><ArticleIdList><ArticleId IdType="pubmed">19216516</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21282661</PMID><DateCompleted><Year>2011</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>108</Volume><Issue>7</Issue><PubDate><Year>2011</Year><Month>Feb</Month><Day>15</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Exercise training increases size of hippocampus and improves memory.</ArticleTitle><Pagination><StartPage>3017</StartPage><EndPage>3022</EndPage><MedlinePgn>3017-22</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1015950108</ELocationID><Abstract><AbstractText>The hippocampus shrinks in late adulthood, leading to impaired memory and increased risk for dementia. Hippocampal and medial temporal lobe volumes are larger in higher-fit adults, and physical activity training increases hippocampal perfusion, but the extent to which aerobic exercise training can modify hippocampal volume in late adulthood remains unknown. Here we show, in a randomized controlled trial with 120 older adults, that aerobic exercise training increases the size of the anterior hippocampus, leading to improvements in spatial memory. Exercise training increased hippocampal volume by 2%, effectively reversing age-related loss in volume by 1 to 2 y. We also demonstrate that increased hippocampal volume is associated with greater serum levels of BDNF, a mediator of neurogenesis in the dentate gyrus. Hippocampal volume declined in the control group, but higher preintervention fitness partially attenuated the decline, suggesting that fitness protects against volume loss. Caudate nucleus and thalamus volumes were unaffected by the intervention. These theoretically important findings indicate that aerobic exercise training is effective at reversing hippocampal volume loss in late adulthood, which is accompanied by improved memory function.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Erickson</LastName><ForeName>Kirk I</ForeName><Initials>KI</Initials><AffiliationInfo><Affiliation>Department of Psychology, University of Pittsburgh, Pittsburgh, PA 15260, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Voss</LastName><ForeName>Michelle W</ForeName><Initials>MW</Initials></Author><Author ValidYN="Y"><LastName>Prakash</LastName><ForeName>Ruchika Shaurya</ForeName><Initials>RS</Initials></Author><Author ValidYN="Y"><LastName>Basak</LastName><ForeName>Chandramallika</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Szabo</LastName><ForeName>Amanda</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Chaddock</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jennifer S</ForeName><Initials>JS</Initials></Author><Author ValidYN="Y"><LastName>Heo</LastName><ForeName>Susie</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Alves</LastName><ForeName>Heloisa</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>Siobhan M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Wojcicki</LastName><ForeName>Thomas R</ForeName><Initials>TR</Initials></Author><Author ValidYN="Y"><LastName>Mailey</LastName><ForeName>Emily</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Vieira</LastName><ForeName>Victoria J</ForeName><Initials>VJ</Initials></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Stephen A</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Pence</LastName><ForeName>Brandt D</ForeName><Initials>BD</Initials></Author><Author ValidYN="Y"><LastName>Woods</LastName><ForeName>Jeffrey A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>McAuley</LastName><ForeName>Edward</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Kramer</LastName><ForeName>Arthur F</ForeName><Initials>AF</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG024827</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG025667</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG025032</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG25032</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG25667</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG025667</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>01</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019208">Brain-Derived Neurotrophic Factor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Proc Natl Acad Sci U S A. 2011 May 3;108(18):E89; author reply E90. doi: 10.1073/pnas.1102593108.</RefSource><PMID Version="1">21504947</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Mov Disord. 2011 Mar;26(4):607. doi: 10.1002/mds.23726.</RefSource><PMID Version="1">21506145</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019208" MajorTopicYN="N">Brain-Derived Neurotrophic Factor</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015444" MajorTopicYN="N">Exercise</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="Y">anatomy &amp; histology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009929" MajorTopicYN="N">Organ Size</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013028" MajorTopicYN="N">Space Perception</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>8</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21282661</ArticleId><ArticleId IdType="pmc">PMC3041121</ArticleId><ArticleId IdType="doi">10.1073/pnas.1015950108</ArticleId><ArticleId IdType="pii">1015950108</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Raz N, et al. Regional brain changes in aging healthy adults: General trends, individual differences and modifiers. Cereb Cortex. 2005;15:1676&#x2013;1689.</Citation><ArticleIdList><ArticleId IdType="pubmed">15703252</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR., Jr. et al. Alzheimer's Disease Neuroimaging Initiative. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain. 2010;133:3336&#x2013;3348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965425</ArticleId><ArticleId IdType="pubmed">20935035</ArticleId></ArticleIdList></Reference><Reference><Citation>Hillman CH, Erickson KI, Kramer AF. Be smart, exercise your heart: Exercise effects on brain and cognition. Nat Rev Neurosci. 2008;9:58&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">18094706</ArticleId></ArticleIdList></Reference><Reference><Citation>van Praag H, Shubert T, Zhao C, Gage FH. Exercise enhances learning and hippocampal neurogenesis in aged mice. J Neurosci. 2005;25:8680&#x2013;8685.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1360197</ArticleId><ArticleId IdType="pubmed">16177036</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotman CW, Berchtold NC. Exercise: A behavioral intervention to enhance brain health and plasticity. Trends Neurosci. 2002;25:295&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">12086747</ArticleId></ArticleIdList></Reference><Reference><Citation>Creer DJ, Romberg C, Saksida LM, van Praag H, Bussey TJ. Running enhances spatial pattern separation in mice. Proc Natl Acad Sci USA. 2010;107:2367&#x2013;2372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2836679</ArticleId><ArticleId IdType="pubmed">20133882</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaynman S, Ying Z, Gomez-Pinilla F. Hippocampal BDNF mediates the efficacy of exercise on synaptic plasticity and cognition. Eur J Neurosci. 2004;20:2580&#x2013;2590.</Citation><ArticleIdList><ArticleId IdType="pubmed">15548201</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, et al. TrkB regulates hippocampal neurogenesis and governs sensitivity to antidepressive treatment. Neuron. 2008;59:399&#x2013;412.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2655199</ArticleId><ArticleId IdType="pubmed">18701066</ArticleId></ArticleIdList></Reference><Reference><Citation>Colcombe SJ, et al. Aerobic exercise training increases brain volume in aging humans. J Gerontol A Biol Sci Med Sci. 2006;61:1166&#x2013;1170.</Citation><ArticleIdList><ArticleId IdType="pubmed">17167157</ArticleId></ArticleIdList></Reference><Reference><Citation>Colcombe SJ, et al. Cardiovascular fitness, cortical plasticity, and aging. Proc Natl Acad Sci USA. 2004;101:3316&#x2013;3321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC373255</ArticleId><ArticleId IdType="pubmed">14978288</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosano C, et al. Psychomotor speed and functional brain MRI 2 years after completing a physical activity treatment. J Gerontol A Biol Sci Med Sci. 2010;65:639&#x2013;647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2869531</ArticleId><ArticleId IdType="pubmed">20348185</ArticleId></ArticleIdList></Reference><Reference><Citation>Erickson KI, et al. Physical activity predicts gray matter volume in late adulthood: The Cardiovascular Health Study. Neurology. 2010;75:1415&#x2013;1422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3039208</ArticleId><ArticleId IdType="pubmed">20944075</ArticleId></ArticleIdList></Reference><Reference><Citation>Erickson KI, et al. Aerobic fitness is associated with hippocampal volume in elderly humans. Hippocampus. 2009;19:1030&#x2013;1039.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3072565</ArticleId><ArticleId IdType="pubmed">19123237</ArticleId></ArticleIdList></Reference><Reference><Citation>Honea RA, et al. Cardiorespiratory fitness and preserved medial temporal lobe volume in Alzheimer's disease. Alzheimer Dis Assoc Disord. 2009;23:188&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2760037</ArticleId><ArticleId IdType="pubmed">19812458</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira AC, et al. An in vivo correlate of exercise-induced neurogenesis in the adult dentate gyrus. Proc Natl Acad Sci USA. 2007;104:5638&#x2013;5643.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1838482</ArticleId><ArticleId IdType="pubmed">17374720</ArticleId></ArticleIdList></Reference><Reference><Citation>Burdette JH, et al. Using network science to evaluate exercise-associated brain changes in older adults. Front Aging Neurosci. 2010;2:23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2893375</ArticleId><ArticleId IdType="pubmed">20589103</ArticleId></ArticleIdList></Reference><Reference><Citation>Moser MB, Moser EI, Forrest E, Andersen P, Morris RG. Spatial learning with a minislab in the dorsal hippocampus. Proc Natl Acad Sci USA. 1995;92:9697&#x2013;9701.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC40869</ArticleId><ArticleId IdType="pubmed">7568200</ArticleId></ArticleIdList></Reference><Reference><Citation>Raji CA, Lopez OL, Kuller LH, Carmichael OT, Becker JT. Age, Alzheimer disease, and brain structure. Neurology. 2009;73:1899&#x2013;1905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2788799</ArticleId><ArticleId IdType="pubmed">19846828</ArticleId></ArticleIdList></Reference><Reference><Citation>Hackert VH, et al. Hippocampal head size associated with verbal memory performance in nondemented elderly. Neuroimage. 2002;17:1365&#x2013;1372.</Citation><ArticleIdList><ArticleId IdType="pubmed">12414276</ArticleId></ArticleIdList></Reference><Reference><Citation>Neeper SA, G&#xf3;mez-Pinilla F, Choi J, Cotman C. Exercise and brain neurotrophins. Nature. 1995;373:109.</Citation><ArticleIdList><ArticleId IdType="pubmed">7816089</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes MM, Galea LA, Mistlberger RE, Kempermann G. Adult hippocampal neurogenesis and voluntary running activity: Circadian and dose-dependent effects. J Neurosci Res. 2004;76:216&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pubmed">15048919</ArticleId></ArticleIdList></Reference><Reference><Citation>Erickson KI, et al. Brain-derived neurotrophic factor is associated with age-related decline in hippocampal volume. J Neurosci. 2010;30:5368&#x2013;5375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3069644</ArticleId><ArticleId IdType="pubmed">20392958</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer AF, et al. Ageing, fitness and neurocognitive function. Nature. 1999;400:418&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pubmed">10440369</ArticleId></ArticleIdList></Reference><Reference><Citation>Colcombe SJ, Kramer AF. Fitness effects on the cognitive function of older adults: A meta-analytic study. Psychol Sci. 2003;14:125&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">12661673</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith PJ, et al. Aerobic exercise and neurocognitive performance: A meta-analytic review of randomized controlled trials. Psychosom Med. 2010;72:239&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2897704</ArticleId><ArticleId IdType="pubmed">20223924</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmussen P, et al. Evidence for a release of brain-derived neurotrophic factor from the brain during exercise. Exp Physiol. 2009;94:1062&#x2013;1069.</Citation><ArticleIdList><ArticleId IdType="pubmed">19666694</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoladz JA, et al. Endurance training increases plasma brain-derived neurotrophic factor concentration in young healthy men. J Physiol Pharmacol. 2008;59(Suppl 7):119&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">19258661</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee R, Kermani P, Teng KK, Hempstead BL. Regulation of cell survival by secreted proneurotrophins. Science. 2001;294:1945&#x2013;1948.</Citation><ArticleIdList><ArticleId IdType="pubmed">11729324</ArticleId></ArticleIdList></Reference><Reference><Citation>Pencea V, Bingaman KD, Wiegand SJ, Luskin MB. Infusion of brain-derived neurotrophic factor into the lateral ventricle of the adult rat leads to new neurons in the parenchyma of the striatum, septum, thalamus, and hypothalamus. J Neurosci. 2001;21:6706&#x2013;6717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763082</ArticleId><ArticleId IdType="pubmed">11517260</ArticleId></ArticleIdList></Reference><Reference><Citation>Figurov A, Pozzo-Miller LD, Olafsson P, Wang T, Lu B. Regulation of synaptic responses to high-frequency stimulation and LTP by neurotrophins in the hippocampus. Nature. 1996;381:706&#x2013;709.</Citation><ArticleIdList><ArticleId IdType="pubmed">8649517</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang H, Schuman EM. A requirement for local protein synthesis in neurotrophin-induced hippocampal synaptic plasticity. Science. 1996;273:1402&#x2013;1406.</Citation><ArticleIdList><ArticleId IdType="pubmed">8703078</ArticleId></ArticleIdList></Reference><Reference><Citation>Pang PT, et al. Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity. Science. 2004;306:487&#x2013;491.</Citation><ArticleIdList><ArticleId IdType="pubmed">15486301</ArticleId></ArticleIdList></Reference><Reference><Citation>Black JE, Isaacs KR, Anderson BJ, Alcantara AA, Greenough WT. Learning causes synaptogenesis, whereas motor activity causes angiogenesis, in cerebellar cortex of adult rats. Proc Natl Acad Sci USA. 1990;87:5568&#x2013;5572.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC54366</ArticleId><ArticleId IdType="pubmed">1695380</ArticleId></ArticleIdList></Reference><Reference><Citation>Redila VA, Christie BR. Exercise-induced changes in dendritic structure and complexity in the adult hippocampal dentate gyrus. Neuroscience. 2006;137:1299&#x2013;1307.</Citation><ArticleIdList><ArticleId IdType="pubmed">16338077</ArticleId></ArticleIdList></Reference><Reference><Citation>Oldfield RC. The assessment and analysis of handedness: The Edinburgh inventory. Neuropsychologia. 1971;9:97&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">5146491</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y, et al. Modified mini-mental state examination: Validity and reliability. Neurology. 1987;37:179.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheikh JI, Yesavage JA. Clinical Gerontology: A Guide to Assessment and Intervention. New York: Haworth Press; 1986. Geriatric Depression Scale (GDS): Recent evidence and development of a shorter version; pp. 165&#x2013;173.</Citation></Reference><Reference><Citation>Patenaude B, et al. Bayesian Shape and Appearance Models. Technical Report TR07BP1. Univ Oxford, UK: FMRIB Centre; 2007.</Citation></Reference><Reference><Citation>Zhang Y, Brady M, Smith S. Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm. IEEE Trans Med Imaging. 2001;20:45&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">11293691</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SM, et al. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage. 2004;23(Suppl 1):S208.</Citation><ArticleIdList><ArticleId IdType="pubmed">15501092</ArticleId></ArticleIdList></Reference><Reference><Citation>Strath SJ, et al. Evaluation of heart rate as a method for assessing moderate intensity physical activity. Med Sci Sports Exerc. 2000;32(9 Suppl):S465&#x2013;S470.</Citation><ArticleIdList><ArticleId IdType="pubmed">10993416</ArticleId></ArticleIdList></Reference><Reference><Citation>Borg G. An Introduction to Borg's RPE-Scale. Ithaca, NY: Mouvement; 1985.</Citation></Reference><Reference><Citation>Heo S, et al. Resting hippocampal blood flow, spatial memory and aging. Brain Res. 2010;1315:119&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2822086</ArticleId><ArticleId IdType="pubmed">20026320</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21285369</PMID><DateCompleted><Year>2011</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>108</Volume><Issue>7</Issue><PubDate><Year>2011</Year><Month>Feb</Month><Day>15</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Presenilin 2 modulates endoplasmic reticulum (ER)-mitochondria interactions and Ca2+ cross-talk.</ArticleTitle><Pagination><StartPage>2777</StartPage><EndPage>2782</EndPage><MedlinePgn>2777-82</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1100735108</ELocationID><Abstract><AbstractText>Presenilin mutations are the main cause of familial Alzheimer's disease (FAD). Presenilins also play a key role in Ca(2+) homeostasis, and their FAD-linked mutants affect cellular Ca(2+) handling in several ways. We previously have demonstrated that FAD-linked presenilin 2 (PS2) mutants decrease the Ca(2+) content of the endoplasmic reticulum (ER) by inhibiting sarcoendoplasmic reticulum Ca(2+)-ATPase (SERCA) activity and increasing ER Ca(2+) leak. Here we focus on the effect of presenilins on mitochondrial Ca(2+) dynamics. By using genetically encoded Ca(2+) indicators specifically targeted to mitochondria (aequorin- and GFP-based probes) in SH-SY5Y cells and primary neuronal cultures, we show that overexpression or down-regulation of PS2, but not of presenilin 1 (PS1), modulates the Ca(2+) shuttling between ER and mitochondria, with its FAD mutants strongly favoring Ca(2+) transfer between the two organelles. This effect is not caused by a direct PS2 action on mitochondrial Ca(2+)-uptake machinery but rather by an increased physical interaction between ER and mitochondria that augments the frequency of Ca(2+) hot spots generated at the cytoplasmic surface of the outer mitochondrial membrane upon stimulation. This PS2 function adds further complexity to the multifaceted nature of presenilins and to their physiological role within the cell. We also discuss the importance of this additional effect of FAD-linked PS2 mutants for the understanding of FAD pathogenesis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zampese</LastName><ForeName>Enrico</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of Padua, 35121 Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fasolato</LastName><ForeName>Cristina</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Kipanyula</LastName><ForeName>Maulilio J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Bortolozzi</LastName><ForeName>Mario</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Pozzan</LastName><ForeName>Tullio</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Pizzo</LastName><ForeName>Paola</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>02</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508861">PSEN2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053766">Presenilin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance></Chemical><Chemical><RegistryNumber>50934-79-7</RegistryNumber><NameOfSubstance UI="D000331">Aequorin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000331" MajorTopicYN="N">Aequorin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020013" MajorTopicYN="N">Calcium Signaling</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004721" MajorTopicYN="N">Endoplasmic Reticulum</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D031541" MajorTopicYN="N">Fluorescence Resonance Energy Transfer</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008856" MajorTopicYN="N">Microscopy, Fluorescence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053766" MajorTopicYN="N">Presenilin-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>2</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21285369</ArticleId><ArticleId IdType="pmc">PMC3041131</ArticleId><ArticleId IdType="doi">10.1073/pnas.1100735108</ArticleId><ArticleId IdType="pii">1100735108</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goedert M, Spillantini MG. A century of Alzheimer's disease. Science. 2006;314:777&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pubmed">17082447</ArticleId></ArticleIdList></Reference><Reference><Citation>Bojarski L, Herms J, Kuznicki J. Calcium dysregulation in Alzheimer's disease. Neurochem Int. 2008;52:621&#x2013;633.</Citation><ArticleIdList><ArticleId IdType="pubmed">18035450</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP. ER calcium and Alzheimer's disease: In a state of flux. Sci Signal. 2010;3:pe10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3091478</ArticleId><ArticleId IdType="pubmed">20332425</ArticleId></ArticleIdList></Reference><Reference><Citation>Zampese E, Brunello L, Fasolato C, Pizzo P. Ca2+ dysregulation mediated by presenilins in familial Alzheimer's disease: Causing or modulating factor? Curr Trends Neurol. 2009;3:1&#x2013;14.</Citation></Reference><Reference><Citation>Green KN, et al. SERCA pump activity is physiologically regulated by presenilin and regulates amyloid beta production. J Cell Biol. 2008;181:1107&#x2013;1116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2442205</ArticleId><ArticleId IdType="pubmed">18591429</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunello L, et al. Presenilin-2 dampens intracellular Ca2+ stores by increasing Ca2+ leakage and reducing Ca2+ uptake. J Cell Mol Med. 2009;13(9B):3358&#x2013;3369.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4516491</ArticleId><ArticleId IdType="pubmed">19382908</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu H, et al. Presenilins form ER Ca2+ leak channels, a function disrupted by familial Alzheimer's disease-linked mutations. Cell. 2006;126:981&#x2013;993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3241869</ArticleId><ArticleId IdType="pubmed">16959576</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson O, et al. Familial Alzheimer disease-linked mutations specifically disrupt Ca2+ leak function of presenilin 1. J Clin Invest. 2007;117:1230&#x2013;1239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1847535</ArticleId><ArticleId IdType="pubmed">17431506</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla FM. Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. Nat Rev Neurosci. 2002;3:862&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">12415294</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran G, Sisodia SS. Presenilins and Alzheimer disease: The calcium conspiracy. Nat Neurosci. 2006;9:1354&#x2013;1355.</Citation><ArticleIdList><ArticleId IdType="pubmed">17066063</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung KH, et al. Mechanism of Ca2+ disruption in Alzheimer's disease by presenilin regulation of InsP3 receptor channel gating. Neuron. 2008;58:871&#x2013;883.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2495086</ArticleId><ArticleId IdType="pubmed">18579078</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung KH, et al. Gain-of-function enhancement of IP3 receptor modal gating by familial Alzheimer's disease-linked presenilin mutants in human cells and mouse neurons. Sci Signal. 2010;3:ra22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2898196</ArticleId><ArticleId IdType="pubmed">20332427</ArticleId></ArticleIdList></Reference><Reference><Citation>Green KN, LaFerla FM. Linking calcium to Abeta and Alzheimer's disease. Neuron. 2008;59:190&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">18667147</ArticleId></ArticleIdList></Reference><Reference><Citation>Area-Gomez E, et al. Presenilins are enriched in endoplasmic reticulum membranes associated with mitochondria. Am J Pathol. 2009;175:1810&#x2013;1816.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2774047</ArticleId><ArticleId IdType="pubmed">19834068</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi T, Rizzuto R, Hajnoczky G, Su TP. MAM: More than just a housekeeper. Trends Cell Biol. 2009;19:81&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2750097</ArticleId><ArticleId IdType="pubmed">19144519</ArticleId></ArticleIdList></Reference><Reference><Citation>Celsi F, et al. Mitochondria, calcium and cell death: A deadly triad in neurodegeneration. Biochim Biophys Acta. 2009;1787:335&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696196</ArticleId><ArticleId IdType="pubmed">19268425</ArticleId></ArticleIdList></Reference><Reference><Citation>Su B, et al. Abnormal mitochondrial dynamics and neurodegenerative diseases. Biochim Biophys Acta. 2010;1802:135&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2790543</ArticleId><ArticleId IdType="pubmed">19799998</ArticleId></ArticleIdList></Reference><Reference><Citation>Swerdlow RH, Burns JM, Khan SM. The Alzheimer's disease mitochondrial cascade hypothesis. J Alzheimers Dis. 2010;20(Suppl 2):S265&#x2013;S279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2883665</ArticleId><ArticleId IdType="pubmed">20442494</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos RX, et al. Alzheimer's disease: Diverse aspects of mitochondrial malfunctioning. Int J Clin Exp Pathol. 2010;3:570&#x2013;581.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2907118</ArticleId><ArticleId IdType="pubmed">20661404</ArticleId></ArticleIdList></Reference><Reference><Citation>Zatti G, et al. Presenilin mutations linked to familial Alzheimer's disease reduce endoplasmic reticulum and Golgi apparatus calcium levels. Cell Calcium. 2006;39:539&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pubmed">16620965</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinton P, Leo S, Wieckowski MR, Di Benedetto G, Rizzuto R. Long-term modulation of mitochondrial Ca2+ signals by protein kinase C isozymes. J Cell Biol. 2004;165:223&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172040</ArticleId><ArticleId IdType="pubmed">15096525</ArticleId></ArticleIdList></Reference><Reference><Citation>Giacomello M, et al. Ca2+ hot spots on the mitochondrial surface are generated by Ca2+ mobilization from stores, but not by activation of store-operated Ca2+ channels. Mol Cell. 2010;38:280&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pubmed">20417605</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzuto R, Pozzan T. Microdomains of intracellular Ca2+: Molecular determinants and functional consequences. Physiol Rev. 2006;86:369&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pubmed">16371601</ArticleId></ArticleIdList></Reference><Reference><Citation>Manders EMM, Verbeek FJ, Aten JA. Measurement of co-localization of object in dual-colour confocal images. J Microsc. 1993;169:375&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pubmed">33930978</ArticleId></ArticleIdList></Reference><Reference><Citation>de Brito OM, Scorrano L. Mitofusin 2 tethers endoplasmic reticulum to mitochondria. Nature. 2008;456:605&#x2013;610.</Citation><ArticleIdList><ArticleId IdType="pubmed">19052620</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzuto R, et al. Close contacts with the endoplasmic reticulum as determinants of mitochondrial Ca2+ responses. Science. 1998;280:1763&#x2013;1766.</Citation><ArticleIdList><ArticleId IdType="pubmed">9624056</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakabayashi T, De Strooper B. Presenilins: Members of the gamma-secretase quartets, but part-time soloists too. Physiology (Bethesda) 2008;23:194&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">18697993</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker ES, Martinez M, Brunkan AL, Goate A. Presenilin 2 familial Alzheimer's disease mutations result in partial loss of function and dramatic changes in Abeta 42/40 ratios. J Neurochem. 2005;92:294&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">15663477</ArticleId></ArticleIdList></Reference><Reference><Citation>Behbahani H, et al. Differential role of Presenilin-1 and -2 on mitochondrial membrane potential and oxygen consumption in mouse embryonic fibroblasts. J Neurosci Res. 2006;84:891&#x2013;902.</Citation><ArticleIdList><ArticleId IdType="pubmed">16883555</ArticleId></ArticleIdList></Reference><Reference><Citation>C&#xe1;rdenas C, et al. Essential regulation of cell bioenergetics by constitutive InsP3 receptor Ca2+ transfer to mitochondria. Cell. 2010;142:270&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2911450</ArticleId><ArticleId IdType="pubmed">20655468</ArticleId></ArticleIdList></Reference><Reference><Citation>Hajn&#xf3;czky G, Robb-Gaspers LD, Seitz MB, Thomas AP. Decoding of cytosolic calcium oscillations in the mitochondria. Cell. 1995;82:415&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pubmed">7634331</ArticleId></ArticleIdList></Reference><Reference><Citation>Scorrano L, et al. BAX and BAK regulation of endoplasmic reticulum Ca2+: A control point for apoptosis. Science. 2003;300:135&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">12624178</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21289194</PMID><DateCompleted><Year>2011</Year><Month>04</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>5</Issue><PubDate><Year>2011</Year><Month>Feb</Month><Day>02</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Sphingolipid storage affects autophagic metabolism of the amyloid precursor protein and promotes Abeta generation.</ArticleTitle><Pagination><StartPage>1837</StartPage><EndPage>1849</EndPage><MedlinePgn>1837-49</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.2954-10.2011</ELocationID><Abstract><AbstractText>Deposition of amyloid &#x3b2; peptides (A&#x3b2;s) in extracellular amyloid plaques within the human brain is a hallmark of Alzheimer's disease (AD). A&#x3b2; derives from proteolytic processing of the amyloid precursor protein (APP) by &#x3b2;- and &#x3b3;-secretases. The initial cleavage by &#x3b2;-secretase results in shedding of the APP ectodomain and generation of APP C-terminal fragments (APP-CTFs), which can then be further processed within the transmembrane domain by &#x3b3;-secretase, resulting in release of A&#x3b2;. Here, we demonstrate that accumulation of sphingolipids (SLs), as occurs in lysosomal lipid storage disorders (LSDs), decreases the lysosome-dependent degradation of APP-CTFs and stimulates &#x3b3;-secretase activity. Together, this results in increased generation of both intracellular and secreted A&#x3b2;. Notably, primary fibroblasts from patients with different SL storage diseases show strong accumulation of potentially amyloidogenic APP-CTFs. By using biochemical, cell biological, and genetic approaches, we demonstrate that SL accumulation affects autophagic flux and impairs the clearance of APP-CTFs. Thus, accumulation of SLs might not only underlie the pathogenesis of LSDs, but also trigger increased generation of A&#x3b2; and contribute to neurodegeneration in sporadic AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tamboli</LastName><ForeName>Irfan Y</ForeName><Initials>IY</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Bonn, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hampel</LastName><ForeName>Heike</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Tien</LastName><ForeName>Nguyen T</ForeName><Initials>NT</Initials></Author><Author ValidYN="Y"><LastName>Tolksdorf</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Breiden</LastName><ForeName>Bernadette</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Mathews</LastName><ForeName>Paul M</ForeName><Initials>PM</Initials></Author><Author ValidYN="Y"><LastName>Saftig</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Sandhoff</LastName><ForeName>Konrad</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Walter</LastName><ForeName>Jochen</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013107">Sphingolipids</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001343" MajorTopicYN="Y">Autophagy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008854" MajorTopicYN="N">Microscopy, Electron</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013107" MajorTopicYN="N">Sphingolipids</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>8</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21289194</ArticleId><ArticleId IdType="pmc">PMC6623751</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2954-10.2011</ArticleId><ArticleId IdType="pii">31/5/1837</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ariga T, McDonald MP, Yu RK. Role of ganglioside metabolism in the pathogenesis of Alzheimer's disease&#x2014;a review. J Lipid Res. 2008;49:1157&#x2013;1175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2386904</ArticleId><ArticleId IdType="pubmed">18334715</ArticleId></ArticleIdList></Reference><Reference><Citation>Auer IA, Schmidt ML, Lee VM, Curry B, Suzuki K, Shin RW, Pentchev PG, Carstea ED, Trojanowski JQ. Paired helical filament tau (PHFtau) in Niemann-Pick type C disease is similar to PHFtau in Alzheimer's disease. Acta Neuropathol. 1995;90:547&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="pubmed">8615074</ArticleId></ArticleIdList></Reference><Reference><Citation>Bach JH, Chae HS, Rah JC, Lee MW, Park CH, Choi SH, Choi JK, Lee SH, Kim YS, Kim KY, Lee WB, Suh YH, Kim SS. C-terminal fragment of amyloid precursor protein induces astrocytosis. J Neurochem. 2001;78:109&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">11432978</ArticleId></ArticleIdList></Reference><Reference><Citation>Boland B, Kumar A, Lee S, Platt FM, Wegiel J, Yu WH, Nixon RA. Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer's disease. J Neurosci. 2008;28:6926&#x2013;6937.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676733</ArticleId><ArticleId IdType="pubmed">18596167</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns M, Duff K. Cholesterol in Alzheimer's disease and tauopathy. Ann N Y Acad Sci. 2002;977:367&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pubmed">12480774</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang KA, Suh YH. Pathophysiological roles of amyloidogenic carboxy-terminal fragments of the beta-amyloid precursor protein in Alzheimer's disease. J Pharmacol Sci. 2005;97:461&#x2013;471.</Citation><ArticleIdList><ArticleId IdType="pubmed">15821343</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, Chan DC. Mitochondrial dynamics&#x2014;fusion, fission, movement, and mitophagy&#x2014;in neurodegenerative diseases. Hum Mol Genet. 2009;18:R169&#x2013;R176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2758711</ArticleId><ArticleId IdType="pubmed">19808793</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong Y. Effect of a carboxy-terminal fragment of the Alzheimer's amyloid precursor protein on expression of proinflammatory cytokines in rat glial cells. Life Sci. 1997;61:2323&#x2013;2333.</Citation><ArticleIdList><ArticleId IdType="pubmed">9408055</ArticleId></ArticleIdList></Reference><Reference><Citation>Clement AB, Gamerdinger M, Tamboli IY, L&#xfc;tjohann D, Walter J, Greeve I, Gimpl G, Behl C. Adaptation of neuronal cells to chronic oxidative stress is associated with altered cholesterol and sphingolipid homeostasis and lysosomal function. J Neurochem. 2009;111:669&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pubmed">19712059</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuervo AM, Bergamini E, Brunk UT, Dr&#xf6;ge W, Ffrench M, Terman A. Autophagy and aging: the importance of maintaining &#x201c;clean&#x201d; cells. Autophagy. 2005;1:131&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">16874025</ArticleId></ArticleIdList></Reference><Reference><Citation>Eskelinen EL, Saftig P. Autophagy: a lysosomal degradation pathway with a central role in health and disease. Biochim Biophys Acta. 2009;1793:664&#x2013;673.</Citation><ArticleIdList><ArticleId IdType="pubmed">18706940</ArticleId></ArticleIdList></Reference><Reference><Citation>Eskelinen EL, Schmidt CK, Neu S, Willenborg M, Fuertes G, Salvador N, Tanaka Y, L&#xfc;llmann-Rauch R, Hartmann D, Heeren J, von Figura K, Knecht E, Saftig P. Disturbed cholesterol traffic but normal proteolytic function in LAMP-1/LAMP-2 double-deficient fibroblasts. Mol Biol Cell. 2004;15:3132&#x2013;3145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC452571</ArticleId><ArticleId IdType="pubmed">15121881</ArticleId></ArticleIdList></Reference><Reference><Citation>Fluhrer R, Capell A, Westmeyer G, Willem M, Hartung B, Condron MM, Teplow DB, Haass C, Walter J. A non-amyloidogenic function of BACE-2 in the secretory pathway. J Neurochem. 2002;81:1011&#x2013;1020.</Citation><ArticleIdList><ArticleId IdType="pubmed">12065613</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghiotto F, Fais F, Bruno S. BH3-only proteins: the death-puppeteer's wires. Cytometry A. 2010;77:11&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">19899133</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Koo EH, Mellon A, Hung AY, Selkoe DJ. Targeting of cell-surface beta-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments. Nature. 1992;357:500&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">1608449</ArticleId></ArticleIdList></Reference><Reference><Citation>Han X. Lipid alterations in the earliest clinically recognizable stage of Alzheimer's disease: implication of the role of lipids in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res. 2005;2:65&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">15977990</ArticleId></ArticleIdList></Reference><Reference><Citation>Hara T, Nakamura K, Matsui M, Yamamoto A, Nakahara Y, Suzuki-Migishima R, Yokoyama M, Mishima K, Saito I, Okano H, Mizushima N. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature. 2006;441:885&#x2013;889.</Citation><ArticleIdList><ArticleId IdType="pubmed">16625204</ArticleId></ArticleIdList></Reference><Reference><Citation>Ichikawa S, Nakajo N, Sakiyama H, Hirabayashi Y. A mouse B16 melanoma mutant deficient in glycolipids. Proc Natl Acad Sci U S A. 1994;91:2703&#x2013;2707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC43438</ArticleId><ArticleId IdType="pubmed">8146177</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaakkola PM, Pursiheimo JP. p62 degradation by autophagy: another way for cancer cells to survive under hypoxia. Autophagy. 2009;5:410&#x2013;412.</Citation><ArticleIdList><ArticleId IdType="pubmed">19197142</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xe4;ger S, Bucci C, Tanida I, Ueno T, Kominami E, Saftig P, Eskelinen EL. Role for Rab7 in maturation of late autophagic vacuoles. J Cell Sci. 2004;117:4837&#x2013;4848.</Citation><ArticleIdList><ArticleId IdType="pubmed">15340014</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeyakumar M, Thomas R, Elliot-Smith E, Smith DA, van der Spoel AC, d'Azzo A, Perry VH, Butters TD, Dwek RA, Platt FM. Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis. Brain. 2003;126:974&#x2013;987.</Citation><ArticleIdList><ArticleId IdType="pubmed">12615653</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y, Mullaney KA, Peterhoff CM, Che S, Schmidt SD, Boyer-Boiteau A, Ginsberg SD, Cataldo AM, Mathews PM, Nixon RA. Alzheimer's-related endosome dysfunction in Down syndrome is Abeta-independent but requires APP and is reversed by BACE-1 inhibition. Proc Natl Acad Sci U S A. 2010;107:1630&#x2013;1635.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2824382</ArticleId><ArticleId IdType="pubmed">20080541</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin LW, Shie FS, Maezawa I, Vincent I, Bird T. Intracellular accumulation of amyloidogenic fragments of amyloid-beta precursor protein in neurons with Niemann-Pick type C defects is associated with endosomal abnormalities. Am J Pathol. 2004;164:975&#x2013;985.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1614713</ArticleId><ArticleId IdType="pubmed">14982851</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, Kominami E, Ohsumi Y, Yoshimori T. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J. 2000;19:5720&#x2013;5728.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC305793</ArticleId><ArticleId IdType="pubmed">11060023</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaether C, Schmitt S, Willem M, Haass C. Amyloid precursor protein and notch intracellular domains are generated after transport of their precursors to the cell surface. Traffic. 2006;7:408&#x2013;415.</Citation><ArticleIdList><ArticleId IdType="pubmed">16536739</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalvodova L, Kahya N, Schwille P, Ehehalt R, Verkade P, Drechsel D, Simons K. Lipids as modulators of proteolytic activity of BACE: involvement of cholesterol, glycosphingolipids, and anionic phospholipids in vitro. J Biol Chem. 2005;280:36815&#x2013;36823.</Citation><ArticleIdList><ArticleId IdType="pubmed">16115865</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HS, Park CH, Cha SH, Lee JH, Lee S, Kim Y, Rah JC, Jeong SJ, Suh YH. Carboxyl-terminal fragment of Alzheimer's APP destabilizes calcium homeostasis and renders neuronal cells vulnerable to excitotoxicity. FASEB J. 2000;14:1508&#x2013;1517.</Citation><ArticleIdList><ArticleId IdType="pubmed">10928985</ArticleId></ArticleIdList></Reference><Reference><Citation>Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation. Science. 2000;290:1717&#x2013;1721.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2732363</ArticleId><ArticleId IdType="pubmed">11099404</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolter T, Sandhoff K. Sphingolipid metabolism diseases. Biochim Biophys Acta. 2006;1758:2057&#x2013;2079.</Citation><ArticleIdList><ArticleId IdType="pubmed">16854371</ArticleId></ArticleIdList></Reference><Reference><Citation>Komatsu M, Waguri S, Chiba T, Murata S, Iwata J, Tanida I, Ueno T, Koike M, Uchiyama Y, Kominami E, Tanaka K. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature. 2006;441:880&#x2013;884.</Citation><ArticleIdList><ArticleId IdType="pubmed">16625205</ArticleId></ArticleIdList></Reference><Reference><Citation>Kov&#xe1;cs AL, Reith A, Seglen PO. Accumulation of autophagosomes after inhibition of hepatocytic protein degradation by vinblastine, leupeptin or a lysosomotropic amine. Exp Cell Res. 1982;137:191&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">7056284</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuma A, Hatano M, Matsui M, Yamamoto A, Nakaya H, Yoshimori T, Ohsumi Y, Tokuhisa T, Mizushima N. The role of autophagy during the early neonatal starvation period. Nature. 2004;432:1032&#x2013;1036.</Citation><ArticleIdList><ArticleId IdType="pubmed">15525940</ArticleId></ArticleIdList></Reference><Reference><Citation>Laplante M, Sabatini DM. mTOR signaling at a glance. J Cell Sci. 2009;122:3589&#x2013;3594.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2758797</ArticleId><ArticleId IdType="pubmed">19812304</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB, Skovronsky DM, Abtahian F, Doms RW, Lee VM. Secretion and intracellular generation of truncated Abeta in beta-site amyloid-beta precursor protein-cleaving enzyme expressing human neurons. J Biol Chem. 2003;278:4458&#x2013;4466.</Citation><ArticleIdList><ArticleId IdType="pubmed">12480937</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell. 2008;132:27&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696814</ArticleId><ArticleId IdType="pubmed">18191218</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine B, Sinha S, Kroemer G. Bcl-2 family members: dual regulators of apoptosis and autophagy. Autophagy. 2008;4:600&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2749577</ArticleId><ArticleId IdType="pubmed">18497563</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Li H, Li XJ. Intracellular degradation of misfolded proteins in polyglutamine neurodegenerative diseases. Brain Res Rev. 2008;59:245&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2577582</ArticleId><ArticleId IdType="pubmed">18773920</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao G, Yao Y, Liu J, Yu Z, Cheung S, Xie A, Liang X, Bi X. Cholesterol accumulation is associated with lysosomal dysfunction and autophagic stress in Npc1 &#x2212;/&#x2212; mouse brain. Am J Pathol. 2007;171:962&#x2013;975.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1959498</ArticleId><ArticleId IdType="pubmed">17631520</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathews PM, Guerra CB, Jiang Y, Grbovic OM, Kao BH, Schmidt SD, Dinakar R, Mercken M, Hille-Rehfeld A, Rohrer J, Mehta P, Cataldo AM, Nixon RA. Alzheimer's disease-related overexpression of the cation-dependent mannose 6-phosphate receptor increases Abeta secretion: role for altered lysosomal hydrolase distribution in beta-amyloidogenesis. J Biol Chem. 2002;277:5299&#x2013;5307.</Citation><ArticleIdList><ArticleId IdType="pubmed">11551970</ArticleId></ArticleIdList></Reference><Reference><Citation>McCray BA, Taylor JP. The role of autophagy in age-related neurodegeneration. Neurosignals. 2008;16:75&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">18097162</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbantoglu J, Tirado-Santiago G, Lahsa&#xef;ni A, Poirier J, Goncalves O, Verge G, Momoli F, Welner SA, Massicotte G, Julien JP, Shapiro ML. Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein. Nature. 1997;387:500&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pubmed">9168112</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA. Endosome function and dysfunction in Alzheimer's disease and other neurodegenerative diseases. Neurobiol Aging. 2005;26:373&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pubmed">15639316</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA. Autophagy, amyloidogenesis and Alzheimer disease. J Cell Sci. 2007;120:4081&#x2013;4091.</Citation><ArticleIdList><ArticleId IdType="pubmed">18032783</ArticleId></ArticleIdList></Reference><Reference><Citation>Osenkowski P, Ye W, Wang R, Wolfe MS, Selkoe DJ. Direct and potent regulation of gamma-secretase by its lipid microenvironment. J Biol Chem. 2008;283:22529&#x2013;22540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2504869</ArticleId><ArticleId IdType="pubmed">18539594</ArticleId></ArticleIdList></Reference><Reference><Citation>Pacheco CD, Lieberman AP. The pathogenesis of Niemann-Pick type C disease: a role for autophagy? Expert Rev Mol Med. 2008;10:e26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2662713</ArticleId><ArticleId IdType="pubmed">18782459</ArticleId></ArticleIdList></Reference><Reference><Citation>Pacheco CD, Kunkel R, Lieberman AP. Autophagy in Niemann-Pick C disease is dependent upon Beclin-1 and responsive to lipid trafficking defects. Hum Mol Genet. 2007;16:1495&#x2013;1503.</Citation><ArticleIdList><ArticleId IdType="pubmed">17468177</ArticleId></ArticleIdList></Reference><Reference><Citation>Page RM, Baumann K, Tomioka M, P&#xe9;rez-Revuelta BI, Fukumori A, Jacobsen H, Flohr A, Luebbers T, Ozmen L, Steiner H, Haass C. Generation of Abeta38 and Abeta42 is independently and differentially affected by familial Alzheimer disease-associated presenilin mutations and gamma-secretase modulation. J Biol Chem. 2008;283:677&#x2013;683.</Citation><ArticleIdList><ArticleId IdType="pubmed">17962197</ArticleId></ArticleIdList></Reference><Reference><Citation>Pattingre S, Bauvy C, Carpentier S, Levade T, Levine B, Codogno P. Role of JNK1-dependent Bcl-2 phosphorylation in ceramide-induced macroautophagy. J Biol Chem. 2009;284:2719&#x2013;2728.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2631952</ArticleId><ArticleId IdType="pubmed">19029119</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravikumar B, Sarkar S, Rubinsztein DC. Clearance of mutant aggregate-prone proteins by autophagy. Methods Mol Biol. 2008;445:195&#x2013;211. 195&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">18425452</ArticleId></ArticleIdList></Reference><Reference><Citation>Razi M, Chan EY, Tooze SA. Early endosomes and endosomal coatomer are required for autophagy. J Cell Biol. 2009;185:305&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2700373</ArticleId><ArticleId IdType="pubmed">19364919</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojo LE, Fern&#xe1;ndez JA, Maccioni AA, Jimenez JM, Maccioni RB. Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer's disease. Arch Med Res. 2008;39:1&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">18067990</ArticleId></ArticleIdList></Reference><Reference><Citation>Saftig P, Beertsen W, Eskelinen EL. LAMP-2: a control step for phagosome and autophagosome maturation. Autophagy. 2008;4:510&#x2013;512.</Citation><ArticleIdList><ArticleId IdType="pubmed">18376150</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarkar S, Rubinsztein DC. Small molecule enhancers of autophagy for neurodegenerative diseases. Mol Biosyst. 2008;4:895&#x2013;901.</Citation><ArticleIdList><ArticleId IdType="pubmed">18704227</ArticleId></ArticleIdList></Reference><Reference><Citation>Seglen PO, Gordon PB. 3-Methyladenine: specific inhibitor of autophagic/lysosomal protein degradation in isolated rat hepatocytes. Proc Natl Acad Sci U S A. 1982;79:1889&#x2013;1892.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC346086</ArticleId><ArticleId IdType="pubmed">6952238</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001;81:741&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>Settembre C, Fraldi A, Rubinsztein DC, Ballabio A. Lysosomal storage diseases as disorders of autophagy. Autophagy. 2008;4:113&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pubmed">18000397</ArticleId></ArticleIdList></Reference><Reference><Citation>Shintani T, Klionsky DJ. Autophagy in health and disease: a double-edged sword. Science. 2004;306:990&#x2013;995.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1705980</ArticleId><ArticleId IdType="pubmed">15528435</ArticleId></ArticleIdList></Reference><Reference><Citation>Simons K, Ehehalt R. Cholesterol, lipid rafts, and disease. J Clin Invest. 2002;110:597&#x2013;603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC151114</ArticleId><ArticleId IdType="pubmed">12208858</ArticleId></ArticleIdList></Reference><Reference><Citation>St George-Hyslop PH. Genetic factors in the genesis of Alzheimer's disease. Ann N Y Acad Sci. 2000;924:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">11193785</ArticleId></ArticleIdList></Reference><Reference><Citation>Takamura A, Higaki K, Kajimaki K, Otsuka S, Ninomiya H, Matsuda J, Ohno K, Suzuki Y, Nanba E. Enhanced autophagy and mitochondrial aberrations in murine G(M1)-gangliosidosis. Biochem Biophys Res Commun. 2008;367:616&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pubmed">18190792</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamboli IY, Prager K, Barth E, Heneka M, Sandhoff K, Walter J. Inhibition of glycosphingolipid biosynthesis reduces secretion of the beta-amyloid precursor protein and amyloid beta-peptide. J Biol Chem. 2005;280:28110&#x2013;28117.</Citation><ArticleIdList><ArticleId IdType="pubmed">15923191</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamboli IY, Prager K, Thal DR, Thelen KM, Dewachter I, Pietrzik CU, St George-Hyslop P, Sisodia SS, De Strooper B, Heneka MT, Filippov MA, M&#xfc;ller U, van Leuvan F, L&#xfc;tjohann D, Walter J. Loss of gamma-secretase function impairs endocytosis of lipoprotein particles and membrane cholesterol homeostasis. J Neurosci. 2008;28:12097&#x2013;12106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6671640</ArticleId><ArticleId IdType="pubmed">19005074</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE, Bertram L. New frontiers in Alzheimer's disease genetics. Neuron. 2001;32:181&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">11683989</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter J, Capell A, Hung AY, Langen H, Schn&#xf6;lzer M, Thinakaran G, Sisodia SS, Selkoe DJ, Haass C. Ectodomain phosphorylation of beta-amyloid precursor protein at two distinct cellular locations. J Biol Chem. 1997;272:1896&#x2013;1903.</Citation><ArticleIdList><ArticleId IdType="pubmed">8999878</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter J, Kaether C, Steiner H, Haass C. The cell biology of Alzheimer's disease: uncovering the secrets of secretases. Curr Opin Neurobiol. 2001;11:585&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pubmed">11595492</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Martinez-Vicente M, Kr&#xfc;ger U, Kaushik S, Wong E, Mandelkow EM, Cuervo AM, Mandelkow E. Tau fragmentation, aggregation and clearance: the dual role of lysosomal processing. Hum Mol Genet. 2009;18:4153&#x2013;4170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2758146</ArticleId><ArticleId IdType="pubmed">19654187</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei J, Fujita M, Sekigawa A, Sekiyama K, Waragai M, Hashimoto M. Gangliosides' protection against lysosomal pathology of synucleinopathies. Autophagy. 2009;5:860&#x2013;861.</Citation><ArticleIdList><ArticleId IdType="pubmed">19458475</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Y, Pattingre S, Sinha S, Bassik M, Levine B. JNK1-mediated phosphorylation of Bcl-2 regulates starvation-induced autophagy. Mol Cell. 2008;30:678&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2478643</ArticleId><ArticleId IdType="pubmed">18570871</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams A, Jahreiss L, Sarkar S, Saiki S, Menzies FM, Ravikumar B, Rubinsztein DC. Aggregate-prone proteins are cleared from the cytosol by autophagy: therapeutic implications. Curr Top Dev Biol. 2006;76:89&#x2013;101. 89&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">17118264</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto N, Matsubara T, Sato T, Yanagisawa K. Age-dependent high-density clustering of GM1 ganglioside at presynaptic neuritic terminals promotes amyloid beta-protein fibrillogenesis. Biochim Biophys Acta. 2008;1778:2717&#x2013;2726.</Citation><ArticleIdList><ArticleId IdType="pubmed">18727916</ArticleId></ArticleIdList></Reference><Reference><Citation>Yankner BA. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron. 1996;16:921&#x2013;932.</Citation><ArticleIdList><ArticleId IdType="pubmed">8630250</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu WH, Cuervo AM, Kumar A, Peterhoff CM, Schmidt SD, Lee JH, Mohan PS, Mercken M, Farmery MR, Tjernberg LO, Jiang Y, Duff K, Uchiyama Y, N&#xe4;slund J, Mathews PM, Cataldo AM, Nixon RA. Macroautophagy&#x2014;a novel beta-amyloid peptide-generating pathway activated in Alzheimer's disease. J Cell Biol. 2005;171:87&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2171227</ArticleId><ArticleId IdType="pubmed">16203860</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21289198</PMID><DateCompleted><Year>2011</Year><Month>04</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>5</Issue><PubDate><Year>2011</Year><Month>Feb</Month><Day>02</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Rescue of progranulin deficiency associated with frontotemporal lobar degeneration by alkalizing reagents and inhibition of vacuolar ATPase.</ArticleTitle><Pagination><StartPage>1885</StartPage><EndPage>1894</EndPage><MedlinePgn>1885-94</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.5757-10.2011</ELocationID><Abstract><AbstractText>Numerous loss-of-function mutations in the progranulin (GRN) gene cause frontotemporal lobar degeneration with ubiquitin and TAR-DNA binding protein 43-positive inclusions by reduced production and secretion of GRN. Consistent with the observation that GRN has neurotrophic properties, pharmacological stimulation of GRN production is a promising approach to rescue GRN haploinsufficiency and prevent disease progression. We therefore searched for compounds capable of selectively increasing GRN levels. Here, we demonstrate that four independent and highly selective inhibitors of vacuolar ATPase (bafilomycin A1, concanamycin A, archazolid B, and apicularen A) significantly elevate intracellular and secreted GRN. Furthermore, clinically used alkalizing drugs, including chloroquine, bepridil, and amiodarone, similarly stimulate GRN production. Elevation of GRN levels occurs via a translational mechanism independent of lysosomal degradation, autophagy, or endocytosis. Importantly, alkalizing reagents rescue GRN deficiency in organotypic cortical slice cultures from a mouse model for GRN deficiency and in primary cells derived from human patients with GRN loss-of-function mutations. Thus, alkalizing reagents, specifically those already used in humans for other applications, and vacuolar ATPase inhibitors may be therapeutically used to prevent GRN-dependent neurodegeneration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Capell</LastName><ForeName>Anja</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, Ludwig Maximilians University, 80336 Munich, Germany. acapell@med.uni-muenchen.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liebscher</LastName><ForeName>Sabine</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Fellerer</LastName><ForeName>Katrin</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Brouwers</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Willem</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Lammich</LastName><ForeName>Sven</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Gijselinck</LastName><ForeName>Ilse</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Bittner</LastName><ForeName>Tobias</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Carlson</LastName><ForeName>Aaron M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Sasse</LastName><ForeName>Florenz</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Kunze</LastName><ForeName>Brigitte</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Steinmetz</LastName><ForeName>Heinrich</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Jansen</LastName><ForeName>Rolf</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Dormann</LastName><ForeName>Dorothee</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Sleegers</LastName><ForeName>Kristel</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Cruts</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Herms</LastName><ForeName>Jochen</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Van Broeckhoven</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Haass</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000468">Alkalies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C495773">Atg5 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071187">Autophagy-Related Protein 5</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019086">Bridged Bicyclo Compounds, Heterocyclic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077155">Granulins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C120204">Grn protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036341">Intercellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018942">Macrolides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008869">Microtubule-Associated Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077153">Progranulins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C117813">apicularen A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C519728">archazolid B</NameOfSubstance></Chemical><Chemical><RegistryNumber>755BO701MA</RegistryNumber><NameOfSubstance UI="D015764">Bepridil</NameOfSubstance></Chemical><Chemical><RegistryNumber>80890-47-7</RegistryNumber><NameOfSubstance UI="C036978">concanamycin A</NameOfSubstance></Chemical><Chemical><RegistryNumber>886U3H6UFF</RegistryNumber><NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>88899-55-2</RegistryNumber><NameOfSubstance UI="C040929">bafilomycin A1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="D025262">Vacuolar Proton-Translocating ATPases</NameOfSubstance></Chemical><Chemical><RegistryNumber>N3RQ532IUT</RegistryNumber><NameOfSubstance UI="D000638">Amiodarone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000468" MajorTopicYN="N">Alkalies</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000638" MajorTopicYN="N">Amiodarone</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071187" MajorTopicYN="N">Autophagy-Related Protein 5</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015764" MajorTopicYN="N">Bepridil</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015152" MajorTopicYN="N">Blotting, Northern</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019086" MajorTopicYN="N">Bridged Bicyclo Compounds, Heterocyclic</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="N">Frontotemporal Lobar Degeneration</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077155" MajorTopicYN="N">Granulins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036341" MajorTopicYN="N">Intercellular Signaling Peptides and Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018942" MajorTopicYN="N">Macrolides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008869" MajorTopicYN="N">Microtubule-Associated Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077153" MajorTopicYN="N">Progranulins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D025262" MajorTopicYN="N">Vacuolar Proton-Translocating ATPases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>8</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21289198</ArticleId><ArticleId IdType="pmc">PMC6623716</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.5757-10.2011</ArticleId><ArticleId IdType="pii">31/5/1885</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R, Lindholm C, Snowden J, Adamson J, Sadovnick AD, Rollinson S, Cannon A, Dwosh E, Neary D, Melquist S, Richardson A, Dickson D, Berger Z, Eriksen J, Robinson T, Zehr C, Dickey CA, Crook R, McGowan E, Mann D, Boeve B, Feldman H, Hutton M. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature. 2006;442:916&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">16862116</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman A, Bennett HP. The granulin gene family: from cancer to dementia. Bioessays. 2009;31:1245&#x2013;1254.</Citation><ArticleIdList><ArticleId IdType="pubmed">19795409</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowman EJ, Graham LA, Stevens TH, Bowman BJ. The bafilomycin/concanamycin binding site in subunit c of the V-ATPases from Neurospora crassa and Saccharomyces cerevisiae. J Biol Chem. 2004;279:33131&#x2013;33138.</Citation><ArticleIdList><ArticleId IdType="pubmed">15180988</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouwers N, Nuytemans K, van der Zee J, Gijselinck I, Engelborghs S, Theuns J, Kumar-Singh S, Pickut BA, Pals P, Dermaut B, Bogaerts V, De Pooter T, Serneels S, Van den Broeck M, Cuijt I, Mattheijssens M, Peeters K, Sciot R, Martin JJ, Cras P, Santens P, Vandenberghe R, De Deyn PP, Cruts M, Van Broeckhoven C, Sleegers K. Alzheimer and Parkinson diagnoses in progranulin null mutation carriers in an extended founder family. Arch Neurol. 2007;64:1436&#x2013;1446.</Citation><ArticleIdList><ArticleId IdType="pubmed">17923627</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouwers N, Sleegers K, Engelborghs S, Maurer-Stroh S, Gijselinck I, van der Zee J, Pickut BA, Van den Broeck M, Mattheijssens M, Peeters K, Schymkowitz J, Rousseau F, Martin JJ, Cruts M, De Deyn PP, Van Broeckhoven C. Genetic variability in progranulin contributes to risk for clinically diagnosed Alzheimer disease. Neurology. 2008;71:656&#x2013;664.</Citation><ArticleIdList><ArticleId IdType="pubmed">18565828</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruts M, Van Broeckhoven C. Loss of progranulin function in frontotemporal lobar degeneration. Trends Genet. 2008;24:186&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">18328591</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruts M, Gijselinck I, van der Zee J, Engelborghs S, Wils H, Pirici D, Rademakers R, Vandenberghe R, Dermaut B, Martin JJ, van Duijn C, Peeters K, Sciot R, Santens P, De Pooter T, Mattheijssens M, Van den Broeck M, Cuijt I, Vennekens K, De Deyn PP, Kumar-Singh S, Van Broeckhoven C. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature. 2006;442:920&#x2013;924.</Citation><ArticleIdList><ArticleId IdType="pubmed">16862115</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Turco D, Deller T. Organotypic entorhino-hippocampal slice cultures: a tool to study the molecular and cellular regulation of axonal regeneration and collateral sprouting in vitro. Methods Mol Biol. 2007;399:55&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">18309925</ArticleId></ArticleIdList></Reference><Reference><Citation>Fais S, De Milito A, You H, Qin W. Targeting vacuolar H+-ATPases as a new strategy against cancer. Cancer Res. 2007;67:10627&#x2013;10630.</Citation><ArticleIdList><ArticleId IdType="pubmed">18006801</ArticleId></ArticleIdList></Reference><Reference><Citation>Finch N, Baker M, Crook R, Swanson K, Kuntz K, Surtees R, Bisceglio G, Rovelet-Lecrux A, Boeve B, Petersen RC, Dickson DW, Younkin SG, Deramecourt V, Crook J, Graff-Radford NR, Rademakers R. Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. Brain. 2009;132:583&#x2013;591.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2664450</ArticleId><ArticleId IdType="pubmed">19158106</ArticleId></ArticleIdList></Reference><Reference><Citation>Forgac M. Vacuolar ATPases: rotary proton pumps in physiology and pathophysiology. Nat Rev Mol Cell Biol. 2007;8:917&#x2013;929.</Citation><ArticleIdList><ArticleId IdType="pubmed">17912264</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghidoni R, Benussi L, Glionna M, Franzoni M, Binetti G. Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration. Neurology. 2008;71:1235&#x2013;1239.</Citation><ArticleIdList><ArticleId IdType="pubmed">18768919</ArticleId></ArticleIdList></Reference><Reference><Citation>Gijselinck I, Van Broeckhoven C, Cruts M. Granulin mutations associated with frontotemporal lobar degeneration and related disorders: an update. Hum Mutat. 2008;29:1373&#x2013;1386.</Citation><ArticleIdList><ArticleId IdType="pubmed">18543312</ArticleId></ArticleIdList></Reference><Reference><Citation>Graff-Radford NR, Woodruff BK. Frontotemporal dementia. Semin Neurol. 2007;27:48&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">17226741</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffiths G, Fuller SD, Back R, Hollinshead M, Pfeiffer S, Simons K. The dynamic nature of the Golgi complex. J Cell Biol. 1989;108:277&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2115421</ArticleId><ArticleId IdType="pubmed">2537312</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerra RR, Kriazhev L, Hernandez-Blazquez FJ, Bateman A. Progranulin is a stress-response factor in fibroblasts subjected to hypoxia and acidosis. Growth Factors. 2007;25:280&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">18092235</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingshead LM, Faulds D, Fitton A. Bepridil. A review of its pharmacological properties and therapeutic use in stable angina pectoris. Drugs. 1992;44:835&#x2013;857.</Citation><ArticleIdList><ArticleId IdType="pubmed">1280569</ArticleId></ArticleIdList></Reference><Reference><Citation>Huss M, Wieczorek H. Inhibitors of V-ATPases: old and new players. J Exp Biol. 2009;212:341&#x2013;346.</Citation><ArticleIdList><ArticleId IdType="pubmed">19151208</ArticleId></ArticleIdList></Reference><Reference><Citation>Huss M, Sasse F, Kunze B, Jansen R, Steinmetz H, Ingenhorst G, Zeeck A, Wieczorek H. Archazolid and apicularen: novel specific V-ATPase inhibitors. BMC Biochem. 2005;6:13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1190152</ArticleId><ArticleId IdType="pubmed">16080788</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayasuga Y, Chiba S, Suzuki M, Kikusui T, Matsuwaki T, Yamanouchi K, Kotaki H, Horai R, Iwakura Y, Nishihara M. Alteration of behavioural phenotype in mice by targeted disruption of the progranulin gene. Behav Brain Res. 2007;185:110&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">17764761</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessenbrock K, Fr&#xf6;hlich L, Sixt M, L&#xe4;mmermann T, Pfister H, Bateman A, Belaaouaj A, Ring J, Ollert M, F&#xe4;ssler R, Jenne DE. Proteinase 3 and neutrophil elastase enhance inflammation in mice by inactivating antiinflammatory progranulin. J Clin Invest. 2008;118:2438&#x2013;2447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2430496</ArticleId><ArticleId IdType="pubmed">18568075</ArticleId></ArticleIdList></Reference><Reference><Citation>Koreeda A, Yonemitsu K, Kohmatsu H, Mimasaka S, Ohtsu Y, Oshima T, Fujiwara K, Tsunenari S. Immunohistochemical demonstration of the distribution of chloroquine (CQ) and its metabolites in CQ-poisoned mice. Arch Toxicol. 2007;81:471&#x2013;478.</Citation><ArticleIdList><ArticleId IdType="pubmed">17593411</ArticleId></ArticleIdList></Reference><Reference><Citation>Lammich S, Sch&#xf6;bel S, Zimmer AK, Lichtenthaler SF, Haass C. Expression of the Alzheimer protease BACE1 is suppressed via its 5&#x2032;-untranslated region. EMBO Rep. 2004;5:620&#x2013;625.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1299076</ArticleId><ArticleId IdType="pubmed">15167888</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Rademakers R. The molecular genetics and neuropathology of frontotemporal lobar degeneration: recent developments. Neurogenetics. 2007;8:237&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pubmed">17805587</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitterreiter S, Page RM, Kamp F, Hopson J, Winkler E, Ha HR, Hamid R, Herms J, Mayer TU, Nelson DJ, Steiner H, Stahl T, Zeitschel U, Rossner S, Haass C, Lichtenthaler SF. Bepridil and amiodarone simultaneously target the Alzheimer's disease beta- and gamma-secretase via distinct mechanisms. J Neurosci. 2010;30:8974&#x2013;8983.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6632893</ArticleId><ArticleId IdType="pubmed">20592218</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizushima N, Yamamoto A, Hatano M, Kobayashi Y, Kabeya Y, Suzuki K, Tokuhisa T, Ohsumi Y, Yoshimori T. Dissection of autophagosome formation using Apg5-deficient mouse embryonic stem cells. J Cell Biol. 2001;152:657&#x2013;668.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2195787</ArticleId><ArticleId IdType="pubmed">11266458</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukherjee O, Wang J, Gitcho M, Chakraverty S, Taylor-Reinwald L, Shears S, Kauwe JS, Norton J, Levitch D, Bigio EH, Hatanpaa KJ, White CL, Morris JC, Cairns NJ, Goate A. Molecular characterization of novel progranulin (GRN) mutations in frontotemporal dementia. Hum Mutat. 2008;29:512&#x2013;521.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2756561</ArticleId><ArticleId IdType="pubmed">18183624</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, McCluskey LF, Miller BL, Masliah E, Mackenzie IR, Feldman H, Feiden W, Kretzschmar HA, Trojanowski JQ, Lee VM. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Rademakers R, Roeber S, Baker M, Kretzschmar HA, Mackenzie IR. A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain. 2009;132:2922&#x2013;2931.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2768659</ArticleId><ArticleId IdType="pubmed">19674978</ArticleId></ArticleIdList></Reference><Reference><Citation>Riva E, Gerna M, Neyroz P, Urso R, Bartosek I, Guaitani A. Pharmacokinetics of amiodarone in rats. J Cardiovasc Pharmacol. 1982;4:270&#x2013;275.</Citation><ArticleIdList><ArticleId IdType="pubmed">6175811</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan CL, Baranowski DC, Chitramuthu BP, Malik S, Li Z, Cao M, Minotti S, Durham HD, Kay DG, Shaw CA, Bennett HP, Bateman A. Progranulin is expressed within motor neurons and promotes neuronal cell survival. BMC Neurosci. 2009;10:130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2779192</ArticleId><ArticleId IdType="pubmed">19860916</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez AM, Thomas D, Gillespie EJ, Damoiseaux R, Rogers J, Saxe JP, Huang J, Manchester M, Bradley KA. Amiodarone and bepridil inhibit anthrax toxin entry into host cells. Antimicrob Agents Chemother. 2007;51:2403&#x2013;2411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1913235</ArticleId><ArticleId IdType="pubmed">17485504</ArticleId></ArticleIdList></Reference><Reference><Citation>Sardiello M, Palmieri M, di Ronza A, Medina DL, Valenza M, Gennarino VA, Di Malta C, Donaudy F, Embrione V, Polishchuk RS, Banfi S, Parenti G, Cattaneo E, Ballabio A. A gene network regulating lysosomal biogenesis and function. Science. 2009;325:473&#x2013;477.</Citation><ArticleIdList><ArticleId IdType="pubmed">19556463</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmid D, Pypaert M, M&#xfc;nz C. Antigen-loading compartments for major histocompatibility complex class II molecules continuously receive input from autophagosomes. Immunity. 2007;26:79&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1805710</ArticleId><ArticleId IdType="pubmed">17182262</ArticleId></ArticleIdList></Reference><Reference><Citation>Schymick JC, Yang Y, Andersen PM, Vonsattel JP, Greenway M, Momeni P, Elder J, Chi&#xf2; A, Restagno G, Robberecht W, Dahlberg C, Mukherjee O, Goate A, Graff-Radford N, Caselli RJ, Hutton M, Gass J, Cannon A, Rademakers R, Singleton AB, Hardiman O, Rothstein J, Hardy J, Traynor BJ. Progranulin mutations and amyotrophic lateral sclerosis or amyotrophic lateral sclerosis-frontotemporal dementia phenotypes. J Neurol Neurosurg Psychiatry. 2007;78:754&#x2013;756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2117704</ArticleId><ArticleId IdType="pubmed">17371905</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankaran SS, Capell A, Hruscha AT, Fellerer K, Neumann M, Schmid B, Haass C. Missense mutations in the progranulin gene linked to frontotemporal lobar degeneration with ubiquitin-immunoreactive inclusions reduce progranulin production and secretion. J Biol Chem. 2008;283:1744&#x2013;1753.</Citation><ArticleIdList><ArticleId IdType="pubmed">17984093</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddoway LA. Amiodarone: guidelines for use and monitoring. Am Fam Physician. 2003;68:2189&#x2013;2196.</Citation><ArticleIdList><ArticleId IdType="pubmed">14677664</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleegers K, Brouwers N, Van Damme P, Engelborghs S, Gijselinck I, van der Zee J, Peeters K, Mattheijssens M, Cruts M, Vandenberghe R, De Deyn PP, Robberecht W, Van Broeckhoven C. Serum biomarker for progranulin-associated frontotemporal lobar degeneration. Ann Neurol. 2009;65:603&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pubmed">19288468</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon VR, Lee H. Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies. Eur J Pharmacol. 2009;625:220&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pubmed">19836374</ArticleId></ArticleIdList></Reference><Reference><Citation>Ullrich S, M&#xfc;nch A, Neumann S, Kremmer E, Tatzelt J, Lichtenthaler SF. The novel membrane protein TMEM59 modulates complex glycosylation, cell surface expression, and secretion of the amyloid precursor protein. J Biol Chem. 2010;285:20664&#x2013;20674.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2898310</ArticleId><ArticleId IdType="pubmed">20427278</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P, Van Hoecke A, Lambrechts D, Vanacker P, Bogaert E, van Swieten J, Carmeliet P, Van Den Bosch L, Robberecht W. Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. J Cell Biol. 2008;181:37&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2287280</ArticleId><ArticleId IdType="pubmed">18378771</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Zee J, Le Ber I, Maurer-Stroh S, Engelborghs S, Gijselinck I, Camuzat A, Brouwers N, Vandenberghe R, Sleegers K, Hannequin D, Dermaut B, Schymkowitz J, Campion D, Santens P, Martin JJ, Lacomblez L, De Pooter T, Peeters K, Mattheijssens M, Vercelletto M, Van den Broeck M, Cruts M, De Deyn PP, Rousseau F, Brice A, Van Broeckhoven C. Mutations other than null mutations producing a pathogenic loss of progranulin in frontotemporal dementia. Hum Mutat. 2007;28:416.</Citation><ArticleIdList><ArticleId IdType="pubmed">17345602</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin F, Banerjee R, Thomas B, Zhou P, Qian L, Jia T, Ma X, Ma Y, Iadecola C, Beal MF, Nathan C, Ding A. Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice. J Exp Med. 2010;207:117&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2812536</ArticleId><ArticleId IdType="pubmed">20026663</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21295279</PMID><DateCompleted><Year>2011</Year><Month>03</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1537-6605</ISSN><JournalIssue CitedMedium="Internet"><Volume>88</Volume><Issue>2</Issue><PubDate><Year>2011</Year><Month>Feb</Month><Day>11</Day></PubDate></JournalIssue><Title>American journal of human genetics</Title><ISOAbbreviation>Am J Hum Genet</ISOAbbreviation></Journal><ArticleTitle>Functional screening of Alzheimer pathology genome-wide association signals in Drosophila.</ArticleTitle><Pagination><StartPage>232</StartPage><EndPage>238</EndPage><MedlinePgn>232-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ajhg.2011.01.006</ELocationID><Abstract><AbstractText>We have leveraged a Drosophila model relevant to Alzheimer disease (AD) for functional screening of findings from a genome-wide scan for loci associated with a quantitative measure of AD pathology in humans. In six of the 15 genomic regions evaluated, we successfully identified a causal gene for the association, on the basis of in&#xa0;vivo interactions with the neurotoxicity of Tau, which forms neurofibrillary tangles in AD. Among the top results, rs10845990 within SLC2A14, encoding a glucose transporter, showed evidence of replication for association with AD pathology, and gain and loss of function in glut1, the Drosophila ortholog, was associated with suppression and enhancement of Tau toxicity, respectively. Our strategy of coupling genome-wide association in humans with functional screening in a model organism is likely to be a powerful approach for gene discovery in AD and other complex genetic disorders.</AbstractText><CopyrightInformation>Copyright &#xa9; 2011 The American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shulman</LastName><ForeName>Joshua M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Brigham and Women's Hospital, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chipendo</LastName><ForeName>Portia</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Chibnik</LastName><ForeName>Lori B</ForeName><Initials>LB</Initials></Author><Author ValidYN="Y"><LastName>Aubin</LastName><ForeName>Cristin</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Tran</LastName><ForeName>Dong</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Keenan</LastName><ForeName>Brendan T</ForeName><Initials>BT</Initials></Author><Author ValidYN="Y"><LastName>Kramer</LastName><ForeName>Patricia L</ForeName><Initials>PL</Initials></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Feany</LastName><ForeName>Mel B</ForeName><Initials>MB</Initials></Author><Author ValidYN="Y"><LastName>De Jager</LastName><ForeName>Philip L</ForeName><Initials>PL</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K08AG034290</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 AG034290</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01GM084947</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG15819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AG10161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM084947</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG17917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>02</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Hum Genet</MedlineTA><NlmUniqueID>0370475</NlmUniqueID><ISSNLinking>0002-9297</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051272">Glucose Transporter Type 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004330" MajorTopicYN="N">Drosophila</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016678" MajorTopicYN="Y">Genome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051272" MajorTopicYN="N">Glucose Transporter Type 1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040641" MajorTopicYN="N">Quantitative Trait Loci</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>7</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>1</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>1</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>8</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21295279</ArticleId><ArticleId IdType="pmc">PMC3035702</ArticleId><ArticleId IdType="doi">10.1016/j.ajhg.2011.01.006</ArticleId><ArticleId IdType="pii">S0002-9297(11)00007-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bertram L., Tanzi R.E. Genome-wide association studies in Alzheimer's disease. Hum. Mol. Genet. 2009;18:R137&#x2013;R145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2758713</ArticleId><ArticleId IdType="pubmed">19808789</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannidis J.P.A., Thomas G., Daly M.J. Validating, augmenting and refining genome-wide association signals. Nat. Rev. Genet. 2009;10:318&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7877552</ArticleId><ArticleId IdType="pubmed">19373277</ArticleId></ArticleIdList></Reference><Reference><Citation>International Schizophrenia Consortium. Purcell S.M., Wray N.R., Stone J.L., Visscher P.M., O'Donovan M.C., Sullivan P.F., Sklar P. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature. 2009;460:748&#x2013;752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3912837</ArticleId><ArticleId IdType="pubmed">19571811</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J., Benyamin B., McEvoy B.P., Gordon S., Henders A.K., Nyholt D.R., Madden P.A., Heath A.C., Martin N.G., Montgomery G.W. Common SNPs explain a large proportion of the heritability for human height. Nat. Genet. 2010;42:565&#x2013;569.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3232052</ArticleId><ArticleId IdType="pubmed">20562875</ArticleId></ArticleIdList></Reference><Reference><Citation>International Multiple Sclerosis Genetics Consortium. Bush W.S., Sawcer S.J., de Jager P.L., Oksenberg J.R., McCauley J.L., Pericak-Vance M.A., Haines J.L. Evidence for polygenic susceptibility to multiple sclerosis&#x2013;the shape of things to come. Am. J. Hum. Genet. 2010;86:621&#x2013;625.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2850422</ArticleId><ArticleId IdType="pubmed">20362272</ArticleId></ArticleIdList></Reference><Reference><Citation>Querfurth H.W., LaFerla F.M. Alzheimer's disease. N. Engl. J. Med. 2010;362:329&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">20107219</ArticleId></ArticleIdList></Reference><Reference><Citation>Harold D., Abraham R., Hollingworth P., Sims R., Gerrish A., Hamshere M.L., Pahwa J.S., Moskvina V., Dowzell K., Williams A. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat. Genet. 2009;41:1088&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845877</ArticleId><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert J.-C., Heath S., Even G., Campion D., Sleegers K., Hiltunen M., Combarros O., Zelenika D., Bullido M.J., Tavernier B. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat. Genet. 2009;41:1094&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>Seshadri S., Fitzpatrick A.L., Ikram M.A., DeStefano A.L., Gudnason V., Boada M., Bis J.C., Smith A.V., Carassquillo M.M., Lambert J.C. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA. 2010;303:1832&#x2013;1840.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2989531</ArticleId><ArticleId IdType="pubmed">20460622</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett D.A., De Jager P.L., Leurgans S.E., Schneider J.A. Neuropathologic intermediate phenotypes enhance association to Alzheimer susceptibility alleles. Neurology. 2009;72:1495&#x2013;1503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677477</ArticleId><ArticleId IdType="pubmed">19398704</ArticleId></ArticleIdList></Reference><Reference><Citation>Shulman J.M., Chibnik L.B., Aubin C., Schneider J., De&#xa0;Jager P., Bennett D. Intermediate phenotypes identify divergent pathways to Alzheimer's disease. PLoS ONE. 2010;5:e1124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2888589</ArticleId><ArticleId IdType="pubmed">20574532</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett D.A., Schneider J., Arvanitakis Z., Kelly J., Aggarwal N., Shah R., Wilson R. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 2006;66:1837&#x2013;1844.</Citation><ArticleIdList><ArticleId IdType="pubmed">16801647</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett D.A., Wilson R., Schneider J., Evans D., Beckett L., Aggarwal N., Barnes L., Fox J., Bach J. Natural history of mild cognitive impairment in older persons. Neurology. 2002;59:198&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">12136057</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett D.A., Schneider J.A., Buchman A.S., Mendes de Leon C., Bienias J.L., Wilson R.S. The Rush Memory and Aging Project: study design and baseline characteristics of the study cohort. Neuroepidemiology. 2005;25:163&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pubmed">16103727</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett D.A., Schneider J.A., Tang Y., Arnold S.E., Wilson R.S. The effect of social networks on the relation between Alzheimer's disease pathology and level of cognitive function in old people: a longitudinal cohort study. Lancet Neurol. 2006;5:406&#x2013;412.</Citation><ArticleIdList><ArticleId IdType="pubmed">16632311</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett D.A., Wilson R.S., Schneider J.A., Evans D.A., Aggarwal N.T., Arnold S.E., Cochran E.J., Berry-Kravis E., Bienias J.L. Apolipoprotein E epsilon4 allele, AD pathology, and the clinical expression of Alzheimer's disease. Neurology. 2003;60:246&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pubmed">12552039</ArticleId></ArticleIdList></Reference><Reference><Citation>Finelli A., Kelkar A., Song H.J., Yang H., Konsolaki M. A model for studying Alzheimer's Abeta42-induced toxicity in Drosophila melanogaster. Mol. Cell. Neurosci. 2004;26:365&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pubmed">15234342</ArticleId></ArticleIdList></Reference><Reference><Citation>Moloney A., Sattelle D.B., Lomas D.A., Crowther D.C. Alzheimer's disease: insights from Drosophila melanogaster models. Trends Biochem. Sci. 2010;35:228&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2856915</ArticleId><ArticleId IdType="pubmed">20036556</ArticleId></ArticleIdList></Reference><Reference><Citation>Wittmann C.W., Wszolek M., Shulman J., Salvaterra P., Lewis J., Hutton M., Feany M. Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science. 2001;293:711&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pubmed">11408621</ArticleId></ArticleIdList></Reference><Reference><Citation>Shulman J.M., Feany M. Genetic modifiers of tauopathy in Drosophila. Genetics. 2003;165:1233&#x2013;1242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1462852</ArticleId><ArticleId IdType="pubmed">14668378</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner L.M., Ke Y.D., Delerue F., Bi M., Gladbach A., van&#xa0;Eersel J., W&#xf6;lfing H., Chieng B.C., Christie M.J., Napier I.A. Dendritic Function of Tau Mediates Amyloid-beta Toxicity in Alzheimer's Disease Mouse Models. Cell. 2010;142:387&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pubmed">20655099</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson E.D., Scearce-Levie K., Palop J., Yan F., Cheng I., Wu T., Gerstein H., Yu G., Mucke L. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science. 2007;316:750&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pubmed">17478722</ArticleId></ArticleIdList></Reference><Reference><Citation>Vossel K.A., Zhang K., Brodbeck J., Daub A.C., Sharma P., Finkbeiner S., Cui B., Mucke L. Tau Reduction Prevents Abeta-Induced Defects in Axonal Transport. Science. 2010;330:198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3024010</ArticleId><ArticleId IdType="pubmed">20829454</ArticleId></ArticleIdList></Reference><Reference><Citation>Fulga T.A., Elson-Schwab I., Khurana V., Steinhilb M.L., Spires T.L., Hyman B.T., Feany M.B. Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in&#xa0;vivo. Nat. Cell Biol. 2007;9:139&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pubmed">17187063</ArticleId></ArticleIdList></Reference><Reference><Citation>Khurana V., Lu Y., Steinhilb M., Oldham S., Shulman J., Feany M. TOR-mediated cell-cycle activation causes neurodegeneration in a Drosophila tauopathy model. Curr. Biol. 2006;16:230&#x2013;241.</Citation><ArticleIdList><ArticleId IdType="pubmed">16461276</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotz J., Chen F., van Dorpe J., Nitsch R. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science. 2001;293:1491&#x2013;1495.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520988</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J., McGowan E., Rockwood J., Melrose H., Nacharaju P., Van Slegtenhorst M., Gwinn-Hardy K., Paul Murphy M., Baker M., Yu X. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet. 2000;25:402&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">10932182</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;tz J., Ittner L.M. Animal models of Alzheimer's disease and frontotemporal dementia. Nat. Rev. Neurosci. 2008;9:532&#x2013;544.</Citation><ArticleIdList><ArticleId IdType="pubmed">18568014</ArticleId></ArticleIdList></Reference><Reference><Citation>Dietzl G., Chen D., Schnorrer F., Su K.C., Barinova Y., Fellner M., Gasser B., Kinsey K., Oppel S., Scheiblauer S. A genome-wide transgenic RNAi library for conditional gene inactivation in Drosophila. Nature. 2007;448:151&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">17625558</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni J.Q., Markstein M., Binari R., Pfeiffer B., Liu L.P., Villalta C., Booker M., Perkins L., Perrimon N. Vector and parameters for targeted transgenic RNA interference in Drosophila melanogaster. Nat. Methods. 2008;5:49&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2290002</ArticleId><ArticleId IdType="pubmed">18084299</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews K.A., Kaufman T.C., Gelbart W.M. Research resources for Drosophila: the expanding universe. Nat. Rev. Genet. 2005;6:179&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">15738962</ArticleId></ArticleIdList></Reference><Reference><Citation>Tweedie S., Ashburner M., Falls K., Leyland P., McQuilton P., Marygold S., Millburn G., Osumi-Sutherland D., Schroeder A., Seal R. FlyBase: enhancing Drosophila Gene Ontology annotations. Nucleic Acids Res. 2009;37:D555&#x2013;D559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2686450</ArticleId><ArticleId IdType="pubmed">18948289</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellen H.J., Levis R.W., Liao G., He Y., Carlson J.W., Tsang G., Evans-Holm M., Hiesinger P.R., Schulze K.L., Rubin G.M. The BDGP gene disruption project: single transposon insertions associated with 40% of Drosophila genes. Genetics. 2004;167:761&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1470905</ArticleId><ArticleId IdType="pubmed">15238527</ArticleId></ArticleIdList></Reference><Reference><Citation>Escher S.A., Rasmuson-Lestander A. The Drosophila glucose transporter gene: cDNA sequence, phylogenetic comparisons, analysis of functional sites and secondary structures. Hereditas. 1999;130:95&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">10479996</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X., Freeze H.H. GLUT14, a duplicon of GLUT3, is specifically expressed in testis as alternative splice forms. Genomics. 2002;80:553&#x2013;557.</Citation><ArticleIdList><ArticleId IdType="pubmed">12504846</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhead B., Karolchik D., Kuhn R.M., Hinrichs A.S., Zweig A.S., Fujita P.A., Diekhans M., Smith K.E., Rosenbloom K.R., Raney B.J. The UCSC Genome Browser database: update 2010. Nucleic Acids Res. 2010;38:D613&#x2013;D619.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2808870</ArticleId><ArticleId IdType="pubmed">19906737</ArticleId></ArticleIdList></Reference><Reference><Citation>Su A.I., Cooke M.P., Ching K.A., Hakak Y., Walker J.R., Wiltshire T., Orth A.P., Vega R.G., Sapinoso L.M., Moqrich A. Large-scale analysis of the human and mouse transcriptomes. Proc. Natl. Acad. Sci. USA. 2002;99:4465&#x2013;4470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC123671</ArticleId><ArticleId IdType="pubmed">11904358</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C., Orozco C., Boyer J., Leglise M., Goodale J., Batalov S., Hodge C.L., Haase J., Janes J., Huss J.W. BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources. Genome Biol. 2009;10:R130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3091323</ArticleId><ArticleId IdType="pubmed">19919682</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Liu F., Iqbal K., Grundke-Iqbal I., Gong C.-X. Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer disease. FEBS Lett. 2008;582:359&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2247364</ArticleId><ArticleId IdType="pubmed">18174027</ArticleId></ArticleIdList></Reference><Reference><Citation>Dias-Santagata D., Fulga T.A., Duttaroy A., Feany M.B. Oxidative stress mediates tau-induced neurodegeneration in Drosophila. J. Clin. Invest. 2007;117:236&#x2013;245.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1697799</ArticleId><ArticleId IdType="pubmed">17173140</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai U.A., Pallos J., Ma A.A.K., Stockwell B.R., Thompson L.M., Marsh J.L., Diamond M.I. Biologically active molecules that reduce polyglutamine aggregation and toxicity. Hum. Mol. Genet. 2006;15:2114&#x2013;2124.</Citation><ArticleIdList><ArticleId IdType="pubmed">16720620</ArticleId></ArticleIdList></Reference><Reference><Citation>Karsten S.L., Sang T.-K., Gehman L.T., Chatterjee S., Liu J., Lawless G.M., Sengupta S., Berry R.W., Pomakian J., Oh H.S. A genomic screen for modifiers of tauopathy&#xa0;identifies puromycin-sensitive aminopeptidase as an inhibitor of tau-induced neurodegeneration. Neuron. 2006;51:549&#x2013;560.</Citation><ArticleIdList><ArticleId IdType="pubmed">16950154</ArticleId></ArticleIdList></Reference><Reference><Citation>Blard O., Feuillette S., Bou J., Chaumette B., Frebourg T., Campion D., Lecourtois M. Cytoskeleton proteins are modulators of mutant tau-induced neurodegeneration in Drosophila. Hum. Mol. Genet. 2007;16:555&#x2013;566.</Citation><ArticleIdList><ArticleId IdType="pubmed">17309878</ArticleId></ArticleIdList></Reference><Reference><Citation>Moloney A., Sattelle D.B., Lomas D.A., Crowther D.C. Alzheimer's disease: insights from Drosophila melanogaster models. Trends Biochem Sci. 2009;35:228&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2856915</ArticleId><ArticleId IdType="pubmed">20036556</ArticleId></ArticleIdList></Reference><Reference><Citation>Fossgreen A., Bruckner B., Czech C., Masters C., Beyreuther K., Paro R. Transgenic Drosophila expressing human amyloid precursor protein show gamma-secretase activity and a blistered-wing phenotype. Proc. Natl. Acad. Sci. USA. 1998;95:13703&#x2013;13708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24883</ArticleId><ArticleId IdType="pubmed">9811864</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin G.M., Yandell M., Wortman J., Gabor Miklos G., Nelson C., Hariharan I., Fortini M., Li P., Apweiler R., Fleischmann W. Comparative genomics of the eukaryotes. Science. 2000;287:2204&#x2013;2215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2754258</ArticleId><ArticleId IdType="pubmed">10731134</ArticleId></ArticleIdList></Reference><Reference><Citation>Battye R., Stevens A., Jacobs J.R. Axon repulsion from the midline of the Drosophila CNS requires slit function. Development. 1999;126:2475&#x2013;2481.</Citation><ArticleIdList><ArticleId IdType="pubmed">10226006</ArticleId></ArticleIdList></Reference><Reference><Citation>Samson M.L., Chalvet F. found in neurons, a third member of the Drosophila elav gene family, encodes a neuronal protein and interacts with elav. Mech. Dev. 2003;120:373&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pubmed">12591606</ArticleId></ArticleIdList></Reference><Reference><Citation>Brand A.H., Perrimon N. Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. Development. 1993;118:401&#x2013;415.</Citation><ArticleIdList><ArticleId IdType="pubmed">8223268</ArticleId></ArticleIdList></Reference><Reference><Citation>Altschul S.F., Madden T.L., Schaffer A.A., Zhang J., Zhang Z., Miller W., Lipman D.J. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 1997;25:3389&#x2013;3402.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC146917</ArticleId><ArticleId IdType="pubmed">9254694</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21300946</PMID><DateCompleted><Year>2011</Year><Month>03</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3636</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>2</Issue><PubDate><Year>2011</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Archives of general psychiatry</Title><ISOAbbreviation>Arch Gen Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Trends in antipsychotic use in dementia 1999-2007.</ArticleTitle><Pagination><StartPage>190</StartPage><EndPage>197</EndPage><MedlinePgn>190-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/archgenpsychiatry.2010.200</ELocationID><Abstract><AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">Use of atypical antipsychotics for neuropsychiatric symptoms of dementia increased markedly in the 1990s. Concerns about their use began to emerge in 2002, and in 2005, the US Food and Drug Administration warned that use of atypical antipsychotics in dementia was associated with increased mortality.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine changes in atypical and conventional antipsychotic use in outpatients with dementia from 1999 through 2007.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Time-series analyses estimated the effect of the various warnings on atypical and conventional antipsychotic usage using national Veterans Affairs data across 3 periods: no warning (1999-2003), early warning (2003-2005), and black box warning (2005-2007).</AbstractText><AbstractText Label="SUBJECTS" NlmCategory="METHODS">Patients aged 65 years or older with dementia (n = 254 564).</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Outpatient antipsychotic use (percentage of patients, percentage of quarterly change, and difference between consecutive study periods).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In 1999, 17.7% (95% confidence interval [CI], 17.2-18.1) of patients with dementia were using atypical or conventional antipsychotics. Overall use began to decline during the no-warning period (rate per quarter, -0.12%; 95% CI, -0.16 to -0.07; P &lt; .001). Following the black box warning, the decline continued (rate, -0.26%; 95% CI, -0.34 to -0.18; P &lt; .001), with a significant difference between the early and black box warning periods (P = .006). Use of atypical antipsychotics as a group increased during the no-warning period (rate, 0.23; 95% CI, 0.17-0.30; P &lt; .001), started to decline during the early-warning period (rate, -0.012; 95% CI, -0.14 to 0.11; P = .85), and more sharply declined during the black box warning period (rate, -0.27; 95% CI, -0.36 to -0.18; P &lt; .001). Olanzapine and risperidone showed declining rates and quetiapine showed an increase during the early-warning period, but rates of use for all 3 antipsychotics declined during the black box warning period. In the black box warning period, there was a small but significant increase in anticonvulsant prescriptions (rate, 0.117; 95% CI, 0.08-0.16; P &lt; .001).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Use of atypical antipsychotics began to decline significantly in 2003, and the Food and Drug Administration advisory was temporally associated with a significant acceleration in the decline.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kales</LastName><ForeName>Helen C</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Veterans Affairs Health Services Researchand Development Center for Clinical Management Research, Serious Mental Illness Treatment, Resource, and Evaluation Center, Ann Arbor, Michigan, USA. kales@umich.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zivin</LastName><ForeName>Kara</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hyungjin Myra</ForeName><Initials>HM</Initials></Author><Author ValidYN="Y"><LastName>Valenstein</LastName><ForeName>Marcia</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Chiang</LastName><ForeName>Claire</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Ignacio</LastName><ForeName>Rosalinda V</ForeName><Initials>RV</Initials></Author><Author ValidYN="Y"><LastName>Ganoczy</LastName><ForeName>Dara</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Cunningham</LastName><ForeName>Francesca</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials></Author><Author ValidYN="Y"><LastName>Blow</LastName><ForeName>Frederic C</ForeName><Initials>FC</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH081070</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-MH081070-01</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Gen Psychiatry</MedlineTA><NlmUniqueID>0372435</NlmUniqueID><ISSNLinking>0003-990X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Arch Gen Psychiatry. 2011 May;68(5):466</RefSource><Note>Ignacio, Rosalindo [corrected to Ignacio, Rosalinda V]</Note></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D016907" MajorTopicYN="N">Adverse Drug Reaction Reporting Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016001" MajorTopicYN="N">Confidence Intervals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004348" MajorTopicYN="N">Drug Labeling</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004363" MajorTopicYN="N">Drug Utilization</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014486" MajorTopicYN="N">United States Food and Drug Administration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014728" MajorTopicYN="N">Veterans</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21300946</ArticleId><ArticleId IdType="doi">10.1001/archgenpsychiatry.2010.200</ArticleId><ArticleId IdType="pii">68/2/190</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21300948</PMID><DateCompleted><Year>2011</Year><Month>03</Month><Day>22</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3636</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>2</Issue><PubDate><Year>2011</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Archives of general psychiatry</Title><ISOAbbreviation>Arch Gen Psychiatry</ISOAbbreviation></Journal><ArticleTitle>The role of clusterin, complement receptor 1, and phosphatidylinositol binding clathrin assembly protein in Alzheimer disease risk and cerebrospinal fluid biomarker levels.</ArticleTitle><Pagination><StartPage>207</StartPage><EndPage>213</EndPage><MedlinePgn>207-13</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/archgenpsychiatry.2010.196</ELocationID><Abstract><AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">Two recent and simultaneously published genome-wide association studies independently implicated clusterin (CLU), complement receptor 1 (CR1), and phosphatidylinositol binding clathrin assembly protein (PICALM) as putative novel Alzheimer disease (AD) risk loci. Despite their strong statistical support, all 3 signals emerged from heterogeneous case-control populations and lack replication in different settings.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine whether genetic variants in CLU, CR1, and PICALM confer risk for AD in independent data sets (n = 4254) and to test the impact of these markers on cerebrospinal fluid (CSF)-A&#x3b2;42 and total-tau protein levels (n = 425).</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Genetic association study using family-based and case-control designs.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Ambulatory or hospitalized care.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Family samples originate from mostly multiplex pedigrees recruited at different centers in the United States (1245 families, 2654 individuals with AD, and 1175 unaffected relatives). Unrelated case-control subjects originate from 1 clinical center in Germany (214 individuals with AD and 211 controls). All subjects were of European descent.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">The association between 5 genetic variants in CLU, CR1, and PICALM and risk for AD, and the correlation between these 5 genetic variants and CSF-A&#x3b2;42 and tau levels.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">All 3 investigated loci showed significant associations between risk for AD (1-tailed P values ranging from &lt;.001 to .02) and consistent effect sizes and direction. For each locus, the overall evidence of association was substantially strengthened on meta-analysis of all available data (2-tailed P values ranging from 1.1 &#xd7; 10(-16) to 4.1 &#xd7; 10&#x207b;&#x2077;). Of all markers tested, only rs541458 in PICALM was shown to have an effect on CSF protein levels, suggesting that the AD risk allele is associated with decreased CSF A&#x3b2;42 levels (2-tailed P = .002).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study provides compelling independent evidence that genetic variants in CLU, CR1, and PICALM are genetically associated with risk for AD. Furthermore, the CSF biomarker analyses provide a first insight into the potentially predominant pathogenetic mechanism(s) underlying the association between AD risk and PICALM.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schjeide</LastName><ForeName>Brit-Maren M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Department Vertebrate Genomics, Max Planck Institute for Molecular Genetics, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schnack</LastName><ForeName>Cathrin</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Lambert</LastName><ForeName>Jean-Charles</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Lill</LastName><ForeName>Christina M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Kirchheiner</LastName><ForeName>Julia</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Tumani</LastName><ForeName>Hayrettin</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Otto</LastName><ForeName>Markus</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Tanzi</LastName><ForeName>Rudolph E</ForeName><Initials>RE</Initials></Author><Author ValidYN="Y"><LastName>Lehrach</LastName><ForeName>Hans</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Amouyel</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>von Arnim</LastName><ForeName>Christine A F</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Bertram</LastName><ForeName>Lars</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Gen Psychiatry</MedlineTA><NlmUniqueID>0372435</NlmUniqueID><ISSNLinking>0003-990X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C495242">CLU protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051152">Clusterin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034041">Monomeric Clathrin Assembly Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C439003">PICALM protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011951">Receptors, Complement</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051152" MajorTopicYN="N">Clusterin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006580" MajorTopicYN="N">Genetic Carrier Screening</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056426" MajorTopicYN="N">Genetic Loci</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N">Germany</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034041" MajorTopicYN="N">Monomeric Clathrin Assembly Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011951" MajorTopicYN="N">Receptors, Complement</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013223" MajorTopicYN="N">Statistics as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21300948</ArticleId><ArticleId IdType="doi">10.1001/archgenpsychiatry.2010.196</ArticleId><ArticleId IdType="pii">68/2/207</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21307267</PMID><DateCompleted><Year>2011</Year><Month>03</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>6</Issue><PubDate><Year>2011</Year><Month>Feb</Month><Day>09</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Inhibition of amyloid-beta (Abeta) peptide-binding alcohol dehydrogenase-Abeta interaction reduces Abeta accumulation and improves mitochondrial function in a mouse model of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>2313</StartPage><EndPage>2320</EndPage><MedlinePgn>2313-20</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.4717-10.2011</ELocationID><Abstract><AbstractText>Amyloid-&#x3b2; (A&#x3b2;) peptide-binding alcohol dehydrogenase (ABAD), an enzyme present in neuronal mitochondria, exacerbates A&#x3b2;-induced cell stress. The interaction of ABAD with A&#x3b2; exacerbates A&#x3b2;-induced mitochondrial and neuronal dysfunction. Here, we show that inhibition of the ABAD-A&#x3b2; interaction, using a decoy peptide (DP) in vitro and in vivo, protects against aberrant mitochondrial and neuronal function and improves spatial learning/memory. Intraperitoneal administration of ABAD-DP [fused to the transduction of human immunodeficiency virus 1-transactivator (Tat) protein and linked to the mitochondrial targeting sequence (Mito) (TAT-mito-DP) to transgenic APP mice (Tg mAPP)] blocked formation of ABAD-A&#x3b2; complex in mitochondria, increased oxygen consumption and enzyme activity associated with the mitochondrial respiratory chain, attenuated mitochondrial oxidative stress, and improved spatial memory. Similar protective effects were observed in Tg mAPP mice overexpressing neuronal ABAD decoy peptide (Tg mAPP/mito-ABAD). Notably, inhibition of the ABAD-A&#x3b2; interaction significantly reduced mitochondrial A&#x3b2; accumulation. In parallel, the activity of mitochondrial A&#x3b2;-degrading enzyme PreP (presequence peptidase) was enhanced in Tg mAPP mitochondria expressing the ABAD decoy peptide. These data indicate that segregating ABAD from A&#x3b2; protects mitochondria/neurons from A&#x3b2; toxicity; thus, ABAD-A&#x3b2; interaction is an important mechanism underlying A&#x3b2;-mediated mitochondrial and neuronal perturbation. Inhibitors of ABAD-A&#x3b2; interaction may hold promise as targets for the prevention and treatment of Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pathology, Taub Institute for Research on Alzheimer Disease and the Aging Brain, Columbia University, New York, New York 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Heng</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Shiqiang</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Fang</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Chaodong</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Lue</LastName><ForeName>Lih-Fen</ForeName><Initials>LF</Initials></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Lan</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Doris</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Stern</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Gunn Moore</LastName><ForeName>Frank J</ForeName><Initials>FJ</Initials></Author><Author ValidYN="Y"><LastName>Xi Chen</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Arancio</LastName><ForeName>Ottavio</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Shirley ShiDu</ForeName><Initials>SS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG017490</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG037319</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01AG17490</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG037319</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058851">GPI-Linked Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.1.1.-</RegistryNumber><NameOfSubstance UI="D015094">3-Hydroxyacyl CoA Dehydrogenases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.1.1.35</RegistryNumber><NameOfSubstance UI="C108634">HSD17B10 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.9.3.1</RegistryNumber><NameOfSubstance UI="D003576">Electron Transport Complex IV</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.1.7</RegistryNumber><NameOfSubstance UI="D000110">Acetylcholinesterase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.1.7</RegistryNumber><NameOfSubstance UI="C548246">Ache protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 7.1.1.8</RegistryNumber><NameOfSubstance UI="D014450">Electron Transport Complex III</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015094" MajorTopicYN="N">3-Hydroxyacyl CoA Dehydrogenases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000110" MajorTopicYN="N">Acetylcholinesterase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014450" MajorTopicYN="N">Electron Transport Complex III</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003576" MajorTopicYN="N">Electron Transport Complex IV</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058851" MajorTopicYN="N">GPI-Linked Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047468" MajorTopicYN="N">Immunoprecipitation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013028" MajorTopicYN="N">Space Perception</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>8</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21307267</ArticleId><ArticleId IdType="mid">NIHMS378253</ArticleId><ArticleId IdType="pmc">PMC3381884</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.4717-10.2011</ArticleId><ArticleId IdType="pii">31/6/2313</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aarts M, Liu Y, Liu L, Besshoh S, Arundine M, Gurd JW, Wang YT, Salter MW, Tymianski M. Treatment of ischemic brain damage by perturbing NMDA receptor-PSD-95 protein interactions. Science. 2002;298:846&#x2013;850.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399596</ArticleId></ArticleIdList></Reference><Reference><Citation>Arancio O, Zhang HP, Chen X, Lin C, Trinchese F, Puzzo D, Liu S, Hegde A, Yan SF, Stern A, Luddy JS, Lue LF, Walker DG, Roher A, Buttini M, Mucke L, Li W, Schmidt AM, Kindy M, Hyslop PA, et al. RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J. 2004;23:4096&#x2013;4105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC524347</ArticleId><ArticleId IdType="pubmed">15457210</ArticleId></ArticleIdList></Reference><Reference><Citation>Beal MF. Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment. J Bioenerg Biomembr. 2004;36:381&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pubmed">15377876</ArticleId></ArticleIdList></Reference><Reference><Citation>Birch-Machin MA, Turnbull DM. Assaying mitochondrial respiratory complex activity in mitochondria isolated from human cells and tissues. Methods Cell Biol. 2001;65:97&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">11381612</ArticleId></ArticleIdList></Reference><Reference><Citation>Blass JP. The mitochondrial spiral. An adequate cause of dementia in the Alzheimer's syndrome. Ann N Y Acad Sci. 2000;924:170&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pubmed">11193795</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosetti F, Brizzi F, Barogi S, Mancuso M, Siciliano G, Tendi EA, Murri L, Rapoport SI, Solaini G. Cytochrome c oxidase and mitochondrial F1F0-ATPase (ATP synthase) activities in platelets and brain from patients with Alzheimer's disease. Neurobiol Aging. 2002;23:371&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pubmed">11959398</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao G, Pei W, Ge H, Liang Q, Luo Y, Sharp FR, Lu A, Ran R, Graham SH, Chen J. In vivo delivery of a Bcl-xL fusion protein containing the TAT protein transduction domain protects against ischemic brain injury and neuronal apoptosis. J Neurosci. 2002;22:5423&#x2013;5431.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758230</ArticleId><ArticleId IdType="pubmed">12097494</ArticleId></ArticleIdList></Reference><Reference><Citation>Caspersen C, Wang N, Yao J, Sosunov A, Chen X, Lustbader JW, Xu HW, Stern D, McKhann G, Yan SD. Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. FASEB J. 2005;19:2040&#x2013;2041.</Citation><ArticleIdList><ArticleId IdType="pubmed">16210396</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaney MO, Stine WB, Kokjohn TA, Kuo YM, Esh C, Rahman A, Luehrs DC, Schmidt AM, Stern D, Yan SD, Roher AE. RAGE and amyloid beta interactions: atomic force microscopy and molecular modeling. Biochim Biophys Acta. 2005;1741:199&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">15882940</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen JX, Yan SD. Amyloid-beta-induced mitochondrial dysfunction. J Alzheimers Dis. 2007;12:177&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3687350</ArticleId><ArticleId IdType="pubmed">17917162</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis RE, Miller S, Herrnstadt C, Ghosh SS, Fahy E, Shinobu LA, Galasko D, Thal LJ, Beal MF, Howell N, Parker WD., JR Mutations in mitochondrial cytochrome c oxidase genes segregate with late-onset Alzheimer disease. Proc Natl Acad Sci U S A. 1997;94:4526&#x2013;4531.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC20756</ArticleId><ArticleId IdType="pubmed">9114023</ArticleId></ArticleIdList></Reference><Reference><Citation>Devi L, Prabhu BM, Galati DF, Avadhani NG, Anandatheerthavarada HK. Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer's disease brain is associated with mitochondrial dysfunction. J Neurosci. 2006;26:9057&#x2013;9068.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675337</ArticleId><ArticleId IdType="pubmed">16943564</ArticleId></ArticleIdList></Reference><Reference><Citation>Du H, Guo L, Fang F, Chen D, Sosunov AA, McKhann GM, Yan Y, Wang C, Zhang H, Molkentin JD, Gunn-Moore FJ, Vonsattel JP, Arancio O, Chen JX, Yan SD. Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. Nat Med. 2008;14:1097&#x2013;1105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2789841</ArticleId><ArticleId IdType="pubmed">18806802</ArticleId></ArticleIdList></Reference><Reference><Citation>Du H, Guo L, Zhang W, Rydzewska M, Yan S. Cyclophilin D deficiency improves mitochondrial function and learning/memory in aging Alzheimer disease mouse model. Neurobiology Aging. 2009 Advance online publication. doi: 10.1016/j.neurobiolaging.2009.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2009.03.003</ArticleId><ArticleId IdType="pmc">PMC3304024</ArticleId><ArticleId IdType="pubmed">19362755</ArticleId></ArticleIdList></Reference><Reference><Citation>Falkevall A, Alikhani N, Bhushan S, Pavlov PF, Busch K, Johnson KA, Eneqvist T, Tjernberg L, Ankarcrona M, Glaser E. Degradation of the amyloid beta-protein by the novel mitochondrial peptidasome, PreP. J Biol Chem. 2006;281:29096&#x2013;29104.</Citation><ArticleIdList><ArticleId IdType="pubmed">16849325</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang F, Flegler AJ, Du P, Lin S, Clevenger CV. Expression of cyclophilin B is associated with malignant progression and regulation of genes implicated in the pathogenesis of breast cancer. Am J Pathol. 2009;174:297&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2631342</ArticleId><ArticleId IdType="pubmed">19056847</ArticleId></ArticleIdList></Reference><Reference><Citation>Floyd RA, Hensley K. Oxidative stress in brain aging. Implications for therapeutics of neurodegenerative diseases. Neurobiol Aging. 2002;23:795&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pubmed">12392783</ArticleId></ArticleIdList></Reference><Reference><Citation>Geula C. Abnormalities of neural circuitry in Alzheimer's disease: hippocampus and cortical cholinergic innervation. Neurology. 1998;51(Suppl 1):S18&#x2013;S29.</Citation><ArticleIdList><ArticleId IdType="pubmed">9674759</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson Petersen CA, Alikhani N, Behbahani H, Wiehager B, Pavlov PF, Alafuzoff I, Leinonen V, Ito A, Winblad B, Glaser E, Ankarcrona M. The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. Proc Natl Acad Sci U S A. 2008;105:13145&#x2013;13150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2527349</ArticleId><ArticleId IdType="pubmed">18757748</ArticleId></ArticleIdList></Reference><Reference><Citation>He XY, Wen GY, Merz G, Lin D, Yang YZ, Mehta P, Schulz H, Yang SY. Abundant type 10 17 beta-hydroxysteroid dehydrogenase in the hippocampus of mouse Alzheimer's disease model. Brain Res Mol Brain Res. 2002;99:46&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">11869808</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, Johnson AB, Kress Y, Vinters HV, Tabaton M, Shimohama S, Cash AD, Siedlak SL, Harris PL, Jones PK, Petersen RB, Perry G, Smith MA. Mitochondrial abnormalities in Alzheimer's disease. J Neurosci. 2001;21:3017&#x2013;3023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762571</ArticleId><ArticleId IdType="pubmed">11312286</ArticleId></ArticleIdList></Reference><Reference><Citation>Humphries KM, Szweda LI. Selective inactivation of alpha-ketoglutarate dehydrogenase and pyruvate dehydrogenase: reaction of lipoic acid with 4-hydroxy-2-nonenal. Biochemistry. 1998;37:15835&#x2013;15841.</Citation><ArticleIdList><ArticleId IdType="pubmed">9843389</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin MT, Beal MF. Alzheimer's APP mangles mitochondria. Nat Med. 2006;12:1241&#x2013;1243.</Citation><ArticleIdList><ArticleId IdType="pubmed">17088888</ArticleId></ArticleIdList></Reference><Reference><Citation>Lissy NA, Davis PK, Irwin M, Kaelin WG, Dowdy SF. A common E2F-1 and p73 pathway mediates cell death induced by TCR activation. Nature. 2000;407:642&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pubmed">11034214</ArticleId></ArticleIdList></Reference><Reference><Citation>Lustbader JW, Cirilli M, Lin C, Xu HW, Takuma K, Wang N, Caspersen C, Chen X, Pollak S, Chaney M, Trinchese F, Liu S, Gunn-Moore F, Lue LF, Walker DG, Kuppusamy P, Zewier ZL, Arancio O, Stern D, Yan SS, et al. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science. 2004;304:448&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">15087549</ArticleId></ArticleIdList></Reference><Reference><Citation>Manczak M, Anekonda TS, Henson E, Park BS, Quinn J, Reddy PH. Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet. 2006;15:1437&#x2013;1449.</Citation><ArticleIdList><ArticleId IdType="pubmed">16551656</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurer I, Zierz S, M&#xf6;ller HJ. A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients. Neurobiol Aging. 2000;21:455&#x2013;462.</Citation><ArticleIdList><ArticleId IdType="pubmed">10858595</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci. 2000;20:4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami K, Kondo T, Kawase M, Li Y, Sato S, Chen SF, Chan PH. Mitochondrial susceptibility to oxidative stress exacerbates cerebral infarction that follows permanent focal cerebral ischemia in mutant mice with manganese superoxide dismutase deficiency. J Neurosci. 1998;18:205&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793388</ArticleId><ArticleId IdType="pubmed">9412501</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren Y, Xu HW, Davey F, Taylor M, Aiton J, Coote P, Fang F, Yao J, Chen D, Chen JX, Yan SD, Gunn-Moore FJ. Endophilin I expression is increased in the brains of Alzheimer disease patients. J Biol Chem. 2008;283:5685&#x2013;5691.</Citation><ArticleIdList><ArticleId IdType="pubmed">18167351</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheehan JP, Swerdlow RH, Miller SW, Davis RE, Parks JK, Parker WD, Tuttle JB. Calcium homeostasis and reactive oxygen species production in cells transformed by mitochondria from individuals with sporadic Alzheimer's disease. J Neurosci. 1997;17:4612&#x2013;4622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573324</ArticleId><ArticleId IdType="pubmed">9169522</ArticleId></ArticleIdList></Reference><Reference><Citation>Shukkur EA, Shimohata A, Akagi T, Yu W, Yamaguchi M, Murayama M, Chui D, Takeuchi T, Amano K, Subramhanya KH, Hashikawa T, Sago H, Epstein CJ, Takashima A, Yamakawa K. Mitochondrial dysfunction and tau hyperphosphorylation in Ts1Cje, a mouse model for Down syndrome. Hum Mol Genet. 2006;15:2752&#x2013;2762.</Citation><ArticleIdList><ArticleId IdType="pubmed">16891409</ArticleId></ArticleIdList></Reference><Reference><Citation>Takuma K, Yao J, Huang J, Xu H, Chen X, Luddy J, Trillat AC, Stern DM, Arancio O, Yan SS. ABAD enhances Abeta-induced cell stress via mitochondrial dysfunction. FASEB J. 2005;19:597&#x2013;598.</Citation><ArticleIdList><ArticleId IdType="pubmed">15665036</ArticleId></ArticleIdList></Reference><Reference><Citation>Wadia JS, Dowdy SF. Protein transduction technology. Curr Opin Biotechnol. 2002;13:52&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">11849958</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan SD, Stern DM. Mitochondrial dysfunction and Alzheimer's disease: role of amyloid-beta peptide alcohol dehydrogenase (ABAD) Int J Exp Pathol. 2005;86:161&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2517415</ArticleId><ArticleId IdType="pubmed">15910550</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan SD, Fu J, Soto C, Chen X, Zhu H, Al-Mohanna F, Collison K, Zhu A, Stern E, Saido T, Tohyama M, Ogawa S, Roher A, Stern D. An intracellular protein that binds amyloid-beta peptide and mediates neurotoxicity in Alzheimer's disease. Nature. 1997;389:689&#x2013;695.</Citation><ArticleIdList><ArticleId IdType="pubmed">9338779</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan SD, Shi Y, Zhu A, Fu J, Zhu H, Zhu Y, Gibson L, Stern E, Collison K, Al-Mohanna F, Ogawa S, Roher A, Clarke SG, Stern DM. Role of ERAB/L-3-hydroxyacyl-coenzyme A dehydrogenase type II activity in Abeta-induced cytotoxicity. J Biol Chem. 1999;274:2145&#x2013;2156.</Citation><ArticleIdList><ArticleId IdType="pubmed">9890977</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan SD, Xiong WC, Stern DM. Mitochondrial amyloid-beta peptide: pathogenesis or late-phase development? J Alzheimers Dis. 2006;9:127&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">16873960</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao J, Taylor M, Davey F, Ren Y, Aiton J, Coote P, Fang F, Chen JX, Yan SD, Gunn-Moore FJ. Interaction of amyloid binding alcohol dehydrogenase/Abeta mediates up-regulation of peroxiredoxin II in the brains of Alzheimer's disease patients and a transgenic Alzheimer's disease mouse model. Mol Cell Neurosci. 2007;35:377&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pubmed">17490890</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao J, Irwin RW, Zhao L, Nilsen J, Hamilton RT, Brinton RD. Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2009;106:14670&#x2013;14675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2732886</ArticleId><ArticleId IdType="pubmed">19667196</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao J, Hamilton RT, Cadenas E, Brinton RD. Decline in mitochondrial bioenergetics and shift to ketogenic profile in brain during reproductive senescence. Biochim Biophys Acta. 2010;1800:1121&#x2013;1126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200365</ArticleId><ArticleId IdType="pubmed">20538040</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21307265</PMID><DateCompleted><Year>2011</Year><Month>03</Month><Day>25</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>6</Issue><PubDate><Year>2011</Year><Month>Feb</Month><Day>09</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>p75NTR regulates Abeta deposition by increasing Abeta production but inhibiting Abeta aggregation with its extracellular domain.</ArticleTitle><Pagination><StartPage>2292</StartPage><EndPage>2304</EndPage><MedlinePgn>2292-304</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.2733-10.2011</ELocationID><Abstract><AbstractText>Accumulation of toxic amyloid-&#x3b2; (A&#x3b2;) in the cerebral cortex and hippocampus is a major pathological feature of Alzheimer's disease (AD). The neurotrophin receptor p75NTR has been proposed to mediate A&#x3b2;-induced neurotoxicity; however, its role in the development of AD remains to be clarified. The p75NTR/ExonIII-/- mice and APPSwe/PS1dE9 mice were crossed to generate transgenic AD mice with deletion of p75NTR gene. In APPSwe/PS1dE9 transgenic mice, p75NTR expression was localized in the basal forebrain neurons and degenerative neurites in neocortex, increased with aging, and further activated by A&#x3b2; accumulation. Deletion of the p75NTR gene in APPSwe/PS1dE9 mice reduced soluble A&#x3b2; levels in the brain and serum, but increased the accumulation of insoluble A&#x3b2; and A&#x3b2; plaque formation. There was no change in the levels of amyloid precursor protein (APP) and its proteolytic derivatives, or &#x3b1;-, &#x3b2;-, and &#x3b3;-secretase activities, or in levels of BACE1, neprilysin (NEP), and insulin-degrading enzyme (IDE) proteins. A&#x3b2; production by cortical neurons of APPSwe/PS1dE9 mice was reduced by deletion of p75NTR gene in vitro. Recombinant extracellular domain of p75NTR attenuated the oligomerization and fibrillation of synthetic A&#x3b2;(42) peptide in vitro, and reduced local A&#x3b2; plaques after hippocampus injection in vivo. In addition, deletion of p75NTR attenuated microgliosis but increased the microhemorrhage profiles in the brain. The deletion of p75NTR did not significantly change the cognitive function of the mice up to the age of 9 months. Our data suggest that p75NTR plays a critical role in regulating A&#x3b2; levels by both increasing A&#x3b2; production and attenuating its aggregation, and they caution that a therapeutic intervention simply reducing p75NTR may exacerbate AD pathology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yan-Jiang</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Department of Human Physiology and Centre for Neuroscience, Flinders University, Adelaide 5001, South Australia, Australia. yanjiang_wang@tmmu.edu.cn</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xin</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Jian-Jun</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Qiao-Xin</ForeName><Initials>QX</Initials></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Chang-Yue</ForeName><Initials>CY</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xiao-Hong</ForeName><Initials>XH</Initials></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Yin</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Miao</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Yoon</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Evin</LastName><ForeName>Genevieve</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Jin-Hua</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Masters</LastName><ForeName>Colin</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Xin-Fu</ForeName><Initials>XF</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017475">Receptors, Nerve Growth Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C517634">Ngfr protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.11</RegistryNumber><NameOfSubstance UI="D015260">Neprilysin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.56</RegistryNumber><NameOfSubstance UI="D007339">Insulysin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007339" MajorTopicYN="N">Insulysin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015260" MajorTopicYN="N">Neprilysin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017475" MajorTopicYN="N">Receptors, Nerve Growth Factor</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>8</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21307265</ArticleId><ArticleId IdType="pmc">PMC6633040</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2733-10.2011</ArticleId><ArticleId IdType="pii">31/6/2292</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ahmed Z, Mazibrada G, Seabright RJ, Dent RG, Berry M, Logan A. TACE-induced cleavage of NgR and p75NTR in dorsal root ganglion cultures disinhibits outgrowth and promotes branching of neurites in the presence of inhibitory CNS myelin. FASEB J. 2006;20:1939&#x2013;1941.</Citation><ArticleIdList><ArticleId IdType="pubmed">16849393</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett GL, Reid CA, Tsafoulis C, Zhu W, Williams DA, Paolini AG, Trieu J, Murphy M. Enhanced spatial memory and hippocampal long-term potentiation in p75 neurotrophin receptor knockout mice. Hippocampus. 2010;20:145&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pubmed">19360854</ArticleId></ArticleIdList></Reference><Reference><Citation>Bengoechea TG, Chen Z, O'Leary DA, Masliah E, Lee KF. p75 reduces beta-amyloid-induced sympathetic innervation deficits in an Alzheimer's disease mouse model. Proc Natl Acad Sci U S A. 2009;106:7870&#x2013;7875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2683130</ArticleId><ArticleId IdType="pubmed">19416837</ArticleId></ArticleIdList></Reference><Reference><Citation>Bronfman FC. Metalloproteases and gamma-secretase: new membrane partners regulating p75 neurotrophin receptor signaling? J Neurochem. 2007;103(Suppl 1):91&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">17986144</ArticleId></ArticleIdList></Reference><Reference><Citation>Buxbaum JD, Gandy SE, Cicchetti P, Ehrlich ME, Czernik AJ, Fracasso RP, Ramabhadran TV, Unterbeck AJ, Greengard P. Processing of Alzheimer beta/A4 amyloid precursor protein: modulation by agents that regulate protein phosphorylation. Proc Natl Acad Sci U S A. 1990;87:6003&#x2013;6006.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC54458</ArticleId><ArticleId IdType="pubmed">2116015</ArticleId></ArticleIdList></Reference><Reference><Citation>Capsoni S, Ugolini G, Comparini A, Ruberti F, Berardi N, Cattaneo A. Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice. Proc Natl Acad Sci U S A. 2000;97:6826&#x2013;6831.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18754</ArticleId><ArticleId IdType="pubmed">10841577</ArticleId></ArticleIdList></Reference><Reference><Citation>Capsoni S, Giannotta S, Cattaneo A. Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice. Proc Natl Acad Sci U S A. 2002;99:12432&#x2013;12437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC129462</ArticleId><ArticleId IdType="pubmed">12205295</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakravarthy B, Gaudet C, M&#xe9;nard M, Atkinson T, Brown L, Laferla FM, Armato U, Whitfield J. Amyloid-beta peptides stimulate the expression of the p75NTR neurotrophin receptor in SHSY5Y human neuroblastoma cells and AD transgenic mice. J Alzheimers Dis. 2010;19:915&#x2013;925.</Citation><ArticleIdList><ArticleId IdType="pubmed">20157247</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, Kang JE, Lee J, Stewart FR, Verges DK, Silverio LM, Bu G, Mennerick S, Holtzman DM. Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron. 2008;58:42&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2390913</ArticleId><ArticleId IdType="pubmed">18400162</ArticleId></ArticleIdList></Reference><Reference><Citation>Costantini C, Weindruch R, Della Valle G, Puglielli L. A TrkA to p75 NTR molecular switch activates amyloid beta-peptide generation during aging. Biochem J. 2005a;391:59&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1237139</ArticleId><ArticleId IdType="pubmed">15966860</ArticleId></ArticleIdList></Reference><Reference><Citation>Costantini C, Rossi F, Formaggio E, Bernardoni R, Cecconi D, Della-Bianca V. Characterization of the signaling pathway downstream p75 neurotrophin receptor involved in beta-amyloid peptide-dependent cell death. J Mol Neurosci. 2005b;25:141&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">15784962</ArticleId></ArticleIdList></Reference><Reference><Citation>Costantini C, Scrable H, Puglielli L. An aging pathway controls the TrkA to p75NTR receptor switch and amyloid beta-peptide generation. EMBO J. 2006;25:1997&#x2013;2006.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1456930</ArticleId><ArticleId IdType="pubmed">16619032</ArticleId></ArticleIdList></Reference><Reference><Citation>Coulson EJ. Does the p75 neurotrophin receptor mediate Abeta-induced toxicity in Alzheimer's disease? J Neurochem. 2006;98:654&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pubmed">16893414</ArticleId></ArticleIdList></Reference><Reference><Citation>Coulson EJ, May LM, Sykes AM, Hamlin AS. The role of the p75 neurotrophin receptor in cholinergic dysfunction in Alzheimer's disease. Neuroscientist. 2009;15:317&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pubmed">19458382</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahlgren KN, Manelli AM, Stine WB, Jr, Baker LK, Krafft GA, LaDu MJ. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem. 2002;277:32046&#x2013;32053.</Citation><ArticleIdList><ArticleId IdType="pubmed">12058030</ArticleId></ArticleIdList></Reference><Reference><Citation>Dechant G, Barde YA. The neurotrophin receptor p75(NTR): novel functions and implications for diseases of the nervous system. Nat Neurosci. 2002;5:1131&#x2013;1136.</Citation><ArticleIdList><ArticleId IdType="pubmed">12404007</ArticleId></ArticleIdList></Reference><Reference><Citation>Fombonne J, Rabizadeh S, Banwait S, Mehlen P, Bredesen DE. Selective vulnerability in Alzheimer's disease: amyloid precursor protein and p75(NTR) interaction. Ann Neurol. 2009;65:294&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3057030</ArticleId><ArticleId IdType="pubmed">19334058</ArticleId></ArticleIdList></Reference><Reference><Citation>Frick KM, Fernandez SM. Enrichment enhances spatial memory and increases synaptophysin levels in aged female mice. Neurobiol Aging. 2003;24:615&#x2013;626.</Citation><ArticleIdList><ArticleId IdType="pubmed">12714119</ArticleId></ArticleIdList></Reference><Reference><Citation>Frid P, Anisimov SV, Popovic N. Congo red and protein aggregation in neurodegenerative diseases. Brain Res Rev. 2007;53:135&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">16959325</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman WJ. Neurotrophins induce death of hippocampal neurons via the p75 receptor. J Neurosci. 2000;20:6340&#x2013;6346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772976</ArticleId><ArticleId IdType="pubmed">10964939</ArticleId></ArticleIdList></Reference><Reference><Citation>George AJ, Holsinger RM, McLean CA, Laughton KM, Beyreuther K, Evin G, Masters CL, Li QX. APP intracellular domain is increased and soluble Abeta is reduced with diet-induced hypercholesterolemia in a transgenic mouse model of Alzheimer disease. Neurobiol Dis. 2004;16:124&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">15207269</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginsberg SD, Che S, Wuu J, Counts SE, Mufson EJ. Down regulation of trk but not p75NTR gene expression in single cholinergic basal forebrain neurons mark the progression of Alzheimer's disease. J Neurochem. 2006;97:475&#x2013;487.</Citation><ArticleIdList><ArticleId IdType="pubmed">16539663</ArticleId></ArticleIdList></Reference><Reference><Citation>Gowrishankar K, Zeidler MG, Vincenz C. Release of a membrane-bound death domain by gamma-secretase processing of the p75NTR homolog NRADD. J Cell Sci. 2004;117:4099&#x2013;4111.</Citation><ArticleIdList><ArticleId IdType="pubmed">15280425</ArticleId></ArticleIdList></Reference><Reference><Citation>Greferath U, Bennie A, Kourakis A, Bartlett PF, Murphy M, Barrett GL. Enlarged cholinergic forebrain neurons and improved spatial learning in p75 knockout mice. Eur J Neurosci. 2000;12:885&#x2013;893.</Citation><ArticleIdList><ArticleId IdType="pubmed">10762318</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatchett CS, Tyler S, Armstrong D, Dawbarn D, Allen SJ. Familial Alzheimer's disease presenilin 1 mutation M146V increases gamma secretase cutting of p75NTR in vitro. Brain Res. 2007;1147:248&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pubmed">17349981</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu XY, Zhang HY, Qin S, Xu H, Swaab DF, Zhou JN. Increased p75(NTR) expression in hippocampal neurons containing hyperphosphorylated tau in Alzheimer patients. Exp Neurol. 2002;178:104&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">12460612</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber LJ, Chao MV. Mesenchymal and neuronal cell expression of the p75 neurotrophin receptor gene occur by different mechanisms. Dev Biol. 1995;167:227&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">7851645</ArticleId></ArticleIdList></Reference><Reference><Citation>Ida N, Hartmann T, Pantel J, Schr&#xf6;der J, Zerfass R, F&#xf6;rstl H, Sandbrink R, Masters CL, Beyreuther K. Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J Biol Chem. 1996;271:22908&#x2013;22914.</Citation><ArticleIdList><ArticleId IdType="pubmed">8798471</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng. 2001;17:157&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">11337275</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung KM, Tan S, Landman N, Petrova K, Murray S, Lewis R, Kim PK, Kim DS, Ryu SH, Chao MV, Kim TW. Regulated intramembrane proteolysis of the p75 neurotrophin receptor modulates its association with the TrkA receptor. J Biol Chem. 2003;278:42161&#x2013;42169.</Citation><ArticleIdList><ArticleId IdType="pubmed">12913006</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowles JK, Rajadas J, Nguyen TV, Yang T, LeMieux MC, Vander Griend L, Ishikawa C, Massa SM, Wyss-Coray T, Longo FM. The p75 neurotrophin receptor promotes amyloid-&#x3b2;(1&#x2013;42)-induced neuritic dystrophy in vitro and in vivo. J Neurosci. 2009;29:10627&#x2013;10637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2771439</ArticleId><ArticleId IdType="pubmed">19710315</ArticleId></ArticleIdList></Reference><Reference><Citation>Koliatsos VE, Applegate MD, Kn&#xfc;sel B, Junard EO, Burton LE, Mobley WC, Hefti FF, Price DL. Recombinant human nerve growth factor prevents retrograde degeneration of axotomized basal forebrain cholinergic neurons in the rat. Exp Neurol. 1991;112:161&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pubmed">2037030</ArticleId></ArticleIdList></Reference><Reference><Citation>Koo EH, Squazzo SL. Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J Biol Chem. 1994;269:17386&#x2013;17389.</Citation><ArticleIdList><ArticleId IdType="pubmed">8021238</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuner P, Schubenel R, Hertel C. Beta-amyloid binds to p75NTR and activates NFkappaB in human neuroblastoma cells. J Neurosci Res. 1998;54:798&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pubmed">9856863</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, Viola KL, Klein WL. A&#x3b2; oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci. 2007;27:796&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672917</ArticleId><ArticleId IdType="pubmed">17251419</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL. Diffusible, nonfibrillar ligands derived from Abeta1&#x2013;42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A. 1998;95:6448&#x2013;6453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee KF, Li E, Huber LJ, Landis SC, Sharpe AH, Chao MV, Jaenisch R. Targeted mutation of the gene encoding the low affinity NGF receptor p75 leads to deficits in the peripheral sensory nervous system. Cell. 1992;69:737&#x2013;749.</Citation><ArticleIdList><ArticleId IdType="pubmed">1317267</ArticleId></ArticleIdList></Reference><Reference><Citation>LeVine H., 3rd Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci. 1993;2:404&#x2013;410.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2142377</ArticleId><ArticleId IdType="pubmed">8453378</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma QL, Lim GP, Harris-White ME, Yang F, Ambegaokar SS, Ubeda OJ, Glabe CG, Teter B, Frautschy SA, Cole GM. Antibodies against beta-amyloid reduce Abeta oligomers, glycogen synthase kinase-3beta activation and tau phosphorylation in vivo and in vitro. J Neurosci Res. 2006;83:374&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">16385556</ArticleId></ArticleIdList></Reference><Reference><Citation>Malaplate-Armand C, Florent-B&#xe9;chard S, Youssef I, Koziel V, Sponne I, Kriem B, Leininger-Muller B, Olivier JL, Oster T, Pillot T. Soluble oligomers of amyloid-beta peptide induce neuronal apoptosis by activating a cPLA2-dependent sphingomyelinase-ceramide pathway. Neurobiol Dis. 2006;23:178&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">16626961</ArticleId></ArticleIdList></Reference><Reference><Citation>Markowska AL, Long JM, Johnson CT, Olton DS. Variable-interval probe test as a tool for repeated measurements of spatial memory in the water maze. Behav Neurosci. 1993;107:627&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pubmed">8397867</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagawa Y, Reed L, Nakamura M, McIntosh TK, Smith DH, Saatman KE, Raghupathi R, Clemens J, Saido TC, Lee VM, Trojanowski JQ. Brain trauma in aged transgenic mice induces regression of established abeta deposits. Exp Neurol. 2000;163:244&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pubmed">10785464</ArticleId></ArticleIdList></Reference><Reference><Citation>Naumann T, Casademunt E, Hollerbach E, Hofmann J, Dechant G, Frotscher M, Barde YA. Complete deletion of the neurotrophin receptor p75NTR leads to long-lasting increases in the number of basal forebrain cholinergic neurons. J Neurosci. 2002;22:2409&#x2013;2418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758339</ArticleId><ArticleId IdType="pubmed">11923404</ArticleId></ArticleIdList></Reference><Reference><Citation>Podlesniy P, Kichev A, Pedraza C, Saurat J, Encinas M, Perez B, Ferrer I, Espinet C. Pro-NGF from Alzheimer's disease and normal human brain displays distinctive abilities to induce processing and nuclear translocation of intracellular domain of p75NTR and apoptosis. Am J Pathol. 2006;169:119&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1698760</ArticleId><ArticleId IdType="pubmed">16816366</ArticleId></ArticleIdList></Reference><Reference><Citation>Salehi A, Ocampo M, Verhaagen J, Swaab DF. p75 neurotrophin receptor in the nucleus basalis of meynert in relation to age, sex, and Alzheimer's disease. Exp Neurol. 2000;161:245&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pubmed">10683291</ArticleId></ArticleIdList></Reference><Reference><Citation>Sotthibundhu A, Sykes AM, Fox B, Underwood CK, Thangnipon W, Coulson EJ. &#x3b2;-Amyloid1&#x2013;42 induces neuronal death through the p75 neurotrophin receptor. J Neurosci. 2008;28:3941&#x2013;3946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6670462</ArticleId><ArticleId IdType="pubmed">18400893</ArticleId></ArticleIdList></Reference><Reference><Citation>Stine WB, Jr, Dahlgren KN, Krafft GA, LaDu MJ. In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J Biol Chem. 2003;278:11612&#x2013;11622.</Citation><ArticleIdList><ArticleId IdType="pubmed">12499373</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran G, Koo EH. APP trafficking, processing and function. J Biol Chem. 2008;283:29615&#x2013;29619.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2573065</ArticleId><ArticleId IdType="pubmed">18650430</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuszynski MH, Roberts J, Senut MC U HS, Gage FH. Gene therapy in the adult primate brain: intraparenchymal grafts of cells genetically modified to produce nerve growth factor prevent cholinergic neuronal degeneration. Gene Ther. 1996;3:305&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pubmed">8732162</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuszynski MH, Smith DE, Roberts J, McKay H, Mufson E. Targeted intraparenchymal delivery of human NGF by gene transfer to the primate basal forebrain for 3 months does not accelerate beta-amyloid plaque deposition. Exp Neurol. 1998;154:573&#x2013;582.</Citation><ArticleIdList><ArticleId IdType="pubmed">9878192</ArticleId></ArticleIdList></Reference><Reference><Citation>Volosin M, Trotter C, Cragnolini A, Kenchappa RS, Light M, Hempstead BL, Carter BD, Friedman WJ. Induction of proneurotrophins and activation of p75NTR-mediated apoptosis via neurotrophin receptor-interacting factor in hippocampal neurons after seizures. J Neurosci. 2008;28:9870&#x2013;9879.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2578816</ArticleId><ArticleId IdType="pubmed">18815271</ArticleId></ArticleIdList></Reference><Reference><Citation>von Schack D, Casademunt E, Schweigreiter R, Meyer M, Bibel M, Dechant G. Complete ablation of the neurotrophin receptor p75NTR causes defects both in the nervous and the vascular system. Nat Neurosci. 2001;4:977&#x2013;978.</Citation><ArticleIdList><ArticleId IdType="pubmed">11559852</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YJ, Zhou HD, Zhou XF. Clearance of amyloid-beta in Alzheimer's disease: progress, problems and perspectives. Drug Discov Today. 2006a;11:931&#x2013;938.</Citation><ArticleIdList><ArticleId IdType="pubmed">16997144</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YJ, Pollard AN, Zhou HD, Zhong JH, Zhou XF. Proceedings of the Australian Neuroscience Society. Sydney: Australian Neuroscience Society; 2006b. Characterization of an Alzheimer's disease mouse model bearing mutant genes of amyloid precursor protein and human presenilin; p. 150.</Citation></Reference><Reference><Citation>Wang YJ, Pollard A, Zhong JH, Dong XY, Wu XB, Zhou HD, Zhou XF. Intramuscular delivery of a single chain antibody gene reduces brain Abeta burden in a mouse model of Alzheimer's disease. Neurobiol Aging. 2009a;30:364&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pubmed">17686552</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YJ, Thomas P, Zhong JH, Bi FF, Kosaraju S, Pollard A, Fenech M, Zhou XF. Consumption of grape seed extract prevents amyloid-beta deposition and attenuates inflammation in brain of an Alzheimer's disease mouse. Neurotox Res. 2009b;15:3&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">19384583</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YJ, Zhou HD, Zhou XF. Modified immunotherapies against Alzheimer's disease: toward safer and effective amyloid-beta clearance. J Alzheimers Dis. 2010a;21:1065&#x2013;1075.</Citation><ArticleIdList><ArticleId IdType="pubmed">21504118</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YJ, Gao CY, Yang M, Liu XH, Sun Y, Pollard A, Dong XY, Wu XB, Zhong JH, Zhou HD, Zhou XF. Intramuscular delivery of a single chain antibody gene prevents brain Abeta deposition and cognitive impairment in a mouse model of Alzheimer's disease. Brain Behav Immun. 2010b;24:1281&#x2013;1293.</Citation><ArticleIdList><ArticleId IdType="pubmed">20595065</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YJ, Valadares D, Sun Y, Wang X, Zhong JH, Liu XH, Majd S, Chen L, Gao CY, Chen S, Lim Y, Pollard A, Aguilar E, Gai WP, Yang M, Zhou XF. Effects of proNGF on neuronal viability, neurite growth and amyloid-beta metabolism. Neurotox Res. 2010c;17:257&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pubmed">19680737</ArticleId></ArticleIdList></Reference><Reference><Citation>Weskamp G, Schl&#xf6;ndorff J, Lum L, Becherer JD, Kim TW, Saftig P, Hartmann D, Murphy G, Blobel CP. Evidence for a critical role of the tumor necrosis factor alpha convertase (TACE) in ectodomain shedding of the p75 neurotrophin receptor (p75NTR) J Biol Chem. 2004;279:4241&#x2013;4249.</Citation><ArticleIdList><ArticleId IdType="pubmed">14638693</ArticleId></ArticleIdList></Reference><Reference><Citation>Woo NH, Teng HK, Siao CJ, Chiaruttini C, Pang PT, Milner TA, Hempstead BL, Lu B. Activation of p75NTR by proBDNF facilitates hippocampal long-term depression. Nat Neurosci. 2005;8:1069&#x2013;1077.</Citation><ArticleIdList><ArticleId IdType="pubmed">16025106</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaar M, Zhai S, Pilch PF, Doyle SM, Eisenhauer PB, Fine RE, Gilchrest BA. Binding of beta-amyloid to the p75 neurotrophin receptor induces apoptosis. A possible mechanism for Alzheimer's disease. J Clin Invest. 1997;100:2333&#x2013;2340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC508430</ArticleId><ArticleId IdType="pubmed">9410912</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaar M, Zhai S, Fine RE, Eisenhauer PB, Arble BL, Stewart KB, Gilchrest BA. Amyloid beta binds trimers as well as monomers of the 75-kDa neurotrophin receptor and activates receptor signaling. J Biol Chem. 2002;277:7720&#x2013;7725.</Citation><ArticleIdList><ArticleId IdType="pubmed">11756426</ArticleId></ArticleIdList></Reference><Reference><Citation>Yau JL, McNair KM, Noble J, Brownstein D, Hibberd C, Morton N, Mullins JJ, Morris RG, Cobb S, Seckl JR. Enhanced hippocampal long-term potentiation and spatial learning in aged 11&#x3b2;-hydroxysteroid dehydrogenase type 1 knock-out mice. J Neurosci. 2007;27:10487&#x2013;10496.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673151</ArticleId><ArticleId IdType="pubmed">17898220</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeo TT, Chua-Couzens J, Butcher LL, Bredesen DE, Cooper JD, Valletta JS, Mobley WC, Longo FM. Absence of p75NTR causes increased basal forebrain cholinergic neuron size, choline acetyltransferase activity, and target innervation. J Neurosci. 1997;17:7594&#x2013;7605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793892</ArticleId><ArticleId IdType="pubmed">9315882</ArticleId></ArticleIdList></Reference><Reference><Citation>Zampieri N, Xu CF, Neubert TA, Chao MV. Cleavage of p75 neurotrophin receptor by alpha-secretase and gamma-secretase requires specific receptor domains. J Biol Chem. 2005;280:14563&#x2013;14571.</Citation><ArticleIdList><ArticleId IdType="pubmed">15701642</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Hong Y, Bounhar Y, Blacker M, Roucou X, Tounekti O, Vereker E, Bowers WJ, Federoff HJ, Goodyer CG, LeBlanc A. p75 neurotrophin receptor protects primary cultures of human neurons against extracellular amyloid &#x3b2; peptide cytotoxicity. J Neurosci. 2003;23:7385&#x2013;7394.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740455</ArticleId><ArticleId IdType="pubmed">12917374</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21320988</PMID><DateCompleted><Year>2011</Year><Month>04</Month><Day>13</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3687</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>2</Issue><PubDate><Year>2011</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Hearing loss and incident dementia.</ArticleTitle><Pagination><StartPage>214</StartPage><EndPage>220</EndPage><MedlinePgn>214-20</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/archneurol.2010.362</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine whether hearing loss is associated with incident all-cause dementia and Alzheimer disease (AD).</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Prospective study of 639 individuals who underwent audiometric testing and were dementia free in 1990 to 1994. Hearing loss was defined by a pure-tone average of hearing thresholds at 0.5, 1, 2, and 4 kHz in the better-hearing ear (normal, &lt;25 dB [n = 455]; mild loss, 25-40 dB [n = 125]; moderate loss, 41-70 dB [n = 53]; and severe loss, &gt;70 dB [n = 6]). Diagnosis of incident dementia was made by consensus diagnostic conference. Cox proportional hazards models were used to model time to incident dementia according to severity of hearing loss and were adjusted for age, sex, race, education, diabetes mellitus, smoking, and hypertension.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Baltimore Longitudinal Study of Aging.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Six hundred thirty-nine individuals aged 36 to 90 years.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURE" NlmCategory="METHODS">Incident cases of all-cause dementia and AD until May 31, 2008.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">During a median follow-up of 11.9 years, 58 cases of incident all-cause dementia were diagnosed, of which 37 cases were AD. The risk of incident all-cause dementia increased log linearly with the severity of baseline hearing loss (1.27 per 10-dB loss; 95% confidence interval, 1.06-1.50). Compared with normal hearing, the hazard ratio (95% confidence interval) for incident all-cause dementia was 1.89 (1.00-3.58) for mild hearing loss, 3.00 (1.43-6.30) for moderate hearing loss, and 4.94 (1.09-22.40) for severe hearing loss. The risk of incident AD also increased with baseline hearing loss (1.20 per 10 dB of hearing loss) but with a wider confidence interval (0.94-1.53).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Hearing loss is independently associated with incident all-cause dementia. Whether hearing loss is a marker for early-stage dementia or is actually a modifiable risk factor for dementia deserves further study.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Frank R</ForeName><Initials>FR</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, The Johns Hopkins School of Medicine, JHOC 6120, 601 N Caroline St, Baltimore, MD 21287, USA. flin1@jhmi.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Metter</LastName><ForeName>E Jeffrey</ForeName><Initials>EJ</Initials></Author><Author ValidYN="Y"><LastName>O'Brien</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Resnick</LastName><ForeName>Susan M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Zonderman</LastName><ForeName>Alan B</ForeName><Initials>AB</Initials></Author><Author ValidYN="Y"><LastName>Ferrucci</LastName><ForeName>Luigi</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>ZIA AG000185</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 DC011279</GrantID><Acronym>DC</Acronym><Agency>NIDCD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1K23DC011279-01</GrantID><Acronym>DC</Acronym><Agency>NIDCD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>Z01 AG000015</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R99 AG999999</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>Z99 AG999999</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001299" MajorTopicYN="N">Audiometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015142" MajorTopicYN="N" Type="Geographic">Baltimore</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016001" MajorTopicYN="N">Confidence Intervals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034381" MajorTopicYN="N">Hearing Loss</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>2</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21320988</ArticleId><ArticleId IdType="mid">NIHMS336097</ArticleId><ArticleId IdType="pmc">PMC3277836</ArticleId><ArticleId IdType="doi">10.1001/archneurol.2010.362</ArticleId><ArticleId IdType="pii">68/2/214</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366:2112&#x2013;2117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2850264</ArticleId><ArticleId IdType="pubmed">16360788</ArticleId></ArticleIdList></Reference><Reference><Citation>Prince M, Jackson J, editors. Alzheimer&#x2019;s Disease International. World Alzheimer Report 2009. 2009.</Citation></Reference><Reference><Citation>Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer&#x2019;s disease. Alzheimers Dement. 2007;3:186&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pubmed">19595937</ArticleId></ArticleIdList></Reference><Reference><Citation>Coley N, Andrieu S, Gardette V, et al. Dementia prevention: methodological explanations for inconsistent results. Epidemiol Rev. 2008;30:35&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">18779228</ArticleId></ArticleIdList></Reference><Reference><Citation>Uhlmann RF, Larson EB, Rees TS, Koepsell TD, Duckert LG. Relationship of hearing impairment to dementia and cognitive dysfunction in older adults. JAMA. 1989;261:1916&#x2013;1919.</Citation><ArticleIdList><ArticleId IdType="pubmed">2926927</ArticleId></ArticleIdList></Reference><Reference><Citation>Ives DG, Bonino P, Traven ND, Kuller LH. Characteristics and comorbidities of rural older adults with hearing impairment. J Am Geriatr Soc. 1995;43:803&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pubmed">7602037</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal Y, Platz EA, Niparko JK. Prevalence of hearing loss and differences by demographic characteristics among US adults: data from the National Health and Nutrition Examination Survey, 1999-2004. Arch Intern Med. 2008;168:1522&#x2013;1530.</Citation><ArticleIdList><ArticleId IdType="pubmed">18663164</ArticleId></ArticleIdList></Reference><Reference><Citation>Shock N, Greulich R, Andres R, et al. Normal human aging: the Baltimore Longitudinal Study of Aging. US Government Printing Office; Washington, D.C.: 1984. NIH Publication 84-2450.</Citation></Reference><Reference><Citation>Kawas C, Gray S, Brookmeyer R, Fozard J, Zonderman A. Age-specific incidence rates of Alzheimer&#x2019;s disease: the Baltimore Longitudinal Study of Aging. Neurology. 2000;54:2072&#x2013;2077.</Citation><ArticleIdList><ArticleId IdType="pubmed">10851365</ArticleId></ArticleIdList></Reference><Reference><Citation>APA . Diagnostic and statistical manual of mental disorders. 3rd ed American Psychiatric Assoiciation; Washington, D.C.: 1987.</Citation></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">10190820</ArticleId></ArticleIdList></Reference><Reference><Citation>Therneau T, Grambsch P. Modeling Survival Data: Extending the Cox Model. Springer; New York: 2000.</Citation></Reference><Reference><Citation>Northridge ME. Public health methods--attributable risk as a link between causality and public health action. Am J Public Health. 1995;85:1202&#x2013;1204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1615585</ArticleId><ArticleId IdType="pubmed">7661224</ArticleId></ArticleIdList></Reference><Reference><Citation>Cacciatore F, Napoli C, Abete P, Marciano E, Triassi M, Rengo F. Quality of life determinants and hearing function in an elderly population: Osservatorio Geriatrico Campano Study Group. Gerontology. 1999;45:323&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pubmed">10559650</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters CA, Potter JF, Scholer SG. Hearing impairment as a predictor of cognitive decline in dementia. J Am Geriatr Soc. 1988;36:981&#x2013;986.</Citation><ArticleIdList><ArticleId IdType="pubmed">3171050</ArticleId></ArticleIdList></Reference><Reference><Citation>Uhlmann RF, Larson EB, Koepsell TD. Hearing impairment and cognitive decline in senile dementia of the Alzheimer&#x2019;s type. J Am Geriatr Soc. 1986;34:207&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">3950288</ArticleId></ArticleIdList></Reference><Reference><Citation>Gennis V, Garry PJ, Haaland KY, Yeo RA, Goodwin JS. Hearing and cognition in the elderly. New findings and a review of the literature. Arch Intern Med. 1991;151:2259&#x2013;2264.</Citation><ArticleIdList><ArticleId IdType="pubmed">1953231</ArticleId></ArticleIdList></Reference><Reference><Citation>Popelka MM, Cruickshanks KJ, Wiley TL, Tweed TS, Klein BE, Klein R. Low prevalence of hearing aid use among older adults with hearing loss: the Epidemiology of Hearing Loss Study. J Am Geriatr Soc. 1998;46:1075&#x2013;1078.</Citation><ArticleIdList><ArticleId IdType="pubmed">9736098</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon-Salant S. Hearing loss and aging: new research findings and clinical implications. J Rehabil Res Dev. 2005;42:9&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">16470462</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickles JO. An introduction to the physiology of hearing. Emerald Group Publishing; Bingley, UK: 2008.</Citation></Reference><Reference><Citation>Grimes AM, Grady CL, Pikus A. Auditory evoked potentials in patients with dementia of the Alzheimer type. Ear Hear. 1987;8:157&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pubmed">3609511</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha UK, Hollen KM, Rodriguez R, Miller CA. Auditory system degeneration in Alzheimer&#x2019;s disease. Neurology. 1993;43:779&#x2013;785.</Citation><ArticleIdList><ArticleId IdType="pubmed">8469340</ArticleId></ArticleIdList></Reference><Reference><Citation>Parvizi J, Van Hoesen GW, Damasio A. The selective vulnerability of brainstem nuclei to Alzheimer&#x2019;s disease. Ann Neurol. 2001;49:53&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">11198297</ArticleId></ArticleIdList></Reference><Reference><Citation>Baloyannis SJ, Mauroudis I, Manolides SL, Manolides LS. Synaptic alterations in the medial geniculate bodies and the inferior colliculi in Alzheimer&#x2019;s disease: a Golgi and electron microscope study. Acta Otolaryngol. 2009;129:416&#x2013;418.</Citation><ArticleIdList><ArticleId IdType="pubmed">19116791</ArticleId></ArticleIdList></Reference><Reference><Citation>Gates GA, Beiser A, Rees TS, D&#x2019;Agostino RB, Wolf PA. Central auditory dysfunction may precede the onset of clinical dementia in people with probable Alzheimer&#x2019;s disease. J Am Geriatr Soc. 2002;50:482&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pubmed">11943044</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Grady G, Boyles AL, Speer M, DeRuyter F, Strittmatter W, Worley G. Apolipoprotein E alleles and sensorineural hearing loss. Int J Audiol. 2007;46:183&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pubmed">17454231</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y. Cognitive reserve. Neuropsychologia. 2009;47:2015&#x2013;2028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2739591</ArticleId><ArticleId IdType="pubmed">19467352</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzer R, Rakitin BC, Steffener J, Flynn J, Kumar A, Stern Y. Age effects on load-dependent brain activations in working memory for novel material. Brain Res. 2009;1249:148&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677982</ArticleId><ArticleId IdType="pubmed">18983833</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarahn E, Rakitin B, Abela D, Flynn J, Stern Y. Age-related changes in brain activation during a delayed item recognition task. Neurobiol Aging. 2007;28:784&#x2013;798.</Citation><ArticleIdList><ArticleId IdType="pubmed">16621168</ArticleId></ArticleIdList></Reference><Reference><Citation>Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C. Age, neuropathology, and dementia. N Engl J Med. 2009;360:2302&#x2013;2309.</Citation><ArticleIdList><ArticleId IdType="pubmed">19474427</ArticleId></ArticleIdList></Reference><Reference><Citation>Tun PA, McCoy S, Wingfield A. Aging, hearing acuity, and the attentional costs of effortful listening. Psychol Aging. 2009;24:761&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2773464</ArticleId><ArticleId IdType="pubmed">19739934</ArticleId></ArticleIdList></Reference><Reference><Citation>Pichora-Fuller MK, Schneider BA, Daneman M. How young and old adults listen to and remember speech in noise. J Acoust Soc Am. 1995;97:593&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pubmed">7860836</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle PA, Wilson RS, Schneider JA, Bienias JL, Bennett DA. Processing resources reduce the effect of Alzheimer pathology on other cognitive systems. Neurology. 2008;70:1534&#x2013;1542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10382255</ArticleId><ArticleId IdType="pubmed">18354077</ArticleId></ArticleIdList></Reference><Reference><Citation>Strawbridge WJ, Wallhagen MI, Shema SJ, Kaplan GA. Negative consequences of hearing impairment in old age: a longitudinal analysis. Gerontologist. 2000;40:320&#x2013;326.</Citation><ArticleIdList><ArticleId IdType="pubmed">10853526</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstein BE, Ventry IM. Hearing impairment and social isolation in the elderly. J Speech Hear Res. 1982;25:593&#x2013;599.</Citation><ArticleIdList><ArticleId IdType="pubmed">7162161</ArticleId></ArticleIdList></Reference><Reference><Citation>Fratiglioni L, Wang HX, Ericsson K, Maytan M, Winblad B. Influence of social network on occurrence of dementia: a community-based longitudinal study. Lancet. 2000;355:1315&#x2013;1319.</Citation><ArticleIdList><ArticleId IdType="pubmed">10776744</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes LL, Mendes de Leon CF, Wilson RS, Bienias JL, Evans DA. Social resources and cognitive decline in a population of older African Americans and whites. Neurology. 2004;63:2322&#x2013;2326.</Citation><ArticleIdList><ArticleId IdType="pubmed">15623694</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Tang Y, Arnold SE, Wilson RS. The effect of social networks on the relation between Alzheimer&#x2019;s disease pathology and level of cognitive function in old people: a longitudinal cohort study. Lancet Neurol. 2006;5:406&#x2013;412.</Citation><ArticleIdList><ArticleId IdType="pubmed">16632311</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalton DS, Cruickshanks KJ, Klein BE, Klein R, Wiley TL, Nondahl DM. The impact of hearing loss on quality of life in older adults. Gerontologist. 2003;43:661&#x2013;668.</Citation><ArticleIdList><ArticleId IdType="pubmed">14570962</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarov O, Robinson J, Tang YP, et al. Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell. 2005;120:701&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pubmed">15766532</ArticleId></ArticleIdList></Reference><Reference><Citation>Verghese J, Lipton RB, Katz MJ, et al. Leisure activities and the risk of dementia in the elderly. N Engl J Med. 2003;348:2508&#x2013;2516.</Citation><ArticleIdList><ArticleId IdType="pubmed">12815136</ArticleId></ArticleIdList></Reference><Reference><Citation>Korn EL, Graubard BI, Midthune D. Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. Am J Epidemiol. 1997;145:72&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">8982025</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhan W, Cruickshanks KJ, Klein BE, et al. Generational differences in the prevalence of hearing impairment in older adults. Am J Epidemiol. 2010;171:260&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2878102</ArticleId><ArticleId IdType="pubmed">20008889</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21325529</PMID><DateCompleted><Year>2011</Year><Month>04</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>7</Issue><PubDate><Year>2011</Year><Month>Feb</Month><Day>16</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Presenilin-1 regulates neural progenitor cell differentiation in the adult brain.</ArticleTitle><Pagination><StartPage>2615</StartPage><EndPage>2623</EndPage><MedlinePgn>2615-23</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.4767-10.2011</ELocationID><Abstract><AbstractText>Presenilin-1 (PS1) is the catalytic core of the aspartyl protease &#x3b3;-secretase. Previous genetic studies using germ-line deletion of PS1 and conditional knock-out mice demonstrated that PS1 plays an essential role in neuronal differentiation during neural development, but it remained unclear whether PS1 plays a similar role in neurogenesis in the adult brain. Here we show that neural progenitor cells infected with lentiviral vectors-expressing short interfering RNA (siRNA) for the exclusive knockdown of PS1 in the neurogenic microenvironments, exhibit a dramatic enhancement of cell differentiation. Infected cells differentiated into neurons, astrocytes and oligodendrocytes, suggesting that multipotentiality of neural progenitor cells is not affected by reduced levels of PS1. Neurosphere cultures treated with &#x3b3;-secretase inhibitors exhibit a similar phenotype of enhanced cell differentiation, suggesting that PS1 function in neural progenitor cells is &#x3b3;-secretase-dependent. Neurospheres infected with lentiviral vectors expressing siRNA for the targeting of PS1 differentiated even in the presence of the proliferation factors epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF), suggesting that PS1 dominates EFG and bFGF signaling pathways. Reduction of PS1 expression in neural progenitor cells was accompanied by a decrease in EGF receptor and &#x3b2;-catenin expression level, suggesting that they are downstream essential transducers of PS1 signaling in adult neural progenitor cells. These findings suggest a physiological role for PS1 in adult neurogenesis, and a potential target for the manipulation of neural progenitor cell differentiation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gadadhar</LastName><ForeName>Archana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Cell Biology, College of Medicine, University of Illinois at Chicago, Chicago, Illinois 60612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marr</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Lazarov</LastName><ForeName>Orly</ForeName><Initials>O</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG033570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG033570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG033570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002219">Carbamates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004151">Dipeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C410009">L 685458</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance></Chemical><Chemical><RegistryNumber>147336-22-9</RegistryNumber><NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>G34N38R2N1</RegistryNumber><NameOfSubstance UI="D001973">Bromodeoxyuridine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D053687" MajorTopicYN="N">Adult Stem Cells</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001973" MajorTopicYN="N">Bromodeoxyuridine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002219" MajorTopicYN="N">Carbamates</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002452" MajorTopicYN="N">Cell Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002552" MajorTopicYN="N">Cerebral Ventricles</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004151" MajorTopicYN="N">Dipeptides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049452" MajorTopicYN="N">Green Fluorescent Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055495" MajorTopicYN="N">Neurogenesis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>8</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21325529</ArticleId><ArticleId IdType="mid">NIHMS273625</ArticleId><ArticleId IdType="pmc">PMC3050597</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.4767-10.2011</ArticleId><ArticleId IdType="pii">31/7/2615</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Adachi K, Mirzadeh Z, Sakaguchi M, Yamashita T, Nikolcheva T, Gotoh Y, Peltz G, Gong L, Kawase T, Alvarez-Buylla A, Okano H, Sawamoto K. Beta-catenin signaling promotes proliferation of progenitor cells in the adult mouse subventricular zone. Stem Cells. 2007;25:2827&#x2013;2836.</Citation><ArticleIdList><ArticleId IdType="pubmed">17673525</ArticleId></ArticleIdList></Reference><Reference><Citation>Aimone JB, Deng W, Gage FH. Adult neurogenesis: integrating theories and separating functions. Trends Cogn Sci. 2010;14:325&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2904863</ArticleId><ArticleId IdType="pubmed">20471301</ArticleId></ArticleIdList></Reference><Reference><Citation>Borghese L, Dolezalova D, Opitz T, Haupt S, Leinhaas A, Steinfarz B, Koch P, Edenhofer F, Hampl A, Br&#xfc;stle O. Inhibition of notch signaling in human embryonic stem cell-derived neural stem cells delays G1/S phase transition and accelerates neuronal differentiation in vitro and in vivo. Stem Cells. 2010;28:955&#x2013;964.</Citation><ArticleIdList><ArticleId IdType="pubmed">20235098</ArticleId></ArticleIdList></Reference><Reference><Citation>Breunig JJ, Silbereis J, Vaccarino FM, Sestan N, Rakic P. Notch regulates cell fate and dendrite morphology of newborn neurons in the postnatal dentate gyrus. Proc Natl Acad Sci U S A. 2007;104:20558&#x2013;20563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2154470</ArticleId><ArticleId IdType="pubmed">18077357</ArticleId></ArticleIdList></Reference><Reference><Citation>Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science. 2002;296:550&#x2013;553.</Citation><ArticleIdList><ArticleId IdType="pubmed">11910072</ArticleId></ArticleIdList></Reference><Reference><Citation>Chae TH, Kim S, Marz KE, Hanson PI, Walsh CA. The hyh mutation uncovers roles for alpha Snap in apical protein localization and control of neural cell fate. Nat Genet. 2004;36:264&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pubmed">14758363</ArticleId></ArticleIdList></Reference><Reference><Citation>Chevallier NL, Soriano S, Kang DE, Masliah E, Hu G, Koo EH. Perturbed neurogenesis in the adult hippocampus associated with presenilin-1 A246E mutation. Am J Pathol. 2005;167:151&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1603433</ArticleId><ArticleId IdType="pubmed">15972961</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SH, Veeraraghavalu K, Lazarov O, Marler S, Ransohoff RM, Ramirez JM, Sisodia SS. Non-cell-autonomous effects of presenilin 1 variants on enrichment-mediated hippocampal progenitor cell proliferation and differentiation. Neuron. 2008;59:568&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3489017</ArticleId><ArticleId IdType="pubmed">18760694</ArticleId></ArticleIdList></Reference><Reference><Citation>Demars M, Hu YS, Gadadhar A, Lazarov O. Impaired neurogenesis is an early event in the etiology of familial Alzheimer's disease in transgenic mice. J Neurosci Res. 2010;88:2103&#x2013;2117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3696038</ArticleId><ArticleId IdType="pubmed">20209626</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, Annaert W, Von Figura K, Van Leuven F. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature. 1998;391:387&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pubmed">9450754</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Annaert W, Cupers P, Saftig P, Craessaerts K, Mumm JS, Schroeter EH, Schrijvers V, Wolfe MS, Ray WJ, Goate A, Kopan R. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain [see comments] Nature. 1999;398:518&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206645</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng R, Rampon C, Tang YP, Shrom D, Jin J, Kyin M, Sopher B, Miller MW, Ware CB, Martin GM, Kim SH, Langdon RB, Sisodia SS, Tsien JZ. Deficient neurogenesis in forebrain-specific presenilin-1 knockout mice is associated with reduced clearance of hippocampal memory traces. Neuron. 2001;32:911&#x2013;926.</Citation><ArticleIdList><ArticleId IdType="pubmed">11738035</ArticleId></ArticleIdList></Reference><Reference><Citation>Handler M, Yang X, Shen J. Presenilin-1 regulates neuronal differentiation during neurogenesis. Development. 2000;127:2593&#x2013;2606.</Citation><ArticleIdList><ArticleId IdType="pubmed">10821758</ArticleId></ArticleIdList></Reference><Reference><Citation>Herreman A, Serneels L, Annaert W, Collen D, Schoonjans L, De Strooper B. Total inactivation of gamma-secretase activity in presenilin-deficient embryonic stem cells. Nat Cell Biol. 2000;2:461&#x2013;462.</Citation><ArticleIdList><ArticleId IdType="pubmed">10878813</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim WY, Shen J. Presenilins are required for maintenance of neural stem cells in the developing brain. Mol Neurodegener. 2008;3:2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2235867</ArticleId><ArticleId IdType="pubmed">18182109</ArticleId></ArticleIdList></Reference><Reference><Citation>Kriegstein A, Alvarez-Buylla A. The glial nature of embryonic and adult neural stem cells. Annu Rev Neurosci. 2009;32:149&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3086722</ArticleId><ArticleId IdType="pubmed">19555289</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarov O, Marr RA. Neurogenesis and Alzheimer's disease: At the crossroads. Exp Neurol. 2010;223:267&#x2013;281.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2864344</ArticleId><ArticleId IdType="pubmed">19699201</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YM, Xu M, Lai MT, Huang Q, Castro JL, DiMuzio-Mower J, Harrison T, Lellis C, Nadin A, Neduvelil JG, Register RB, Sardana MK, Shearman MS, Smith AL, Shi XP, Yin KC, Shafer JA, Gardell SJ. Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. Nature. 2000;405:689&#x2013;694.</Citation><ArticleIdList><ArticleId IdType="pubmed">10864326</ArticleId></ArticleIdList></Reference><Reference><Citation>Lie DC, Colamarino SA, Song HJ, D&#xe9;sir&#xe9; L, Mira H, Consiglio A, Lein ES, Jessberger S, Lansford H, Dearie AR, Gage FH. Wnt signalling regulates adult hippocampal neurogenesis. Nature. 2005;437:1370&#x2013;1375.</Citation><ArticleIdList><ArticleId IdType="pubmed">16251967</ArticleId></ArticleIdList></Reference><Reference><Citation>Machon O, van den Bout CJ, Backman M, Kemler R, Krauss S. Role of beta-catenin in the developing cortical and hippocampal neuroepithelium. Neuroscience. 2003;122:129&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">14596855</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori H, Ninomiya K, Kino-oka M, Shofuda T, Islam MO, Yamasaki M, Okano H, Taya M, Kanemura Y. Effect of neurosphere size on the growth rate of human neural stem/progenitor cells. J Neurosci Res. 2006;84:1682&#x2013;1691.</Citation><ArticleIdList><ArticleId IdType="pubmed">17044035</ArticleId></ArticleIdList></Reference><Reference><Citation>Morohashi Y, Kan T, Tominari Y, Fuwa H, Okamura Y, Watanabe N, Sato C, Natsugari H, Fukuyama T, Iwatsubo T, Tomita T. C-terminal fragment of presenilin is the molecular target of a dipeptidic gamma-secretase-specific inhibitor DAPT (N-[N-(3,5-difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl ester) J Biol Chem. 2006;281:14670&#x2013;14676.</Citation><ArticleIdList><ArticleId IdType="pubmed">16569643</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakajima M, Watanabe S, Okuyama S, Shen J, Furukawa Y. Restricted growth and insulin-like growth factor-1 deficiency in mice lacking presenilin-1 in the neural crest cell lineage. Int J Dev Neurosci. 2009;27:837&#x2013;843.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3425391</ArticleId><ArticleId IdType="pubmed">19665542</ArticleId></ArticleIdList></Reference><Reference><Citation>Paxinos G, Franklin KJB. The mouse brain in stereotaxic coordinates. San Diego: Academic; 2004.</Citation></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001;81:741&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>Shearman MS, Beher D, Clarke EE, Lewis HD, Harrison T, Hunt P, Nadin A, Smith AL, Stevenson G, Castro JL. L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid beta-protein precursor gamma-secretase activity. Biochemistry. 2000;39:8698&#x2013;8704.</Citation><ArticleIdList><ArticleId IdType="pubmed">10913280</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen J, Bronson RT, Chen DF, Xia W, Selkoe DJ, Tonegawa S. Skeletal and CNS defects in Presenilin-1-deficient mice. Cell. 1997;89:629&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">9160754</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Sun G, Zhao C, Stewart R. Neural stem cell self-renewal. Crit Rev Oncol Hematol. 2008;65:43&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2235812</ArticleId><ArticleId IdType="pubmed">17644000</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu T, Kagawa T, Inoue T, Nonaka A, Takada S, Aburatani H, Taga T. Stabilized beta-catenin functions through TCF/LEF proteins and the Notch/RBP-Jkappa complex to promote proliferation and suppress differentiation of neural precursor cells. Mol Cell Biol. 2008;28:7427&#x2013;7441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2593432</ArticleId><ArticleId IdType="pubmed">18852283</ArticleId></ArticleIdList></Reference><Reference><Citation>Suh H, Deng W, Gage FH. Signaling in adult neurogenesis. Annu Rev Cell Dev Biol. 2009;25:253&#x2013;275.</Citation><ArticleIdList><ArticleId IdType="pubmed">19575663</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesco G, Tanzi RE. GSK3 beta forms a tetrameric complex with endogenous PS1-CTF/NTF and beta-catenin. Effects of the D257/D385A and FAD-linked mutations. Ann N Y Acad Sci. 2000;920:227&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">11193155</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesco G, Kim TW, Diehlmann A, Beyreuther K, Tanzi RE. Abrogation of the presenilin 1/beta-catenin interaction and preservation of the heterodimeric presenilin 1 complex following caspase activation. J Biol Chem. 1998;273:33909&#x2013;33914.</Citation><ArticleIdList><ArticleId IdType="pubmed">9852041</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiscornia G, Singer O, Verma IM. Design and cloning of lentiviral vectors expressing small interfering RNAs. Nat Protoc. 2006a;1:234&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pubmed">17406238</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiscornia G, Singer O, Verma IM. Production and purification of lentiviral vectors. Nat Protoc. 2006b;1:241&#x2013;245.</Citation><ArticleIdList><ArticleId IdType="pubmed">17406239</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R, Dineley KT, Sweatt JD, Zheng H. Presenilin 1 familial Alzheimer's disease mutation leads to defective associative learning and impaired adult neurogenesis. Neuroscience. 2004;126:305&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pubmed">15207348</ArticleId></ArticleIdList></Reference><Reference><Citation>Weihofen A, Martoglio B. Intramembrane-cleaving proteases: controlled liberation of proteins and bioactive peptides. Trends Cell Biol. 2003;13:71&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">12559757</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen PH, Hof PR, Chen X, Gluck K, Austin G, Younkin SG, Younkin LH, DeGasperi R, Gama Sosa MA, Robakis NK, Haroutunian V, Elder GA. The presenilin-1 familial Alzheimer disease mutant P117L impairs neurogenesis in the hippocampus of adult mice. Exp Neurol. 2004;188:224&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pubmed">15246822</ArticleId></ArticleIdList></Reference><Reference><Citation>Wines-Samuelson M, Shen J. Presenilins in the developing, adult, and aging cerebral cortex. Neuroscientist. 2005;11:441&#x2013;451.</Citation><ArticleIdList><ArticleId IdType="pubmed">16151045</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature. 1999;398:513&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206644</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Z, Romano DM, Kovacs DM, Tanzi RE. Effects of RNA interference-mediated silencing of gamma-secretase complex components on cell sensitivity to caspase-3 activation. J Biol Chem. 2004;279:34130&#x2013;34137.</Citation><ArticleIdList><ArticleId IdType="pubmed">15184387</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, Handler M, Shen J. Role of presenilin-1 in murine neural development. Ann N Y Acad Sci. 2000;920:165&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">11193146</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Nadeau P, Song W, Donoviel D, Yuan M, Bernstein A, Yankner BA. Presenilins are required for gamma-secretase cleavage of beta-APP and transmembrane cleavage of Notch-1. Nat Cell Biol. 2000;2:463&#x2013;465.</Citation><ArticleIdList><ArticleId IdType="pubmed">10878814</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21330548</PMID><DateCompleted><Year>2011</Year><Month>03</Month><Day>08</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>331</Volume><Issue>6019</Issue><PubDate><Year>2011</Year><Month>Feb</Month><Day>18</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Early tagging of cortical networks is required for the formation of enduring associative memory.</ArticleTitle><Pagination><StartPage>924</StartPage><EndPage>928</EndPage><MedlinePgn>924-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.1196164</ELocationID><Abstract><AbstractText>Although formation and stabilization of long-lasting associative memories are thought to require time-dependent coordinated hippocampal-cortical interactions, the underlying mechanisms remain unclear. Here, we present evidence that neurons in the rat cortex must undergo a "tagging process" upon encoding to ensure the progressive hippocampal-driven rewiring of cortical networks that support remote memory storage. This process was AMPA- and N-methyl-D-aspartate receptor-dependent, information-specific, and capable of modulating remote memory persistence by affecting the temporal dynamics of hippocampal-cortical interactions. Post-learning reinforcement of the tagging process via time-limited epigenetic modifications resulted in improved remote memory retrieval. Thus, early tagging of cortical networks is a crucial neurobiological process for remote memory formation whose functional properties fit the requirements imposed by the extended time scale of systems-level memory consolidation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lesburgu&#xe8;res</LastName><ForeName>Edith</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institut des Maladies Neurod&#xe9;g&#xe9;n&#xe9;ratives, CNRS UMR 5293, Universit&#xe9;s Bordeaux 1 et 2, Talence, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gobbo</LastName><ForeName>Oliviero L</ForeName><Initials>OL</Initials></Author><Author ValidYN="Y"><LastName>Alaux-Cantin</LastName><ForeName>St&#xe9;phanie</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Hambucken</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Trifilieff</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Bontempi</LastName><ForeName>Bruno</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018691">Excitatory Amino Acid Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006657">Histones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018091">Receptors, AMPA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Science. 2011 Feb 18;331(6019):869-70. doi: 10.1126/science.1202283.</RefSource><PMID Version="1">21330525</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2011 Apr;12(4):188. doi: 10.1038/nrn3019.</RefSource><PMID Version="1">21562503</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000107" MajorTopicYN="N">Acetylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044127" MajorTopicYN="N">Epigenesis, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018691" MajorTopicYN="N">Excitatory Amino Acid Antagonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005518" MajorTopicYN="N">Food Preferences</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006657" MajorTopicYN="N">Histones</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007858" MajorTopicYN="N">Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057567" MajorTopicYN="Y">Memory, Long-Term</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009434" MajorTopicYN="N">Neural Pathways</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009812" MajorTopicYN="N">Odorants</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018091" MajorTopicYN="N">Receptors, AMPA</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012054" MajorTopicYN="N">Reinforcement, Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21330548</ArticleId><ArticleId IdType="doi">10.1126/science.1196164</ArticleId><ArticleId IdType="pii">331/6019/924</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21335237</PMID><DateCompleted><Year>2011</Year><Month>03</Month><Day>31</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>144</Volume><Issue>4</Issue><PubDate><Year>2011</Year><Month>Feb</Month><Day>18</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>Stable kinesin and dynein assemblies drive the axonal transport of mammalian prion protein vesicles.</ArticleTitle><Pagination><StartPage>551</StartPage><EndPage>565</EndPage><MedlinePgn>551-65</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2011.01.021</ELocationID><Abstract><AbstractText>Kinesin and dynein are opposite-polarity microtubule motors that drive the tightly regulated transport of a variety of cargoes. Both motors can bind to cargo, but their overall composition on axonal vesicles and whether this composition directly modulates transport activity are unknown. Here we characterize the intracellular transport and steady-state motor subunit composition of mammalian prion protein (PrP(C)) vesicles. We identify Kinesin-1 and cytoplasmic dynein as major PrP(C) vesicle motor complexes and show that their activities are tightly coupled. Regulation of normal retrograde transport by Kinesin-1 is independent of dynein-vesicle attachment and requires the vesicle association of a complete Kinesin-1 heavy and light chain holoenzyme. Furthermore, motor subunits remain stably associated with stationary as well as with moving vesicles. Our data suggest a coordination model wherein PrP(C) vesicles maintain a stable population of associated motors whose activity is modulated by regulatory factors instead of by structural changes to motor-cargo associations.</AbstractText><CopyrightInformation>Copyright &#xa9; 2011 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Encalada</LastName><ForeName>Sandra E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, School of Medicine, University of California, San Diego, La Jolla, 92093, USA. sencalada@ucsd.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szpankowski</LastName><ForeName>Lukasz</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Xia</LastName><ForeName>Chun-hong</ForeName><Initials>CH</Initials></Author><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Lawrence S B</ForeName><Initials>LS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 GM008806</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG032180</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS047101</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG032180</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG000216</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG000216</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018621">PrPC Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.2</RegistryNumber><NameOfSubstance UI="D004398">Dyneins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.4</RegistryNumber><NameOfSubstance UI="D016547">Kinesins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004398" MajorTopicYN="N">Dyneins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016547" MajorTopicYN="N">Kinesins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018621" MajorTopicYN="N">PrPC Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D022161" MajorTopicYN="N">Transport Vesicles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>11</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>1</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>2</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>2</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>2</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21335237</ArticleId><ArticleId IdType="mid">NIHMS276602</ArticleId><ArticleId IdType="pmc">PMC3576050</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2011.01.021</ArticleId><ArticleId IdType="pii">S0092-8674(11)00060-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Akhmanova A, Hammer JA., 3rd Linking molecular motors to membrane cargo. Curr Opin Cell Biol. 2010;22:479&#x2013;487.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3393125</ArticleId><ArticleId IdType="pubmed">20466533</ArticleId></ArticleIdList></Reference><Reference><Citation>Ally S, Larson AG, Barlan K, Rice SE, Gelfand VI. Opposite-polarity motors activate one another to trigger cargo transport in live cells. J Cell Biol. 2009;187:1071&#x2013;1082.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2806283</ArticleId><ArticleId IdType="pubmed">20038680</ArticleId></ArticleIdList></Reference><Reference><Citation>Baas PW, Deitch JS, Black MM, Banker GA. Polarity orientation of microtubules in hippocampal neurons: uniformity in the axon and nonuniformity in the dendrite. Proc Natl Acad Sci U S A. 1988;85:8335&#x2013;8339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC282424</ArticleId><ArticleId IdType="pubmed">3054884</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt DR, Davis J, Fischer M, Lee MK, Slunt HH, Ratovitsky T, Regard J, Copeland NG, Jenkins NA, Sisodia SS, et al. A vector for expressing foreign genes in the brains and hearts of transgenic mice. Genet Anal. 1996;13:159&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">9117892</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt DR, Koliatsos VE, Guarnieri M, Pardo CA, Sisodia SS, Price DL. Rapid anterograde axonal transport of the cellular prion glycoprotein in the peripheral and central nervous systems. J Biol Chem. 1994;269:14711&#x2013;14714.</Citation><ArticleIdList><ArticleId IdType="pubmed">7514179</ArticleId></ArticleIdList></Reference><Reference><Citation>Butowt R, Abdelraheim S, Brown DR, von Bartheld CS. Anterograde axonal transport of the exogenous cellular isoform of prion protein in the chick visual system. Mol Cell Neurosci. 2006;31:97&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">16203158</ArticleId></ArticleIdList></Reference><Reference><Citation>Butowt R, Davies P, Brown DR. Anterograde axonal transport of chicken cellular prion protein (PrPc) in vivo requires its N-terminal part. J Neurosci Res. 2007;85:2567&#x2013;2579.</Citation><ArticleIdList><ArticleId IdType="pubmed">17335074</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai D, Hoppe AD, Swanson JA, Verhey KJ. Kinesin-1 structural organization and conformational changes revealed by FRET stoichiometry in live cells. J Cell Biol. 2007;176:51&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2063625</ArticleId><ArticleId IdType="pubmed">17200416</ArticleId></ArticleIdList></Reference><Reference><Citation>Caughey B, Baron GS, Chesebro B, Jeffrey M. Getting a grip on prions: oligomers, amyloids, and pathological membrane interactions. Annu Rev Biochem. 2009;78:177&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2794486</ArticleId><ArticleId IdType="pubmed">19231987</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui J, Wang Z, Cheng Q, Lin R, Xin-Mei Z, Leung PS, Copeland NG, Jenkins NA, Yao KM, Huang JD. Targeted Inactivation of Kinesin-1 in Pancreatic {beta}-Cells in vivo Leads to Insulin Secretory Deficiency. Diabetes. 2010 doi: 10.2337/db09-1078.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db09-1078</ArticleId><ArticleId IdType="pmc">PMC3012189</ArticleId><ArticleId IdType="pubmed">20870970</ArticleId></ArticleIdList></Reference><Reference><Citation>DeBoer SR, You Y, Szodorai A, Kaminska A, Pigino G, Nwabuisi E, Wang B, Estrada-Hernandez T, Kins S, Brady ST, et al. Conventional kinesin holoenzymes are composed of heavy and light chain homodimers. Biochemistry (Mosc) 2008;47:4535&#x2013;4543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2644488</ArticleId><ArticleId IdType="pubmed">18361505</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixit R, Ross JL, Goldman YE, Holzbaur EL. Differential regulation of dynein and kinesin motor proteins by tau. Science. 2008;319:1086&#x2013;1089.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2866193</ArticleId><ArticleId IdType="pubmed">18202255</ArticleId></ArticleIdList></Reference><Reference><Citation>Falzone TL, Stokin GB, Lillo C, Rodrigues EM, Westerman EL, Williams DS, Goldstein LS. Axonal stress kinase activation and tau misbehavior induced by kinesin-1 transport defects. J Neurosci. 2009;29:5758&#x2013;5767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3849468</ArticleId><ArticleId IdType="pubmed">19420244</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraley C. MCLUST: Software for Model-Based Cluster Analysis. Journal of Classification. 1999;16:297&#x2013;306.</Citation></Reference><Reference><Citation>Glater EE, Megeath LJ, Stowers RS, Schwarz TL. Axonal transport of mitochondria requires milton to recruit kinesin heavy chain and is light chain independent. J Cell Biol. 2006;173:545&#x2013;557.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2063864</ArticleId><ArticleId IdType="pubmed">16717129</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein AY, Wang X, Schwarz TL. Axonal transport and the delivery of pre-synaptic components. Curr Opin Neurobiol. 2008;18:495&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2653082</ArticleId><ArticleId IdType="pubmed">18950710</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross SP. Hither and yon: a review of bi-directional microtubule-based transport. Phys Biol. 2004;1:R1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">16204815</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross SP, Tuma MC, Deacon SW, Serpinskaya AS, Reilein AR, Gelfand VI. Interactions and regulation of molecular motors in Xenopus melanophores. J Cell Biol. 2002;156:855&#x2013;865.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2173315</ArticleId><ArticleId IdType="pubmed">11864991</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris DA. Trafficking, turnover and membrane topology of PrP. Br Med Bull. 2003;66:71&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">14522850</ArticleId></ArticleIdList></Reference><Reference><Citation>Hendricks AG, Perlson E, Ross JL, Schroeder HW, 3rd, Tokito M, Holzbaur EL. Motor Coordination via a Tug-of-War Mechanism Drives Bidirectional Vesicle Transport. Curr Biol 2010</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2908734</ArticleId><ArticleId IdType="pubmed">20399099</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirokawa N, Takemura R. Molecular motors and mechanisms of directional transport in neurons. Nat Rev Neurosci. 2005;6:201&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">15711600</ArticleId></ArticleIdList></Reference><Reference><Citation>Howard J. Mechanics of motor proteins and the cytoskeleton. Sunderland, Mass: Sinauer Associates; 2001.</Citation></Reference><Reference><Citation>Jaqaman K, Loerke D, Mettlen M, Kuwata H, Grinstein S, Schmid SL, Danuser G. Robust single-particle tracking in live-cell time-lapse sequences. Nat Methods. 2008;5:695&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2747604</ArticleId><ArticleId IdType="pubmed">18641657</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamal A, Stokin GB, Yang Z, Xia CH, Goldstein LS. Axonal transport of amyloid precursor protein is mediated by direct binding to the kinesin light chain subunit of kinesin-I. Neuron. 2000;28:449&#x2013;459.</Citation><ArticleIdList><ArticleId IdType="pubmed">11144355</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang JS, Tian JH, Pan PY, Zald P, Li C, Deng C, Sheng ZH. Docking of axonal mitochondria by syntaphilin controls their mobility and affects short-term facilitation. Cell. 2008;132:137&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2259239</ArticleId><ArticleId IdType="pubmed">18191227</ArticleId></ArticleIdList></Reference><Reference><Citation>Kardon JR, Vale RD. Regulators of the cytoplasmic dynein motor. Nat Rev Mol Cell Biol. 2009;10:854&#x2013;865.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3394690</ArticleId><ArticleId IdType="pubmed">19935668</ArticleId></ArticleIdList></Reference><Reference><Citation>Karki S, Holzbaur EL. Cytoplasmic dynein and dynactin in cell division and intracellular transport. Curr Opin Cell Biol. 1999;11:45&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">10047518</ArticleId></ArticleIdList></Reference><Reference><Citation>King SJ, Brown CL, Maier KC, Quintyne NJ, Schroer TA. Analysis of the dynein-dynactin interaction in vitro and in vivo. Mol Biol Cell. 2003;14:5089&#x2013;5097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC284810</ArticleId><ArticleId IdType="pubmed">14565986</ArticleId></ArticleIdList></Reference><Reference><Citation>Kural C, Kim H, Syed S, Goshima G, Gelfand VI, Selvin PR. Kinesin and dynein move a peroxisome in vivo: a tug-of-war or coordinated movement? Science. 2005;308:1469&#x2013;1472.</Citation><ArticleIdList><ArticleId IdType="pubmed">15817813</ArticleId></ArticleIdList></Reference><Reference><Citation>Ligon LA, Tokito M, Finklestein JM, Grossman FE, Holzbaur EL. A direct interaction between cytoplasmic dynein and kinesin I may coordinate motor activity. J Biol Chem. 2004;279:19201&#x2013;19208.</Citation><ArticleIdList><ArticleId IdType="pubmed">14985359</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu H, Ali MY, Bookwalter CS, Warshaw DM, Trybus KM. Diffusive movement of processive kinesin-1 on microtubules. Traffic. 2009;10:1429&#x2013;1438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2746881</ArticleId><ArticleId IdType="pubmed">19682327</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyman MG, Enquist LW. Herpesvirus interactions with the host cytoskeleton. J Virol. 2009;83:2058&#x2013;2066.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2643721</ArticleId><ArticleId IdType="pubmed">18842724</ArticleId></ArticleIdList></Reference><Reference><Citation>Malaga-Trillo E, Solis GP, Schrock Y, Geiss C, Luncz L, Thomanetz V, Stuermer CA. Regulation of embryonic cell adhesion by the prion protein. PLoS Biol. 2009;7:e55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2653553</ArticleId><ArticleId IdType="pubmed">19278297</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin M, Iyadurai SJ, Gassman A, Gindhart JG, Jr, Hays TS, Saxton WM. Cytoplasmic dynein, the dynactin complex, and kinesin are interdependent and essential for fast axonal transport. Mol Biol Cell. 1999;10:3717&#x2013;3728.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC25669</ArticleId><ArticleId IdType="pubmed">10564267</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazumdar M, Mikami A, Gee MA, Vallee RB. In vitro motility from recombinant dynein heavy chain. Proc Natl Acad Sci U S A. 1996;93:6552&#x2013;6556.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC39062</ArticleId><ArticleId IdType="pubmed">8692854</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore DS, McCabe GP. Introduction to the Practice of Statistics. 5. W. H. Freeman; 2005.</Citation></Reference><Reference><Citation>Mouillet-Richard S, Ermonval M, Chebassier C, Laplanche JL, Lehmann S, Launay JM, Kellermann O. Signal transduction through prion protein. Science. 2000;289:1925&#x2013;1928.</Citation><ArticleIdList><ArticleId IdType="pubmed">10988071</ArticleId></ArticleIdList></Reference><Reference><Citation>Moya KL, Hassig R, Creminon C, Laffont I, Di Giamberardino L. Enhanced detection and retrograde axonal transport of PrPc in peripheral nerve. J Neurochem. 2004;88:155&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">14675159</ArticleId></ArticleIdList></Reference><Reference><Citation>Okada Y, Yamazaki H, Sekine-Aizawa Y, Hirokawa N. The neuron-specific kinesin superfamily protein KIF1A is a unique monomeric motor for anterograde axonal transport of synaptic vesicle precursors. Cell. 1995;81:769&#x2013;780.</Citation><ArticleIdList><ArticleId IdType="pubmed">7539720</ArticleId></ArticleIdList></Reference><Reference><Citation>Plitz T, Pfeffer K. Intact lysosome transport and phagosome function despite kinectin deficiency. Mol Cell Biol. 2001;21:6044&#x2013;6055.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC87321</ArticleId><ArticleId IdType="pubmed">11486041</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahman A, Friedman DS, Goldstein LS. Two kinesin light chain genes in mice. Identification and characterization of the encoded proteins. J Biol Chem. 1998;273:15395&#x2013;15403.</Citation><ArticleIdList><ArticleId IdType="pubmed">9624122</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahman A, Kamal A, Roberts EA, Goldstein LS. Defective kinesin heavy chain behavior in mouse kinesin light chain mutants. J Cell Biol. 1999;146:1277&#x2013;1288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2156125</ArticleId><ArticleId IdType="pubmed">10491391</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodolfo K, Hassig R, Moya KL, Frobert Y, Grassi J, Di Giamberardino L. A novel cellular prion protein isoform present in rapid anterograde axonal transport. Neuroreport. 1999;10:3639&#x2013;3644.</Citation><ArticleIdList><ArticleId IdType="pubmed">10619658</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato-Yoshitake R, Yorifuji H, Inagaki M, Hirokawa N. The phosphorylation of kinesin regulates its binding to synaptic vesicles. J Biol Chem. 1992;267:23930&#x2013;23936.</Citation><ArticleIdList><ArticleId IdType="pubmed">1429730</ArticleId></ArticleIdList></Reference><Reference><Citation>Shubeita GT, Tran SL, Xu J, Vershinin M, Cermelli S, Cotton SL, Welte MA, Gross SP. Consequences of motor copy number on the intracellular transport of kinesin-1-driven lipid droplets. Cell. 2008;135:1098&#x2013;1107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2768369</ArticleId><ArticleId IdType="pubmed">19070579</ArticleId></ArticleIdList></Reference><Reference><Citation>Soppina V, Rai AK, Ramaiya AJ, Barak P, Mallik R. Tug-of-war between dissimilar teams of microtubule motors regulates transport and fission of endosomes. Proc Natl Acad Sci U S A 2009</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2770008</ArticleId><ArticleId IdType="pubmed">19864630</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugiyama Y, Kawabata I, Sobue K, Okabe S. Determination of absolute protein numbers in single synapses by a GFP-based calibration technique. Nat Methods. 2005;2:677&#x2013;684.</Citation><ArticleIdList><ArticleId IdType="pubmed">16118638</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka Y, Kanai Y, Okada Y, Nonaka S, Takeda S, Harada A, Hirokawa N. Targeted disruption of mouse conventional kinesin heavy chain, kif5B, results in abnormal perinuclear clustering of mitochondria. Cell. 1998;93:1147&#x2013;1158.</Citation><ArticleIdList><ArticleId IdType="pubmed">9657148</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor AM, Blurton-Jones M, Rhee SW, Cribbs DH, Cotman CW, Jeon NL. A microfluidic culture platform for CNS axonal injury, regeneration and transport. Nat Methods. 2005;2:599&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1558906</ArticleId><ArticleId IdType="pubmed">16094385</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorn KS, Ubersax JA, Vale RD. Engineering the processive run length of the kinesin motor. J Cell Biol. 2000;151:1093&#x2013;1100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2174356</ArticleId><ArticleId IdType="pubmed">11086010</ArticleId></ArticleIdList></Reference><Reference><Citation>Verhey KJ, Hammond JW. Traffic control: regulation of kinesin motors. Nat Rev Mol Cell Biol. 2009;10:765&#x2013;777.</Citation><ArticleIdList><ArticleId IdType="pubmed">19851335</ArticleId></ArticleIdList></Reference><Reference><Citation>Verhey KJ, Lizotte DL, Abramson T, Barenboim L, Schnapp BJ, Rapoport TA. Light chain-dependent regulation of Kinesin&#x2019;s interaction with microtubules. J Cell Biol. 1998;143:1053&#x2013;1066.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2132950</ArticleId><ArticleId IdType="pubmed">9817761</ArticleId></ArticleIdList></Reference><Reference><Citation>Welte MA. Bidirectional transport along microtubules. Curr Biol. 2004;14:R525&#x2013;537.</Citation><ArticleIdList><ArticleId IdType="pubmed">15242636</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia C, Rahman A, Yang Z, Goldstein LS. Chromosomal localization reveals three kinesin heavy chain genes in mouse. Genomics. 1998;52:209&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">9782088</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia CH, Roberts EA, Her LS, Liu X, Williams DS, Cleveland DW, Goldstein LS. Abnormal neurofilament transport caused by targeted disruption of neuronal kinesin heavy chain KIF5A. J Cell Biol. 2003;161:55&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172877</ArticleId><ArticleId IdType="pubmed">12682084</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21357834</PMID><DateCompleted><Year>2011</Year><Month>04</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>76</Volume><Issue>9</Issue><PubDate><Year>2011</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Progressive regional atrophy in normal adults with a maternal history of Alzheimer disease.</ArticleTitle><Pagination><StartPage>822</StartPage><EndPage>829</EndPage><MedlinePgn>822-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0b013e31820e7b74</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Beyond age, having a family history is the most significant risk factor for Alzheimer disease (AD). This longitudinal brain imaging study examines whether there are differential patterns of regional gray matter atrophy in cognitively healthy elderly subjects with (FH+) and without (FH-) a family history of late-onset AD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">As part of the KU Brain Aging Project, cognitively intact individuals with a maternal history (FHm, n = 11), paternal history (FHp, n = 10), or no parental history of AD (FH-, n = 32) similar in age, gender, education, and Mini-Mental State Examination (MMSE) score received MRI at baseline and 2-year follow-up. A custom voxel-based morphometry processing stream was used to examine regional differences in atrophy between FH groups, controlling for age, gender, and APOE &#x3b5;4 (APOE4) status. We also analyzed APOE4-related atrophy.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Cognitively normal FH+ individuals had significantly increased whole-brain gray matter atrophy and CSF expansion compared to FH-. When FH+ groups were split, only FHm was associated with longitudinal measures of brain change. Moreover, our voxel-based analysis revealed that FHm subjects had significantly greater atrophy in the precuneus and parahippocampus/hippocampus regions compared to FH- and FHp subjects, independent of APOE4 status, gender, and age. Individuals with an &#x3b5;4 allele had more regional atrophy in the frontal cortex compared to &#x3b5;4 noncarriers.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We conclude that FHm individuals without dementia have progressive gray matter volume reductions in select AD-vulnerable brain regions, specifically the precuneus and parahippocampal gyrus. These data complement and extend reports of regional cerebral metabolic differences and increases in amyloid-&#x3b2; burden in FHm subjects, which may be related to a higher risk for developing AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Honea</LastName><ForeName>Robyn A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Kansas School of Medicine, Kansas City, KS 66160, USA. rhonea@kumc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swerdlow</LastName><ForeName>Russell H</ForeName><Initials>RH</Initials></Author><Author ValidYN="Y"><LastName>Vidoni</LastName><ForeName>Eric D</ForeName><Initials>ED</Initials></Author><Author ValidYN="Y"><LastName>Burns</LastName><ForeName>Jeffrey M</ForeName><Initials>JM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>M01RR023940</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG029615</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>M01 RR023940</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R03AG026374</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23NS058252</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009035" MajorTopicYN="Y">Mothers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020534" MajorTopicYN="N">Parahippocampal Gyrus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>3</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>3</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21357834</ArticleId><ArticleId IdType="pmc">PMC3053329</ArticleId><ArticleId IdType="doi">10.1212/WNL.0b013e31820e7b74</ArticleId><ArticleId IdType="pii">76/9/822</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Reiman EM. Linking brain imaging and genomics in the study of Alzheimer's disease and aging. Ann NY Acad Sci 2007;1097:94&#x2013;113</Citation><ArticleIdList><ArticleId IdType="pubmed">17413015</ArticleId></ArticleIdList></Reference><Reference><Citation>Cupples LA, Farrer LA, Sadovnick AD, et al. Estimating risk curves for first-degree relatives of patients with Alzheimer's disease: the REVEAL study. Genet Med 2004;6:192&#x2013;196</Citation><ArticleIdList><ArticleId IdType="pubmed">15266206</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Tortosa E, Barquero MS, Baron M, et al. Variability of age at onset in siblings with familial Alzheimer disease. Arch Neurol 2007;64:1743&#x2013;1748</Citation><ArticleIdList><ArticleId IdType="pubmed">18071037</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu G, McLaren DG, Ries ML, et al. The influence of parental history of Alzheimer's disease and apolipoprotein E epsilon4 on the BOLD signal during recognition memory. Brain 2009;132:383&#x2013;391</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2724919</ArticleId><ArticleId IdType="pubmed">18829694</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L, Mistur R, Switalski R, et al. Declining brain glucose metabolism in normal individuals with a maternal history of Alzheimer disease. Neurology 2009;72:513&#x2013;520</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677512</ArticleId><ArticleId IdType="pubmed">19005175</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L, Rinne JO, Tsui WH, et al. Increased fibrillar amyloid-&#x3b2; burden in normal individuals with a family history of late-onset Alzheimer's. Proc Natl Acad Sci USA 2010;107:5949&#x2013;5954</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2851906</ArticleId><ArticleId IdType="pubmed">20231448</ArticleId></ArticleIdList></Reference><Reference><Citation>Honea RA, Swerdlow RH, Vidoni ED, et al. Reduced gray matter volume in normal adults with a maternal family history of Alzheimer disease. Neurology 2010;74:113&#x2013;120</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2809030</ArticleId><ArticleId IdType="pubmed">20065246</ArticleId></ArticleIdList></Reference><Reference><Citation>Leow AD, Klunder AD, Jack CR, Jr, et al. Longitudinal stability of MRI for mapping brain change using tensor-based morphometry. Neuroimage 2006;31:627&#x2013;640</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1941663</ArticleId><ArticleId IdType="pubmed">16480900</ArticleId></ArticleIdList></Reference><Reference><Citation>Hua X, Lee S, Yanovsky I, et al. Optimizing power to track brain degeneration in Alzheimer's disease and mild cognitive impairment with tensor-based morphometry: an ADNI study of 515 subjects. Neuroimage 2009;48:668&#x2013;681</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2971697</ArticleId><ArticleId IdType="pubmed">19615450</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412b&#x2013;2414</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189&#x2013;198</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns JM, Donnelly JE, Anderson HS, et al. Peripheral insulin and brain structure in early Alzheimer disease. Neurology 2007;69:1094&#x2013;1104</Citation><ArticleIdList><ArticleId IdType="pubmed">17846409</ArticleId></ArticleIdList></Reference><Reference><Citation>van Exel E, Eikelenboom P, Comijs H, et al. Vascular factors and markers of inflammation in offspring with a parental history of late-onset Alzheimer disease. Arch Gen Psychiatry 2009;66:1263&#x2013;1270</Citation><ArticleIdList><ArticleId IdType="pubmed">19884614</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns JM, Donnelly JE, Anderson HS, et al. Peripheral insulin and brain structure in early Alzheimer disease. Neurology 2007;69:1094&#x2013;1104</Citation><ArticleIdList><ArticleId IdType="pubmed">17846409</ArticleId></ArticleIdList></Reference><Reference><Citation>Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease: The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;2(suppl):S33&#x2013;S39</Citation><ArticleIdList><ArticleId IdType="pubmed">9236950</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner J, Andersson JL, Friston KJ. Image registration using a symmetric prior: in three dimensions. Hum Brain Mapp 2000;9:212&#x2013;225</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871943</ArticleId><ArticleId IdType="pubmed">10770230</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner J, Friston KJ. Unified segmentation. Neuroimage 2005;26:839&#x2013;851</Citation><ArticleIdList><ArticleId IdType="pubmed">15955494</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner J. A fast diffeomorphic image registration algorithm. Neuroimage 2007;38:95&#x2013;113</Citation><ArticleIdList><ArticleId IdType="pubmed">17761438</ArticleId></ArticleIdList></Reference><Reference><Citation>Honea RA, Thomas GP, Harsha A, et al. Cardiorespiratory fitness and preserved medial temporal lobe volume in Alzheimer disease. Alzheimer Dis Assoc Disord 2009;23:188&#x2013;197</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2760037</ArticleId><ArticleId IdType="pubmed">19812458</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L, Brys M, Switalski R, et al. Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism. Proc Natl Acad Sci USA 2007;104:19067&#x2013;19072</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2141909</ArticleId><ArticleId IdType="pubmed">18003925</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson SC, Schmitz TW, Trivedi MA, et al. The influence of Alzheimer disease family history and apolipoprotein E epsilon4 on mesial temporal lobe activation. J Neurosci 2006;26:6069&#x2013;6076</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2684824</ArticleId><ArticleId IdType="pubmed">16738250</ArticleId></ArticleIdList></Reference><Reference><Citation>Fjell AM, Walhovd KB, Fennema-Notestine C, et al. One-year brain atrophy evident in healthy aging. J Neurosci 2009;29:15223&#x2013;15231</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2827793</ArticleId><ArticleId IdType="pubmed">19955375</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L, Sorbi S, de Leon MJ, et al. Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. J Nucl Med 2006;47:1778&#x2013;1786</Citation><ArticleIdList><ArticleId IdType="pubmed">17079810</ArticleId></ArticleIdList></Reference><Reference><Citation>Karas G, Scheltens P, Rombouts S, et al. Precuneus atrophy in early-onset Alzheimer's disease: a morphometric structural MRI study. Neuroradiol 2007;49:967&#x2013;976</Citation><ArticleIdList><ArticleId IdType="pubmed">17955233</ArticleId></ArticleIdList></Reference><Reference><Citation>Risacher SL, Saykin AJ, West JD, et al. Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort. Curr Alzheimer Res 2009;6:347&#x2013;361</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2764863</ArticleId><ArticleId IdType="pubmed">19689234</ArticleId></ArticleIdList></Reference><Reference><Citation>Risacher SL, Shen L, West JD, et al. Longitudinal MRI atrophy biomarkers: relationship to conversion in the ADNI cohort. Neurobiol Aging 2010;31:1401&#x2013;1418</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2904350</ArticleId><ArticleId IdType="pubmed">20620664</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrawis JP, Hwang KS, Green AE, et al. Effects of ApoE4 and maternal history of dementia on hippocampal atrophy. Neurobiol Aging Epub 2010 Sept 15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3010297</ArticleId><ArticleId IdType="pubmed">20833446</ArticleId></ArticleIdList></Reference><Reference><Citation>Chetelat G, Villemagne VL, Bourgeat P, et al. Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol 2010;67:317&#x2013;324</Citation><ArticleIdList><ArticleId IdType="pubmed">20373343</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavanna AE, Trimble MR. The precuneus: a review of its functional anatomy and behavioural correlates. Brain 2006;129:564&#x2013;583</Citation><ArticleIdList><ArticleId IdType="pubmed">16399806</ArticleId></ArticleIdList></Reference><Reference><Citation>Fransson P, Marrelec G. The precuneus/posterior cingulate cortex plays a pivotal role in the default mode network: Evidence from a partial correlation network analysis. Neuroimage 2008;42:1178&#x2013;1184</Citation><ArticleIdList><ArticleId IdType="pubmed">18598773</ArticleId></ArticleIdList></Reference><Reference><Citation>Rombouts SA, Barkhof F, Goekoop R, et al. Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: an fMRI study. Hum Brain Mapp 2005;26:231&#x2013;239</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871685</ArticleId><ArticleId IdType="pubmed">15954139</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai F, Zhang Z, Yu H, et al. Default-mode network activity distinguishes amnestic type mild cognitive impairment from healthy aging: a combined structural and resting-state functional MRI study. Neurosci Lett 2008;438:111&#x2013;115</Citation><ArticleIdList><ArticleId IdType="pubmed">18455308</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheline YI, Raichle ME, Snyder AZ, et al. Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Biol Psychiatry 2010;67:584&#x2013;587</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2829379</ArticleId><ArticleId IdType="pubmed">19833321</ArticleId></ArticleIdList></Reference><Reference><Citation>Duara R, Barker WW, Lopez-Alberola R, et al. Alzheimer's disease: interaction of apolipoprotein E genotype, family history of dementia, gender, education, ethnicity, and age of onset. Neurology 1996;46:1575&#x2013;1579</Citation><ArticleIdList><ArticleId IdType="pubmed">8649551</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L, Berti V, Swerdlow RH, et al. Maternal transmission of Alzheimer's disease: prodromal metabolic phenotype and the search for genes. Hum Genomics 2010;4:170&#x2013;193</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3033750</ArticleId><ArticleId IdType="pubmed">20368139</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006;443:787&#x2013;795</Citation><ArticleIdList><ArticleId IdType="pubmed">17051205</ArticleId></ArticleIdList></Reference><Reference><Citation>Swerdlow RH, Khan SM. The Alzheimer's disease mitochondrial cascade hypothesis: an update. Exp Neurol 2009;218:308&#x2013;315</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2710413</ArticleId><ArticleId IdType="pubmed">19416677</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang WS, Reiman EM, Valla J, et al. Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons. Proc Natl Acad Sci USA 2008;105:4441&#x2013;4446</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2393743</ArticleId><ArticleId IdType="pubmed">18332434</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynn BC, Wang J, Markesbery WR, Lovell MA. Quantitative changes in the mitochondrial proteome from subjects with mild cognitive impairment, early stage, and late stage Alzheimer's disease. J Alzheimers Dis 2010;19:325&#x2013;339</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2905865</ArticleId><ArticleId IdType="pubmed">20061648</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawas C, Segal J, Stewart WF, et al. A validation study of the Dementia Questionnaire. Arch Neurol 1994;51:901&#x2013;906</Citation><ArticleIdList><ArticleId IdType="pubmed">8080390</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>